<SEC-DOCUMENT>0001193125-19-274989.txt : 20191028
<SEC-HEADER>0001193125-19-274989.hdr.sgml : 20191028
<ACCEPTANCE-DATETIME>20191025183818
ACCESSION NUMBER:		0001193125-19-274989
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		25
FILED AS OF DATE:		20191028
DATE AS OF CHANGE:		20191025

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Phathom Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001783183
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				824151574
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-234020
		FILM NUMBER:		191170924

	BUSINESS ADDRESS:	
		STREET 1:		2150 E. LAKE COOK ROAD, SUITE 800
		CITY:			BUFFALO GROVE
		STATE:			IL
		ZIP:			60089
		BUSINESS PHONE:		650-325-5156

	MAIL ADDRESS:	
		STREET 1:		2150 E. LAKE COOK ROAD, SUITE 800
		CITY:			BUFFALO GROVE
		STATE:			IL
		ZIP:			60089
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>d63338d424b4.htm
<DESCRIPTION>424B4
<TEXT>
<HTML><HEAD>
<TITLE>424B4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">Filed Pursuant to Rule 424(b)(4)<BR>Registration No. 333-234020<BR>Registration No. 333-234312
</FONT></P> <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="4"><B>9,563,157 Shares </B></FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g45n03.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:20px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="4">Common Stock </FONT></P> <P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">This is an initial public
offering of shares of common stock of Phathom Pharmaceuticals, Inc. We are offering 9,563,157&nbsp;shares of our common stock. </FONT></P> <P STYLE="margin-top:10px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Prior to
this offering, there has been no public market for our common stock. The initial public offering price per share is $19.00. </FONT></P> <P STYLE="margin-top:10px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our common
stock has been approved for listing on the Nasdaq Global Select Market under the symbol &#147;PHAT.&#148; </FONT></P> <P STYLE="margin-top:10px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We are an &#147;emerging
growth company&#148; as defined under the federal securities laws and, as such, we have elected to comply with certain reduced public company reporting requirements for this prospectus and may elect to do so in future filings. </FONT></P>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>See &#147;<A HREF="#toc63338_2">Risk Factors</A>&#148; beginning on page 13 to read about factors you should consider before buying shares of
our common stock. </I></FONT></P> <P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Neither the Securities and Exchange Commission nor any other state securities commission has approved or disapproved of these securities or
passed on the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></FONT></P> <P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Per&nbsp;Share</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1">Total</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Initial public offering price</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">19.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">181,699,983</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Underwriting
discount</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1.33</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">12,718,999</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Proceeds, before expenses, to Phathom Pharmaceuticals, Inc.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">17.67</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">168,980,984</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">See the section titled &#147;Underwriting&#148; for additional information regarding compensation payable to the underwriters.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:10px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">To the extent that the underwriters sell more than 9,563,157 shares of common stock, the underwriters have the option
to purchase up to an additional 1,434,473 shares from us at the initial price to the public less the underwriting discount. </FONT></P> <P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:10px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The underwriters expect
to deliver the shares against payment in New York, New York on October 29, 2019. </FONT></P> <P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="3"><B>Goldman&nbsp;Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="3"><B>Jefferies&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="3"><B>Evercore&nbsp;ISI</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:10px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Needham &amp; Company </B></FONT></P>
<P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">Prospectus dated October 24, 2019. </FONT></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Page</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_1">Prospectus Summary</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_2">Risk Factors</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_3">Special Note Regarding Forward-Looking Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">76</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_4">Market and Industry Data</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">77</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_5">Use of Proceeds</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">78</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_6">Dividend Policy</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">79</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_7">Capitalization</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">80</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_8">Dilution</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">82</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_9">Selected Combined Financial Data</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">85</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_10">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">87</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_11">Business</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">101</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_12">Management</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">148</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_13">Executive and Director Compensation</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">157</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_14">Certain Relationships and Related Person Transactions</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">176</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_15">Principal Stockholders</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">182</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_16">Description of Capital Stock</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">184</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_17">Shares Eligible for Future Sale</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">190</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_18">Material United States Federal Income Tax Consequences to Non-U.S. Holders</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">193</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_19">Underwriting</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">198</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_20">Legal Matters</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">205</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_21">Experts</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">205</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_22">Where You Can Find More Information</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">205</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#toc63338_23">Index to Combined Financial Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:10px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Neither we nor the underwriters have authorized anyone to provide you with information other than that contained in this prospectus or any free
writing prospectus prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. We and the
underwriters are offering to sell, and seeking offers to buy, common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus or any free writing prospectus is accurate only as of its date,
regardless of its time of delivery or of any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">For investors outside of the United States: We have not, and the underwriters have not, done anything that would permit this offering or possession
or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and
observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside of the United States. </FONT></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_1"></A>PROSPECTUS SUMMARY </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>This summary highlights information contained elsewhere in this prospectus. This summary does not contain all of the information you should
consider before investing in our common stock. You should read this entire prospectus carefully, especially the section titled &#147;Risk Factors&#148; and our combined financial statements and related notes included elsewhere in this prospectus,
before making an investment decision. As used in this prospectus, unless the context otherwise requires, references to &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;the Company,&#148; &#147;Phathom Pharmaceuticals&#148; and
&#147;Phathom&#148; refer to Phathom Pharmaceuticals, Inc. </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Overview </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We are a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal, or GI,
diseases. Our initial product candidate, vonoprazan, is an oral small molecule potassium competitive acid blocker, or <FONT STYLE="white-space:nowrap">P-CAB.</FONT> <FONT STYLE="white-space:nowrap">P-CABs</FONT> are a novel class of medicines that
block acid secretion in the stomach. Vonoprazan has shown rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits over standard of care treatments as a single agent in the treatment of gastroesophageal reflux
disease, or GERD, and in combination with antibiotics for the treatment of <I>Helicobacter pylori, </I>or <I>H. pylori,</I> infection. Takeda Pharmaceutical Company Limited, or Takeda, developed vonoprazan and has received marketing approval in nine
countries in Asia and Latin America. Vonoprazan generated over $500&nbsp;million in net sales in its fourth full year on the market since its approval in Japan in late 2014. In May 2019, we <FONT STYLE="white-space:nowrap">in-licensed</FONT> the
U.S.,&nbsp;European, and Canadian rights to vonoprazan from Takeda. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We believe we can leverage Takeda&#146;s extensive clinical data,
including results from 17 Phase&nbsp;3 clinical trials, to advance vonoprazan through pivotal trials in the United States and Europe. We plan to initiate two pivotal Phase 3 clinical trials in the fourth quarter of 2019 for vonoprazan: one for the
treatment of erosive GERD, also known as erosive esophagitis, and a second for the treatment of <I>H. pylori</I> infection. We expect to report <FONT STYLE="white-space:nowrap">top-line</FONT> data from both trials in 2021. We believe that the
successful completion of our Phase 3 clinical trials, together with the existing clinical data, will support regulatory submissions in 2021 and 2022 for marketing approval for the treatment of <I>H. pylori </I>infection and erosive esophagitis,
respectively. In August 2019, we received qualified infectious disease product, or QIDP, designation from the U.S. Food and Drug Administration, or FDA, for vonoprazan in combination with certain antibiotics for the treatment of <I>H. pylori
</I>infection which provides, among other benefits, extension of any regulatory exclusivity and potential eligibility for priority review. Vonoprazan has the potential to be the first gastric anti-secretory agent from a novel class approved in the
United States, Europe, or Canada in over 30&nbsp;years. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Our Pipeline </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The following chart summarizes our current development programs. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g74s47.jpg" ALT="LOGO">
 </P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">1 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Overview of Acid-Related GI Diseases </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">GI diseases where treatment is related to acid control, such as GERD and <I>H. pylori</I> infection, are significant medical problems because of
their high prevalence, chronic nature, and clinical sequelae. GERD results from the effects of acid on compromised mucosal defenses in the gastrointestinal tract. The reflux of gastric acid into the esophagus produces frequent and/or severe
heartburn, indigestion, and reflux symptoms. Chronic GERD may damage esophageal tissue and progress to more severe diseases including erosive esophagitis, Barrett&#146;s esophagus, and esophageal cancer. In <I>H. pylori </I>infection, gastric acid
limits the effectiveness of antibiotics used to eradicate infection. Chronic <I>H. pylori </I>infection can lead to dyspepsia, peptic ulcer disease, gastric cancer, and mucosa-associated lymphoid tissue (MALT) lymphoma. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">GERD and <I>H. pylori</I> infection are two of the most common acid-related GI diseases and impact millions of people. The prevalence of GERD is
estimated to be 20% of the U.S. population and 15% of the population in the five major countries in the European Union (France, Germany, Italy, Spain, and the United Kingdom, or the EU5). We estimate that there are approximately 65&nbsp;million
individuals in the United States and 50&nbsp;million individuals in the EU5 with GERD. Approximately 30% of GERD patients have erosive esophagitis. <I>H. pylori</I> is a bacterial pathogen that infects approximately 35% of the U.S. population and
45% of the EU5 population. We estimate that there are approximately 115&nbsp;million individuals in the United States and 145&nbsp;million individuals in the EU5 infected with <I>H. pylori</I>. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Current Standard of Care for GERD and </B><B><I>H. pylori</I></B><B> </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Over the last thirty years, the proton pump inhibitor, or PPI, class, has been the standard of care for the treatment of acid-related GI diseases. PPIs are generally used as a single agent for the treatment of GERD
and in combination with antibiotics<I> </I>for the treatment of <I>H. pylori</I> infection. The PPI class includes drugs such as Prilosec (omeprazole), Nexium (esomeprazole), and Prevacid (lansoprazole). Prior to the introduction of generic and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter,</FONT></FONT> or OTC, alternatives, annual PPI class sales reached approximately $12.5&nbsp;billion in the United States, and peak sales for individual brands were
approximately $3.7&nbsp;billion for Prilosec, $3.5&nbsp;billion for Nexium, and $3.4&nbsp;billion for Prevacid in the United States. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">While PPIs are the current standard of care and have experienced significant commercial success, they have significant limitations that result in a
large unmet medical need. In GERD, PPI therapy is suboptimal for many patients due to the slow onset and insufficient duration of acid control which can lead to inadequate symptom relief. Approximately 15% to 45% of GERD patients remain inadequately
treated with PPIs. In the treatment of <I>H.&nbsp;pylori </I>infection, the standard of care consists of a combination of a PPI and at least two oral antibiotics. However, increasing antibiotic resistance has resulted in declining eradication rates
with <FONT STYLE="white-space:nowrap">PPI-based</FONT> therapy. We believe these unmet medical needs are in part driven by limitations associated with the mechanism of action and pharmacokinetics of PPIs. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Gastric acid is secreted by proton pumps that are expressed on the channeled surfaces of parietal cells in the stomach. Proton pumps are
continuously synthesized and switch between active and inactive states in response to various stimuli, such as food. When activated, proton pumps increase acid secretion. PPIs reduce gastric acid secretion by irreversibly binding to and inhibiting
active proton pumps expressed on the parietal cells. PPIs require activation by gastric acid, but they are unstable in the presence of acid. This instability, combined with the short circulating half-life of PPIs, limits their efficacy.
Additionally, because proton pumps continuously switch between active and inactive states, multiple doses of PPIs are required to inhibit enough proton pumps to achieve a clinical benefit. As a result, PPIs have a relatively slow onset of action and
limited potency and duration of </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">2 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
effect, which may result in patients experiencing only partial relief, increasing PPI dosage, and/or cycling through multiple PPIs seeking relief. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Our Solution: Vonoprazan </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Vonoprazan has a
differentiated mechanism of action from PPIs. Unlike PPIs, vonoprazan: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">does not require activation by gastric acid; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">is stable in the presence of acid; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">binds with a slow dissociation rate to both active and inactive proton pumps; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">has a long plasma half-life that replenishes the drug at the site of action over the course of the day. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">These factors have enabled vonoprazan to demonstrate more rapid and potent acid suppression versus the PPI esomeprazole in human subjects two hours
after oral dosing and maintain target acid inhibition over a <FONT STYLE="white-space:nowrap">24-hour</FONT> period in a randomized, open-label, crossover clinical trial. In contrast, PPIs require three to five days to reach steady state acid
suppression and do not reliably maintain target acid inhibition over a <FONT STYLE="white-space:nowrap">24-hour</FONT> period. In addition, vonoprazan demonstrated approximately 10-to-100-fold better acid control compared to esomeprazole.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We believe that vonoprazan&#146;s anti-secretory profile may demonstrate clinically meaningful advantages over PPIs, such as:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">faster, more complete, and more durable healing of erosive esophagitis; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">faster, more complete, and more durable control of GERD symptoms; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">higher <I>H. pylori</I> eradication rates in combination with antibiotics compared to standard of care triple therapy and the potential for antibiotic-sparing
dual therapy; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">more flexible dosing, including dosing independent of food and time of day, and the potential for rapid symptom relief through
<FONT STYLE="white-space:nowrap">on-demand</FONT> dosing. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Vonoprazan generated over $500&nbsp;million in net sales in
its fourth full year on the market in Japan, a 20% increase over the previous year. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Vonoprazan Clinical Data </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Vonoprazan has demonstrated clinical advantages over PPIs in the treatment of erosive esophagitis and <I>H.</I><I></I><I>&nbsp;pylori</I> infection
in completed Phase 3 clinical trials conducted in Japan and other Asian countries. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Erosive
esophagitis</B><B>.</B>&nbsp;&nbsp;&nbsp;&nbsp;In two Phase 3 clinical trials conducted in Japan assessing vonoprazan versus the PPI lansoprazole in the healing and maintenance of healing of erosive esophagitis, vonoprazan met its primary endpoint
in demonstrating <FONT STYLE="white-space:nowrap">non-inferiority</FONT> to lansoprazole. In a post hoc analysis of the healing trial, vonoprazan demonstrated faster healing and a superior overall healing rate compared to lansoprazole in patients
with more severe erosive esophagitis. After two weeks of treatment, 88% of erosive esophagitis patients with more severe disease were healed after treatment with vonoprazan versus 64% with lansoprazole (p&#061;0.0008). In the maintenance of healing
trial, vonoprazan demonstrated lower recurrence rates of erosive esophagitis six months after treatment versus lansoprazole across all grades of severity of erosive esophagitis. Vonoprazan demonstrated a 2% recurrence rate compared to 17% for
lansoprazole (p&lt;0.0001). </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">3 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>H. pylori</I></B><B>.</B>&nbsp;&nbsp;&nbsp;&nbsp;A Phase 3 clinical trial was conducted in
Japan assessing vonoprazan in combination with the antibiotics amoxicillin and clarithromycin versus lansoprazole in combination with these same antibiotics in first line treatment of <I>H. pylori </I>infection. In this trial, the vonoprazan-based
regimen met its primary endpoint in demonstrating a non-inferior eradication rate of 93% compared to 76% for lansoprazole-based regimen (p&lt;0.0001) and was also superior in a post hoc analysis of this trial (p&lt;0.0001). In patients who failed
first line therapy, vonoprazan in combination with the antibiotics metronidazole and amoxicillin demonstrated a 98% eradication rate as second line therapy. A p-value is the probability that the reported result was achieved purely by chance, such
that a <FONT STYLE="white-space:nowrap">p-value</FONT> of less than or equal to 0.05 or 0.01 means that there is a 5.0% or 1.0% or less probability, respectively, that the difference between the control group and the treatment group is purely due to
chance. A p-value of 0.05 or less typically represents a statistically significant result. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Safety.</B>&nbsp;&nbsp;&nbsp;&nbsp;As of
December 2018, 6,683 subjects have been exposed to vonoprazan in completed and ongoing Phase 1 to 3 clinical trials. The doses studied have ranged from 1 to 120&nbsp;mg with durations up to one year. The most commonly reported adverse events, or
AEs, in the clinical development program for vonoprazan, as reflected in the Japanese prescribing information published by Japan&#146;s Pharmaceuticals and Medical Devices Agency, were diarrhea, constipation, nausea, elevated liver enzymes, rash,
and eosinophilia. All such events had an incidence rate of less than 5.0%, other than diarrhea in the treatment of <I>H. pylori</I> which had an incidence rate of 10.6% in combination with antibiotics. No dose-related increase in treatment-emergent
AEs, or TEAEs, or serious AEs, or SAEs, was observed. The safety profile of vonoprazan and incidence of TEAEs, drug-related TEAEs, and TEAEs leading to drug discontinuation were similar between vonoprazan and lansoprazole across studies. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The most recent post-marketing safety report from December 2018 includes an estimated 23&nbsp;million patients who have received vonoprazan in
Japan since its launch. Based on the post-marketing experience, the clinically significant adverse reactions section of the Japanese prescribing information for vonoprazan was updated to include skin reactions such as toxic epidermal necrolysis,
Steven-Johnson syndrome, and erythema multiforme. The incidence of these skin reactions was considered extremely rare (less than 1 in 100,000 patients) and a causal relationship to vonoprazan could not be ruled out. We believe the overall
post-marketing safety and tolerability profile of vonoprazan has been consistent with that observed in clinical trials. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Our Strategy </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our goal is to be a leader in the development and commercialization of novel treatments for GI diseases. Our strategy is initially focused on
developing and commercializing vonoprazan as a potential <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> <FONT STYLE="white-space:nowrap">P-CAB</FONT> in the United States, Europe, and Canada for the
treatment of acid-related GI diseases. Key elements of this strategy include: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Advance the clinical development of vonoprazan in erosive esophagitis and H. pylori infection and seek marketing
approval</I></B><I>.&nbsp;&nbsp;&nbsp;&nbsp;</I>We believe we can leverage the existing clinical data and post-marketing experience, as well as our management team&#146;s experience with vonoprazan, to advance vonoprazan through a single pivotal
Phase 3 clinical trial in each of erosive esophagitis and <I>H. pylori</I> infection beginning in the fourth quarter of 2019, and we expect to report <FONT STYLE="white-space:nowrap">top-line</FONT> data from both trials in 2021.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Commercialize vonoprazan in the United States</I></B><I>.&nbsp;&nbsp;&nbsp;&nbsp;</I>We plan to independently commercialize vonoprazan, if approved, in the
United States by building a leading specialty gastroenterology commercial infrastructure to support the adoption of vonoprazan. </FONT></P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">4 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Seek commercial partnerships to maximize the vonoprazan opportunity outside of the United States</I></B><I>.&nbsp;&nbsp;&nbsp;&nbsp;</I>We believe there is
a significant commercial opportunity for vonoprazan in Europe and Canada. To address these markets, we plan to seek one or more partners with existing commercial infrastructure and expertise in these markets. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Expand the development of vonoprazan across indications, dosing regimens, and alternative formulations and packaging</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;We
plan to pursue vonoprazan lifecycle extension strategies in areas with clear unmet need, clinical rationale, and commercial justification. These strategies may include additional indications, flexible dosing regimens, and alternative formulations
and packaging. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">In-license</FONT> or acquire additional clinical or commercial stage product candidates for the treatment of GI diseases
in a capital efficient manner</I></B><I>.</I>&nbsp;&nbsp;&nbsp;&nbsp;We intend to take advantage of our management team&#146;s GI expertise to opportunistically <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire additional innovative
therapies for diseases treated by gastroenterologists. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Our Team </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our founders and management team have deep expertise in developing GI therapeutics, including anti-secretory agents, and direct experience
developing vonoprazan at Takeda. Our Chairman, Tadataka (Tachi) Yamada, M.D., is the former Chief Medical Officer and Chief Scientific Officer at Takeda. He is the former President of the American Gastroenterological Association and former Chief of
Gastroenterology and Internal Medicine at the University of Michigan. Our Chief Executive Officer, David Socks, is the former Chief Executive Officer of Outpost Medicine, LLC, a GI and urology focused company. Mr.&nbsp;Socks was also President and
Chief Operating Officer of Incline Therapeutics Inc. through its sale to The Medicines Company in 2013, and Senior Vice President, Corporate Development and Strategy of Cadence Pharmaceuticals, Inc. Azmi Nabulsi, M.D., M.P.H., our Chief Operating
Officer, is the former Deputy Chief Medical and Scientific Officer at Takeda. Our Head of Regulatory, Tom Harris, is the former Senior Vice President and Head of Global Regulatory at Takeda. Dr.&nbsp;Yamada, Dr.&nbsp;Nabulsi, and Mr.&nbsp;Harris
were extensively involved with the development of vonoprazan at Takeda. Our investors include Frazier Healthcare Partners, Medicxi, RA Capital Management, Abingworth, certain accounts managed by Janus Henderson Investors and BVF Partners LP.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As part of a planned transition, we expect that Terrie Curran, a member of our board of directors, will succeed Mr.&nbsp;Socks as Chief
Executive Officer effective upon the closing of the acquisition of her current employer, Celgene Corporation, by Bristol-Myers Squibb Company. Ms.&nbsp;Curran has served as President, Global Inflammation and Immunology (I&amp;I) Franchise and as a
member of the Executive Committee at Celgene since 2017. Ms.&nbsp;Curran joined Celgene in 2013 as the U.S. Commercial Head of the I&amp;I Franchise and built the capabilities and recruited the teams that executed the launch of OTEZLA. Following
Ms.&nbsp;Curran&#146;s appointment as CEO, Mr.&nbsp;Socks will serve as interim Chief Financial Officer and continue to serve as a member of our board of directors. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>Financial Update </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We estimate that our cash and cash equivalents were approximately
$74.5&nbsp;million as of September&nbsp;30, 2019. This amount is unaudited and preliminary and is subject to completion of financial closing procedures. As a result, this amount may differ from the amount that will be reflected in our financial
statements as of and for the quarter ended September&nbsp;30, 2019. Our financial statements for the quarter ended September&nbsp;30, 2019 will not be available until after this offering is completed, and consequently will not be available to you
prior to investing in this offering. </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">5 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Risks Related to Our Business </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our ability to execute our business strategy is subject to numerous risks, as more fully described in the section titled &#147;Risk Factors&#148;
immediately following this Prospectus Summary. These risks include, among others: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">We have a limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable
future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at all,
could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">We currently depend entirely on the success of vonoprazan, which is our only product candidate. Our assumptions about vonoprazan&#146;s development and
commercial potential are based in large part on the development, including data from clinical trials conducted by Takeda and independent investigators, and commercial experience of vonoprazan in Japan and other Asian countries, which data the FDA or
comparable foreign regulatory authorities may not accept to support approval. If we are unable to advance vonoprazan in clinical development, obtain regulatory approval and ultimately commercialize vonoprazan, or experience significant delays in
doing so, our business will be materially harmed. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">We rely on our license agreement with Takeda to provide us rights to develop and commercialize vonoprazan in the United States, Europe, and Canada. If the
license agreement is terminated, we would lose our rights to develop and commercialize vonoprazan. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and the results of prior clinical trials and other
investigator-initiated clinical trials of vonoprazan are not necessarily predictive of our future results. Vonoprazan may not have favorable results in our clinical trials, or receive regulatory approval on a timely basis, if at all.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Any difficulties or delays in the commencement or completion, or termination or suspension, of our planned clinical trials could result in increased costs to us,
delay or limit our ability to generate revenue and adversely affect our commercial prospects. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">We intend to enroll patients in Europe in both of our planned Phase&nbsp;3 clinical trials. However, the FDA and other comparable foreign regulatory authorities
may not accept data from such trials, in which case our clinical development plans will be delayed, which could materially harm our business. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">We rely on third parties to conduct some or all aspects of our product manufacturing, research and preclinical and clinical testing, and these third parties may
not perform satisfactorily. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">We face significant competition, and if our competitors develop technologies or product candidates more rapidly than we do or their technologies are more
effective, our ability to develop and successfully commercialize products may be adversely affected. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Our success depends on our ability to protect our intellectual property and our proprietary technologies. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">After this offering, our executive officers, directors, and principal stockholders, if they choose to act together, will continue to have the ability to control
or significantly influence all matters submitted to stockholders for approval. Furthermore, many of our current directors were appointed by our principal stockholders. </FONT></P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">6 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Corporate Information </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We were originally incorporated under the laws of the state of Delaware on January&nbsp;9, 2018 under the name North Bridge IV, Inc. On
March&nbsp;13, 2019, we changed our name to Phathom Pharmaceuticals, Inc. and merged YamadaCo IIA, Inc., a Delaware corporation, with and into our company, with Phathom Pharmaceuticals, Inc. as the surviving entity, or the Merger. References
throughout this registration statement to Phathom Pharmaceuticals, Inc. include North Bridge IV, Inc. prior to the Merger. Our principal executive offices are located at 2150 E. Lake Cook Road, Suite 800, Buffalo Grove, Illinois 60089, and our
telephone number is <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">650-325-5156.</FONT></FONT> Our website address is www.phathompharma.com<I>.</I> The information contained in, or accessible through, our website does not
constitute part of this prospectus. We have included our website address as an inactive textual reference only. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%;padding-bottom:0px; "><FONT STYLE="font-family:ARIAL" SIZE="2">We
use our pending trademark Phathom Pharmaceuticals in this prospectus. This prospectus also includes trademarks, tradenames, and service marks that are the property of other organizations. Solely for convenience, trademarks and tradenames referred to
in this prospectus appear without the <FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> and <FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&#153;</SUP></FONT> symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the
applicable owner will not assert its rights, to these trademarks and tradenames. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Presentation of Japanese Sales Numbers
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">All Japanese sales numbers presented in this prospectus are shown in U.S. dollars based on the June&nbsp;30, 2019 conversion ratio
of 0.009 yen to one dollar. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Implications of Being an Emerging Growth Company and a Smaller Reporting Company </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As a company with less than $1.07&nbsp;billion in revenue during our last fiscal year, we qualify as an &#147;emerging growth company&#148; as
defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. An emerging growth company may take advantage of reduced reporting requirements that are otherwise applicable to public companies. These provisions include, but are not
limited to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with
correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended, or Sarbanes-Oxley Act;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or
a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements, unless the SEC determines the new rules are necessary for protecting the public; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">reduced disclosure obligations regarding executive compensation; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not
previously approved. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We may take advantage of these provisions until the last day of our fiscal year following the
fifth anniversary of the date of the first sale of our common equity securities pursuant to an effective </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">7 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
registration statement under the Securities Act of 1933, as amended, or the Securities Act, which such fifth anniversary will occur in 2024. However, if certain events occur prior to the end of
such five-year period, including if we become a &#147;large accelerated filer&#148; as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Securities Exchange Act of 1934, or the Exchange Act, our annual gross revenues exceed
$1.07&nbsp;billion or we issue more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have elected to take advantage of certain of the reduced disclosure obligations in this prospectus and in the registration statement
of which this prospectus is a part and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information in this prospectus and that we provide to our stockholders in the future may be different than
what you might receive from other public reporting companies in which you hold equity interests. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, the JOBS Act provides
that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. We have irrevocably elected not to avail ourselves of this exemption and, therefore, we will be subject to
the same new or revised accounting standards as other public companies that are not emerging growth companies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We are also a smaller
reporting company as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting
companies and will be able to take advantage of these scaled disclosures for so long as our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than
$250.0&nbsp;million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year and our voting and
<FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million measured on the last business day of our second fiscal quarter. </FONT></P>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">8 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>The Offering </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Common stock offered by us</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">9,563,157 shares.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Underwriters&#146; option to purchase additional shares from us</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE=0><BR></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="2">The underwriters have a <FONT STYLE="white-space:nowrap">30-day</FONT> option to purchase up to a total of 1,434,473 additional shares of our common
stock.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Common stock to be outstanding immediately after this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT SIZE=0><BR></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="2">27,547,593&nbsp;shares (28,982,066 shares if the underwriters exercise their option to purchase additional shares of common stock in full).</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Use of proceeds</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">We intend to use the net proceeds of this offering to fund the clinical development of vonoprazan and for working capital and general corporate purposes, including <FONT
STYLE="white-space:nowrap">pre-commercial</FONT> activities. See &#147;Use of Proceeds.&#148;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Risk factors</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">See &#147;Risk Factors&#148; and other information included in this prospectus for a discussion of factors you should consider carefully before deciding to invest in our common
stock.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Directed share program</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">At our request, the underwriters have reserved up to 3.0% of the shares of common stock to be offered by this prospectus for sale, at the initial public offering price, to certain of our
directors, officers, employees, and their friends and family members through a directed share program. If these persons purchase reserved shares, this will reduce the number of shares available for sale to the general public. Any reserved shares
that are not so purchased will be offered by the underwriters to the general public on the same terms as the other shares offered by this prospectus.</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Nasdaq Global Select Market symbol</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">&#147;PHAT&#148;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The number of shares of our common stock to be outstanding after this offering set forth above is based on
17,984,436 shares of our common stock outstanding as of June&nbsp;30, 2019, including 4,657,250 shares subject to forfeiture or our right of repurchase, and gives effect to the automatic conversion of $90.3&nbsp;million of aggregate principal
amount, plus accrued interest thereon, of convertible promissory notes we issued in May 2019, or the May 2019 Notes, into an aggregate of 6,107,918 shares of our common stock immediately prior to the closing of this offering (based on the initial
public offering price of $19.00 per share and assuming the conversion occurs on October 29, 2019), and excludes: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">7,588,000 shares of common stock issuable to Takeda upon the exercise of an outstanding warrant, or the Takeda Warrant, as of June&nbsp;30, 2019, at an exercise
price of $0.00004613 per share; </FONT></P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">9 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">1,400,528 shares of common stock issuable upon exercise of stock options granted after June&nbsp;30, 2019, at a weighted-average exercise price of $9.10 per
share; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">2,700,000 shares of common stock reserved for future issuance under our 2019 Equity Incentive Plan, or the 2019 Plan, which became effective in connection with
this offering (which number does not include any potential evergreen increases pursuant to the terms of the 2019 Plan); </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">270,000 shares of common stock reserved for future issuance under our 2019 Employee Stock Purchase Plan, or ESPP, which became effective in connection with this
offering (which number does not include any potential evergreen increases pursuant to the terms of the ESPP); and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">16,446 shares of common stock which may become issuable to the lenders under our loan and security agreement, or the Loan Agreement, upon the exercise of
warrants outstanding as of June&nbsp;30, 2019, or the Lender Warrants, at an exercise price of $15.20 per share (based on the initial public offering price of $19.00 per share), which warrants will only become exercisable if and when we borrow an
additional $25.0 million under our Loan Agreement. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Unless otherwise indicated, all information contained in this
prospectus assumes or gives effect to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the filing and effectiveness of our amended and restated certificate of incorporation and the adoption of our amended and restated bylaws, each of which will
occur immediately prior to the closing of this offering; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the issuance of 6,107,918 shares of common stock upon the automatic conversion of the May 2019 Notes immediately prior to the closing of this offering (based on
the initial public offering price of $19.00 per share and assuming the conversion occurs on October 29, 2019); </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the expiration of the right granted to Takeda to receive an additional common stock warrant, or the Takeda Warrant Right, upon the closing of this offering
(based on the initial public offering price of $19.00 per share, as further described below in the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#151;Overview&#151;License Agreement
with Takeda&#148;); </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a<B> </B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1,559.1183-for-1</FONT></FONT> forward stock split of our common stock effected on
March&nbsp;13, 2019; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a subsequent <FONT STYLE="white-space:nowrap">2.168-for-1</FONT> forward stock split of our common stock, which we effected on October&nbsp;11, 2019;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">no exercise of the outstanding options or warrants described above; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">no exercise by the underwriters of their option to purchase 1,434,473 additional shares of our common stock. </FONT></P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">10 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Summary Combined Financial Data </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The following tables set forth a summary of our historical combined financial data as of, and for the periods ended on, the dates indicated. The
combined financial statements include the accounts of our company and YamadaCo IIA, Inc., both of which were entities under common control prior to the Merger. We have derived the summary combined statements of operations data for the year ended
December&nbsp;31, 2018 from our audited combined financial statements included elsewhere in this prospectus. We have derived the summary combined statements of operations data for the six months ended June&nbsp;30, 2018 and 2019 and the summary
combined balance sheet data as of June&nbsp;30, 2019 from our unaudited combined financial statements included elsewhere in this prospectus. The unaudited combined financial statements have been prepared on a basis consistent with our audited
combined financial statements included in this prospectus and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, necessary to fairly state our results of operations for the six months ended
June&nbsp;30, 2018 and 2019 and financial position as of June&nbsp;30, 2019. You should read these data together with our combined financial statements and related notes included elsewhere in this prospectus and the sections titled &#147;Selected
Combined Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; Our historical results for any prior period are not necessarily indicative of our future results. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Year
Ended<BR>December&nbsp;31,</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2018</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Six Months Ended</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(in thousands, except share and per share data)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2018</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Combined Statements of Operations Data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Operating expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">3,201</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="white-space:nowrap">In-process</FONT> research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">78,897</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">General and administrative (includes related party amounts of $321, $124 and $18, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,205</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2,142</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,225</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">84,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Loss from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,225</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(84,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Other income (expense):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Interest income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">101</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Interest expense (includes related party amounts of $(13), $(4) and $(82), respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,148</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Change in fair value of warrant liabilities (includes related party amounts of $0, $0 and $(1,277), respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,284</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Change in fair value of convertible promissory notes (includes related party amounts of $(50), $(4) and $(502),
respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(2,442</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total other income (expense)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(63</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(4,773</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(514</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(89,013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net loss per share, basic and diluted</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(0.21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(0.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(13.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Weighted-average shares of common stock outstanding, basic and diluted</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6,051,675</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">5,331,270</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6,640,394</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Pro forma net loss per share, basic and diluted (unaudited)</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(0.20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(9.85</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Pro forma weighted-average shares of common stock outstanding, basic and diluted
(unaudited)</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6,098,429</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">8,578,296</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">See Note&nbsp;1 to our combined financial statements included elsewhere in this prospectus for an explanation of the method used to calculate the
historical and pro forma net loss per share, basic and diluted, and the number of shares used in the computation of the per share amounts. </FONT></P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">11 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1pt solid #000000;BORDER-LEFT:1pt solid #000000;BORDER-RIGHT:1pt solid #000000;BORDER-TOP:1pt solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>As of</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>June&nbsp;30, 2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Actual</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Pro</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Forma<SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Pro
Forma<BR>As<BR>Adjusted<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Combined Balance Sheet Data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">82,917</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">82,917</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">249,098</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Working capital
(deficit)</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(60,210</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">82,520</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">249,038</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">84,879</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">84,879</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">250,723</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Convertible promissory notes payable at fair value (including accrued interest)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">93,559</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Warrant liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">49,597</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">426</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">426</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Long-term debt, including final payment fee and net of debt discount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">24,512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">24,512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">24,512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(90,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(90,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(90,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total stockholders&#146; equity (deficit)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(84,385</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">58,345</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">224,526</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">Gives effect to the (i)&nbsp;automatic conversion of the May 2019 Notes into an aggregate of 6,107,918 shares of our common stock immediately prior to
the closing of this offering (based on the initial public offering price of $19.00 per share and assuming the conversion occurs on October 29, 2019), and (ii)&nbsp;the reclassification of the Takeda Warrant to stockholders&#146; equity (deficit).
</FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">Gives effect to (i)&nbsp;the pro forma adjustments set forth in footnote (1)&nbsp;above, and (ii)&nbsp;the issuance and sale of 9,563,157 shares of our
common stock in this offering at the initial public offering price of $19.00 per share, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">We define working capital (deficit) as current assets less current liabilities. See our combined financial statements included elsewhere in this
prospectus for further details regarding our current assets and current liabilities. </FONT></P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">12 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_2"></A>RISK FACTORS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Investing in our common stock involves a high degree of risk. You should consider carefully the risks and uncertainties described below,
together with all of the other information in this prospectus, including our combined financial statements and related notes included elsewhere in this prospectus and the section titled &#147;Management&#146;s Discussion and Analysis of Financial
Condition and Results of Operations&#148; before making an investment decision. If any of the following risks are realized, our business, financial condition, results of operations and prospects could be materially and adversely affected. In that
event, the trading price of our common stock could decline and you could lose part or all of your investment. </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Risks Related to Our Limited
Operating History, Financial Position and Capital Requirements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We have a limited operating history, have incurred significant operating losses
since our inception and expect to incur significant losses for the foreseeable future. We may never generate any revenue or become profitable or, if we achieve profitability, we may not be able to sustain it. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We are a late clinical-stage
biopharmaceutical company with a limited operating history upon which you can evaluate our business and prospects. We commenced operations in 2018, and to date, we have focused primarily on organizing and staffing our company, business planning,
raising capital, <FONT STYLE="white-space:nowrap">in-licensing</FONT> our initial product candidate, vonoprazan, meeting with regulatory authorities, and preparing for our planned Phase 3 clinical trials of vonoprazan. As a company, we have not yet
demonstrated an ability to successfully complete any clinical trials, obtain regulatory approvals, manufacture a commercial scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for
successful product commercialization. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing biopharmaceutical products.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have incurred significant operating losses since our inception. If vonoprazan is not successfully developed and approved in the
United States, Europe and/or Canada, we may never generate any revenue. Our net losses were $1.3&nbsp;million and $89.0&nbsp;million for the year ended December&nbsp;31, 2018 and the six months ended June&nbsp;30, 2019, respectively. As of
June&nbsp;30, 2019, we had an accumulated deficit of $90.3&nbsp;million. Substantially all of our losses have resulted from expenses incurred in connection with <FONT STYLE="white-space:nowrap">in-licensing</FONT> and developing vonoprazan and from
general and administrative costs associated with our operations. Vonoprazan and any future product candidates will require substantial additional development time and resources before we will be able to apply for or receive regulatory approvals and
begin generating revenue from product sales. We expect to continue to incur losses for the foreseeable future, and we anticipate these losses will increase substantially as we continue our development of, seek regulatory approval for, and
potentially commercialize vonoprazan and seek to identify, assess, acquire, <FONT STYLE="white-space:nowrap">in-license,</FONT> or develop additional product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">To become and remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities,
including completing clinical trials and preclinical studies of vonoprazan and any future product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing and selling any products. We are only in the
preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability. In addition, we have not yet demonstrated an ability to
successfully overcome many of the risks and uncertainties frequently encountered by </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">13 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
companies in new and rapidly evolving fields, particularly in the biopharmaceutical industry. Because of the numerous risks and uncertainties associated with biopharmaceutical product
development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a
quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, continue our product development efforts, diversify our product
candidate pipeline or even continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We will require substantial additional financing to achieve our goals, and a failure to obtain this necessary capital when needed on acceptable terms, or at
all, could force us to delay, limit, reduce or terminate our product development programs, commercialization efforts or other operations. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The development of biopharmaceutical product candidates is capital-intensive. We expect our expenses to increase in connection with our ongoing activities, particularly as we conduct our planned Phase 3 clinical
trials of vonoprazan and seek regulatory approval for vonoprazan. In addition, if vonoprazan receives approval and is commercialized, we will be required to make milestone and royalty payments to Takeda, from whom we have <FONT
STYLE="white-space:nowrap">in-licensed</FONT> the rights to develop and commercialize vonoprazan in the United States, Europe, and Canada pursuant to the license agreement, dated May&nbsp;7, 2019, between us and Takeda, or the Takeda License.
Furthermore, if and to the extent we seek to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> additional product candidates in the future, we may be required to make significant upfront payments, milestone payments, and/or licensing
payments. If we obtain regulatory approval for vonoprazan or any future product candidate, we also expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. Because the outcome of any
clinical trial is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of vonoprazan or any future product candidate. Furthermore, following the completion of
this offering, we expect to incur additional costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when
needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">We believe that the net proceeds from this offering, together with our existing cash and cash equivalents, will enable us to fund our operations for at least the next 24&nbsp;months. In particular, we expect that
the net proceeds from this offering will allow us to complete our planned Phase&nbsp;3 clinical trials of vonoprazan in the treatment of erosive esophagitis and <I>H. pylori</I> infection. We have based these estimates on assumptions that may prove
to be wrong, and we could use our capital resources sooner than we currently expect. Our operating plans and other demands on our cash resources may change as a result of many factors currently unknown to us, and we may need to seek additional funds
sooner than planned, through public or private equity or debt financings or other capital sources, including potentially collaborations, licenses and other similar arrangements. In addition, we may seek additional capital due to favorable market
conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Attempting to secure additional financing may divert our management from our <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to develop vonoprazan or any future product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Our future capital requirements will depend on many factors, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the initiation, type, number, scope, results, costs and timing of, our clinical trials of vonoprazan, and preclinical studies or clinical trials of other
potential product candidates we may choose to pursue in the future, including feedback received from regulatory authorities; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">14 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the costs and timing of manufacturing for vonoprazan or any future product candidates, including commercial scale manufacturing if any product candidate is
approved; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the costs, timing and outcome of regulatory review of vonoprazan or any future product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company, including enhanced internal controls
over financial reporting; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the costs associated with hiring additional personnel and consultants as our business grows, including additional executive officers, clinical development
personnel and commercial personnel; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the timing and amount of the milestone or other payments we must make to Takeda and any future licensors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the costs and timing of establishing or securing sales and marketing capabilities if vonoprazan or any future product candidate is approved;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any
approved products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">patients&#146; willingness to pay <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> for any approved products in the
absence of coverage and/or adequate reimbursement from third-party payors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the costs associated with any products or technologies that we may <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Conducting clinical trials and preclinical studies is a time consuming, expensive, and uncertain process that takes years to complete, and we may
never generate the necessary data or results required to obtain regulatory approval and achieve product sales. In addition, vonoprazan and other potential product candidates, if approved, may not achieve commercial success. Our commercial revenues,
if any, would initially be derived from sales of vonoprazan, which we do not expect to be commercially available in our licensed territories for many years, if at all. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. In addition, we may
seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Raising additional capital may cause dilution to our stockholders, including purchasers of common stock in this offering, restrict our operations or require us to relinquish rights to our technologies or
product candidates. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash
needs through equity offerings, our loan and security agreement, or the Loan Agreement, with Silicon Valley Bank, or SVB, as administrative and collateral agent, and lenders SVB and WestRiver Innovation Lending Fund VIII, L.P., or WestRiver, debt
financings, or other capital sources, including potential collaborations, licenses and other similar arrangements. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will
be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Our Loan Agreement includes, and any future debt financing and
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">15 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making
capital expenditures or declaring dividends. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If we raise funds through future collaborations, licenses and other similar arrangements,
we may have to relinquish valuable rights to our future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or that may reduce the value of our common stock. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Our management, as of December&nbsp;31, 2018, and our independent registered public accounting firm, in their report on our combined
financial statements as of and for the fiscal year ended December&nbsp;31, 2018, have concluded that there is substantial doubt as to our ability to continue as a going concern. </I></B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our audited combined financial statements for the fiscal year ended December&nbsp;31, 2018 were prepared assuming that we will continue as a going
concern. The going concern basis of presentation assumes that we will continue in operation for the foreseeable future and will be able to realize our assets and satisfy our liabilities in the normal course of business and do not include any
adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of liabilities that may result from our inability to continue as a going concern. As of December&nbsp;31, 2018, our
management concluded that, based on our expected operating losses, negative cash flows and maturities of outstanding convertible promissory notes, there is substantial doubt about our ability to continue as a going concern for the twelve months
after the date the combined financial statements were issued. Our ability to continue as a going concern is subject to our ability to obtain sufficient financing. If we cannot continue as a going concern, we may have to liquidate our assets and may
receive less than the value at which those assets are carried on our combined financial statements, and it is likely that our stockholders may lose some or all of their investment in us. After this offering, we may not raise the funding we require
such that substantial doubt about our ability to continue as a going concern continues. If we seek additional financing to fund our business activities in the future and there remains substantial doubt about our ability to continue as a going
concern, investors or other financing sources may be unwilling to provide additional funding on commercially reasonable terms or at all. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">16 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Risks Related to the Development and Regulatory Approval of Product Candidates </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We currently depend entirely on the success of vonoprazan, which is our only product candidate. If we are unable to advance vonoprazan in clinical
development, obtain regulatory approval and ultimately commercialize vonoprazan, or experience significant delays in doing so, our business will be materially harmed. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">We currently only have one product candidate, vonoprazan, which we <FONT STYLE="white-space:nowrap">in-licensed</FONT> from Takeda. Our business presently depends entirely on our ability to successfully develop,
obtain regulatory approval for, and commercialize vonoprazan in a timely manner. This may make an investment in our company riskier than similar companies that have multiple product candidates in active development that may be able to better sustain
failure of a lead product candidate. We plan to initiate two pivotal Phase 3 clinical trials in the fourth quarter of 2019 for vonoprazan: one for the treatment of erosive esophagitis, and a second for the treatment of <I>H. pylori </I>infection.
Our assumptions about vonoprazan&#146;s development and commercial potential are based in large part on the development and commercial experience of vonoprazan in Japan and other Asian countries. However, our assumptions may prove to be wrong, and
we may encounter a materially and adversely different development and commercial experience. The success of vonoprazan will depend on several factors, including the following: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">acceptance by the FDA or by comparable foreign regulatory authorities of our proposed design of the planned Phase&nbsp;3 clinical trials of vonoprazan and any
future clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">successful enrollment in clinical trials and completion of clinical trials with favorable results; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the willingness of the FDA, the European Medicines Agency, or EMA, and other comparable foreign regulatory authorities to accept the data from our planned Phase
3 clinical trials conducted in Europe and preclinical studies and clinical trials conducted outside of our licensed territories by Takeda and independent investigators as part of the basis for review and approval of vonoprazan;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">demonstrating safety and efficacy to the satisfaction of applicable regulatory authorities; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the outcome, timing and cost of meeting regulatory requirements established by the FDA, EMA, and other comparable foreign regulatory authorities;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">receipt of marketing approvals from applicable regulatory authorities, including one or more new drug applications, or NDAs, from the FDA and maintaining such
approvals; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">making arrangements with Takeda or any future third-party manufacturers for, or establishing, commercial manufacturing capabilities and receiving/importing
commercial supplies approved by FDA and other regulators from Takeda or any future third-party manufacturer; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">establishing sales, marketing and distribution capabilities and commercializing vonoprazan, if approved, whether alone or in collaboration with others;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">establishment and maintenance of patent and trade secret protection or regulatory exclusivity for vonoprazan; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">maintaining an acceptable safety profile of vonoprazan following approval; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">maintaining and growing an organization of people who can develop and, if approved, commercialize, market, and sell vonoprazan to physicians, patients,
healthcare payors, and others in the medical community. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The success of our business, including our ability to finance
our company and generate any revenue in the future, will primarily depend on the successful development, regulatory approval and commercialization of vonoprazan, which may never occur. We have not yet succeeded and may not succeed in demonstrating
efficacy and safety for vonoprazan in clinical trials or in obtaining marketing approval thereafter. It may be several years, if at all, before we have demonstrated the safety and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">17 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
efficacy of a treatment sufficient to warrant approval for commercialization. If we are unable to develop, or obtain regulatory approval for, or, if approved, successfully commercialize
vonoprazan, we may not be able to generate sufficient revenue to continue our business. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Clinical drug development involves a lengthy and
expensive process with an uncertain outcome, and the results of prior clinical trials and other investigator-initiated clinical trials of vonoprazan are not necessarily predictive of our future results. Vonoprazan may not have favorable results in
our clinical trials, or receive regulatory approval on a timely basis, if at all. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Clinical drug development is expensive and can
take many years to complete, and its outcome is inherently uncertain. Our clinical trials may not be conducted as planned or completed on schedule, if at all, and failure can occur at any time during the preclinical study or clinical trial process.
Despite promising preclinical or clinical results, any product candidate can unexpectedly fail at any stage of preclinical or clinical development. The historical failure rate for product candidates in our industry is high. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The results from clinical trials or preclinical studies of a product candidate may not predict the results of later clinical trials of the product
candidate, and interim results of a clinical trial are not necessarily indicative of final results. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy characteristics despite having progressed
through preclinical studies and initial clinical trials. In particular, while vonoprazan has been studied in an extensive clinical program by Takeda, including 17 Phase 3 clinical trials, we do not know how vonoprazan will perform in future clinical
trials, including as a result of differences between the clinical trials conducted to date by Takeda or other third parties and our planned Phase 3 clinical trial designs. These differences include, among other things: including higher doses of
antibiotics and longer duration of treatment and inclusion of a dual therapy arm in our planned Phase 3 clinical trial for the treatment of <I>H. pylori</I> infection, and conducting a single Phase 3 clinical trial for both the healing and
maintenance of erosive esophagitis, rather than two separate trials. Further, the large majority of the clinical development of vonoprazan was conducted in Asian subjects, who naturally have differences in height, weight, drug metabolism, and
potentially, acid-secretory capacity from Western populations. Although there are data across two Phase 1 clinical trials in healthy volunteers showing that the vonoprazan pharmacokinetic and pharmacodynamic profile is similar in Japanese and <FONT
STYLE="white-space:nowrap">non-Japanese</FONT> subjects, our clinical trials of vonoprazan in a broader population comprised of patients in the United States and Europe may not yield the same results as prior clinical trials. Additionally, Western
patients may be more likely to deviate from clinical trial protocols or drop out of clinical trials than Japanese patients, which may negatively impact the results of our clinical trials. Further, in our planned Phase 3 clinical trial for the
treatment of <I>H. pylori</I> infection, the vonoprazan dual therapy arm will not be double-blinded because patients in this arm will be administered amoxicillin three times daily, versus twice daily for the triple therapy regimens. Both triple
therapy regimens will be double-blinded. The inability to double-blind the dual therapy arm may impact the results of this trial and how regulatory agencies or healthcare payors interpret such results. For example, the EMA has noted that it expects
additional analyses of treatment compliance and drop-out rates in the dual therapy arm because it will not be double-blinded. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">A number
of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after the product candidate achieved promising results in earlier clinical trials. The results of our planned trials may
not be comparable to those achieved previously, whether as a result of differences in trial design, patient population or otherwise. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Further, the FDA, the EMA, or other comparable foreign regulatory authorities may not view the data from clinical trials conducted by Takeda and
other third parties discussed above, together with our single planned Phase&nbsp;3 clinical trial in each of erosive esophagitis and <I>H. pylori</I> infection, as sufficient to support the regulatory approval of vonoprazan for the treatment of
erosive esophagitis or <I>H.&nbsp;pylori</I> infection. The FDA, EMA, or other comparable foreign regulatory authorities may also disagree with the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">18 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
adequacy of our trial designs, including as a result of the differences between our designs and those of Takeda&#146;s Phase&nbsp;3 clinical trials discussed above. As a result, we could be
required to conduct additional clinical trials prior to seeking and obtaining regulatory approval and our planned development timeline could materially change. In addition, in July 2019, we received scientific advice from the EMA on our planned
Phase&nbsp;3 clinical trial of vonoprazan in the healing and maintenance of healing of erosive esophagitis. For the healing phase of the study, the EMA recommended that we include an endoscopy to assess healing at Week&nbsp;4 in addition to the
planned endoscopies at Week&nbsp;2 and Week&nbsp;8 because the summary of product characteristics for lansoprazole suggests four weeks of treatment to assess healing in erosive esophagitis. We have decided not to incorporate this change into the
study design given the additional burden on study subjects to return for a third endoscopy in an eight-week period. This decision may impact the future summary of product characteristics for vonoprazan or may cause the EMA to require us to conduct
additional clinical trials for vonoprazan to support marketing approval. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, Takeda, a third party over which we have no
control, has the right to develop and commercialize vonoprazan outside of the United States, Europe, and Canada. Takeda has marketing approval for vonoprazan in certain countries in Asia and Latin America, and Takeda has ongoing clinical trials of
vonoprazan in certain indications that we are also pursuing. If such ongoing trials fail to meet their primary endpoints, have serious adverse events or encounter other problems, the development potential of vonoprazan could be materially and
adversely affected. In addition, if serious adverse events or other problems occur with patients using vonoprazan marketed outside of our licensed territories, or if the results of ongoing or future clinical trials of vonoprazan conducted by Takeda
or others generate negative results or results that conflict with the results of our clinical trials, the FDA, EMA, or other regulatory authorities may delay, limit, or deny approval of vonoprazan, require us to conduct additional clinical trials as
a condition to marketing approval, or withdraw their approval of vonoprazan or otherwise restrict our ability to market and sell vonoprazan, if approved. In addition, treating physicians may be less willing to prescribe vonoprazan due to concerns
over such trial results or adverse events, which would limit our ability to commercialize vonoprazan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">For the foregoing reasons, our
planned clinical trials may not be successful. Any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of vonoprazan or any future product candidates in those and
other indications, which could have a material adverse effect on our business, financial condition and results of operations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Any difficulties or
delays in the commencement or completion, or termination or suspension, of our planned clinical trials could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Before obtaining marketing approval from regulatory authorities for the sale of vonoprazan or any future product candidates, we
must conduct extensive clinical trials to demonstrate the safety and efficacy of vonoprazan or any future product candidates in humans. In August 2019, we submitted three separate INDs to the FDA for vonoprazan: one for erosive esophagitis; a second
for dual therapy treatment of <I>H. pylori</I> infection; and a third for triple therapy treatment of <I>H. pylori </I>infection. These three INDs were accepted by the FDA in September 2019. We plan to initiate two pivotal Phase&nbsp;3 clinical
trials in the fourth quarter of 2019 for vonoprazan: one for the treatment of erosive esophagitis and a second for the treatment of <I>H. pylori</I> infection. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">We will have to submit the results of preclinical studies to the FDA along with other information, including information about product candidate chemistry, manufacturing and controls and our proposed clinical trial
protocol, as part of an IND for any future product candidates that we advance to clinical </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">19 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
development, and we may also be required to submit regulatory filings to foreign regulatory authorities to the extent we initiate clinical trials outside of the United States. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We do not know whether our planned trials will begin on time or be completed on schedule, if at all. The commencement and completion of clinical
trials can be delayed for a number of reasons, including delays related to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the FDA, EMA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical trials and reaching consensus among the
FDA and EMA over the design of the same clinical trial; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">any failure or delay in obtaining regulatory authorizations to commence a trial; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">any failure or delay in reaching an agreement with contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to
extensive negotiation and may vary significantly among different CROs and trial sites; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">institutional review boards, or IRBs, refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of additional
subjects, or withdrawing their approval of the trial; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">changes to clinical trial protocols; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">clinical sites deviating from trial protocols or dropping out of a trial; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">manufacturing or obtaining sufficient quantities of vonoprazan and any future product candidates and obtaining sufficient quantities of lansoprazole, which will
be used in both of our planned Phase 3 clinical trials, and/or antibiotics for use in clinical trials, including amoxicillin and clarithromycin, which will be used in our planned Phase 3 clinical trial of vonoprazan for the treatment of <I>H.
pylori</I> infection; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">subjects failing to enroll or remain in our trials at the rate we expect, or failing to return for post- treatment
<FONT STYLE="white-space:nowrap">follow-up;</FONT> </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">subjects choosing an alternative treatment for the indication for which we are developing vonoprazan and any future product candidates, or participating in
competing clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">lack of adequate funding to continue the clinical trial; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">subjects experiencing severe or unexpected drug-related adverse effects; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">occurrence of serious adverse events in trials of the same class of agents conducted by other companies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a facility manufacturing vonoprazan or any future product candidates or any of their components being ordered by the FDA or comparable foreign regulatory
authorities to temporarily or permanently shut down due to violations of current good manufacturing, or cGMP, regulations or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">any changes to our manufacturing process that may be necessary or desired; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated
schedule or consistent with the clinical trial protocol, good clinical practices, or GCP, or other regulatory requirements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">third-party contractors not performing data collection or analysis in a timely or accurate manner; or </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">20 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations of
regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We could also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being
conducted or by the FDA or comparable foreign regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements
or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory authorities, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug,
changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to
comply with these changes. Amendments may require us to resubmit our clinical trial protocols to IRBs for reexamination, which may impact the costs, timing, or successful completion of a clinical trial. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Further, conducting clinical trials in foreign countries, as we may do for vonoprazan or any future product candidates, presents additional risks
that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional
administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Moreover, principal investigators for our clinical trials currently serve and may continue to serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such
services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authority may conclude that a financial relationship
between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the clinical trial. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at
the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the
case may be, and may ultimately lead to the denial of marketing approval of vonoprazan or any future product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If we
experience delays in the completion of, or termination of, any clinical trial of vonoprazan or any future product candidates, the commercial prospects of vonoprazan and any future product candidates will be harmed, and our ability to generate
product revenues from any of these product candidates will be delayed. Moreover, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and approval process and jeopardize our ability to
commence product sales and generate revenues. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, many of the factors that cause, or lead to, termination or suspension of, or
a delay in the commencement or completion of, clinical trials may also ultimately lead to the denial of regulatory approval of a product candidate. We may make formulation or manufacturing changes to vonoprazan or any future product candidates, in
which case we may need to conduct additional preclinical studies to bridge our modified product candidates to earlier versions. Any delays to our clinical trials that occur as a result could shorten any period during which we may have the exclusive
right to commercialize vonoprazan or any future product candidates and our competitors may be able to bring products to market before we do, and the commercial viability of vonoprazan and any future product candidates could be significantly reduced.
Any of these occurrences may harm our business, financial condition, and prospects significantly. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">21 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We may find it difficult to enroll patients in our clinical trials. If we encounter difficulties enrolling
patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We may
not be able to initiate or continue clinical trials for vonoprazan or any future product candidates if we are unable to identify and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar
regulatory authorities outside the United States. Subject enrollment, a significant factor in the timing of clinical trials, is affected by many factors including the size and nature of the patient population, the proximity of patients to clinical
sites, the eligibility and exclusion criteria for the trial, the design of the clinical trial, the risk that enrolled patients will not complete a clinical trial, our ability to recruit clinical trial investigators with the appropriate competencies
and experience, competing clinical trials and clinicians&#146; and patients&#146; perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new drugs that may
be approved for the indications we are investigating as well as any drugs under development. We will be required to identify and enroll a sufficient number of patients for each of our clinical trials. Potential patients for any planned clinical
trials may not be adequately diagnosed or identified with the diseases which we are targeting or may not meet the entry criteria for such trials. For example, a key secondary analysis in our planned Phase 3 clinical trial for the treatment of <I>H.
pylori </I>infection is the eradication rate in clarithromycin-resistant patients. However, because the process of assessing antibiotic resistance to <I>H. pylori</I> takes several weeks, we believe it is not practical to use resistance as an
enrollment criteria in our clinical trial. Therefore, the percentage of clarithromycin-resistant patients enrolled in this clinical trial is unpredictable and may affect the results of the trial. We also may encounter difficulties in identifying and
enrolling patients with a stage of disease appropriate for our planned clinical trials and monitoring such patients adequately during and after treatment. For example, in our Phase 3 clinical trial of vonoprazan in erosive esophagitis, we intend for
30% of the patients to have Los Angeles Class&nbsp;C or D erosive esophagitis, which are the most severe forms of erosive esophagitis and are estimated to only represent approximately 10 to 20% of erosive esophagitis patients. We may not be able to
initiate or continue clinical trials if we are unable to locate a sufficient number of eligible patients to participate in the clinical trials required by the FDA or comparable foreign regulatory authorities. In addition, the process of finding and
diagnosing patients may prove costly as these patients are required to undergo an endoscopy before being diagnosed as having Los Angeles Class&nbsp;C or D erosive esophagitis. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The timing of our clinical trials depends, in part, on the speed at which we can recruit patients to participate in our trials, as well as completion of required <FONT STYLE="white-space:nowrap">follow-up</FONT>
periods. The eligibility criteria of our clinical trials, once established, will further limit the pool of available trial participants. If patients are unwilling to participate in our trials for any reason, including the existence of concurrent
clinical trials for similar patient populations, if they are unwilling to enroll in a clinical trial with a placebo-controlled design or the availability of approved therapies, or we otherwise have difficulty enrolling a sufficient number of
patients, the timeline for recruiting patients, conducting trials and obtaining regulatory approval of vonoprazan and any future product candidates may be delayed. Our inability to enroll a sufficient number of patients for any of our future
clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our assumptions
used in determining expected clinical trial timelines may not be correct, and we may experience delays in enrollment, which would result in the delay of completion of such trials beyond our expected timelines. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">22 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Use of vonoprazan or any future product candidates could be associated with side effects, adverse events or
other properties or safety risks, which could delay or preclude approval, cause us to suspend or discontinue clinical trials, abandon a product candidate, limit the commercial profile of an approved label or result in other significant negative
consequences that could severely harm our business, prospects, operating results and financial condition. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As is the case with
pharmaceuticals generally, it is likely that there may be side effects and adverse events associated with vonoprazan&#146;s or any future product candidates&#146; use. Results of our clinical trials could reveal a high and unacceptable severity and
prevalence of side effects or unexpected characteristics. Undesirable side effects caused by vonoprazan and any future product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more
restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory authorities. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or
result in potential product liability claims. Any of these occurrences may harm our business, financial condition, and prospects significantly. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Moreover, if vonoprazan or any other future product candidates are associated with undesirable side effects in clinical trials or have characteristics that are unexpected, we may elect to abandon their development
or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial
expectations for the product candidate, if approved. We may also be required to modify our study plans based on findings in our clinical trials. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">As of December 2018, 6,683 subjects have been exposed to vonoprazan in completed and ongoing Phase 1 to 3 clinical trials. The doses studied have ranged from 1 to 120 mg with durations up to one year. The most
commonly reported AEs in the clinical development program for vonoprazan, as reflected in the Japanese prescribing information published by Japan&#146;s Pharmaceutical and Medical Devices Agency, or PMDA, were diarrhea, constipation, nausea,
elevated liver enzymes, rash, and eosinophilia. All such events had an incidence rate of less than 5.0% other than diarrhea in the treatment of <I>H. pylori</I> which had an incidence rate of 10.6% in combination with antibiotics. No dose-related
increase in TEAEs or SAEs was observed. The safety profile of vonoprazan and incidence of TEAEs, drug-related TEAEs, and TEAEs leading to drug discontinuation were similar between vonoprazan and lansoprazole across studies. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Certain earlier generation <FONT STYLE="white-space:nowrap">P-CABs</FONT> previously under development by other companies may have been
discontinued in part due to their hepatic safety profile. These hepatic safety concerns may be compound-specific and not generalizable to the <FONT STYLE="white-space:nowrap">P-CAB</FONT> class. Vonoprazan has had a similar hepatic safety profile to
lansoprazole across all clinical studies conducted by Takeda, in which 1.0% of subjects treated with vonoprazan 10 mg or 20 mg and 0.8% of subjects treated with lansoprazole 15 mg or 30&nbsp;mg had ALT or AST elevations greater than three times the
upper limit of normal or bilirubin elevations greater than two times the upper limit of normal. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The most recent post-marketing safety
report from December 2018 includes an estimated 23&nbsp;million patients who have received vonoprazan in Japan since launch. Based on the post-marketing experience, the clinically significant adverse reactions section of the Japanese prescribing
information for vonoprazan was updated to include skin reactions such as toxic epidermal necrolysis, Steven-Johnson syndrome, and erythema multiforme. The incidence of these skin reactions was considered extremely rare (less than 1 in 100,000
patients) and a causal relationship to vonoprazan could not be ruled out. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Serious hepatic adverse events have also been observed among
patients exposed to vonoprazan in Japan in the post-marketing setting. These cases were typically confounded by comorbidities or </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">23 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
other concomitant medications and are believed to be idiosyncratic reactions. The incidence of these events was considered extremely rare (less than 1 in 100,000 patients). The post-marketing
safety data, including the December 2018 post-marketing safety report and the reported hepatic safety events, have been submitted to the PMDA. To date, there have been no changes to the Japan prescribing information related to hepatic safety. We may
also observe hepatic-related events in our clinical trials. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">It is possible that as we test vonoprazan and any future product candidates
in our clinical trials, or as the use of vonoprazan and any future product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were observed in earlier trials, as
well as conditions that did not occur or went undetected in previous trials, will be reported by patients. If such side effects become known later in development or upon approval, if any, such findings may harm our business, financial condition and
prospects significantly. Further, if a serious safety issue is identified in connection with use of vonoprazan commercially or in third-party clinical trials in Asia or elsewhere, such issues may adversely affect the development potential of
vonoprazan or result in regulatory authorities restricting our ability to develop vonoprazan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, if vonoprazan or any future
product candidate receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">regulatory authorities may withdraw, suspend or limit approvals of such product, or seek an injunction against its manufacturer; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">we may be required to recall a product or change the way such product is administered to patients; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">regulatory authorities may require additional warnings on the label, such as a &#147;black box&#148; warning or a contraindication; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">we may be required to implement a Risk Evaluation and Mitigation Strategy, or REMS, or create a medication guide outlining the risks of such side effects for
distribution to patients; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">we may be required to change the way a product is distributed or administered, conduct additional clinical trials or change the labeling of a product or be
required to conduct additional post-marketing studies or surveillance; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">we could be sued and held liable for harm caused to patients; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">sales of the product may decrease significantly or the product could become less competitive; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">our reputation may suffer. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could
significantly harm our business, results of operations and prospects. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>As a company, we have never conducted a clinical trial or submitted an NDA
or comparable foreign regulatory filing, and may be unable to do so for vonoprazan or any future product candidates. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We are
early in our development efforts for vonoprazan, and we will need to successfully complete pivotal clinical trials in order to obtain FDA, EMA or comparable foreign regulatory approval to market vonoprazan or any future product candidates. Carrying
out late-stage clinical trials and the submission of a successful new drug application, or NDA, is a complicated process. As an </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">24 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
organization, we plan to commence pivotal Phase 3 clinical trials of vonoprazan in erosive esophagitis and <I>H. pylori </I>infection<I> </I>in the fourth quarter of 2019. We have not yet
conducted any clinical trials for vonoprazan or any other product candidates and have limited experience as a company in preparing, submitting and prosecuting regulatory filings. As a company, we have not previously submitted an NDA, whether for one
or multiple indications, or other comparable foreign regulatory submission for any product candidate. In addition, we have had limited interactions with the FDA and cannot be certain how many clinical trials of vonoprazan or any other product
candidates will be required or how such trials should be designed. Consequently, we may be unable to successfully and efficiently execute and complete necessary clinical trials in a way that leads to regulatory submission and approval of vonoprazan
or any future product candidates. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop. Failure to commence or complete, or delays in, our
planned clinical trials, could prevent us from or delay us in submitting NDAs for and commercializing vonoprazan or any future product candidates. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Vonoprazan and any future product candidates are subject to extensive regulation and compliance obligations, which is costly and time consuming, and such
regulation may cause unanticipated delays or prevent the receipt of the required approvals to commercialize vonoprazan and any future product candidates. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The clinical development, manufacturing, labeling, storage, record-keeping, advertising, promotion, import, export, marketing and distribution of vonoprazan and any future product candidates are subject to
extensive regulation by the FDA in the United States, the EMA in the European Union and by comparable foreign regulatory authorities in other foreign markets. In the United States, we are not permitted to market vonoprazan and any future product
candidates until we receive regulatory approval from the FDA and in Europe, we are not permitted to market vonoprazan and any future product candidates until we receive regulatory approval from the EMA. The process of obtaining regulatory approval
is expensive, often takes many years following the commencement of clinical trials and can vary substantially based upon the type, complexity and novelty of the product candidates involved, as well as the target indications and patient population.
The ability of the FDA and EMA to review and approve new products can be affected by a variety of factors, including government budget and funding levels and the ability to hire and retain key personnel. In addition, approval policies or regulations
may change, and the FDA and EMA have substantial discretion in the drug approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. Despite the time and expense invested in clinical development
of product candidates, regulatory approval is never guaranteed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Prior to obtaining approval to commercialize a product candidate in the
United States or internationally, we must demonstrate with substantial evidence from adequate and well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidates are safe
and effective for their intended uses. Results from nonclinical studies and clinical trials can be interpreted in different ways. Even if we believe the nonclinical or clinical data for vonoprazan and any future product candidates are promising,
such data may not be sufficient to support approval by the FDA and comparable foreign regulatory authorities. The FDA or comparable foreign regulatory authorities, as the case may be, may also require us to conduct additional preclinical studies or
clinical trials for vonoprazan and any future product candidates either prior to or post-approval, or may object to elements of our clinical development program. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The FDA, EMA or other comparable foreign regulatory authorities can delay, limit or deny approval of a product candidate for many reasons, including: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">such authorities may disagree with the design or implementation of our clinical trials; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">25 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">negative or ambiguous results from our clinical trials or results may not meet the level of statistical significance required by the FDA, EMA, or other
comparable foreign regulatory agencies for approval; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">serious and unexpected drug-related side effects may be experienced by participants in our clinical trials or in clinical trials conducted by Takeda or others
outside of our licensed territories, or by patients using vonoprazan or drugs similar to vonoprazan; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the population studied in the clinical trial may not be sufficiently broad or representative to assure safety in the full population for which we seek approval;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">such authorities may not accept clinical data from trials which are conducted at clinical facilities or in countries where the standard of care is potentially
different from that of the United States; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">we may be unable to demonstrate to the satisfaction of such authorities that a product candidate is safe and effective for its proposed indication and that a
product candidate&#146;s clinical and other benefits outweigh its safety risks; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">such authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">such authorities may not agree that the data collected from clinical trials of vonoprazan, including data collected from clinical trials conducted by Takeda and
independent investigators outside of our licensed territories, and any future product candidates are acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval, and such authorities may impose
requirements for additional preclinical studies or clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">such authorities may disagree regarding the formulation, labeling and/or the specifications of vonoprazan and any future product candidates;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">approval may be granted only for indications that are significantly more limited than what we apply for and/or with other significant restrictions on
distribution and use; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">such authorities may find deficiencies in the manufacturing processes or facilities of Takeda or any future third-party manufacturers with which we contract for
clinical and commercial supplies; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">regulations of such authorities may significantly change in a manner rendering our or any of our potential future collaborators&#146; clinical data insufficient
for approval; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">such authorities may not accept a submission due to, among other reasons, the content or formatting of the submission. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">With respect to foreign markets, approval procedures vary among countries and, in addition to the foregoing risks, may involve additional product
testing, administrative review periods and agreements with pricing authorities. In addition, events raising questions about the safety of certain marketed pharmaceuticals may result in increased cautiousness by the FDA, EMA, and other comparable
foreign regulatory authorities in reviewing new drugs based on safety, efficacy, or other regulatory considerations and may result in significant delays in obtaining regulatory approvals. Any delay in obtaining, or inability to obtain, applicable
regulatory approvals would prevent us or any of our potential future collaborators from commercializing vonoprazan and any future product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Of the large number of drugs in development, only a small percentage successfully complete the FDA, EMA or foreign regulatory approval processes and are commercialized. The lengthy approval process as well as the
unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market vonoprazan and any future product candidates, which would significantly harm our business, financial condition, results of operations
and prospects. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">26 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Even if we eventually complete clinical trials and receive approval of an NDA or foreign
marketing application for vonoprazan and any future product candidates, the FDA, EMA or other comparable foreign regulatory authority may grant approval contingent on the performance of costly additional clinical trials, including confirmatory Phase
3 clinical trials, Phase 4 clinical trials, and/or the implementation of a REMS, which may be required to ensure safe use of the drug after approval. The FDA, EMA or other comparable foreign regulatory authority also may approve a product candidate
for a more limited indication or patient population than we originally requested, and the FDA, EMA or other comparable foreign regulatory authority may not approve the labeling that we believe is necessary or desirable for the successful
commercialization of a product. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of that product candidate and would materially adversely impact our business and prospects.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Designation of vonoprazan as a QIDP, and the potential to receive priority review or fast track designations, may not actually lead to a faster
development or regulatory review, and would not assure FDA approval of vonoprazan or any future product candidates which may receive such designations. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Vonoprazan has been designated as a QIDP by the FDA for the treatment of <I>H. pylori</I> infection in combination with both amoxicillin and clarithromycin, and with amoxicillin alone, respectively, and we may seek
QIDP designation for future product candidates. A QIDP is an antibacterial or antifungal drug for human use intended to treat serious or life-threatening infections, including those caused by either (1)&nbsp;an antibacterial or antifungal resistant
pathogen, including novel or emerging infectious pathogens, or (2)&nbsp;a so-called &#147;qualifying pathogen&#148; found on a list of potentially dangerous, drug-resistant organisms to be established and maintained by the FDA under the Generating
Antibiotic Incentives Now, or GAIN Act. The benefits of QIDP designation include potential eligibility for priority review and fast track designation, and an extension by an additional five years of any non-patent exclusivity period awarded, such as
a five-year exclusivity period awarded for a new chemical entity. This extension is in addition to any pediatric exclusivity extension that may be awarded. Receipt of QIDP status also does not assure ultimate approval by the FDA or related GAIN Act
exclusivity benefits. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">While QIDP designation makes vonoprazan potentially eligible for priority review and fast track designation, the
FDA has broad discretion, so even if we believe vonoprazan or any future product candidate is eligible for fast track designation or priority review status, the FDA could decide not to grant it. The fast track program is intended to expedite or
facilitate the process for reviewing new drug candidates that meet certain criteria. Specifically, new drugs are eligible for fast track designation if they are intended, alone or in combination with one or more drugs, to treat a serious or
life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the drug candidate and the specific indication for which it is
being studied. With a fast track drug candidate, the FDA may consider for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA,
the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. Priority review means the FDA&#146;s goal is to take action on
an application within 6 months (compared to 10&nbsp;months under standard review). The FDA automatically grants priority review to the first application or efficacy supplement submitted for a specific drug and indication that has received the QIDP
designation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Obtaining a QIDP designation, priority review, or fast track designation does not change the standards for product
approval, but may expedite the development or approval process. Even though the FDA has granted QIDP designation for vonoprazan, and even if vonoprazan receives priority review or fast track designations, it may not actually result in faster
clinical development or regulatory review or approval. Furthermore, QIDP designation, priority review, and fast track designation do not increase the likelihood that vonoprazan will receive marketing approval in the United States. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">27 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We may not be successful in our efforts to expand our pipeline by identifying additional indications and
formulations for which to investigate vonoprazan in the future. We may expend our limited resources to pursue a particular indication or formulation for vonoprazan and fail to capitalize on product candidates, indications or formulations that may be
more profitable or for which there is a greater likelihood of success. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Because we have limited financial and managerial
resources, we focus on specific indications and formulations for vonoprazan. As a result, we may fail to generate additional clinical development opportunities for vonoprazan for a number of reasons, including, vonoprazan may in certain indications,
on further study, be shown to have harmful side effects, limited to no efficacy, or other characteristics that suggest it is unlikely to receive marketing approval and achieve market acceptance in such additional indications. For example, we believe
the rapid onset of action of vonoprazan may enable <FONT STYLE="white-space:nowrap">on-demand,</FONT> or as needed, use for the management of <FONT STYLE="white-space:nowrap">non-erosive</FONT> reflux disease, or NERD. However, two Phase 3 clinical
trials of vonoprazan in Japanese patients with endoscopically confirmed NERD conducted by Takeda did not demonstrate a statistically significant difference in symptom scores between vonoprazan and placebo. We believe that this result may be due to
the selection of patients with mild to moderate symptoms rather than more frequent and severe symptoms. In addition, Takeda conducted a Phase 2 clinical trial in Europe in 256 patients with NERD who were partial responders to high dose PPIs.
Patients were randomized to receive vonoprazan 20 mg, vonoprazan 40 mg, or esomeprazole 40 mg for four weeks. Neither vonoprazan dose demonstrated a benefit versus esomeprazole on the primary endpoint of the percentage of heartburn free days over
the treatment period. We believe this result may be due to patient selection. Specifically, the trial may not have adequately selected for patients with NERD and may have included patients with functional GI disorders that are unrelated to acid,
such as functional dyspepsia or functional heartburn. We may be incorrect in our beliefs regarding the results of such trials and any future clinical trials we conduct in NERD patients may not succeed for similar or other reasons, including as a
result of our design and enrollment criteria. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Furthermore, research programs to identify additional indications for vonoprazan require
substantial technical, financial and human resources. We may also pursue additional formulations and packaging for vonoprazan, such as orally disintegrating tablets and other oral dosage forms for patients with difficulty swallowing, an intravenous
formulation for <FONT STYLE="white-space:nowrap">in-hospital</FONT> applications, and <FONT STYLE="white-space:nowrap">pre-packaged</FONT> convenience packs for the treatment of <I>H. pylori </I>infection. However, we may not successfully develop
these additional formulations for chemistry-related, stability-related or other reasons. If we do not accurately evaluate the commercial potential or target market for vonoprazan or any future product candidates, we may relinquish valuable rights to
that product candidate through future collaborations, licenses and other similar arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Additionally, we may pursue additional <FONT STYLE="white-space:nowrap">in-licenses</FONT> or acquisitions of development-stage assets
or programs, which entails additional risk to us. Identifying, selecting and acquiring promising product candidates requires substantial technical, financial and human resources expertise. Efforts to do so may not result in the actual acquisition or
license of a particular product candidate, potentially resulting in a diversion of our management&#146;s time and the expenditure of our resources with no resulting benefit. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>We intend to enroll patients in Europe in both of our planned Phase 3 clinical trials. Additionally, we may conduct future clinical trials outside of the United States. However, the FDA and other comparable
foreign regulatory authorities may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">We plan to enroll patients in Europe in both of our planned Phase 3 clinical trials, and we may conduct one or more of our future clinical trials outside the United States. Although the FDA may
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">28 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
accept data from clinical trials conducted outside the United States, acceptance of this data is subject to certain conditions imposed by the FDA. For example, the FDA requires the clinical trial
to have been conducted in accordance with GCPs, and the FDA must be able to validate the data from the clinical trial through an onsite inspection if it deems such inspection necessary. In addition, when clinical trials are conducted only at sites
outside of the United States, the FDA generally does not provide advance comment on the clinical protocols for the trials, and therefore there is an additional potential risk that the FDA could determine that the study design or protocol for a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> clinical trial was inadequate, which would likely require us to conduct additional clinical trials. The FDA may not accept data from clinical trials conducted outside of the United States. If the FDA does
not accept data from our clinical trials of vonoprazan and any future product candidates, it would likely result in the need for additional clinical trials, which would be costly and time consuming and delay or permanently halt our development of
vonoprazan and any future product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Conducting clinical trials outside the United States also exposes us to additional risks,
including risks associated with: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">additional foreign regulatory requirements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">foreign exchange fluctuations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">compliance with foreign manufacturing, customs, shipment and storage requirements; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">cultural differences in medical practice and clinical research; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">diminished protection of intellectual property in some countries. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Interim, top-line and preliminary data from clinical trials that we or others announce or publish from time to time may change as more patient data become available and are subject to audit and verification
procedures that could result in material changes in the final data. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">From time to time, we or others, such as Takeda, may
publicly disclose preliminary or top-line data from clinical trials, which are based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review
of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all
data.&nbsp;As a result, the top-line results that we or others report may differ from future results of the same clinical trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully
evaluated.&nbsp;Top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data previously published. As a result, top-line data should be viewed with
caution until the final data are available. From time to time, we or others may also disclose interim data from clinical trials. Interim data from clinical trials are subject to the risk that one or more of the clinical outcomes may materially
change as patient enrollment continues and more patient data become available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or
may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the
information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate
information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">29 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
decisions, conclusions, views, activities or otherwise regarding a particular drug, drug candidate or our business. If the top-line data that we report differ from actual results, or if others,
including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, vonoprazan and any future product candidates may be harmed, which could harm our business, operating results, prospects,
or financial condition. &nbsp;</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Risks Related to Our Reliance on Third Parties </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>We rely on the Takeda License to provide us rights to develop and commercialize vonoprazan in the United States, Europe, and Canada. If the license agreement is terminated, we would lose our rights to develop
and commercialize vonoprazan. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Pursuant to the Takeda License, we have secured an exclusive license from Takeda to commercialize
vonoprazan products using specified formulations for all human therapeutic uses in the United States, Europe, and Canada, and a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license to develop and manufacture vonoprazan products anywhere in
the world (subject to Takeda&#146;s consent as to each country) for the purposes of commercializing the vonoprazan products in the United States, Europe, and Canada. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The Takeda License will continue until the expiration of the obligation to pay royalties in all countries and on all products, unless terminated earlier. We may terminate the Takeda License in its entirety without
cause upon prior written notice. We and Takeda may terminate the Takeda License in the case of the other party&#146;s insolvency or for the other party&#146;s material uncured breach. Takeda may terminate the Takeda License in its entirety if we
challenge the licensed patents, or if we assist any third party in challenging such patents. In addition, if any of the regulatory milestones or other cash payments become due under the terms of the Takeda License, we may not have sufficient funds
available to meet our obligations, which would allow Takeda to terminate the Takeda License. If the license agreement is terminated, we would lose our rights to develop and commercialize vonoprazan, which in turn would have a material adverse effect
on our business, operating results and prospects. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We intend to rely on third parties to conduct our clinical trials. Any failure by a third party
to conduct the clinical trials according to GCPs and other requirements and in a timely manner may delay or prevent our ability to seek or obtain regulatory approval for or commercialize vonoprazan and any future product candidates.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We will be dependent on third parties to conduct our preclinical and clinical trials, including our planned Phase 3 clinical
trials of vonoprazan. Specifically, we intend to use and rely on, medical institutions, clinical investigators, CROs and consultants to conduct our clinical trials in accordance with our clinical protocols and regulatory requirements. These CROs,
investigators and other third parties will play a significant role in the conduct and timing of these trials and subsequent collection and analysis of data. While we have agreements governing the activities of our third-party contractors, we have
limited influence over their actual performance. Nevertheless, we are responsible for ensuring that each of our clinical trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance
on the CROs and other third parties does not relieve us of our regulatory responsibilities. We and our CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory
authorities for vonoprazan and any future product candidates that reach clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs
or trial sites fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before
approving our marketing applications. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the
regulatory approval process. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">30 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">CROs, investigators or other third parties may not devote adequate time and resources to such
trials or perform as contractually required. If any of these third parties fail to meet expected deadlines, adhere to our clinical protocols or meet regulatory requirements, or otherwise performs in a substandard manner, our clinical trials may be
extended, delayed, or terminated. In addition, many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug
development activities that could harm our competitive position. In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in
connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or the FDA concludes that the financial relationship may have affected the interpretation of the study, the
integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of any NDA we submit by the FDA. Any such delay or
rejection could prevent us from commercializing vonoprazan and any future product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If any of our relationships with these
third parties terminate, we may not be able to enter into arrangements with alternative third parties or do so on commercially reasonable terms. Switching or adding additional CROs, investigators and other third parties involves additional cost and
requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we
carefully manage our relationships with our CROs, investigators and other third parties, we may encounter challenges or delays in the future and these delays or challenges may have a material adverse impact on our business, financial condition and
prospects. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We currently rely on Takeda for the manufacture of vonoprazan for clinical development and expect to continue to do so for the
foreseeable future. This reliance on a third party increases the risk that we will not have sufficient quantities of vonoprazan or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization
efforts. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We do not own or operate manufacturing facilities and have no plans to build our own clinical or commercial scale
manufacturing capabilities. Pursuant to the Takeda License, we entered in a clinical manufacturing and supply agreement with Takeda for the supply of vonoprazan for our clinical trials. In addition, we have the option to negotiate in good faith to
enter into a commercial supply agreement with Takeda for the commercial supply of vonoprazan, and we are exploring additional options for commercial supply of vonoprazan from other third party contract manufacturers. As a result, we currently rely,
and expect to continue to rely, on Takeda for the manufacture of vonoprazan and related raw materials for clinical development, as well as for commercial manufacture if vonoprazan receives marketing approval. However, we may not be able to enter
into a commercial supply agreement with Takeda or other third parties on acceptable terms, or at all. The facilities used by Takeda to manufacture vonoprazan must be approved by the FDA for the manufacture of vonoprazan pursuant to inspections that
may be conducted after we submit marketing authorizations to the FDA and comparable foreign regulatory authorities. We do not control the manufacturing process of, and are completely dependent on, Takeda for compliance with cGMP requirements for
manufacture of drug products. If Takeda, or any other third party manufacturer we contract with in the future, cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others,
including requirements related to the manufacturing of high potency compounds, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. In addition, we have no control over Takeda&#146;s ability to
maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">31 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
not approve of facilities of the third-party manufacturer for the manufacture of vonoprazan or if it withdraws any such approval in the future, we may need to find alternative manufacturing
facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market vonoprazan, if approved. Our failure, or Takeda&#146;s failure, to comply with applicable regulations could result in sanctions being
imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could
significantly and adversely affect supplies of our products. Furthermore, Takeda may choose to prioritize the manufacture of vonoprazan for its markets over the manufacture of vonoprazan for our licensed markets. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our or Takeda&#146;s failure, or the failure of any future third-party manufacturer, to execute on our manufacturing requirements, to do so on
commercially reasonable terms and comply with cGMP could adversely affect our business in a number of ways, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">an inability to initiate and continue clinical trials of vonoprazan or any future product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">delay in submitting regulatory applications, or receiving marketing approvals, for vonoprazan and any future product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory authorities;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">requirements to cease development or to recall batches of vonoprazan and any future product candidates; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">in the event of approval to market and commercialize vonoprazan or any future product candidates, an inability to meet commercial demands for vonoprazan or any
future product candidates. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Reliance on third-party manufacturers entails additional risks, including: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">failure of third-party manufacturers to comply with regulatory requirements and maintain quality assurance; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">breach of the manufacturing agreement by the third party; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">failure to manufacture our product according to our specifications; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">failure to manufacture our product according to our schedule or at all; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">misappropriation of our proprietary information, including our trade secrets and <FONT STYLE="white-space:nowrap">know-how;</FONT> and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Vonoprazan and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities.
Moreover, there may be a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Any performance failure on the part of Takeda or any future manufacturers could delay clinical development or marketing approval, and any related remedial measures may be costly or time consuming to implement. We
do not currently have arrangements in place for redundant supply or a second source for all required raw materials used in the manufacture of vonoprazan and any future product candidates. If Takeda cannot perform as agreed, we may be required to
replace Takeda and we may be unable to replace them on a timely basis or at all. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">32 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our current and anticipated future dependence upon others for the manufacture of vonoprazan or
any future product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Our reliance on third parties, including Takeda, requires us to share our trade secrets, which increases the possibility that a competitor will discover them
or that our trade secrets will be misappropriated or disclosed. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Because we currently rely on Takeda to manufacture vonoprazan
and to perform quality testing, we must, at times, share our proprietary technology and confidential information, including trade secrets, with them. We seek to protect our proprietary technology, in part, by entering into confidentiality
agreements, consulting agreements or other similar agreements with our advisors, employees and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or
disclose our confidential information. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our
competitors, are intentionally or inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our
<FONT STYLE="white-space:nowrap">know-how</FONT> and trade secrets and despite our efforts to protect our trade secrets, a competitor&#146;s discovery of our proprietary technology and confidential information or other unauthorized use or disclosure
would impair our competitive position and may have a material adverse effect on our business, financial condition, results of operations and prospects. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We may seek to enter into collaborations, licenses and other similar arrangements and may not be successful in doing so, and even if we are, we may not
realize the benefits of such relationships. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We may seek to enter into collaborations, joint ventures, licenses and other similar
arrangements for the development or commercialization of vonoprazan and any future product candidates, due to capital costs required to develop or commercialize vonoprazan and any future product candidates or manufacturing constraints. We may not be
successful in our efforts to establish such collaborations for vonoprazan and any future product candidates because vonoprazan and any future product candidates may be deemed to be at too early of a stage of development for collaborative effort or
third parties may not view vonoprazan and any future product candidates as having the requisite potential to demonstrate safety and efficacy or significant commercial opportunity. In addition, we face significant competition in seeking appropriate
strategic partners, and the negotiation process can be time consuming and complex. Further, any future collaboration agreements may restrict us from entering into additional agreements with potential collaborators. Following a strategic transaction
or license, we may not achieve an economic benefit that justifies such transaction. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Even if we are successful in our efforts to
establish such collaborations, the terms that we agree upon may not be favorable to us, and we may not be able to maintain such collaborations if, for example, development or approval of a product candidate is delayed, the safety of a product
candidate is questioned or sales of an approved product candidate are unsatisfactory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, any potential future collaborations
may be terminable by our strategic partners, and we may not be able to adequately protect our rights under these agreements. Furthermore, strategic partners may negotiate for certain rights to control decisions regarding the development and
commercialization of vonoprazan and any future product candidates, if approved, and may not conduct those activities in the same manner as we do. Any termination of collaborations we enter into in the future, or any delay in entering into
collaborations related to vonoprazan or any future product candidates, could delay the development and commercialization of vonoprazan or any future product </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">33 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
candidates and reduce their competitiveness if they reach the market, which could have a material adverse effect on our business, financial condition and results of operations. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Risks Related to Commercialization of Vonoprazan and Any Future Product Candidates </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Even if we receive regulatory approval for vonoprazan and any future product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant
additional expense. Additionally, vonoprazan and any future product candidates, if approved, could be subject to labeling and other restrictions on marketing or withdrawal from the market, and we may be subject to penalties if we fail to comply with
regulatory requirements or if we experience unanticipated problems with vonoprazan and any future product candidates, if approved. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Following potential approval of vonoprazan or any future product candidates, the FDA, EMA or other comparable regulatory authority may impose
significant restrictions on a product&#146;s indicated uses or marketing or impose ongoing requirements for potentially costly and time consuming post-approval studies, post-market surveillance or clinical trials to monitor the safety and efficacy
of the product. The FDA may also require a REMS as a condition of approval of vonoprazan or any future product candidates, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe
use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA, EMA or a comparable foreign regulatory authority approves vonoprazan or any future product candidates, the manufacturing
processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our products will be subject to extensive and ongoing regulatory requirements. These requirements include
submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCP requirements for any clinical trials that we conduct post-approval. Later discovery of previously unknown
problems with our products, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">restrictions on the marketing or manufacturing of our products, withdrawal of the product from the market or voluntary or mandatory product recalls;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">restrictions on product distribution or use, or requirements to conduct post-marketing studies or clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">fines, restitutions, disgorgement of profits or revenues, warning letters, untitled letters or holds on clinical trials; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">refusal by the FDA or comparable foreign regulatory authority to approve pending applications or supplements to approved applications filed by us or suspension
or revocation of approvals; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">product seizure or detention, or refusal to permit the import or export of our products; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">injunctions or the imposition of civil or criminal penalties. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The occurrence of any event or penalty described above may inhibit our ability to commercialize vonoprazan and any future product candidates and generate revenue and could require us to expend significant time and
resources in response and could generate negative publicity. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, if vonoprazan or any future product candidate is approved,
our product labeling, advertising and promotion will be subject to regulatory requirements and continuing regulatory review. The FDA strictly regulates the promotional claims that may be made about drug products. In particular, a product may not be
promoted for uses that are not approved by the FDA as reflected in the product&#146;s </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">34 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
approved labeling. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#146;s FDA approved labeling. If we receive marketing approval
for vonoprazan or any future product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such
<FONT STYLE="white-space:nowrap">off-label</FONT> uses, we may become subject to significant liability. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of
<FONT STYLE="white-space:nowrap">off-label</FONT> uses, and a company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to significant sanctions. The federal government has levied large
civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in <FONT STYLE="white-space:nowrap">off-label</FONT> promotion. The FDA has also requested that companies enter into consent
decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The FDA&#146;s and other regulatory
authorities&#146; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of vonoprazan and any future product candidates. If we are slow or unable to adapt to changes in
existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or
executive action, either in the United States or internationally. The policies of the FDA and of other regulatory authorities may change and additional governmental regulations may be enacted that could prevent, limit or delay regulatory approval of
vonoprazan or any future product candidates. For example, certain policies of the current U.S. administration may impact our business and industry. Namely, the current U.S. administration has taken several executive actions, including the issuance
of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#146;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of
guidance, and review and approval of marketing applications. It is difficult to predict how these executive actions, including the Executive Orders, will be implemented, and the extent to which they will impact the FDA&#146;s ability to exercise its
regulatory authority. If these executive actions impose constraints on the FDA&#146;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to
maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business, prospects, financial condition and results of operations. <FONT
STYLE="white-space:nowrap">Non-compliance</FONT> by us or any future collaborator with regulatory requirements, including safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric
population can also result in significant financial penalties. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>The commercial success of vonoprazan or any future product candidates will depend
upon the degree of market acceptance of such product candidates by physicians, patients, healthcare payors and others in the medical community. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Vonoprazan and any future product candidates may not be commercially successful. The commercial success of vonoprazan or any future product candidates, if approved, will depend significantly on the broad adoption
and use of such product by physicians and patients for approved indications. The degree of market acceptance of vonoprazan or any future products, if approved, will depend on a number of factors, including: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">demonstration of clinical efficacy and safety compared to other more-established products; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">35 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the indications for which vonoprazan or any future product candidates are approved; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the limitation of our targeted patient population and other limitations or warnings contained in any <FONT STYLE="white-space:nowrap">FDA-approved</FONT>
labeling; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">acceptance of a new drug for the relevant indication by healthcare providers and their patients; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the pricing and cost-effectiveness of our products, as well as the cost of treatment with our products in relation to alternative treatments and therapies;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">our ability to obtain and maintain sufficient third-party coverage and adequate reimbursement from government healthcare programs, including Medicare and
Medicaid, private health insurers and other third-party payors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the willingness of patients to pay all, or a portion of, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs
associated with our products in the absence of sufficient third-party coverage or adequate reimbursement; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">any restrictions on the use of our products, and the prevalence and severity of any adverse effects; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">potential product liability claims; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the timing of market introduction of our products as well as competitive drugs; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the effectiveness of our or any of our potential future collaborators&#146; sales and marketing strategies; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">unfavorable publicity relating to the product. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">If vonoprazan or any future product candidate is approved but does not achieve an adequate level of acceptance by physicians, hospitals, healthcare payors or patients, we may not generate sufficient revenue from
that product and may not become or remain profitable. Our efforts to educate the medical community and third-party payors regarding the benefits of our products may require significant resources and may never be successful. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">With respect to vonoprazan, Takeda has the right to develop and commercialize the product outside of the United States, Europe, and Canada and has
received marketing approval for vonoprazan in certain countries in Asia and Latin America. We have little or no control over Takeda&#146;s commercialization activities with respect to vonoprazan outside of our licensed territories even though those
activities could impact our ability to successfully commercialize vonoprazan.&nbsp;For example, Takeda can make statements or use promotional materials with respect to vonoprazan outside of our licensed territories that are inconsistent with our
positioning of the product in the United States, Europe, and Canada, and could sell vonoprazan in foreign countries at prices that are dramatically lower than the prices we would charge in our licensed territories.&nbsp;These activities and
decisions, while occurring outside of our licensed territories, could harm our commercialization strategy.&nbsp;In addition, product recalls or safety issues with vonoprazan outside our licensed territories could result in serious damage to the
brand and impair our ability to successfully market vonoprazan in our licensed territories. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>The FDA and other regulatory agencies actively
enforce the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses. If we are found or alleged to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses, we may become
subject to significant liability. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The FDA and other regulatory agencies strictly regulate the promotional claims that may be
made about prescription products, as vonoprazan and any future product candidates would be, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the
product&#146;s approved labeling. If we receive marketing approval for a product candidate, physicians may nevertheless prescribe it to their patients in a manner that is </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">36 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
inconsistent with the approved label. If we are found to have promoted such <FONT STYLE="white-space:nowrap">off-label</FONT> uses, we may become subject to significant liability. The federal
government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in <FONT STYLE="white-space:nowrap">off-label</FONT> promotion. The FDA has also requested that
companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of vonoprazan or any future product candidates, if approved, we could
become subject to significant liability, which would materially adversely affect our business and financial condition. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>The successful
commercialization of vonoprazan or any future product candidates, if approved, will depend in part on the extent to which governmental authorities and health insurers establish coverage, adequate reimbursement levels and favorable pricing policies.
Failure to obtain or maintain coverage and adequate reimbursement for our products could limit our ability to market those products and decrease our ability to generate revenue. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The availability of coverage and the adequacy of reimbursement by governmental healthcare programs, such as Medicare and Medicaid, private health
insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as vonoprazan or any future product candidate, if approved. Our ability to achieve coverage and acceptable levels of
reimbursement for our products by third-party payors will have an effect on our ability to successfully commercialize those products. Even if we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates
may not be adequate or may require <FONT STYLE="white-space:nowrap">co-payments</FONT> that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United&nbsp;States, the European Union or elsewhere will be
available for any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs when an
equivalent generic drug or a less expensive therapy is available. It is possible that a third-party payor may consider our products as substitutable and only offer to reimburse patients for the less expensive product. Even if we are successful in
demonstrating improved efficacy or improved convenience of administration with our products, pricing of existing drugs may limit the amount we will be able to charge for our products. These payors may deny or revoke the reimbursement status of a
given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in product development. If reimbursement is not available or is available only at
limited levels, we may not be able to successfully commercialize our products and may not be able to obtain a satisfactory financial return on products that we may develop. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the
Medicare and Medicaid programs, play an important role in determining the extent to which new drugs will be covered. Some third-party payors may require <FONT STYLE="white-space:nowrap">pre-approval</FONT> of coverage for new or innovative devices
or drug therapies before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our products. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Obtaining and maintaining reimbursement status is time consuming, costly and uncertain. The Medicare and Medicaid programs increasingly are used as
models for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs. However, no uniform policy for coverage and reimbursement for products exists among third-party payors in the United States.
Therefore, coverage and reimbursement for products can differ significantly from payor </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">37 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
to payor. As a result, the coverage determination process will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that
coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these
rules and regulations are likely. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Outside the United States, international operations are generally subject to extensive governmental
price controls and other market regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe and other countries has and will continue to put pressure on the pricing and usage of our products. In many countries, the
prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits. Additional foreign
price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our products. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the
United States and may be insufficient to generate commercially reasonable revenue and profits. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Moreover, increasing efforts by
governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover
or provide adequate payment for our products. We expect to experience pricing pressures in connection with the sale of any of our products due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and
additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and surgical procedures and other treatments, has become very intense. As a result, increasingly high barriers are being erected to
the entry of new products. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We face significant competition, and if our competitors develop technologies or product candidates more rapidly than
we do or their technologies are more effective, our ability to develop and successfully commercialize products may be adversely affected. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates. Our
competitors have developed, are developing or may develop products, product candidates and processes competitive with vonoprazan. Any product candidates that we successfully develop and commercialize will compete with existing therapies and new
therapies that may become available in the future. We believe that a significant number of products are currently under development, and may become commercially available in the future, for the treatment of GI diseases for which we may attempt to
develop vonoprazan or any future product candidates. Our competitors include larger and better funded pharmaceutical, biopharmaceutical, biotechnological and therapeutics companies. Moreover, we may also compete with universities and other research
institutions who may be active in the indications we are targeting and could be in direct competition with us. We also compete with these organizations to recruit management, scientists and clinical development personnel, which could negatively
affect our level of expertise and our ability to execute our business plan. We will also face competition in establishing clinical trial sites, enrolling patients for clinical trials and in identifying and
<FONT STYLE="white-space:nowrap">in-licensing</FONT> new product candidates. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We expect that vonoprazan, if approved for the treatment of erosive esophagitis and treatment of <I>H. pylori </I>infection, will
primarily compete with generic PPIs marketed by multiple pharmaceutical companies in both the prescription and OTC markets. Additionally, RedHill Biopharma Ltd. is </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">38 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
developing Talicia, a <FONT STYLE="white-space:nowrap">co-formulated</FONT> capsule comprising generic omeprazole, amoxicillin, and rifabutin for the treatment of <I>H. pylori</I> infection, and
filed an NDA in the United States in May 2019. Ironwood Pharmaceuticals, Inc. is developing <FONT STYLE="white-space:nowrap">IW-3718,</FONT> a bile acid sequestrant, currently in Phase 3 clinical trials as an adjunct to PPIs for the treatment of
patients with persistent GERD. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We are also aware of other <FONT STYLE="white-space:nowrap">P-CABs</FONT> in territories outside of the
United States that, if developed and approved in our territories, may compete with vonoprazan. Revaprazan is marketed by Yuhan Corporation in South Korea. Tegoprazan is marketed by CJ Healthcare Corp. in South Korea and is currently in Phase 3
development in Japan by RaQualia Pharma, Inc. Daewoong Pharmaceutical Co., Ltd.&#146;s DWP14012 has been studied in Phase 2 clinical trials in South Korea, and Cinclus Pharma AG&#146;s X842 has completed a Phase 1 clinical trial in Europe.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Additionally, we are aware of several clinical-stage PPIs in territories outside of the United States that if developed and approved in
our licensed territories may compete with vonoprazan. These include Dexa Medica&#146;s DLBS-2411, currently in Phase 3 clinical trials in Indonesia, Sihuan Pharmaceutical&#146;s anaprazole, currently in Phase 3 clinical trials in China, Eisai&#146;s
azeloprazole, currently in a Phase 2 clinical trial in Japan, and Sidem Pharma&#146;s tenatoprazole, currently in Phase 2 clinical trials in Europe and Canada. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">In July 2012, the Food and Drug Administration Safety and Innovation Act was passed, which included the GAIN Act. The GAIN Act is intended to provide incentives for the development of new, qualified infectious
disease products. In December&nbsp;2016, the 21st Century Cures Act was passed, providing additional support for the development of new infectious disease products. These incentives may result in more competition in the market for new antibiotics
and may cause pharmaceutical and biotechnology companies with more resources than we have to shift their efforts towards the development of product candidates that could be competitive with vonoprazan or any future product candidates. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we
do. If we successfully obtain approval for vonoprazan or any future product candidate, we will face competition based on many different factors, including the safety and effectiveness of our products, the ease with which our products can be
administered and the extent to which patients accept relatively new routes of administration, the timing and scope of regulatory approvals for these products, the availability and cost of manufacturing, marketing and sales capabilities, price,
reimbursement coverage and patent position. Competing products could present superior treatment alternatives, including by being more effective, safer, more convenient, less expensive or marketed and sold more effectively than any products we may
develop. Competitive products may make any products we develop obsolete or noncompetitive before we recover the expense of developing and commercializing vonoprazan or any future product candidates. If we are unable to compete effectively, our
opportunity to generate revenue from the sale of our products we may develop, if approved, could be adversely affected. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>If the market
opportunities for vonoprazan or any future products are smaller than we believe they are, our revenue may be adversely affected, and our business may suffer. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The precise incidence and prevalence for all the conditions we aim to address with vonoprazan or any future product candidates are unknown. Our projections of both the number of people who have these diseases, as
well as the subset of people with these diseases who have the potential to benefit from treatment of vonoprazan or any future product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources,
including the scientific literature, surveys of clinics or market research, and may prove to be incorrect. Further, new trials may change the estimated incidence or prevalence of these diseases. The total addressable market across
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">39 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
vonoprazan and any future product candidates will ultimately depend upon, among other things, the diagnosis criteria included in the final label for each of vonoprazan and any future product
candidates approved for sale for these indications, the availability of alternative treatments and the safety, convenience, cost and efficacy of vonoprazan and any future product candidates relative to such alternative treatments, acceptance by the
medical community and patient access, drug pricing and reimbursement. The number of patients in the United States and other major markets and elsewhere may turn out to be lower than expected, patients may not be otherwise amenable to treatment with
our products or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our results of operations and our business. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>We currently have no marketing and sales organization and have no experience as a company in commercializing products, and we may have to invest significant resources to develop these capabilities. If we are
unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have no internal sales, marketing or distribution capabilities, nor have we commercialized a product. If vonoprazan or any future product
candidates ultimately receive regulatory approval, we must build a marketing and sales organization with technical expertise and supporting distribution capabilities to commercialize each such product in major markets, which will be expensive and
time consuming, or collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. We plan
to independently commercialize vonoprazan in the United States by building a leading specialty gastroenterology commercial infrastructure to support the adoption of vonoprazan and we plan to seek one or more partners with existing commercial
infrastructure and expertise in Europe and Canada. We have no prior experience as a company in the marketing, sale and distribution of biopharmaceutical products and there are significant risks involved in building and managing a marketing and sales
organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and
marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may not be able to enter into collaborations or hire
consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms, or at all. In addition, our product revenues and our profitability, if any, may be lower if we rely on third parties
for these functions than if we were to market, sell and distribute any products that we develop ourselves. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell
and market our products effectively. If we are not successful in commercializing vonoprazan or any future product candidates, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product
revenue and we would incur significant additional losses. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Our future growth may depend, in part, on our ability to operate in foreign markets,
particularly Europe and Canada, where we would be subject to additional regulatory burdens and other risks and uncertainties. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our future growth may depend, in part, on our ability to develop and commercialize vonoprazan and any future product candidates in foreign markets,
particularly Europe and Canada. We are not permitted to market or promote vonoprazan and any future product candidates before we receive regulatory approval from applicable regulatory authorities in foreign markets, and we may never receive such
regulatory approvals for vonoprazan or any future product candidates. To obtain separate regulatory approval in any other countries we must comply with numerous and varying regulatory requirements regarding safety and efficacy and governing, among
other things, clinical trials, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">40 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
commercial sales, pricing and distribution of vonoprazan and any future product candidates. If we obtain regulatory approval of vonoprazan and any future product candidates and ultimately
commercialize our products in foreign markets, we would be subject to additional risks and uncertainties, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">different regulatory requirements for approval of drugs in foreign countries; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">reduced protection for intellectual property rights; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the existence of additional third-party patent rights of potential relevance to our business; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">unexpected changes in tariffs, trade barriers and regulatory requirements; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">economic weakness, including inflation, or political instability in particular foreign economies and markets; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">compliance with tax, employment, immigration and labor laws for employees living or traveling internationally; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">foreign currency fluctuations, which could result in increased operating expenses and reduced revenues, and other obligations incident to doing business in
another country; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">foreign reimbursement, pricing and insurance regimes; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">workforce uncertainty in countries where labor unrest is common; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">production shortages resulting from any events affecting raw material supply or manufacturing capabilities internationally; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Risks Related to Our Business Operations and Industry </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may
provide. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our quarterly and annual operating results may fluctuate significantly, which makes it difficult for us to predict our
future operating results. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the timing and cost of, and level of investment in, research, development, regulatory approval and commercialization activities relating to vonoprazan or any
future product candidates, which may change from time to time; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">coverage and reimbursement policies with respect to vonoprazan or any future product candidates, if approved, and potential future drugs that compete with such
products, if approved; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the cost of manufacturing vonoprazan or any future product candidates, which may vary depending on the quantity of production and the terms of our agreements
with Takeda and any future third-party manufacturers; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the timing and amount of the milestone or other payments we will be required to pay to Takeda pursuant to the Takeda License; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">expenditures that we may incur to acquire, develop or commercialize additional product candidates and technologies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the level of demand for any approved products, which may vary significantly; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">41 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">future accounting pronouncements or changes in our accounting policies; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the timing and success or failure of preclinical studies or clinical trials for vonoprazan or any future product candidates or competing product candidates, or
any other change in the competitive landscape of our industry, including consolidation among our competitors or partners. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for
any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or
investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings guidance we may provide. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Our indebtedness may limit our flexibility in operating our business and adversely affect our financial health and competitive position, and all of our
obligations under our indebtedness are&nbsp;secured by&nbsp;substantially all of our assets, excluding our intellectual property and certain other assets. If we default on these obligations, our lenders could foreclose on our assets.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In May 2019, we entered into the Loan Agreement with SVB and WestRiver. We borrowed $25.0&nbsp;million, or Term Loan&nbsp;A, at
the inception of the Loan Agreement and have the right to borrow an additional $25.0&nbsp;million, or Term Loan B, and which we collectively refer to as the Term Loans. Term Loan B is available through March&nbsp;31, 2020, provided that (i)&nbsp;we
have received at least $150.0&nbsp;million of net cash proceeds in connection with the issuance and sale, subsequent to April&nbsp;1, 2019, of our equity securities and subordinated debt, (ii)&nbsp;we have initiated Phase 3 clinical trials for
vonoprazan, and (iii)&nbsp;no event of default has occurred. All obligations under the Term Loans are secured by a first priority lien on substantially all of our assets, excluding intellectual property and certain other assets. We have agreed not
to encumber our intellectual property assets without SVB&#146;s prior written consent unless a security interest in the underlying intellectual property is necessary to have a security interest in the accounts and proceeds that are part of the
assets securing the Term Loans, in which case our intellectual property will automatically be included within the assets securing the Term Loans. As a result, if we default on any of our obligations under the Loan Agreement, SVB could foreclose on
its security interest and liquidate some or all of the collateral, which would harm our business, financial condition and results of operations and could require us to reduce or cease operations. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In order to service this indebtedness and any additional indebtedness we may incur in the future, we need to generate cash from our operating
activities. Our ability to generate cash is subject, in part, to our ability to successfully execute our business strategy, as well as general economic, financial, competitive, regulatory and other factors beyond our control. Our business may not be
able to generate sufficient cash flow from operations, and future borrowings or other financings may not be available to us in an amount sufficient to enable us to service our indebtedness and fund our other liquidity needs. To the extent we are
required to use cash from operations or the proceeds of any future financing to service our indebtedness instead of funding working capital, capital expenditures or other general corporate purposes, we will be less able to plan for, or react to,
changes in our business, industry and in the economy generally. This could place us at a competitive disadvantage compared to our competitors that have less indebtedness. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The Loan Agreement contains customary affirmative and negative covenants that limit our ability to engage in certain transactions that may be in our long-term best interest. The affirmative covenants
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">42 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
include, among others, covenants requiring us to maintain our legal existence and governmental approvals, deliver certain financial reports, maintain insurance coverage and satisfy certain
requirements regarding our operating accounts. The negative covenants include, among others, limitations on our ability to incur additional indebtedness and liens, merge with other companies or consummate certain changes of control, acquire other
companies, engage in new lines of business, make certain investments, pay dividends, transfer or dispose of assets, amend certain material agreements or enter into various specified transactions.</FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">While we believe we are currently in compliance with the covenants contained in the Loan Agreement, we may breach these covenants in the future.
Our ability to comply with these covenants may be affected by events and factors beyond our control. In the event that we breach one or more covenants, the lenders may choose to declare an event of default and require that we immediately repay all
amounts outstanding under the Loan Agreement, terminate any commitment to extend further credit and foreclose on the collateral. The occurrence of any of these events could have a material adverse effect on our business, financial condition and
results of operations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We are dependent on the services of our current management and other clinical and scientific personnel, and if we are not
able to retain these individuals or recruit additional management or clinical and scientific personnel, our business will suffer. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific
personnel.&nbsp;We are highly dependent upon our current senior management team, our Chairman and our development personnel. The loss of services of any of these individuals or personnel could delay or prevent the successful development of our
product pipeline, initiation or completion of our planned clinical trials or the commercialization of vonoprazan or any other future product candidates. Although we have executed employment agreements or offer letters with each member of our senior
management team, these agreements are terminable at will with or without notice and, therefore, we may not be able to retain their services as expected. We do not currently maintain &#147;key person&#148; life insurance on the lives of our
executives or any of our employees. This lack of insurance means that we may not have adequate compensation for the loss of the services of these individuals. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">In addition, we expect that Terrie Curran, a member of our board of directors, will become our Chief Executive Officer effective upon the closing of the acquisition of her current employer, Celgene Corporation, by
Bristol-Myers Squibb Company. In the event Ms. Curran succeeds Mr. Socks as Chief Executive Officer, Mr. Socks will serve as interim Chief Financial Officer and continue to serve on our board of directors. If Ms. Curran decides not to join us as
Chief Executive Officer, our board of directors will evaluate additional candidates for the position, during which time David Socks will continue to serve as our Chief Executive Officer. Although this is a planned management transition, we may
experience business disruptions and our ability to achieve our development objections could be adversely affected. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We will continue to
expand and need to effectively manage our managerial, operational, financial and other resources in order to successfully pursue our clinical development and commercialization efforts. We may not be successful in maintaining our unique company
culture and continuing to attract or retain qualified management and scientific and clinical personnel in the future due to the intense competition for qualified personnel among pharmaceutical, biotechnology and other businesses. Our industry has
experienced a high rate of turnover of management personnel in recent years. If we are not able to attract, integrate, retain and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will
significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">43 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We have recently substantially increased the size of our organization, and we may encounter difficulties in
managing our growth and expanding our operations successfully. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have substantially increased our organization from four
employees in February 2018 to 16&nbsp;full-time employees as of September&nbsp;30, 2019. As we continue development and pursue the potential commercialization of vonoprazan and any future product candidates, as well as function as a public company,
we will continue to expand our financial, development, regulatory, manufacturing, marketing and sales capabilities or contract with third parties to provide these capabilities for us. As our operations expand, we expect that we will need to manage
additional relationships with various strategic partners, suppliers and other third parties. Our future financial performance and our ability to develop and commercialize vonoprazan and any future product candidates and to compete effectively will
depend, in part, on our ability to manage our recent substantial growth and any future growth effectively. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We are subject to various foreign,
federal, and state healthcare and privacy laws and regulations, and our failure to comply with these laws and regulations could harm our results of operations and financial condition. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient
organizations and customers expose us to broadly applicable foreign, federal and state fraud and abuse and other healthcare and privacy laws and regulations. These laws may constrain the business or financial arrangements and relationships through
which we conduct our operations, including how we research, market, sell and distribute any products for which we obtain marketing approval. Such laws include, but are not limited to: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or
providing any remuneration (including any kickback, bribe or certain rebates), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease,
or order, or arranging for or recommending the purchase, lease, or order of any good, facility, item or service, for which payment may be made, in whole or in part, under any U.S. federal healthcare program, such as Medicare and Medicaid. A person
or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert that a claim including items or services resulting
from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the U.S. civil and criminal federal false claims and civil monetary penalties laws, including the civil False Claims Act, which can be enforced through civil
whistleblower or qui tam actions, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false or fraudulent, knowingly
making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making or causing to be made a false statement to avoid, decrease or conceal an obligation to pay money to the U.S.
federal government; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which imposes criminal and civil liability for, among other things,
knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection
with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or
specific intent to violate it in order to have committed a violation; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">44 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and its implementing regulations, also impose
obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information of covered entities subject to the rule, such as health plans, healthcare
clearinghouses and certain healthcare providers as well as their business associates that perform certain services for or on their behalf involving the use or disclosure of individually identifiable health information; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the U.S. federal Physician Payments Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is
available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) to report annually to the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS, information related to certain payments and other
&#147;transfers of value&#148; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by the physicians described above and
their immediate family members; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to our business practices, including but not
limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers, or by the
patients themselves; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict
payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information or which require tracking gifts and
other remuneration and items of value provided to physicians, other healthcare providers and entities; state and local laws that require the registration of pharmaceutical sales representatives; state and foreign laws governing the privacy and
security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA; state and foreign governments that have enacted or proposed requirements regarding the collection,
distribution, use, security, and storage of personally identifiable information and other data relating to individuals (including the EU General Data Protection Regulation 2016/679, or GDPR, and the California Consumer Privacy Act, or CCPA), and
federal and state consumer protection laws are being applied to enforce regulations related to the online collection, use, and dissemination of data, thus complicating compliance efforts. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We may also be subject to additional regulation in the conduct of our business. For example, we may be subject to the U.S. Foreign Corrupt
Practices Act of 1977, as amended, which prohibits, among other things, U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value
to foreign government officials, employees of public international organizations and foreign government owned or affiliated entities, candidates for foreign political office, and foreign political parties or officials thereof. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, California recently enacted the CCPA, which creates new individual privacy rights for California consumers (as defined in the law) and
places increased privacy and security obligations on entities handling certain personal data of consumers or households. The CCPA will require covered companies to provide new disclosure to consumers about such companies&#146; data collection, use
and sharing practices, provide such consumers new ways to <FONT STYLE="white-space:nowrap">opt-out</FONT> of certain sales or transfers of personal information, and provide consumers with additional causes of action. The CCPA goes into effect on
January&nbsp;1, 2020, and the California Attorney General may bring enforcement actions for violations beginning July&nbsp;1, 2020. The CCPA was amended on September&nbsp;23, 2018, and it remains
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">45 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
unclear what, if any, further modifications will be made to this legislation or how it will be interpreted. As currently written, the CCPA may impact our business activities and exemplifies the
vulnerability of our business to the evolving regulatory environment related to personal data and protected health information. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Ensuring that our internal operations and business arrangements with third parties comply with applicable healthcare laws and regulations could
involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other
healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including civil,
criminal and administrative penalties, damages, fines, exclusion from U.S. government funded healthcare programs, such as Medicare and Medicaid, or similar programs in other countries or jurisdictions, disgorgement, imprisonment, contractual
damages, reputational harm, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these
laws, diminished profits and the curtailment or restructuring of our operations. Further, defending against any such actions can be costly, time consuming and may require significant financial and personnel resources. Therefore, even if we are
successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other providers or entities with whom we expect to do business are found not to be in compliance with
applicable laws, they may be subject to significant criminal, civil or administrative sanctions, including exclusion from government funded healthcare programs and imprisonment. If any of the above occur, it could adversely affect our ability to
operate our business and our results of operations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Enacted and future legislation and healthcare reform measures may increase the difficulty and
cost for us to obtain marketing approval for and commercialize vonoprazan and any future product candidates and may affect the prices we may set. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">In the United States and some foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system, including
cost-containment measures that may reduce or limit coverage and reimbursement for newly approved drugs and affect our ability to profitably sell any product candidates for which we obtain marketing approval. In particular, there have been and
continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively the Affordable Care Act, was enacted in the United States.
Among the provisions of the Affordable Care Act of importance to our potential product candidates, the Affordable Care Act includes: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic agents, which is apportioned among
these entities according to their market share in certain government healthcare programs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a Medicare Part D coverage gap discount program, in which manufacturers must agree to offer
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the
manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13.0% of the average manufacturer price
for branded and generic drugs, respectively; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">46 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled,
implanted or injected; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">an extension of a manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care
organizations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding
for such research; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">establishment of a Center for Medicare Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending,
potentially including prescription drug spending. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Since its enactment, there have been judicial and political
challenges to certain aspects of the Affordable Care Act, and we expect there will be additional challenges and amendments to the Affordable Care Act in the future. For example, the Tax Cuts and Jobs Act of 2017, or Tax Act, includes a provision
repealing, effective January&nbsp;1, 2019, the <FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part
of a year that is commonly referred to as the &#147;individual mandate.&#148; On December&nbsp;14, 2018, a U.S. District Court Judge in the Northern District of Texas, or Texas District Court Judge, ruled that the individual mandate is a critical
and inseverable feature of the Affordable Care Act, and therefore, because it was repealed as part of the Tax Act, the remaining provisions of the Affordable Care Act are invalid as well. While the Texas District Court Judge, as well as the Trump
Administration and CMS, have stated that the ruling will have no immediate effect, it is unclear how this decision, subsequent appeals, and other efforts to repeal and replace the Affordable Care Act will impact the Affordable Care Act and our
business. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. These
changes included aggregate reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April&nbsp;1, 2013 and, due to subsequent legislative amendments to the statute, including the Bipartisan Budget Act of 2018,
will remain in effect through 2027 unless additional Congressional action is taken. On January&nbsp;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers,
including hospitals, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Further, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs. Such scrutiny has resulted in several recent
congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform
government program reimbursement methodologies for products. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">At the federal level, the Trump administration&#146;s budget proposal for
fiscal year 2019 contains further drug price control measures that could be enacted during the 2019 budget process or in other future legislation, including, for example, measures to permit Medicare Part D plans to negotiate the price of certain
drugs under Medicare Part B, to allow some states to negotiate drug prices under Medicaid and to eliminate cost sharing for generic drugs for <FONT STYLE="white-space:nowrap">low-income</FONT> patients. While proposed measures will require
authorization through additional legislation to become effective, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">47 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">At the state level, legislatures have increasingly passed legislation and implemented regulations
designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases,
designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers
will be included in their prescription drug and other healthcare programs. Furthermore, there has been increased interest by third party payors and governmental authorities in reference pricing systems and publication of discounts and list prices.
These reforms could reduce the ultimate demand for vonoprazan and any future product candidates, if approved, or put pressure on our product pricing, which could negatively affect our business, results of operations, financial condition and
prospects. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Additionally, on May&nbsp;30, 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try
Act of 2017, or Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial. Under certain
circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a drug manufacturer to make its drug products available
to eligible patients as a result of the Right to Try Act. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We expect that these new laws and other healthcare reform measures that may
be adopted in the future may result in more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other
government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or
commercialize vonoprazan and any future product candidates, if approved. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We and any of our third-party manufacturers or suppliers may use potent
chemical agents and hazardous materials, and any claims relating to improper handling, storage or disposal of these materials could be time consuming or costly. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">We and any of our third-party manufacturers or suppliers will use biological materials, potent chemical agents and may use hazardous materials, including chemicals and biological agents and compounds that could be
dangerous to human health and safety of the environment. Our operations and the operations of our third-party manufacturers and suppliers also produce hazardous waste products. Federal, state and local laws and regulations govern the use,
generation, manufacture, storage, handling and disposal of these materials and wastes. Compliance with applicable environmental laws and regulations may be expensive, and current or future environmental laws and regulations may impair our product
development efforts. In addition, we cannot eliminate the risk of accidental injury or contamination from these materials or wastes. We do not carry specific biological or hazardous waste insurance coverage, and our property, casualty and general
liability insurance policies specifically exclude coverage for damages and fines arising from biological or hazardous waste exposure or contamination. In the event of contamination or injury, we could be held liable for damages or be penalized with
fines in an amount exceeding our resources, and our clinical trials or regulatory approvals could be suspended. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Although we maintain
workers&#146; compensation insurance for certain costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials or other work-related injuries, this insurance may not provide adequate coverage against
potential liabilities. We do not maintain insurance for toxic tort claims that may be asserted against us in connection with our storage or disposal of biologic, hazardous or radioactive materials. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">48 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, we may incur substantial costs in order to comply with current or future
environmental, health and safety laws and regulations, which have tended to become more stringent over time. These current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws
and regulations also may result in substantial fines, penalties or other sanctions or liabilities, which could materially adversely affect our business, financial condition, results of operations and prospects. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We face an inherent risk of product liability as a result of the clinical trials of vonoprazan and any future product candidates
and will face an even greater risk if we commercialize vonoprazan and any future product candidates. For example, we may be sued if vonoprazan and any future product candidates allegedly cause injury or are found to be otherwise unsuitable during
product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product candidate, negligence, strict liability
and a breach of warranties. Claims may be brought against us by clinical trial participants, patients or others using, administering or selling products that may be approved in the future. Claims could also be asserted under state consumer
protection acts. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or
be required to limit or cease the commercialization of our products. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">decreased demand for our products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">injury to our reputation and significant negative media attention; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">withdrawal of clinical trial participants; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">costs to defend the related litigation; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a diversion of management&#146;s time and our resources; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">substantial monetary awards to trial participants or patients; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">product recalls, withdrawals or labeling, marketing or promotional restrictions; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">significant negative financial impact; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the inability to commercialize vonoprazan and any future product candidates; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a decline in our stock price. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We currently do not have product liability insurance coverage, but will need to obtain such coverage as we begin our clinical trials or if we
commence commercialization of vonoprazan and any future product candidates. Insurance coverage is increasingly expensive. Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential
product liability claims could prevent or inhibit the commercialization of vonoprazan and any future product candidates. Although we plan to maintain such insurance, any claim that may be brought against us could result in a court judgment or
settlement in an amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies will also have various exclusions, and we may be subject to a product liability
claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient
capital to pay such amounts. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">49 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We and others, including any of our potential future collaborators, will be required to report to
regulatory authorities if any of our approved products cause or contribute to adverse medical events, and any failure to do so would result in sanctions that would materially harm our business. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If we or any of our potential future collaborators are successful in commercializing vonoprazan or any future product candidates, the FDA and
foreign regulatory authorities would require that we and Takeda (with respect to vonoprazan) and any of our current or potential future collaborators, report certain information about adverse medical events if those products may have caused or
contributed to those adverse events. The timing of our obligation to report would be triggered by the date we become aware of the adverse event as well as the nature of the event. We, Takeda and any of our potential future collaborators or CROs may
fail to report adverse events within the prescribed timeframe. If we, Takeda or any of our potential future collaborators or CROs fail to comply with such reporting obligations, the FDA or a foreign regulatory authority could take action, including
criminal prosecution, the imposition of civil monetary penalties, seizure of our products or delay in approval or clearance of future products. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Our internal computer systems, or those of any of our CROs, manufacturers, other contractors or consultants or potential future collaborators, may fail or
suffer security breaches, which could result in a material disruption of our product development programs. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The United States
federal and various state and foreign governments have adopted or proposed requirements regarding the collection, distribution, use, security, and storage of personally identifiable information and other data relating to individuals, and federal and
state consumer protection laws are being applied to enforce regulations related to the online collection, use, and dissemination of data. Despite the implementation of security measures, our internal computer systems and those of our current and any
future CROs and other contractors, consultants and collaborators are vulnerable to damage from computer viruses, cybersecurity threats, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. If such an
event were to occur and cause interruptions in our operations or result in the unauthorized disclosure of or access to personally identifiable information or individually identifiable health information (violating certain privacy laws such as GDPR),
it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other similar disruptions. Some of the federal, state and foreign government requirements include
obligations of companies to notify individuals of security breaches involving particular personally identifiable information, which could result from breaches experienced by us or by our vendors, contractors, or organizations with which we have
formed strategic relationships. Even though we may have contractual protections with such vendors, contractors, or other organizations, notifications and <FONT STYLE="white-space:nowrap">follow-up</FONT> actions related to a security breach could
impact our reputation, cause us to incur significant costs, including legal expenses, harm customer confidence, hurt our expansion into new markets, cause us to incur remediation costs, or cause us to lose existing customers. For example, the loss
of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. We also rely on third parties to manufacture vonoprazan
and any future product candidates, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our
data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, the further development and commercialization of vonoprazan and any future product candidates could be delayed, and we could be
subject to significant fines, penalties or liabilities for any noncompliance to certain privacy and security laws. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">50 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Business disruptions could seriously harm our future revenue and financial condition and increase our costs
and expenses. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our operations could be subject to earthquakes, power shortages, telecommunications failures, water shortages,
floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or manmade disasters or business interruptions, for which we are predominantly self-insured. We rely on third-party manufacturers to produce
vonoprazan and any future product candidates. Our ability to obtain clinical supplies of vonoprazan and any future product candidates could be disrupted if the operations of these suppliers were affected by a
<FONT STYLE="white-space:nowrap">man-made</FONT> or natural disaster or other business interruption. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Our employees and independent contractors, including principal investigators, CROs, consultants and vendors, may engage in misconduct or other
improper activities, including noncompliance with regulatory standards and requirements. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We are exposed to the risk that our
employees and independent contractors, including principal investigators, CROs, consultants and vendors may engage in misconduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or
other unauthorized activities that violate: (i)&nbsp;the laws and regulations of the FDA and other similar regulatory bodies, including those laws that require the reporting of true, complete and accurate information to such regulatory bodies,
(ii)&nbsp;manufacturing standards, including cGMP requirements, or (iii)&nbsp;federal and state healthcare, security, fraud and abuse laws, data privacy and security laws, and other similar <FONT STYLE="white-space:nowrap">non-U.S.&nbsp;laws</FONT>
that require the true, complete and accurate reporting of financial information or data. Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of
fraudulent data in our preclinical studies or clinical trials, or illegal misappropriation of product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by
employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or
lawsuits stemming from a failure to be in compliance with such laws or regulations. In addition, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are
instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including, without limitation, the imposition of significant civil,
criminal and administrative penalties, damages, monetary fines, disgorgement, possible exclusion from participation in Medicare, Medicaid and other U.S. federal healthcare programs or healthcare programs in other jurisdictions, integrity oversight
and reporting obligations to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance,</FONT> imprisonment, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which
could adversely affect our ability to operate our business and our results of operations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We are subject to U.S. and certain foreign export and
import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We could face criminal
liability and other serious consequences for violations, which could harm our business. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We are subject to export control and
import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#146;s Office of Foreign Assets Controls,
and anti-corruption and anti-money laundering laws and regulations, including the U.S. Foreign Corrupt </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">51 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and other state and national anti-bribery and
anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, clinical research organizations, contractors and other collaborators and
partners from authorizing, promising, offering, providing, soliciting or receiving, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties for clinical trials
outside of the United States, to sell our products abroad once we enter a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with
officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, clinical research organizations,
contractors and other collaborators and partners, even if we do not explicitly authorize or have actual knowledge of such activities. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and
penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>We may engage in strategic transactions that could impact our liquidity, increase our expenses and present significant distractions to our management. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">From time to time, we may consider strategic transactions, such as acquisitions of companies, asset purchases and
<FONT STYLE="white-space:nowrap">out-licensing</FONT> or <FONT STYLE="white-space:nowrap">in-licensing</FONT> of intellectual property, products or technologies, similar to our approach in <FONT STYLE="white-space:nowrap">in-licensing</FONT> and
acquiring our current product candidates. Any future transactions could increase our near and long-term expenditures, result in potentially dilutive issuances of our equity securities, including our common stock, or the incurrence of debt,
contingent liabilities, amortization expenses or acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development expenses, any of which could affect our financial condition, liquidity and results of operations. Additional
potential transactions that we may consider in the future include a variety of business arrangements, including spin-offs, strategic partnerships, joint ventures, restructurings, divestitures, business combinations and investments. Future
acquisitions may also require us to obtain additional financing, which may not be available on favorable terms or at all. These transactions may never be successful and may require significant time and attention of management. In addition, the
integration of any business that we may acquire in the future may disrupt our existing business and may be a complex, risky and costly endeavor for which we may never realize the full benefits of the acquisition. Accordingly, although we may not
undertake or successfully complete any additional transactions of the nature described above, any additional transactions that we do complete could have a material adverse effect on our business, results of operations, financial condition and
prospects. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Risks Related to Our Intellectual Property </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Our success depends on our ability to protect our intellectual property and our proprietary technologies. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Our commercial success depends in part on our ability to obtain and maintain patent protection and trade secret protection for vonoprazan and any future product candidates, proprietary technologies and their uses
as well as our ability to operate without infringing upon the proprietary rights of others. If we are unable to protect our intellectual property rights or if our intellectual property rights are inadequate for our technology or vonoprazan or any
future product candidates, our competitive position could be harmed. We generally seek to protect our proprietary position by filing patent applications in the United States and abroad related to vonoprazan or any future product candidates,
proprietary technologies and their uses that are important to our business. We do not currently own any issued patents or pending patent applications. We also seek to protect our proprietary position by acquiring or
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">52 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
<FONT STYLE="white-space:nowrap">in-licensing</FONT> relevant issued patents or pending patent applications from third parties. We have <FONT STYLE="white-space:nowrap">in-licensed</FONT> from
Takeda a number of United States, European, and Canadian patents and patent applications relating to the compound vonoprazan as well as the use and manufacture of vonoprazan products. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until,
patents issue from such applications, and then only to the extent the issued claims cover the technology. There can be no assurance that our future patent applications or the patent applications of our current and future licensors will result in
patents being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the patents if issued will not be infringed, designed around or invalidated by third
parties. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by
third parties before various patent offices or in courts. The degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep any
competitive advantage. These uncertainties and/or limitations in our ability to properly protect the intellectual property rights relating to vonoprazan and any future product candidates could have a material adverse effect on our financial
condition and results of operations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We cannot be certain that the claims in our licensor&#146;s U.S. pending patent applications,
corresponding international patent applications and patent applications in certain foreign countries will be considered patentable by the United States Patent and Trademark Office, or USPTO, courts in the United States or by the patent offices and
courts in foreign countries, nor can we be certain that the claims in our licensor&#146;s issued patents will not be found invalid or unenforceable if challenged. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting vonoprazan and any
future product candidates by obtaining and defending patents. These risks and uncertainties include the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during
the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">patent applications may not result in any patents being issued; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">our competitors, many of whom have substantially greater resources than we do and many of whom have made significant investments in competing technologies, may
seek or may have already obtained patents that will limit, interfere with or block our ability to make, use and sell vonoprazan and any future product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside
the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts, allowing foreign competitors a better
opportunity to create, develop and market competing products. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">53 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The patent prosecution process is also expensive and time consuming, and we and our licensor may
not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. It is also possible that we and our licensor will
fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances such as under the Takeda License, we do not have the right to control the preparation,
filing and prosecution of patent applications, or to maintain the patents, directed to technology that we license from third parties. We may also require the cooperation of our licensors in order to enforce the licensed patent rights, and such
cooperation may not be provided. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. We cannot be certain that patent prosecution and maintenance activities by
our licensors have been or will be conducted in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such applications. If they fail to do so, this could
cause us to lose rights in any applicable intellectual property that we <FONT STYLE="white-space:nowrap">in-license,</FONT> and as a result our ability to develop and commercialize products or product candidates may be adversely affected and we may
be unable to prevent competitors from making, using and selling competing products. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, although we enter into <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, outside scientific collaborators, CROs, third-party
manufacturers, consultants, advisors and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties, including our rights in
vonoprazan licensed from Takeda, or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We are a party to the Takeda License under which we are granted rights to intellectual property that are important to our business and we may enter
into additional license agreements in the future with other third parties. The Takeda License imposes, and we expect that any future license agreements where we <FONT STYLE="white-space:nowrap">in-license</FONT> intellectual property, will impose on
us, various development, regulatory and/or commercial diligence obligations, payment of milestones and/or royalties and other obligations. If we fail to comply with our obligations under these agreements, or we are subject to bankruptcy-related
proceedings, the licensor may have the right to terminate the license, in which event we would not be able to market products covered by the license. Additionally, if a future license agreement includes a sublicense from a third party who is not the
original licensor of the intellectual property at issue, then we must rely on our direct licensor to comply with its obligations under the primary license agreements under which such licensor obtained rights in the applicable intellectual property,
where we may have no relationship with the original licensor of such rights. If such a licensor fails to comply with its obligations under its upstream license agreement, the original third-party licensor may have the right to terminate the original
license, which may terminate our sublicense. If this were to occur, we would no longer have rights to the applicable intellectual property unless we are able to secure our own direct license with the owner of the relevant rights, which we may not be
able to do on reasonable terms, or at all, which may impact our ability to continue to develop and commercialize vonoprazan and any future product candidates incorporating the relevant intellectual property. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We may need to obtain further licenses from third parties to advance our research or allow commercialization of vonoprazan and any future product
candidates, and we cannot provide any assurances that third-party patents do not exist which might be enforced against vonoprazan and any future product candidates in the absence of such a license. We may fail to obtain any of these licenses
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">54 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
on commercially reasonable terms, if at all. Even if we are able to obtain a license, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the
same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected product
candidates, which could materially harm our business and the third parties owning such intellectual property rights could seek either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties
and/or other forms of compensation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Licensing of intellectual property is of critical importance to our business and involves complex
legal, business and scientific issues. Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the scope of rights granted under the license agreement and other interpretation-related issues; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">our right to sublicense patents and other rights to third parties; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of vonoprazan and any future
product candidates, and what activities satisfy those diligence obligations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">our right to transfer or assign the license; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint creation or use of intellectual property by our
licensors and us and our partners. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If disputes over intellectual property that we have licensed prevent or impair our
ability to maintain our current licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize the affected product candidates, which would have a material adverse effect on our business. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, certain of our agreements may limit or delay our ability to consummate certain transactions, may impact the value of those
transactions, or may limit our ability to pursue certain activities. For example, if we choose to sublicense or assign to any third parties our rights under our existing license agreement with Takeda with respect to any licensed product, we may be
required to wait for a certain period or until the occurrence of certain funding or development milestones. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>If the scope of any patent protection
we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The patent position of biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been the
subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our <FONT STYLE="white-space:nowrap">in-licensed</FONT> pending and future patent
applications may not result in patents being issued which protect vonoprazan or any future product candidates or which effectively prevent others from commercializing competitive product candidates. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted
after issuance. Even if patent applications we own in the future or license currently issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with
us, or otherwise provide us with any competitive advantage. Any future patents that we own or license, now </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">55 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
or in the future, may be challenged or circumvented by third parties or may be narrowed or invalidated as a result of challenges by third parties. Consequently, we do not know whether vonoprazan
or any future product candidates will be protectable or remain protected by valid and enforceable patents. Our competitors or other third parties may be able to circumvent our future patents or the patents of our current and future licensors by
developing similar or alternative technologies or products in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner which could materially adversely affect our business, financial condition, results of operations and prospects. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our future patents or the patents of our
current and future licensors may not cover vonoprazan or any future product candidates or may be challenged in the courts or patent offices in the United States and abroad. We may be subject to a third party
<FONT STYLE="white-space:nowrap">pre-issuance</FONT> submission of prior art to the USPTO, or become involved in opposition, derivation, revocation, reexamination, post-grant review, or PGR, and inter partes review, or IPR, or other similar
proceedings in the USPTO or foreign patent offices challenging our patent rights. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain
that there is no invalidating prior art, of which we or our predecessors and the patent examiner were unaware during prosecution. There is no assurance that all potentially relevant prior art relating to our
<FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications has been found. There is also no assurance that there is not prior art of which we, our predecessors or licensors are aware, but which we do not believe affects the
validity or enforceability of a claim in our <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications, which may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. An adverse
determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize vonoprazan or any future product candidates and compete directly
with us, without payment to us. It is possible that defects of form in the preparation or filing of our or our current and future licensors&#146; patents or patent applications may exist, or may arise in the future, for example with respect to
proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If there are material defects in the form, preparation, prosecution, or enforcement of our future patents or future patent applications or our current and
future licensors&#146; patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Any loss of patent rights, loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable could limit our ability to stop others from using or commercializing similar or identical
technology and products, or limit the duration of the patent protection of vonoprazan or any future product candidates, which could materially and adversely impact our business. Such proceedings also may result in substantial cost and require
significant time from our scientists and management, even if the eventual outcome is favorable to us. In addition, if the breadth or strength of protection provided by our future patents and future patent applications or the patents and patent
applications of our current and future licensors is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop or commercialize vonoprazan or any future product candidates. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>The patent protection and patent prosecution for vonoprazan or any future product candidates may be dependent on third parties. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We may rely on third parties to file and prosecute patent applications and maintain patents and otherwise protect the licensed intellectual property
under certain current and future license agreements, such as the Takeda License. Under such arrangements, we may not have primary control over these activities for certain of licensed patents or patent applications and other intellectual property
rights. We cannot be certain that such activities by third parties have been or will be conducted in compliance with applicable laws and regulations or will result in valid and enforceable patents or other
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">56 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
intellectual property rights. In addition, our current and future licensors may not be fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent
rights, which could compromise such patent rights. We may in the future enter into license agreements where the licensors may have the right to control enforcement of our licensed patents or defense of any claims asserting the invalidity of these
patents and even if we are permitted to pursue such enforcement or defense, we will require the cooperation of our licensors. We cannot be certain that our licensors will allocate sufficient resources or prioritize their or our enforcement of such
patents or defense of such claims to protect our interests in the licensed patents. Even if we are not a party to these legal actions, an adverse outcome could harm our business because it might prevent us from continuing to license intellectual
property that we may need to operate our business. If any of our licensors or any of our future licensors or future collaborators fail to appropriately prosecute and maintain patent protection for patents covering vonoprazan or any future product
candidates, our ability to develop and commercialize those product candidates may be adversely affected and we may not be able to prevent competitors from making, using and selling competing products. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, even where we have the right to control prosecution of patent applications or enforcement of patents we have acquired or licensed from
third parties, we may still be adversely affected or prejudiced by actions or inactions of our predecessors or licensors and their counsel that took place prior to us assuming control over such activities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Third parties may retain certain rights to the technology that they license to us, including the right to use the underlying technology for
noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. For example, under the
Takeda License, Takeda retained the rights to the inventions in all countries other than the United States, Europe, and Canada. Takeda also retained the right to development certain drug products that contain vonoprazan where vonoprazan is not the
only active pharmaceutical ingredient. It is difficult to monitor whether our predecessors or licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the
event of misuse. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If we are limited in our ability to utilize acquired or licensed technologies, or if we lose our rights to critical <FONT
STYLE="white-space:nowrap">in-licensed</FONT> technology, we may be unable to successfully develop, <FONT STYLE="white-space:nowrap">out-license,</FONT> market and sell our products, which could prevent or delay new product introductions. Our
business strategy depends on the successful development of licensed and acquired technologies into commercial products. Therefore, any limitations on our ability to utilize these technologies may impair our ability to develop, <FONT
STYLE="white-space:nowrap">out-license</FONT> or market and sell our product candidate. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Intellectual property rights do not necessarily address
all potential threats to our competitive advantage. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The degree of future protection afforded by our intellectual property rights
is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">others may be able to develop products that are similar to vonoprazan or any future product candidates but that are not covered by the claims of the patents that
we own in the future or license; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">we or our current and future licensors or predecessors might not have been the first to make the inventions covered by the issued patents or patent applications
that we own in the future or license; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">we or our current and future licensors or predecessors might not have been the first to file patent applications covering certain of the claimed inventions;
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">57 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">it is possible that the pending patent applications we own or license will not lead to issued patents; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">issued patents that we own in the future or license may be held invalid or unenforceable, as a result of legal challenges by our competitors;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such
activities to develop competitive products for sale in our major commercial markets; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">we may not develop additional proprietary technologies that are patentable; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the patents of others may have an adverse effect on our business. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Should any of these events occur, it could significantly harm our business, results of operations and prospects. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims
by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Our commercial success depends in part on avoiding infringement of the patents and proprietary rights of third parties. However, our research, development and commercialization activities may be subject to claims
that we infringe or otherwise violate patents or other intellectual property rights owned or controlled by third parties. Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale
or import vonoprazan and any future product candidates and products that may be approved in the future, or impair our competitive position. There is a substantial amount of litigation, both within and outside the United States, involving patent and
other intellectual property rights in the biopharmaceutical industry, including patent infringement lawsuits, oppositions, reexaminations, IPR proceedings and PGR proceedings before the USPTO and/or foreign patent offices. Numerous third-party U.S.
and foreign issued patents and pending patent applications exist in the fields in which we are developing product candidates. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or
methods for treatment related to the use or manufacture of vonoprazan and any future product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As the biopharmaceutical
industry expands and more patents are issued, the risk increases that vonoprazan and any future product candidates may be subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained as
confidential for a certain period of time, until the relevant application is published we may be unaware of third-party patents that may be infringed by commercialization of vonoprazan and any future product candidates, and we cannot be certain that
we were the first to file a patent application related to a product candidate or technology. Moreover, because patent applications can take many years to issue, there may be currently-pending patent applications that may later result in issued
patents that vonoprazan and any future product candidates may infringe. In addition, identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in
terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Any claims
of patent infringement asserted by third parties would be time consuming and could: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">result in costly litigation that may cause negative publicity; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">58 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">divert the time and attention of our technical personnel and management; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">cause development delays; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">prevent us from commercializing vonoprazan and any future product candidates until the asserted patent expires or is held finally invalid or not infringed in a
court of law; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">require us to develop <FONT STYLE="white-space:nowrap">non-infringing</FONT> technology, which may not be possible on a cost-effective basis;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">subject us to significant liability to third parties; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all, or which might be <FONT
STYLE="white-space:nowrap">non-exclusive,</FONT> which could result in our competitors gaining access to the same technology. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Although no third party has asserted a claim of patent infringement against us as of the date of this prospectus, others may hold proprietary rights that could prevent vonoprazan and any future product candidates
from being marketed. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Any patent-related legal action against us claiming damages and seeking to enjoin activities relating to
vonoprazan and any future product candidates or processes could subject us to potential liability for damages, including treble damages if we were determined to willfully infringe, and require us to obtain a license to manufacture or develop
vonoprazan and any future product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. We cannot predict whether we
would prevail in any such actions or that any license required under any of these patents would be made available on commercially acceptable terms, if at all. Moreover, even if we or our future strategic partners were able to obtain a license, the
rights may be nonexclusive, which could result in our competitors gaining access to the same intellectual property. In addition, we cannot be certain that we could redesign vonoprazan and any future product candidates or processes to avoid
infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing vonoprazan and any future product
candidates, which could harm our business, financial condition and operating results. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Parties making claims against us may be able to
sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation
or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material
adverse effect on our ability to raise additional funds or otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>We may not be successful in obtaining or maintaining necessary rights to vonoprazan and any future product candidates through acquisitions and <FONT STYLE="white-space:nowrap">in-licenses.</FONT>
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Because our development programs may in the future require the use of proprietary rights held by other third parties, the growth
of our business may depend in part on our ability to acquire, <FONT STYLE="white-space:nowrap">in-license,</FONT> or use these third-party proprietary rights. We may be unable to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> any
compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for vonoprazan and any future product candidates. The licensing and acquisition of third-party intellectual
property rights is a competitive area, and a number of more established </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">59 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage
over us due to their size, cash resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to
license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain
the existing intellectual property rights we have, we may have to abandon development of that program and our business and financial condition could suffer. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>We may be involved in lawsuits to protect or enforce our future patents or the patents of our current and future licensors, which could be expensive, time consuming and unsuccessful. Further, our future
issued patents or the patents of our current and future licensors could be found invalid or unenforceable if challenged in court. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Competitors may infringe our intellectual property rights or those of our current and future licensors. To prevent infringement or unauthorized use,
we and/or any such licensors may be required to file infringement claims, which can be expensive and time consuming. In addition, in a patent infringement proceeding, a court may decide that a patent we own or license is not valid, is unenforceable
and/or is not infringed. If we or any of our current and future licensors were to initiate legal proceedings against a third party to enforce a patent directed at vonoprazan and any future product candidates, the defendant could counterclaim that
our patent or the patent of our current or future licensor is invalid and/or unenforceable in whole or in part. In patent litigation, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity
challenge include an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description, <FONT STYLE="white-space:nowrap">non-enablement,</FONT> or obviousness-type double patenting. Grounds
for an unenforceability assertion could include an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the
patent protection on such product candidate. In addition, if the breadth or strength of protection provided by our future patents and future patent applications or those of our current and future licensors is threatened, it could dissuade companies
from collaborating with us to license, develop or commercialize current or future product candidates. Such a loss of patent protection would have a material adverse impact on our business. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant
expenses, and could distract our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or
any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or
proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal
proceedings relating to our intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">60 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the
market price of our common shares to decline. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">During the course of any intellectual property litigation, there could be public
announcements of the initiation of the litigation as well as results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of
our existing products, programs or intellectual property could be diminished. Accordingly, the market price of shares of our common stock may decline. Such announcements could also harm our reputation or the market for our future products, which
could have a material adverse effect on our business. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Derivation or interference proceedings may be necessary to determine priority of
inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Derivation or interference proceedings provoked by third parties or brought by us or declared by the USPTO or similar proceedings in foreign patent offices may be necessary to determine the priority of inventions
with respect to our future patents or future patent applications or those of our current and future licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing
party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of such proceedings may fail and, even if successful, may result in substantial costs and distract our management
and other employees. In addition, the uncertainties associated with such proceedings could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary
technology from third parties or enter into development or manufacturing partnerships that would help us bring vonoprazan and any future product candidates to market. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our future patent applications or those of our current and future licensors and the enforcement or
defense of our future issued patents or those of our current and future licensors. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">On September&nbsp;16, 2011, the Leahy-Smith
America Invents Act, or Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect
patent litigation. In particular, under the Leahy-Smith Act, the United States transitioned in March 2013 to a &#147;first inventor to file&#148; system in which, assuming that other requirements of patentability are met, the first inventor to file
a patent application will be entitled to the patent regardless of whether a third party was first to invent the claimed invention. A third party that files a patent application in the USPTO after March 2013 but before us could therefore be awarded a
patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Furthermore, our ability
to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Since patent applications in the United States and most other
countries are confidential for a period of time after filing or until issuance, we may not be certain that we or our current and future licensors are the first to either (1)&nbsp;file any patent application related to vonoprazan and any future
product candidates or (2)&nbsp;invent any of the inventions claimed in the patents or patent applications. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The Leahy-Smith Act also
includes a number of significant changes that affect the way patent applications will be prosecuted and also may affect patent litigation. These include allowing third-party </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">61 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant proceedings, including PGR, IPR, and
derivation proceedings. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to
invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a
district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Thus,
the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our future patent applications or those of our current and future licensors and the enforcement or defense of our future issued
patents or those of our current and future licensors, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect vonoprazan and any future product candidates.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly
patents. Obtaining and enforcing patents in the biopharmaceutical industry involve a high degree of technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time consuming and inherently uncertain.
Changes in either the patent laws or in the interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property and may increase the uncertainties and costs surrounding the prosecution of
patent applications and the enforcement or defense of issued patents. We cannot predict the breadth of claims that may be allowed or enforced in our future patents or in third-party patents. In addition, Congress or other foreign legislative bodies
may pass patent reform legislation that is unfavorable to us. For example, a new bill (Terminating the Extension of Rights Misappropriated Act H.R. 3199) percolating through the United States Congress aims to reduce the term of certain drug patents
in order to ease generic entry and increase competition. Evolving judicial interpretation of patent law could also adversely affect our business. For example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing
the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of
events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the U.S. federal courts, the USPTO, or similar authorities in foreign jurisdictions, the laws and regulations governing
patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce the existing licensed patents and the patents we might obtain or license in the future. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We may be subject to claims challenging the inventorship or ownership of our future patents, the patents of our current and future licensors, or other
intellectual property. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We may also be subject to claims that former employees or other third parties have an ownership interest
in our future patents,<I> </I>the patents of our current and future licensors or other intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any
such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation
could result in substantial costs and distraction to management and other employees. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">62 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Patent terms may be inadequate to protect our competitive position on vonoprazan and any future product
candidates for an adequate amount of time. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Patents have a limited lifespan. In the United States, if all maintenance fees are
timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. Various extensions may be available, but the life of a patent, and the protection it
affords, is limited. Even if patents covering vonoprazan and any future product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products. Given the amount of time required for the
development, testing and regulatory review of product candidates, patents protecting vonoprazan and any future product candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not
provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>If we do not obtain patent term
extension for vonoprazan and any future product candidates, our business may be materially harmed. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Depending upon the timing,
duration and specifics of FDA marketing approval of vonoprazan and any future product candidates, one or more of our U.S. patents or those of our current and future licensors, may be eligible for limited patent term restoration under the Drug Price
Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Amendments. The Hatch- Waxman Amendments permit a patent restoration term of up to five years as compensation for patent term lost during product development and the FDA
regulatory review process. A maximum of one patent may be extended per FDA approved product as compensation for the patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent
beyond a total of 14 years from the date of product approval and only those claims covering such approved drug product, a method for using it or a method for manufacturing it may be extended. Patent term extension may also be available in certain
foreign countries upon regulatory approval of vonoprazan and any future product candidates. However, we may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of
relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration
or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially. Further, if this occurs, our competitors may
take advantage of our investment in development and trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>We may not be able to protect our intellectual property rights throughout our licensed territories. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Although we have issued patents and pending patent applications in the United States and certain other countries in which we intend to commercialize our products, filing, prosecuting and defending patents in all
relevant countries throughout the could be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign
countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United
States or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own
products and, further, may export otherwise infringing products to territories where we have patent protection but enforcement is not as strong as that in the United States. These products may compete with vonoprazan or any future product
candidates, and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">63 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
our patents, the patents of our current and future licensors or other intellectual property rights may not be effective or sufficient to prevent them from competing. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal
systems of many foreign countries do not favor the enforcement of patents and other intellectual property protection, which could make it difficult for us to stop the infringement of our intellectual property rights or marketing of competing
products in violation of our proprietary rights. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our future
patents or the patents of our current and future licensors at risk of being invalidated or interpreted narrowly and our future patent applications or the patent applications of our current and future licensors at risk of not issuing and could
provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual
property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government
agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents relevant
to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by regulations and governmental patent agencies, and our
patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the USPTO and various foreign patent offices at various points over the
lifetime of our future patents and/or future applications and those of our current and future licensors. We have systems in place to remind us to pay these fees, and we rely on third parties to pay these fees when due. Additionally, the USPTO and
various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and
in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse
of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, we rely on the protection of our trade secrets, including unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> technology and
other proprietary information to maintain our competitive position. Although we have taken steps to protect our trade secrets and unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> including entering into confidentiality agreements with
third parties, and confidential information and inventions agreements with employees, consultants and advisors, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach the agreements and
disclose our </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">64 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a
trade secret is difficult, expensive and time consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Moreover, third parties may still obtain this information or may come upon this or similar information independently, and we would have no right to
prevent them from using that technology or information to compete with us. If any of these events occurs or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced and our competitive position
would be harmed. If we cannot otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to protect our trade secret information may be jeopardized. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged
confidential information or trade secrets of their former employers. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As is common in the biopharmaceutical industry, in addition
to our employees, we engage the services of consultants to assist us in the development of vonoprazan and any future product candidates. Many of these consultants, and many of our employees, were previously employed at, or may have previously
provided or may be currently providing consulting services to, other biopharmaceutical companies including our competitors or potential competitors. We may become subject to claims that we, our employees or a consultant inadvertently or otherwise
used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying
monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely affect our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a
distraction to our management team and other employees. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>If our trademarks and trade names are not adequately protected, then we may not be able
to build name recognition in our markets of interest and our business may be adversely affected. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We intend to use registered or
unregistered trademarks or trade names to brand and market ourselves and our products. Our trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to
protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby
impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks or trademarks that incorporate variations
of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely
affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our
trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade
secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our financial condition or results of operations. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">65 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Any collaboration arrangements that we have or may enter into in the future may not be successful, which
could adversely affect our ability to develop and commercialize our products. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The success of our collaboration arrangements will
depend heavily on the efforts and activities of our collaborators and partners. Under the Takeda License, for example, Takeda has certain obligations with respect to assisting with the transition of information and materials to us as well as
providing clinical and commercial supply of the vonoprazan product. Collaborations and partnerships are subject to numerous risks, which may include that: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">collaborators have significant discretion in determining the efforts and resources that they will apply to collaborations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">collaborators may not pursue development and commercialization of our products or may elect not to continue or renew development or commercialization programs
based on trial or test results, changes in their strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing
priorities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a collaborator with marketing, manufacturing and distribution rights to one or more products may not commit sufficient resources to or otherwise not perform
satisfactorily in carrying out these activities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">we could grant exclusive rights to our collaborators that would prevent us from collaborating with others; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that
gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">disputes may arise between us and a collaborator that causes the delay or termination of the research, development or commercialization of our current or future
products or that results in costly litigation or arbitration that diverts management attention and resources; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">collaborations may be terminated, and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the
applicable current or future products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">&#149;</FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">collaborators may own or <FONT STYLE="white-space:nowrap">co-own</FONT> intellectual property covering our products that results from our collaborating with
them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a collaborator&#146;s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal
proceedings. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Intellectual property discovered through government funded programs may be subject to federal regulations such as <FONT
STYLE="white-space:nowrap">&#147;march-in&#148;</FONT> rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> manufacturers. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We may acquire or license in the future intellectual property rights
that have been generated through the use of U.S. government funding or grant. Pursuant to the Bayh-Dole Act of 1980, the U.S. government has certain rights in inventions developed with government funding. These U.S. government rights include a <FONT
STYLE="white-space:nowrap">non-exclusive,</FONT> <FONT STYLE="white-space:nowrap">non-transferable,</FONT> irrevocable worldwide license to use </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">66 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
inventions for any governmental purpose. In addition, the U.S. government has the right, under certain limited circumstances, to require us to grant exclusive, partially exclusive, or <FONT
STYLE="white-space:nowrap">non-exclusive</FONT> licenses to any of these inventions to a third party if it determines that: (i)&nbsp;adequate steps have not been taken to commercialize the invention; (ii)&nbsp;government action is necessary to meet
public health or safety needs; or (iii)&nbsp;government action is necessary to meet requirements for public use under federal regulations (also referred to as <FONT STYLE="white-space:nowrap">&#147;march-in</FONT> rights&#148;). The U.S. government
also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an application to register the intellectual property within specified time limits. Intellectual property
generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In addition, the U.S. government requires that any products embodying any of these
inventions or produced through the use of any of these inventions be manufactured substantially in the United States. This preference for U.S. industry may be waived by the federal agency that provided the funding if the owner or assignee of the
intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances
domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with <FONT STYLE="white-space:nowrap">non-U.S.</FONT> product manufacturers for products covered by such intellectual property.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Risks Related to Our Common Stock and This Offering </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>An active, liquid and orderly market for our common stock may not develop, and you may not be able to resell your common stock at or above the public offering price. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Prior to this offering, there has been no public market for our common stock. Although our common stock has been approved for listing on Nasdaq, an
active trading market for our common stock may never develop or be sustained following this offering. We and the representatives of the underwriters determined the initial public offering price of our common stock through negotiation. This price
does not necessarily reflect the price at which investors in the market will be willing to buy and sell our shares following this offering. In addition, an active trading market may not develop following the consummation of this offering or, if it
is developed, may not be sustained. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you consider reasonable. An inactive market may also impair our ability to raise
capital by selling shares and may impair our ability to acquire other businesses or technologies using our shares as consideration, which, in turn, could materially adversely affect our business. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>The trading price of the shares of our common stock could be highly volatile, and purchasers of our common stock could incur substantial losses.
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our stock price is likely to be volatile. The stock market in general and the market for stock of biopharmaceutical companies in
particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors may not be able to sell their common stock at or above the initial public
offering price. The market price for our common stock may be influenced by those factors discussed in this &#147;Risk Factors&#148; section and many others, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">our ability to enroll patients in our planned clinical trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">results of our clinical trials and preclinical studies, the results of clinical trials conducted by Takeda and others for vonoprazan, and the results of trials
of our competitors or those of other companies in our market sector; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">regulatory approval of vonoprazan and any future product candidates, or limitations to specific label indications or patient populations for its use, or changes
or delays in the regulatory review process; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">67 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">any termination or loss of rights under the Takeda License; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">regulatory developments in the United States and foreign countries; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">changes in the structure of healthcare payment systems, especially in light of current reforms to the U.S. healthcare system; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the success or failure of our efforts to acquire, license or develop additional product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">innovations or new products developed by us or our competitors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures or capital commitments; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">manufacturing, supply or distribution delays or shortages; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">any changes to our relationship with any manufacturers, suppliers, licensors, future collaborators or other strategic partners; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">achievement of expected product sales and profitability; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">variations in our financial results or those of companies that are perceived to be similar to us; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">market conditions in the biopharmaceutical sector and issuance of securities analysts&#146; reports or recommendations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">trading volume of our common stock; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">an inability to obtain additional funding; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">sales of our stock by insiders and stockholders, including Takeda; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">general economic, industry and market conditions other events or factors, many of which are beyond our control; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">additions or departures of key personnel; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">intellectual property, product liability or other litigation against us; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">changes in our capital structure, such as future issuances of securities and the incurrence of additional debt; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">changes in accounting standards, policies, guidelines, interpretations or principles. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, in the past, stockholders have initiated class action lawsuits against biopharmaceutical companies following periods of volatility in
the market prices of these companies&#146; stock. Such litigation, if instituted against us, could cause us to incur substantial costs and divert management&#146;s attention and resources, which could have a material adverse effect on our business,
financial condition and results of operations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Our failure to meet the continued listing requirements of the Nasdaq could result in a delisting
of our common stock. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If, after listing, we fail to satisfy the continued listing requirements of the Nasdaq, such as the
corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair your ability to
sell or purchase our common stock when you wish to do so. In the event of a delisting, any action taken by us to restore compliance with listing requirements may not allow our common stock to become listed again, stabilize the market price or
improve the liquidity of our common stock, prevent our common stock from dropping below the Nasdaq minimum bid price requirement or prevent future <FONT STYLE="white-space:nowrap">non-compliance</FONT> with Nasdaq&#146;s listing requirements.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">68 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We may allocate the net proceeds from this offering in ways that you and other stockholders may not
approve. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our management will have broad discretion in the application of the net proceeds from this offering, including for any
of the purposes described in the section titled &#147;Use of Proceeds.&#148; Because of the number and variability of factors that will determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their
currently intended use. Our management might not apply our net proceeds in ways that ultimately increase the value of your investment, and the failure by our management to apply these funds effectively could harm our business. Pending their use, we
may invest the net proceeds from this offering in short- and intermediate-term, investment grade interest-bearing instruments. These investments may not yield a favorable return to our stockholders. If we do not invest or apply the net proceeds from
this offering in ways that enhance stockholder value, we may fail to achieve expected results, which could cause our stock price to decline. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>You
will suffer immediate and substantial dilution in the net tangible book value of the common stock you purchase. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The initial
public offering price of our common stock is substantially higher than the pro forma as adjusted net tangible book value per share of our outstanding common stock immediately after the completion of this offering. Purchasers of common stock in this
offering will experience immediate dilution of approximately $10.85 per share, based on the initial public offering price of $19.00 per share. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>After this offering, our executive officers, directors and principal stockholders, if they choose to act together, will continue to have the ability to
control or significantly influence all matters submitted to stockholders for approval. Furthermore, many of our current directors were appointed by our principal stockholders. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Following the completion of this offering, our executive officers, directors and greater than 5% stockholders, in the aggregate, will own
approximately 45.0% of our outstanding common stock (assuming no exercise of the underwriters&#146; option to purchase additional shares and no exercise of outstanding options, warrants or other rights, and without giving effect to any purchases
that these holders may make through our directed share program), based on the initial public offering price of $19.00 per share. Furthermore, many of our current directors were appointed by our principal stockholders. As a result, such persons or
their appointees to our board of directors, acting together, will have the ability to control or significantly influence all matters submitted to our board of directors or stockholders for approval, including the appointment of our management, the
election and removal of directors and approval of any significant transaction, as well as our management and business affairs. In addition, if any of our executive officers, directors and greater than 5% stockholders purchase shares in this
offering, or if any of our other current investors purchase shares in this offering and become greater than 5% stockholders as a result, the ability of such persons, acting together, to control or significantly influence such matters will increase.
This concentration of ownership may have the effect of delaying, deferring or preventing a change in control, impeding a merger, consolidation, takeover or other business combination involving us, or discouraging a potential acquiror from making a
tender offer or otherwise attempting to obtain control of our business, even if such a transaction would benefit other stockholders. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We do not
currently intend to pay dividends on our common stock, and, consequently, your ability to achieve a return on your investment will depend on appreciation, if any, in the price of our common stock. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have never declared or paid any cash dividend on our common stock. We currently anticipate that we will retain future earnings for the
development, operation and expansion of our business and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">69 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, under the terms of the Loan Agreement, we are prohibited from paying any cash dividends without
the consent of the lenders. Any return to stockholders will therefore be limited to the appreciation of their stock. Shares of our common stock may not appreciate in value or even maintain the price at which stockholders have purchased their shares.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Sales of a substantial number of shares of our common stock by our existing stockholders, including Takeda, in the public market could cause our
stock price to fall. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Sales of a substantial number of shares of our common stock in the public market or the perception that
these sales might occur could significantly reduce the market price of our common stock and impair our ability to raise adequate capital through the sale of additional equity securities. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Based on shares of common stock outstanding as of June&nbsp;30, 2019, upon the closing of this offering, we will have outstanding a total of
27,547,593 shares of common stock after this offering, assuming no exercise of the underwriters&#146; option to purchase additional shares and no exercise of outstanding options, warrants or other rights. Of these shares, only the 9,563,157 shares
of common stock sold in this offering by us, plus any shares sold upon exercise of the underwriters&#146; option to purchase additional shares, will be freely tradable, without restriction, in the public market immediately following this offering,
unless they are purchased by one of our affiliates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, immediately following the completion of this offering, Takeda will
beneficially own 24.7%&nbsp;of our outstanding shares of common stock, including 7,588,000 shares of common stock issuable pursuant to the Takeda Warrant (or 23.7%&nbsp;if the underwriters exercise their option to purchase additional shares in
full). The sale by Takeda of a substantial number of shares after this offering, or a perception that such sales could occur, could significantly reduce the market price of our common stock. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our officers, directors and holders of substantially all of our outstanding securities have entered into
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters pursuant to which they may not, with limited exceptions, for a period of 180 days from the date of this prospectus, offer, sell or otherwise transfer or dispose of any
of our securities, without the prior written consent of Goldman Sachs&nbsp;&amp; Co. LLC, Jefferies LLC and Evercore Group L.L.C. The underwriters may permit our officers, directors and other securityholders who are subject to the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements to sell shares prior to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, subject to limitations. Sales of these shares, or perceptions that they will be sold,
could cause the trading price of our common stock to decline. After the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements expire, up to an additional 17,984,436 shares of common stock will be eligible for sale in the public market of which
13,414,828 shares are held by directors, executive officers and other affiliates and will be subject to volume limitations under Rule 144 under the Securities Act. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">In addition, as of June&nbsp;30, 2019, up to 9,819,925&nbsp;shares of common stock that are either subject to outstanding options, warrants or other rights or reserved for future issuance under our employee benefit
plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, exercise limitations, the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and Rule 144 and Rule 701 under the
Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of our common stock could decline. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">After this offering, the holders of 12,069,916 shares of our outstanding common stock, or approximately 43.8% of our total outstanding common stock
as of June&nbsp;30, 2019, will be entitled to rights with respect to the registration of their shares under the Securities Act, subject to vesting and the <FONT STYLE="white-space:nowrap">180-day</FONT>
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above. In addition, upon the closing of this offering Takeda will be entitled to the same rights with respect to the registration of 7,588,000 shares of our common stock
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">70 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
underlying the Takeda Warrant. Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for
shares held by affiliates, as defined in Rule 144 under the Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We are an emerging growth company and a smaller reporting company, and the reduced disclosure requirements applicable to emerging growth companies and
smaller reporting company may make our common stock less attractive to investors. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We are an emerging growth company, as defined
in the JOBS Act, and may remain an emerging growth company until the last day of the fiscal year following the fifth anniversary of the completion of this offering. However, if certain events occur prior to the end of such five-year period,
including if we become a &#147;large accelerated filer&#148; as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Exchange Act, our annual gross revenues exceed $1.07&nbsp;billion or we issue more than $1.0&nbsp;billion of <FONT
STYLE="white-space:nowrap">non-convertible</FONT> debt in any three-year period, we will cease to be an emerging growth company prior to the end of such five-year period. For so long as we remain an emerging growth company, we are permitted and
intend to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not emerging growth companies. These exemptions include: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements, with
correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting pursuant to the
Sarbanes-Oxley Act; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or
a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements, unless the SEC, determines the new rules are necessary for protecting the public; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">reduced disclosure obligations regarding executive compensation; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not
previously approved. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have taken advantage of reduced reporting burdens in this prospectus. In particular, we have
not included all of the executive compensation related information that would be required if we were not an emerging growth company. Investors may find our common stock less attractive if we rely on these exemptions. If some investors find our
common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be reduced or more volatile. In addition, the JOBS Act provides that an emerging growth company can take advantage of an
extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of these accounting standards until they would otherwise apply to private companies. We have irrevocably
elected not to avail ourselves of this exemption and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We are also a smaller reporting company as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no
longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our voting and non-voting common
stock held by non-affiliates is less than $250.0&nbsp;million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">71 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0&nbsp;million measured on the last business day of our second fiscal quarter. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new
compliance initiatives. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As a public company, we will incur significant legal, accounting and other expenses that we did not
incur as a private company. We will be subject to the reporting requirements of the Exchange Act, which will require, among other things, that we file with the SEC, annual, quarterly and current reports with respect to our business and financial
condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and Nasdaq to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment and
maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, the SEC has adopted additional rules and
regulations in these areas, such as mandatory &#147;say on pay&#148; voting requirements that will apply to us when we cease to be an emerging growth company. Stockholder activism, the current political environment and the current high level of
government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently
anticipate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We expect the rules and regulations applicable to public companies to substantially increase our legal and financial
compliance costs and to make some activities more time consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business,
financial condition and results of operations. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For
example, we expect these rules and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to incur substantial costs to maintain the same or similar coverage. We
cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our
board of directors, our board committees or as executive officers. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>If securities or industry analysts do not publish research or reports or
publish unfavorable research or reports about our business, our stock price and trading volume could decline. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The trading market
for our common stock will depend in part on the research and reports that securities or industry analysts publish about us, our business, our market or our competitors. We do not currently have and may never obtain research coverage by securities
and industry analysts. If no securities or industry analysts commence coverage of our company, the trading price for our stock would be negatively impacted. In the event we obtain securities or industry analyst coverage, if one or more of the
analysts who covers us downgrades our stock, our stock price would likely decline. If one or more of these analysts ceases to cover us or fails to regularly publish reports on us, interest in our stock could decrease, which could cause our stock
price or trading volume to decline. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>If we fail to maintain proper and effective internal control over financial reporting, our ability to produce
accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Pursuant to Section&nbsp;404 of Sarbanes-Oxley, our management will be required to report upon the effectiveness of our internal control over
financial reporting beginning with our second annual report after this offering. When we lose our status as an &#147;emerging growth company&#148; and reach an </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">72 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
accelerated filer threshold, our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting. The rules
governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting
company under the Exchange Act, we will need to upgrade our information technology systems; implement additional financial and management controls, reporting systems and procedures; and hire additional accounting and finance staff. If we or, if
required, our auditors are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting and the trading price of our common stock may decline. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">There could be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to
maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting
is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting once that firm begin its Section&nbsp;404 reviews, investors may
lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to
remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Provisions in our charter documents and under Delaware law could discourage a takeover that stockholders may consider favorable and may lead to entrenchment
of management. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our amended and restated certificate of incorporation and amended and restated bylaws that will be in effect
immediately prior to the consummation of this offering will contain provisions that could significantly reduce the value of our shares to a potential acquiror or delay or prevent changes in control or changes in our management without the consent of
our board of directors. The provisions in our charter documents will include the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a classified board of directors with three-year staggered terms, which may delay the ability of stockholders to change the membership of a majority of our board
of directors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">no cumulative voting in the election of directors, which limits the ability of minority stockholders to elect director candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the exclusive right of our board of directors, unless the board of directors grants such right to the stockholders, to elect a director to fill a vacancy created
by the expansion of the board of directors or the resignation, death or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the required approval of at least <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of the shares entitled to vote to remove a director for cause, and the
prohibition on removal of directors without cause; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the ability of our board of directors to authorize the issuance of shares of preferred stock and to determine the price and other terms of those shares,
including preferences and voting rights, without stockholder approval, which could be used to significantly dilute the ownership of a hostile acquiror; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the ability of our board of directors to alter our amended and restated bylaws without obtaining stockholder approval; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the required approval of at least <FONT STYLE="white-space:nowrap">66-2/3%</FONT> of the shares entitled to vote to adopt, amend or repeal our amended and
restated bylaws or repeal the provisions of our amended and restated certificate of incorporation regarding the election and removal of directors; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">73 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a prohibition on stockholder action by written consent, which forces stockholder action to be taken at an annual or special meeting of our stockholders;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">an exclusive forum provision providing that the Court of Chancery of the State of Delaware will be the exclusive forum for certain actions and proceedings;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the requirement that a special meeting of stockholders may be called only by the board of directors, which may delay the ability of our stockholders to force
consideration of a proposal or to take action, including the removal of directors; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">advance notice procedures that stockholders must comply with in order to nominate candidates to our board of directors or to propose matters to be acted upon at
a stockholders&#146; meeting, which may discourage or deter a potential acquiror from conducting a solicitation of proxies to elect the acquiror&#146;s own slate of directors or otherwise attempting to obtain control of us.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We are also subject to the anti-takeover provisions contained in Section&nbsp;203 of the Delaware General Corporation
Law. Under Section&nbsp;203, a corporation may not, in general, engage in a business combination with any holder of 15% or more of its capital stock unless the holder has held the stock for three years or, among other exceptions, the board of
directors has approved the transaction. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Our amended and restated certificate of incorporation and amended and restated bylaws will provide that
the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or
our directors, officers or employees. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our amended and restated certificate of incorporation and amended and restated bylaws will
provide that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf under Delaware statutory or common law, including any action asserting a breach of fiduciary duty, any
action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws, or any action asserting a claim against us that is governed by
the internal affairs doctrine; provided, that, this provision would not apply to suits brought to enforce a duty or liability created by the Securities Act or the Exchange Act, or any other claim for which the federal courts have exclusive
jurisdiction. To the extent that any such claims may be based upon federal law claims, Section&nbsp;27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or
the rules and regulations thereunder. The choice of forum provisions in our amended and restated certificate of incorporation may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or
our directors, officers or other employees, which may discourage such lawsuits against us and our directors, officers and other employees. By agreeing to these provisions, however, stockholders will not be deemed to have waived our compliance with
the federal securities laws and the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other companies&#146; certificates of incorporation has been challenged in legal proceedings, and it is
possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the choice of forum provisions in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an
action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Our ability to use net operating loss carryforwards and other tax attributes may be limited in connection with this offering or other ownership changes. </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have incurred substantial losses during our history and do not expect to become profitable in the near future, and we may never achieve
profitability. To the extent that we continue to generate </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">74 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire (if at all). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Under recently enacted U.S. tax legislation, federal net operating loss, or NOL, carryforwards generated in periods after December&nbsp;31, 2017,
may be carried forward indefinitely but may only be used to offset 80% of our taxable income annually. Our NOL carryforwards are subject to review and possible adjustment by the Internal Revenue Service, or the IRS, and state tax authorities. Under
Section&nbsp;382 of the Internal Revenue Code of 1986, as amended, or the Code, our federal NOL carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders
over a three-year period in excess of 50 percentage points. Our ability to utilize our NOL carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes, including potential
changes in connection with this offering. Similar rules may apply under state tax laws. We have not yet determined the amount of the cumulative change in our ownership resulting from this offering or other transactions, or any resulting limitations
on our ability to utilize our NOL carryforwards and other tax attributes. If we earn taxable income, such limitations could result in increased future tax liability to us and our future cash flows could be adversely affected. We have recorded a full
valuation allowance related to our NOLs and other deferred tax assets due to the uncertainty of the ultimate realization of the future benefits of those assets. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Recent U.S. tax legislation may materially adversely affect our financial condition, results of operations and cash flows. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The Tax Act has significantly changed the U.S. federal income taxation of U.S. corporations, including by reducing the U.S. corporate income tax rate and revising the rules governing NOLs. Many of these changes
became effective beginning in 2018, without any transition periods or grandfathering for existing transactions. The legislation is unclear in many respects and could be subject to potential amendments and technical corrections, as well as
interpretations and implementing regulations by the U.S. Treasury Department and the IRS, any of which could lessen or increase certain adverse impacts of the legislation. In addition, it is unclear how these U.S. federal income tax changes will
affect state and local taxation, which often uses federal taxable income as a starting point for computing state and local tax liabilities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">There may be other material adverse effects resulting from the legislation that we have not yet identified. While some of the changes made by the tax legislation may adversely affect us in one or more reporting
periods and prospectively, other changes may be beneficial on a going forward basis. We continue to work with our tax advisors to determine the full impact that the recent tax legislation as a whole will have on us. We urge our investors to consult
with their legal and tax advisors with respect to such legislation and the potential tax consequences of investing in our common stock. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>We could
be subject to securities class action litigation. </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In the past, securities class action litigation has often been brought against
a company following a decline in the market price of its securities. This risk is especially relevant for us, because biotechnology and pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such
litigation, it could result in substantial costs and a diversion of management&#146;s attention and resources, which could harm our business. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">75 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">This prospectus contains forward-looking statements. All statements other than statements of historical facts contained in this prospectus,
including statements regarding our future results of operations and financial position, business strategy, research and development plans, the anticipated timing, costs, design and conduct of our planned clinical trials for vonoprazan, our only
product candidate, the timing and likelihood of regulatory filings and approvals for vonoprazan, our ability to commercialize vonoprazan, if approved, the pricing and reimbursement of vonoprazan, if approved, the potential to develop future product
candidates, the potential benefits of strategic collaborations and our intent to enter into any strategic arrangements, the timing and likelihood of success, plans and objectives of management for future operations, and future results of anticipated
product development efforts, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from
any future results, performance or achievements expressed or implied by the forward-looking statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In some cases, you can identify
forward-looking statements by terms such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;could,&#148; &#147;intend,&#148; &#147;target,&#148; &#147;project,&#148;
&#147;contemplates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential&#148; or &#147;continue&#148; or the negative of these terms or other similar expressions. The forward-looking statements in this prospectus
are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations.
These forward-looking statements speak only as of the date of this prospectus and are subject to a number of risks, uncertainties and assumptions described under the sections titled &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and
Analysis of Financial Condition and Results of Operations&#148; and elsewhere in this prospectus. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which
are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ
materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors
and uncertainties. Except as required by applicable law, we undertake no obligation to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or
otherwise. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this prospectus. See the section titled &#147;Where You Can Find More Information.&#148;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, statements that &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the relevant subject.
These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements
should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and you are cautioned not to rely unduly upon them. </FONT></P>

 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">76 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_4"></A>MARKET AND INDUSTRY DATA </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We obtained the industry, market and competitive position data used throughout this prospectus from our own internal estimates and research, as
well as from independent market research, industry and general publications and surveys, governmental agencies and publicly available information in addition to research, surveys and studies conducted by third parties. Internal estimates are derived
from publicly available information released by industry analysts and third-party sources, our internal research and our industry experience, and are based on assumptions made by us based on such data and our knowledge of our industry and market,
which we believe to be reasonable. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data
of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires. In addition, while we believe the industry, market and competitive position data included in this
prospectus is reliable and based on reasonable assumptions, such data involve risks and uncertainties and are subject to change based on various factors, including those discussed in the section titled &#147;Risk Factors.&#148; These and other
factors could cause results to differ materially from those expressed in the estimates made by the independent parties or by us. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">77 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_5"></A>USE OF PROCEEDS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We estimate that the net proceeds to us from the sale of the common stock that we are offering will be approximately $166.2 million (or $191.5
million if the underwriters exercise their option to purchase additional shares in full), based on the initial public offering price of $19.00 per share, and after deducting the underwriting discounts and commissions and estimated offering expenses
payable by us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The principal purposes of this offering are to obtain additional capital to support our operations, to create a public
market for our common stock and to facilitate our future access to the public equity markets. We intend to use approximately $100.0&nbsp;million of the net proceeds from this offering to fund the clinical development of vonoprazan and the remainder
for working capital and general corporate purposes, including <FONT STYLE="white-space:nowrap">pre-commercial</FONT> activities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We may
also use a portion of the remaining net proceeds and our existing cash and cash equivalents to <FONT STYLE="white-space:nowrap">in-license,</FONT> acquire, or invest in complementary businesses, technologies, products or assets. However, we have no
current commitments or obligations to do so. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We believe, based on our current operating plan, that the net proceeds from this offering
together with our existing cash and cash equivalents, will be sufficient to fund our operations for at least the next 24&nbsp;months, although there can be no assurance in that regard. In particular, we expect that the net proceeds from this
offering will allow us to complete our planned Phase 3 clinical trials of vonoprazan in the treatment of erosive esophagitis and <I>H. pylori</I> infection. However, our expected use of proceeds from this offering described above represents our
current intentions based on our present plans and business condition. We cannot predict with certainty all of the particular uses of the net from this offering or the actual amounts that we will spend on the uses set forth above. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The amounts and timing of our actual expenditures will depend on numerous factors, including the time and cost necessary to conduct our planned
clinical trials, the results of such trials, and other factors described in the section titled &#147;Risk Factors,&#148; as well as the amount of cash used in our operations and any unforeseen cash needs. Therefore, our actual expenditures may
differ materially from the estimates described above. We may find it necessary or advisable to use the net proceeds for other purposes, and we will have broad discretion in the application of the net proceeds. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Pending the uses described above, we plan to invest the net proceeds from this offering in short- and intermediate-term, investment grade
interest-bearing instruments. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">78 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_6"></A>DIVIDEND POLICY </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have never declared or paid any cash dividends on our capital stock. We intend to retain future earnings, if any, to finance the operation of
our business and do not anticipate paying any cash dividends in the foreseeable future. Any future determination related to dividend policy will be made at the discretion of our board of directors after considering our financial condition, results
of operations, capital requirements, business prospects and other factors the board of directors deems relevant, and subject to the restrictions contained in any future financing instruments. In addition, under the terms of our Loan Agreement, we
are prohibited from paying any cash dividends without the consent of the lenders. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">79 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_7"></A>CAPITALIZATION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The following table sets forth our cash and cash equivalents and capitalization as of June&nbsp;30, 2019: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">on an actual basis; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">on a pro forma basis to reflect (i)&nbsp;the automatic conversion of the May 2019 Notes into an aggregate of 6,107,918 shares of our common stock immediately
prior to the closing of this offering (based on the initial public offering price of $19.00 per share and assuming the conversion occurs on October 29, 2019), (ii) the reclassification of the Takeda Warrant to stockholders&#146; equity (deficit),
and (iii)&nbsp;the filing and effectiveness of our amended and restated certificate of incorporation immediately prior to the closing of this offering; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">on a pro forma as adjusted basis to give further effect to our issuance and sale of <B></B><B></B>9,563,157 shares of our common stock in this offering at the
initial public offering price of $19.00 per share, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">You should read this information in conjunction with our combined financial statements and related notes included in this prospectus and the section titled &#147;Management&#146;s Discussion and Analysis of
Financial Condition and Results of Operations&#148; and other financial information contained in this prospectus. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>As of June&nbsp;30, 2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(in thousands, except share and par value data)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Actual</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Pro Forma</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Pro Forma<BR>As<BR>Adjusted</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">82,917</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">82,917</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">249,098</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Capitalization:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Convertible promissory notes payable at fair value (including accrued interest)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">93,559</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Warrant liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">49,597</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">426</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">426</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Long-term debt, including final payment fee and net of debt discount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">24,512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">24,512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">24,512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Stockholders&#146; equity (deficit):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Preferred stock, $0.0001 par value; no shares authorized, issued and outstanding, actual; 40,000,000&nbsp;shares authorized and no shares
issued and outstanding, pro forma and pro forma as adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Common stock, $0.0001 par value; 50,000,000&nbsp;shares authorized, 11,876,518&nbsp;shares issued and 7,219,268&nbsp;shares outstanding,
actual; 400,000,000&nbsp;shares authorized, 17,984,436 shares issued and 13,327,186 shares outstanding, pro forma; 400,000,000&nbsp;shares authorized, 27,547,593&nbsp;shares issued and 22,890,343 shares outstanding, pro forma as
adjusted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">5,916</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">148,645</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">314,825</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(90,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(90,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(90,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total stockholders&#146; equity (deficit)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(84,385</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">58,345</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">224,526</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total capitalization</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">83,283</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">83,283</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">249,464</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">80 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The number of shares of common stock issued and outstanding pro forma and pro forma as adjusted
in the table above is based on 17,984,436 shares of our common stock outstanding as of June&nbsp;30, 2019, including 4,657,250 shares subject to forfeiture or our right of repurchase, and gives effect to the automatic conversion of the May 2019
Notes into an aggregate of 6,107,918 shares of our common stock immediately prior to the closing of this offering (based on the initial public offering price of $19.00 per share and assuming the conversion occurs on October 29, 2019), and excludes:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">7,588,000 shares of common stock issuable to Takeda upon the exercise of the Takeda Warrant as of June 30, 2019, at an exercise price of $0.00004613 per share;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">1,400,528&nbsp;shares of common stock issuable upon exercise of stock options granted after June&nbsp;30, 2019, at a weighted-average exercise price of $9.10 per
share; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">2,700,000 shares of our common stock reserved for future issuance under our 2019 Plan, which became effective in connection with this offering (which number does
not include any potential evergreen increases pursuant to the terms of the 2019 Plan); </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">270,000 shares of common stock reserved for future issuance under our ESPP, which became effective in connection with this offering (which number does not
include any potential evergreen increases pursuant to the terms of the ESPP); and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">16,446 shares of our common stock which may become issuable to the lenders under our Loan Agreement upon the exercise of the Lender Warrants, at an exercise
price of $15.20 per share (based on the initial public offering price of $19.00 per share), which warrants will only become exercisable if and when we borrow an additional $25.0 million under our Loan Agreement. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">81 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_8"></A>DILUTION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If you invest in our common stock in this offering, your ownership interest will be immediately diluted to the extent of the difference between the
initial public offering price per share and the pro forma as adjusted net tangible book value per share of our common stock after this offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">As of June&nbsp;30, 2019, our historical net tangible book value (deficit) was $(84.4) million, or $(7.11) per share of our common stock, based on 11,876,518&nbsp;shares of common stock issued and outstanding as of
such date, including 4,657,250&nbsp;shares subject to forfeiture or our right of repurchase as of such date. Our historical net tangible book value per share represents total tangible assets less total liabilities, divided by the number of shares of
common stock outstanding at June&nbsp;30, 2019. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">On a pro forma basis, after giving effect to (i)&nbsp;the automatic conversion of the
May 2019 Notes into an aggregate of 6,107,918 shares of our common stock immediately prior to the closing of this offering (based on the initial public offering price of $19.00 per share and assuming the conversion occurs on October&nbsp;29, 2019),
and (ii)&nbsp;the reclassification of the Takeda Warrant to stockholders&#146; equity (deficit), our pro forma net tangible book value as of June&nbsp;30, 2019 would have been approximately $58.3 million, or approximately $3.24 per share of our
common stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">After giving further effect to the sale of 9,563,157 shares of common stock in this offering at the initial public
offering price of $19.00 per share, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of June&nbsp;30, 2019 would have been
approximately $224.5 million, or approximately $8.15 per share. This amount represents an immediate increase in pro forma net tangible book value of approximately $4.91 per share to our existing stockholders and an immediate dilution in pro forma
net tangible book value of approximately $10.85 per share to new investors purchasing shares of common stock in this offering. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Dilution
per share to new investors is determined by subtracting pro forma as adjusted net tangible book value per share after this offering from the initial public offering price per share paid by new investors. The following table illustrates this dilution
(without giving effect to any exercise by the underwriters of their option to purchase additional shares): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Initial public offering price per share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">19.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Historical net tangible book value (deficit) per share as of June&nbsp;30, 2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(7.11</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Pro forma increase in historical net tangible book value per share as of June&nbsp;30, 2019 attributable to the pro forma adjustments
described above</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">10.35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Pro forma net tangible book value per share as of June&nbsp;30, 2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">3.24</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Increase in pro forma net tangible book value per share attributable to new investors participating in this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">4.91</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Pro forma as adjusted net tangible book value per share after this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">8.15</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Dilution per share to new investors participating in this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">10.85</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If the underwriters exercise their option to
purchase additional shares of our common stock in full in this offering, the pro forma as adjusted net tangible book value after the offering would be approximately $8.62 per share, the increase in pro forma as adjusted net tangible book value per
share to existing stockholders would be approximately $5.38 and the dilution per share to new investors would be $10.38, in each case based upon the initial public offering price of $19.00 per share. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">82 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The following table summarizes on the pro forma as adjusted basis described above, as of
June&nbsp;30, 2019, the differences between the number of shares purchased from us, the total consideration paid to us in cash and the average price per share paid by existing stockholders for shares issued prior to this offering and the price to be
paid by new investors in this offering. The calculations below are based on the initial public offering price of $19.00 per share, before deducting the underwriting discounts and commissions and estimated offering expenses payable by us. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Shares</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Purchased</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Total</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Consideration</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Weighted-<BR>Average<BR>Price</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Per
Share</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Percent</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Percent</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Existing stockholders before this offering</FONT><FONT STYLE="font-family:ARIAL" SIZE="2"></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">17,984,436</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">65</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">92,840,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">34</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">5.16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">New investors participating in this offering</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">9,563,157</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">181,699,983</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">66</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">19.00</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">27,547,593</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">274,539,983</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If the Takeda Warrant and Lender Warrants had been exercised as of June&nbsp;30, 2019, the pro forma as adjusted
net tangible book value after this offering would be approximately $224.8&nbsp;million, or approximately $6.39 per share, and total dilution per share to new investors would be approximately $12.61 per share. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If the underwriters exercise their option to purchase additional shares of our common stock in full: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the percentage of shares of common stock held by existing stockholders before this offering will decrease to approximately 62% of the total number of shares of
our common stock outstanding after this offering; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the number of shares held by new investors participating in this offering will increase to 10,997,630, or approximately 38% of the total number of shares of our
common stock outstanding after this offering. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The foregoing tables and calculations on a pro forma and pro forma as
adjusted basis are based on 17,984,436 shares of our common stock outstanding as of June&nbsp;30, 2019, including 4,657,250 shares subject to forfeiture or our right of repurchase, and gives effect to the automatic conversion of the May 2019 Notes
into an aggregate of 6,107,918 shares of our common stock immediately prior to the closing of this offering (based on the initial public offering price of $19.00 per share, and assuming the conversion occurs on October 29, 2019) and excludes:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">7,588,000 shares of common stock issuable to Takeda upon the exercise of the Takeda Warrant as of June 30, 2019, at an exercise price of $0.00004613 per share;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">1,400,528 shares of common stock issuable upon exercise of stock options granted after June&nbsp;30, 2019, at a weighted-average exercise price of $9.10 per
share; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">2,700,000 shares of our common stock reserved for future issuance under our 2019 Plan, which became effective in connection with this offering (which number does
not include any potential evergreen increases pursuant to the terms of the 2019 Plan); </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">270,000 shares of common stock reserved for future issuance under our ESPP, which became effective in connection with this offering (which number does not
include any potential evergreen increases pursuant to the terms of the ESPP); and </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">83 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">16,446 shares of our common stock which may become issuable to the lenders under our Loan Agreement upon the exercise of the Lender Warrants, at an exercise
price of $15.20 per share (based on the initial public offering price of $19.00 per share), which warrants will only become exercisable if and when we borrow an additional $25.0 million under our Loan Agreement. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">To the extent any outstanding options, warrants or other rights are exercised, or we issue additional equity or convertible securities in the
future, there will be further dilution to new investors. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">84 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_9"></A>SELECTED COMBINED FINANCIAL DATA </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The following tables set forth our selected historical combined financial data as of, and for the periods ended on, the dates indicated. The
combined financial statements include the accounts of our company and YamadaCo IIA, Inc., both of which were entities under common control prior to the Merger. We have derived the selected combined statements of operations data for the year ended
December&nbsp;31, 2018 and the selected combined balance sheet data as of December&nbsp;31, 2018 from our audited combined financial statements included elsewhere in this prospectus. We have derived the selected combined statements of operations
data for the six months ended June&nbsp;30, 2018 and 2019 and the selected combined balance sheet data as of June&nbsp;30, 2019 from our unaudited combined financial statements included elsewhere in this prospectus. The unaudited combined financial
statements have been prepared on a basis consistent with our audited combined financial statements included in this prospectus and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, necessary to
fairly state our results of operations for the six months ended June&nbsp;30, 2018 and 2019 and financial position as of June&nbsp;30, 2019. You should read these data together with our combined financial statements and related notes included
elsewhere in this prospectus and the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; Our historical results for any prior period are not necessarily indicative of our future
results. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Year
Ended<BR>December&nbsp;31,</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2018</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Six Months Ended</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(in thousands, except share and per share data)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2018</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Combined Statements of Operations Data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Operating expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">3,201</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="white-space:nowrap">In-process</FONT> research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">78,897</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">General and administrative (includes related party amounts of $321, $124 and $18, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,205</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2,142</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,225</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">84,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Loss from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,225</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(84,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Other income (expense):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Interest income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">101</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Interest expense (includes related party amounts of $(13), $(4) and $(82), respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,148</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Change in fair value of warrant liabilities (includes related party amounts of $0, $0 and $(1,277), respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,284</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Change in fair value of convertible promissory notes (includes related party amounts of $(50), $(4) and $(502),
respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(2,442</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total other income (expense)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(63</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(4,773</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(514</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(89,013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net loss per share, basic and diluted</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(0.21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(0.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(13.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Weighted-average shares of common stock outstanding, basic and diluted</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6,051,675</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">5,331,270</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6,640,394</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Pro forma net loss per share, basic and diluted<BR>(unaudited)</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(0.20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(9.85</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Pro forma weighted-average shares of common stock outstanding, basic and diluted
(unaudited)</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6,098,429</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">8,578,296</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">See Note 1 to our combined financial statements included elsewhere in this prospectus for an explanation of the method used to calculate the historical
and pro forma net loss per share, basic and diluted, and the number of shares used in the computation of the per share amounts. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">85 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(in thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>As of<BR>December&nbsp;31,<BR>2018</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>As of<BR>June&nbsp;30,<BR>2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Combined Balance Sheet Data:</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">879</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">82,917</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Working capital
(deficit)</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(60,210</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">902</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">84,879</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Convertible promissory notes payable at fair value (including accrued interest)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,963</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">93,559</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Warrant liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">49,597</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Long-term debt, including final payment fee and net of debt discount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">24,512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(90,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total stockholders&#146; equity (deficit)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(84,385</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">We define working capital (deficit) as current assets less current liabilities. See our combined financial statements included elsewhere in this
prospectus for further details regarding our current assets and current liabilities. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">86 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_10"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>You should read the following discussion and analysis of our financial condition and results of operations
together with our combined financial statements and related notes included elsewhere in this prospectus. Some of the information contained in this discussion and analysis are set forth elsewhere in this prospectus, including information with respect
to our plans and strategy for our business and related financing, and includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the section titled &#147;Risk
Factors,&#148; our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. </I></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>Overview </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We are a late clinical-stage biopharmaceutical company focused on developing and
commercializing novel treatments for GI diseases. Our initial product candidate, vonoprazan, is an oral small molecule <FONT STYLE="white-space:nowrap">P-CAB.</FONT> <FONT STYLE="white-space:nowrap">P-CABs</FONT> are a novel class of medicines that
block acid secretion in the stomach. Vonoprazan has rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits over the current standard of care as a single agent in the treatment of GERD, and in combination with
antibiotics for the treatment of <I>H.</I><I>&nbsp;pylori</I> infection. Takeda developed vonoprazan and has received marketing approval in nine countries in Asia and Latin America. Vonoprazan generated over $500&nbsp;million in net sales in its
fourth full year on the market since its approval in Japan in late 2014. In May 2019, we <FONT STYLE="white-space:nowrap">in-licensed</FONT> the U.S., European, and Canadian rights to vonoprazan from Takeda. We plan to initiate two pivotal Phase 3
clinical trials of vonoprazan in the fourth quarter of 2019. We believe that the successful completion of our Phase 3 clinical trials, together with the existing clinical data, will support regulatory submissions in 2021 and 2022 for marketing
approval for the treatment of <I>H. pylori</I> infection and erosive esophagitis, respectively. If approved, we plan to independently commercialize vonoprazan in the United States. We also plan to seek commercial partnerships for vonoprazan in
Europe and Canada, expand development of vonoprazan across indications, dosing regimens and alternative formulations and packaging, and <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire additional clinical or commercial stage product
candidates for the treatment of GI diseases in a capital efficient manner. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We commenced our operations in 2018 and have devoted
substantially all of our resources to date to organizing and staffing our company, business planning, raising capital, <FONT STYLE="white-space:nowrap">in-licensing</FONT> our initial product candidate, vonoprazan, meeting with regulatory
authorities, preparing for our planned Phase 3 clinical trials of vonoprazan, and providing other general and administrative support for these operations. Our operations to date have been funded primarily through the issuance of convertible
promissory notes and commercial bank debt. From our inception through June&nbsp;30, 2019, we have raised aggregate gross proceeds of $90.3&nbsp;million from the issuance of convertible promissory notes and $25.0&nbsp;million of commercial bank debt.
As of June&nbsp;30, 2019, we had cash and cash equivalents of $82.9&nbsp;million. Based on our current operating plan, we believe that our existing cash and cash equivalents, together with the estimated net proceeds from this offering, will be
sufficient to meet our anticipated cash requirements through at least the next 24&nbsp;months.</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We do not have any products approved for
sale and have incurred net losses since our inception. Our net losses for the year ended December&nbsp;31, 2018 and the six months ended June&nbsp;30, 2019 were $1.3&nbsp;million and $89.0&nbsp;million, respectively. As of June&nbsp;30, 2019, we had
an accumulated deficit of $90.3&nbsp;million. Our net losses may fluctuate significantly from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">year-to-year,</FONT></FONT> depending on the timing of our clinical development activities, other research and development activities and <FONT STYLE="white-space:nowrap">pre-commercialization</FONT> activities. We expect
our expenses and operating losses will increase substantially as we advance vonoprazan through clinical trials, seek regulatory approval for </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">87 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
vonoprazan, expand our clinical, regulatory, quality, manufacturing and commercialization capabilities, incur significant commercialization expenses for marketing, sales, manufacturing and
distribution if we obtain marketing approval for vonoprazan, protect our intellectual property, expand our general and administrative support functions, including hiring additional personnel, and incur additional costs associated with operating as a
public company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have never generated any revenue and do not expect to generate any revenues from product sales unless and until we
successfully complete development and obtain regulatory approval for vonoprazan, which will not be for several years, if ever. Accordingly, until such time as we can generate significant revenue from sales of vonoprazan, if ever, we expect to
finance our cash needs through equity offerings, our existing Loan Agreement, debt financings, or other capital sources, including potential collaborations, licenses and other similar arrangements. However, we may be unable to raise additional funds
or enter into such other arrangements when needed on favorable terms or at all. Our failure to raise capital or enter into such other arrangements when needed would have a negative impact on our financial condition and could force us to delay,
limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Financial Operations Overview </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our
combined financial statements include the accounts of Phathom (the receiving entity) and YamadaCo IIA prior to being merged into a single entity effective March&nbsp;13, 2019. Phathom and YamadaCo IIA were entities under common control of Frazier,
as a result of, among other things, Frazier&#146;s: (i)&nbsp;ownership of a majority of the outstanding capital stock of both companies; (ii)&nbsp;financing of both companies; (iii)&nbsp;control of the board of directors of both companies; and
(iv)&nbsp;management of both companies. Both Phathom and YamadaCo IIA were formed for the purpose of identifying potential assets around which to form an operating company. As the merged entities were under common control, the combined financial
statements report the financial position, results of operations and cash flows of Phathom and YamadaCo IIA as though the transfer of net assets and equity interests had occurred at the beginning of 2018. All intercompany accounts and transactions
have been eliminated in combination. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>License Agreement with Takeda </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">On May&nbsp;7,&nbsp;2019, we and Takeda entered into the Takeda License, pursuant to which we <FONT STYLE="white-space:nowrap">in-licensed</FONT>
the U.S., European, and Canadian rights to vonoprazan. During the term of the Takeda License, we and our affiliates are not permitted to commercialize any pharmaceutical product, other than vonoprazan, that treats acid-related disorders, except for
certain generic and OTC competing products in specified circumstances. We will be responsible at our cost for the development, manufacture and commercialization of vonoprazan products. We are required to use commercially reasonable efforts to
develop and commercialize the vonoprazan products in our licensed territory. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Under the Takeda License, Takeda has the sole right and
authority, with our input, to prepare, file, prosecute, and maintain all Takeda and joint patents on a worldwide basis at its own cost. We are responsible, at our cost, for preparing, filing, prosecuting, and maintaining patents on inventions made
solely by us in connection with vonoprazan, subject to input from Takeda. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We paid Takeda upfront consideration consisting of a cash fee
of $25.0&nbsp;million, 1,084,000 shares of our common stock, a warrant to purchase 7,588,000 shares of our common stock at an exercise price of $0.00004613 per share, or the Takeda Warrant, and issued Takeda a right to receive an additional common
stock warrant, or the Takeda Warrant Right, if Takeda&#146;s fully-diluted ownership of the Company represents less than a certain specified percentage of the fully-diluted capitalization, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">88 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
including shares issuable upon conversion of outstanding convertible promissory notes, calculated immediately prior to the closing of our initial public offering. We agreed to make milestone
payments to Takeda upon achieving certain tiered aggregate annual net sales of licensed products in the United States, Europe and Canada up a total maximum milestone amount of $250.0&nbsp;million. We also agreed to make tiered royalty payments at
percentages in the very low to mid double digits on net sales of licensed products, subject to specified offsets and reductions. Royalties will be payable, on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis from the first commercial sale of such
product in such country, until the latest of expiration of the licensed patents covering the applicable product, expiration of regulatory exclusivity in such country, or 15 years following first commercial sale in such country. For additional
information regarding the Takeda License, see &#147;Business&#151;Intellectual Property&#151;License Agreement with Takeda Pharmaceutical Company Limited.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>Components of Results of Operations </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Operating Expenses </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Research and Development </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">To date, our research and development expenses have related to the development of vonoprazan. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services
to be used in research and development are capitalized until the goods or services are received. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Research and development expenses
include: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">salaries, payroll taxes, employee benefits, and stock-based compensation charges for those individuals involved in research and development efforts;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">external research and development expenses incurred under agreements with contract research organizations, or CROs, and consultants to conduct and support our
planned clinical trials of vonoprazan; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">costs related to manufacturing vonoprazan clinical trials. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">We plan to substantially increase our research and development expenses for the foreseeable future as we continue the development of vonoprazan. We cannot determine with certainty the timing of initiation, the
duration or the completion costs of current or future clinical trials and nonclinical studies of vonoprazan or any future product candidates due to the inherently unpredictable nature of clinical and preclinical development. Clinical and preclinical
development timelines, the probability of success and development costs can differ materially from expectations. In addition, we cannot forecast which product candidates may be subject to future collaborations, when such arrangements will be
secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our future
clinical development costs may vary significantly based on factors such as:<B> </B> </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">per patient trial costs; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the number of trials required for approval; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the number of sites included in the trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the countries in which the trials are conducted; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the length of time required to enroll eligible patients; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the number of patients that participate in the trials; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">89 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the number of doses evaluated in the trials; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the <FONT STYLE="white-space:nowrap">drop-out</FONT> or discontinuation rates of patients; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">potential additional safety monitoring requested by regulatory agencies; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the duration of patient participation in the trials and <FONT STYLE="white-space:nowrap">follow-up;</FONT> </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the phase of development of the product candidate; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the efficacy and safety profile of the product candidate. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">In-Process</FONT> Research and Development </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT
STYLE="white-space:nowrap">In-process</FONT> research and development expenses relate to the Takeda License, and include the $78.9&nbsp;million purchase price of the acquired research and development assets. The purchase price of the Takeda License
consisted of the following: (i) $25.0&nbsp;million in cash; (ii)&nbsp;issuance to Takeda of 1,084,000 shares of our common stock at a fair value of $5.9&nbsp;million; (iii)&nbsp;issuance of the Takeda Warrant at an initial fair value of
$47.9&nbsp;million; (iv)&nbsp;issuance of the Takeda Warrant Right, with a nominal initial fair value due to the low probability of issuance; and (v) $0.1&nbsp;million of transaction costs incurred by us. The fair value of the Takeda Warrant and
Takeda Warrant Right were determined using the methodologies described below under &#147;Change in Fair Value of Warrant Liabilities,&#148; and the fair value of the common stock was determined using the methodologies described below under
&#147;Critical Accounting Policies and Significant Judgments and Estimates&#151;Common Stock Valuations.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>General and
Administrative </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">General and administrative expenses consist of salaries and employee-related costs, including stock-based
compensation, for personnel in executive, finance and other administrative functions, legal fees relating to intellectual property and corporate matters, and professional fees for accounting and consulting services. We anticipate that our general
and administrative expenses will increase in the future to support our continued research and development activities, <FONT STYLE="white-space:nowrap">pre-commercial</FONT> preparation activities for vonoprazan and, if any future product candidate
receives marketing approval, commercialization activities. We also anticipate increased expenses related to audit, legal, regulatory, and <FONT STYLE="white-space:nowrap">tax-related</FONT> services associated with maintaining compliance with
exchange listing and SEC requirements, director and officer insurance premiums, and investor relations costs associated with operating as a public company. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Interest Income </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Interest income consists of interest on our money market fund.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Interest Expense </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Interest expense consists of (i)&nbsp;interest on our outstanding convertible promissory notes at per annum interest rates ranging from 1.68% to
6.00% and (ii)&nbsp;interest on our outstanding commercial bank debt at a floating per annum interest rate (7.25% as of June&nbsp;30, 2019) and amortization of the commercial bank debt discount recorded in connection with the fair value of warrants
issued to the lenders, debt issuance costs incurred and the obligation to make a final payment fee. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Change in Fair Value of Warrant Liabilities
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In connection with the Takeda License, we issued the Takeda Warrant and Takeda Warrant Right, or together the Takeda Warrants.
In connection with our commercial bank debt, we issued the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">90 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
lenders warrants to purchase our capital stock, or the Lender Warrants. The Takeda Warrants are accounted for as liabilities as they do not meet all the conditions for equity classification due
to (i)&nbsp;insufficient authorized shares for the Takeda Warrant and (ii)&nbsp;the Takeda Warrant Right is not indexed to our own stock. The Lender Warrants are accounted for as liabilities as they contain a holder put right under which the lenders
could require us to pay cash in exchange for the warrants. We adjust the carrying value of our warrant liabilities to their estimated fair value at each reporting date, with any change in fair value of the warrant liabilities recorded as an increase
or decrease to change in fair value of warrant liabilities in the combined statements of operations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The fair value of the Takeda
Warrants is derived from the model used to estimate the fair value of our common stock and the fair value of the Lender Warrants is estimated using a probability-weighted model considering initial public offering and
<FONT STYLE="white-space:nowrap">non-initial</FONT> public offering scenarios. The initial public offering scenarios utilize a binomial lattice model to estimate a distribution of total equity values as of a projected initial public offering date.
The <FONT STYLE="white-space:nowrap">non-initial</FONT> public offering scenario utilizes the repurchase price associated with the warrant put right discounted to present value based on venture capital rates of return and the term associated with
the put right. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Upon the closing of this offering, (i)&nbsp;the Takeda Warrant will become reclassified to stockholders&#146; equity and
require a final adjustment to fair value, (ii)&nbsp;the Takeda Warrant Right (based on the initial public offering price of $19.00 per share) will expire without effect since no fair value has been allocated to it, and (iii)&nbsp;the Lender
Warrants, as a result of a put option, will continue as warrant liabilities adjusted to fair value at each reporting date. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Change in Fair Value
of Convertible Promissory Notes </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We issued convertible promissory notes in 2018 and 2019 for which we have elected the fair value
option. We adjust the carrying value of our convertible promissory notes to their estimated fair value at each reporting date, with any change in fair value of the convertible promissory notes recorded as an increase or decrease to change in fair
value of convertible promissory notes in our combined statements of operations. All outstanding convertible promissory notes and related accrued interest will convert to shares of our common stock upon the closing of this offering. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Prior to their exchange into convertible promissory notes issued in May 2019, the fair value of convertible promissory notes issued from inception
through April 2019 was estimated using a scenario-based analysis that estimated the fair value of the convertible promissory notes based on the probability-weighted present value of expected future investment returns, considering possible outcomes
available to the noteholders, including conversions in subsequent equity financings, change of control transactions, settlement and dissolution. The fair value of the convertible promissory notes issued in May 2019 is estimated using a
scenario-based analysis that estimates the fair value of the convertible promissory notes based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to the noteholders,
including various initial public offering, settlement, equity financing, corporate transaction and dissolution scenarios. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">91 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Results of Operations </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Comparison of the Six Months Ended June&nbsp;30, 2018 and 2019 </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The following table
summarizes our results of operations for each of the periods indicated (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Six Months Ended<BR>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Change</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2018</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Operating expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">3,201</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">3,201</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="white-space:nowrap">In-process</FONT> research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">78,897</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">78,897</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">General and administrative</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2,142</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,636</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">84,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">83,734</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Loss from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(84,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(83,734</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Other income (expense):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Interest income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">101</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">101</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Interest expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,148</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,144</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Change in fair value of warrant liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,284</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,284</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Change in fair value of convertible promissory notes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(2,442</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(2,438</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total other income (expense)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(4,773</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(4,765</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(514</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(89,013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(88,499</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Research and Development Expenses.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;We had no research and development expenses
for the six months ended June&nbsp;30, 2018 as we had not yet identified or in-licensed a product candidate. The $3.2&nbsp;million of research and development expenses for the six months ended June&nbsp;30, 2019 consisted of $3.0&nbsp;million of
clinical development of vonoprazan and $0.2&nbsp;million of personnel-related expenses. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">In-Process</FONT> Research and Development Expenses.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;We had no <FONT
STYLE="white-space:nowrap">in-process</FONT> research and development expenses for the six months ended June&nbsp;30, 2018. The $78.9&nbsp;million of <FONT STYLE="white-space:nowrap">in-process</FONT> research and development expenses for the six
months ended June&nbsp;30, 2019 consisted of the purchase price for the research and development assets we acquired as part of the Takeda License. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>General and Administrative Expenses.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;General and administrative expenses were $0.5&nbsp;million and $2.1&nbsp;million for the six months ended June&nbsp;30, 2018 and 2019,
respectively. The increase of $1.6&nbsp;million was due to increases of $0.6&nbsp;million in legal fees related to corporate and intellectual property matters, $0.4&nbsp;million in professional services expenses for accounting, audit, tax, valuation
and other services, $0.3&nbsp;million in personnel-related expenses, $0.2&nbsp;million of consulting services expenses, and $0.1&nbsp;million of other operating expenses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Other Income (Expense).</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Other expense of $8,000 for the six months ended June&nbsp;30, 2018 consisted of $4,000 of interest expense on our outstanding convertible promissory
notes and $4,000 of other expense related to the increase in fair value of those convertible promissory notes. Other expense of $4.8&nbsp;million for the six months ended June&nbsp;30, 2019 consisted of $2.4&nbsp;million of other expense related to
the increase in the fair value of our convertible promissory notes, $1.3&nbsp;million of other expense related to the increase in the fair value of warrant liabilities, $0.9&nbsp;million of interest expense on our outstanding convertible promissory
notes, $0.3&nbsp;million of interest expense on outstanding commercial bank debt, and partially offset by $0.1&nbsp;million of interest income. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">92 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Liquidity and Capital Resources </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">We have incurred net losses and negative cash flows from operations since our inception and anticipate we will continue to incur net losses for the foreseeable future. As of June&nbsp;30, 2019, we had cash and cash
equivalents of $82.9&nbsp;million. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Commercial Bank Debt </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">On May&nbsp;14, 2019, we entered into the Loan Agreement with SVB, as administrative and collateral agent, and lenders SVB and WestRiver. We borrowed $25.0&nbsp;million, or Term Loan A, at the inception of the Loan
Agreement and have the right to borrow an additional $25.0&nbsp;million, or Term Loan B, and which we collectively refer to as the Term Loans. Term Loan B is available through March&nbsp;31, 2020, provided that (i)&nbsp;we have received at least
$150.0&nbsp;million of net cash proceeds in connection with the issuance and sale, subsequent to April&nbsp;1, 2019, of our equity securities and subordinated debt, (ii)&nbsp;we have initiated Phase 3 clinical trials for vonoprazan, and
(iii)&nbsp;no event of default has occurred. As of June&nbsp;30, 2019, we had outstanding Term Loans of $25.0&nbsp;million and accrued interest of $0.2&nbsp;million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The Term Loans bear interest at a floating rate of the higher of the Wall Street Journal Prime rate plus 1.75% (7.25% at June&nbsp;30, 2019) or 7.25%. The monthly payments consist of interest-only through
June&nbsp;1, 2021 or, in the event of positive data with respect to our Phase 3 clinical trials in both indications for vonoprazan sufficient to file an NDA with the FDA, through June&nbsp;1, 2022. Subsequent to the interest-only period, the Term
Loans will be payable in equal monthly installments of principal, plus accrued and unpaid interest through the maturity date of May&nbsp;1, 2024. In addition, we are obligated to pay a final payment fee of 8.25% of the original principal amount of
the Term Loans. We may elect to prepay all or a portion of the Term Loans prior to maturity, subject to a prepayment fee of up to 2.0% of the then outstanding principal balance and payment of a pro rata portion of the final payment fee. After
repayment, no Term Loan amounts may be borrowed again. The borrowings under the Loan Agreement are collateralized by substantially all of our assets, excluding intellectual property and certain other assets. We have agreed not to encumber our
intellectual property assets without SVB&#146;s prior written consent unless a security interest in the underlying intellectual property is necessary to have a security interest in the accounts and proceeds that are part of the assets securing the
Term Loans, in which case our intellectual property will automatically be included within the assets securing the Term Loans. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The Loan
Agreement contains certain customary affirmative and negative covenants and events of default. The affirmative covenants include, among others, covenants requiring us to maintain our legal existence and governmental approvals, deliver certain
financial reports, maintain insurance coverage and satisfy certain requirements regarding our operating accounts. The negative covenants include, among others, limitations on our ability to incur additional indebtedness and liens, merge with other
companies or consummate certain changes of control, acquire other companies, engage in new lines of business, make certain investments, pay dividends, transfer or dispose of assets, amend certain material agreements or enter into various specified
transactions. Upon the occurrence of an event of default, subject to any specified cure periods, all amounts owed by us would begin to bear interest at a rate that is 4.00% above the rate effective immediately before the event of default and may be
declared immediately due and payable by SVB, as collateral agent. As of June&nbsp;30, 2019, we were in compliance with all applicable covenants under the Loan Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">In connection with the Loan Agreement, we issued the Lender Warrants, which become exercisable only if we borrow Term Loan B, and the number, class and per share exercise price of the shares subject to the warrants
is dependent on the terms of certain future equity financing transactions of the Company, including an initial public offering. The Lender Warrants expire ten years from the date of issuance, subject to earlier termination on September&nbsp;30, 2020
if we do not draw down Term Loan B </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">93 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
on or before March&nbsp;31, 2020. The Lender Warrants include a put option pursuant to which, in the event that we do not draw down Term Loan B on or before March&nbsp;31, 2020, the warrant
holders may require us to repurchase the warrants for a total aggregate repurchase price of $0.5&nbsp;million. The put right is exercisable through September&nbsp;30, 2020. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Convertible Note Financings </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">From January 2018 to April 2019, we issued an aggregate of
$2.4&nbsp;million of convertible promissory notes to Frazier, or the Frazier Notes, bearing interest at per annum rates ranging from 1.68% to 2.55%. In May 2019, these notes and related accrued interest were exchanged, at their then fair value of
$2.4&nbsp;million, for the May 2019 convertible promissory notes described below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">On May&nbsp;7, 2019, we entered into a note purchase
agreement under which we issued an aggregate of $90.3&nbsp;million of unsecured convertible promissory notes, or the May 2019 Notes, resulting in gross proceeds to us of $87.8&nbsp;million in cash and $2.4&nbsp;million related to the exchange of the
Frazier Notes. Including the conversion of the Frazier Notes, Frazier purchased $20.0&nbsp;million of the May 2019 Notes. The May 2019 Notes bear interest at a rate of 6% per annum and are subordinated to borrowings under our Loan Agreement. The May
2019 Notes become payable upon demand of the holders of at least 60% of the outstanding principal amount of the May 2019 Notes, including Frazier, on May&nbsp;7, 2020, or the Maturity Date, and become due and payable on May&nbsp;7, 2022, subject to
earlier conversion or repayment in the event we complete certain equity financings or a change of control. The note purchase agreement includes certain customary covenants and events of default. The May 2019 Notes will automatically convert into
shares of our common stock immediately prior to the completion of this offering. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Funding Requirements </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Based on our current operating plan, we believe that our existing cash and cash equivalents, together with the estimated net proceeds from this
offering, will be sufficient to meet our anticipated cash requirements through at least the next 24&nbsp;months. In particular, we expect the net proceeds from this offering will allow us to complete our planned Phase 3 clinical trials of vonoprazan
in the treatment of erosive esophagitis and <I>H.&nbsp;pylori</I> infection. However, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves
risks and uncertainties, and actual results could vary materially. We have based this estimate on assumptions that may prove to be wrong, and we could deplete our capital resources sooner than we expect. Additionally, the process of testing product
candidates in clinical trials is costly, and the timing of progress and expenses in these trials is uncertain. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our future capital
requirements will depend on many factors, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the initiation, type, number, scope, results, costs and timing of, our clinical trials of vonoprazan, and preclinical studies or clinical trials of other
potential product candidates we may choose to pursue in the future, including feedback received from regulatory authorities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the costs and timing of manufacturing for vonoprazan or any future product candidates, including commercial scale manufacturing if any product candidate is
approved; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the costs, timing and outcome of regulatory review of vonoprazan or any future product candidates; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the costs of obtaining, maintaining and enforcing our patents and other intellectual property rights; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">our efforts to enhance operational systems and hire additional personnel to satisfy our obligations as a public company, including enhanced internal controls
over financial reporting; </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">94 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the costs associated with hiring additional personnel and consultants as our business grows, including additional executive officers and clinical development
personnel; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the timing and amount of the milestone or other payments we must make to Takeda and any future licensors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the costs and timing of establishing or securing sales and marketing capabilities if vonoprazan or any future product candidate is approved;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any
approved products; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">patients&#146; willingness to pay <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> for any approved products in the
absence of coverage and/or adequate reimbursement from third-party payors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">costs associated with any products or technologies that we may <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Until such time, if ever, as we can generate substantial product revenues to support our cost structure, we expect to finance our cash needs
through equity offerings, the Loan Agreement, debt financings, or other capital sources, including potential collaborations, licenses and other similar arrangements. To the extent that we raise additional capital through the sale of equity or
convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt
financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we
raise funds through collaborations, or other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may
not be favorable to us and/or may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or
future commercialization efforts or grant rights to develop and market our product candidates even if we would otherwise prefer to develop and market such product candidates ourselves. We have prepared cash flow forecasts which indicate that based
on our expected operating losses and negative cash flows, there is substantial doubt about our ability to continue as a going concern without raising additional capital within 12 months after the date that the combined financial statements for the
year ended December&nbsp;31, 2018 and for the six months ended June&nbsp;30, 2019 are issued. Our independent registered public accounting firm also included an explanatory paragraph in its report on our combined financial statements as of and for
the year ended December&nbsp;31, 2018 indicating that there is substantial doubt about our ability to continue as a going concern. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">95 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Cash Flows </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The following table sets forth a summary of the net cash flow activity for each of the periods indicated (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Year
Ended<BR>December&nbsp;31,</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2018</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Six Months</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Ended June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2018</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net cash provided by (used in):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(452</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(6,018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(25,118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,902</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">552</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">113,174</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net increase in cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;879</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;82,038</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Operating Activities </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Net cash used in operating activities was approximately $1.0&nbsp;million for the year ended December&nbsp;31, 2018, and $0.5&nbsp;million and $6.0&nbsp;million for the six months ended June&nbsp;30, 2018 and 2019,
respectively. The net cash used in operating activities for the year ended December&nbsp;31, 2018 and the six months ended June&nbsp;30, 2018 was primarily due to our net loss in each period. The net cash used in operating activities for the six
months ended June&nbsp;30, 2019 was due to our net loss of $89.0&nbsp;million, adjusted for $82.7&nbsp;million of noncash charges and a $0.3&nbsp;million net change in operating assets and liabilities. Noncash charges consisted of our <FONT
STYLE="white-space:nowrap">in-process</FONT> research and development charges of $78.9&nbsp;million related to the Takeda License, $2.4&nbsp;million related to the change in fair value of convertible promissory notes, $1.3&nbsp;million related to
the change in fair value of warrant liabilities, and $0.1&nbsp;million of amortization of debt discounts on our commercial bank debt. The net change in operating assets and liabilities related to a $1.0&nbsp;million increase in accrued interest on
our outstanding convertible promissory notes and commercial bank debt and a $0.9&nbsp;million increase in accounts payable and accrued expenses in support of the growth in our operating activities, partially offset by a $1.6&nbsp;million increase in
prepaid clinical activities. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Investing Activities </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Net cash used in investing activities for the six months ended June&nbsp;30, 2019 was primarily due to the cash we paid, including transaction
costs, to acquire the Takeda License. We had no investing activities for the year ended December&nbsp;31, 2018. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Financing
Activities </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Net cash provided by financing activities for the year ended December&nbsp;31, 2018 and the six months ended
June&nbsp;30, 2018 was primarily due to proceeds from our issuance of convertible promissory notes. Net cash provided by financing activities for the six months ended June&nbsp;30, 2019 was $113.2&nbsp;million, due to $88.3&nbsp;million of net
proceeds from our issuance of convertible promissory notes and $24.9&nbsp;million of net proceeds from our commercial bank debt. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">96 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Contractual Obligations and Commitments </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The following table summarizes our contractual obligations as of June&nbsp;30, 2019 (in thousands): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Payments Due by Period</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Less&nbsp;than<BR>1 Year</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>1-3 Years</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>3-5 Years</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>More&nbsp;than<BR>5 Years</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Long-term debt, including interest and final payment fee</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">33,425</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,843</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">12,372</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">19,210</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Convertible promissory notes, including interest</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">95,680</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">95,680</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">129,105</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">97,523</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">12,372</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">19,210</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">Our outstanding long-term debt bears interest at a variable rate. The interest amounts included herein are based on the interest rate in effect as of
June&nbsp;30, 2019. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">Our outstanding convertible promissory notes become payable upon demand of the holders of at least 60% of the outstanding principal amount of the notes
on May&nbsp;7, 2020, and become due and payable on May&nbsp;7, 2022, subject to earlier conversion or repayment in the event we complete certain equity financings or a change of control. The amounts herein assume repayment on May&nbsp;7, 2020.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Under the Takeda License, we have milestone payment obligations that are contingent upon the achievement of specified
levels of product sales and are required to make certain royalty payments in connection with the sale of products developed under the agreement. As of June&nbsp;30, 2019, we are unable to estimate the timing or likelihood of achieving the milestones
or making future product sales and, therefore, any related payments are not included in the table above. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We enter into contracts in the
normal course of business for contract research services, contract manufacturing services, professional services and other services and products for operating purposes. These contracts generally provide for termination after a notice period, and,
therefore, are cancelable contracts and not included in the table above. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Critical Accounting Policies and Significant Judgments and Estimates
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our management&#146;s discussion and analysis of our financial condition and results of operations is based on our combined
financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of our combined financial statements requires us to make estimates and assumptions that affect
the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our combined financial statements and accompanying notes. We evaluate these estimates and judgments on an ongoing basis. We base our
estimates on historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily
apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">While our
significant accounting policies are more fully described in Note 1 to our combined financial statements included elsewhere in this prospectus, we believe that the following accounting policies are the most critical for fully understanding and
evaluating our financial condition and results of operations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Accrued Research and Development Expenses </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As part of the process of preparing our combined financial statements, we are required to estimate our accrued expenses as of each balance sheet
date. This process involves reviewing open </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">97 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost
incurred for the service when we have not yet been invoiced or otherwise notified of the actual cost. We make estimates of our accrued expenses as of each balance sheet date based on facts and circumstances known to us at that time. We periodically
confirm the accuracy of our estimates with the service providers and make adjustments, if necessary. The significant estimates in our accrued research and development expenses include the costs incurred for services performed by our vendors in
connection with research and development activities for which we have not yet been invoiced. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We base our expenses related to research
and development activities on our estimates of the services received and efforts expended pursuant to quotes and contracts with vendors that conduct research and development on our behalf. The financial terms of these agreements are subject to
negotiation, vary from contract to contract and may result in uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the research and development
expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from our
estimate, we adjust the accrual or prepaid expense accordingly. Advance payments for goods and services that will be used in future research and development activities are expensed when the activity has been performed or when the goods have been
received rather than when the payment is made. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Although we do not expect our estimates to be materially different from amounts actually
incurred, if our estimates of the status and timing of services performed differ from the actual status and timing of services performed, it could result in us reporting amounts that are too high or too low in any particular period. To date, there
have been no material differences between our estimates of such expenses and the amounts actually incurred. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">In-Process</FONT> Research and Development </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">We evaluate whether acquired intangible assets are a business under applicable accounting standards. Additionally, we evaluate whether the acquired assets have a future alternative use. Intangible assets that do
not have future alternative use, such as the Takeda License, are considered acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development. When the acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and
development assets are not part of a business combination, the value of the consideration paid is expensed on the acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Fair Value of Warrant Liabilities and Convertible Promissory Notes </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As described above, our warrant liabilities and convertible promissory notes are revalued at each reporting period with changes in the fair value of
the liabilities recorded as a component of other income (expense) in the combined statements of operations. There are significant judgments and estimates inherent in the determination of the fair value of these liabilities. If we had made different
assumptions including, among others, those related to the timing and probability of various corporate scenarios, discount rates, volatilities and exit valuations, the carrying values of our warrant liabilities and convertible promissory notes, and
our net loss and net loss per common share could have been significantly different. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Stock-Based Compensation Expense </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Stock-based compensation expense represents the cost of the grant date fair value of equity awards recognized over the requisite service period of
the awards (generally the vesting period) on a </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">98 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
straight-line basis with forfeitures recognized as they occur. Through June&nbsp;30, 2019, our stock-based compensation expense primarily consisted of our issuance of restricted stock awards, or
RSAs, for which the fair value is determined based on the fair value of the underlying common stock. As of June&nbsp;30, 2019, the unrecognized stock-based compensation expense was $59,000, which is expected to be recognized as expense over a
weighted-average period of approximately 0.7 years. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Common Stock Valuations </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Prior to obtaining the Takeda License in May 2019 and entering into the May 2019 Notes, the fair value of our common stock was nominal because we
were not sufficiently capitalized and held no assets that could be used to generate future revenues. Subsequent to obtaining the Takeda License and entering into the May 2019 Notes, we estimated the fair value of our common stock using
methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants Accounting and Valuation Guide: <I>Valuation of Privately Held Company Equity Securities Issued as Compensation</I>, or the Practice
Aid. The Practice Aid prescribes several valuation approaches for setting the value of an enterprise, such as the cost, income and market approaches, and various methodologies for allocating the value of an enterprise to its common stock. We
utilized a scenario-based analysis that estimated the fair value per share based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to us, including various initial
public offering, stay private and dissolution scenarios, and applying a discount for lack of marketability. We considered various stay private scenarios using the income approach and allocated the indicated equity value to each class of equity based
on the current-value method. We also considered various initial public offering scenarios based on expected equity values in an initial public offering and allocated the indicated equity value to each class of equity on a fully-diluted basis
considering the dilutive impacts of the May 2019 Notes and the Lender Warrants. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We considered various objective and subjective factors
to determine the fair value of our common stock, including: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">valuations of our common stock performed with the assistance of independent third-party valuation specialists; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">our stage of development and business strategy, including the status of research and development efforts of vonoprazan, and the material risks related to our
business and industry; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">our results of operations and financial position, including our levels of available capital resources; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the valuation of publicly-traded companies in the life sciences and biotechnology sectors; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the lack of marketability of our common stock as a private company; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the likelihood of achieving a liquidity event for the holders of our common stock, such as an initial public offering or a sale of our company, given prevailing
market conditions; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">trends and developments in our industry; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">external market conditions affecting the life sciences and biotechnology industry sectors. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">There are significant judgments and estimates inherent in the determination of the fair value of our common stock. These judgments and estimates
include assumptions regarding our future operating performance, the time to complete an initial public offering or other liquidity event and the determination of the appropriate valuation methods. If we had made different assumptions, our net loss
and net loss per common share could have been significantly different. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Following the completion of this offering, the fair value of our
common stock will be based on the closing price as reported on the date of grant on the primary stock exchange on which our common stock is traded. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">99 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>JOBS Act </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">As an emerging growth company under the JOBS Act, we can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the
adoption of certain accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption and, therefore, we will be subject to the same new or revised accounting
standards as other public companies that are not emerging growth companies. We intend to rely on other exemptions provided by the JOBS Act, including without limitation, not being required to comply with the auditor attestation requirements of
Section&nbsp;404(b) of Sarbanes-Oxley. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We will remain an emerging growth company until the earliest of (i)&nbsp;the last day of the
fiscal year following the fifth anniversary of the consummation of this offering, (ii)&nbsp;the last day of the fiscal year in which we have total annual gross revenue of at least $1.07&nbsp;billion, (iii)&nbsp;the last day of the fiscal year in
which we are deemed to be a &#147;large accelerated filer&#148; as defined in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> under the Exchange Act, which would occur if the market value of our common stock held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeded $700.0&nbsp;million as of the last business day of the second fiscal quarter of such year, or (iv)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT
STYLE="white-space:nowrap">non-convertible</FONT> debt securities during the prior three-year period. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Recent Accounting Pronouncements
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">See Note 1 to our combined financial statements included elsewhere in this prospectus. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">During the periods presented we did not have, nor do we currently have, any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements as defined under SEC rules. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Quantitative and Qualitative Disclosures about Market Risk </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Interest Rate Risk </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our cash and cash
equivalents consist of cash in readily available checking accounts and money market funds. As a result, the fair value of our portfolio is relatively insensitive to interest rate changes. Our outstanding convertible promissory notes bear interest at
a fixed rate. Our long-term debt bears interest at a variable rate. A 10% increase or decrease in the interest rate on our long-term debt would not have a material effect on our financial position, results of operations or cash flows. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Effects of Inflation </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Inflation
generally affects us by increasing our cost of labor and research and development contract costs. We do not believe inflation has had a material effect on our results of operations during the periods presented. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">100 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_11"></A>BUSINESS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Overview </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We are a late clinical-stage
biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Our initial product candidate, vonoprazan, is an oral small molecule potassium competitive acid blocker, or <FONT
STYLE="white-space:nowrap">P-CAB.</FONT> <FONT STYLE="white-space:nowrap">P-CABs</FONT> are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has shown rapid, potent, and durable anti-secretory effects and has
demonstrated clinical benefits over standard of care treatments as a single agent in the treatment of gastroesophageal reflux disease, or GERD, and in combination with antibiotics for the treatment of <I>Helicobacter pylori, </I>or <I>H. pylori,</I>
infection. Takeda Pharmaceutical Company Limited, or Takeda, developed vonoprazan and has received marketing approval in nine countries in Asia and Latin America. Vonoprazan generated over $500&nbsp;million in net sales in its fourth full year on
the market since its approval in Japan in late 2014. In May 2019, we <FONT STYLE="white-space:nowrap">in-licensed</FONT> the U.S., European, and Canadian rights to vonoprazan from Takeda. We intend to initiate two pivotal Phase 3 clinical trials of
vonoprazan in the fourth quarter of 2019. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We believe we can leverage Takeda&#146;s extensive clinical data, including results from 17
Phase&nbsp;3 clinical trials, to advance vonoprazan through pivotal trials in the United States and Europe. We plan to initiate two pivotal Phase 3 clinical trials in the fourth quarter of 2019 for vonoprazan: one for the treatment of erosive GERD,
also known as erosive esophagitis, and a second for the treatment of <I>H.&nbsp;pylori</I> infection. We expect to report <FONT STYLE="white-space:nowrap">top-line</FONT> data from both trials in 2021. We believe that the successful completion of
our Phase 3 clinical trials, together with the existing clinical data, will support regulatory submissions in 2021 and 2022 for marketing approval for the treatment of <I>H.&nbsp;pylori </I>infection and erosive esophagitis, respectively. In August
2019, we received qualified infectious disease product, or QIDP, designation from the U.S. Food and Drug Administration, or FDA, for vonoprazan in combination with certain antibiotics for the treatment of <I>H. pylori </I>infection which provides,
among other benefits, extension of any regulatory exclusivity and potential eligibility for priority review. Vonoprazan has the potential to be the first gastric anti-secretory agent from a novel class approved in the United States, Europe, or
Canada in over 30 years. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">GERD and <I>H. pylori</I> infection are two of the most common acid-related GI diseases and impact millions of
people. The prevalence of GERD is estimated to be 20% of the U.S. population and 15% of the population in the five major countries in the European Union (France, Germany, Italy, Spain and the United Kingdom, or the EU5). GERD is a disease that
develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. Approximately 30% of GERD patients have erosive esophagitis. <I>H. pylori</I> is a bacterial pathogen that infects approximately 35% of the U.S.
population and 45% of the EU5 population. As a result of the chronic inflammation induced by <I>H. pylori</I> infection, approximately 20% of infected patients will develop a range of pathologies, including dyspepsia, peptic ulcer disease, gastric
cancer, and mucosa-associated lymphoid tissue (MALT) lymphoma. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Over the last thirty years, the proton pump inhibitor, or PPI, class,
has been the standard of care for the treatment of acid-related GI diseases. PPIs are generally used as a single agent for the treatment of GERD and in combination with antibiotics<I> </I>for the treatment of <I>H. pylori</I> infection. The PPI
class includes drugs such as Prilosec (omeprazole), Nexium (esomeprazole), and Prevacid (lansoprazole). Prior to the introduction of generic and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter,</FONT></FONT> or
OTC, alternatives, annual PPI class sales reached approximately $12.5&nbsp;billion in the United States, and peak sales for individual brands were approximately $3.7&nbsp;billion for Prilosec, $3.5&nbsp;billion for Nexium, and $3.4&nbsp;billion for
Prevacid in the United States. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">While PPIs are the current standard of care and have experienced significant commercial success, they
have significant limitations that result in a large unmet medical need. In GERD, PPI </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">101 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
therapy is suboptimal for many patients due to the slow onset and insufficient duration of acid control which can lead to inadequate symptom relief. Approximately 15% to 45% of GERD patients
remain inadequately treated with PPIs. In the treatment of <I>H. pylori </I>infection, the standard of care consists of a combination of a PPI and at least two oral antibiotics. However, increasing antibiotic resistance has resulted in declining
eradication rates with <FONT STYLE="white-space:nowrap">PPI-based</FONT> therapy. We believe these unmet medical needs are in part driven by limitations associated with the mechanism of action and pharmacokinetics of PPIs. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">PPIs reduce gastric acid secretion by irreversibly binding to and inhibiting active proton pumps expressed on the parietal cells. PPIs require
activation by gastric acid, but they are unstable in the presence of acid. This instability, combined with the short circulating half-life of PPIs, limits their efficacy. Additionally, because proton pumps continuously switch between active and
inactive states, multiple doses of PPIs are required to inhibit enough proton pumps to achieve a clinical benefit. As a result, PPIs have a relatively slow onset of action and limited potency and duration of effect, which may result in patients
experiencing only partial relief, increasing PPI dosage, and/or cycling through multiple PPIs seeking relief. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Vonoprazan has a
differentiated mechanism of action from PPIs. Unlike PPIs, vonoprazan: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">does not require activation by gastric acid; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">is stable in the presence of acid; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">binds with a slow dissociation rate to both active and inactive proton pumps; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">has a long plasma half-life that replenishes the drug at the site of action over the course of the day. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">These factors have enabled vonoprazan to demonstrate more rapid and potent acid suppression versus the PPI esomeprazole in human subjects two hours
after oral dosing and maintain target acid inhibition over a <FONT STYLE="white-space:nowrap">24-hour</FONT> period in a randomized, open-label, crossover clinical trial. In contrast, PPIs require three to five days to reach steady state acid
suppression and do not reliably maintain target acid inhibition over a <FONT STYLE="white-space:nowrap">24-hour</FONT> period. In addition, vonoprazan demonstrated approximately 10-to-100-fold better acid control compared to esomeprazole.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We believe that vonoprazan&#146;s anti-secretory profile may demonstrate clinically meaningful advantages over PPIs, such as:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">faster, more complete, and more durable healing of erosive esophagitis; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">faster, more complete, and more durable control of GERD symptoms; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">higher <I>H. pylori</I> eradication rates in combination with antibiotics compared to standard of care triple therapy and the potential for antibiotic-sparing
dual therapy; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">more flexible dosing, including dosing independent of food and time of day, and the potential for rapid symptom relief through
<FONT STYLE="white-space:nowrap">on-demand</FONT> dosing. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Vonoprazan has demonstrated clinical advantages over PPIs
in the treatment of erosive esophagitis and <I>H.&nbsp;pylori</I> infection in completed Phase 3 clinical trials conducted in Japan and other Asian countries. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Erosive esophagitis.&nbsp;&nbsp;&nbsp;&nbsp;</I></B>In two Phase 3 clinical trials<B> </B>conducted in Japan assessing vonoprazan versus the PPI lansoprazole in the healing and maintenance of healing of
erosive esophagitis, vonoprazan met its primary endpoint in demonstrating <FONT STYLE="white-space:nowrap">non-inferiority</FONT> to lansoprazole. In a post hoc analysis of the healing trial, vonoprazan demonstrated faster healing and a superior
overall healing rate compared to lansoprazole in patients with more severe erosive esophagitis. After two weeks of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">102 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
treatment, 88% of erosive esophagitis patients with more severe disease were healed after treatment with vonoprazan versus 64% with lansoprazole (p&#061;0.0008). In the maintenance of healing
trial, vonoprazan demonstrated lower recurrence rates of erosive esophagitis six months after treatment versus lansoprazole across all grades of severity of erosive esophagitis. Vonoprazan achieved a 2% recurrence rate compared to 17% for
lansoprazole (p&lt;0.0001). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>H. pylori.&nbsp;&nbsp;&nbsp;&nbsp;</I></B>A Phase 3 clinical trial was conducted in Japan assessing
vonoprazan in combination with the antibiotics amoxicillin and clarithromycin versus lansoprazole in combination with these same antibiotics in first line treatment of <I>H. pylori </I>infection. In this trial, the vonoprazan-based regimen met its
primary endpoint in demonstrating a non-inferior eradication rate of 93% compared to 76% for lansoprazole-based regimen (p&lt;0.0001) and was also superior in a post hoc analysis of this trial (p&lt;0.0001). In patients who failed first line
therapy, vonoprazan in combination with the antibiotics metronidazole and amoxicillin demonstrated a 98% eradication rate as second line therapy. A <FONT STYLE="white-space:nowrap">p-value</FONT> is the probability that the reported result was
achieved purely by chance, such that a <FONT STYLE="white-space:nowrap">p-value</FONT> of less than or equal to 0.05 or 0.01 means that there is a 5.0% or 1.0% or less probability, respectively, that the difference between the control group and the
treatment group is purely due to chance. A <FONT STYLE="white-space:nowrap">p-value</FONT> of 0.05 or less typically represents a statistically significant result. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">We have used this clinical experience to inform our planned Phase 3 clinical development program in these indications. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Our company was founded as a collaboration between Takeda and Frazier Healthcare Partners. Our founders and management team have deep expertise in developing GI therapeutics, including anti-secretory agents, and
direct experience developing vonoprazan at Takeda. Our Chairman, Tadataka (Tachi) Yamada, M.D., is the former Chief Medical Officer and Chief Scientific Officer at Takeda. He is the former President of the American Gastroenterological Association
and former Chief of Gastroenterology and Internal Medicine at the University of Michigan. Our Chief Executive Officer, David Socks, is the former Chief Executive Officer of Outpost Medicine, LLC, a GI and urology focused company. Mr.&nbsp;Socks was
also President and Chief Operating Officer of Incline Therapeutics Inc. through its sale to the Medicines Company in 2013, and Senior Vice President, Corporate Development and Strategy of Cadence Pharmaceuticals, Inc. Azmi Nabulsi, M.D., M.P.H., our
Chief Operating Officer, is the former Deputy Chief Medical and Scientific Officer at Takeda. Our Head of Regulatory, Tom Harris, is the former Senior Vice President and Head of Global Regulatory at Takeda. Dr.&nbsp;Yamada, Dr.&nbsp;Nabulsi, and
Mr.&nbsp;Harris were extensively involved with the development of vonoprazan at Takeda. Our investors include Frazier Healthcare Partners, Medicxi, RA Capital Management, Abingworth, certain accounts managed by Janus Henderson Investors and BVF
Partners LP. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As part of a planned transition, we expect that Terrie Curran, a member of our board of directors, will succeed Mr. Socks
as Chief Executive Officer effective upon the closing of the acquisition of her current employer, Celgene Corporation, by Bristol-Myers Squibb Company. Ms. Curran has served as President, Global Inflammation and Immunology (I&amp;I) Franchise and as
a member of the Executive Committee at Celgene since 2017. Ms. Curran joined Celgene in 2013 as the U.S. Commercial Head of the I&amp;I Franchise and built the capabilities and recruited the teams that executed the launch of OTEZLA. Following
Ms.&nbsp;Curran&#146;s appointment as CEO, Mr.&nbsp;Socks will serve as interim Chief Financial Officer and continue to serve as a member of our board of directors. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">103 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Our Pipeline </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The following chart summarizes our current development programs. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g74s47.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Our Strategy </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Our goal is to be a leader in the development and commercialization of novel treatments for GI diseases. Our strategy is initially focused on developing and commercializing vonoprazan as a potential <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> <FONT STYLE="white-space:nowrap">P-CAB</FONT> in the United States, Europe, and Canada for the treatment of acid-related GI diseases. Key elements of this
strategy include: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Advance the clinical development of vonoprazan in erosive esophagitis and H. pylori infection and seek marketing
approval</I></B><I>.&nbsp;&nbsp;&nbsp;&nbsp;</I>We believe we can leverage the existing clinical data and post-marketing experience, as well as our management team&#146;s experience with vonoprazan, to advance vonoprazan through our planned pivotal
Phase&nbsp;3 clinical trials. We plan to initiate a single pivotal Phase 3 clinical trial of vonoprazan in each of erosive esophagitis and <I>H.&nbsp;pylori</I> infection beginning in the fourth quarter of 2019. We expect to report <FONT
STYLE="white-space:nowrap">top-line</FONT> data from both trials in 2021, and if successful, file regulatory submissions for marketing approval for the treatment of <I>H. pylori </I>infection in 2021 and for erosive esophagitis in 2022. If approved
by the FDA as a new chemical entity, vonoprazan would receive a five-year period of marketing exclusivity within the United States and vonoprazan&#146;s QIDP designation would extend the U.S. marketing exclusivity for an additional five years.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Commercialize vonoprazan in the United States</I></B><I>.</I>&nbsp;&nbsp;&nbsp;&nbsp;We plan to independently commercialize vonoprazan, if approved, in the
United States by building a leading specialty gastroenterology commercial infrastructure to support the adoption of vonoprazan. We believe we can successfully launch vonoprazan in the United States with a focused specialty sales force targeting high
prescribers of PPIs, particularly gastroenterologists. PPI prescribing is highly concentrated, with approximately 1.5% of U.S. PPI prescribers (approximately 12,000 total) accounting for approximately 20% of PPI prescriptions and approximately 6.0%
of U.S. PPI prescribers (approximately 50,000 total) accounting for approximately 50% of PPI prescriptions, according to IQVIA. We believe we have an opportunity to achieve significant share of voice and exposure to physicians given the scarcity of
actively marketed anti-secretory medicines. Given the limitations of PPIs and current unmet need, we believe the commercial opportunity for vonoprazan is substantial. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Seek commercial partnerships to maximize the vonoprazan opportunity outside of the United States</I></B><I>.&nbsp;&nbsp;&nbsp;&nbsp;</I>We believe there is
a significant commercial opportunity for vonoprazan in Europe and Canada. To address these markets, we plan to seek one or more partners with existing commercial infrastructure and expertise in these markets. We believe this strategy will allow us
to realize the value of the market opportunity in Europe and Canada while focusing our resources on the U.S. market. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">104 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Expand the development of vonoprazan across indications, dosing regimens, and alternative formulations and packaging</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;We
plan to pursue vonoprazan lifecycle extension strategies in areas with clear unmet need, clinical rationale, and commercial justification. These strategies may include: (i)&nbsp;additional indications, including treatment of gastric ulcers and
duodenal ulcers, Barrett&#146;s esophagus, and eosinophilic esophagitis; (ii)&nbsp;flexible dosing regimens, such as <FONT STYLE="white-space:nowrap">on-demand</FONT> therapy for symptom relief of GERD; and (iii)&nbsp;alternative formulations and
packaging, such as orally disintegrating tablets and other oral dosage forms for patients with difficulty swallowing, an intravenous formulation for <FONT STYLE="white-space:nowrap">in-hospital</FONT> applications, and
<FONT STYLE="white-space:nowrap">pre-packaged</FONT> convenience packs for the treatment of <I>H. pylori </I>infection. Additionally, we believe that vonoprazan has the ideal profile for an OTC product, including the potential for <FONT
STYLE="white-space:nowrap">on-demand</FONT> symptom relief and a well-tolerated safety profile. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">In-license</FONT> or acquire additional clinical or commercial stage product candidates for the treatment of GI diseases
in a capital efficient manner</I></B><I>.</I>&nbsp;&nbsp;&nbsp;&nbsp;We intend to take advantage of our management team&#146;s GI expertise to opportunistically <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire additional innovative
therapies for diseases treated by gastroenterologists. We plan to leverage our development and planned commercial infrastructure to support multiple assets targeting GI indications. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Acid-Related GI Diseases </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Overview </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Gastric acid is a digestive fluid formed in the stomach. The highly acidic environment of the stomach causes the unfolding, or denaturing, of food
proteins that are subsequently broken down by gastric enzymes. Gastric acid is secreted by the hydrogen potassium ATPase enzyme, which is known as the proton pump. Proton pumps are expressed on the channeled surfaces, or canaliculi, of parietal
cells in the stomach, which secrete acid. Proton pumps are continuously synthesized and switch between active and inactive states in response to various stimuli, such as food. When activated, proton pumps increase acid secretion. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">GI diseases where treatment is related to acid control, such as GERD, peptic ulcer disease, Zollinger Ellison syndrome, and <I>H. pylori</I>
infection, are significant medical problems because of their high prevalence, chronic nature and clinical sequelae. GERD results from the effects of acid on compromised mucosal defenses in the gastrointestinal tract. The reflux of gastric acid into
the esophagus produces frequent and/or severe heartburn, indigestion, and reflux symptoms. Chronic GERD may damage esophageal tissue and progress to more severe diseases including erosive esophagitis, Barrett&#146;s esophagus, and esophageal cancer.
GERD and related diseases are associated with impaired quality of life and substantial costs to the healthcare system given their chronic nature and sequelae. In <I>H. pylori </I>infection, gastric acid limits the effectiveness of antibiotics used
to eradicate infection. Chronic <I>H. pylori </I>infection can lead to dyspepsia, peptic ulcer disease, gastric cancer, and mucosa-associated lymphoid tissue (MALT) lymphoma. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">105 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Prevalence </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The prevalence of GI diseases is high. Approximately 20% to 40% of Western adults report chronic heartburn or regurgitation symptoms potentially related to GERD. We estimate that there are approximately
65&nbsp;million individuals in the United States and 50&nbsp;million individuals in the EU5 with GERD. In the United States, GERD is the most common gastroenterology-related outpatient diagnosis. Additionally, approximately 35% of the U.S.
population and 45% of the EU5 population are infected with <I>H. pylori</I>. We estimate that there are approximately 115&nbsp;million individuals in the United States and 145&nbsp;million individuals in the EU5 infected with <I>H.&nbsp;pylori</I>.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Prevalence of GERD and </B><B><I>H. pylori </I></B><B>Infection </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g19t07.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Treatments </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Treatments of acid-related GI diseases aim to provide relief of acute symptoms, healing of damaged tissue, and prevention of long-term clinical sequelae associated with chronic acid exposure. Gastric acidity is
measured by the pH scale, a logarithmic scale where 7.0 describes a neutral state and lower levels indicate a higher level of acidity. The pH of the stomach typically ranges from 1.5 to 3.5. In patients with acid-related GI diseases, increasing
gastric pH has been shown to improve mucosal healing rates and provide more rapid symptom relief for patients. For example, the duration of time that intra-gastric acidity is greater than pH 3.0 correlates with the healing of duodenal and gastric
ulcers, and pH greater than 4.0 is correlated with the healing of erosive esophagitis. Similarly, in patients with <I>H. pylori</I> infection, a more neutral gastric pH of 5.0 to 7.6 preserves antibiotic function and is optimal for successful
eradication. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Drug-induced gastric acid suppression is a key component of the management of acid-related GI diseases. Three classes of
drugs with distinct mechanisms of action are principally used for treatment in the United States and Europe: antacids, histamine receptor antagonists, or H2RAs, and PPIs. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2"><I>Antacids </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Antacids, first commercially available in the 1930s, directly neutralize gastric acid
to raise intra-gastric pH and can alleviate intermittent, mild symptoms of acid-related GI diseases, such as heartburn, but they are only effective for a short duration and require frequent administrations per day. In addition, antacids do not
significantly help heal or prevent complications of acid-related diseases. Antacids include commonly-known OTC products, such as Alka-Seltzer, Pepto-Bismol, Rolaids, and TUMS. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2"><I>Histamine Receptor Antagonists (H2RAs) </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">H2RAs, first commercially available in the 1970s,
decrease gastric acid secretion in order to raise gastric pH. H2RAs represented a dramatic improvement over antacids in the control of gastric acid and consequently in the management of acid-related GI diseases. H2RAs are also generally safe and
well-tolerated. Among the H2RA class were the first commercial blockbuster drugs, Pepcid (famotidine), Tagamet (cimetidine), and Zantac (ranitidine). Zantac was the world&#146;s highest-selling prescription drug
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">106 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
in the <FONT STYLE="white-space:nowrap">mid-1990s,</FONT> with global sales of $3.7&nbsp;billion and U.S. sales of $2.2&nbsp;billion. Prior to the launch of generic H2RAs and increasing
competition from PPIs, the H2RA class achieved sales of approximately $3.5&nbsp;billion in the United States. H2RAs achieved commercial success despite clinical limitations, including unreliable <FONT STYLE="white-space:nowrap">24-hour</FONT> acid
control, poor control of post-meal symptoms, and loss of efficacy over time. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px; margin-left:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Proton Pump Inhibitors (PPIs) </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">PPIs, first commercially available in 1989, offered improved acid control over H2RAs. Pharmacodynamic data demonstrated that PPIs maintain gastric
pH above target levels for a longer duration than H2RAs. A commonly used benchmark of anti-secretory activity is the percentage of time in a <FONT STYLE="white-space:nowrap">24-hour</FONT> period that gastric pH exceeds 4.0, which we refer to as
time above pH 4.0, which ranges from 40% to 71% for PPIs versus 33% for H2RAs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Given this improved pharmacodynamic profile, PPIs
demonstrated improved clinical symptom relief and healing over H2RAs. In a meta-analysis of results from 33 randomized clinical trials with over 3,000 GERD patients, a reduction in symptoms was achieved in 83% of patients taking PPIs versus 60% of
those on H2RAs. In a second meta-analysis, the eight-week healing rate in patients with erosive esophagitis was 82% for PPIs versus 52% for H2RAs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%;padding-bottom:0px; "><FONT
STYLE="font-family:ARIAL" SIZE="2">The PPI class is currently the first-line treatment of acid-related GI diseases. Prior to the introduction and adoption of generic and OTC alternatives, annual PPI class sales reached approximately
$12.5&nbsp;billion in the United States, and peak sales for individual brands were approximately $3.7&nbsp;billion for Prilosec, $3.5&nbsp;billion for Nexium, and $3.4&nbsp;billion for Prevacid. As recently as 2015, the last branded PPI, Dexilant
(dexlansoprazole), reached approximately $530&nbsp;million in sales in the United States</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex"> </SUP></FONT><FONT
STYLE="font-family:ARIAL" SIZE="2">despite limited differentiation from other PPIs. While Dexilant demonstrated a modest improvement in time above pH 4.0 compared to other PPIs, the approved dose did not demonstrate consistent superiority in Phase 3
trials against other PPIs on the healing of erosive esophagitis and has not been tested against PPIs in other indications. We believe that the commercial success of Dexilant highlights the value to physicians and patients of even incremental
improvements over other PPIs. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>History of Pharmaceutical Agents for Control of Gastric Acid </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g79w07.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">107 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><U>PPI Limitations </U></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">While PPIs provide clinically meaningful symptom relief and healing for millions of patients suffering from acid-related GI diseases, they are inadequate for many patients. The suboptimal anti-secretory profile of
PPIs results in slow onset of symptom relief, breakthrough nighttime or postprandial heartburn, and treatment failure. Approximately 15% to 45% of GERD patients are inadequately treated with PPIs, experiencing persistent, troublesome symptoms, such
as heartburn and regurgitation. In approximately two thirds of symptomatic GERD patients, reflux symptoms are not adequately controlled after the first dose of a PPI, and nearly 50% of patients still suffer from symptoms three days later. Given
these limitations, more than 20% of GERD patients on PPI therapy take their PPI twice daily, which is not FDA approved, or purchase OTC heartburn treatments in addition to their prescription medicine. In a survey of approximately 1,000 GERD patients
and 1,000 physicians, approximately one third of GERD patients reported persistent symptoms and were dissatisfied with PPI therapy and 35% of physicians perceived patients as somewhat satisfied to completely dissatisfied with PPI treatment. In
addition, in July 2019 we conducted a U.S. market research study of 100 gastroenterologists and 100 primary care physicians who commonly prescribe PPIs and treat patients with GERD and <I>H. pylori</I> infection. Surveyed physicians reported that
approximately 25% of patients are not satisfied on PPIs. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In patients with more severe grades of erosive esophagitis, studies with PPIs
have reported failure rates of healing of esophageal erosions exceeding 25%. Additionally, recurrence of erosions is common in healed erosive esophagitis patients receiving maintenance PPI therapy. One study reported recurrence in 15% to 23% of
patients with less severe erosive esophagitis and 24% to 41% of patients with more severe erosive esophagitis. We believe that these limitations of PPIs are in part driven by their mechanism of action and pharmacokinetics. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Mechanistic Differences Between PPIs and Vonoprazan </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>PPIs </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">After oral dosing, PPIs reach
the gastric parietal cells through the bloodstream. PPIs are prodrugs that are converted to their active form in the acidic environment of the secretory canaliculus of the parietal cell but degrade quickly because their active form is unstable in
acid. For example, the half-life of omeprazole (Prilosec) is less than 10 minutes at pH 2.0. The active form of a PPI blocks acid production by covalently binding to active proton pumps that have moved to the surface of the secretory canaliculi
after activation of the parietal cell with stimuli, such as a meal. Because PPIs bind only to actively secreting pumps, it is generally recommended that they be administered 30 to 60 minutes before a meal to achieve maximal efficacy. Once covalently
bound to the proton pumps, the active PPI molecule is no longer available to bind to newly synthesized or activated proton pumps. Furthermore, given the relatively short plasma half-life of most PPIs of one to two hours, resupply of additional PPI
molecules from the bloodstream is limited, and newly activated pumps are not inhibited. Due to this profile, PPI dosing over several days is required to inhibit enough proton pumps to increase gastric pH to a clinically meaningful threshold, and
PPIs have a limited window of efficacy leading to incomplete acid suppression over the <FONT STYLE="white-space:nowrap">24-hour</FONT> dosing interval. In addition, PPIs are primarily metabolized by CYP2C19, an enzyme which has significant
interpatient metabolic variability based on genotype. As a result, PPI exposure levels in some patients may not achieve target levels, potentially reducing clinical efficacy. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Vonoprazan </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Vonoprazan has a differentiated mechanism of action from PPIs. When
vonoprazan reaches gastric parietal cells from the bloodstream, it accumulates in the secretory canaliculus where the proton pumps are present in their active state. In contrast to most PPIs, vonoprazan does not require gastric acid for activation,
is stable in the presence of gastric acid, reversibly binds to proton pumps in both </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">108 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
their inactive and active states, and remains in the secretory canaliculus where it continues to inhibit acid secretion over an extended period. Vonoprazan&#146;s prolonged effect is also
maintained through a slow dissociation rate from the proton pumps and resupply from the bloodstream due to its seven-hour half-life. These characteristics allow vonoprazan to rapidly achieve target <FONT STYLE="white-space:nowrap">24-hour</FONT>
acid suppression within two hours of a single dose, unlike PPIs that require three to five days to achieve stable acid suppression. In addition, vonoprazan is primarily metabolized by CYP3A4/5, an enzyme which has less genetic variability than
CYP2C19, and may exhibit more consistent activity than PPIs across U.S. and European populations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The mechanistic and pharmacologic
differences of PPIs and vonoprazan are summarized in the table below. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g35q69.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Vonoprazan Pharmacodynamics vs. PPIs </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Vonoprazan&#146;s more rapid, potent, and durable anti-secretory effects versus the PPI esomeprazole (Nexium) were demonstrated in a randomized, open-label, crossover clinical trial comparing 20 mg of once daily,
or QD, vonoprazan to 20 mg QD of esomeprazole in 20 healthy volunteers. As shown below, vonoprazan achieved rapid and potent pH control on Day 1 relative to esomeprazole (left). Vonoprazan maintained pH approximately 1 to 2 units higher than
esomeprazole at Day 7 (right), which represents a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">10-to-100-fold</FONT></FONT></FONT> reduction in acidity. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">109 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Improved Onset and Potency of pH Control of Vonoprazan vs. Esomeprazole at Day&nbsp;1 and
Day&nbsp;7 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g03h86.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">This improved potency and duration of pH control with vonoprazan, as measured by time above pH&nbsp;4.0, was
evident not only at Day&nbsp;1, but also at Day&nbsp;7 when esomeprazole had reached its steady-state (see table below). </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Improved
Time Above pH 4.0 of Vonoprazan vs. Esomeprazole at Day 1 and Day 7 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g76g88.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Vonoprazan for the Potential Treatment of Acid-Related GI Diseases </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Given the shortcomings of PPI therapy, we believe that there is a significant unmet medical need for a safe and effective anti-secretory agent with
rapid, potent, and durable activity. Vonoprazan was developed in markets outside of the United States by Takeda through an extensive clinical program, including 17 Phase 3 clinical trials. As of December 2018, 6,683 subjects were exposed to
vonoprazan in completed and ongoing clinical trials. In <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> Phase 3 trials versus a PPI, vonoprazan demonstrated faster onset of healing in more severe erosive
esophagitis patients, lower recurrence rates of erosions in erosive esophagitis patients across all levels of severity, and a superior eradication rate in combination with antibiotics in patients with <I>H. pylori</I> infection than <FONT
STYLE="white-space:nowrap">PPI-based</FONT> triple therapy. Vonoprazan received marketing approval in Japan in late 2014 and generated over $500&nbsp;million in net sales in its fourth full year on the market in Japan. We plan to initiate a single
pivotal Phase&nbsp;3 clinical trial of vonoprazan in each of erosive esophagitis and <I>H.&nbsp;pylori</I> infection in the fourth quarter of 2019. We expect to report <FONT STYLE="white-space:nowrap">top-line</FONT> data from both trials in 2021,
and if successful, file regulatory submissions for marketing approval for the treatment of <I>H. pylori </I>infection in 2021 and for erosive esophagitis in 2022. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">110 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Vonoprazan in GERD </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Based on the significant unmet medical need, previous Phase 3 trial results, and commercial potential, we have prioritized the development of vonoprazan in GERD in: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the healing of erosive esophagitis and relief of heartburn; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the maintenance of healing of erosive esophagitis and relief of heartburn. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>GERD Disease Overview </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">GERD is one of the most prevalent diseases of any kind and is the
most prevalent GI disease, affecting approximately 20% of the U.S. population and approximately 15% of the European population. We estimate there are approximately 65&nbsp;million individuals with GERD in the United States and 50&nbsp;million
individuals with GERD in the EU5. GERD is a disease that develops when the reflux of acidic stomach contents into the esophagus causes troublesome symptoms and/or complications, and the term covers a spectrum of diseases, including erosive
esophagitis, <FONT STYLE="white-space:nowrap">non-erosive</FONT> reflux disease, and Barrett&#146;s esophagus. These diseases are detailed below: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Erosive esophagitis</I></B>:<B>&nbsp;&nbsp;&nbsp;&nbsp;</B>Approximately 30% of GERD patients have erosive esophagitis, which is classified by erosions in
the gastric mucosa caused by acidic reflux of stomach contents into the esophagus. Erosive esophagitis is commonly graded by the Los Angeles classification system, which characterizes the extent of erosions in the esophagus and is graded on a scale
of increasing severity from A to D, with D being the most severe. Approximately 10% to 20% of erosive esophagitis patients have the more severe Los Angeles Class&nbsp;C or D disease. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">Non-erosive</FONT> reflux disease (NERD)</I></B>:<B>&nbsp;&nbsp;&nbsp;&nbsp;</B>Approximately 60% of GERD patients have
NERD, which is classified by an endoscopically normal esophagus, but abnormal gastric acid exposure in the esophagus and persistent symptoms. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Barrett&#146;s esophagus</I></B>:&nbsp;&nbsp;&nbsp;&nbsp;Approximately 10% of GERD patients have Barrett&#146;s esophagus, which is classified by<B>
</B>endoscopic and histological evidence of metaplasia or dysplasia in the mucosal cell lining in the lower portion of the esophagus; approximately 1% of patients annually progress to esophageal cancer. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g25i85.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">GERD patients typically present with heartburn and reflux symptoms. Based on these symptoms, patients are
typically treated first-line with PPIs prior to a diagnostic endoscopy for specific disease classification of erosive esophagitis, NERD or Barrett&#146;s esophagus. Clinical guidelines suggest that endoscopy only be performed in patients who
continue to have symptoms despite a four- to-eight-week course of daily PPIs or have alarm symptoms, including GI bleeding, anemia, weight loss, chest pain, or difficult or painful swallowing. Our market research suggests that most patients are
treated empirically based on symptoms rather than based on endoscopic characterization of disease. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">111 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>GERD Treatment Paradigm </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Approximately 80% of GERD patients are pharmacologically treated with prescription or OTC medications. PPIs are currently the most effective anti-secretory agents available in the United States and Europe for
relieving GERD symptoms and healing erosions in gastric mucosa. Our market research suggests that approximately 80% of patients who are pharmacologically treated receive PPIs, and approximately 75% of PPI use is prescription rather than OTC. The
majority of PPI use is chronic, with more than 70% of patients prescribed PPIs for daily use. According to IQVIA NDTI, there were approximately 120&nbsp;million oral PPI prescriptions written in the United States and 6.1&nbsp;billion doses
prescribed for the 12&nbsp;months ended May&nbsp;31, 2019. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">While PPIs provide clinically meaningful symptom relief and healing for
millions of patients suffering from acid-related GI diseases, they are inadequate for many patients. The suboptimal anti-secretory profile of PPIs results in slow onset of symptom relief, breakthrough nighttime or postprandial heartburn, and
treatment failure. Approximately 15% to 45% of GERD patients are inadequately treated with PPIs, experiencing persistent, troublesome symptoms, such as heartburn and regurgitation. In approximately two thirds of symptomatic GERD patients, reflux
symptoms are not adequately controlled after the first dose of a PPI, and nearly 50% of patients still suffer from symptoms three days later. Given these limitations, more than 20% of GERD patients on PPI therapy are taking their PPI twice daily,
which is not FDA approved, or purchasing OTC heartburn treatments in addition to their prescription medicine. In a survey of approximately 1,000 GERD patients and 1,000 physicians, approximately <FONT STYLE="white-space:nowrap">one-third</FONT> of
GERD patients reported persistent symptoms and were dissatisfied with PPI therapy and 35% of physicians perceived patients as somewhat satisfied to completely dissatisfied with PPI treatment. In our U.S. market research study, physicians highlighted
control of nighttime and daytime heartburn symptoms and efficacy in the healing and maintenance of healing of esophageal erosions as key unmet needs in GERD and reported that approximately 25% of patients are not satisfied on PPIs. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">There are few treatment options for GERD patients who are inadequately managed on PPI therapy. Our U.S. market research survey reported that 26% of
patients who are unsatisfied with therapy on a given PPI will switch to a different PPI to improve symptom control or heal esophageal erosions; however, physicians surveyed did not believe there are meaningful differences in outcomes between PPIs.
Even though safety and efficacy of twice daily dosing of PPIs has not been evaluated in large controlled clinical studies and is not included on the label for any PPIs, surveyed physicians reported that 23% of patients resort to this dosing regimen
given dissatisfaction of once daily PPIs. A limited number of patients proceed to a surgical procedure, such as Nissen fundoplication. However, this procedure results in postoperative morbidity of 5% to 20%, as well as a two- to <FONT
STYLE="white-space:nowrap">six-week</FONT> recovery period and a median hospital stay of two days. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Vonoprazan has the potential to be
the first gastric anti-secretory agent from a novel class approved in the United States, Europe, or Canada in over 30 years. Our U.S. market research survey reported that physicians would prefer to use vonoprazan in 59% of all of their GERD patients
and believe that vonoprazan&#146;s mechanism of action and gastric pH control is meaningfully improved over PPIs, that vonoprazan could be a more effective treatment than PPIs in healing and maintenance of healing of esophageal erosions, and that
vonoprazan would improve their ability to treat GERD patients. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Clinical Data for Vonoprazan in GERD </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Four Phase 3 clinical trials have been completed comparing vonoprazan to PPIs in erosive esophagitis: a healing trial in Japan; a maintenance of
healing trial in Japan; a healing trial in Asia (China, Taiwan, and Korea); and a maintenance of healing trial in Asia. In addition to these Phase 3 trials, several published investigator-sponsored studies have compared vonoprazan to PPIs across
dosing regimens and endpoints. Results of these clinical trials are summarized below. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">112 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Healing of Erosive Esophagitis Clinical Trials in Japan and Asia </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In a Phase 3 multicenter, randomized, double-blind, parallel group trial, 409 patients in Japan with endoscopically confirmed erosive esophagitis
were randomized to receive vonoprazan 20 mg QD or lansoprazole 30 mg QD for up to eight weeks. The primary endpoint was the <FONT STYLE="white-space:nowrap">non-inferiority</FONT> of the percent of patients with healed erosive esophagitis up to Week
8, as assessed by endoscopy. <FONT STYLE="white-space:nowrap">Non-inferiority</FONT> is intended to show that the effect of a new treatment is not worse than the active control by more than a specified margin, while superiority is intended to show
that one treatment is more effective than a comparator by any margin. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Design of Japan Phase 3 Clinical Trial for the Healing of
Erosive Esophagitis </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g60n53.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Vonoprazan achieved the primary endpoint of <FONT STYLE="white-space:nowrap">non-inferiority</FONT> versus
lansoprazole on the percent of patients with healed erosive esophagitis up to Week 8 (99% vs. 96%, p&lt;0.0001). Further, a post hoc analysis demonstrated that vonoprazan was superior to lansoprazole on the percent of patients with healed erosive
esophagitis up to Week 8 (p&#061;0.0337). In the subset of 147 patients with more severe erosive esophagitis of Los Angeles Class&nbsp;C or D, vonoprazan healing was also shown to be superior (99% vs. 88%, p&#061;0.0082). We believe this result is
due to the improved acid control of vonoprazan over lansoprazole, and we believe lansoprazole is representative of the PPI class. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Vonoprazan further demonstrated a more rapid clinical effect versus lansoprazole with a superior healing rate at Week 2 (91% vs. 82%, p&lt;0.0001
for <FONT STYLE="white-space:nowrap">non-inferiority</FONT> and p&#061;0.0132 in a post hoc superiority analysis). The treatment effect was more pronounced in the more severe patients with Los Angeles Class&nbsp;C or D disease (88% vs. 64%,
p&#061;0.0008 for superiority). Of the seven patients who failed lansoprazole treatment and continued into the additional treatment period, six healed with four weeks of treatment of 40 mg vonoprazan QD. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">113 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Results of Japan Phase 3 Clinical Trial in the Healing of Erosive Esophagitis </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g06o81.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, in the lead-in period of the Japan Phase 3 maintenance of healing clinical trial discussed below,
patients were treated with vonoprazan 20&nbsp;mg for up to eight weeks before proceeding into treatment for the maintenance of healing of erosive esophagitis. The healing rate at Week 2 and through Week 8 during this lead-in healing period was 91%
and 99%, respectively. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In another multicenter, randomized, double-blind, parallel group Phase 3 clinical trial in China, Taiwan, Korea,
and Malaysia, 481 patients with endoscopically confirmed erosive esophagitis were randomized to receive vonoprazan 20 mg QD or lansoprazole 30 mg QD for eight weeks. Vonoprazan achieved the primary endpoint of
<FONT STYLE="white-space:nowrap">non-inferiority</FONT> versus lansoprazole on the percent of patients with healed erosive esophagitis up to Week 8, 92% and 91%, respectively (95% confidence interval of treatment difference of -3.8% to 6.1%). The
difference in healing rates of 1% between the treatment groups had a confidence interval of -3.8 to 6.1, which means that statistically there is 95% certainty that the true difference in healing rates lies within this range of values.
Non-inferiority was established in this trial as the lower bound (-3.8%) of the confidence interval was greater than the pre-established non-inferiority margin of -10%. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><I>Maintenance of Healing of Erosive Esophagitis Clinical Trials in Japan and Asia </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In a
multicenter, randomized, double-blind, parallel-group Phase 3 clinical trial in Japan, 627 patients with erosive esophagitis were treated with vonoprazan 20 mg QD for two, four, or eight weeks. After this
<FONT STYLE="white-space:nowrap">lead-in</FONT> period, a total of 607 patients with healed erosive esophagitis, of whom 124 had Los Angeles Class&nbsp;C or D disease, were randomized to receive vonoprazan 10 mg QD, vonoprazan 20 mg QD, or
lansoprazole 15 mg QD for 24 weeks. The primary endpoint was the percent of patients with recurrence of erosive esophagitis at Week 24 as assessed by endoscopy. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">114 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Design of Japan Phase 3 Clinical Trial in Maintenance of Healing of Erosive Esophagitis
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g10h25.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Vonoprazan achieved the primary endpoint of <FONT STYLE="white-space:nowrap">non-inferiority</FONT> versus
lansoprazole on the percent of patients with recurrence of erosive esophagitis during the <FONT STYLE="white-space:nowrap">24-week</FONT> maintenance period. Patients on lansoprazole had a 17% recurrence rate of erosive esophagitis after 24 weeks of
daily treatment, versus 5% for patients on vonoprazan 10 mg and 2% for patients on vonoprazan 20 mg (p&lt;0.0001 for <FONT STYLE="white-space:nowrap">non-inferiority</FONT> of both vonoprazan doses vs. lansoprazole). Both vonoprazan doses were
superior to lansoprazole in a post hoc analysis (p&#061;0.0002 for vonoprazan 10 mg and p&lt;0.0001 for vonoprazan 20 mg). As shown below, the superiority of each dose of vonoprazan to lansoprazole was demonstrated in both Los Angeles Class&nbsp;A
and B patients, as well as the more severe Los Angeles Class&nbsp;C and D patients. We believe this result demonstrates the improved potency and durability of vonoprazan versus lansoprazole in all patients with erosive esophagitis. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Results of Japan Phase 3 Clinical Trial in Maintenance of Healing of Erosive Esophagitis </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g12v65.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">A second multicenter, randomized, double-blind, parallel group Phase 3 clinical trial was conducted in China,
Taiwan, and Korea in 703 patients with healed erosive esophagitis, who were randomized to receive vonoprazan 20 mg QD, vonoprazan 10 mg QD, or lansoprazole 15 mg QD for 24 weeks. This trial has been completed, but final results are not yet
available. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">115 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Symptom Relief </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">We believe the rapid pharmacodynamic effects of vonoprazan may provide complete and sustained heartburn relief more quickly compared to PPIs. A double-blind, randomized, investigator-sponsored clinical trial in 32
patients with erosive esophagitis compared the effects of vonoprazan 20&nbsp;mg and lansoprazole 30 mg on the time to achieve complete heartburn relief, defined as seven days without heartburn symptoms. Vonoprazan demonstrated a faster time to
complete heartburn relief than lansoprazole, and this complete relief was most pronounced for nighttime heartburn. The results of the trial are summarized below. We plan to evaluate a similar endpoint in our planned Phase 3 clinical trial.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Faster Onset and Higher Rate of Complete Heartburn Relief </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g17p85.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">On-Demand</FONT> Dosing </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We believe the rapid onset of action of vonoprazan may also enable <FONT STYLE="white-space:nowrap">on-demand,</FONT> or as needed, use for the
relief of symptoms as an alternative to chronic daily treatment. In two open-label, investigator-sponsored clinical trials in Japan, one in erosive esophagitis and a second in NERD, the effectiveness of vonoprazan as an <FONT
STYLE="white-space:nowrap">on-demand</FONT> therapy was compared to that of daily PPI therapy with a number of different PPIs. In both clinical trials, patients utilized approximately 80% fewer doses of vonoprazan compared to PPIs but demonstrated
similar levels of patient satisfaction. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Our Erosive Esophagitis Phase 3 Program </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We plan to initiate a single Phase&nbsp;3 clinical trial of vonoprazan to assess the healing of erosive esophagitis and relief of heartburn, and the
maintenance of healing of erosive esophagitis and relief of heartburn in the fourth quarter of 2019. Our IND for vonoprazan in erosive esophagitis was accepted by the FDA in September 2019. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We plan to enroll approximately 1,000 patients with endoscopically confirmed erosive esophagitis in this clinical trial and enrich the clinical
trial for more severe patients, targeting 30% Los Angeles Class&nbsp;C or D patients. The clinical trial will have both a healing phase and a maintenance phase. As patients will be <FONT STYLE="white-space:nowrap">re-randomized</FONT> between the
healing phase and the maintenance phase, each phase will be analyzed independently and have independent primary and secondary endpoints. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">116 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Healing phase</I></B><I>:</I><B>&nbsp;&nbsp;&nbsp;&nbsp;</B>During the healing phase, patients will be randomized 1:1 to receive either vonoprazan 20 mg QD
or lansoprazole 30 mg QD for up to eight weeks. The lansoprazole 30 mg QD dose is recommended in the FDA prescribing information for lansoprazole. The primary endpoint for this phase will be the percentage of patients with complete healing of
erosive esophagitis by Week 8 as assessed by endoscopy with a primary analysis of <FONT STYLE="white-space:nowrap">non-inferiority.</FONT> If <FONT STYLE="white-space:nowrap">non-inferiority</FONT> is demonstrated, then an analysis for superiority
will also be performed. Key secondary endpoints will include: the percentage of patients with complete healing of erosive esophagitis at Week 2; percentage of patients with Los Angeles Class&nbsp;C or D erosive esophagitis disease with complete
healing at Week 2 and Week 8; percentage of patients with onset of complete heartburn relief by Day 3 of treatment; and the percentage of <FONT STYLE="white-space:nowrap">24-hour</FONT> heartburn free days over the healing phase.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Maintenance phase</I></B><I>:&nbsp;&nbsp;&nbsp;&nbsp;</I>Patients with complete healing of erosive esophagitis at Week 2 or Week 8 in the healing phase
will be <FONT STYLE="white-space:nowrap">re-randomized</FONT> 1:1:1 into the maintenance phase. During this phase, patients will receive either vonoprazan 10 mg QD, vonoprazan 20 mg QD, or lansoprazole 15 mg QD for 24 weeks. The lansoprazole 15 mg
QD dose is recommended in the FDA prescribing information for the maintenance of healing indication. The primary endpoint for this phase will be the percent of patients who maintain complete healing after 24 weeks as assessed by endoscopy with a
primary analysis of <FONT STYLE="white-space:nowrap">non-inferiority.</FONT> If <FONT STYLE="white-space:nowrap">non-inferiority</FONT> is demonstrated, then an analysis for superiority will also be performed. Key secondary endpoints will include
the percentage of patients with Los Angeles Class&nbsp;C or D erosive esophagitis disease who maintain complete healing after 24 weeks and the percentage of <FONT STYLE="white-space:nowrap">24-hour</FONT> heartburn free days over the maintenance
phase. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our Phase 3 trial design is modeled after the successful Phase 3 clinical trials conducted in Japan and Asia
with limited differences other than combining both the healing and maintenance of erosive esophagitis into a single study. In Japan and Asia, separate clinical trials were conducted for each of these indications. We believe we can simplify patient
recruitment by conducting a single clinical trial and <FONT STYLE="white-space:nowrap">re-randomizing</FONT> patients between phases. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Design for Planned Phase 3 Erosive Esophagitis Clinical Trial </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g14x63.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We expect to report <FONT STYLE="white-space:nowrap">top-line</FONT> data from this trial in 2021 and, if
successful, file a regulatory submission for marketing approval in 2022. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">117 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Vonoprazan in Combination with Antibiotics for the Treatment of </B><B><I>H. pylori</I></B><B> Infection
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Disease Burden and Outcomes </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2"><I>H. pylori</I> is a bacterial pathogen that infects approximately 35% of the U.S. population and 45% of the EU5 population. We estimate that there are approximately 115&nbsp;million individuals in the United
States and 145&nbsp;million individuals in the EU5 infected with <I>H. pylori</I>, and we believe there are approximately 2.5&nbsp;million patients treated for <I>H. pylori </I>infection in the United States each year. As a result of the chronic
inflammation induced by <I>H. pylori</I> infection, approximately 20% of infected patients develop a range of pathologies including dyspepsia, peptic ulcer disease, gastric cancer, and mucosa-associated lymphoid tissue (MALT) lymphoma. Gastric
cancer is the third most common cause of cancer-related death worldwide, and over 80% of gastric cancers are attributed to <I>H. pylori</I> infection. Globally there are more than one million new cases of gastric cancer and approximately 782,000
deaths each year. Eradication of <I>H. pylori</I> infection has been proven to reduce the incidence of gastric cancer, and the American College of Gastroenterologists, or ACG, guidelines recommend treatment for all patients diagnosed with <I>H.
pylori </I>infection. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>H.</I><I></I><I>&nbsp;pylori </I>eradication rates have fallen from &gt;90% in the 1990s to current rates of
&lt;80% due to increasing antibiotic resistance. In 2017, the World Health Organization (WHO) listed <I>H. pylori</I> among the 16 antibiotic-resistant bacteria that pose the greatest threat to human health and designated <I>H.&nbsp;pylori</I> as a
Class&nbsp;1 carcinogen, meaning that it is a definite known cause of cancer. In 2014, the FDA added <I>H. pylori </I>to the agency&#146;s list of qualifying pathogens that have the potential to pose a serious threat to public health under the GAIN
Act. We believe that <FONT STYLE="white-space:nowrap">vonoprazan-based</FONT> treatment regimens have the potential to restore eradication rates to greater than 90% in the United States and Europe given the clinical and post-marketing experience in
the Japanese market. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">A recent study compiled real-world health insurance claims data in Japan from 2008 to 2016 for <I>H. pylori
</I>eradication. Prior to vonoprazan&#146;s approval in late 2014, the <I>H. pylori </I>eradication rate across Japan fell to below 80% as shown in the figure below. Approximately one year after vonoprazan&#146;s launch, the eradication rate
increased to greater than 85%. From January 2015 to March 2016, the eradication rate with <FONT STYLE="white-space:nowrap">PPI-containing</FONT> regimens in Japan was between 78% and 82% while the eradication rate with
<FONT STYLE="white-space:nowrap">vonoprazan-containing</FONT> regimens was 91% across all claims in this analysis. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Eradication Rate
of </B><B><I>H. pylori</I></B><B> Infection in Japan Before and After Launch of Vonoprazan </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g38z28.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">118 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In Japan, <FONT STYLE="white-space:nowrap">vonoprazan-containing</FONT> regimens have become the
most common first line treatment. <FONT STYLE="white-space:nowrap">One-year</FONT> post launch, approximately 80% of all treated <I>H. pylori-</I>infected<I> </I>patients received <FONT STYLE="white-space:nowrap">vonoprazan-based</FONT> regimens as
shown below. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Current Treatment Paradigm in the United States and Europe </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The ACG treatment guidelines for <I>H. pylori</I> infection recommend using PPIs in conjunction with antibiotics to improve antibiotic efficacy against <I>H. pylori</I> infection. The use of anti-secretory agents
enhances the effect of antibiotics in two ways. First, anti-secretory agents increase gastric pH, which in turn increases the stability of the antibiotics. For example, amoxicillin and clarithromycin are chemically unstable at the low pH typically
found in the human stomach. Second, several antibiotics, including amoxicillin and clarithromycin, are most potent against <I>H.</I><I></I><I>&nbsp;pylori </I>at the time of maximum bacterial replication, which occurs at pH 6.0 to 7.0.
<I>H.</I><I></I><I>&nbsp;pylori </I>is in a dormant state at lower pH values, which reduces the effectiveness of the antibiotics. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%;padding-bottom:0px; "><FONT
STYLE="font-family:ARIAL" SIZE="2">The table below shows the minimum inhibitory concentration of antibiotic required to eradicate 90% of <I>H. pylori in vitro</I>, or MIC</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUB
STYLE="vertical-align:baseline; position:relative; top:.4ex">90</SUB></FONT><FONT STYLE="font-family:ARIAL" SIZE="2"><I>. </I>As pH increases, the amount of antibiotic required for 90% eradication decreases substantially. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B></B><B><I>H. pylori</I></B><B>
MIC<FONT STYLE="font-family:ARIAL" SIZE="1"><SUB STYLE="vertical-align:baseline; position:relative; top:.4ex">90</SUB></FONT> Values as a Function of pH </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g25v11.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">A triple therapy regimen (PPI, clarithromycin, and either amoxicillin or metronidazole) is the most commonly
used in clinical practice for the first-line treatment of <I>H. pylori </I>infection. However, <I>H. pylori</I> eradication rates with PPI triple therapy have fallen from &gt;90% in the 1990s to current levels of &lt;80%, primarily due to increased
resistance of <I>H. pylori</I> to clarithromycin and metronidazole. A recent meta-analysis indicates that U.S. resistance rates measured from 2012 to 2016 were 20% for clarithromycin, 29% for metronidazole, and 19% for levofloxacin. These figures
represent a marked increase from 2009 to 2011 for both clarithromycin and metronidazole, for which resistance was 9% for clarithromycin, 21% for metronidazole, and 11% for levofloxacin. <I>H. pylori</I> resistance to amoxicillin remains low despite
its use in most triple therapy regimens; resistance is generally &lt;2% among isolates in the United States and Europe. There is a similar trend of increasing resistance to key antibiotics in Europe. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Given the declining eradication rates for <I>H. pylori,</I> quadruple therapy is recommended as first-line treatment in areas with known high rates
of clarithromycin or metronidazole resistance; however, our U.S. market research study reported that physicians prescribe quadruple therapy to only 17% of first-line patients. The surveyed physicians are concerned with patient adherence to treatment
and patient compliance and tolerability issues associated with dosing multiple drugs at multiple times throughout the day. Further, geographic patterns of resistance in the United States are poorly understood and treatment is largely empiric, with
susceptibility testing rarely conducted prior to first-line treatment. Our U.S. market research study reported that only 8% and 16% of physicians conduct resistance testing prior to prescribing treatment for first-line and second-line <I>H.
pylori</I> infection, respectively. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">119 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In our U.S. market research study, physicians highlighted the need for more effective and simpler
first-line treatment options. For the treatment of <I>H. pylori </I>infection, surveyed physicians highlighted the declining eradication rate and low patient compliance rate with treatment regimens as key unmet needs, and 93% of these physicians
believe that vonoprazan offers clinically meaningful benefits over PPIs. Surveyed physicians reported that they would prefer to use vonoprazan dual or triple therapy in, on average, 67% of first-line and 69% of second-line patients with <I>H. pylori
</I>infection. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Phase 3 Clinical Trial in Japan of Vonoprazan in Combination with Antibiotics to Treat H. pylori Infection </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">A randomized, double-blind, multicenter Phase 3 clinical trial in <I>H. pylori-</I>positive patients was completed in Japan. Patients with <I>H.
pylori </I>infection and a history of gastric or duodenal ulcer who had not previously received <I>H. pylori </I>treatment were eligible for inclusion in the clinical trial. A total of 650&nbsp;patients were randomized to receive seven days of:
</FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>vonoprazan triple therapy</I></B>:&nbsp;&nbsp;&nbsp;&nbsp;vonoprazan 20&nbsp;mg twice daily, or BID, amoxicillin 750&nbsp;mg BID, and clarithromycin
(200&nbsp;mg or 400&nbsp;mg) BID; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>lansoprazole triple therapy</I></B>:&nbsp;&nbsp;&nbsp;&nbsp;lansoprazole 30&nbsp;mg BID, amoxicillin 750&nbsp;mg BID, and clarithromycin (200&nbsp;mg or
400&nbsp;mg) BID. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Patients who did not achieve <I>H. pylori</I> eradication after first-line treatment received a
second-line regimen of vonoprazan 20 mg BID, amoxicillin 750 mg BID, and metronidazole 250 mg BID for seven days. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Design of Japan
Phase 3 </B><B><I>H. pylori</I></B><B> Treatment Clinical Trial </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g27k60.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%;padding-bottom:0px; "><FONT STYLE="font-family:ARIAL" SIZE="2">The primary endpoint of the clinical trial was confirmed <I>H. pylori </I>eradication
determined by </FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">13</SUP></FONT><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="white-space:nowrap">C-urea</FONT> breath test, a
standard test for the diagnosis of <I>H. pylori</I>, four weeks after the completion of treatment. The primary analysis was <FONT STYLE="white-space:nowrap">non-inferiority,</FONT> and key secondary endpoints included the second line eradication
rate and eradication rate in antibiotic-resistant subgroups. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="white-space:nowrap">Vonoprazan-based</FONT> triple therapy
demonstrated a <FONT STYLE="white-space:nowrap">non-inferior</FONT> eradication rate of 93% compared to 76% for <FONT STYLE="white-space:nowrap">lansoprazole-based</FONT> triple therapy (p&lt;0.0001). Post hoc analyses indicated that <FONT
STYLE="white-space:nowrap">vonoprazan-based</FONT> triple therapy was superior to <FONT STYLE="white-space:nowrap">lansoprazole-based</FONT> triple therapy (p&lt;0.0001). Patients who were not eradicated on
<FONT STYLE="white-space:nowrap">vonoprazan-based</FONT> triple therapy or <FONT STYLE="white-space:nowrap">lansoprazole-based</FONT> triple therapy were treated with a triple therapy regimen of vonoprazan, amoxicillin, and metronidazole. In this
second-line setting, the <I>H.</I><I></I><I>&nbsp;pylori</I> eradication rate with vonoprazan triple therapy was 98%. Across </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">120 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
first- and second-line patients, the <I>H. pylori</I> eradication rate in clarithromycin resistant strains was higher with <FONT STYLE="white-space:nowrap">vonoprazan-based</FONT> triple therapy
(82%) than with <FONT STYLE="white-space:nowrap">lansoprazole-based</FONT> triple therapy (40%) as shown below. We believe that this result is significant, as <I>H. pylori </I>antibiotic resistance testing is rare in the United States, and <I>H.
pylori </I>treatment is generally empiric. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Results of Japan Phase 3 Clinical Trial in the Treatment of </B><B><I>H. pylori</I></B><B>
Infection </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g28q09.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Other Studies of Vonoprazan in H. pylori Treatment </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">A meta-analysis of 14 studies in Japan with over 14,636 patients found that the pooled eradication rates of
<FONT STYLE="white-space:nowrap">vonoprazan-containing</FONT> regimens were superior to those of <FONT STYLE="white-space:nowrap">PPI-containing</FONT> regimens in a first-line setting (85% vs. 68%, p&lt;0.00001). Subgroup analysis further indicated
the superiority of vonoprazan in patients with either clarithromycin-resistant strains (82% vs. 41%, p&lt;0.00001) or clarithromycin-susceptible strains (95% vs 90%, p&#061;0.006). A second study retrospectively confirmed that empiric <FONT
STYLE="white-space:nowrap">vonoprazan-based</FONT> triple therapy was <FONT STYLE="white-space:nowrap">non-inferior</FONT> to <FONT STYLE="white-space:nowrap">PPI-based</FONT> triple therapy based on <I>H. pylori </I>antibiotic susceptibility
testing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition to demonstrating superiority to PPIs in triple therapy regimens, vonoprazan was studied in a dual therapy regimen
with amoxicillin in two investigator-initiated clinical trials in Japan. The first trial involving 67 Japanese patients assessed vonoprazan dual therapy (vonoprazan 20 mg BID in combination with amoxicillin 500 mg three times daily, or TID, for
seven days) compared to vonoprazan triple therapy (vonoprazan 20 mg BID in combination with amoxicillin 750 mg BID and clarithromycin 200 mg BID for seven days). As shown below, vonoprazan dual therapy was similarly efficacious to vonoprazan triple
therapy (eradication rates of 94% in both treatment arms). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">121 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Results of Vonoprazan Dual and Triple Therapy in the Treatment of </B><B><I>H.
pylori</I></B><B> Infection </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g30a16.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">A second clinical trial compared <FONT STYLE="white-space:nowrap">vonoprazan-based</FONT> dual therapy to
esomeprazole or rabeprazole <FONT STYLE="white-space:nowrap">PPI-based</FONT> triple therapy. This clinical trial enrolled 81 Japanese patients including 40 first-line treatment patients and 41 second-line treatment patients who had failed standard
therapy and compared vonoprazan dual therapy and PPI triple therapy in both first- and second-line therapy. Patients assigned to vonoprazan dual therapy were treated with vonoprazan 20 mg BID in combination with amoxicillin 500 mg TID for
seven&nbsp;days. Patients assigned to PPI triple therapy were treated first-line with esomeprazole 20 mg or rabeprazole 10 mg BID, amoxicillin 750 mg BID, and clarithromycin 200 mg BID or second-line with esomeprazole 20 mg or rabeprazole 10&nbsp;mg
BID, amoxicillin 750 mg BID, and metronidazole 250 mg BID for seven days. As shown below, dual therapy with vonoprazan was efficacious in both first- and second-line therapy with eradication rates of 95% and 90%, respectively, versus 81% and 85% for
<FONT STYLE="white-space:nowrap">PPI-based</FONT> triple therapies. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Results of Vonoprazan Dual and PPI Triple Therapy in the
Treatment of </B><B><I>H. pylori</I></B><B> Infection </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:0px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g29j70.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Antibiotic resistance is a significant clinical issue, and we believe that vonoprazan has the potential to
address the growing resistance to <I>H. pylori</I> by eradicating infection after first-line of treatment. Vonoprazan dual therapy has further potential for improved convenience and compliance
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">122 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
over triple or quadruple therapy regimens, and importantly, spares the use of clarithromycin, metronidazole, and levofloxacin, representing an opportunity both for effective treatment and sound
antibiotic stewardship through the avoidance of additional antibiotics to which <I>H. pylori</I> is known to acquire resistance. Less frequent use of these antibiotics, which have important roles aside from the treatment of <I>H. pylori</I>
infection, may help to limit the spread of resistance among other pathogenic bacteria within populations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Our H. pylori Phase 3 Program
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We plan to initiate a Phase&nbsp;3 clinical trial of vonoprazan for the treatment of <I>H. pylori</I> infection. Our INDs for
vonoprazan in treatment of <I>H.&nbsp;pylori</I> infection were accepted by the FDA in September 2019. In August 2019, we received QIDP designation from the FDA for vonoprazan in combination with both amoxicillin and clarithromycin and in
combination with amoxicillin alone for the treatment of <I>H. pylori</I> infection. Subject to limited exceptions, QIDP designation extends any non-patent marketing exclusivity by an additional five years, and also provides potential eligibility for
priority review and fast track designation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%;padding-bottom:0px; "><FONT STYLE="font-family:ARIAL" SIZE="2">We plan to enroll approximately 975 patients with <I>H. pylori
</I>infection as assessed by </FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">13</SUP></FONT><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="white-space:nowrap">C-urea</FONT>
breath test in this clinical trial. The clinical trial will compare vonoprazan dual therapy and vonoprazan triple therapy regimens each <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> with a standard of
care lansoprazole triple therapy regimen. Patients will be randomized in a 1:1:1 manner into the three treatment arms as follows: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>vonoprazan dual therapy</I></B>:&nbsp;&nbsp;&nbsp;&nbsp;vonoprazan 20 mg BID and amoxicillin 1 g TID for 14&nbsp;days; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>vonoprazan triple therapy</I></B>:&nbsp;&nbsp;&nbsp;&nbsp;vonoprazan 20 mg BID, amoxicillin 1 g BID and clarithromycin 500 mg BID for 14 days; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>PPI triple therapy</I></B>:&nbsp;&nbsp;&nbsp;&nbsp;lansoprazole 30 mg BID, amoxicillin 1 g BID and clarithromycin 500 mg BID for 14 days.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%;padding-bottom:0px; "><FONT STYLE="font-family:ARIAL" SIZE="2">The primary endpoint for this trial will be the percentage of patients with successful
eradication of <I>H. pylori </I>infection as assessed by </FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">13</SUP></FONT><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT
STYLE="white-space:nowrap">C-urea</FONT> breath test four weeks after completion of treatment. The primary analysis will assess the <FONT STYLE="white-space:nowrap">non-inferiority</FONT> of vonoprazan dual therapy to lansoprazole triple therapy and
vonoprazan triple therapy to lansoprazole triple therapy excluding patients who have <I>H.&nbsp;pylori</I> infection that is resistant to clarithromycin or amoxicillin. We will also conduct secondary analyses for superiority in all patients
regardless of antibiotic resistance and in patients with clarithromycin-resistant <I>H. pylori </I>infection. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our Phase 3 trial design
is modeled after the successful Phase 3 clinical trial conducted in Japan. Key differences include: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Inclusion of patients with H. pylori infection and dyspeptic symptoms</I></B><I>.&nbsp;&nbsp;&nbsp;&nbsp;</I>Our clinical trial will enroll patients with
active <I>H. pylori </I>infection and dyspeptic symptoms. The Japan Phase 3 trial enrolled patients with <I>H. pylori </I>infection and a history of gastric or duodenal ulcers; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Treatment duration and antibiotic doses</I></B><I>.&nbsp;&nbsp;&nbsp;&nbsp;</I>Standard of care regimens in Western countries include higher doses of
antibiotics and a longer duration of treatment (typically 14 days) than in Japan (typically seven days); and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Inclusion of dual therapy arm</I></B><I>.&nbsp;&nbsp;&nbsp;&nbsp;</I>Vonoprazan dual therapy has only been studied in investigator-initiated clinical
trials and not yet in a pivotal trial. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our clinical trial design conforms to standard of care treatment regimens in
the United States and Europe and follows the ACG treatment guidelines. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">123 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Design for Planned Phase 3 </B><B><I>H. pylori</I></B><B> Clinical Trial </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g34u44.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We expect to report <FONT STYLE="white-space:nowrap">top-line</FONT> data from this trial in 2021 and, if
successful, file a regulatory submission for marketing approval in 2021. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Vonoprazan Pharmacokinetics and Pharmacodynamics in Japanese vs. <FONT
STYLE="white-space:nowrap">non-Japanese</FONT> Subjects </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The vonoprazan pharmacokinetic and pharmacodynamic profile is similar
between Japanese and <FONT STYLE="white-space:nowrap">non-Japanese</FONT> subjects as assessed in two randomized, double-blind, placebo-controlled Phase 1 clinical trials in healthy volunteers. Sixty Japanese subjects in the first study and 48 <FONT
STYLE="white-space:nowrap">non-Japanese</FONT> subjects in the second study, of whom 85% were Caucasian, received doses from 10 mg up to 40 mg QD for seven consecutive days. At all doses, pharmacokinetics between the two populations were similar. In
addition, the pharmacodynamics were similar between Japanese and <FONT STYLE="white-space:nowrap">non-Japanese</FONT> subjects as shown in the figure below. On Day 7, mean time above pH 4.0 for vonoprazan 20 mg QD was 83% for Japanese subjects and
85% for <FONT STYLE="white-space:nowrap">non-Japanese</FONT> subjects. Night-time <FONT STYLE="white-space:nowrap">12-hour</FONT> time above pH 4.0 was 73% for Japanese subjects and 75% for <FONT STYLE="white-space:nowrap">non-Japanese</FONT>
subjects. We believe that these results show that vonoprazan has a similar profile in Japanese and <FONT STYLE="white-space:nowrap">non-Japanese</FONT> subjects. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>Comparative Pharmacodynamics of Vonoprazan in Japanese and <FONT STYLE="white-space:nowrap">non-Japanese</FONT> Subjects </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g35m07.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Summary of Vonoprazan Safety Data </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Safety in Clinical Studies </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As of December 2018, 6,683 subjects have been exposed to
vonoprazan in completed and ongoing Phase 1 to 3 clinical trials. The doses studied have ranged from 1 to 120 mg with durations up </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">124 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
to one year. The most commonly reported adverse events, or AEs, in the clinical development program for vonoprazan, as reflected in the Japanese prescribing information published by Japan&#146;s
Pharmaceuticals and Medical Devices Agency, or PMDA, were diarrhea, constipation, nausea, elevated liver enzymes, rash, and eosinophilia. All such events had an incidence rate of less than 5.0% other than diarrhea in the treatment of <I>H.
pylori</I> which had an incidence rate of 10.6% in combination with antibiotics. No dose-related increase in treatment-emergent AEs, or TEAEs, or serious AEs was observed. The safety profile of vonoprazan and incidence of TEAEs, drug-related TEAEs,
and TEAEs leading to drug discontinuation were similar between vonoprazan and lansoprazole across studies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Certain earlier generation <FONT
STYLE="white-space:nowrap">P-CABs</FONT> previously under development by other companies may have been discontinued <FONT STYLE="white-space:nowrap">in-part</FONT> due to their hepatic safety profile. These hepatic safety concerns may be
compound-specific and not generalizable to the <FONT STYLE="white-space:nowrap">P-CAB</FONT> class. It is notable that vonoprazan is based on a pyrrole chemical structure and is chemically distinct from previously discontinued <FONT
STYLE="white-space:nowrap">P-CABs</FONT> that were based on an imidazole structure. Vonoprazan has had a similar hepatic safety profile to lansoprazole across all clinical studies conducted by Takeda, in which 1.0% of subjects treated with
vonoprazan 10 mg or 20 mg and 0.8% of subjects treated with lansoprazole 15 mg or 30 mg had ALT or AST elevations greater than three times the upper limit of normal or bilirubin elevations greater than two times the upper limit of normal.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Vonoprazan Post-Marketing Safety in Japan </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The most recent post-marketing safety report from December 2018 includes an estimated 23&nbsp;million patients who have received vonoprazan in Japan since its launch. Based on the post-marketing experience, the
clinically significant adverse reactions section of the Japanese prescribing information for vonoprazan was updated to include skin reactions such as toxic epidermal necrolysis, Steven-Johnson syndrome, and erythema multiforme. The incidence of
these skin reactions was considered extremely rare (less than 1 in 100,000 patients) and a causal relationship to vonoprazan could not be ruled out. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Serious hepatic adverse events have also been observed among patients exposed to vonoprazan in Japan in the post-marketing setting. These cases were typically confounded by comorbidities or other concomitant
medications and believed to be idiosyncratic reactions. The incidence of these events was considered extremely rare (less than 1 in 100,000 patients). The post-marketing safety data, including the December 2018 post-marketing safety report and the
reported hepatic safety events, have been submitted to the PMDA. To date, there have been no changes to the Japan prescribing information related to hepatic safety. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>Vonoprazan Launch in Japan </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Vonoprazan Regulatory Status </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%;padding-bottom:0px; "><FONT STYLE="font-family:ARIAL" SIZE="2">Vonoprazan first received approval in Japan on December&nbsp;26, 2014 as TAKECAB<FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">&reg;</SUP></FONT> for the following indications: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Healing and maintenance of healing of erosive esophagitis; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Adjunct to antibiotics in <I>H. pylori</I> treatment; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Gastric ulcer; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Duodenal ulcer; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Prevention of recurrence of gastric ulcer or duodenal ulcer during <FONT STYLE="white-space:nowrap">low-dose</FONT> aspirin administration; and
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">125 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Prevention of recurrence of gastric ulcer or duodenal ulcer during nonsteroidal anti-inflammatory drug (NSAID) administration. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Vonoprazan was subsequently approved in Japan in February 2016 for the treatment of <I>H.&nbsp;pylori </I>in combination packs with antibiotics
(Vonosap Pack 400, Vonosap Pack 800, and Vonopion Pack), and as VOCINTI in the Philippines (October 2017), Singapore (March 2018), Thailand (July 2018), Argentina (September 2018), Peru (September 2018), South Korea (March 2019), Taiwan (March
2019), and Malaysia (May 2019). Vonoprazan is currently under review for approval by regulatory authorities in additional countries in Latin America and Asia, including China. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Vonoprazan Commercialization in Japan </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Vonoprazan was approved in Japan in December
2014. In its fourth full year on the market vonoprazan generated $524&nbsp;million in net sales, a 20% increase over the prior year. In addition, in the quarter ended June&nbsp;30, 2019, vonoprazan generated $164.7&nbsp;million in net sales, a 28%
increase over the corresponding quarter from the prior fiscal year. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Vonoprazan Net Sales Since Approval </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="font-size:1px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g70f21.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We believe that the market dynamic for anti-secretory agents in Japan is similar to that in the United States.
In both countries, the anti-secretory market is largely genericized. Ahead of the vonoprazan launch in Japan, all PPIs, other than Nexium, were available as generics. As of 2017, generic drugs in Japan represent approximately 70% of the market by
volume, compared to the United&nbsp;States where generics are approximately 90% of the market by volume. Additionally, the Japanese government set a goal to increase generic use to 80% by 2020. Although vonoprazan and Dexilant are priced at a
premium to generic PPIs in Japan and the United States, respectively, both have experienced commercial success. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Vonoprazan Commercial Opportunity
and Strategy </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The market for prevention and treatment of acid-related GI diseases in the United States and Europe is large. There
were approximately 120&nbsp;million oral PPI prescriptions written in the United States and 6.1&nbsp;billion doses prescribed for the 12&nbsp;months ended May&nbsp;31, 2019. We estimate there are approximately 65&nbsp;million individuals with GERD
in the United States and 50&nbsp;million individuals with GERD in the EU5, of whom 15% to 45% are inadequately treated with PPIs. In addition, we estimate that there are approximately 115&nbsp;million individuals in the United States, of which
2.5&nbsp;million are treated each year, and 145&nbsp;million individuals in the EU5 infected with <I>H. pylori</I>. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">126 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Over many decades of use, multiple drug classes and individual drugs have demonstrated the
substantial commercial opportunity for therapies treating acid-related GI diseases. H2RAs including Axid, Pepcid, Tagamet, and Zantac provided the first significant improvement in disease management over antacids and as a class reached
$3.5&nbsp;billion in annual sales. After H2RAs, PPIs emerged as the new standard of care. Prior to the introduction of generic and OTC alternatives, annual PPI class sales reached approximately $12.5&nbsp;billion in the United States, and peak sales
for individual brands were approximately $3.7&nbsp;billion for Prilosec, approximately $3.5&nbsp;billion for Nexium, and $3.4&nbsp;billion for Prevacid. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%;padding-bottom:0px; "><FONT
STYLE="font-family:ARIAL" SIZE="2">As recently as 2015, the last branded PPI, Dexilant, reached approximately $530&nbsp;million in sales in the United States</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex"> </SUP></FONT><FONT STYLE="font-family:ARIAL" SIZE="2">despite limited differentiation from other PPIs. As of June&nbsp;30, 2019, Dexilant was priced at a significant premium to generic
PPIs on the market. Even with premium pricing, Dexilant obtained broad insurance coverage and favorable access. As of June&nbsp;30,</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">
</SUP></FONT><FONT STYLE="font-family:ARIAL" SIZE="2">2019, approximately 90% of commercially covered lives and 80% of Medicare covered lives had access to Dexilant. Furthermore, of those commercially covered lives, 65% had unrestricted access to
the drug without prior authorization or step edits and 35% of patients had access at the lowest branded cost tier. We believe that, if approved in our markets, vonoprazan will be the first of the next generation of anti-secretory therapies to
improve the standard of care for acid-related GI diseases by providing a safe and effective treatment option for the millions of patients in need of more potent, rapid, or durable acid suppression. Additionally, we believe the potential
differentiation of vonoprazan compared to PPIs could result in attractive market access and formulary positioning. <B></B> </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In July
2019, we conducted a U.S. market research study which surveyed 100 gastroenterologists and 100 primary care physicians who commonly prescribe PPIs and treat patients with GERD and <I>H. pylori</I> infection. For the treatment of GERD, surveyed
physicians highlighted control of nighttime and daytime heartburn symptoms and efficacy in the healing and maintenance of healing of esophageal erosions as key unmet needs. These physicians reported that vonoprazan&#146;s mechanism of action and
gastric pH control is considered meaningfully improved over PPIs and that vonoprazan could be a more effective treatment than PPIs in healing and maintenance of healing of esophageal erosions. These physicians would prefer to use vonoprazan in, on
average, 59% of all of their GERD patients. For the treatment of <I>H. pylori</I> infection, surveyed physicians highlighted the declining eradication rate and low patient compliance rate with treatment regimens as key unmet needs, and 93% of these
physicians believe that vonoprazan offers clinically meaningful benefits over PPIs. Surveyed physicians reported that they would prefer to use vonoprazan dual or triple therapy in, on average, 67% of first-line and 69% of second-line patients with
<I>H. pylori</I> infection. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Sales and Marketing </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">We do not currently have our own marketing, sales, or distribution capabilities. We plan to independently commercialize vonoprazan in the United States by building a leading specialty gastroenterology-focused
commercial infrastructure to support the adoption of vonoprazan. We believe we can successfully launch vonoprazan in the United States with a focused specialty sales force targeting high prescribers of PPIs, particularly gastroenterologists. PPI
prescribing is highly concentrated with approximately 1.5% of U.S. PPI prescribers (approximately 12,000 total) accounting for approximately 20% of PPI prescriptions and approximately 6.0% of U.S. PPI prescribers (approximately 50,000 total)
accounting for approximately 50% of PPI prescriptions, according to IQVIA. We believe we have an opportunity to achieve significant share of voice and exposure to physicians given the scarcity of actively marketed anti-secretory medicines.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">To address the commercial opportunity for vonoprazan in Europe and Canada, we plan to seek one or more partners with existing
commercial infrastructure and expertise in these markets. Additional clinical trials of vonoprazan may be required to obtain regulatory approval and/or ensure access to these markets. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">127 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Additional Vonoprazan Development Opportunities </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Indications </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">While we are initially focused on the development of vonoprazan for the
treatment of erosive esophagitis and the treatment of <I>H. pylori </I>infection, we believe there are opportunities to expand the use of vonoprazan to other indications in our licensed territories. For example, in Japan, vonoprazan is also approved
for the treatment of gastric ulcers, treatment of duodenal ulcers, prevention of recurrence of gastric ulcer or duodenal ulcer during <FONT STYLE="white-space:nowrap">low-dose</FONT> aspirin administration, and prevention of recurrence of gastric
ulcer or duodenal ulcer during NSAID administration. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition to those indications for which vonoprazan is approved in Japan, we
believe there are additional opportunities to develop vonoprazan for the treatment of GI diseases. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>NERD.</I></B> We believe that
there is opportunity to broadly position vonoprazan&#146;s use in GERD with an indication in NERD, also known as symptomatic GERD, in addition to an indication in erosive esophagitis. We may develop vonoprazan in NERD with daily and/or <FONT
STYLE="white-space:nowrap">on-demand,</FONT> or <FONT STYLE="white-space:nowrap">as-needed,</FONT> dosing regimens. We believe the rapid onset of action of vonoprazan may enable <FONT STYLE="white-space:nowrap">on-demand</FONT> use for the
management of GERD-related symptoms as an alternative to chronic daily treatment with PPIs. An <FONT STYLE="white-space:nowrap">on-demand</FONT> dosing regimen may be especially attractive in NERD, as NERD patients have symptoms related to acid, but
do not have esophageal erosions which require chronic treatment for healing. In an open-label, investigator-sponsored clinical trial in Japan in NERD patients, <FONT STYLE="white-space:nowrap">on-demand</FONT> treatment with vonoprazan was compared
to daily treatment with PPIs. Patients utilized approximately 80% fewer doses of vonoprazan compared to PPIs, but demonstrated similar levels of satisfaction. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Takeda conducted two Phase 3 multicenter, randomized, double-blind, parallel group trials with vonoprazan in Japanese patients with endoscopically confirmed NERD. In the first clinical trial, vonoprazan
demonstrated a significant reduction in symptom severity versus placebo (p&#061;0.0139), and in the second trial, vonoprazan demonstrated a faster onset of symptom relief versus placebo (p&#061;0.0003). However, the studies did not show a
statistically significant difference in the primary endpoint of proportion of days over a 4-week period without heartburn between vonoprazan and placebo (p&#061;0.0504 and p&#061;0.0643). In the first clinical trial, Takeda enrolled patients with
symptoms including a three-week history of heartburn or regurgitation with two or more days of heartburn per week, or a three-week history of any acid-reflux symptoms of moderate or higher severity. In the second clinical trial, patients with a
three-week history of recurrent heartburn with two or more days of heartburn per week were enrolled. We believe that these results may be due to the selection of patients with a limited history of symptoms, a low threshold for frequency of symptoms
of two or more days per week, and with mostly mild to moderate symptoms rather severe symptoms. In contrast, all PPIs approved for NERD in the United States enrolled subjects with greater than six-month history of heartburn and heartburn on at least
four of the seven days immediately preceding randomization. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, in a Phase&nbsp;2 clinical trial in European patients with
NERD who were partial responders to high dose PPIs, vonoprazan did not demonstrate superiority versus esomeprazole in the primary endpoint of the percentage of heartburn free days over the four-week treatment period. We believe this result may have
been due to inclusion of patients with GI disorders unrelated to acid. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Other Indications</I></B>. Barrett&#146;s esophagus and
Zollinger Ellison syndrome are severe diseases related to acid secretion where PPIs are the current standard of care. The improved acid control of vonoprazan relative to PPIs may lead to improved results over PPIs. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Eosinophilic esophagitis is an autoimmune disease with significant unmet need. Although not approved for this indication, PPIs are prescribed for
the treatment of eosinophilic esophagitis. Vonoprazan demonstrated similar efficacy to PPIs in an investigator-sponsored clinical trial in Japan. In </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">128 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
this clinical trial, 112 patients with eosinophilic esophagitis were treated with vonoprazan, or the PPI rabeprazole or esomeprazole. Of patients treated with vonoprazan, 82% had complete relief
of symptoms compared to 70% for esomeprazole and <FONT STYLE="white-space:nowrap">76-78%</FONT> for rabeprazole. Similarly, 35% of patients treated with vonoprazan demonstrated complete remission of eosinophilic esophagitis by histology, compared to
37% for esomeprazole and <FONT STYLE="white-space:nowrap">31-38%</FONT> for rabeprazole. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Formulations and Packaging </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Orally Disintegrating Tablet</I></B><I>.</I>&nbsp;&nbsp;&nbsp;&nbsp;An orally disintegrating tablet, or ODT, formulation for vonoprazan is
currently in development by Takeda. We may conduct one or more Phase I trials to support potential approval of the ODT formulation. We believe that the ODT represents a meaningful commercial opportunity for patients with difficulty swallowing, as
estimated peak U.S. sales of the lansoprazole ODT formulation were over $450&nbsp;million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Intravenous
Formulation</I></B><I>.</I>&nbsp;&nbsp;&nbsp;&nbsp;We are exploring the potential to develop an intravenous formulation of vonoprazan for use in acute bleeding, critically ill patients, or other <FONT STYLE="white-space:nowrap">in-hospital</FONT>
applications. Several PPIs have approved intravenous formulations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Pediatric
Formulation</I></B><I>.</I>&nbsp;&nbsp;&nbsp;&nbsp;We are exploring the potential to develop an oral formulation, in addition to an ODT formulation, for pediatric use. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Convenience Pack for H.&nbsp;pylori</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;In Japan, vonoprazan is marketed both as a stand-alone medicine as well as in <FONT STYLE="white-space:nowrap">pre-packaged</FONT>
convenience packs with either clarithromycin and amoxicillin (Vonosap) or metronidazole and amoxicillin (Vonopion). <FONT STYLE="white-space:nowrap">Pre-packaged</FONT> products for the treatment of <I>H.&nbsp;pylori</I> infection may improve
patient adherence and treatment outcomes, and we believe there is a meaningful market opportunity for such a product. In the United States, PrevPac was formerly marketed as a <FONT STYLE="white-space:nowrap">pre-packaged</FONT> convenience pack of
lansoprazole, clarithromycin, and amoxicillin and achieved peak sales of $150&nbsp;million. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Over the Counter Use </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We believe that vonoprazan has the ideal profile for an OTC product, including the potential for <FONT STYLE="white-space:nowrap">on-demand</FONT>
symptom relief and a well-tolerated safety profile. The market for OTC heartburn relief is substantial, with 2018 sales of $3.2&nbsp;billion in the United States. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>Competition </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The biopharmaceutical industry is characterized by rapidly advancing technologies,
intense competition and strong emphasis on proprietary products. We face potential competition from many sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions and government agencies and
public and private research institutions. If vonoprazan receives marketing approval in the United States, Europe or Canada, it will compete with existing therapies and new therapies that may become available in the future. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Some of our competitors, either alone or with their strategic partners, have substantially greater financial, technical and human resources and
significantly greater experience in the discovery and development of product candidates, obtaining FDA and other regulatory approvals of treatments and commercializing those treatments. These same competitors may invent technology that competes with
vonoprazan. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated among a smaller number of our competitors. These competitors also compete with us in recruiting and
retaining qualified scientific and management personnel and establishing clinical trial sites and subject recruitment for clinical trials, as well as in </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">129 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative
arrangements with large and established companies. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our commercial opportunity could be reduced or eliminated if our competitors develop
and commercialize products that are more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their
products more rapidly than we may obtain approval for vonoprazan, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, we expect that vonoprazan, if approved, will be priced
at a premium over competitive generic products and our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%;padding-bottom:0px; "><FONT STYLE="font-family:ARIAL" SIZE="2">We expect that vonoprazan, if approved for the treatment of erosive esophagitis and treatment of <I>H.&nbsp;pylori</I>
infection, will primarily compete with generic PPIs marketed by multiple pharmaceutical companies in both the prescription and OTC markets. Additionally, RedHill Biopharma Ltd. is developing Talicia, a
<FONT STYLE="white-space:nowrap">co-formulated</FONT> capsule comprising generic omeprazole, amoxicillin, and rifabutin for the treatment of <I>H.&nbsp;pylori</I> infection, and filed a new drug application, or NDA, in the United States in May 2019.
Ironwood Pharmaceuticals, Inc. is developing <FONT STYLE="white-space:nowrap">IW-3718,</FONT> a bile acid sequestrant, currently in Phase&nbsp;3 clinical trials as an adjunct to PPIs for the treatment of patients with persistent GERD. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We are also aware of other <FONT STYLE="white-space:nowrap">P-CABs</FONT> in territories outside of the United States that, if developed and
approved in our territories, may compete with vonoprazan. Revaprazan is marketed by Yuhan Corporation in South Korea. Tegoprazan is marketed by CJ Healthcare Corp. in South Korea and is currently in Phase 3 development in Japan by RaQualia Pharma,
Inc. Daewoong Pharmaceutical Co., Ltd.&#146;s DWP14012 has been studied in Phase 2 clinical trials in South Korea, and Cinclus Pharma AG&#146;s X842 has completed a Phase 1 clinical trial in Europe. To our knowledge, none of these compounds have
demonstrated superiority to PPIs on clinical endpoints. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Additionally, we are aware of several clinical-stage PPIs in territories
outside of the United States that if developed and approved in our licensed territories may compete with vonoprazan. These include Dexa Medica&#146;s DLBS-2411, currently in Phase 3 clinical trials in Indonesia, Sihuan Pharmaceutical&#146;s
anaprazole, currently in Phase 3 clinical trials in China, Eisai&#146;s azeloprazole, currently in a Phase 2 clinical trial in Japan, and Sidem Pharma&#146;s tenatoprazole, currently in Phase 2 clinical trials in Europe and Canada. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Manufacturing </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We do not currently own or
operate manufacturing facilities for the production of clinical or commercial quantities of vonoprazan. Vonoprazan is a small molecule that can be manufactured using commercially available technologies. We currently rely on Takeda to supply us with
vonoprazan drug product for clinical use. We intend to enter into a commercial supply agreement with Takeda, and we are exploring additional options for commercial supply of vonoprazan from other third party contract manufacturers. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">With respect to any future product candidates, we expect to continue to rely on third-party contract manufacturers to manufacture clinical supplies
and commercial quantities of any approved product. Although we rely on contract manufacturers, we have personnel with manufacturing experience to oversee our relationship with Takeda. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>Intellectual Property </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Intellectual property, including patents, trade secrets, trademarks and
copyrights, is important to our business. Our commercial success depends in part on our ability to obtain and maintain proprietary </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">130 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
intellectual property protection for vonoprazan, as well as for future product candidates and novel discoveries, product development technologies, and
<FONT STYLE="white-space:nowrap">know-how.</FONT> Our commercial success also depends in part on our ability to operate without infringing on the proprietary rights of others and to prevent others from infringing our proprietary rights. Our policy
is to develop and maintain protection of our proprietary position by, among other methods, licensing or filing U.S. and foreign patents and applications relating to our technology, inventions, and improvements that are important to the development
and implementation of our business. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our patent portfolio, comprising patents and patent applications exclusively licensed to us, is
built with a goal of establishing broad protection that generally includes, for the product candidate compound, claims directed to composition of matter, pharmaceutical compositions or formulations, methods of synthesis, and methods of treatment
using such pharmaceutical compositions or formulations. As of September&nbsp;30, 2019, our patent portfolio covering vonoprazan consists solely of exclusively licensed patents and patent applications from Takeda. Subject to the terms of the license
agreement we entered into with Takeda on May&nbsp;7, 2019, or the Takeda License, we have licensed from Takeda exclusive rights in the United States, Europe, and Canada to patents and patent applications covering the composition of matter,
formulation, use and/or manufacture of vonoprazan. Our patent portfolio comprises 11 distinct patent families protecting the technology relating to the compound vonoprazan and its synthetic intermediates, methods of synthesizing vonoprazan and
related compounds, various formulations of vonoprazan products, as well as methods of treating diseases with vonoprazan and related compounds. As of September 30, 2019, our portfolio consists of approximately 17 issued U.S. patents, 6 pending U.S.
applications, 9 issued European patents subsequently validated in individual European countries, 6 pending European applications, 3 issued Canadian patents, 5 pending Canadian applications, and one pending PCT application. The issued patents and
pending applications have nominal expiration dates ranging from 2024 to 2038, without accounting for any available patent term adjustments or extensions. The issued U.S. patent covering the composition of matter of vonoprazan is expected to expire
in August 2028, not including patent term extension. The issued U.S. patent covering the formulation of vonoprazan is expected to expire in August 2030, not including patent term extension. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The term of individual patents in our portfolio depends upon the legal term of patents in the countries in which they are obtained. In most
countries in which we file, including the United States, the patent term is 20 years from the earliest date of filing a <FONT STYLE="white-space:nowrap">non-provisional</FONT> patent application. In the United&nbsp;States, the term of a patent may
be eligible for patent term adjustment, which permits patent term restoration as compensation for delays incurred at the USPTO during the patent prosecution process. In addition, for patents that cover an
<FONT STYLE="white-space:nowrap">FDA-approved</FONT> drug, the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the expiration of the patent. While
the length of the patent term extension is related to the length of time the drug is under regulatory review, patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, and only
one patent per approved drug may be extended under the Hatch-Waxman Act. Similar provisions are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our products
receive FDA approval, we expect to apply for patent term extensions on patents covering those products. We plan to seek any available patent term extension to any issued patents we may be granted in any jurisdiction where such extensions are
available; however, there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and if granted, the length of such extensions.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The patent positions of companies like ours are generally uncertain and involve complex legal and factual questions. The relevant
patent laws and their interpretation outside of the United States is also uncertain. Changes in either the patent laws or their interpretation in the United States and other </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">131 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
countries may diminish our ability to protect our technology or product candidates and could affect the value of such intellectual property. In particular, our ability to stop third parties from
making, using, selling, offering to sell or importing products that infringe our intellectual property will depend in part on our success in obtaining and enforcing patent claims that cover our technology, inventions and improvements. We cannot
guarantee that patents will be granted with respect to any of our licensed pending patent applications or with respect to any patent applications we may file in the future, nor can we be sure that any patents that may be granted to us or Takeda in
the future will be commercially useful in protecting our products, the methods of use or manufacture of those products. Moreover, issued patents do not guarantee the right to practice our technology in relation to the commercialization of our
products. Issued patents only allow us to block potential competitors from practicing the claimed inventions of the issued patents. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Further, patents and other intellectual property rights in the pharmaceutical and biotechnology space are evolving and involve many risks and
uncertainties. For example, third parties may have blocking patents that could be used to prevent us from commercializing vonoprazan and any future product candidates and practicing our proprietary technology, and any issued patents may be
challenged, invalidated or circumvented, which could limit our ability to stop competitors from marketing related products or could limit the term of patent protection that otherwise may exist for vonoprazan and any future product candidates. In
addition, the scope of the rights granted under any issued patents may not provide us with protection or competitive advantages against competitors with similar technology. Furthermore, our competitors may independently develop similar technologies
that are outside the scope of the rights granted under any issued patents. For these reasons, we may face competition with respect to vonoprazan and any future product candidates. Moreover, because of the extensive time required for development,
testing and regulatory review of a potential product, it is possible that, before any particular product candidate can be commercialized, any patent protection for such product may expire or remain in force for only a short period following
commercialization, thereby reducing the commercial advantage the patent provides. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">It is our policy to require our employees,
consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us, and for employees and consultants to enter into
invention assignment agreements with us. These agreements provide that all confidential information developed or made known to the individual during the course of the individual&#146;s relationship with us is to be kept confidential and not
disclosed to third parties except in specific circumstances. Where applicable, the agreements provide that all inventions to which the individual contributed as an inventor shall be assigned to Phathom, and as such, will become our property. There
can be no assurance, however, that these agreements will provide meaningful protection or adequate remedies for our trade secrets in the event of unauthorized use or disclosure of such information. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Further, we have filed for and are pursuing trademark protection for our company name &#147;Phathom Pharmaceuticals&#148; in the United States and
foreign jurisdictions. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>License Agreement with Takeda Pharmaceutical Company Limited </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">On May&nbsp;7,&nbsp;2019, we and Takeda entered into the Takeda License. Pursuant to the Takeda License, Takeda granted us an exclusive,
sublicensable (with Takeda&#146;s reasonable consent) license under certain patents and know how relating to vonoprazan and owned or controlled by Takeda during the term of the Takeda License to commercialize vonoprazan products using specified
formulations for all human therapeutic uses in the United States, Europe and Canada, and a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license under such patents and know how to develop and manufacture such vonoprazan products anywhere in
the world (subject to Takeda&#146;s consent as to each country) for the purposes of commercializing the vonoprazan products in the United States, Europe and Canada. We granted Takeda a <FONT STYLE="white-space:nowrap">non-exclusive,</FONT>
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">132 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
royalty-free, sublicensable license under our rights in any patents and <FONT STYLE="white-space:nowrap">know-how</FONT> that are necessary or useful to enable Takeda to develop and manufacture
vonoprazan products anywhere in the world for the purposes of commercialization outside United States, Europe and Canada. We also granted Takeda an exclusive, royalty-free license under our rights in certain patents and <FONT
STYLE="white-space:nowrap">know-how</FONT> owned or controlled by us and necessary for the exploitation of vonoprazan products, in each case for Takeda to commercialize any vonoprazan product outside of the United States, Canada, and Europe and for
purposes other than human therapeutic use. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">During the term of the Takeda License, we and our affiliates are not permitted to
commercialize any pharmaceutical product, other than vonoprazan, that treats acid-related disorders, except for certain generic and OTC competing products in specified circumstances. We will be responsible, at our cost, for the development,
manufacture and commercialization of the vonoprazan products. We are required to use commercially reasonable efforts to develop and commercialize the vonoprazan products in our licensed territory. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Under the Takeda License, Takeda has the sole right and authority, with our input, to prepare, file, prosecute, and maintain all Takeda and joint
patents on a worldwide basis at its own cost. We are responsible, at our cost, for preparing, filing, prosecuting, and maintaining patents on inventions made solely by us in connection with vonoprazan, subject to input from Takeda. We have the first
right to enforce the licensed patent rights with respect to certain infringing products in the United States, Europe and Canada. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We
paid Takeda upfront consideration consisting of a cash payment of $25.0&nbsp;million, 1,084,000 shares of common stock and a warrant to purchase 7,588,000 shares of common stock, or the Takeda Warrant. In the event that Takeda&#146;s fully-diluted
ownership, including the Takeda Warrant, represents less than a certain specified percentage of our fully-diluted capitalization, including shares issuable upon conversion of outstanding convertible promissory notes, calculated immediately prior to
the closing of this offering, we further agreed to issue an additional warrant to purchase shares of common stock such that Takeda would hold a certain specified percentage of the fully-diluted capitalization immediately before the closing of this
offering. We agreed to make milestone payments to Takeda upon achieving certain tiered aggregate annual net sales of licensed products in the United States, Europe and Canada up a total maximum milestone amount of $250.0&nbsp;million. We also agreed
to make tiered royalty payments in the low double digits to the mid-teens on net sales of licensed products, subject to specified offsets and reductions. Royalties will be payable, on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis from the first commercial sale of such
product in such country, until the latest of expiration of the licensed patents covering the applicable product, expiration of regulatory exclusivity in such country, or 15 years following first commercial sale in such country. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The Takeda License will continue until the expiration of the obligation to pay royalties in all countries and on all products. We may terminate the
Takeda License in its entirety without cause upon six months&#146; prior written notice. We and Takeda may terminate the Takeda License in the case of the other party&#146;s insolvency, or upon prior written notice within a specified time period for
the other party&#146;s material uncured breach. Takeda may terminate the Takeda License in its entirety if we challenge the licensed patents, or if we assist any third party in challenging such patents. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In connection with the Takeda License, we entered into a clinical manufacturing and supply agreement with Takeda whereby Takeda provides certain
quantities of vonoprazan. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Government Regulation </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Government authorities in the United States, at the federal, state and local level, and other countries extensively regulate, among other things, the research, development, testing, manufacture,
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">133 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing and export and import of products such as those we are developing. A new
drug must be approved by the FDA through the NDA process before it may be legally marketed in the United States. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>U.S. Drug Development Process
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In the United States, the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act, or the FDCA, and its implementing
regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to
comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval may subject an applicant to administrative or judicial sanctions. These sanctions could include the FDA&#146;s
refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts,
restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The process required by the FDA before a drug may be marketed in the United States generally involves the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">completion of preclinical laboratory tests, animal studies and formulation studies in accordance with Good Laboratory Practice, or GLP, regulations and other
applicable regulations; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">submission to the FDA of an IND, which must become effective before human clinical trials may begin; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">approval by an independent institutional review board, or IRB, at each clinical site before each trial may be initiated; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">performance of adequate and well-controlled human clinical trials in accordance with Good Clinical Practice, or GCP, regulations to establish the safety and
efficacy of the proposed drug for its intended use; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">submission to the FDA of an NDA; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">satisfactory completion of an FDA advisory committee review, if applicable; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug is produced to assess compliance with current GMP, or
cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the drug&#146;s identity, strength, quality and purity; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">FDA review and approval of the NDA to permit commercial marketing of the product for particular indications for use in the United States.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Once a pharmaceutical candidate is identified for development, it enters the preclinical testing stage. Preclinical
tests include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information and analytical data, to the FDA
as part of the IND. An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. The sponsor will also include a protocol detailing, among other things, the objectives of the first phase of the
clinical trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated, if the first phase lends itself to an efficacy evaluation. Some preclinical testing may continue even after the IND is submitted. The IND
automatically becomes effective 30 days after receipt by the FDA, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">134 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
unless the FDA, within the <FONT STYLE="white-space:nowrap">30-day</FONT> time period, places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any
outstanding concerns before the clinical trial can begin. Clinical holds also may be imposed by the FDA at any time before or during clinical trials due to safety concerns about <FONT STYLE="white-space:nowrap">on-going</FONT> or proposed clinical
trials or <FONT STYLE="white-space:nowrap">non-compliance</FONT> with specific FDA requirements, and the trials may not begin or continue until the FDA notifies the sponsor that the hold has been lifted. Submission of an IND therefore may or may not
result in FDA authorization to begin a clinical trial. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">All clinical trials must be conducted under the supervision of one or more
qualified investigators in accordance with GCP regulations, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. They must be conducted under protocols
detailing, among other things, the objectives of the trial, dosing procedures, subject selection and exclusion criteria and the safety and effectiveness criteria to be evaluated. Each protocol must be submitted to the FDA as part of the IND as well
as any subsequent protocol amendments, and timely safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events. An IRB at each institution participating in the clinical trial must review and approve
each protocol before a clinical trial commences at that institution and must also approve the information regarding the trial and the consent form that must be provided to each trial subject or his or her legal representative, monitor the study
until completed and otherwise comply with IRB regulations. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Human clinical trials are typically conducted in three sequential phases
that may overlap or be combined: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Phase 1</I></B>:&nbsp;&nbsp;&nbsp;&nbsp;The product candidate is initially introduced into healthy human volunteers and tested for safety, dosage
tolerance, absorption, metabolism, distribution and excretion and, if possible, to gain an early indication of its effectiveness. In the case of some products for severe or life-threatening diseases, such as cancer, especially when the product may
be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients. Sponsors sometimes designate their Phase 1 clinical trials as Phase 1a or Phase 1b. Phase 1b clinical trials are
typically aimed at confirming dosing, pharmacokinetics and safety in larger number of patients. Some Phase 1b studies evaluate biomarkers or surrogate markers that may be associated with efficacy in patients with specific types of diseases.
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Phase 2</I></B>:&nbsp;&nbsp;&nbsp;&nbsp;This phase involves clinical trials in a limited patient population to identify possible adverse effects and safety
risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and appropriate dosage. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Phase 3</I></B>:&nbsp;&nbsp;&nbsp;&nbsp;Clinical trials are undertaken to further evaluate dosage, clinical efficacy and safety in an expanded patient
population, generally at geographically dispersed clinical study sites. These clinical trials are intended to establish the overall risk-benefit ratio of the product candidate and provide, if appropriate, an adequate basis for product labeling.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Post-approval trials, sometimes referred to as Phase 4 studies, may be conducted after initial marketing approval.
These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or
patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if
the drug has been associated with unexpected serious harm to patients. In addition, some clinical trials are overseen by an independent group of qualified experts organized by the sponsor, known as a data safety monitoring board or committee.
Depending on its charter, this group may determine whether a trial may move forward at designated check points based on access to certain data from the trial. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">135 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">During the development of a new drug, sponsors are given opportunities to meet with the FDA at
certain points. These points may be prior to submission of an IND, at the end of Phase 2, and before an NDA is submitted. Meetings at other times may be requested. These meetings can provide an opportunity for the sponsor to share information about
the data gathered to date, for the FDA to provide advice, and for the sponsor and the FDA to reach agreement on the next phase of development. Sponsors typically use the meetings at the end of the Phase 2 trial to discuss Phase 2 clinical results
and present plans for the pivotal Phase 3 clinical trials that they believe will support approval of the new drug. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Concurrent with
clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial
quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity,
strength, quality and purity of the final drug. In addition, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its
shelf life. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">While the IND is active and before approval, progress reports summarizing the results of the clinical trials and
nonclinical studies performed since the last progress report must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and investigators for serious and unexpected suspected adverse events, findings
from other studies suggesting a significant risk to humans exposed to the same or similar drugs, findings from animal or <I>in vitro </I>testing suggesting a significant risk to humans, and any clinically important increased incidence of a serious
suspected adverse reaction compared to that listed in the protocol or investigator brochure. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">There are also requirements governing the
reporting of ongoing clinical trials and completed trial results to public registries. Sponsors of certain clinical trials of <FONT STYLE="white-space:nowrap">FDA-regulated</FONT> products are required to register and disclose specified clinical
trial information, which is publicly available at www.clinicaltrials.gov. Information related to the product, patient population, phase of investigation, trial sites and investigators and other aspects of the clinical trial is then made public as
part of the registration. Sponsors are also obligated to discuss the results of their clinical trials after completion. Disclosure of the results of these trials can be delayed until the new product or new indication being studied has been approved.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>NDA Review and Approval Process </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The results of product development, preclinical and other <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies and clinical trials, along with descriptions of the manufacturing process, analytical tests
conducted on the chemistry of the drug, proposed labeling and other relevant information are submitted to the FDA as part of an NDA requesting approval to market the product. The submission of an NDA is subject to the payment of substantial user
fees; a waiver of such fees may be obtained under certain limited circumstances. The FDA reviews an NDA to determine, among other things, whether a product is safe and effective for its intended use and whether its manufacturing is cGMP-compliant to
assure and preserve the product&#146;s identity, strength, quality and purity. Under the Prescription Drug User Fee Act, or PDUFA, guidelines that are currently in effect, the FDA has a goal of ten months from the date of &#147;filing&#148; of a
standard NDA for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to FDA because the FDA has approximately two months to make a &#147;filing&#148; decision after
it the application is submitted. The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review The FDA
may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">136 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The FDA may refer an application for a novel drug to an advisory committee. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and
provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. Before
approving an NDA, the FDA will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP
requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">After the FDA evaluates an NDA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes
commercial marketing of the drug with prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A
Complete Response Letter usually describes the specific deficiencies in the NDA identified by the FDA and may require additional clinical data, such as an additional pivotal Phase 3 trial or other significant and time-consuming requirements related
to clinical trials, nonclinical studies or manufacturing. If a Complete Response Letter is issued, the sponsor must resubmit the NDA or, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and
information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If a product receives regulatory
approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. In addition, the FDA may require a sponsor to conduct
Phase 4 testing, which involves clinical trials designed to further assess a drug&#146;s safety and effectiveness after NDA approval, and may require testing and surveillance programs to monitor the safety of approved products which have been
commercialized. The FDA may also place other conditions on approval including the requirement for a risk evaluation and mitigation strategy, or REMS, to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA
must submit a proposed REMS. The FDA will not approve the NDA without an approved REMS, if required. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods,
patient registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Marketing approval may be withdrawn for <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with regulatory requirements or if problems occur following initial marketing. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The
Pediatric Research Equity Act, or PREA, requires a sponsor to conduct pediatric clinical trials for most drugs, for a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration. Under PREA, original
NDAs and supplements must contain a pediatric assessment unless the sponsor has received a deferral or waiver. The required assessment must evaluate the safety and effectiveness of the product for the claimed indications in all relevant pediatric
subpopulations and support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor or FDA may request a deferral of pediatric clinical trials for some or all of the pediatric
subpopulations. A deferral may be granted for several reasons, including a finding that the drug is ready for approval for use in adults before pediatric clinical trials are complete or that additional safety or effectiveness data needs to be
collected before the pediatric clinical trials begin. The FDA must send a <FONT STYLE="white-space:nowrap">non-compliance</FONT> letter to any sponsor that fails to submit the required assessment, keep a deferral current or fails to submit a request
for approval of a pediatric formulation. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">137 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Expedited Development and Review Programs </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">A sponsor may seek approval of its product candidate under programs designed to accelerate FDA&#146;s review and approval of new drugs and
biological products that meet certain criteria. The FDA has a fast track designation program that is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria. Specifically, new drugs are eligible for
Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Unique to a fast track product, the FDA may consider
for review sections of the NDA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the
schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Any product
submitted to the FDA for approval, including a product with a fast track designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. A product is
eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention of a
serious disease or condition. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug designated for priority review in an effort to facilitate the review. The FDA endeavors to review applications with
priority review designations within six months of the filing date as compared to ten months for review of new molecular entity NDAs under its current PDUFA review goals. Priority review designation does not change the scientific/medical standard for
approval or the quality of evidence necessary to support approval. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, a product may be eligible for accelerated approval.
Drug products intended to treat serious or life-threatening diseases or conditions may be eligible for accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical
benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the
severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled
post-marketing clinical trials. In addition, the FDA currently requires as a condition for accelerated approval <FONT STYLE="white-space:nowrap">pre-approval</FONT> of promotional materials, which could adversely impact the timing of the commercial
launch of the product. FDA may withdraw approval of a drug or indication approved under accelerated approval if, for example, the confirmatory trial fails to verify the predicted clinical benefit of the product. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The FDA can also designate a drug as a &#147;breakthrough therapy.&#148; A sponsor may seek FDA designation of a product candidate as a
&#147;breakthrough therapy&#148; if the product is intended, alone or in combination with one or more other products, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product may
demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. If the FDA designates a breakthrough therapy, it may take
actions appropriate to expedite the development and review of the application, which may include holding meetings with the sponsor and the review team throughout the development of the therapy; providing timely advice to, and interactive
communication with, the sponsor regarding the development of the drug to ensure that the development program to gather the nonclinical and clinical data necessary for approval is as efficient as practicable; involving senior managers and experienced
review staff, as appropriate, in a collaborative, cross-disciplinary review; assigning a cross-disciplinary project lead for the FDA review team to facilitate an efficient review of the development program and to
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">138 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
serve as a scientific liaison between the review team and the sponsor; and considering alternative clinical trial designs when scientifically appropriate, which may result in smaller trials or
more efficient trials that require less time to complete and may minimize the number of patients exposed to a potentially less efficacious treatment. The designation includes all of the fast track program features, which means that the sponsor may
file sections of the NDA for review on a rolling basis if certain conditions are satisfied, including an agreement with FDA on the proposed schedule for submission of portions of the application and the payment of applicable user fees before the FDA
may initiate a review. The breakthrough therapy designation is a distinct status from both accelerated approval and priority review, which can also be granted to the same drug if relevant criteria are met. If a product is designated as breakthrough
therapy, the FDA will work to expedite the development and review of such drug. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Fast track designation, priority review and
breakthrough therapy designation do not change the standards for approval but may expedite the development or approval process. Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets
the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. We may explore some of these opportunities for vonoprazan and any future product candidates as appropriate. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Post-Approval Requirements </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Once an
approval is granted, the FDA may withdraw the approval if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product may result in
restrictions on the product or even complete withdrawal of the product from the market. After approval, some types of changes to the approved product, such as adding new indications, certain manufacturing changes and additional labeling claims, are
subject to further FDA review and approval. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies, and are subject
to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP regulations and other laws and regulations. In addition, the FDA may impose a number of post-approval requirements as a condition of approval of an
NDA. For example, the FDA may require post-marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product&#146;s safety and effectiveness after commercialization. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Any drug products manufactured or distributed by us or our partners pursuant to FDA approvals will be subject to pervasive and continuing
regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the drug, providing the FDA with updated safety and efficacy information, drug sampling and distribution requirements, complying
with certain electronic records and signature requirements, and complying with FDA promotion and advertising requirements. The FDA strictly regulates labeling, advertising, promotion and other types of information on products that are placed on the
market and imposes requirements and restrictions on drug manufacturers, such as those related to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising, the prohibition on promoting products
for uses or in patient populations that are not described in the product&#146;s approved labeling (known as <FONT STYLE="white-space:nowrap">&#147;off-label</FONT> use&#148;), industry-sponsored scientific and educational activities, and promotional
activities involving the internet. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Discovery of previously unknown problems or the failure to comply with the applicable regulatory
requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions. Failure to comply with the applicable U.S. requirements at any time during the
product development process, approval process or after approval, may subject an applicant or manufacturer to administrative or judicial civil or criminal sanctions and </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">139 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
adverse publicity. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical holds on post-approval clinical trials, warning or untitled letters,
product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement
of profits, or civil or criminal penalties. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Marketing Exclusivity </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Market exclusivity provisions under the FDCA can delay the submission or the approval of certain marketing applications. The FDCA provides a
five-year period of <FONT STYLE="white-space:nowrap">non-patent</FONT> marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not
previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve or even accept for review an abbreviated
new drug application, or ANDA, or an NDA submitted under Section&nbsp;505(b)(2), or 505(b)(2) NDA, submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as
the original innovative drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a
certification of patent invalidity or <FONT STYLE="white-space:nowrap">non-infringement</FONT> to one of the patents listed with the FDA by the innovator NDA holder. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The FDCA alternatively provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored
by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received
approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity
will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials
necessary to demonstrate safety and effectiveness. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Pediatric exclusivity is another type of marketing exclusivity available in the
United States. Pediatric exclusivity provides for an additional six months of marketing exclusivity attached to another period of exclusivity if a sponsor conducts clinical trials in children in response to a written request from the FDA. The
issuance of a written request does not require the sponsor to undertake the described clinical trials. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Additionally, under the GAIN
Act, the FDA may designate a product as a &#147;qualified infectious disease product,&#148; or QIDP. In order to receive this designation, a drug must qualify as an antibacterial or antifungal drug for human use intended to treat serious or
life-threatening infections, including those caused by either (1) an antibacterial or antifungal resistant pathogen, including novel or emerging infectious pathogens, or (2) a so-called &#147;qualifying pathogen&#148; found on a list of potentially
dangerous, drug-resistant organisms established and maintained by the FDA under the law. A sponsor must request such designation before submitting a marketing application. FDA granted QIDP designation for vonoprazan for the treatment of <I>H.
pylori</I> infection in combination with both amoxicillin and clarithromycin, and with amoxicillin alone, respectively. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The benefits of
QIDP designation include potential eligibility for priority review and fast track designation, and an extension by an additional five years of any non-patent marketing exclusivity period awarded, such as a five-year exclusivity period awarded for a
new molecular entity. This </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">140 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
extension is in addition to any pediatric exclusivity extension that may be awarded, and the extension will be awarded only to a drug first approved on or after the date of enactment. The GAIN
Act provisions prohibit the grant of an exclusivity extension where the application is a supplement to an application for which an extension is in effect or has expired, is a subsequent application for a specified change to an approved product, or
is an application for a product that does not meet the definition of QIDP based on the uses for which it is ultimately approved. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>U.S. Healthcare
Fraud and Abuse Laws and Compliance Requirements </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition to FDA regulation of pharmaceutical products, U.S. federal and
state healthcare laws and regulations restrict business practices in the pharmaceutical industry. These laws may impact, among other things, our current and future business operations, including our clinical research activities, and constrain the
business or financial arrangements and relationships with healthcare providers and other parties. These laws include anti-kickback and false claims laws, civil monetary penalties laws, data privacy and security laws, and physician payment
transparency laws. In addition to the federal laws summarized below, we may also be subject to similar state and local laws and regulations that may apply to business practices, including but not limited to, research, distribution, sales and
marketing arrangements and claims involving healthcare items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers, or by patients themselves. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The federal Anti-Kickback Statute prohibits, among other things, individuals or entities from knowingly and willfully offering, paying, soliciting
or receiving remuneration, directly or indirectly, overtly or covertly, in cash or in kind to induce or in return for purchasing, leasing, ordering or arranging for or recommending the purchase, lease or order of any item or service reimbursable
under Medicare, Medicaid or other federal healthcare programs. A person or entity does not need to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In addition, the government may assert
that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act and the civil monetary penalties statute. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalties laws prohibit, among other
things, any individual or entity from knowingly presenting, or causing to be presented, a false claim for payment to the federal government, knowingly making, using or causing to be made or used a false record or statement material to a false or
fraudulent claim to the federal government, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to
defraud any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the
delivery of or payment for healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the healthcare fraud statute implemented under HIPAA or specific
intent to violate it in order to have committed a violation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, HIPAA, as amended by the Health Information Technology for
Economic and Clinical Health Act, and their implementing regulations, imposes certain requirements relating to the privacy, security and transmission of protected health information on HIPAA covered entities, which include certain healthcare
providers, health plans and healthcare clearinghouses, and their business associates who conduct certain activities for or on their behalf involving protected health information on their behalf. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">141 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The federal Physician Payments Sunshine Act requires certain manufacturers of drugs, devices,
biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program, with specific exceptions, to report annually to the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS,
information related to payments or other transfers of value made to physicians and teaching hospitals, and applicable manufacturers and applicable group purchasing organizations to report annually to CMS ownership and investment interests held by
physicians and their immediate family members. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Similar state and local laws and regulations may also restrict business practices in the
pharmaceutical industry, such as state anti-kickback and false claims laws, which may apply to business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or
services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers, or by patients themselves; state laws that require pharmaceutical companies to comply with the pharmaceutical
industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and
regulations that require drug manufacturers to file reports relating to pricing and marketing information or which require tracking gifts and other remuneration and items of value provided to physicians, other healthcare providers and entities;
state and local laws that require the registration of pharmaceutical sales representatives; and state and local laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant
ways and often are not preempted by HIPAA, thus complicating compliance efforts. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Violation of any of such laws or any other
governmental regulations that apply may result in significant criminal, civil and administrative penalties including damages, fines, imprisonment, disgorgement, additional reporting requirements and oversight if we become subject to a corporate
integrity agreement or similar agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, contractual damages, reputational harm, diminished profits and future earnings, disgorgement, exclusion from
participation in government healthcare programs and the curtailment or restructuring of our operations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>U.S. Coverage and Reimbursement
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Significant uncertainty exists as to the coverage and reimbursement status of any product candidate for which we may seek
regulatory approval. Sales in the United States will depend, in part, on the availability of sufficient coverage and adequate reimbursement from third-party payors, which include government health programs such as Medicare, Medicaid, TRICARE and the
Veterans Administration, as well as managed care organizations and private health insurers. Prices at which we or our customers seek reimbursement for vonoprazan and any future product candidates can be subject to challenge, reduction or denial by
third-party payors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The process for determining whether a third-party payor will provide coverage for a product is typically separate
from the process for setting the reimbursement rate that the payor will pay for the product. In the United States, there is no uniform policy among payors for coverage or reimbursement. Decisions regarding whether to cover any of a product, the
extent of coverage and amount of reimbursement to be provided are made on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">plan-by-plan</FONT></FONT> basis. Third-party payors often rely upon Medicare coverage policy and payment
limitations in setting their own coverage and reimbursement policies, but also have their own methods and approval processes. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage
determination process is often a time-consuming and costly process that can require manufacturers to provide scientific and clinical support for the use of a product to each payor separately, with no assurance that coverage and adequate
reimbursement will be applied consistently or obtained in the first instance. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">142 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Third-party payors are increasingly challenging the price and examining the medical necessity and
cost-effectiveness of medical products and services, in addition to their safety and efficacy. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures,
could further limit sales of any product that receives approval. Third-party payors may not consider vonoprazan and any future product candidates to be medically necessary or cost-effective compared to other available therapies, or the rebate
percentages required to secure favorable coverage may not yield an adequate margin over cost or may not enable us to maintain price levels sufficient to realize an appropriate return on our investment in drug development. Additionally, decreases in
third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>U.S. Healthcare Reform </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In the United States, there has been, and continues to be,
several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect the profitable sale of
product candidates. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Among policy makers and payors in the United States, there is significant interest in promoting changes in
healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by
major legislative initiatives. In March 2010, the Patient Protection and Affordable Care Act, or the Affordable Care Act, was passed, which substantially changed the way healthcare is financed by both governmental and private insurers, and
significantly affected the pharmaceutical industry. The Affordable Care Act, increased the minimum level of Medicaid rebates payable by manufacturers of brand name drugs from 15.1% to 23.1%; required collection of rebates for drugs paid by Medicaid
managed care organizations; required manufacturers to participate in a coverage gap discount program, in which manufacturers must agree to offer <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts
off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; imposed a
<FONT STYLE="white-space:nowrap">non-deductible</FONT> annual fee on pharmaceutical manufacturers or importers who sell certain &#147;branded prescription drugs&#148; to specified federal government programs, implemented a new methodology by which
rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected; expanded eligibility criteria for Medicaid programs; creates a new Patient-Centered Outcomes
Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; and established a Center for Medicare Innovation at the CMS to test innovative payment and service
delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Since its enactment, there
have been judicial and political challenges to certain aspects of the Affordable Care Act. For example, the Tax Cuts and Jobs Act of 2017, or Tax Act, includes a provision repealing, effective January&nbsp;1, 2019, the
<FONT STYLE="white-space:nowrap">tax-based</FONT> shared responsibility payment imposed by the Affordable Care Act, on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the
&#147;individual mandate.&#148; On December&nbsp;14, 2018, a U.S. District Court Judge in the Northern District of Texas, or the Texas District Court Judge, ruled that the individual mandate is a critical and inseverable feature of the Affordable
Care Act, and therefore, because it was repealed as part of the Tax Act, the remaining provisions of the Affordable Care Act, are invalid as well. While the Texas District Court Judge, as well as the Trump Administration and CMS, have stated that
the ruling will have no immediate effect, and on December&nbsp;30, 2018 the Texas District Court Judge issued an order staying the judgment pending appeal, it is unclear how this </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">143 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
decision, subsequent appeals, and other efforts to repeal and replace the Affordable Care Act, will impact the Affordable Care Act. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. These changes included aggregate
reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April&nbsp;1, 2013 and, due to subsequent legislative amendments to the statute, including the Bipartisan Budget Act of 2018, will remain in effect through
2027 unless additional Congressional action is taken. On January&nbsp;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, reduced Medicare payments to several providers, including hospitals, and
increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Moreover,
there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation
designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products. Further,
the Trump Administration released a &#147;Blueprint&#148; to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase manufacturer competition, increase the negotiating power of certain federal
healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of pharmaceutical products paid by consumers. Individual states in the United States have also become increasingly active in
implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in
some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine which drugs and suppliers will be
included in their healthcare programs Furthermore, there has been increased interest by third party payors and governmental authorities in reference pricing systems and publication of discounts and list prices. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Foreign Regulation </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In order to
market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical
trials, marketing authorization, commercial sales and distribution of our products. Whether or not we obtain FDA approval for a product, we would need to obtain the necessary approvals by the comparable foreign regulatory authorities before we can
commence clinical trials or marketing of the product in foreign countries and jurisdictions. Although many of the issues discussed above with respect to the United States apply similarly in the context of the European Union, or EU, the approval
process varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer
than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively
impact the regulatory process in others. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">To market a medicinal product in the European Economic Area, or EEA (which is comprised of the
28 Member States of the EU plus Norway, Iceland and Liechtenstein), we must obtain a Marketing Authorization, or MA. There are two types of marketing authorizations: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the Community MA, which is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for
Human Use of </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">144 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P><FONT STYLE="font-family:ARIAL" SIZE="2">
the EMA and which is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan
medicinal products, advanced therapy products, and medicinal products containing a new active substance indicated for the treatment certain diseases, such as AIDS, cancer, neurodegenerative disorders, diabetes,
<FONT STYLE="white-space:nowrap">auto-immune</FONT> and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic,
scientific or technical innovation or which are in the interest of public health in the EU; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products
not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in another Member State through the Mutual Recognition
Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Under the above described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA make an
assessment of the <FONT STYLE="white-space:nowrap">risk-benefit</FONT> balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><I>Data and marketing exclusivity </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In the EEA, new products authorized for marketing, or reference
products, qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from relying on the <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the EU during a period of eight years from the date on
which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until 10&nbsp;years have elapsed from the initial
authorization of the reference product in the EU. The <FONT STYLE="white-space:nowrap">10-year</FONT> market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those 10&nbsp;years, the marketing
authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Pediatric investigation plan </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In
the EEA, marketing authorization applications for new medicinal products not authorized have to include the results of studies conducted in the pediatric population, in compliance with a pediatric investigation plan, or PIP, agreed with the
EMA&#146;s Pediatric Committee, or PDCO. The PIP sets out the timing and measures proposed to generate data to support a pediatric indication of the drug for which marketing authorization is being sought. The PDCO can grant a deferral of the
obligation to implement some or all of the measures of the PIP until there are sufficient data to demonstrate the efficacy and safety of the product in adults. Further, the obligation to provide pediatric clinical trial data can be waived by the
PDCO when these data is not needed or appropriate because the product is likely to be ineffective or unsafe in children, the disease or condition for which the product is intended occurs only in adult populations, or when the product does not
represent a significant therapeutic benefit over existing treatments for pediatric patients. Once the marketing authorization is obtained in all Member States of the EU and study results are included in the product information, even when negative,
the product is eligible for six months&#146; supplementary protection certificate extension. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">145 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Clinical trials </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Clinical trials of medicinal products in the European Union must be conducted in accordance with European Union and national regulations and the International Conference on Harmonization, or ICH, guidelines on
GCPs. Additional GCP guidelines from the European Commission, focusing in particular on traceability, apply to clinical trials of advanced therapy medicinal products. If the sponsor of the clinical trial is not established within the European Union,
it must appoint an entity within the European Union to act as its legal representative. The sponsor must take out a clinical trial insurance policy, and in most EU countries, the sponsor is liable to provide &#145;no fault&#146; compensation to any
study subject injured in the clinical trial. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Prior to commencing a clinical trial, the sponsor must obtain a clinical trial
authorization from the competent authority, and a positive opinion from an independent ethics committee. The application for a clinical trial authorization must include, among other things, a copy of the trial protocol and an investigational
medicinal product dossier containing information about the manufacture and quality of the medicinal product under investigation. Currently, clinical trial authorization applications must be submitted to the competent authority in each EU Member
State in which the trial will be conducted. Under the new Regulation on Clinical Trials, which is currently expected to take effect in 2019, there will be a centralized application procedure where one national authority takes the lead in reviewing
the application and the other national authorities have only a limited involvement. Any substantial changes to the trial protocol or other information submitted with the clinical trial applications must be notified to or approved by the relevant
competent authorities and ethics committees. Medicines used in clinical trials must be manufactured in accordance with cGMP. Other national and European Union-wide regulatory requirements also apply. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Privacy and data protection laws </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We are
also subject to laws and regulations in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> countries covering data privacy and the protection of health-related and other personal information. EU member states and other jurisdictions have adopted data
protection laws and regulations, which impose significant compliance obligations. Laws and regulations in these jurisdictions apply broadly to the collection, use, storage, disclosure, processing and security of personal information that identifies
or may be used to identify an individual, such as names, contact information, and sensitive personal data such as health data. These laws and regulations are subject to frequent revisions and differing interpretations, and have generally become more
stringent over time. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As of May&nbsp;25, 2018, Regulation 2016/676, known as the General Data Protection Regulation, or GDPR, replaced
the Data Protection Directive with respect to the processing of personal data in the European Union. The GDPR imposes many requirements for controllers and processors of personal data, including, for example, higher standards for obtaining consent
from individuals to process their personal data, more robust disclosures to individuals and a strengthened individual data rights regime, shortened timelines for data breach notifications, limitations on retention and secondary use of information,
increased requirements pertaining to health data and pseudonymised (i.e., <FONT STYLE="white-space:nowrap">key-coded)</FONT> data and additional obligations when we contract third-party processors in connection with the processing of the personal
data. The GDPR allows EU member states to make additional laws and regulations further limiting the processing of genetic, biometric or health data. Failure to comply with the requirements of GDPR and the applicable national data protection laws of
the EU member states may result in fines of up to <FONT STYLE="font-family:SANS-SERIF" SIZE="2" COLOR="#000000">&#128;</FONT><FONT STYLE="font-family:ARIAL" SIZE="2"></FONT>20,000,000 or up to 4% of the total worldwide annual turnover of the
preceding financial year, whichever is higher, and other administrative penalties. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">146 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Employees </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">As of September 30, 2019, we had 16&nbsp;full-time employees, 3 of whom have a Ph.D. or M.D. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our
relationship with our employees to be good. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Legal Proceedings </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">We are not currently subject to any material legal proceedings. From time to time, we may be involved in legal proceedings or subject to claims incident to the ordinary course of business. Regardless of the
outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that favorable outcomes will be obtained. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">147 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_12"></A>MANAGEMENT </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Executive Officers and Directors </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The
following table sets forth the name, age and position of each of our executive officers and directors as of September&nbsp;30, 2019. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="46%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Name</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Age</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Position</B></FONT></P></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Executive Officers</I></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">David Socks</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">45</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">President, Chief Executive Officer, Treasurer, Secretary and Director</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Azmi Nabulsi, M.D., M.P.H.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">Chief Operating Officer</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Aditya Kohli, Ph.D.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">31</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">Chief Business Officer</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><B></B><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors</I></B><B></B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Tadataka Yamada,
M.D.</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)(3)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">74</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">Chairman</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Michael F.
Cola</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)(2)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">60</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">Director</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Terrie Curran</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">Director</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Jonathan Edwards,
Ph.D.</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)(3)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">35</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">Director</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Heidi
Kunz</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">64</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">Director</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Chris
Slavinsky</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">47</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">Director</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">James Topper, M.D.,
Ph.D.</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)(3)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">57</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">Director</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">Member of the compensation committee </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">Member of the audit committee </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">Member of the nominating and corporate governance committee </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Executive Officers </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>David Socks</I> is our
<FONT STYLE="white-space:nowrap">co-founder</FONT> and has served as our Chief Executive Officer, Treasurer and Secretary, and as a member of our board of directors since January 2018, and as our President since March 2019. As part of a planned
transition, Terrie Curran, a member of our board of directors, will succeed Mr. Socks as Chief Executive Officer effective upon the closing of the acquisition of her current employer, Celgene Corporation, by Bristol-Myers Squibb Company. Following
Ms.&nbsp;Curran&#146;s appointment as CEO, Mr.&nbsp;Socks will serve as interim Chief Financial Officer and continue to serve as a member of our board of directors. Since August 2014, Mr.&nbsp;Socks has been a Venture Partner at Frazier Healthcare
Partners, or Frazier, a venture capital firm. In this capacity, he <FONT STYLE="white-space:nowrap">co-founded</FONT> Arcutis, Inc., Nexcida Therapeutics, Inc., Outpost Medicine, LLC, Passage Bio, Inc., Recida Therapeutics, Inc., and Scout Bio, Inc.
Mr.&nbsp;Socks served as Chief Executive Officer of Nexcida Therapeutics, Outpost Medicine and Scout Bio. Mr.&nbsp;Socks also serves as Executive Chairman of the board of directors of Recida Therapeutics and as a board member of Outpost Medicine.
Prior to joining Frazier, Mr.&nbsp;Socks <FONT STYLE="white-space:nowrap">co-founded</FONT> Incline Therapeutics, Inc. in 2010 and served as its President and Chief Operating Officer from 2010 until its sale to The Medicines Company in 2013. He also
<FONT STYLE="white-space:nowrap">co-founded</FONT> Cadence Pharmaceuticals, Inc. in 2004 and served as its Vice President of Business Development and then as its Senior Vice President, Corporate Development and Strategy from 2004 until 2010. From
2000 to 2004, Mr.&nbsp;Socks was a Venture Partner at Windamere Venture Partners, a venture capital firm founding and investing in early stage life science companies, where he <FONT STYLE="white-space:nowrap">co-founded</FONT> several
biopharmaceutical companies including Avera Pharmaceuticals, Inc. and Kanisa Pharmaceuticals, Inc. Previously, he worked at Neurocrine Biosciences, EFO Holdings, L.P., an investment firm, and Kaiser Associates, Inc., a strategic management
consulting firm. Mr.&nbsp;Socks holds a B.S. from Georgetown University and an M.B.A. from Stanford University. Mr.&nbsp;Socks&#146; knowledge of our business and significant experience as a biopharmaceutical executive and board member, contributed
to our board of directors&#146; conclusion that he should serve as a director of our company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Azmi Nabulsi, M.D., M.P.H.</I> is our <FONT
STYLE="white-space:nowrap">co-founder</FONT> and has served as our Chief Operating Officer since March 2019. Dr.&nbsp;Nabulsi has been an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">entrepreneur-in-residence</FONT></FONT> at
Frazier since October 2018. Also, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">148 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
since January 2019, Dr.&nbsp;Nabulsi has served as a business and clinical advisor to Saama Technologies, Inc., a clinical data and analytics company. Previously, through October 2018,
Dr.&nbsp;Nabulsi spent fourteen years at Takeda. Dr.&nbsp;Nabulsi held a number of leadership positions at Takeda, most recently as the Deputy Chief Medical&nbsp;&amp; Scientific Officer and Head of Global Development from 2014 until October 2018.
In his roles at Takeda, Dr.&nbsp;Nabulsi oversaw global drug development for both early and late stage product candidates and led global medical, analytic and operational functions responsible for bringing new medicines in multiple therapeutic areas
to many markets. Prior to joining Takeda, Dr.&nbsp;Nabulsi held numerous positions at Abbott Laboratories, including Head of Immunology and Oncology Ventures from 1998 to 2002. Dr.&nbsp;Nabulsi has an M.D. from
<FONT STYLE="white-space:nowrap">Ain-Shams</FONT> University in Cairo and a M.P.H. from the University of Minnesota. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Aditya Kohli,
Ph.D.</I><B> </B>is our <FONT STYLE="white-space:nowrap">co-founder</FONT> and has served as our Chief Business Officer since March 2019. Since January 2018, Dr.&nbsp;Kohli has served as Vice President of Frazier. From September 2016 to December
2017, Dr.&nbsp;Kohli served as Senior Associate of Frazier. In this capacity, he has <FONT STYLE="white-space:nowrap">co-founded</FONT> Passage Bio, Scout Bio, and Recida Therapeutics, Inc., and also served as VP, Business Development and serves on
the board of directors of Scout Bio. Prior to joining Frazier, Dr.&nbsp;Kohli worked at McKinsey&nbsp;&amp; Company as an Engagement Manager from June 2016 until September 2016 and as an Associate from September 2014 until May 2016, where he
consulted with biopharmaceutical companies on business development, research and development, and marketing and sales strategy. Dr.&nbsp;Kohli received his Ph.D. from the UC Berkeley and UC San Francisco joint graduate program in bioengineering and
holds B.S. and M.Eng. degrees in biological engineering from the Massachusetts Institute of Technology. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2"><I>Tadataka Yamada, M.D.</I> has served as Chairman of our board of directors since March 2019. Dr.&nbsp;Yamada currently serves as a Venture Partner on the Life Sciences team of Frazier. From June 2011 to June
2015, Dr.&nbsp;Yamada served as the Chief Medical and Scientific Officer and as a member of the board of directors of Takeda. Dr.&nbsp;Yamada has served since 2011 as a member of the board of directors of Agilent Technologies, a global scientific
instrument manufacturing and clinical diagnostics company listed on the New York Stock Exchange. Since June 2016, Dr.&nbsp;Yamada has served on the board of directors of CSL Limited, a biotechnology company that is publicly traded on the Australian
Securities Exchange. Dr.&nbsp;Yamada previously served as President of the Global Health Program of the Bill&nbsp;&amp; Melinda Gates Foundation from June 2006 to June 2011. From 2000 to 2006, Dr.&nbsp;Yamada was Chairman of Research and Development
and a member of the board of directors of GlaxoSmithKline Inc. and prior to that, he held research and development positions at SmithKline Beecham. Prior to joining SmithKline Beecham, Dr.&nbsp;Yamada was Chairman of the Department of Internal
Medicine at the University of Michigan Medical School and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Physician-in-Chief</FONT></FONT> of the University of Michigan Medical Center. Dr.&nbsp;Yamada serves as chair of the board
of directors at the Clinton Health Access Initiative and a member of the National Academy of Medicine. He is also a Fellow of the Imperial College of Medicine, a Master of the American College of Physicians, a Fellow of the Royal College of
Physicians, a Member of the American Academy of Arts and Sciences and a past-President of the American Gastroenterological Association and the Association of American Physicians. Dr.&nbsp;Yamada received his M.D. from New York University School of
Medicine and a B.A. in History from Stanford University. He has authored over 150 manuscripts in peer reviewed journals and is the editor of The Textbook of Gastroenterology. He has been the recipient of numerous awards including the Distinguished
Achievement Award in Gastrointestinal Physiology from the American Physiological Society, the Friedenwald Medal from the American Gastroenterological Association, and the Watanabe Prize in Translational Research from Indiana University and Eli
Lilly&nbsp;&amp; Co. Dr.&nbsp;Yamada&#146;s extensive research and experience in gastrointestinal drug development, particularly his involvement in the development of vonoprazan at Takeda, as well as his service as a director or officer of other
healthcare companies, contributed to our board of directors&#146; conclusion that he should serve as Chairman of our board of directors. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">149 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Michael F. Cola</I> has served as a member of our board of directors since September 2019.
Mr.&nbsp;Cola has served as Chief Executive Officer and President of Aevi Genomic Medicine, Inc. since September 2013. Mr.&nbsp;Cola served as President of Shire plc&#146;s Specialty Pharmaceuticals business from 2007 until April 2012. Mr.&nbsp;Cola
joined Shire in July 2005 as Executive Vice President for Global Therapeutic Business Units and Portfolio Management prior to being named President of the Specialty Pharmaceuticals business. Prior to joining Shire, Mr.&nbsp;Cola spent more than five
years at Safeguard Scientifics, where he served as President of the Life Sciences Group. As part of his role with Safeguard Scientifics, Mr.&nbsp;Cola served as Chairman and CEO of Clarient, a cancer diagnostics company, and Chairman of Laureate
Pharma, a full service contract manufacturing organization serving research based biologics companies. Prior to joining Safeguard Scientifics, Mr.&nbsp;Cola held progressively senior positions in product development and commercialization at
AstraMerck, and later with AstraZeneca. Mr.&nbsp;Cola currently serves on the board of directors of Aevi Genomic Medicine, Inc., Sage Therapeutics, Inc. and Vanda Pharmaceuticals Inc. Mr.&nbsp;Cola received his Bachelor of Arts degree in biology and
physics from Ursinus College and his Master of Science degree in biomedical science from Drexel University. Mr.&nbsp;Cola&#146;s executive experience in the biopharmaceutical industry, knowledge of our business and service as a director of other
biopharmaceutical companies contributed to our board of directors&#146; conclusion that he should serve as a director of our company. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Terrie Curran</I> has served as a member of our board of directors since August 2019. As part of a planned transition, Ms. Curran will succeed
Mr. Socks as Chief Executive Officer effective upon the closing of the acquisition of her current employer, Celgene Corporation, by Bristol-Myers Squibb Company. Ms.&nbsp;Curran has served as the President, Global Inflammation and Immunology
Franchise at Celgene and a member of the Executive Committee since April 2017. Ms.&nbsp;Curran joined Celgene in 2013 as the U.S. Commercial Head of the I&amp;I Franchise and built the capabilities and recruited the teams that executed the
successful launch of OTEZLA, before becoming Head of Worldwide Markets. Prior to joining Celgene, she served as Senior Vice President and General Manager - Global Women&#146;s Health at Merck &amp; Co. Before joining Merck, Ms.&nbsp;Curran held a
number of Country General Manager positions at Schering-Plough and Pharmacia across Europe and Asia Pacific. She currently serves on the board of Myovant Sciences Ltd., a biotechnology company, and previously served on the board of H.&nbsp;Lundbeck
A/S, a global pharmaceutical company. Ms.&nbsp;Curran holds a Graduate Diploma of Marketing and a Bachelor of Applied Science (B.A.S.) from the University of Technology, Sydney. Ms.&nbsp;Curran&#146;s extensive 22 year biopharmaceutical industry
experience contributed to our board of directors&#146; conclusion that she should serve as a director of our company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Jon Edwards,
Ph.D.</I> has served as a member of our board of directors since May 2019. Dr.&nbsp;Edwards is a Partner at Medicxi, a life sciences-focused investment firm. Dr.&nbsp;Edwards was part of the Medicxi co-founding team and joined the firm&#146;s
investment team as an Associate in February 2016. Prior to joining Medicxi, Dr.&nbsp;Edwards was an Associate in the investment team at Index Ventures, a venture capital firm, from September 2014 until February 2016. Dr.&nbsp;Edwards currently
serves on the board of a number of private U.S. and European biotechnology and biopharmaceutical companies, including Palladio Biosciences Inc., Xenikos B.V., UltraHuman Limited, Breakpoint Therapeutics GmbH and Sydnexis Inc. Prior to joining Index
Ventures, Dr.&nbsp;Edwards was a life sciences strategy consultant at ClearView Healthcare Partners from January 2013 until September 2014. Dr.&nbsp;Edwards received a Ph.D. in Biochemistry and Biophysics from the University of North Carolina at
Chapel Hill and conducted postdoctoral research at the Massachusetts Institute of Technology. Dr.&nbsp;Edwards&#146; knowledge of our business and prior service as a director of multiple biopharmaceutical and biotechnology companies contributed to
our board of directors&#146; conclusion that he should serve as a director of our company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Heidi Kunz</I> has served as a member of
our board of directors since September 2019. Ms.&nbsp;Kunz served as Executive Vice President and Chief Financial Officer of Blue Shield of California from </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">150 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
September 2003 until her retirement in December 2012. Prior to joining Blue Shield of California, she served as Executive Vice President and Chief Financial Officer of Gap, Inc. from 1999 to
January 2003. From 1995 to 1999, Ms.&nbsp;Kunz served as the Chief Financial Officer of ITT Industries, Inc. She has also held senior financial management positions at General Motors Corporation, including Vice President and Treasurer during her <FONT
STYLE="white-space:nowrap">16-year</FONT> tenure from 1979 to 1995. Ms.&nbsp;Kunz currently serves as a director of Agilent Technologies Inc., a global scientific instrument manufacturing and clinical diagnostics company and Avanos Medical, Inc., a
public medical device company, and previously served as a director of Financial Engines, Inc., an investment advisement company. Ms.&nbsp;Kunz received an MBA in Finance and Accounting from Columbia Business School and a bachelor&#146;s degree in
Russian Language from Georgetown University. Ms.&nbsp;Kunz&#146;s extensive experience as a chief financial officer and service as a director of other public companies contributed to our board of directors&#146; conclusion that she should serve as a
director of our company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Chris Slavinsky</I> has served as a member of our board of directors since August 2019. Since December
2018, Mr.&nbsp;Slavinsky has served as Vice President, Takeda Center for External Innovation as well as Head, Gastroenterology Business Development, Externalization and Special Projects at Takeda. From June 2003 to December 2018, Chris served in a
number of capacities at Pfizer, Inc., including as Chief Counsel of several Pfizer business units starting in 2011. Mr.&nbsp;Slavinsky received a J.D. from the Washington University in St. Louis School of Law, an M.S. in biochemistry and molecular
biology from Thomas Jefferson University (Philadelphia), and a B.S. in biochemistry from the State University of New York at Stony Brook. Mr.&nbsp;Slavinsky&#146;s knowledge of our business and experience in the biopharmaceutical industry has
contributed to our board of directors&#146; conclusion that he should serve as director of our company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>James Topper, M.D.,
Ph.D.</I> has served as a member of our board of directors since January 2018. Since 2005, Dr.&nbsp;Topper has also served as the Managing General Partner at Frazier with whom he served as a Partner from 2003 to 2005. Prior to that, from 2002 to
2003, Dr.&nbsp;Topper served as head of the Cardiovascular Research and Development Division at Millennium Pharmaceuticals, Inc., a biopharmaceutical company. Dr.&nbsp;Topper has served as a member of the board of directors of Allena
Pharmaceuticals, Inc., a biopharmaceutical company, since September 2011, Alpine lmmunosciences Inc., a biotechnology company, since June 2016, Aptinyx Inc., a biopharmaceutical company, since May 2016, and Amunix Pharmaceuticals, Inc., a
pharmaceutical company, since October 2018. In addition, from April 2014 to March 2017, Dr.&nbsp;Topper served as a member of the board of directors of Sierra Oncology, Inc. (formerly ProNai Therapeutics, Inc.), an oncology company, and since 2007,
Dr.&nbsp;Topper has served as a member of the board of directors of AnaptysBio, Inc., a biotechnology company. From March 2011 to December 2013, Dr.&nbsp;Topper served as a member of the board of directors of Portola Pharmaceuticals, Inc., a
biopharmaceutical company, and from 2004 to April 2015 as a member of the board of directors of Amicus Therapeutics, Inc., a biopharmaceutical company. Dr.&nbsp;Topper received a B.S. in Biology from the University of Michigan and an M.D. and a
Ph.D. in Biophysics from the Stanford University School of Medicine. He did his postgraduate training in internal medicine and cardiovascular disease at the Brigham and Women&#146;s Hospital in Boston and was board certified in both disciplines.
Dr.&nbsp;Topper&#146;s extensive service as a director of other biopharmaceutical companies contributed to our board of directors&#146; conclusion that he should serve as a director of our company. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Board Composition and Election of Directors </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Director
Independence </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our board of directors currently consists of eight members. Our board of directors has determined that
Dr.&nbsp;Yamada, Mr.&nbsp;Cola, Dr.&nbsp;Edwards, Ms.&nbsp;Kunz and Dr.&nbsp;Topper are independent directors in accordance with the listing requirements of the Nasdaq Global Select Market, or Nasdaq.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">151 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
The Nasdaq independence definition includes a series of objective tests, including that the director is not, and has not been for at least three years, one of our employees and that neither the
director nor any of his or her family members has engaged in various types of business dealings with us. In addition, as required by Nasdaq rules, our board of directors has made a subjective determination as to each independent director that no
relationships exist, which, in the opinion of our board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of the director. In making these determinations, our board of directors reviewed and
discussed information provided by the directors and us with regard to each director&#146;s business and personal activities and relationships as they may relate to us and our management. There are no family relationships among any of our directors
or executive officers. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Classified Board of Directors </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">In accordance with the terms of our amended and restated certificate of incorporation that will go into effect immediately prior to the closing of this offering, our board of directors will be divided into three
classes with staggered, three-year terms. At each annual meeting of stockholders, the directors whose terms then expire will be eligible for reelection until the third annual meeting following reelection. Effective upon the closing of this offering,
our directors will be divided among the three classes as follows: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the Class&nbsp;I directors will be Terrie Curran and Jonathan Edwards, Ph.D., and their terms will expire at our first annual meeting of stockholders following
this offering; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the Class&nbsp;II directors will be Michael F. Cola, Chris Slavinsky and James Topper, M.D., Ph.D., and their terms will expire at our second annual meeting of
stockholders following this offering; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the Class&nbsp;III directors will be Heidi Kunz, David Socks and Tadataka Yamada, M.D., and their terms will expire at our third annual meeting of stockholders
following this offering. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our amended and restated certificate of incorporation that will go into effect immediately
prior to the closing of this offering will provide that the authorized number of directors may be changed only by resolution of the board of directors. Any additional directorships resulting from an increase in the number of directors will be
distributed among the three classes so that, as nearly as possible, each class will consist of <FONT STYLE="white-space:nowrap">one-third</FONT> of the directors. The division of our board of directors into three classes with staggered three-year
terms may delay or prevent a change of our board of directors or a change in control of our company. Our directors may be removed only for cause by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of
our outstanding voting stock then entitled to vote in an election of directors. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Board Leadership Structure </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our board of directors is currently led by its chairman, Dr.&nbsp;Yamada. Our board of directors recognizes that it is important to determine an
optimal board leadership structure to ensure the independent oversight of management as the company continues to grow. We separate the roles of chief executive officer and chairman of the board of directors in recognition of the differences between
the two roles. The chief executive officer is responsible for setting the strategic direction for our company and the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> leadership and performance of our
company, while the chairman of the board of directors provides guidance to the chief executive officer and presides over meetings of the full board of directors. We believe that this separation of responsibilities provides a balanced approach to
managing the board of directors and overseeing our company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our board of directors has concluded that our current leadership structure
is appropriate at this time. However, our board of directors will continue to periodically review our leadership structure and may make such changes in the future as it deems appropriate. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">152 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Role of Board in Risk Oversight Process </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our board of directors has responsibility for the oversight of our risk management processes and, either as a whole or through its committees,
regularly discusses with management our major risk exposures, their potential impact on our business and the steps we take to manage them. The risk oversight process includes receiving regular reports from board committees and members of senior
management to enable our board of directors to understand our risk identification, risk management and risk mitigation strategies with respect to areas of potential material risk, including operations, finance, legal, regulatory, strategic and
reputational risk. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The audit committee reviews information regarding liquidity and operations, and oversees our management of financial
risks. Periodically, the audit committee reviews our policies with respect to risk assessment, risk management, loss prevention and regulatory compliance. Oversight by the audit committee includes direct communication with our external auditors, and
discussions with management regarding significant risk exposures and the actions management has taken to limit, monitor or control such exposures. The compensation committee is responsible for assessing whether any of our compensation policies or
programs has the potential to encourage excessive risk-taking. The nominating and corporate governance committee manages risks associated with the independence of the board of directors, corporate disclosure practices and potential conflicts of
interest. While each committee is responsible for evaluating certain risks and overseeing the management of such risks, the entire board of directors is regularly informed through committee reports about such risks. Matters of significant strategic
risk are considered by our board of directors as a whole. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Board Committees and Independence </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our board of directors has established three standing committees&#151;audit, compensation and nominating and corporate governance&#151;each of which
operates under a charter that has been approved by our board of directors. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Audit Committee </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The audit committee&#146;s main function is to oversee our accounting and financial reporting processes and the audits of our financial statements.
This committee&#146;s responsibilities include, among other things: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">appointing our independent registered public accounting firm; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">evaluating the qualifications, independence and performance of our independent registered public accounting firm; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">approving the audit and <FONT STYLE="white-space:nowrap">non-audit</FONT> services to be performed by our independent registered public accounting firm;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">reviewing the design, implementation, adequacy and effectiveness of our internal accounting controls and our critical accounting policies;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">discussing with management and the independent registered public accounting firm the results of our annual audit and the review of our quarterly unaudited
combined financial statements; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">reviewing, overseeing and monitoring the integrity of our financial statements and our compliance with legal and regulatory requirements as they relate to
financial statements or accounting matters; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">reviewing on a periodic basis, or as appropriate, any investment policy and recommending to our board of directors any changes to such investment policy;
</FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">153 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">reviewing with management and our auditors any earnings announcements and other public announcements regarding our results of operations;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">preparing the report that the SEC requires in our annual proxy statement; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">reviewing and approving any related party transactions and reviewing and monitoring compliance with our code of conduct and ethics; and
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">reviewing and evaluating, at least annually, the performance of the audit committee and its members including compliance of the audit committee with its charter.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The members of our audit committee are Ms.&nbsp;Kunz, Mr.&nbsp;Cola and Mr.&nbsp;Slavinsky. Ms.&nbsp;Kunz serves as
the chairperson of the committee. All members of our audit committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and Nasdaq. Our board of directors has determined that Ms.&nbsp;Kunz is an
&#147;audit committee financial expert&#148; as defined by applicable SEC rules and has the requisite financial sophistication as defined under the applicable Nasdaq listing standards. Our board of directors has determined each of Ms.&nbsp;Kunz and
Mr.&nbsp;Cola is independent under the applicable rules of the SEC and Nasdaq. Under the applicable Nasdaq rules, we are permitted to phase in our compliance with the independent audit committee requirements of Nasdaq on the same schedule as we are
permitted to phase in our compliance with the independent audit committee requirements pursuant to Rule <FONT STYLE="white-space:nowrap">10A-3</FONT> under the Exchange Act, which requires all members to be independent within one year of listing. We
will comply with the <FONT STYLE="white-space:nowrap">phase-in</FONT> requirements of the Nasdaq rules and within one year of our listing on Nasdaq, all members of our audit committee will be independent under Nasdaq rules and Rule <FONT
STYLE="white-space:nowrap">10A-3.</FONT> Upon the listing of our common stock on Nasdaq, the audit committee will operate under a written charter that satisfies the applicable standards of the SEC and Nasdaq. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Compensation Committee </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our
compensation committee approves policies relating to compensation and benefits of our officers and employees. The compensation committee approves corporate goals and objectives relevant to the compensation of our Chief Executive Officer and other
executive officers, evaluates the performance of these officers in light of those goals and objectives and approves the compensation of these officers based on such evaluations. The compensation committee also approves the issuance of stock options
and other awards under our equity plans. The compensation committee will review and evaluate, at least annually, the performance of the compensation committee and its members, including compliance by the compensation committee with its charter.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The members of our compensation committee are Mr.&nbsp;Cola, Dr.&nbsp;Edwards, Dr.&nbsp;Topper and Dr.&nbsp;Yamada. Mr.&nbsp;Cola
serves as the chairperson of the committee. Our board of directors has determined that each member of this committee is independent under the applicable Nasdaq listing standards, is a &#147;non-employee director&#148; as defined in Rule <FONT
STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act. Upon the listing of our common stock on Nasdaq, the compensation committee will operate under a written charter, which the compensation committee will review and evaluate at
least annually. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Nominating and Corporate Governance Committee </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The nominating and corporate governance committee is responsible for assisting our board of directors in discharging the board of directors&#146; responsibilities regarding the identification of qualified
candidates to become board members, the selection of nominees for election as directors at our annual meetings of stockholders (or special meetings of stockholders at which directors are to be elected), and the selection of candidates to fill any
vacancies on our board of directors and any committees thereof. In addition, the nominating and corporate governance committee is responsible for </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">154 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
overseeing our corporate governance policies, reporting and making recommendations to our board of directors concerning governance matters and oversight of the evaluation of our board of
directors. The members of our nominating and corporate governance committee are Dr.&nbsp;Edwards, Dr.&nbsp;Topper and Dr.&nbsp;Yamada. Dr.&nbsp;Edwards serves as the chairperson of the committee. Our board of directors has determined that each
member of this committee is independent under the applicable Nasdaq listing standards. Upon the listing of our common stock on Nasdaq, the nominating and corporate governance committee will operate under a written charter, which the nominating and
corporate governance committee will review and evaluate at least annually. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Compensation Committee Interlocks and Insider Participation
</B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">None of the members of our compensation committee has ever been one of our officers or employees. None of our executive officers
currently serves, or has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving as a member of our board of directors or compensation committee. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Board Diversity </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Upon the closing of this
offering, our nominating and corporate governance committee will be responsible for reviewing with the board of directors, on an annual basis, the appropriate characteristics, skills and experience required for the board of directors as a whole and
its individual members. In evaluating the suitability of individual candidates (both new candidates and current members) for election or appointment, the nominating and corporate governance committee and the board of directors will take into account
many factors, including the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">personal and professional integrity, ethics and values; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">experience in corporate management, such as serving as an officer or former officer of a publicly-held company; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">experience as a board member or executive officer of another publicly-held company; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">strong finance experience; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">diversity of expertise and experience in substantive matters pertaining to our business relative to other board members; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">diversity of background and perspective, including, but not limited to, with respect to age, gender, race, place of residence and specialized experience;
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">experience relevant to our business industry and with relevant social policy concerns; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">relevant academic expertise or other proficiency in an area of our business operations. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Currently, our board of directors evaluates, and following the closing of this offering will evaluate, each individual in the context of the board
of directors as a whole, with the objective of assembling a group that can best maximize the success of the business and represent stockholder interests through the exercise of sound judgment using its diversity of experience in these various areas.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">155 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Code of Conduct and Ethics </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">We have adopted a written code of conduct and ethics that applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or
controller, or persons performing similar functions, which will be effective upon the closing of this offering. Upon the closing of this offering, our code of conduct and ethics will be available under the Corporate Governance section of our website
at www.phathompharma.com. In addition, we intend to post on our website all disclosures that are required by law or the listing standards of Nasdaq concerning any amendments to, or waivers from, any provision of the code. The reference to our
website address does not constitute incorporation by reference of the information contained at or available through our website, and you should not consider it to be a part of this prospectus. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">156 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_13"></A>EXECUTIVE AND DIRECTOR COMPENSATION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">This section discusses the material components of the executive compensation program for our named executive officer who is named in the
&#147;Summary Compensation Table&#148; below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">For 2018, our only &#147;named executive officer&#148; was David Socks, our President,
Chief Executive Officer, Treasurer and Secretary, and member of our board of directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">This discussion may contain forward-looking
statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. Actual compensation programs that we adopt following the closing of this offering may differ materially from the
currently planned programs summarized in this discussion. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We are an &#147;emerging growth company,&#148; as that term is used in the
JOBS Act, and have elected to comply with the reduced compensation disclosure requirements available to emerging growth companies under the JOBS Act. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Summary Compensation Table </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The following
table presents summary information regarding the total compensation that was awarded to, earned by or paid to our named executive officer for services rendered during the year ended December&nbsp;31, 2018. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Name and Principal Position</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Year</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Salary<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Bonus<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Stock<BR>Awards<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>All
Other<BR>Compensation<BR>($)<SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Total<BR>($)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>David Socks<BR>President, Chief Executive Officer, Treasurer, Secretary and Director</I></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">153,333</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">16,812</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">170,145</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP>&nbsp;&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">Represents benefit costs paid on behalf of Mr.&nbsp;Socks by our company. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>Narrative Disclosure to Summary Compensation Table </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Annual Base Salary </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The compensation of our executive officers is generally determined and approved at the time of their commencement of employment by our board of
directors or the compensation committee. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The annual base salary for Mr.&nbsp;Socks for his service as our Chief Executive Officer was
$160,000 for 2018. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In connection with the Takeda License and Mr.&nbsp;Socks&#146; increased responsibilities as our President and Chief
Executive Officer, our board of directors increased his base salary to $340,000, effective May&nbsp;1, 2019. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Bonus Compensation
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">From time to time our board of directors or compensation committee may approve bonuses for our executive officers based on
individual performance, company performance or as otherwise determined appropriate. No formal bonus plan was in effect during 2018. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">157 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Equity-Based Incentive Awards </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our equity-based incentive awards are designed to align our interests and the interests of our stockholders with those of our employees and
consultants, including our named executive officer. Our board of directors or the compensation committee approves equity grants. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">On
February&nbsp;13, 2018, we issued and sold to Mr.&nbsp;Socks, 1,686,704&nbsp;shares of our common stock for a per share purchase price of $0.0002958. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">On March&nbsp;13, 2019, we entered into a stock restriction agreement with Mr.&nbsp;Socks whereby Mr.&nbsp;Socks&#146; previously-acquired 1,686,704 shares of our common stock were subjected to new vesting
conditions, such that 421,676 shares were deemed vested as of March&nbsp;13, 2019 and the remaining 1,265,028 shares were converted into unvested shares of restricted stock that vest in equal monthly installments over the 48 months thereafter ending
on March&nbsp;13, 2023, subject, in each case, to continued employment or status as a service provider. Any unvested shares held by Mr.&nbsp;Socks upon a termination of employment or service (after giving effect to any accelerated vesting provisions
described further below), will be subject to repurchase by us at the original purchase price. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Under Mr.&nbsp;Socks&#146; stock
restriction agreement, 100% of any unvested shares will automatically accelerate and vest upon (i)&nbsp;a termination of service by us without cause or by him for good reason following a change in control, or (ii)&nbsp;the refusal by us to enter
into a consulting agreement with him in connection with his resignation, subject to his continued employment or service through the date of such event. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Defined Terms Applicable to Stock Restriction Agreement </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">For purposes of the stock restriction agreement with Mr.&nbsp;Socks, &#147;change in control&#148; generally has the same meaning given to such term in our Existing Incentive Plan, as described below. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">For purposes of the stock restriction agreement with Mr.&nbsp;Socks, &#147;good reason&#148; means the occurrence of any of the following events or
conditions without his consent: (i)&nbsp;a material diminution in authority, duties or responsibilities; (ii)&nbsp;a material diminution in base compensation, unless such reduction is imposed <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">across-the-board</FONT></FONT> to senior management of the Company; (iii)&nbsp;a material change in the geographic location at which he must perform his duties (and the parties acknowledge that a relocation of our
principal executive offices to a location more than fifty (50)&nbsp;miles from our then-current offices at which the individual is providing services (excepting reasonable travel on business) shall constitute a material change for purposes of this
clause (iii)); or (iv)&nbsp;any other action or inaction that constitutes a material breach by us or any successor or affiliate of our obligations to him under the stock restriction agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">For purposes of the stock restriction agreement with Mr.&nbsp;Socks, &#147;cause&#148; means one or more of the following has occurred, as
determined in good faith by us in our reasonable discretion: (i)&nbsp;conviction of, or plea of nolo contendere to, any felony or of any crime involving either moral turpitude or dishonesty; (ii)&nbsp;intentional participation in a fraud or
intentional act of dishonesty against our company or any of our customers or business partners; (iii)&nbsp;material breach of duties; (iv)&nbsp;material breach of any written agreement with us if such breach has not been cured, or services ceased,
within thirty (30)&nbsp;days of receiving written notice thereof; and (v)&nbsp;failure to comply with the reasonable and lawful directives of management. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">158 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Employment Letters with our Executive Officers </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In 2018, none of our executive officers were parties to employment agreements or other similar arrangements with us. Each of our executive
officers&#146; employment is &#147;at will&#148; and may be terminated at any time, subject to our contractual obligations to them as described below. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Employment Letter with David Socks </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We entered into an employment letter with Mr.&nbsp;Socks setting forth the terms of his employment, effective May&nbsp;7, 2019 in connection with
entering into the Takeda License. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The employment letter for Mr.&nbsp;Socks provides for an annual base salary of $340,000, and an
annual bonus with a target amount equal to 50% of Mr.&nbsp;Socks&#146; annual base salary. Under the employment letter for Mr.&nbsp;Socks, he will devote at least 80% of his time to our company. Additionally, under the employment letter,
Mr.&nbsp;Socks is eligible to participate in all employee benefit plans and programs generally available to similarly situated employees of our company and is entitled to vacation benefits in accordance with our policies. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Employment Letter with Terrie Curran </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have entered into an employment letter with Ms. Curran, pursuant to which we have appointed her as a member of our board of directors and offered
her employment as our Chief Executive Officer. Under the terms of the employment letter, Ms.&nbsp;Curran must commence full-time employment with us as our Chief Executive Officer within two weeks after the completion of the planned acquisition of
her current employer but in no event later than December&nbsp;31, 2019, or the Start Date Deadline. In the event Ms.&nbsp;Curran has not commenced full-time employment with us as our Chief Executive Officer prior to such deadline, the employment
offer will cease to be outstanding. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The employment letter for Ms. Curran provides for an initial annual base salary of $500,000, and an
annual bonus with a target amount equal to 50% of her annual base salary. Her annual bonus for 2019 will be pro-rated based on the portion of the year she is employed by us. Additionally, under the employment letter, Ms.&nbsp;Curran will be eligible
to participate in all employee benefit plans and programs generally available to similarly situated employees of our company and is entitled to vacation benefits in accordance with our policies. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Effective August&nbsp;29, 2019, we appointed Ms.&nbsp;Curran to our board of directors. In connection with her appointment to the board, we granted
her stock options to purchase 867,200 shares of our common stock under the Existing Incentive Plan. The stock options have a ten-year term and an exercise price of $6.95 per share, which our board of directors determined was equal to the fair market
value per share of our common stock on the date of grant. Ms.&nbsp;Curran&#146;s options will vest over a four-year period, with 25% of the stock options vesting on the first anniversary of her commencement of employment with us and the remaining
stock options vesting in 36 equal monthly installments thereafter, subject to her continued employment or service on each vesting date. In the event Ms.&nbsp;Curran does not commence employment with us as our Chief Executive Officer prior to the
Start Date Deadline, all of the stock options granted to her in connection with her appointment to the board will terminate immediately, regardless of her continued service on the board of directors. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Regardless of the manner in which Ms.&nbsp;Curran&#146;s employment terminates, she will be entitled to receive amounts previously earned during
her term of employment, including unpaid salary and accrued but unused vacation. In addition, Ms.&nbsp;Curran will be entitled to certain severance benefits under her employment letter, subject to her execution of a release of claims, returning of
all company property, compliance with post-termination obligations and resignation from positions with us. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">159 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Ms.&nbsp;Curran&#146;s employment letter provides for severance benefits for certain terminations
that arise during and outside a change in control period (as defined below). Upon a termination without cause or resignation for good reason outside of a change in control period, Ms.&nbsp;Curran will be entitled to: (1)&nbsp;continuation of her
base salary for 12&nbsp;months (such applicable period, the &#147;severance period&#148;), (2)&nbsp;a lump sum equal to her target bonus for the year during which such termination occurs, plus any unpaid annual bonus for the calendar year prior to
the year in which her termination occurs, to the extent she is entitled to such bonus and if such bonus has not already been paid, (3)&nbsp;payment of the COBRA premiums for her and her eligible dependents until the earliest of (a)&nbsp;the end the
severance period, (b)&nbsp;expiration of her eligibility under for continuation coverage under COBRA, or (c)&nbsp;the date she becomes eligible for health insurance coverage in connection with her new employment, and (4)&nbsp;acceleration of the
vesting of all outstanding equity awards that would have vested during the severance period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Upon a termination without cause or
resignation for good reason that occurs during the period that is three months prior to or any time on or after a change in control (such period, the &#147;change in control period&#148;), Ms. Curran will be entitled to all of the same severance
benefits described above, except (1)&nbsp;the severance period is increased from 12&nbsp;months to 18&nbsp;months, (2)&nbsp;Ms.&nbsp;Curran will be entitled to a lump sum payment equal to 1.5&nbsp;times her target bonus for the year during which
such termination occurs, plus any unpaid annual bonus for the calendar year prior to the year in which her termination occurs, to the extent she is entitled to such bonus and if such bonus has not already been paid, and (3)&nbsp;all unvested and
outstanding equity awards will become fully vested on the later of the date her release of claims becomes effective or the date of the change in control. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">For purposes of Ms. Curran&#146;s employment letter: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">&#147;cause&#148; means (1)&nbsp;her commission of an act of fraud, embezzlement or dishonesty, or the commission of some other illegal act, that has a
demonstrable adverse impact on us or any successor or affiliate thereof; (2)&nbsp;her conviction of, or plea of &#147;guilty&#148; or &#147;no contest&#148; to, a felony or any crime involving fraud, dishonesty or moral turpitude under the laws of
the United States or any state thereof; (3)&nbsp;any intentional, unauthorized use or disclosure by her of the confidential information or trade secrets of the company or any successor or affiliate thereof; (4)&nbsp;her gross negligence,
insubordination or material violation of any duty of loyalty to us or any successor or affiliate thereof, or any other demonstrable material misconduct on her part; (5)&nbsp;her ongoing and repeated failure or refusal to perform or neglect of her
duties as required by the employment letter or her ongoing and repeated failure or refusal to comply with the instructions given to her by the board of directors, which failure, refusal or neglect continues for 15&nbsp;days following her receipt of
written notice from the board of directors stating with specificity the nature of such failure, refusal or neglect; or (6)&nbsp;her willful, material breach of any material company policy or any material provision of the employment letter or her
proprietary information and inventions assignment agreement. </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">&#147;change in control&#148; has the same meaning given to such term in our Existing Incentive Plan; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">&#147;good reason&#148; means any of the following without her written consent: (1) a material diminution in her authority, duties or responsibilities; (2) a
material diminution in her base compensation (and any diminution of 10% or more shall be considered material for this purpose, regardless of whether such diminution occurs due to a single reduction or a series of reductions in her base
compensation), unless such a reduction is imposed across-the-board to senior management; (3) a material change in the geographic location at which she must perform her duties; or (4) any other action or inaction that constitutes a material breach by
us or any successor or affiliate of its obligations to her under the employment letter. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">160 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Employment Letters with Other Executives </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have also entered into employment letters with each of our other executive officers, Aditya Kohli, Ph.D., our Chief Business Officer, and Azmi
Nabulsi, M.D., M.P.H., our Chief Operating Officer. Each employment letter sets forth the terms of their employment, each effective on May&nbsp;7, 2019 in connection with entering into the Takeda License. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The employment letters for Drs. Kohli and Nabulsi each provide for an annual base salary of $180,000 and $470,000, respectively, and an annual
bonus with a target amount equal to 35% and 40% of the executive&#146;s annual base salary, respectively. Pursuant to his employment letter, Dr.&nbsp;Kohli&#146;s base salary will increase to $220,000, effective August&nbsp;1, 2019. Under his
employment letter, Dr.&nbsp;Nabulsi will work for our company on a full-time basis. Under his employment letter, Dr.&nbsp;Kohli will devote at least 80% of his time to our company. Additionally, under the employment letters, each executive is
eligible to participate in all employee benefit plans and programs generally available to similarly situated employees of our company and is entitled to vacation benefits in accordance with our policies. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In September 2019, we amended and restated the employment letter for Dr.&nbsp;Nabulsi to provide certain severance benefits under his employment
letter, subject to his execution of a release of claims, returning of all company property, compliance with post-termination obligations and resignation from positions with us. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Dr.&nbsp;Nabulsi&#146;s amended and restated employment letter provides for severance benefits for certain terminations that arise during and
outside a change in control period (as defined below). Upon a termination without cause or resignation for good reason outside of a change in control period, Dr.&nbsp;Nabulsi will be entitled to: (1)&nbsp;continuation of his base salary for 9 months
(such applicable period, the &#147;severance period&#148;), (2)&nbsp;a lump sum equal to his prorated target bonus for the year during which such termination occurs, plus any unpaid annual bonus for the calendar year prior to the year in which his
termination occurs, to the extent he is entitled to such bonus and if such bonus has not already been paid, (3)&nbsp;payment of the COBRA premiums for him and his eligible dependents until the earliest of (a)&nbsp;the end the severance period,
(b)&nbsp;expiration of his eligibility under for continuation coverage under COBRA, or (c)&nbsp;the date he becomes eligible for health insurance coverage in connection with his new employment, and (4)&nbsp;acceleration of the vesting of all
outstanding equity awards that would have vested during the severance period. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Upon a termination without cause or resignation for good
reason that occurs during the period that is three months prior to or the 24 months following a change in control (such period, the &#147;change in control period&#148;), Dr.&nbsp;Nabulsi will be entitled to all of the same severance benefits
described above, except (1)&nbsp;the severance period is increased from 9 months to 12 months, (2)&nbsp;Dr.&nbsp;Nabulsi will be entitled to a lump sum payment equal to his target bonus for the year during which such termination occurs, plus any
unpaid annual bonus for the calendar year prior to the year in which his termination occurs, to the extent he is entitled to such bonus and if such bonus has not already been paid, and (3)&nbsp;all unvested and outstanding equity awards will become
fully vested on the later of the date his release of claims becomes effective or the date of the change in control. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">For purposes of
Dr.&nbsp;Nabulsi&#146;s amended and restated offer letter, &#147;cause&#148;, &#147;change in control&#148; and &#147;good reason&#148; have the same definitions as set forth in Ms.&nbsp;Curran&#146;s employment letter described above. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Outstanding Equity Awards at Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our named executive officer did not hold any unvested equity awards granted as of December&nbsp;31, 2018. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">161 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Other Elements of Compensation </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Perquisites, Health, Welfare and Retirement Benefits </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We generally do not maintain
employee benefit plans or provide perquisites or personal benefits to our executive officers. We do, however, reimburse certain of our executive officers for costs related to health and welfare benefits they receive pursuant to other sources. Our
board of directors may elect to adopt qualified or <FONT STYLE="white-space:nowrap">non-qualified</FONT> benefit plans in the future if it determines that doing so is in our best interests. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Nonqualified Deferred Compensation </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We do not maintain nonqualified defined contribution
plans or other nonqualified deferred compensation plans. Our board of directors may elect to provide our officers and other employees with <FONT STYLE="white-space:nowrap">non-qualified</FONT> defined contribution or other nonqualified deferred
compensation benefits in the future if it determines that doing so is in our best interests. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Change in Control Benefits </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our named executive officer may become entitled to certain benefits or enhanced benefits in connection with a change in control of our company. The
stock restriction agreement with our named executive officer provides for accelerated vesting of all outstanding equity awards upon a qualifying termination in connection with a change in control of our company. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Incentive Award Plans </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>2019 Incentive Award Plan
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our board of directors and stockholders have adopted the 2019 Plan, which became effective in connection with this offering.
Under the 2019 Plan, we may grant cash and equity incentive awards to eligible employees, directors and consultants in order to attract, motivate and retain the talent for which we compete. The material terms of the 2019 Plan are summarized below.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Eligibility and Administration </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our employees, consultants and directors, and employees and consultants of our subsidiaries, will be eligible to receive awards under the 2019 Plan.
Following our initial public offering, the 2019 Plan will generally be administered by our board of directors with respect to awards to <FONT STYLE="white-space:nowrap">non-employee</FONT> directors and by our compensation committee with respect to
other participants, each of which may delegate its duties and responsibilities to committees of our directors and/or officers (referred to collectively as the plan administrator below), subject to certain limitations that may be imposed under the
2019 Plan, Section&nbsp;16 of the Exchange Act and/or stock exchange rules, as applicable. The plan administrator will have the authority to make all determinations and interpretations under, prescribe all forms for use with, and adopt rules for the
administration of, the 2019 Plan, subject to its express terms and conditions. The plan administrator will also set the terms and conditions of all awards under the 2019 Plan, including any vesting and vesting acceleration conditions. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Limitation on Awards and Shares Available </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">An aggregate of 2,700,000&nbsp;shares of our common stock will initially be available for issuance under awards granted pursuant to the 2019 Plan.
The number of shares initially available for issuance will be increased by (i)&nbsp;the number of shares subject to stock options or similar awards granted under our existing 2019 Equity Incentive Plan, or the Existing Incentive Plan, that expire or
otherwise </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">162 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
terminate without having been exercised in full after the effective date of the 2019 Plan and unvested shares issued pursuant to awards granted under our Existing Incentive Plan, that are
forfeited to or repurchased by us after the effective date of the 2019 Plan, with the maximum number of shares to be added to the 2019 Plan pursuant to clause (i)&nbsp;above equal to 1,416,788&nbsp;shares, and (ii)&nbsp;an annual increase on
January&nbsp;1 of each calendar year beginning in 2020 and ending in 2029, equal to the lesser of (a)&nbsp;5% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (b)&nbsp;such smaller number of
shares as determined by our board of directors. No more than 40,000,000 shares of common stock may be issued upon the exercise of incentive stock options under the 2019 Plan. Shares issued under the 2019 Plan may be authorized but unissued shares,
shares purchased in the open market or treasury shares. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If an award under the 2019 Plan or the Existing Incentive Plan expires, lapses
or is terminated, exchanged for cash, surrendered, repurchased, canceled without having been fully exercised or forfeited, any shares subject to such award will, as applicable, become or again be available for new grants under the 2019 Plan.
Further, shares delivered to us to satisfy the applicable exercise or purchase price of an award under the 2019 Plan or the Existing Incentive Plan and/or to satisfy any applicable tax withholding obligations (including shares retained by us from
the award under the 2019 Plan or the Existing Incentive Plan being exercised or purchased and/or creating the tax obligation) will become or again be available for award grants under the 2019 Plan. Awards granted under the 2019 Plan upon the
assumption of, or in substitution for, awards authorized or outstanding under a qualifying equity plan maintained by an entity with which we enter into a merger or similar corporate transaction will not reduce the shares available for grant under
the 2019 Plan. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Awards </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The 2019
Plan provides for the grant of stock options, including incentive stock options, or ISOs, and nonqualified stock options, or NSOs, restricted stock, dividend equivalents, restricted stock units, or RSUs, stock appreciation rights, or SARs, and other
stock or cash-based awards. Certain awards under the 2019 Plan may constitute or provide for a deferral of compensation, subject to Section&nbsp;409A of the Code, which may impose additional requirements on the terms and conditions of such awards.
All awards under the 2019 Plan will be set forth in award agreements, which will detail the terms and conditions of the awards, including any applicable vesting and payment terms and post-termination exercise limitations. A brief description of each
award type follows. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Stock Options</I>.&nbsp;&nbsp;&nbsp;&nbsp;Stock options provide for the purchase of shares of our common stock
in the future at an exercise price set on the grant date. ISOs, by contrast to NSOs, may provide tax deferral beyond exercise and favorable capital gains tax treatment to their holders if certain holding period and other requirements of the Code are
satisfied. The exercise price of a stock option will not be less than 100% of the fair market value of the underlying share on the date of grant (or 110% in the case of ISOs granted to certain significant stockholders), except with respect to
certain substitute options granted in connection with a corporate transaction. The term of a stock option may not be longer than ten years (or five years in the case of ISOs granted to certain significant stockholders). Vesting conditions determined
by the plan administrator may apply to stock options and may include continued service, performance and/or other conditions. ISOs generally may be granted only to our employees and employees of our parent or subsidiary corporations, if any.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>SARs</I>.&nbsp;&nbsp;&nbsp;&nbsp;SARs entitle their holder, upon exercise, to receive from us an amount equal to the appreciation of
the shares subject to the award between the grant date and the exercise date. The exercise price of a SAR will not be less than 100% of the fair market value of the underlying share on the date of grant (except with respect to certain substitute
SARs granted in connection with a corporate transaction), and the term of a SAR may not be longer than ten years. Vesting conditions determined by the plan administrator may apply to SARs and may include continued service, performance and/or other
conditions. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">163 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Restricted Stock and RSUs</I>.&nbsp;&nbsp;&nbsp;&nbsp;Restricted stock is an award of
nontransferable shares of our common stock that remain forfeitable unless and until specified conditions are met, and which may be subject to a purchase price. RSUs are contractual promises to deliver shares of our common stock in the future, which
may also remain forfeitable unless and until specified conditions are met and may be accompanied by the right to receive the equivalent value of dividends paid on shares of our common stock prior to the delivery of the underlying shares. Delivery of
the shares underlying RSUs may be deferred under the terms of the award or at the election of the participant, if the plan administrator permits such a deferral. Conditions applicable to restricted stock and RSUs may be based on continuing service,
the attainment of performance goals and/or such other conditions as the plan administrator may determine. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Other Stock or Cash-Based
Awards.</I>&nbsp;&nbsp;&nbsp;&nbsp;Other stock or cash-based awards are awards of cash, fully vested shares of our common stock and other awards valued wholly or partially by referring to, or otherwise based on, shares of our common stock. Other
stock or cash-based awards may be granted to participants and may also be available as a payment form in the settlement of other awards, as standalone payments and as payment in lieu of base salary, bonus, fees or other cash compensation otherwise
payable to any individual who is eligible to receive awards. The plan administrator will determine the terms and conditions of other stock or cash-based awards, which may include vesting conditions based on continued service, performance and/or
other conditions. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Performance Awards </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Performance awards include any of the foregoing awards that are granted subject to vesting and/or payment based on the attainment of specified performance goals or other criteria the plan administrator may
determine, which may or may not be objectively determinable. Performance criteria upon which performance goals are established by the plan administrator may include: net earnings or losses (either before or after one or more of interest, taxes,
depreciation, amortization and <FONT STYLE="white-space:nowrap">non-cash</FONT> equity-based compensation expense); gross or net sales or revenue or sales or revenue growth; net income (either before or after taxes) or adjusted net income; profits
(including, but not limited to, gross profits, net profits, profit growth, net operation profit or economic profit), profit return ratios or operating margin; budget or operating earnings (either before or after taxes or before or after allocation
of corporate overhead and bonus); cash flow (including operating cash flow and free cash flow or cash flow return on capital); return on assets; return on capital or invested capital; cost of capital; return on stockholders&#146; equity; total
stockholder return; return on sales; costs, reductions in costs and cost control measures; expenses; working capital; earnings or loss per share; adjusted earnings or loss per share; price per share or dividends per share (or appreciation in or
maintenance of such price or dividends); regulatory achievements or compliance; implementation, completion or attainment of objectives relating to research, development, regulatory, commercial or strategic milestones or developments; market share;
economic value or economic value added models; division, group or corporate financial goals; customer satisfaction/growth; customer service; employee satisfaction; recruitment and maintenance of personnel; human resources management; supervision of
litigation and other legal matters; strategic partnerships and transactions; financial ratios (including those measuring liquidity, activity, profitability or leverage); debt levels or reductions; sales-related goals; financing and other capital
raising transactions; cash on hand; acquisition activity; investment sourcing activity; and marketing initiatives, any of which may be measured in absolute terms or as compared to any incremental increase or decrease. Such performance goals also may
be based solely by reference to our performance or the performance of a subsidiary, division, business segment or business unit, or based upon performance relative to performance of other companies or upon comparisons of any of the indicators of
performance relative to performance of other companies. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">164 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Provisions of the 2019 Plan Relating to Director Compensation </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The 2019 Plan provides that the plan administrator may establish compensation for <FONT STYLE="white-space:nowrap">non-employee</FONT> directors
from time to time subject to the 2019 Plan&#146;s limitations. Prior to commencing this offering, our stockholders approved the initial terms of our <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation program, which is
described below under the heading &#147;&#151;Director Compensation.&#148; Our board of directors or its authorized committee may modify the <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation program from time to time in the
exercise of its business judgment, taking into account such factors, circumstances and considerations as it shall deem relevant from time to time, provided that the sum of any cash compensation or other compensation and the grant date fair value (as
determined in accordance with ASC 718, or any successor thereto) of any equity awards granted as compensation for services as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director during any fiscal year may not exceed $750,000, increased
to $1,000,000, in the fiscal year of a <FONT STYLE="white-space:nowrap">non-employee</FONT> director&#146;s initial service as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director. The plan administrator may make exceptions to this limit
for individual <FONT STYLE="white-space:nowrap">non-employee</FONT> directors in extraordinary circumstances, as the plan administrator may determine in its discretion, provided that the <FONT STYLE="white-space:nowrap">non-employee</FONT> director
receiving such additional compensation may not participate in the decision to award such compensation or in other contemporaneous compensation decisions involving <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Certain Transactions </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In connection with
certain transactions and events affecting our common stock, including a change in control, or change in any applicable laws or accounting principles, the plan administrator has broad discretion to take action under the 2019 Plan to prevent the
dilution or enlargement of intended benefits, facilitate such transaction or event, or give effect to such change in applicable laws or accounting principles. This includes canceling awards in exchange for either an amount in cash or other property
with a value equal to the amount that would have been obtained upon exercise or settlement of the vested portion of such award or realization of the participant&#146;s rights under the vested portion of such award, accelerating the vesting of
awards, providing for the assumption or substitution of awards by a successor entity, adjusting the number and type of shares available, replacing awards with other rights or property or terminating awards under the 2019 Plan. In the event of a
change in control where the acquirer does not assume awards granted under the 2019 Plan, awards issued under the 2019 Plan shall be subject to accelerated vesting such that 100% of the awards will become vested and exercisable or payable, as
applicable, and which may be subject to such terms and conditions as apply generally to holders of common stock under the change in control documents. In addition, in the event of certain <FONT STYLE="white-space:nowrap">non-reciprocal</FONT>
transactions with our stockholders, or an &#147;equity restructuring,&#148; the plan administrator will make equitable adjustments to the 2019 Plan and outstanding awards as it deems appropriate to reflect the equity restructuring. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">For purposes of the 2019 Plan, a &#147;change in control&#148; means and includes each of the following: (i)&nbsp;a transaction or series of
transactions (other than an offering of our common stock to the general public through a registration statement filed with the SEC or a transaction or series of transactions that meets the requirements of clauses (x)&nbsp;and (y) of clause
(iii)&nbsp;below) whereby any &#147;person&#148; or related &#147;group&#148; of &#147;persons&#148; (as such terms are used in Sections 13(d) and 14(d)(2) of the Exchange Act) (other than us, any of our subsidiaries, an employee benefit plan
maintained by us or any of our subsidiaries or a &#147;person&#148; that, prior to such transaction, directly or indirectly controls, is controlled by, or is under common control with, us) directly or indirectly acquires beneficial ownership (within
the meaning of Rule <FONT STYLE="white-space:nowrap">13d-3</FONT> under the Exchange Act) of our securities possessing more than 50% of the total combined voting power of our securities outstanding immediately after such acquisition; or
(ii)&nbsp;during any period of two consecutive years, individuals who, at the beginning of such period, constitute the board of directors together with any new director(s) (other than a director designated by a person who shall have entered into an
agreement with us to effect a transaction described in clauses </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">165 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
(i)&nbsp;or (iii)) whose election by the board of directors or nomination for election by our stockholders was approved by a vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of
the directors then still in office who either were directors at the beginning of the <FONT STYLE="white-space:nowrap">two-year</FONT> period or whose election or nomination for election was previously so approved, cease for any reason to constitute
a majority thereof; or (iii)&nbsp;the consummation by us (whether directly involving us or indirectly involving us through one or more intermediaries) of (a)&nbsp;a merger, consolidation, reorganization, or business combination or (b)&nbsp;a sale or
other disposition of all or substantially all of our assets in any single transaction or series of related transactions or (c)&nbsp;the acquisition of assets or stock of another entity, in each case other than a transaction: (x)&nbsp;which results
in our voting securities outstanding immediately before the transaction continuing to represent (either by remaining outstanding or by being converted into our voting securities or the voting securities of a successor entity, directly or indirectly,
at least a majority of the combined voting power of our outstanding voting securities or the successor entity&#146;s outstanding voting securities immediately after the transaction, and (y)&nbsp;after which no person or group beneficially owns
voting securities representing 50% or more of the combined voting power of us or the successor entity (provided that no person will be treated as beneficially owning 50% or more of the combined voting power of us or the successor entity for purposes
of this clause (y)&nbsp;solely as a result of the voting power held in us prior to the consummation of the transaction). </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Foreign Participants,
Claw-Back Provisions, Transferability and Participant Payments </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">With respect to foreign participants, the plan administrator may
modify award terms, establish subplans and/or adjust other terms and conditions of awards, subject to the share limits described above. All awards will be subject to the provisions of any claw-back policy implemented by our company to the extent set
forth in such claw-back policy or in the applicable award agreement. With limited exceptions for estate planning, domestic relations orders, certain beneficiary designations and the laws of descent and distribution, awards under the 2019 Plan are
generally <FONT STYLE="white-space:nowrap">non-transferable</FONT> prior to vesting and are exercisable only by the participant. With regard to tax withholding obligations arising in connection with awards under the 2019 Plan and exercise price
obligations arising in connection with the exercise of stock options under the 2019 Plan, the plan administrator may, in its discretion, accept cash, wire transfer, or check, shares of our common stock that meet specified conditions, a &#147;market
sell order&#148; or such other consideration as it deems suitable or any combination of the foregoing. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Plan Amendment and Termination
</I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our board of directors may amend or terminate the 2019 Plan at any time; however, except in connection with certain changes in our
capital structure, stockholder approval will be required for any amendment that increases the number of shares available under the 2019 Plan. The plan administrator will have the authority, without the approval of our stockholders, to amend any
outstanding stock option or SAR to reduce its exercise price per share. No award may be granted pursuant to the 2019 Plan after the tenth anniversary of the date on which our board of directors adopted the 2019 Plan. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Securities Laws </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The 2019 Plan is intended
to conform to all provisions of the Securities Act, and the Exchange Act and any and all regulations and rules promulgated by the SEC thereunder, including, without limitation, Rule <FONT STYLE="white-space:nowrap">16b-3.</FONT> The 2019 Plan will
be administered, and awards will be granted and may be exercised, only in such a manner as to conform to such laws, rules and regulations. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Federal
Income Tax Consequences </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The material federal income tax consequences of the 2019 Plan under current federal income tax law are
summarized in the following discussion, which deals with the general tax principles applicable </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">166 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
to the 2019 Plan. The following discussion is based upon laws, regulations, rulings and decisions now in effect, all of which are subject to change. Foreign, state and local tax laws, and
employment, estate and gift tax considerations are not discussed due to the fact that they may vary depending on individual circumstances and by locality. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Stock Options and SARs. A 2019 Plan participant generally will not recognize taxable income and we generally will not be entitled to a tax deduction upon the grant of a stock option or SAR. The tax consequences of
exercising a stock option and the subsequent disposition of the shares received upon exercise will depend upon whether the option qualifies as an ISO or an NSO. Upon exercising an NSO when the fair market value of our stock is higher than the
exercise price of the option, a 2019 Plan participant generally will recognize taxable income at ordinary income tax rates equal to the excess of the fair market value of the stock on the date of exercise over the purchase price, and we (or our
subsidiaries, if any) generally will be entitled to a corresponding tax deduction for compensation expense, in the amount equal to the amount by which the fair market value of the shares purchased exceeds the purchase price for the shares. Upon a
subsequent sale or other disposition of the option shares, the participant will recognize a short-term or long-term capital gain or loss in the amount of the difference between the sales price of the shares and the participant&#146;s tax basis in
the shares. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Upon exercising an ISO, a 2019 Plan participant generally will not recognize taxable income, and we will not be entitled to
a tax deduction for compensation expense. However, upon exercise, the amount by which the fair market value of the shares purchased exceeds the purchase price will be an item of adjustment for alternative minimum tax purposes. The participant will
recognize taxable income upon a sale or other taxable disposition of the option shares. For federal income tax purposes, dispositions are divided into two categories: qualifying and disqualifying. A qualifying disposition generally occurs if the
sale or other disposition is made more than two years after the date the option was granted and more than one year after the date the shares are transferred upon exercise. If the sale or disposition occurs before these two periods are satisfied,
then a disqualifying disposition generally will result. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Upon a qualifying disposition of ISO shares, the participant will recognize
long-term capital gain in an amount equal to the excess of the amount realized upon the sale or other disposition of the shares over their purchase price. If there is a disqualifying disposition of the shares, then the excess of the fair market
value of the shares on the exercise date (or, if less, the price at which the shares are sold) over their purchase price will be taxable as ordinary income to the participant. If there is a disqualifying disposition in the same year of exercise, it
eliminates the item of adjustment for alternative minimum tax purposes. Any additional gain or loss recognized upon the disposition will be recognized as a capital gain or loss by the participant. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We will not be entitled to any tax deduction if the participant makes a qualifying disposition of ISO shares. If the participant makes a
disqualifying disposition of the shares, we should be entitled to a tax deduction for compensation expense in the amount of the ordinary income recognized by the participant. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Upon exercising or settling a SAR, a 2019 Plan participant will recognize taxable income at ordinary income tax rates, and we should be entitled to a corresponding tax deduction for compensation expense, in the
amount paid or value of the shares issued upon exercise or settlement. Payments in shares will be valued at the fair market value of the shares at the time of the payment, and upon the subsequent disposition of the shares the participant will
recognize a short-term or long-term capital gain or loss in the amount of the difference between the sales price of the shares and the participant&#146;s tax basis in the shares. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Restricted Stock and RSUs</I>.&nbsp;&nbsp;&nbsp;&nbsp;A 2019 Plan participant generally will not recognize taxable income at ordinary income tax
rates and we generally will not be entitled to a tax deduction upon the grant of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">167 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
restricted stock or RSUs. Upon the termination of restrictions on restricted stock or the payment of RSUs, the participant will recognize taxable income at ordinary income tax rates, and we
should be entitled to a corresponding tax deduction for compensation expense, in the amount paid to the participant or the amount by which the then fair market value of the shares received by the participant exceeds the amount, if any, paid for
them. Upon the subsequent disposition of any shares, the participant will recognize a short-term or long-term capital gain or loss in the amount of the difference between the sales price of the shares and the participant&#146;s tax basis in the
shares. However, a 2019 Plan participant granted restricted stock that is subject to forfeiture or repurchase through a vesting schedule such that it is subject to a &#147;risk of forfeiture&#148; (as defined in Section&nbsp;83 of the Code) may make
an election under Section&nbsp;83(b) of the Code to recognize taxable income at ordinary income tax rates, at the time of the grant, in an amount equal to the fair market value of the shares of common stock on the date of grant, less the amount
paid, if any, for such shares. We will be entitled to a corresponding tax deduction for compensation, in the amount recognized as taxable income by the participant. If a timely Section&nbsp;83(b) election is made, the participant will not recognize
any additional ordinary income on the termination of restrictions on restricted stock, and we will not be entitled to any additional tax deduction. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2"><I>Other Stock or Cash-Based Awards</I>.&nbsp;&nbsp;&nbsp;&nbsp;A 2019 Plan participant will not recognize taxable income and we will not be entitled to a tax deduction upon the grant of other stock or cash-based
awards until cash or shares are paid or distributed to the participant. At that time, any cash payments or the fair market value of shares that the participant receives will be taxable to the participant at ordinary income tax rates and we should be
entitled to a corresponding tax deduction for compensation expense. Payments in shares will be valued at the fair market value of the shares at the time of the payment, and upon the subsequent disposition of the shares, the participant will
recognize a short-term or long-term capital gain or loss in the amount of the difference between the sales price of the shares and the participant&#146;s tax basis in the shares. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Existing Equity Incentive Plan </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">On May&nbsp;6, 2019, our board of directors and our
stockholders approved the adoption of the Existing Incentive Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">A total of 2,231,739 shares of our common stock are reserved for
issuance under the Existing Incentive Plan. As of June&nbsp;30, 2019, 16,260 shares of our common stock were subject to outstanding restricted stock awards under the Existing Incentive Plan and 2,215,479 shares of our common stock remained available
for future issuance under the Existing Incentive Plan. Since June&nbsp;30, 2019, options to purchase a total of 1,400,528 shares of our common stock have been granted under the Existing Incentive Plan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">After the effective date of the 2019 Plan, no additional awards will be granted under the Existing Incentive Plan. However, the Existing Incentive
Plan will continue to govern the terms and conditions of the outstanding awards granted under it. Shares of our common stock subject to awards granted under the Existing Incentive Plan that expire, lapse or are terminated, exchanged for cash,
surrendered, repurchased or forfeited following the effective date of the Existing Incentive Plan will be available for issuance under the Existing Incentive Plan in accordance with its terms. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Administration</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors administers the Existing Incentive Plan, unless it delegates authority for
administration of the plan. Subject to the terms and conditions of the Existing Incentive Plan, the administrator has the authority to select the persons to whom awards are to be made, to determine the type or types of awards to be granted to each
person, determine the number of awards to grant, determine the number of shares to be subject to such awards, and the terms and conditions of such awards, and make all other determinations and decisions and to take all other
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">168 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
actions necessary or advisable for the administration of the Existing Incentive Plan. The plan administrator is also authorized to establish, adopt, amend or revise rules relating to
administration of the Existing Incentive Plan, subject to certain restrictions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Eligibility</I>.&nbsp;&nbsp;&nbsp;&nbsp;Awards under
the Existing Incentive Plan may be granted to individuals who are then our employees, consultants and members of our board of directors and our subsidiaries. Only employees may be granted ISOs. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Awards</I>.&nbsp;&nbsp;&nbsp;&nbsp;The Existing Incentive Plan provides that our administrator may grant or issue stock options (including NSOs
and ISOs), restricted stock, RSUs, other stock-based awards, or any combination thereof. The administrator considers each award grant subjectively, considering factors such as the individual performance of the recipient and the anticipated
contribution of the recipient to the attainment of our long-term goals. Each award is set forth in a separate agreement with the person receiving the award and indicates the type, terms and conditions of the award. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Corporate Transactions</I>.&nbsp;&nbsp;&nbsp;&nbsp;The plan administrator has broad discretion to equitably adjust the provisions of the
Existing Incentive Plan and the terms and conditions of existing and future awards, including with respect to aggregate number and type of shares subject to the Existing Incentive Plan and awards granted pursuant to the Existing Incentive Plan, to
prevent the dilution or enlargement of intended benefits and/or facilitate necessary or desirable changes in the event of certain transactions and events affecting our common stock, such as stock dividends, stock splits, mergers, acquisitions,
consolidations and other corporate transactions. The plan administrator may also provide for the acceleration, <FONT STYLE="white-space:nowrap">cash-out,</FONT> termination, assumption, substitution or conversion of awards in the event of a change
in control or certain other unusual or nonrecurring events or transactions. In addition, in the event of certain <FONT STYLE="white-space:nowrap">non-reciprocal</FONT> transactions with our stockholders, or an &#147;equity restructuring,&#148; the
plan administrator will make equitable adjustments to the Existing Incentive Plan and outstanding awards as it deems appropriate to reflect the equity restructuring. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">In the event of a change of control where the acquirer does not assume awards granted under the Existing Incentive Plan, awards issued under the Existing Incentive Plan held by persons who have not experienced a
termination of service will be subject to accelerated vesting such that 100% of the awards will become vested and exercisable or payable, as applicable, immediately prior to the change in control. Under the Existing Incentive Plan, a change of
control is generally defined as: (i)&nbsp;a merger or consolidation of our company with or into any other corporation or other entity or person; (ii)&nbsp;a sale, lease, exchange or other transfer in one transaction or a series of related
transactions of all or substantially all of our company&#146;s assets; or (iii)&nbsp;any other transaction, including the sale by us of new shares of our capital stock or a transfer of existing shares of our capital stock, the result of which is
that a third party that is not an affiliate of us or our stockholders (or a group of third parties not affiliated with us or our stockholders) immediately prior to such transaction acquires or holds capital stock representing a majority of our
outstanding voting power immediately following such transaction; provided that the following events shall not constitute a &#147;change in control&#148; under the Existing Incentive Plan: (a)&nbsp;a transaction (other than a sale of all or
substantially all of our assets) in which the holders of our voting securities immediately prior to the merger or consolidation hold, directly or indirectly, at least a majority of the voting securities in the successor corporation or its parent
immediately after the merger or consolidation; (b)&nbsp;a sale, lease, exchange or other transaction in one transaction or a series of related transactions of all or substantially all of our assets to an affiliate of ours; (c)&nbsp;an initial public
offering of any of our securities or any other transaction principally for bona fide equity financing purposes; (d)&nbsp;a reincorporation solely to change our jurisdiction; or (e)&nbsp;a transaction undertaken for the primary purpose of creating a
holding company that will be owned in substantially the same proportion by the persons who held our securities immediately before such transaction. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2"><I>Amendment and Termination of the Existing Incentive Plan</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors may terminate, amend or modify the Existing Incentive Plan. However, stockholder approval of any
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">169 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
amendment to the Existing Incentive Plan must be obtained to the extent necessary and desirable to comply with any applicable law, regulation or stock exchange rule, or for any amendment to the
Existing Incentive Plan that increases the number of shares available under the Existing Incentive Plan. If not terminated earlier by the compensation committee or the board of directors, the Existing Incentive Plan will terminate on May&nbsp;6,
2029. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Securities Laws and Federal Income Tax Consequences</I>.&nbsp;&nbsp;&nbsp;&nbsp;The Existing Incentive Plan is designed to
comply with applicable securities laws in the same manner as described above in the description of the 2019 Plan under the heading &#147;&#151;2019 Incentive Award Plan&#151;Securities Laws.&#148; The general federal tax consequences of awards under
the Existing Incentive Plan are the same as those described above in the description of the 2019 Plan under the heading &#147;&#151;2019 Incentive Award Plan&#151;Federal Income Tax Consequences.&#148; </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>2019 Employee Stock Purchase Plan </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our board of directors and our stockholders have approved the ESPP, which became effective in connection with this offering. The material terms of
the ESPP are summarized below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Shares Available; Administration.&nbsp;&nbsp;&nbsp;&nbsp;</I>A total of 270,000 shares of our common
stock are initially reserved for issuance under our ESPP. In addition, the number of shares available for issuance under the ESPP will be annually increased on January&nbsp;1 of each calendar year beginning in 2020 and ending in 2029, by an amount
equal to the lesser of: (i) 1% of the shares outstanding on the final day of the immediately preceding calendar year and (ii)&nbsp;such smaller number of shares as is determined by our board of directors. In no event will more than 10,000,000 shares
of our common stock be available for issuance under the ESPP. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our board of directors or its committee will have authority to interpret
the terms of the ESPP and determine eligibility of participants. We expect that the compensation committee will be the initial administrator of the ESPP. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2"><I>Eligibility.&nbsp;&nbsp;&nbsp;&nbsp;</I>Our employees are eligible to participate in the ESPP if they meet the eligibility requirements under the ESPP established from time to time by the plan administrator.
However, an employee may not be granted rights to purchase stock under our ESPP if such employee, immediately after the grant, would own (directly or through attribution) stock possessing 5% or more of the total combined voting power or value of all
classes of our common or other class of stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Grant of Rights.&nbsp;&nbsp;&nbsp;&nbsp;</I>The ESPP is intended to qualify under
Section&nbsp;423 of the Code and stock will be offered under the ESPP during offering periods. The length of the offering periods under the ESPP will be determined by the plan administrator and may be up to 27 months long. Employee payroll
deductions will be used to purchase shares on each purchase date during an offering period. The number of purchase periods within, and purchase dates during each offering period will be established by the plan administrator prior to the commencement
of each offering period. Offering periods under the ESPP will commence when determined by the plan administrator. The plan administrator may, in its discretion, modify the terms of future offering periods. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation, which includes a
participant&#146;s gross base compensation for services to us, including overtime payments and excluding sales commissions, incentive compensation, bonuses, expense reimbursements, fringe benefits and other special payments. The plan administrator
will establish a maximum number of shares that may be purchased by a participant during any offering period or purchase period, which, in the absence of a contrary designation, will be </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">170 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
100,000&nbsp;shares. In addition, no employee will be permitted to accrue the right to purchase stock under the ESPP at a rate in excess of $25,000 worth of shares during any calendar year during
which such a purchase right is outstanding (based on the fair market value per share of our common stock as of the first day of the offering period). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">On the first trading day of each offering period, each participant will automatically be granted an option to purchase shares of our common stock. The option will be exercised on the applicable purchase date(s)
during the offering period, to the extent of the payroll deductions accumulated during the applicable purchase period. The purchase price of the shares, in the absence of a contrary determination by the plan administrator, will be 85% of the lower
of the fair market value of our common stock on the first trading day of the offering period or on the applicable purchase date, which will be the final trading day of the applicable purchase period. Participants may voluntarily end their
participation in the ESPP at any time at least one week prior to the end of the applicable offering period (or such shorter or longer period specified by the plan administrator), and will be paid their accrued payroll deductions that have not yet
been used to purchase shares of common stock. Participation ends automatically upon a participant&#146;s termination of employment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">A
participant may not transfer rights granted under the ESPP other than by will, the laws of descent and distribution or as otherwise provided under the ESPP. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2"><I>Certain Transactions.&nbsp;&nbsp;&nbsp;&nbsp;</I>In the event of certain transactions or events affecting our common stock, such as any stock dividend or other distribution, change in control, reorganization,
merger, consolidation or other corporate transaction, the plan administrator will make equitable adjustments to the ESPP and outstanding rights. In addition, in the event of the foregoing transactions or events or certain significant transactions,
including a change in control, the plan administrator may provide for (i)&nbsp;either the replacement of outstanding rights with other rights or property or termination of outstanding rights in exchange for cash, (ii)&nbsp;the assumption or
substitution of outstanding rights by the successor or survivor corporation or parent or subsidiary thereof, if any, (iii)&nbsp;the adjustment in the number and type of shares of stock subject to outstanding rights, (iv)&nbsp;the use of
participants&#146; accumulated payroll deductions to purchase stock on a new purchase date prior to the next scheduled purchase date and termination of any rights under ongoing offering periods or (v)&nbsp;the termination of all outstanding rights.
Under the ESPP, a change in control has the same definition as given to such term in the Existing Incentive Plan. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Plan Amendment;
Termination.&nbsp;&nbsp;&nbsp;&nbsp;</I>The plan administrator may amend, suspend or terminate the ESPP at any time. However, stockholder approval of any amendment to the ESPP will be obtained for any amendment which increases the aggregate number
or changes the type of shares that may be sold pursuant to rights under the ESPP, changes the corporations or classes of corporations whose employees are eligible to participate in the ESPP or changes the ESPP in any manner that would cause the ESPP
to no longer be an employee stock purchase plan within the meaning of Section&nbsp;423(b) of the Code. The ESPP will remain in effect until terminated by our board of directors. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Securities Laws.&nbsp;&nbsp;&nbsp;&nbsp;</I>The ESPP has been designed to comply with various securities laws in the same manner as described
above in the description of the 2019 Plan under the heading &#147;&#151;2019 Incentive Award Plan&#151;Securities Laws.&#148;. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Federal Income Taxes.&nbsp;&nbsp;&nbsp;&nbsp;</I>The material federal income tax consequences of the ESPP under current federal income tax law
are summarized in the following discussion, which deals with the general tax principles applicable to the ESPP. The following discussion is based upon laws, regulations, rulings and decisions now in effect, all of which are subject to change.
Foreign, state and local tax laws, and employment, estate and gift tax considerations are not discussed due to the fact that they may vary depending on individual circumstances and from locality to locality. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">171 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The ESPP, and the right of participants to make purchases thereunder, is intended to qualify
under the provisions of Section&nbsp;423 of the Code. Under the applicable Code provisions, no income will be taxable to a participant until the sale or other disposition of the shares purchased under the ESPP. This means that an eligible employee
will not recognize taxable income on the date the employee is granted an option under the ESPP (i.e., the first day of the offering period). In addition, the employee will not recognize taxable income upon the purchase of shares. Upon such sale or
disposition, the participant will generally be subject to tax in an amount that depends upon the length of time such shares are held by the participant prior to disposing of them. If the shares are sold or disposed of more than two years from the
first day of the offering period during which the shares were purchased and more than one year from the date of purchase, or if the participant dies while holding the shares, the participant (or his or her estate) will recognize ordinary income
measured as the lesser of: (i)&nbsp;the excess of the fair market value of the shares at the time of such sale or disposition over the purchase price; or (ii)&nbsp;an amount equal to 15% of the fair market value of the shares as of the first day of
the offering period. Any additional gain will be treated as long-term capital gain. If the shares are held for the holding periods described above but are sold for a price that is less than the purchase price, there is no ordinary income and the
participating employee has a long-term capital loss for the difference between the sale price and the purchase price. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If the shares are
sold or otherwise disposed of before the expiration of the holding periods described above, the participant will recognize ordinary income generally measured as the excess of the fair market value of the shares on the date the shares are purchased
over the purchase price and we will be entitled to a tax deduction for compensation expense in the amount of ordinary income recognized by the employee. Any additional gain or loss on such sale or disposition will be long-term or short-term capital
gain or loss, depending on how long the shares were held following the date they were purchased by the participant prior to disposing of them. If the shares are sold or otherwise disposed of before the expiration of the holding periods described
above but are sold for a price that is less than the purchase price, the participant will recognize ordinary income equal to the excess of the fair market value of the shares on the date of purchase over the purchase price (and we will be entitled
to a corresponding deduction), but the participant generally will be able to report a capital loss equal to the difference between the sales price of the shares and the fair market value of the shares on the date of purchase. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Director Compensation </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Historically, we have
not paid cash or stock-based compensation to directors for their service on our board of directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">On January&nbsp;23, 2018, YamadaCo
IIA issued and sold to Dr.&nbsp;Yamada, 1,686,704 shares of common stock of YamadaCo IIA for a per share purchase price of $0.0002958. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">On March&nbsp;13, 2019, we entered into a stock restriction agreement with Dr.&nbsp;Yamada whereby Dr.&nbsp;Yamada&#146;s previously-acquired
1,686,704 shares of our common stock were subjected to new vesting conditions, such that 421,676 shares were deemed vested as of March&nbsp;13, 2019 and the remaining 1,265,028 shares were converted into unvested shares of restricted stock that vest
in equal monthly installments over the 48 months thereafter ending on March&nbsp;13, 2023, subject, in each case, to continued employment or status as a service provider. Any unvested shares held by Dr.&nbsp;Yamada upon a termination of employment
or service (after giving effect to any accelerated vesting provisions described further below), will be subject to repurchase by us at the original purchase price. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Under Dr.&nbsp;Yamada&#146;s stock restriction agreement, 100% of any unvested shares will automatically accelerate and vest upon (i)&nbsp;a termination of service by us without cause or by him for good reason
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">172 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
following a change in control, or (ii)&nbsp;the refusal by us to enter into a consulting agreement with him in connection with his resignation, subject to his continued employment or service
through the date of such event. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The defined terms &#147;change in control,&#148; &#147;cause&#148; and &#147;good reason&#148; have the
same meanings in Dr. Yamada&#146;s stock restriction agreement as given to such terms in Mr.&nbsp;Socks&#146; stock restriction agreement and described above under &#147;Executive and Director Compensation&#151;Equity-Based Incentive Awards.&#148;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">On May&nbsp;7, 2019, we entered into an offer letter with Dr.&nbsp;Yamada, our Chairman of the board of directors. Pursuant to
Dr.&nbsp;Yamada&#146;s offer letter, Dr.&nbsp;Yamada will be paid an annual cash fee of $100,000, paid quarterly, for his services as Chairman. Additionally, as a member of our board of directors, we will reimburse Dr.&nbsp;Yamada for reasonable
travel and other expenses to attend board meetings and other board-related functions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Effective August&nbsp;29, 2019, we appointed
Terrie Curran to our board of directors. In connection with Ms. Curran&#146;s appointment to our board of directors, we granted to her stock options to purchase 867,200 shares of our common stock under the Existing Incentive Plan. For a description
of the stock options granted to Ms. Curran, see &#147;&#151;Employment Letter with Terrie Curran&#148; above. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Effective
September&nbsp;26, 2019, we entered into an offer letter with each of Heidi Kunz and Michael Cola in connection with their appointment to our board of directors. Pursuant to each offer letter, Ms.&nbsp;Kunz and Mr.&nbsp;Cola will be paid an annual
cash retainer of $40,000, paid quarterly, which retainer will commence immediately. Additionally, as a member of our board of directors, we will reimburse Ms.&nbsp;Kunz and Mr.&nbsp;Cola for reasonable travel and other expenses to attend board
meetings and other board-related functions. Pursuant to their offer letters, we also granted each of Ms.&nbsp;Kunz and Mr.&nbsp;Cola stock options to purchase 43,360 shares of our common stock. The stock options have a
<FONT STYLE="white-space:nowrap">ten-year</FONT> term and an exercise price of $13.04 per share, which our board of directors determined was equal to the fair market value per share of our common stock on the date of grant. The options will vest
over a three-year period, with <FONT STYLE="white-space:nowrap">one-third</FONT> vesting on the first anniversary of the date of grant and the remainder vesting quarterly over the 24 months thereafter, subject to continued service with us on each
vesting date. Such stock options will accelerate in full upon a change in control of our company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In connection with this offering, our
board of directors and our stockholders have approved a <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation program. The material terms of the <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation program
are summarized below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation program will provide for annual
retainer fees and/or long-term equity awards for our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. Each <FONT STYLE="white-space:nowrap">non-employee</FONT> director will receive an annual retainer of $40,000. <FONT
STYLE="white-space:nowrap">Non-employee</FONT> directors serving as the chairs of the audit, compensation and nominating and corporate governance committees will receive additional annual retainers of $20,000, $15,000 and $10,000, respectively. <FONT
STYLE="white-space:nowrap">Non-employee</FONT> directors serving as members of the audit, compensation and nominating and corporate governance committees will receive additional annual retainers of $10,000, $7,500 and $5,000, respectively.
Additionally, the non-executive chairman of the board will receive an additional annual retainer of $40,000. The <FONT STYLE="white-space:nowrap">non-employee</FONT> directors will also receive initial grants of options to purchase
20,000&nbsp;shares of our common stock upon election to the board of directors, one-third of which will vest on the first anniversary of the grant date and the remainder of which will vest in quarterly installments over the following 24&nbsp;months,
and thereafter annual grants of options to purchase 10,000&nbsp;shares of our common stock, vesting on the first to occur of (i)&nbsp;the first anniversary of the grant date or (ii)&nbsp;the next occurring annual meeting of our stockholders, in each
case, subject to the non-employee director continuing in service on our board of directors through such vesting date. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">173 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Compensation under our <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation
program will be subject to the annual limits on <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation set forth in the 2019 Plan, as described above. Our board of directors or its authorized committee may modify the <FONT
STYLE="white-space:nowrap">non-employee</FONT> director compensation program from time to time in the exercise of its business judgment, taking into account such factors, circumstances and considerations as it shall deem relevant from time to time,
subject to the annual limit on <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation set forth in the 2019 Plan. As provided in the 2019 Plan, our board of directors or its authorized committee may make exceptions to this limit
for individual <FONT STYLE="white-space:nowrap">non-employee</FONT> directors in extraordinary circumstances, as the board of directors or its authorized committee may determine in its discretion, provided that the
<FONT STYLE="white-space:nowrap">non-employee</FONT> director receiving such additional compensation may not participate in the decision to award such compensation or in other compensation decisions involving
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Limitations of Liability and Indemnification Matters </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our amended and restated certificate of incorporation and our amended and restated bylaws provide that we will indemnify our directors and officers
to the fullest extent permitted by the Delaware General Corporation Law, which prohibits our amended and restated certificate of incorporation from limiting the liability of our directors for the following: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">any breach of the director&#146;s duty of loyalty to us or our stockholders; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">unlawful payment of dividends or unlawful stock repurchases or redemptions; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">any transaction from which the director derived an improper personal benefit. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our amended and restated certificate of incorporation and our amended and restated bylaws also provide that if Delaware law is amended to authorize
corporate action further eliminating or limiting the personal liability of a director, then the liability of our directors will be eliminated or limited to the fullest extent permitted by Delaware law, as so amended. This limitation of liability
does not apply to liabilities arising under the federal securities laws and does not affect the availability of equitable remedies such as injunctive relief or rescission. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Our amended and restated certificate of incorporation and our amended and restated bylaws also provide that we shall have the power to indemnify our employees and agents to the fullest extent permitted by law. Our
amended and restated bylaws also permit us to secure insurance on behalf of any officer, director, employee or other agent for any liability arising out of his or her actions in this capacity, regardless of whether our amended and restated bylaws
would permit indemnification. We have obtained directors&#146; and officers&#146; liability insurance. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have entered into separate
indemnification agreements with our directors and executive officers, in addition to indemnification provided for in our amended and restated certificate of incorporation and amended and restated bylaws. These agreements, among other things, provide
for indemnification of our directors and executive officers for expenses, judgments, fines and settlement amounts incurred by this person in any action or proceeding arising out of this person&#146;s services as a director or executive officer or at
our request. We believe that these provisions in our amended and restated certificate of incorporation and amended and restated bylaws and indemnification agreements are necessary to attract and retain qualified persons as directors and executive
officers. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The above description of the indemnification provisions of our amended and restated certificate of incorporation, our amended
and restated bylaws and our indemnification agreements is not complete and is qualified in its entirety by reference to these documents, each of which is filed as an exhibit to the registration statement of which this prospectus is a part.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">174 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The limitation of liability and indemnification provisions in our amended and restated
certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors
and officers, even though an action, if successful, might benefit us and our stockholders. A stockholder&#146;s investment may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these
indemnification provisions. Insofar as indemnification for liabilities under the Securities Act may be permitted to directors, officers or persons controlling us pursuant to the foregoing provisions, we have been informed that in the opinion of the
SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. There is no pending litigation or proceeding naming any of our directors or officers as to which indemnification is being sought,
nor are we aware of any pending or threatened litigation that may result in claims for indemnification by any director or officer. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">175 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_14"></A>CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The following includes a summary of transactions since our inception to which we have been a party in which the amount involved exceeded or will
exceed the lesser of $120,000 and one percent of the average of our total assets at year-end for the last two completed fiscal years, and in which any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of
our capital stock or any member of the immediate family of any of the foregoing persons had or will have a direct or indirect material interest, other than equity and other compensation, termination, change in control and other arrangements, which
are described under &#147;Executive and Director Compensation.&#148; The transactions below also include transactions of YamadaCo IIA, Inc. prior to the Merger. We also describe below certain other transactions with our directors, executive officers
and stockholders. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Convertible Promissory Note Financings </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2"><I>Prior Convertible Promissory Note Financings with Frazier Life Sciences IX, L.P. </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In January
2018, YamadaCo IIA, Inc. entered into a convertible promissory note purchase agreement with Frazier Life Sciences IX, L.P., or FLS IX, pursuant to which from January 2018 to December 2018 YamadaCo IIA issued and sold to FLS IX three convertible
promissory notes, or the YamadaCo Notes, in the aggregate principal amount of $1.5&nbsp;million. The YamadaCo Notes accrued interest at the then applicable federal rate (1.68%, 2.38% and 2.55%, respectively) per annum, and were due and payable upon
demand by FLS IX nine months from the date of issuance, subject to earlier conversion or repayment in the event YamadaCo IIA completed an equity financing or a change of control. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In January 2018, we entered into a convertible promissory note purchase agreement with FLS IX, pursuant to which from January 2018 to April 2019,
we issued and sold to FLS IX three convertible promissory notes, or the Phathom Notes, in the aggregate principal amount of $0.9&nbsp;million. The Phathom Notes accrued interest at the then applicable federal rate (1.68%, 2.42% and 2.52%,
respectively) per annum, and were due and payable upon demand by FLS IX nine months from the date of issuance, subject to earlier conversion or repayment in the event we completed an equity financing or a change of control. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The YamadaCo Notes and Phathom Notes, in the aggregate amount of $2.4&nbsp;million, including accrued interest thereon, were cancelled and
exchanged for May 2019 Notes issued in the May 2019 convertible note financing described below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The general partner of FLS IX is FHMLS
IX, L.P., and the general partner of FHMLS IX, L.P. is FHMLS IX, L.L.C. James Topper, M.D., Ph.D., a member of our board of directors, is one of the managing members of FHMLS IX, L.L.C. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">176 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>May 2019 Convertible Promissory Note Financing </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In May 2019, we entered into a convertible promissory note purchase agreement with certain investors, or the 2019 Note Purchase Agreement, pursuant
to which in May 2019 we issued and sold to such investors convertible promissory notes, or the May 2019 Notes, in the aggregate principal amount of approximately $90.3&nbsp;million. The May 2019 Notes accrue interest at a rate of 6% per annum and
become payable upon demand of the holders of at least 60% of the outstanding principal amount of the May 2019 Notes one year from the date of issuance, subject to earlier conversion or repayment in the event we complete an equity financing or a
change of control. We have not paid any interest on the May 2019 Notes to date. The participants in this May 2019 Note financing included the following 5% or greater stockholders and or entities affiliated with members of our board of directors.
</FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Participants</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Aggregate&nbsp;Principal<BR>Amount&nbsp;of&nbsp;May&nbsp;2019<BR>Notes</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Frazier Life Sciences IX, L.P.</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">20,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Entities affiliated with Medicxi Growth</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">15,000,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">Consists of convertible promissory notes held by FLS IX, or the Frazier May 2019 Notes. Additional details regarding FLS&nbsp;IX and its equity holdings
are provided under the section titled &#147;Principal Stockholders.&#148; James Topper, M.D., Ph.D., a member of our board of directors, is one of the managing members of FHMLS IX, L.L.C, which is an affiliate of FLS IX.
</FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">Consists of convertible promissory notes, or the Medicxi Notes, held by Medicxi Growth I LP and Medicxi Growth
<FONT STYLE="white-space:nowrap">Co-Invest</FONT> I LP, collectively Medicxi Growth. Jonathan Edwards, Ph.D., a member of our board of directors, is a Partner of Medicxi, an affiliate of Medicxi Growth. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The outstanding principal and unpaid accrued interested due on the Frazier May 2019 Notes and the Medicxi Notes will automatically convert into an
aggregate of 1,353,640&nbsp;shares and 1,015,230&nbsp;shares of our common stock, respectively, immediately prior to the closing of this offering, each based on the initial public offering price of $19.00&nbsp;per share and assuming the conversion
occurs on October&nbsp;29, 2019. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The May 2019 Notes are subordinated to borrowings under our Loan Agreement with Silicon Valley Bank
and WestRiver Innovation Lending Fund VIII, L.P. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Investor Rights Under the 2019 Note Purchase Agreement </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Registration Rights </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The 2019 Note Purchase
Agreement provides FLS IX, Takeda, and all holders of the May 2019 Notes with specified registration rights relating to the registration of shares of common stock held by such entities, including shares of our common stock issuable upon conversion
of the May 2019 Notes and shares of our common stock issuable upon the exercise or conversion of any securities exercisable or convertible into shares of our common stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The registration rights terminate upon the earlier of: (i)&nbsp;five years after the closing of this offering or (ii)&nbsp;with respect to a particular holder, such time at which such holder can sell all shares
held by it in compliance with Rule 144 under the Securities Act. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">See the section titled &#147;Description of Capital
Stock&#151;Registration Rights&#148; for more information regarding these registration rights. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Voting Rights </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The 2019 Note Purchase Agreement provides for rights relating to the election of members to serve on our board of directors. Pursuant to the 2019
Note Purchase Agreement, as amended in </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">177 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
September 2019, the following directors were each elected to serve as members on our board of directors and, as of the date of this prospectus, continue to so serve: David Socks, Tadataka Yamada,
M.D., Michael F. Cola, Terrie Curran, Jonathan Edwards, Ph.D., Heidi Kunz, Chris Slavinsky, and James Topper, M.D., Ph.D. Mr.&nbsp;Socks, our President and Chief Executive Officer, was initially selected to serve on our board of directors in his
role as Chief Executive Officer. Dr.&nbsp;Yamada was initially selected to serve on our board of directors as a representative of holders of our common stock, as designated by a majority of our common stockholders. Dr.&nbsp;Topper was initially
selected to serve on our board of directors as a representative of holders of our common stock, as designated by FLS IX. Dr.&nbsp;Edwards was initially selected to serve on our board of directors as a representative of the holders of the May 2019
Notes. Mr.&nbsp;Cola, Ms.&nbsp;Curran, Ms.&nbsp;Kunz, and Mr.&nbsp;Slavinsky were initially selected to serve on our board of directors as representatives of holders of our common stock, with Mr.&nbsp;Slavinsky being designated by Takeda.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The 2019 Note Purchase Agreement provides that Takeda may designate a member to serve on our board of directors as a representative of
holders of our common stock, provided that such right does not apply at any time the board of directors consists of fewer than five individuals that are not affiliated with Takeda. In connection with our appointment of Ms. Curran to our board of
directors in August 2019, at which time we had five directors serving on our board, we also appointed Mr.&nbsp;Slavinsky to our board pursuant this right. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The voting rights provisions of the 2019 Note Purchase Agreement will terminate upon the closing of this offering, and members previously elected to our board of directors pursuant to this agreement will continue
to serve as directors until they resign, are removed or their successors are duly elected by holders of our common stock. The composition of our board of directors after this offering is described in more detail under &#147;Management&#151;Board
Composition and Election of Directors.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Other Rights </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The 2019 Note Purchase Agreement provides certain holders of our May 2019 Notes with various additional rights including, among others, information rights, <FONT STYLE="white-space:nowrap">pre-emptive</FONT>
rights, drag along rights, rights of first refusal, <FONT STYLE="white-space:nowrap">co-sale</FONT> rights, and certain additional covenants made by us. Except as set forth above, all rights under the 2019 Note Purchase Agreement will terminate upon
the closing of this offering. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Takeda Agreements </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>License Agreement and Clinical Manufacturing and Supply Agreement </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">On May&nbsp;7, 2019, we and Takeda, one of our 5% stockholders, entered into the Takeda License and a clinical manufacturing and supply agreement. Such agreements are described in &#147;Business&#151;Intellectual
Property&#151;License Agreement with Takeda Pharmaceutical Company Limited.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In connection with the Takeda License, we
(i)&nbsp;entered into a Stock Issuance Agreement with Takeda, pursuant to which we issued Takeda 1,084,000 shares of our common stock, (ii)&nbsp;issued the Takeda Warrant to purchase 7,588,000 shares of common stock at an exercise price of
$0.00004613 per share and (iii)&nbsp;granted the Takeda Warrant Right, pursuant to which Takeda has a right to receive an additional common stock warrant upon the closing of this offering if Takeda&#146;s fully-diluted ownership represents less than
a specified percentage of our fully-diluted capitalization, including shares issuable upon conversion of outstanding convertible promissory notes, calculated immediately prior to the closing of this offering, each as partial consideration under the
Takeda License. The Takeda Warrant expires ten years from its date of issuance, subject to its earlier termination upon the completion of certain mergers, acquisitions and similar transactions. The Takeda Warrant Right will expire upon the
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">178 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
closing of this offering based on the initial public offering price of $19.00 per share. See the section titled &#147;Description of Capital Stock&#151;Warrants&#148; for more information
regarding the Takeda Warrant and the Takeda Warrant Right. In connection with the Takeda License, we provided Takeda with various investor rights, including <FONT STYLE="white-space:nowrap">pre-emptive</FONT> rights, drag along rights, voting rights
and certain registration rights. See &#147;&#151;Investor Rights Under the 2019 Note Purchase Agreement&#148; above for more information regarding these voting rights and registration rights. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>Merger </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Initial Founder Equity Issuances </I></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">On January&nbsp;23, 2018, YamadaCo IIA issued and sold to Tadataka Yamada, M.D., our Chairman, 1,686,704 shares of YamadaCo IIA common stock at a
purchase price of $0.0002958 per share, after giving effect to the merger described below. On February&nbsp;14, 2018, YamadaCo IIA issued and sold to FLS IX 1,693,463 shares of YamadaCo IIA common stock at a purchase price of $0.0002958 per share,
after giving effect to the merger described below. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">On February&nbsp;13, 2018, we issued and sold to David Socks, our President and
Chief Executive Officer and a member of our board of directors, 1,686,704&nbsp;shares of our common stock at a purchase price of $0.0002958 per share. On February&nbsp;14, 2018, we issued and sold to FLS IX 1,693,463 shares of our common stock at a
purchase price of $0.0002958 per share. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">On March&nbsp;13, 2019, we entered into stock restriction agreements with each of
Mr.&nbsp;Socks and Dr.&nbsp;Yamada providing for vesting and a company right to repurchase the unvested shares held by Mr.&nbsp;Socks and Dr.&nbsp;Yamada upon the occurrence of certain events. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">For more information regarding these stock issuances to Dr.&nbsp;Yamada and Mr.&nbsp;Socks, see the section in this prospectus entitled
&#147;Executive and Director Compensation&#151;Equity-Based Incentive Awards&#148; and &#147;Executive and Director Compensation&#151;Narrative Disclosure to Summary Compensation Table&#151;Director Compensation.&#148; </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Merger Agreement </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">On March&nbsp;13, 2019,
YamadaCo IIA merged with and into our company, with our company surviving the merger, or the Merger. Immediately prior to the Merger, we effected a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1,559.1183-for-1</FONT></FONT>
forward stock split for each outstanding share of our common stock. Effective upon the closing of the Merger, each issued and outstanding share of YamadaCo IIA was converted into 1,559.1183 shares of our common stock. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Additional Equity Issuances </I></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Following the
Merger, on March&nbsp;13, 2019, we issued and sold to FLS IX 1,491,072 shares of our common stock at a purchase price of $0.0002958 per share. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Additional Executive Officer Equity Issuances </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Following the Merger, on March&nbsp;13, 2019, we issued and sold to each of Azmi Nabulsi, M.D., M.P.H., our Chief Operating Officer, and Aditya
Kohli, Ph.D., our Chief Business Officer, 867,200 and 843,352 shares of our common stock, respectively, at a purchase price of $0.0002958 per share. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">179 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Shared Operating Expenses </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Frazier is a principal stockholder of our company and is represented on our board of directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">For
the year ended December&nbsp;31, 2018 and the six months ended June&nbsp;30, 2019, we conducted our operations within office space controlled by Frazier and Frazier allocated a portion of the costs associated with this office to us. In addition,
Frazier paid for various goods and services, such as employee wages, insurance and expense reimbursements and various administrative services associated with our operations and charged us for those expenses. For the year ended December&nbsp;31, 2018
and the six months ended June&nbsp;30, 2018 and 2019, we incurred $0.3&nbsp;million, $0.1&nbsp;million and $0.1&nbsp;million, respectively, of shared operating expenses. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>Employment Arrangements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have entered into employment letter agreements with our executive
officers. For more information regarding these employment agreements, see the section in this prospectus entitled &#147;Executive and Director Compensation&#151;Employment Letters with our Executive Officers.&#148; </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Director and Officer Indemnification </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We
have entered into indemnification agreements with each of our directors and executive officers. These agreements, among other things, require us or will require us to indemnify each director (and in certain cases their related venture capital funds)
and executive officer to the fullest extent permitted by Delaware law, including indemnification of expenses such as attorneys&#146; fees, judgments, fines and settlement amounts incurred by the director or executive officer in any action or
proceeding, including any action or proceeding by or in right of us, arising out of the person&#146;s services as a director or executive officer. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Our amended and restated certificate of incorporation and our amended and restated bylaws provide that we will indemnify each of our directors and officers to the fullest extent permitted by the Delaware General
Corporation Law. Further, we have purchased a policy of directors&#146; and officers&#146; liability insurance that insures our directors and officers against the cost of defense, settlement or payment of a judgment under certain circumstances. For
further information, see &#147;Executive and Director Compensation&#151;Limitations of Liability and Indemnification Matters.&#148; </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Directed Share
Program </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">At our request, the underwriters have reserved up to 3.0% of the shares of common stock to be offered by this prospectus for
sale, at the initial public offering price, to certain of our directors, officers, employees, and their friends and family members through a directed share program. We do not currently know whether any of our directors, officers, or their
affiliates, or holders of more than 5% of our common stock will purchase more than $120,000 in value of such reserved shares of our common stock in this offering. See &#147;Underwriting&#151;Directed Share Program.&#148; </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Policies and Procedures for Related Person Transactions </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Our board of directors has adopted a written related person transaction policy, to be effective upon the closing of this offering, setting forth the policies and procedures for the review and approval or
ratification of related-person transactions. This policy will cover, with certain exceptions set forth in Item 404 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act, any transaction, arrangement or relationship, or
any series of similar transactions, arrangements or relationships in which we were or are to be a participant, where the amount involved exceeds $120,000, and a related person had or will have a
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">180 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
direct or indirect material interest, including, without limitation, purchases of goods or services by or from the related person or entities in which the related person has a material interest,
indebtedness, guarantees of indebtedness and employment by us of a related person. In reviewing and approving any such transactions, our audit committee is tasked to consider all relevant facts and circumstances, including, but not limited to,
whether the transaction is on terms comparable to those that could be obtained in an arm&#146;s length transaction and the extent of the related person&#146;s interest in the transaction. All of the transactions described in this section occurred
prior to the adoption of this policy. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">181 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_15"></A>PRINCIPAL STOCKHOLDERS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The following table sets forth information with respect to the beneficial ownership of our common stock as of September&nbsp;30, 2019, and as
adjusted to reflect the sale of shares of common stock in this offering, by: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">our named executive officer; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">each of our directors; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">all of our executive officers and directors as a group; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">each person<B> </B>or group of affiliated persons known by us to beneficially own more than 5% of our common stock. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The number of shares beneficially owned by each stockholder is determined under rules issued by the SEC. Under these rules, beneficial ownership
includes any shares as to which a person has sole or shared voting power or investment power. Applicable percentage ownership prior to this offering is based on 11,876,518 shares of common stock outstanding on September&nbsp;30, 2019, which includes
4,455,525&nbsp;shares subject to forfeiture or a right of repurchase. Applicable percentage ownership after this offering is based on the sale of 9,563,157 shares of common stock in this offering and gives effect to the automatic conversion of the
May 2019 Notes into an aggregate of 6,107,918 shares of our common stock immediately prior to the closing of this offering (based on the initial public offering price of $19.00 per share and assuming the conversion occurs on October 29, 2019). In
computing the number of shares beneficially owned by a person and the percentage ownership of that person, shares of common stock subject to options, warrants or other rights held by such person that are currently exercisable or will become
exercisable within 60 days of September&nbsp;30, 2019 are considered outstanding, although these shares are not considered outstanding for purposes of computing the percentage ownership of any other person. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Unless otherwise indicated, the address of each beneficial owner listed below is c/o Phathom Pharmaceuticals, Inc., 2150 E. Lake Cook Road, Suite
800, Buffalo Grove, Illinois 60089. We believe, based on information provided to us, that each of the stockholders listed below has sole voting and investment power with respect to the shares beneficially owned by the stockholder unless noted
otherwise, subject to community property laws where applicable. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">182 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Beneficial&nbsp;Ownership<BR>Prior to this Offering</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Beneficial&nbsp;Ownership<BR>After this Offering</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Name of Beneficial Owner</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Percent</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Number</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Percent</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>5% or Greater Stockholders</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Takeda Pharmaceutical Company Limited</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(1)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,084,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">9.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">8,672,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">24.7</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Frazier Life Sciences IX, L.P.</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">4,877,998</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">41.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6,231,638</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">22.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Executive Officers and Directors</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">David
Socks</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(3)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,686,704</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">14.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,686,704</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Tadataka Yamada,
M.D.</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(4)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,686,704</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">14.2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,686,704</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Michael F. Cola</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Terrie Curran</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Azmi Nabulsi, M.D., M.P.H.</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(5)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">867,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">7.3</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">867,200</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">3.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Aditya Kohli,
Ph.D.</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(6)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">843,352</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">7.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">843,352</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">3.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">James Topper, M.D.,
Ph.D.</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(2)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">4,877,998</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">41.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6,231,638</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">22.6</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Jonathan Edwards, Ph.D</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Heidi Kunz</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Chris Slavinsky</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#151;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">*</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">All executive officers and directors as a group (10&nbsp;persons)</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">(7)</SUP></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">9,961,958</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">83.9</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">11,315,598</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">41.1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">%&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="line-height:8px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">*</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">Less than 1%. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(1)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">The number of shares beneficially owned before the offering does not include 7,588,000 shares of common stock issuable upon exercise of the Takeda Warrant, which
becomes exerciseable upon the closing of this offering. The number of shares beneficially owned after the offering includes 7,588,000&nbsp;shares of common stock issuable upon the exercise of the Takeda Warrant. The address for Takeda Pharmaceutical
Company Limited is <FONT STYLE="white-space:nowrap">1-1,</FONT> <FONT STYLE="white-space:nowrap">Doshomachi&nbsp;4-chome,</FONT> <FONT STYLE="white-space:nowrap">Chuo-ku,</FONT> Osaka <FONT STYLE="white-space:nowrap">540-8645,</FONT> Japan.
</FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(2)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">The shares are held directly by Frazier Life Sciences IX, L.P., or FLS IX. The general partner of FLS IX is FHMLS IX, L.P., and the general partner of FHMLS IX,
L.P. is FHMLS IX, L.L.C. James Topper, M.D., Ph.D., and Patrick Heron are the sole managing members of FHMLS IX, L.L.C. and share voting and investment power of the securities held by FLS IX. Dr.&nbsp;Topper and Mr.&nbsp;Heron disclaim beneficial
ownership of such securities except to the extent of their pecuniary interest therein. The number of shares beneficially owned after the offering includes 1,353,640 shares of common stock issuable upon the conversion of May 2019 Notes in the
aggregate principal amount of $20,000,000 plus accrued interest held by Frazier Life Sciences IX, L.P. immediately prior to the closing of this offering (based on the initial public offering price of $19.00&nbsp;per share and assuming the conversion
occurs on October 29, 2019). The address for FLS IX is 601 Union Street, Suite 3200, Seattle, WA 98101. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(3)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">Consists of 1,686,704 shares of common stock held by the David A. Socks 2013 Revocable Trust, 1,106,900 of which were subject to a right of repurchase
by us as of September&nbsp;30, 2019. David Socks is a trustee of the David A. Socks 2013 Revocable Trust and in such capacity has the sole power to vote and dispose of such shares. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(4)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">Consists of 1,686,704 shares of common stock held by Dr.&nbsp;Yamada, 1,106,900 of which were subject to a right of repurchase by us as of
September&nbsp;30, 2019. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(5)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">Consists of 867,200 shares of common stock held by Dr.&nbsp;Nabulsi, all of which were subject to a right of repurchase by us as of September&nbsp;30,
2019, </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(6)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">Consists of 843,352 shares of common stock held by Dr.&nbsp;Kohli, 553,450 of which were subject to a right of repurchase by us as of September&nbsp;30,
2019. </FONT></P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">(7)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="1">Consists of the shares held by the executive officers and directors described in footnotes 2 through 6 above. </FONT></P></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">183 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_16"></A>DESCRIPTION OF CAPITAL STOCK </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>General </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The following description
summarizes some of the terms of our amended and restated certificate of incorporation and amended and restated bylaws and of the Delaware General Corporation Law. Because it is only a summary, it does not contain all the information that may be
important to you. For a complete description you should refer to our amended and restated certificate of incorporation and amended and restated bylaws, copies of which have been filed as exhibits to the registration statement of which the prospectus
is a part. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Following the closing of this offering, our authorized capital stock will consist of 400,000,000&nbsp;shares of common
stock, $0.0001 par value per share, and 40,000,000&nbsp;shares of preferred stock, $0.0001 par value per share. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Common Stock </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As of June&nbsp;30, 2019, there were 11,876,518 shares of our common stock outstanding, including 4,657,250 shares of restricted common stock which
are subject to forfeiture or our right of repurchase as of June&nbsp;30, 2019, and held of record by 20 stockholders. Based on the number of shares of common stock outstanding as of June&nbsp;30, 2019, and assuming (i)&nbsp;the automatic conversion
of the May 2019 Notes into an aggregate of 6,107,918 shares of our common stock immediately prior to the closing of this offering (based on the initial public offering price of $19.00 per share and assuming the conversion occurs on October 29, 2019)
and (ii)&nbsp;the issuance by us of 9,563,157 shares of common stock in this offering, there will be 27,547,593 shares of common stock outstanding upon the closing of this offering. Holders of our common stock are entitled to one vote for each share
held on all matters submitted to a vote of stockholders, including the election of directors, and do not have cumulative voting rights. Accordingly, the holders of a majority of the outstanding shares of common stock entitled to vote in any election
of directors can elect all of the directors standing for election, if they so choose, other than any directors that holders of any preferred stock we may issue may be entitled to elect. Subject to the supermajority votes for some matters, other
matters shall be decided by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matter. Our amended and restated certificate of incorporation and
amended and restated bylaws also provide that our directors may be removed only for cause and only by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of
capital stock entitled to vote thereon. In addition, the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of capital stock entitled to vote thereon is required
to amend or repeal, or to adopt any provision inconsistent with, several of the provisions of our amended and restated certificate of incorporation. See below under &#147;&#151;Anti-Takeover Effects of Delaware Law and Our Certificate of
Incorporation and Bylaws&#151;Amendment of Charter Provisions.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Subject to preferences that may be applicable to any then
outstanding preferred stock, holders of common stock are entitled to receive ratably those dividends, if any, as may be declared by the board of directors out of legally available funds. In the event of our liquidation, dissolution or winding up,
the holders of common stock will be entitled to share ratably in the assets legally available for distribution to stockholders after the payment of or provision for all of our debts and other liabilities, subject to the prior rights of any preferred
stock then outstanding. Holders of common stock have no preemptive or conversion rights or other subscription rights and there are no redemption or sinking funds provisions applicable to the common stock. All outstanding shares of common stock are,
and the common stock to be outstanding upon the closing of this offering will be, duly authorized, validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are subject to and
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">184 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Preferred Stock </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As of the date of this
prospectus, we do not have shares of preferred stock authorized or outstanding. Under the terms of our amended and restated certificate of incorporation, which became effective immediately prior to the closing of this offering, our board of
directors has the authority, without further action by our stockholders, to issue up to 40,000,000&nbsp;shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series, to fix
the dividend, voting and other rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon, and to increase or decrease the number of shares of any such series, but not
below the number of shares of such series then outstanding. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our board of directors may authorize the issuance of preferred stock with
voting or conversion rights that could adversely affect the voting power or other rights of the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate
purposes, could, among other things, have the effect of delaying, deterring or preventing a change in our control and may adversely affect the market price of the common stock and the voting and other rights of the holders of common stock. We have
no current plans to issue any shares of preferred stock. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Warrants </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">In May 2019, in connection with the Takeda License, we issued the Takeda Warrant to purchase 7,588,000 shares of our common stock with an exercise price of $0.00004613 per share. The Takeda Warrant contains a net
exercise provision under which Takeda may, in lieu of payment of the exercise price in cash, surrender the warrant and receive a net amount of shares of our common stock based on the fair market value of our common stock at the time of the net
exercise of the warrant after deduction of the aggregate exercise price. The Takeda Warrant expires ten years from its date of issuance, subject to its earlier termination upon the completion of certain mergers, acquisitions and similar
transactions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In May 2019, in connection with the Takeda License, we granted to Takeda the Takeda Warrant Right, pursuant to which
Takeda has a right to right to receive an additional common stock warrant should Takeda&#146;s fully-diluted ownership represent less than a certain specified percentage of our fully-diluted capitalization, including shares issuable upon conversion
of the outstanding May 2019 Notes in connection with this offering, calculated immediately prior to the closing of this offering. The Takeda Warrant Right will expire upon the closing of this offering (based on the initial public offering price of
$19.00 per share). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In May 2019, in connection with the entry into the Loan Agreement, we issued to the lenders the Lender Warrants to
purchase an aggregate of 16,446 shares of our common stock with an exercise price equal to $15.20 per share (based on the initial public offering price of $19.00 per share). The Lender Warrants only become exercisable if and when we borrow Term Loan
B under our Loan Agreement. The Lender Warrants expire ten years from the date of issuance, subject to their earlier termination on September&nbsp;30, 2020 if we do not draw down on Term Loan&nbsp;B on or before March&nbsp;31, 2020. The Lender
Warrants also include a put option pursuant to which, in the event that we do not draw down on Term Loan&nbsp;B on or before March&nbsp;31, 2020, the lenders may require us to repurchase the Lender Warrants for a total aggregate repurchase price of
$500,000. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">185 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Registration Rights </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">As of June&nbsp;30, 2019, upon the closing of this offering holders of 12,069,916&nbsp;shares of our common stock, which includes all of the shares of common stock issuable upon the automatic conversion of the May
2019 Notes, or their transferees, will be entitled to the following rights with respect to the registration of such shares for public resale under the Securities Act, pursuant to the 2019 Note Purchase Agreement by and among us and certain
investors. In addition, upon the closing of this offering, Takeda will be entitled to the same rights with respect to the registration of 7,588,000 shares of our common stock underlying the Takeda Warrant. The registration of shares of common stock
as a result of the following rights being exercised would enable holders to trade these shares without restriction under the Securities Act when the applicable registration statement is declared effective. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Demand Registration Rights </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>Form <FONT
STYLE="white-space:nowrap">S-1.&nbsp;&nbsp;&nbsp;&nbsp;</FONT></I> If at any time beginning six months following the effective date of the registration statement of which this prospectus forms a part, the holders of at least 25% of the registrable
securities request in writing that we effect a registration with respect to all or a part of the registrable securities then outstanding where the price to the public of the offering is $10.0&nbsp;million or more, we may be required to provide
notice to all holders of registrable securities and to use commercially reasonable efforts to effect such registration; provided, however, that we will not be required to effect such a registration if, within the preceding 12 months, we have already
effected two registrations for the holders of registrable securities in response to these demand registration rights, subject to certain exceptions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2"><I>Form S-</I>3.&nbsp;&nbsp;&nbsp;&nbsp; If at any time we become entitled under the Securities Act to register our shares on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> the holders of at least 20% of the
registrable securities request in writing that we effect a registration with respect to all or a part of the registrable securities then outstanding where the price to the public of the offering is $3.0&nbsp;million or more, we may be required to
provide notice to all holders of registrable securities and to use commercially reasonable efforts to effect such registration; provided, however, that we will not be required to effect such a registration if, within the preceding 12 months, we have
already effected two registrations on Form <FONT STYLE="white-space:nowrap">S-3</FONT> for the holders of registrable securities. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If
the holders requesting registration intend to distribute their shares by means of an underwriting, the underwriter of such offering will have the right to limit the numbers of shares to be underwritten for reasons related to the marketing of the
shares. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Piggyback Registration Rights </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">If at any time following the closing of this offering we propose to register any shares of our common stock under the Securities Act, subject to certain exceptions, the holders of registrable securities will be
entitled to notice of the registration and to include their shares of registrable securities in the registration. If our proposed registration involves an underwriting, the managing underwriter of such offering will have the right to limit the
number of shares to be underwritten for reasons related to the marketing of the shares. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Indemnification </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The 2019 Note Purchase Agreement contains customary cross indemnification provisions, under which we are obligated to indemnify holders of
registrable securities in the event of material misstatements or omissions in a registration statement attributable to us, and they are obligated to indemnify us for material misstatements or omissions attributable to them. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">186 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Expenses </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Ordinarily, other than underwriting discounts and commissions, we will be required to pay all expenses incurred by us related to any registration effected pursuant to the exercise of these registration rights.
These expenses may include all registration and filing fees, printing expenses, fees and disbursements of our counsel, reasonable fees and disbursements of a counsel for the selling securityholders, blue sky fees and expenses and the expenses of any
special audits incident to the registration. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Termination of Registration Rights </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The registration rights terminate upon the earlier of: (i)&nbsp;five years after the closing of this offering or (ii)&nbsp;with respect to a
particular holder, such time at which such holder can sell all shares held by it in compliance with Rule 144 under the Securities Act. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Anti-Takeover
Effects of Delaware Law and Our Certificate of Incorporation and Bylaws </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Some provisions of Delaware law, our amended and restated
certificate of incorporation and our amended and restated bylaws contain provisions that could make the following transactions more difficult: an acquisition of us by means of a tender offer; an acquisition of us by means of a proxy contest or
otherwise; or the removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or
in our best interests, including transactions which provide for payment of a premium over the market price for our shares. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">These
provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of
directors. We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these
proposals because negotiation of these proposals could result in an improvement of their terms. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Undesignated Preferred Stock </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The ability of our board of directors, without action by the stockholders, to issue up to 40,000,000 shares of undesignated preferred stock with
voting or other rights or preferences as designated by our board of directors could impede the success of any attempt to change control of us. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in
control or management of our company. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Stockholder Meetings </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Our amended and restated bylaws provide that a special meeting of stockholders may be called only by our chairman of the board of directors, chief executive officer or president, or by a resolution adopted by a
majority of our board of directors. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Requirements for Advance Notification of Stockholder Nominations and Proposals </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder meeting
and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">187 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Elimination of Stockholder Action by Written Consent </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our amended and restated certificate of incorporation and amended and restated bylaws eliminate the right of stockholders to act by written consent
without a meeting. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Staggered Board of Directors </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Our board of directors is divided into three classes. The directors in each class will serve for a three-year term, one class being elected each year by our stockholders. For more information on the classified
board of directors, see &#147;Management&#151;Board Composition and Election of Directors.&#148; This system of electing and removing directors may tend to discourage a third party from attempting to obtain control of us, because it generally makes
it more difficult for stockholders to replace a majority of the directors. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Removal of Directors </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our amended and restated certificate of incorporation provides that no member of our board of directors may be removed from office except for cause
and, in addition to any other vote required by law, upon the approval of not less than two thirds of the total voting power of all of our outstanding voting stock then entitled to vote in the election of directors. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Stockholders Not Entitled to Cumulative Voting </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Our amended and restated certificate of incorporation does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of the outstanding shares of our
common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of our preferred stock may be entitled to elect. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Delaware Anti-Takeover Statute </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We
are subject to Section&nbsp;203 of the Delaware General Corporation Law, which prohibits persons deemed to be &#147;interested stockholders&#148; from engaging in a &#147;business combination&#148; with a publicly held Delaware corporation for three
years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception
applies. Generally, an &#147;interested stockholder&#148; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#146;s
voting stock. Generally, a &#147;business combination&#148; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect
with respect to transactions not approved in advance by the board of directors. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Choice of Forum </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative form, the Court
of Chancery of the State of Delaware will be the sole and exclusive forum under Delaware statutory or common law: (i)&nbsp;any derivative action or proceeding brought on our behalf; (ii)&nbsp;any action asserting a claim of breach of a fiduciary
duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders, creditors or other constituents; (iii)&nbsp;any action asserting a claim against us arising pursuant to any provision of the General
Corporation Law of the State of Delaware or our amended and restated certificate of </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">188 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
incorporation or amended and restated bylaws; (iv)&nbsp;any action to interpret, apply, enforce or determine the validity of our certificate of incorporation or bylaws; or (v)&nbsp;any action
asserting a claim governed by the internal affairs doctrine. The provision would not apply to suits brought to enforce a duty or liability created by the Securities Act or the Exchange Act, or any other claim for which the federal courts have
exclusive jurisdiction. To the extent that any such claims may be based upon federal law claims, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange
Act or the rules and regulations thereunder. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the
rules and regulations thereunder. In any case, stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. The enforceability of similar choice of forum provisions in other
companies&#146; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. Our amended and restated certificate of incorporation
also provides that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to this choice of forum provision. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Amendment of Charter Provisions </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The
amendment of any of the above provisions, except for the provision making it possible for our board of directors to issue preferred stock, would require approval by holders of at least two thirds of the total voting power of all of our outstanding
voting stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws
could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often result from actual or rumored hostile takeover
attempts. These provisions may also have the effect of preventing changes in the composition of our board of directors and management. It is possible that these provisions could make it more difficult to accomplish transactions that stockholders may
otherwise deem to be in their best interests. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Transfer Agent and Registrar </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The transfer agent and registrar for our common stock will be Computershare Trust Company, N.A. The transfer agent and registrar&#146;s address is
250 Royall Street, Canton, Massachusetts 02021. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>The Nasdaq Global Select Market Listing </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our common stock has been approved for listing on the Nasdaq Global Select Market under the symbol &#147;PHAT.&#148; </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Limitations of Liability and Indemnification Matters </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">For a discussion of liability and indemnification, see &#147;Executive and Director Compensation&#151;Limitations of Liability and Indemnification Matters.&#148; </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">189 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_17"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Immediately prior to this offering, there was no public market for our common stock. Future sales of substantial amounts of common stock in the
public market, or the perception that such sales may occur, could adversely affect the market price of our common stock. Although our common stock has been approved for listing on the Nasdaq Global Select Market, we cannot assure you that there will
be an active public market for our common stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Based on the number of shares of our common stock outstanding as of June&nbsp;30,
2019, and assuming (i)&nbsp;the issuance of 9,563,157 shares in this offering, (ii)&nbsp;the automatic conversion of the May 2019 Notes into an aggregate of 6,107,918 shares of our common stock immediately prior to the closing of this offering
(based on the initial public offering price of $19.00&nbsp;per share and assuming the conversion occurs on October 29, 2019), (iii) no exercise of the underwriters&#146; option to purchase additional shares of common stock, and (iv)&nbsp;no exercise
of outstanding options, warrants, or other rights we will have outstanding an aggregate of 27,547,593 shares of common stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Of these
shares, all shares sold in this offering will be freely tradable without restriction or further registration under the Securities Act, except for any shares purchased by our &#147;affiliates,&#148; as that term is defined in Rule 144 under the
Securities Act. Shares purchased by our affiliates would be subject to the Rule 144 resale restrictions described below, other than the holding period requirement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The remaining 17,984,436 shares of common stock will be &#147;restricted securities,&#148; as that term is defined in Rule 144 under the Securities Act. These restricted securities are eligible for public sale only
if they are registered under the Securities Act or if they qualify for an exemption from registration under Rule 144 or 701 under the Securities Act, each of which is summarized below. We expect that substantially all of these shares will be subject
to the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> period under the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described below. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In addition, 7,588,000 shares of common stock issuable to Takeda upon the exercise of the Takeda Warrant became exercisable upon the closing of
this offering. Upon exercise of the Takeda Warrant, these shares of common stock will be eligible for sale subject to the lock&#150;up agreements described below and Rules 144 and 701 under the Securities Act. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">We, our officers, directors and holders of substantially all of our securities, have agreed with the underwriters that for a period of 180 days, after the date of this prospectus, subject to specified exceptions,
we or they will not offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to sale of, or otherwise dispose of or transfer any shares of common
stock or any securities convertible into or exercisable or exchangeable for shares of common stock, request or demand that we file a registration statement related to our common stock or enter into any swap or other agreement that transfers to
another, in whole or in part, directly or indirectly, the economic consequence of ownership of the common stock. Upon expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, certain of our stockholders will have the right to
require us to register their shares under the Securities Act. See &#147;&#151;Registration Rights&#148; below and &#147;Description of Capital Stock&#151;Registration Rights.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Goldman Sachs&nbsp;&amp; Co. LLC, Jefferies LLC, and Evercore Group L.L.C. may, in their sole discretion and at any time or from time to time
before the termination of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, in certain cases without public notice, release all or any portion of the securities subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. There
are no existing agreements between the underwriters and any of our stockholders who will </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">190 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
execute a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement providing consent to the sale of shares prior to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Upon the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, substantially all of the shares subject to such <FONT
STYLE="white-space:nowrap">lock-up</FONT> restrictions will become eligible for sale, subject to the limitations discussed above. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Rule <FONT
STYLE="white-space:nowrap">10b5-1</FONT> Trading Plans </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Following the closing of this offering, certain of our officers, directors
and significant stockholders may adopt written plans, known as Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> trading plans, in which they will contract with a broker to buy or sell shares of our common stock on a periodic basis to diversify
their assets and investments. Under these <FONT STYLE="white-space:nowrap">10b5-1</FONT> trading plans, a broker may execute trades pursuant to parameters established by the officer, director or stockholder when entering into the plan, without
further direction from such officer, director or stockholder. Such sales would not commence until the expiration of the applicable <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements entered into by such officer, director or stockholder in
connection with this offering. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Rule 144 </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Affiliate Resales of Restricted Securities </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">In general, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, a person who is an affiliate of ours, or who was an affiliate at any time during the 90 days
before a sale, who has beneficially owned shares of our common stock for at least six months would be entitled to sell in &#147;broker&#146;s transactions&#148; or certain &#147;riskless principal transactions&#148; or to market makers, a number of
shares within any three-month period that does not exceed the greater of: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">1% of the number of shares of our common stock then outstanding, which will equal approximately 275,475 shares immediately after this offering; or
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the average weekly trading volume in our common stock on the Nasdaq Global Select Market during the four calendar weeks preceding the filing of a notice on Form
144 with respect to such sale. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Affiliate resales under Rule 144 are also subject to the availability of current
public information about us. In addition, if the number of shares being sold under Rule 144 by an affiliate during any three-month period exceeds 5,000 shares or has an aggregate sale price in excess of $50,000, the seller must file a notice on Form
144 with the SEC and the Nasdaq Global Select Market concurrently with either the placing of a sale order with the broker or the execution of a sale directly with a market maker. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">Non-Affiliate</FONT> Resales of Restricted Securities </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In general, beginning 90 days after the effective date of the registration statement of which this prospectus is a part, a person who is not an
affiliate of ours at the time of sale, and has not been an affiliate at any time during the three months preceding a sale, and who has beneficially owned shares of our common stock for at least six months but less than a year, is entitled to sell
such shares subject only to the availability of current public information about us. If such person has held our shares for at least one year, such person can resell under Rule 144(b)(1) without regard to any Rule 144 restrictions, including the <FONT
STYLE="white-space:nowrap">90-day</FONT> public company requirement and the current public information requirement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT
STYLE="white-space:nowrap">Non-affiliate</FONT> resales are not subject to the manner of sale, volume limitation or notice filing provisions of Rule 144. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Rule 701 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In general, under Rule 701, any of
an issuer&#146;s employees, directors, officers, consultants or advisors who purchases shares from the issuer in connection with a compensatory stock or option plan </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">191 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
or other written agreement before the effective date of a registration statement under the Securities Act is entitled to sell such shares 90 days after such effective date in reliance on Rule
144. An affiliate of the issuer can resell shares in reliance on Rule 144 without having to comply with the holding period requirement, and <FONT STYLE="white-space:nowrap">non-affiliates</FONT> of the issuer can resell shares in reliance on Rule
144 without having to comply with the current public information and holding period requirements. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Equity Plans </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We intend to file one or more registration statements on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act to register all
shares of common stock subject to outstanding stock options and common stock issued or issuable under our equity incentive plans and employee stock purchase plan. We expect to file the registration statement covering shares offered pursuant to these
stock plans shortly after the date of this prospectus, permitting the resale of such shares by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> in the public market without restriction under the Securities Act and the sale by affiliates in the
public market subject to compliance with the resale provisions of Rule 144. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Registration Rights </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As of June&nbsp;30, 2019, upon the closing of this offering holders of 12,069,916&nbsp;shares of our common stock, which includes all of the shares
of common stock issuable upon the automatic conversion of the May 2019 Notes, or their transferees will be entitled to various rights with respect to the registration of these shares under the Securities Act. In addition, upon the closing of this
offering, Takeda will be entitled to the same rights with respect to the registration of 7,588,000 shares of our common stock underlying the Takeda Warrant. Registration of these shares under the Securities Act would result in these shares becoming
fully tradable without restriction under the Securities Act immediately upon the effectiveness of the registration. See &#147;Description of Capital Stock&#151;Registration Rights&#148; for additional information. Shares covered by a registration
statement will be eligible for sale in the public market upon the expiration or release from the terms of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">192 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_18"></A>MATERIAL UNITED STATES FEDERAL INCOME TAX CONSEQUENCES TO <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The following discussion is a summary of the material U.S. federal income tax
consequences to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders (as defined below) of the purchase, ownership and disposition of our common stock issued pursuant to this offering, but does not purport to be a complete analysis of all
potential tax effects. The effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws are not discussed. This discussion is based on the U.S.
Internal Revenue Code of 1986, as amended, or the Code, Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the U.S. Internal Revenue Service, or the IRS, in each case in effect
as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary
position to that discussed below regarding the tax consequences of the purchase, ownership and disposition of our common stock. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">This
discussion is limited to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders that hold our common stock as a &#147;capital asset&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This
discussion does not address all U.S. federal income tax consequences relevant to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s particular circumstances, including the impact of the alternative minimum tax or the Medicare
contribution tax on net investment income. In addition, it does not address consequences relevant to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders subject to special rules, including, without limitation: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">U.S. expatriates and former citizens or long-term residents of the United States; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">persons holding our common stock as part of a hedge, straddle or other risk reduction strategy or as part of a conversion transaction or other integrated
investment; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">banks, insurance companies, and other financial institutions; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">brokers, dealers or traders in securities; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies,&#148; and corporations that accumulate earnings to avoid U.S. federal
income tax; </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors therein);
</FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations or governmental organizations; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">persons deemed to sell our common stock under the constructive sale provisions of the Code; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">persons who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise as compensation; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">persons subject to special tax accounting rules as a result of any item of gross income with respect to our common stock being taken into account in an
&#147;applicable financial statement&#148; (as defined in the Code); </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; and </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">&#147;qualified foreign pension funds&#148; as defined in Section&nbsp;897(l)(2) of the Code and entities all of the interests of which are held by qualified
foreign pension funds. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If an entity treated as a partnership for U.S. federal income tax purposes holds our common
stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Accordingly, partnerships holding our common stock and the
partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">193 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>THIS DISCUSSION IS FOR INFORMATION PURPOSES ONLY AND IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX
ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT
TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY. </B></FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>Definition of a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">For purposes of this
discussion, a <FONT STYLE="white-space:nowrap">&#147;Non-U.S.</FONT> Holder&#148; is any beneficial owner of our common stock that is neither a &#147;U.S. person&#148; nor an entity treated as a partnership for U.S. federal income tax purposes. A
U.S. person is any person that, for U.S. federal income tax purposes, is or is treated as any of the following: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">an individual who is a citizen or resident of the United States; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a corporation created or organized under the laws of the United States, any state thereof, or the District of Columbia; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a trust that (i)&nbsp;is subject to the primary supervision of a U.S. court and the control of one or more &#147;United States persons&#148; (within the meaning
of Section&nbsp;7701(a)(30) of the Code), or (ii)&nbsp;has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>Distributions </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As described in the section entitled &#147;Dividend Policy,&#148; we do not
anticipate declaring or paying dividends to holders of our common stock in the foreseeable future. However, if we do make distributions of cash or property on our common stock, such distributions will constitute dividends for U.S. federal income tax
purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute a return of capital and
first be applied against and reduce a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s adjusted tax basis in its common stock, but not below zero. Any excess will be treated as capital gain and will be treated as described below under
&#147;&#151;Sale or Other Taxable Disposition.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Subject to the discussion below on effectively connected income, dividends paid to
a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder of our common stock will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax treaty,
provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder furnishes a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or other
applicable documentation) certifying qualification for the lower treaty rate). If a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder holds the stock through a financial institution or other agent acting on the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s behalf, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be required to provide appropriate documentation to the agent, who then will be required to provide certification
to the applicable withholding agent, either directly or through other intermediaries. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that does not timely furnish the required documentation, but that qualifies for a reduced treaty rate,
may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding their entitlement to benefits
under any applicable income tax treaty. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">If dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder are effectively
connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States (and, if required by an applicable income tax </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">194 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent establishment in the United States to which such dividends are attributable), the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be exempt from the U.S. federal withholding tax described above. To claim the exemption, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder must furnish to the applicable withholding
agent a valid IRS Form <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> certifying that the dividends are effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United
States. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Any such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the regular rates.
A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected dividends,
as adjusted for certain items. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding any applicable tax treaties that may provide for different rules. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Sale or Other Taxable Disposition </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">A <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will not be subject to U.S. federal income tax on any gain realized upon the sale or other taxable disposition of our common stock unless: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s conduct of a trade or business within the United States
(and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent establishment in the United States to which such gain is attributable); </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a nonresident alien individual present in the United States for 183 days or more during the
taxable year of the disposition and certain other requirements are met; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">our common stock constitutes a U.S. real property interest, or USRPI, by reason of our status as a U.S. real property holding corporation, or USRPHC, for U.S.
federal income tax purposes. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Gain described in the first bullet point above generally will be subject to U.S. federal
income tax on a net income basis at the regular rates. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income
tax treaty) on such effectively connected gain, as adjusted for certain items. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Gain described in the second bullet point above will be
subject to U.S. federal income tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty), which may be offset by U.S. source capital losses of the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder (even though the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is not considered a resident of the United States), provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder has timely filed U.S. federal income tax returns with respect to such losses.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">With respect to the third bullet point above, we believe we currently are not, and do not anticipate becoming, a USRPHC. Because the
determination of whether we are a USRPHC depends, however, on the fair market value of our USRPIs relative to the fair market value of our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> real property interests and our other business assets, there
can be no assurance we currently are not a USRPHC or will not become one in the future. Even if we are or were to become a USRPHC, gain arising from the sale or other taxable disposition by a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder
of our common stock will not be subject to U.S. federal income tax if our common stock is &#147;regularly traded,&#148; as defined by applicable Treasury Regulations, on an established securities market, and such
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder owned, actually or constructively, 5% or less of our common stock throughout the shorter of the five-year period ending on the date of the sale or other taxable disposition or the <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s holding period. If we are a USRPHC and either our common stock is not regularly traded on an established securities market or a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder holds,
or is treated as holding, more than 5% of our outstanding common stock, directly or indirectly, during the applicable testing period, such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will generally be taxed on any gain in the same manner
as gain that is effectively connected with the conduct of a U.S. trade </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">195 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
or business, except that the branch profits tax generally will not apply. If we are a USRPHC and our common stock is not regularly traded on an established securities market, a <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s proceeds received on the disposition of shares will also generally be subject to withholding at a rate of 15%. Prospective investors are encouraged to consult their own tax advisors regarding
the possible consequences to them if we are, or were to become, a USRPHC. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders
should consult their tax advisors regarding potentially applicable income tax treaties that may provide for different rules. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Information Reporting
and Backup Withholding </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Payments of dividends on our common stock will not be subject to backup withholding, provided the applicable
withholding agent does not have actual knowledge or reason to know the holder is a United States person and the holder either certifies its <FONT STYLE="white-space:nowrap">non-U.S.</FONT> status, such as by furnishing a valid IRS Form <FONT
STYLE="white-space:nowrap">W-8BEN,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> or otherwise establishes an exemption. However, information returns
are required to be filed with the IRS in connection with any dividends on our common stock paid to the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder, regardless of whether any tax was actually withheld. In addition, proceeds of the sale or
other taxable disposition of our common stock within the United States or conducted through certain U.S.-related brokers generally will not be subject to backup withholding or information reporting, if the applicable withholding agent receives the
certification described above and does not have actual knowledge or reason to know that such holder is a United States person, or the holder otherwise establishes an exemption. Proceeds of a disposition of our common stock conducted through a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> office of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker generally will not be subject to backup withholding or information reporting. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Copies of information returns that are filed with the IRS may also be made available under the provisions of an applicable treaty or agreement to
the tax authorities of the country in which the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder resides or is established. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against
a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#146;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>Additional Withholding Tax on Payments Made to Foreign Accounts </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Withholding taxes may be
imposed under Sections 1471 to 1474 of the Code (such Sections are commonly referred to as the Foreign Account Tax Compliance Act, or FATCA) on certain types of payments made to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> financial institutions
and certain other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities. Specifically, a 30% withholding tax may be imposed on dividends on, or subject to the proposed Treasury Regulations discussed below, gross proceeds from the sale or other
disposition of, our common stock paid to a &#147;foreign financial institution&#148; or a <FONT STYLE="white-space:nowrap">&#147;non-financial</FONT> foreign entity&#148; (each as defined in the Code), unless (i)&nbsp;the foreign financial
institution undertakes certain diligence and reporting obligations, (ii)&nbsp;the <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity either certifies it does not have any &#147;substantial United States owners&#148; (as defined in
the Code) or furnishes identifying information regarding each substantial United States owner, or (iii)&nbsp;the foreign financial institution or <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity otherwise qualifies for an
exemption from these rules. If the payee is a foreign financial institution and is subject to the diligence and reporting requirements in clause (i)&nbsp;above, it must enter into an agreement with the U.S. Department of the Treasury requiring,
among other things, that it undertake to identify accounts held by certain &#147;specified United States persons&#148; or &#147;United States owned foreign entities&#148; (each as defined in the Code), annually report certain information about such
accounts, and withhold 30% on certain payments to <FONT STYLE="white-space:nowrap">non-compliant</FONT> foreign financial institutions and certain other account holders. Foreign financial institutions located in jurisdictions that have an
intergovernmental agreement with the United States governing FATCA may be subject to different rules. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">196 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Under the applicable Treasury Regulations and administrative guidance, withholding under FATCA
generally applies to payments of dividends on our common stock. While withholding under FATCA would also have applied to payments of gross proceeds from the sale or other disposition of stock on or after January&nbsp;1, 2019, recently proposed
Treasury Regulations eliminate FATCA withholding on payments of gross proceeds entirely. Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Prospective investors should consult their tax advisors regarding the potential application of withholding under FATCA to their investment in our
common stock. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">197 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_19"></A>UNDERWRITING </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We and the underwriters named below have entered into an underwriting agreement with respect to the shares being offered. Subject to certain
conditions, each underwriter has severally agreed to purchase the number of shares indicated in the following table. Goldman Sachs&nbsp;&amp; Co. LLC, Jefferies LLC, and Evercore Group L.L.C. are the representatives of the underwriters. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Underwriters</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Number&nbsp;of</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Goldman Sachs&nbsp;&amp; Co. LLC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">3,825,263</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Jefferies LLC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2,868,947</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Evercore Group L.L.C.</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2,390,789</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Needham &amp; Company, LLC</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">478,158</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">9,563,157</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The underwriters are committed to take and pay for all of the shares being offered, if any are taken, other than
the shares covered by the option described below unless and until this option is exercised. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The underwriters have an option to buy up
to an additional 1,434,473 shares from us to cover sales by the underwriters of a greater number of shares than the total number set forth in the table above. They may exercise that option for 30 days. If any shares are purchased pursuant to this
option, the underwriters will severally purchase shares in approximately the same proportion as set forth in the table above. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The
following table shows the per share and total underwriting discounts and commissions to be paid to the underwriters by us. Such amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase 1,434,473
additional shares. </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>No&nbsp;Exercise</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Full&nbsp;Exercise</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Per Share</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1.33</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1.33</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">12,718,999</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">14,626,848</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Shares sold by the underwriters to the public will initially be offered at the initial public offering price set
forth on the cover page of this prospectus. Any shares sold by the underwriters to securities dealers may be sold at a discount of up to $0.798 per share from the initial public offering price. After the initial offering of the shares, the
representatives may change the offering price and the other selling terms. The offering of the shares by the underwriters is subject to receipt and acceptance and subject to the underwriters&#146; right to reject any order in whole or in part.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We and our officers, directors, and holders of substantially all of our securities have agreed with the underwriters, subject to
certain exceptions, not to dispose of or hedge any of their common stock or securities convertible into or exchangeable for shares of common stock during the period from the date of this prospectus continuing through the date 180 days after the date
of this prospectus, except with the prior written consent of the representatives. This agreement does not apply to any existing employee benefit plans. See &#147;Shares Eligible for Future Sale&#148; for a discussion of certain transfer
restrictions. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Prior to the offering, there has been no public market for the shares. The initial public offering price was negotiated
among our company and the representatives. Among the factors considered in determining the initial public offering price of the shares, in addition to prevailing market conditions, </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">198 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
was our historical performance, estimates of our business potential and earnings prospects, an assessment of our management and the consideration of the above factors in relation to market
valuation of companies in related businesses. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our common stock has been approved for listing on the Nasdaq Global Select Market under
the symbol &#147;PHAT.&#148; </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In connection with the offering, the underwriters may purchase and sell shares of our common stock in the
open market. These transactions may include short sales, stabilizing transactions and purchases to cover positions created by short sales. Short sales involve the sale by the underwriters of a greater number of shares than they are required to
purchase in the offering, and a short position represents the amount of such sales that have not been covered by subsequent purchases. A &#147;covered short position&#148; is a short position that is not greater than the amount of additional shares
for which the underwriters&#146; option described above may be exercised. The underwriters may cover any covered short position by either exercising their option to purchase additional shares or purchasing shares in the open market. In determining
the source of shares to cover the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase additional shares
pursuant to the option described above. &#147;Naked&#148; short sales are any short sales that create a short position greater than the amount of additional shares for which the option described above may be exercised. The underwriters must cover
any such naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market
after pricing that could adversely affect investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of common stock made by the underwriters in the open market prior to the completion of the offering.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the
underwriting discount received by it because the representatives have repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Purchases to cover a short position and stabilizing transactions, as well as other purchases by the underwriters for their own accounts, may have
the effect of preventing or retarding a decline in the market price of our stock, and together with the imposition of the penalty bid, may stabilize, maintain or otherwise affect the market price of the common stock. As a result, the price of the
common stock may be higher than the price that otherwise might exist in the open market. The underwriters are not required to engage in these activities and may end any of these activities at any time. These transactions may be effected on the
Nasdaq Global Select Market, in the OTC market or otherwise. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We estimate that our share of the total expenses of the offering,
excluding underwriting discounts and commissions, will be approximately $2.8 million. We have also agreed to reimburse the underwriters for certain expenses incurred by them in connection with the offering in an amount up to $40,000. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have agreed to indemnify the several underwriters against certain liabilities, including liabilities under the Securities Act. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">At our request, the underwriters have reserved up to 3.0% of the shares of common stock to be offered by this prospectus for sale, at the initial
public offering price, to certain of our directors, officers, employees, and their friends and family members through a directed share program. Goldman Sachs &amp; Co. LLC will administer our directed share program. The number of shares available
for sale to the general public in the offering will be reduced to the extent these persons purchase the reserved shares. Any reserved shares not so purchased will be offered by the underwriters to the general public
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">199 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
on the same terms as the other shares offered by this prospectus. The underwriters will receive the same discount from such reserved shares as they will from other shares of our common stock sold
to the public in this offering. We have agreed to indemnify the underwriters against certain liabilities and expenses, including liabilities under the Securities Act, in connection with sales of the reserved shares. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may include sales and
trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage and other financial and <FONT STYLE="white-space:nowrap">non-financial</FONT> activities and
services. Certain of the underwriters and their respective affiliates have provided, and may in the future provide, a variety of these services to the issuer and to persons and entities with relationships with the issuer, for which they received or
will receive customary fees and expenses.</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In the ordinary course of their various business activities, the underwriters and their
respective affiliates, officers, directors and employees may purchase, sell or hold a broad array of investments and actively trade securities, derivatives, loans, commodities, currencies, credit default swaps and other financial instruments for
their own account and for the accounts of their customers, and such investment and trading activities may involve or relate to assets, securities and/or instruments of the issuer (directly, as collateral securing other obligations or otherwise)
and/or persons and entities with relationships with the issuer. The underwriters and their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent
research views in respect of such assets, securities or instruments and may at any time hold, or recommend to clients that they should acquire, long and/or short positions in such assets, securities and instruments. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>European Economic Area </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In relation to each
Member State of the European Economic Area (each a &#147;Member State&#148;), no shares of common stock (the &#147;Shares&#148;) have been offered or will be offered pursuant to the offering to the public in that Member State prior to the
publication of a prospectus in relation to the Shares which has been approved by the competent authority in that Member State or, where appropriate, approved in another Member State and notified to the competent authority in that Member State, all
in accordance with the Prospectus Regulation), except that offers of Shares may be made to the public in that Member State at any time under the following exemptions under the Prospectus Regulation: </FONT></P>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">to any legal entity which is a qualified investor as defined under the Prospectus Regulation; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">to fewer than 150 natural or legal persons (other than qualified investors as defined under the Prospectus Regulation), subject to obtaining the prior
consent of the representatives for any such offer; or </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">(c)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">provided that no such offer of Shares shall require the company or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation or
supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">For the purposes of this provision, the expression an
&#147;offer to the public&#148; in relation to any Shares in any Member State means the communication in any form and by any means of sufficient information on the terms of the offer and any Shares to be offered so as to enable an investor to decide
to purchase or subscribe for any Shares, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">200 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>United Kingdom </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Each Underwriter has represented and agreed that: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">(a)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">it has only communicated or caused to be communicated and will only communicate or cause to be communicated an invitation or inducement to engage in
investment activity (within the meaning of Section 21 of the Financial Services and Markets Act 2000 (FSMA)) received by it in connection with the issue or sale of the Shares in circumstances in which Section 21(1) of the FSMA does not apply to the
company or the underwriter; and </FONT></P></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="6%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">(b)</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by it in relation to the Shares in, from or
otherwise involving the United Kingdom. </FONT></P></TD></TR></TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Canada </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The securities may be sold in Canada only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument
<FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT> Registration
Requirements, Exemptions, and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance with an exemption form, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this
prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s
province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory of these rights or consult with a legal advisor. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Pursuant to section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI <FONT
STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this
offering. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Hong Kong </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The shares
may not be offered or sold in Hong Kong by means of any document other than (i)&nbsp;in circumstances which do not constitute an offer to the public within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32 of
the Laws of Hong Kong) (&#147;Companies (Winding Up and Miscellaneous Provisions) Ordinance&#148;) or which do not constitute an invitation to the public within the meaning of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong)
(&#147;Securities and Futures Ordinance&#148;), or (ii)&nbsp;to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance and any rules made thereunder, or (iii)&nbsp;in other circumstances which do not result in the
document being a &#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance, and no advertisement, invitation or document relating to the shares may be issued or may be in the possession of any person for
the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong (except if permitted to do so under the securities laws of Hong Kong)
other than with respect to shares which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; in Hong Kong as defined in the Securities and Futures Ordinance and any rules made
thereunder. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">201 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Singapore </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">This prospectus has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation
for subscription or purchase, of the shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore
other than (i)&nbsp;to an institutional investor (as defined under Section&nbsp;4A of the Securities and Futures Act, Chapter 289 of Singapore (the &#147;SFA&#148;)) under Section&nbsp;274 of the SFA, (ii)&nbsp;to a relevant person (as defined in
Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA, or any person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified in Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant
to, and in accordance with the conditions of, any other applicable provision of the SFA, in each case subject to conditions set forth in the SFA. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole
business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor, the securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation shall not
be transferable for 6 months after that corporation has acquired the shares under Section&nbsp;275 of the SFA except: (i)&nbsp;to an institutional investor under Section&nbsp;274 of the SFA or to a relevant person (as defined in Section&nbsp;275(2)
of the SFA), (ii) where such transfer arises from an offer in that corporation&#146;s securities pursuant to Section&nbsp;275(1A) of the SFA, (iii)&nbsp;where no consideration is or will be given for the transfer, (iv)&nbsp;where the transfer is by
operation of law, (v)&nbsp;as specified in Section&nbsp;276(7) of the SFA, or (vi)&nbsp;as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore (&#147;Regulation
32&#148;). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is a trust (where
the trustee is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) whose sole purpose is to hold investments and each beneficiary of the trust is an accredited investor, the beneficiaries&#146; rights and interest (howsoever
described) in that trust shall not be transferable for 6 months after that trust has acquired the shares under Section&nbsp;275 of the SFA except: (i)&nbsp;to an institutional investor under Section&nbsp;274 of the SFA or to a relevant person (as
defined in Section&nbsp;275(2) of the SFA), (ii) where such transfer arises from an offer that is made on terms that such rights or interest are acquired at a consideration of not less than S$200,000 (or its equivalent in a foreign currency) for
each transaction (whether such amount is to be paid for in cash or by exchange of securities or other assets), (iii) where no consideration is or will be given for the transfer, (iv)&nbsp;where the transfer is by operation of law, (v)&nbsp;as
specified in Section&nbsp;276(7) of the SFA, or (vi)&nbsp;as specified in Regulation 32. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Japan </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The securities have not been and will not be registered under the Financial Instruments and Exchange Act of Japan (Act No.&nbsp;25 of 1948, as
amended), or the FIEA. The securities may not be offered or sold, directly or indirectly, in Japan or to or for the benefit of any resident of Japan (including any person resident in Japan or any corporation or other entity organized under the laws
of Japan) or to others for reoffering or resale, directly or indirectly, in Japan or to or for the benefit of any resident of Japan, except pursuant to an exemption from the registration requirements of the FIEA and otherwise in compliance with any
relevant laws and regulations of Japan. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Australia </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">This prospectus is not a disclosure document for the purposes of Australia&#146;s Corporations Act 2001 (Cth) of Australia, or Corporations Act, has not been lodged with the Australian Securities&nbsp;&amp;
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">202 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
Investments Commission and is only directed to the categories of exempt persons set out below. Accordingly, if you receive this prospectus in Australia: </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">You confirm and warrant that you are either: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a &#147;sophisticated investor&#148; under section 708(8)(a) or (b)&nbsp;of the Corporations Act; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a &#147;sophisticated investor&#148; under section 708(8)(c) or (d)&nbsp;of the Corporations Act and that you have provided an accountant&#146;s certificate to
the Company which complies with the requirements of section 708(8)(c)(i) or (ii)&nbsp;of the Corporations Act and related regulations before the offer has been made; </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a person associated with the Company under Section&nbsp;708(12) of the Corporations Act; or </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#149;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">a &#147;professional investor&#148; within the meaning of section 708(11)(a) or (b)&nbsp;of the Corporations Act. </FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">To the extent that you are unable to confirm or warrant that you are an exempt sophisticated investor, associated person or professional investor
under the Corporations Act any offer made to you under this prospectus is void and incapable of acceptance. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">You warrant and agree that
you will not offer any of the securities issued to you pursuant to this prospectus for resale in Australia within 12 months of those securities being issued unless any such resale offer is exempt from the requirement to issue a disclosure document
under section 708 of the Corporations Act. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Israel </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">This document does not constitute a prospectus under the Israeli Securities Law, 5728-1968, or the Securities Law, and has not been filed with or approved by the Israel Securities Authority. In Israel, this
prospectus is being distributed only to, and is directed only at, and any offer of the shares is directed only at, (i)&nbsp;a limited number of persons in accordance with the Israeli Securities Law and (ii)&nbsp;investors listed in the first
addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange,
underwriters, venture capital funds, entities with equity in excess of NIS 50&nbsp;million and &#147;qualified individuals,&#148; each as defined in the Addendum (as it may be amended from time to time), collectively referred to as qualified
investors (in each case, purchasing for their own account or, where permitted under the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors are required to submit written confirmation that they
fall within the scope of the Addendum, are aware of the meaning of same and agree to it. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Switzerland </B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (&#147;SIX&#148;) or on any other stock
exchange or regulated trading facility in Switzerland. This prospectus has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards
for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this prospectus nor any other offering or marketing material relating to the
securities or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Neither this prospectus nor
any other offering or marketing material relating to the offering, our company or the securities have been or will be filed with or approved by any Swiss regulatory authority. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">203 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
In particular, this prospectus will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, and the offer of securities
has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (&#147;CISA&#148;). The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to
acquirers of securities. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">204 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_20"></A>LEGAL MATTERS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The validity of the shares of common stock offered hereby will be passed upon for us by Latham&nbsp;&amp; Watkins LLP, San Diego, California. The
underwriters are being represented by Cooley LLP, San Diego, California. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_21"></A>EXPERTS </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Ernst &amp; Young LLP, independent registered public accounting firm, has audited our combined financial statements at December 31, 2018 and for
the year then ended, as set forth in their report (which contains an explanatory paragraph describing conditions that raise substantial doubt about Phathom Pharmaceuticals, Inc.&#146;s ability to continue as a going concern as described in
Note&nbsp;1 to the combined financial statements). We have included our combined financial statements in the prospectus and elsewhere in the registration statement in reliance on Ernst &amp; Young LLP&#146;s report, given on their authority as
experts in accounting and auditing. </FONT></P> <P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_22"></A>WHERE YOU CAN FIND MORE INFORMATION </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act with respect to
the shares of common stock offered hereby. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement or the exhibits and schedules filed therewith. For
further information about us and the common stock offered hereby, we refer you to the registration statement and the exhibits and schedules filed thereto. Statements contained in this prospectus regarding the contents of any contract or any other
document that is filed as an exhibit to the registration statement are not necessarily complete, and each such statement is qualified in all respects by reference to the full text of such contract or other document filed as an exhibit to the
registration statement. Upon the closing of this offering, we will be required to file periodic reports, proxy statements and other information with the SEC pursuant to the Exchange Act. The SEC maintains an Internet website that contains reports,
proxy statements and other information about registrants, like us, that file electronically with the SEC. The address of that site is www.sec.gov. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Upon the closing of this offering, we will become subject to the information and periodic reporting requirements of the Exchange Act and, in accordance therewith, will file periodic reports, proxy statements and
other information with the SEC. Such periodic reports, proxy statements and other information will be available at the website of the SEC referred to above. We maintain a website at www.phathompharma.com. Upon the closing of this offering, you may
access our annual reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> and amendments to those
reports filed or furnished pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act with the SEC free of charge at our website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The
reference to our website address does not constitute incorporation by reference of the information contained on our website, and you should not consider the contents of our website in making an investment decision with respect to our common stock.
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">205 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="toc63338_23"></A>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>INDEX TO COMBINED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Page</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#fin63338_1">Report of Independent Registered Public Accounting Firm</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="white-space:nowrap">F-2</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#fin63338_2">Combined Balance Sheets</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="white-space:nowrap">F-3</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#fin63338_3">Combined Statements of&nbsp;Operations</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="white-space:nowrap">F-4</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#fin63338_4">Combined Statements&nbsp;of&nbsp;Stockholders&#146; Deficit</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="white-space:nowrap">F-5</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#fin63338_5">Combined Statements of Cash Flows</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="white-space:nowrap">F-6</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><A HREF="#fin63338_6">Notes to Combined Financial Statements</A></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="white-space:nowrap">F-7</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-1 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="fin63338_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
</B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:ARIAL" SIZE="2">To the Stockholders and the Board of Directors of </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:ARIAL" SIZE="2">Phathom Pharmaceuticals, Inc. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Opinion on the Financial Statements </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We have audited the accompanying combined balance sheet of Phathom Pharmaceuticals, Inc. (the Company) as of December&nbsp;31, 2018, the related
combined statement of operations, stockholders&#146; deficit and cash flows for the year then ended, and the related notes (collectively referred to as the &#147;combined financial statements&#148;). In our opinion, the combined financial statements
present fairly, in all material respects, the financial position of the Company at December&nbsp;31, 2018, and the results of its operations and its cash flows for the year then ended in conformity with U.S. generally accepted accounting principles.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>The Company&#146;s Ability to Continue as a Going Concern </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The accompanying combined financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has incurred net losses
and negative cash flows from operating activities since its inception, and has stated that substantial doubt exists about the Company&#146;s ability to continue as a going concern. Management&#146;s evaluation of the events and conditions and
management&#146;s plans regarding these matters are also described in Note 1. The combined financial statements do not include any adjustments that might result from the outcome of these uncertainties. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Basis for Opinion </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">These financial
statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial statements based on our audit. We are a public accounting firm registered with the Public Company
Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform
the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control
over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over
financial reporting. Accordingly, we express no such opinion. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Our audit included performing procedures to assess the risks of material
misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial
statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable
basis for our opinion. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:55%; text-indent:-2%"><FONT STYLE="font-family:ARIAL" SIZE="2">/s/ Ernst&nbsp;&amp; Young LLP </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2">We have served as the Company&#146;s auditor since 2019. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:ARIAL" SIZE="2">San Diego, California
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT STYLE="font-family:ARIAL" SIZE="2">July 26, 2019 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:2%; text-indent:-2%"><FONT
STYLE="font-family:ARIAL" SIZE="2">except for the last paragraph in Note&nbsp;8, as to which the date is </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">October&nbsp;15, 2019 </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-2 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="fin63338_2"></A>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>COMBINED BALANCE SHEETS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>(in
thousands, except share and par value data) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>December&nbsp;31,<BR>2018</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>June&nbsp;30, 2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Pro&nbsp;Forma<BR>June&nbsp;30, 2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Assets</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Current assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Cash and cash equivalents</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">879</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">82,917</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Prepaid expenses and other current assets (including related party amounts of $19 and $15, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,625</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total current assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">902</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">84,542</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Other assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">337</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">902</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">84,879</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Liabilities and Stockholders&#146; Deficit</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Current liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Accounts payable (including related party amounts of $45 and $31, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">55</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">450</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Accrued expenses (including related party amounts of $2 and $19, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">170</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">995</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Accrued interest (including related party amounts of $13 and $82, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">967</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">151</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Convertible promissory notes payable at fair value (including related party amounts of $1,950 and $20,552, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,950</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">92,743</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Warrant liabilities (including related party amounts of ($0 and $49,171, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">49,597</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">426</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total current liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2,188</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">144,752</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Long-term debt, net of discount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">22,449</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Other long-term liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2,063</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2,188</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">169,264</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Commitments and contingencies (Note 3)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Stockholders&#146; deficit:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Common stock, $0.0001 par value; authorized shares&#151;50,000,000 at June&nbsp;30, 2019 (unaudited); issued shares&#151;11,876,518 at
June&nbsp;30, 2019 (unaudited); outstanding shares&#151;7,219,268 at June&nbsp;30, 2019 (unaudited); 17,984,436 and 13,327,186&nbsp;shares issued and outstanding, respectively, pro forma (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">5,916</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">148,645</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Accumulated deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(90,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(90,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total stockholders&#146; deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(84,385</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">58,345</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total liabilities and stockholders&#146; deficit</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;902</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;84,879</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>See accompanying notes. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-3 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="fin63338_3"></A>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>COMBINED STATEMENTS OF OPERATIONS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(in thousands, except share and per share data) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Year&nbsp;Ended<BR>December<BR>31,&nbsp;2018</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Six&nbsp;Months&nbsp;Ended</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2018</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Operating expenses:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">3,201</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><FONT STYLE="white-space:nowrap">In-process</FONT> research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">78,897</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">General and administrative (includes related party amounts of $321, $124 and $18, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,205</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2,142</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total operating expenses</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,225</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">84,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Loss from operations</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,225</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(506</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(84,240</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Other income (expense):</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Interest income</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">101</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Interest expense (includes related party amounts of $(13), $(4) and $(82), respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,148</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Change in fair value of warrant liabilities (includes related party amounts of $0, $0 and $(1,277), respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,284</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Change in fair value of convertible promissory notes (includes related party amounts of $(50), $(4) and $(502),
respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(2,442</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total other income (expense)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(63</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(8</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(4,773</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(514</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(89,013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net loss per share, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(0.21</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(0.10</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(13.40</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Weighted-average shares of common stock outstanding, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6,051,675</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">5,331,270</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6,640,394</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Pro forma net loss per share, basic and diluted (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(0.20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(9.85</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Pro forma weighted-average shares of common stock outstanding, basic and diluted (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6,098,429</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">8,578,296</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>See accompanying notes. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-4 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="fin63338_4"></A>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>COMBINED STATEMENTS OF STOCKHOLDERS&#146; DEFICIT </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(in thousands, except share data) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Common&nbsp;Stock</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Accumulated<BR>Deficit</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Total<BR>Stockholders&#146;<BR>Deficit</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Combined balance at January&nbsp;1, 2018</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Issuance of common stock to founders</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Combined balance at December&nbsp;31, 2018</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,286</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Merger of entities under common control into the Company (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6,760,334</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Vesting restrictions placed on previously issued and outstanding common stock (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(3,373,408</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Issuance of common stock (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,491,072</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Issuance of common stock in connection with license agreement (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,084,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">5,885</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">5,885</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Vesting of restricted shares (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,257,270</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Stock-based compensation (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net loss (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(89,013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(89,013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Balance at June&nbsp;30, 2019 (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">7,219,268</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">5,916</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(90,301</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(84,385</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="8"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Common&nbsp;Stock</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-in</FONT><BR>Capital</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Accumulated</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Deficit&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Total<BR>Stockholders&#146;<BR>Deficit</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Shares</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Amount</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Combined balance at January&nbsp;1, 2018</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Issuance of common stock to founders (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net loss (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(514</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(514</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Combined balance at June&nbsp;30, 2018 (unaudited)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(514</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(512</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>See accompanying notes. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-5 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="fin63338_5"></A>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>COMBINED STATEMENTS OF CASH FLOWS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(in thousands) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Year&nbsp;Ended<BR>December&nbsp;
31,</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2018</B></FONT></TD>
<TD VALIGN="bottom" ROWSPAN="2"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Six&nbsp;Months&nbsp;Ended</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>June&nbsp;30,</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2018</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(unaudited)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Cash flows from operating activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(514</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(89,013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Adjustments to reconcile net loss to net cash used in operating activities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Stock-based compensation</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Amortization of debt discount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">81</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">78,897</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Change in fair value of warrant liabilities (includes related party amounts of $0, $0 and $1,277, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,284</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Change in fair value of convertible promissory notes (includes related party amounts of $50, $4 and $502, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2,442</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Changes in operating assets and liabilities:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Prepaid expenses and other current assets (includes related party amounts of $(19), $(13) and $4, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(23</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(18</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,602</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Accounts payable and accrued expenses (includes related party amounts of $47, $54 and $3, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">225</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">72</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">883</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Accrued interest (includes related party amounts of $13, $4 and $82, respectively)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">4</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">981</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net cash used in operating activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,023</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(452</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(6,018</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Cash flows from investing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Cash paid for purchased <FONT STYLE="white-space:nowrap">in-process</FONT> research and development</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(25,118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net cash used in investing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(25,118</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Cash flows from financing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Proceeds from issuance of common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Proceeds from issuance of convertible promissory notes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">550</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">88,324</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Proceeds from issuance of long-term debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">24,850</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net cash provided by financing activities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,902</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">552</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">113,174</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net increase in cash</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">879</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">82,038</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Cash and cash equivalents&#151;beginning of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">879</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Cash and cash equivalents&#151;end of period</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">879</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">82,917</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Supplemental disclosure of cash flow information</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Interest paid</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">86</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Supplemental disclosure of noncash investing and financing activities</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Exchange of accrued interest for convertible promissory notes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">27</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Issuance of Takeda Warrants in connection with Takeda License</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">47,894</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Issuance of common stock in connection with Takeda License</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">5,885</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Issuance of common stock warrants in connection with long-term debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">419</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Unpaid initial public offering costs</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">337</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Final interest payment fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2,063</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><I>See accompanying notes. </I></FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-6 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><A NAME="fin63338_6"></A>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>1. Organization, Basis of Presentation and Summary of Significant Accounting Policies </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Organization
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Phathom Pharmaceuticals, Inc. (the &#147;Company&#148; or &#147;Phathom&#148;) was incorporated in the state of Delaware in
January 2018 under the name North Bridge IV, Inc. On March&nbsp;13, 2019, the Company changed its name to Phathom Pharmaceuticals, Inc. and merged with YamadaCo IIA, Inc. (&#147;YamadaCo&#148;), a Delaware corporation formed in September 2017, with
Phathom being the surviving entity (the &#147;Merger&#148;). All activities of YamadaCo prior to 2018 related to formation and were insignificant. The Company is a late clinical-stage biopharmaceutical company focused on developing and
commercializing novel treatments for gastrointestinal diseases. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Stock Split and Conversion </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">During 2018, without consideration of the forward stock split described in Note&nbsp;8, both the Company and YamadaCo issued 1,000 shares of common
stock at a purchase price of $1.00 per share, and had no other capital transactions prior to the Merger. Immediately prior to the Merger, the Company effected a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1,559.1183-for-1</FONT></FONT> forward stock split for each outstanding share of its common stock and, effective upon the closing of the Merger, each issued and outstanding share of
YamadaCo was converted into 1,559.1183 shares of the Company&#146;s common stock. Upon completion of the Merger, the Company had 6,760,334 shares of common stock outstanding, with the prior stockholders of each YamadaCo and Phathom holding an equal
number of shares. The accompanying combined financial statements and notes to the combined financial statements give retroactive effect to the forward stock split and conversion for all periods presented. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Basis of Presentation </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The
Company&#146;s combined financial statements are prepared in accordance with U.S. generally accepted accounting principles (&#147;GAAP&#148;). The accompanying combined financial statements include the accounts of the Company (the receiving entity)
and YamadaCo, prior to the Merger. The Company and YamadaCo were entities under the common control of Frazier Life Sciences IX, L.P. (&#147;Frazier&#148;) as a result of, among others, Frazier&#146;s; (i)&nbsp;ownership of a majority of the
outstanding capital stock of both companies, (ii)&nbsp;financing of both companies, (iii)&nbsp;control of board of directors of both companies, and (iv)&nbsp;management of both companies. Both the Company and YamadaCo were formed for the purpose of
identifying potential assets around which to form an operating company. As the merged entities were under common control, the combined financial statements report the financial position, results of operations and cash flows of the Company and
YamadaCo as though the transfer of net assets and equity interests had occurred at the beginning of 2018. All intercompany accounts and transactions have been eliminated in combination. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Liquidity and Capital Resources </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">From inception to June&nbsp;30, 2019, the Company has
devoted substantially all of its efforts to organizing and staffing the Company, business planning, raising capital, <FONT STYLE="white-space:nowrap">in-licensing</FONT> its initial product candidate, vonoprazan, meeting with regulatory authorities,
and preparing for the planned Phase 3 clinical trials of vonoprazan. The Company has a limited operating history, has never generated any revenue, and the sales and income potential of its business is unproven. The Company has incurred net losses
and negative cash flows from operating activities since its inception and expects to continue to incur net losses into the foreseeable future as it continues the development and commercialization
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-7 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(CONTINUED) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
of vonoprazan. From inception to June&nbsp;30, 2019, the Company has funded its operations through the issuance of convertible promissory notes and commercial bank debt. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The accompanying combined financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the
realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or amounts and classification of
liabilities that may result from the outcome of this uncertainty. Management is required to perform a <FONT STYLE="white-space:nowrap">two-step</FONT> analysis over the Company&#146;s ability to continue as a going concern. Management must first
evaluate whether there are conditions and events that raise substantial doubt about the Company&#146;s ability to continue as a going concern (Step 1). If management concludes that substantial doubt is raised, management is also required to consider
whether its plans alleviate that doubt (Step 2). Management has prepared cash flow forecasts which indicate that based on the Company&#146;s expected operating losses, negative cash flows and maturities of outstanding convertible promissory notes,
there is substantial doubt about the Company&#146;s ability to continue as a going concern for twelve months after the date the combined financial statements for the year ended December&nbsp;31, 2018 and the six months ended June&nbsp;30, 2019 are
issued. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The Company&#146;s ability to continue as a going concern is dependent upon its ability to raise additional funding. Management
plans to raise additional capital through equity offerings, the Company&#146;s existing loan and security agreement, debt financings, or other capital sources, including potential collaborations, licenses and other similar arrangements. While
management believes this plan to raise additional funds will alleviate the conditions that raise substantial doubt, these plans are not entirely within its control and cannot be assessed as being probable of occurring. The Company may not be able to
secure additional financing in a timely manner or on favorable terms, if at all. Furthermore, if the Company issues equity securities to raise additional funds, its existing stockholders may experience dilution, and the new equity securities may
have rights, preferences and privileges senior to those of the Company&#146;s existing stockholders. If the Company raises additional funds through collaboration, licensing or other similar arrangements, it may be necessary to relinquish valuable
rights to its potential products on terms that are not favorable to the Company. If the Company is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce or eliminate its research and development programs or
other operations. If any of these events occur, the Company&#146;s ability to achieve the development and commercialization goals would be adversely affected. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Use of Estimates </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The preparation of the Company&#146;s combined financial statements
requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#146;s combined financial statements and accompanying notes.
The most significant estimates in the Company&#146;s combined financial statements relate to accruals for research and development expenses, and the valuation of convertible promissory notes, warrant liabilities and various other equity instruments.
Although these estimates are based on the Company&#146;s knowledge of current events and actions it may undertake in the future, actual results could differ materially from those estimates and assumptions. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Unaudited Interim Financial Information </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The accompanying interim balance sheet as of June&nbsp;30, 2019, the combined statements of operations and cash flows for the six months ended June&nbsp;30, 2018 and 2019 and the combined
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-8 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(CONTINUED) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
statement of stockholders&#146; deficit for the six months ended June&nbsp;30, 2018 and 2019 and the related footnote disclosures are unaudited. In management&#146;s opinion, the unaudited
interim financial statements have been prepared on the same basis as the audited combined financial statements and include all adjustments, which include only normal recurring adjustments, necessary for the fair presentation of the Company&#146;s
financial position as of June&nbsp;30, 2019 and its results of operations and cash flows for the six months ended June&nbsp;30, 2018 and 2019 in accordance with GAAP. The results for the six months ended June&nbsp;30, 2019 are not necessarily
indicative of the results expected for the full fiscal year or any other interim period. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Unaudited Pro Forma Balance Sheet Information
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The unaudited pro forma balance sheet information as of June&nbsp;30, 2019 in the accompanying combined balance sheet gives
effect to: (i)&nbsp;the automatic conversion of all outstanding convertible promissory notes and related accrued interest (see Note 4) into&nbsp;6,107,918 shares of common stock (assuming the initial public offering (&#147;IPO&#148;) price of $19.00
per share and assuming the conversion occurs on&nbsp;October 29, 2019), the expected closing date of the Company&#146;s IPO, and (ii)&nbsp;the reclassification of the Takeda Warrant to stockholders&#146; equity. Shares of common stock issued in the
IPO and any related net proceeds are excluded from the pro forma information. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Fair Value Option </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As permitted under Accounting Standards Codification (&#147;ASC&#148;) 825, <I>Financial Instruments</I>, (&#147;ASC 825&#148;), the Company has
elected the fair value option to account for its convertible promissory notes issued since inception. In accordance with ASC 825, the Company records these convertible promissory notes at fair value with changes in fair value recorded in the
combined statements of operations. As a result of applying the fair value option, direct costs and fees related to the convertible promissory notes were recognized in earnings as incurred and not deferred. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Fair Value Measurements </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The
accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or
<FONT STYLE="white-space:nowrap">non-recurring</FONT> basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market
participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance
establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Level&nbsp;1:</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Observable inputs such as quoted prices in active markets. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Level&nbsp;2:</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Inputs, other than the quoted prices in active markets that are observable either directly or indirectly. </FONT></P></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="9%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Level&nbsp;3:</FONT></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="" ALIGN="left"><FONT STYLE="font-family:ARIAL" SIZE="2">Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
</FONT></P></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The carrying amounts of the Company&#146;s financial instruments, including cash and cash equivalents classified
within the Level&nbsp;1 designation discussed above, prepaid and other current </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-9 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(CONTINUED) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
assets, accounts payable, and accrued liabilities, approximate fair value due to their short maturities. Warrant liabilities and convertible promissory notes are recorded at fair value on a
recurring basis. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The Company has no financial assets measured at fair value on a recurring basis. None of the Company&#146;s <FONT
STYLE="white-space:nowrap">non-financial</FONT> assets or liabilities are recorded at fair value on a <FONT STYLE="white-space:nowrap">non-recurring</FONT> basis. No transfers between levels have occurred during the periods presented. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Liabilities measured at fair value on a recurring basis are as follows (in thousands): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD COLSPAN="2" VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Fair&nbsp;Value&nbsp;Measurements&nbsp;at<BR>Reporting&nbsp;Date&nbsp;Using:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Total</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Quoted&nbsp;Prices&nbsp;in<BR>Active&nbsp;Markets<BR>for&nbsp;Identical<BR>Assets</B></FONT><br><FONT
STYLE="font-family:ARIAL" SIZE="1"><B>(Level&nbsp;1)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Significant<BR>Other<BR>Observable<BR>Inputs</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(Level&nbsp;
2)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Significant<BR>Unobservable<BR>Inputs</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(Level&nbsp;
3)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">As of December&nbsp;31, 2018:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Convertible promissory notes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,950</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,950</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">As of June&nbsp;30, 2019:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Warrant liabilities</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">49,597</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">49,597</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Convertible promissory notes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">92,743</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">92,743</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;142,340</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;142,340</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The warrant liabilities consist of an issued and outstanding common stock warrant (the &#147;Takeda Warrant&#148;)
and a right to receive an additional common stock warrant (the &#147;Takeda Warrant Right&#148;, and together with the Takeda Warrant, the &#147;Takeda Warrants&#148;) issued to Takeda Pharmaceutical Company Limited (&#147;Takeda&#148;) in
connection with a May 2019 license agreement (see Note 3) and warrants (the &#147;Lender Warrants&#148;) issued in connection with a loan and security agreement for commercial bank debt (see Note 5). The Takeda Warrants are accounted for as
liabilities as they do not meet all the conditions for equity classification due to (i)&nbsp;insufficient authorized shares for the Takeda Warrant and (ii)&nbsp;the Takeda Warrant Right is not indexed to the Company&#146;s own stock. The Lender
Warrants are accounted for as liabilities as they contain a holder put right under which the lenders could require the Company to pay cash in exchange for the warrants. The fair value of the Takeda Warrants is derived from the model used to estimate
the fair value the Company&#146;s common stock (see Note 6). The fair value of the Lender Warrants is estimated using a probability-weighted model considering IPO and <FONT STYLE="white-space:nowrap">non-IPO</FONT> scenarios. The IPO scenarios
utilize a binomial lattice model to estimate a distribution of total equity values as of a projected IPO date. The <FONT STYLE="white-space:nowrap">non-IPO</FONT> scenario utilizes the repurchase price associated with the warrant put right
discounted to present value based on venture capital rates of return and the term associated with the put right. As of June&nbsp;30, 2019, the fair value of the Takeda Warrants was $49.2&nbsp;million and the fair value of the Lender Warrants was
$0.4&nbsp;million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As further described in Note 4, the Company issued convertible promissory notes to Frazier (the &#147;Frazier
Notes&#148;) from January 2018 to April 2019 and issued convertible promissory notes in May 2019 (the &#147;May 2019 Notes&#148;) to investors including Frazier. The Company has elected the fair value option for each of its convertible promissory
note issuances. The fair value of the Frazier Notes was estimated using a scenario-based analysis that estimated the fair value of the convertible promissory notes based on the probability-weighted present value of expected future investment
returns, considering possible </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-10 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
outcomes available to the noteholders, including conversions in subsequent equity financings, change of control transactions, settlement and dissolution. The fair value of the May 2019 Notes is
estimated using a scenario-based analysis that estimates the fair value of the convertible promissory notes based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to
the noteholders, including various IPO, settlement, equity financing, corporate transaction and dissolution scenarios. As of December&nbsp;31, 2018, the fair value of the Frazier Notes was $2.0&nbsp;million and the Frazier Notes were exchanged for
May 2019 Notes in May 2019. As of June&nbsp;30, 2019, the fair value of the May 2019 Notes was $92.7&nbsp;million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The Company adjusts
the carrying value of its warrant liabilities and convertible promissory notes to their estimated fair value at each reporting date, with any related increases or decreases in the fair value recorded as change in fair value of warrant liabilities
and change in fair value of convertible promissory notes, respectively, in the combined statements of operations. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The following table
summarizes information about the significant unobservable inputs used in the fair value measurements for the Takeda Warrants and the May 2019 Notes: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000 ; display:table-cell;"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Liability</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Fair&nbsp;value<BR>as&nbsp;of&nbsp;initial<BR>valuation
date</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Fair&nbsp;value<BR>as&nbsp;of<BR>June&nbsp;30,&nbsp;
2019</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(in&nbsp;thousands)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Fair value method as
of<BR>initial&nbsp;valuation&nbsp;date</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>(and relative weighting)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Fair&nbsp;value&nbsp;method</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>as&nbsp;of June&nbsp;30,&nbsp;2019</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="1"><B>(and relative weighting)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1px solid #000000"> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Key&nbsp;unobservable&nbsp;inputs</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Range</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="1">Takeda Warrants</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">47,894</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">49,171</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="1">Financing&nbsp;transactions&nbsp;(40%)</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:ARIAL" SIZE="1">Income
approach (60%)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="1">Financing&nbsp;transactions&nbsp;(40%)</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:ARIAL" SIZE="1">Income
approach (60%)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="1">Transaction&nbsp;prices&nbsp;per&nbsp;share</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="1">Estimated time to liquidity</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:ARIAL" SIZE="1">Discount rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="1">&nbsp;</FONT><BR> <P STYLE="margin-bottom:0px; margin-top:0px"></P> <P STYLE="margin-bottom:1px; margin-top:0px"></P></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1"><FONT STYLE="white-space:nowrap">$9.33-$10.56</FONT></FONT><BR> <P STYLE="margin-bottom:0px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1"><FONT
STYLE="white-space:nowrap">0.29-1.73&nbsp;years</FONT></FONT></P> <P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">13</FONT></P></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="1">&nbsp;</FONT><BR> <P STYLE="margin-bottom:0px; margin-top:0px"><FONT STYLE="font-family:ARIAL" SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT
STYLE="font-family:ARIAL" SIZE="1">%&nbsp;</FONT></P></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="1">May&nbsp;2019 Notes</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">90,250</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="1">$</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">92,743</FONT></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="1">Financing&nbsp;transactions&nbsp;(40%)</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:ARIAL" SIZE="1">Income
approach (60%)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="1">Financing transactions (40%)</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:ARIAL" SIZE="1">Income approach
(60%)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="1">Estimated&nbsp;time&nbsp;to liquidity</FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="1">Volatility</FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px"><FONT STYLE="font-family:ARIAL" SIZE="1">Discount rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="1">&nbsp;</FONT><BR> <P STYLE="margin-bottom:0px; margin-top:0px"></P> <P STYLE="margin-bottom:1px; margin-top:0px"></P></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1"><FONT STYLE="white-space:nowrap">0.29-1.73&nbsp;years</FONT></FONT><BR>
<P STYLE="margin-bottom:0px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1">70</FONT></P>
<P STYLE="margin-bottom:1px; margin-top:0px" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="1"><FONT STYLE="white-space:nowrap">22.6%-25</FONT></FONT></P></TD>
<TD NOWRAP VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="1">&nbsp;</FONT><BR> <P STYLE="margin-bottom:0px; margin-top:0px"><FONT STYLE="font-family:ARIAL" SIZE="1">%&nbsp;</FONT></P> <P STYLE="margin-bottom:1px; margin-top:0px"><FONT
STYLE="font-family:ARIAL" SIZE="1">%&nbsp;</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">There are significant judgments, assumptions and estimates inherent in the determination of the fair value of each
of the instruments described above. These include determination of a valuation method and selection of the possible outcomes available to the Company, including the determination of timing and expected future investment returns for such scenarios.
The Company considered the equity value of an initial public offering using market transactions and have determined the expected value of various stay private and dissolution scenarios using the income approach, which is based on assumptions
regarding the Company&#146;s future operating performance. The related judgments, assumptions and estimates are highly interrelated and changes in any one assumption could necessitate changes in another. In particular, any changes in the probability
of a particular outcome would require a related change to the probability of another outcome. In addition, the fair value of the May 2019 Notes is derived using assumptions that are consistent with the assumptions used to value the Company&#146;s
common stock and the Takeda Warrants, and the concluded fair value of the May 2019 Notes is used in the determination of both the fair value of the Company&#146;s common stock and the Takeda Warrants. In the future, depending on the valuation
approaches used and the expected timing and weighting of each, the inputs described above, or other inputs, may have a greater or lesser impact on the Company&#146;s estimates of fair value. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-11 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The following table provides a reconciliation of all liabilities measured at fair value using
Level&nbsp;3 significant unobservable inputs (in thousands): </FONT></P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Warrant<BR>Liabilities</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Convertible<BR>Promissory<BR>Notes</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Balance at January&nbsp;1, 2018</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Issuance of convertible promissory notes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,900</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Change in fair value</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Balance at December&nbsp;31, 2018</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,950</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Issuance of convertible promissory notes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">90,750</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Exchange of convertible promissory notes (Note 4)</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(2,399</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Issuance of warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">48,313</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Change in fair value</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,284</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2,442</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Balance at June&nbsp;30, 2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">49,597</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">92,743</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Cash and Cash Equivalents </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The Company considers all highly liquid investments with original maturities of three months or less when purchased to be cash equivalents. Cash and cash equivalents include cash in readily available checking
accounts and money market funds. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Concentrations of Credit Risk </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial
institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository
institutions in which those deposits are held. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Deferred Offering Costs </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The Company has deferred offering costs consisting of legal, accounting and other fees and costs directly attributable to its planned IPO. The
deferred offering costs will be offset against the proceeds received upon the completion of the planned IPO. In the event the planned IPO is terminated, all of the deferred offering costs will be expensed within the Company&#146;s statements of
operations. As of June&nbsp;30, 2019, $0.3&nbsp;million of deferred offering costs were recorded within other long-term assets on the balance sheet. No such costs were included on the combined balance sheet as of December&nbsp;31, 2018. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Research and Development Expenses and Accruals </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">All research and development costs are expensed in the period incurred and consist primarily of salaries, payroll taxes, employee benefits, stock-based compensation charges for those individuals involved in
research and development efforts, external research and development costs incurred under agreements with contract research organizations and consultants to conduct and support the Company&#146;s planned clinical trials of vonoprazan, and costs
related to manufacturing vonoprazan for clinical trials. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-12 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The Company has entered into various research and development contracts with clinical research
organizations, clinical manufacturing organizations and other companies. Payments for these activities are based on the terms of the individual agreements, which may differ from the pattern of costs incurred, and payments made in advance of
performance are reflected in the accompanying balance sheets as prepaid expenses or accrued liabilities. The Company records accruals for estimated costs incurred for ongoing research and development activities. When evaluating the adequacy of the
accrued liabilities, the Company analyzes progress of the services, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the prepaid or accrued balances
at the end of any reporting period. Actual results could differ from the Company&#146;s estimates. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I><FONT STYLE="white-space:nowrap">In-Process</FONT> Research and Development </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The Company evaluates whether acquired intangible assets are a business under applicable accounting standards. Additionally, the Company evaluates whether the acquired assets have a future alternative use.
Intangible assets that do not have future alternative use are considered acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and development. When the acquired <FONT STYLE="white-space:nowrap">in-process</FONT> research and
development assets are not part of a business combination, the value of the consideration paid is expensed on the acquisition date. Future costs to develop these assets are recorded to research and development expense as they are incurred.
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Stock-Based Compensation </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Stock-based compensation expense represents the cost of the grant date fair value of equity awards recognized over the requisite service period of
the awards (generally the vesting period) on a straight-line basis. The Company recognizes forfeitures as they occur. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Income Taxes
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax
assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, deferred tax assets and liabilities are determined on the basis of the differences between the
financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in
the statement of operations in the period that includes the enactment date. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The Company recognizes net deferred tax assets to the
extent that the Company believes these assets are more likely than not to be realized. In making such a determination, management considers all available positive and negative evidence, including future reversals of existing taxable temporary
differences, projected future taxable income, <FONT STYLE="white-space:nowrap">tax-planning</FONT> strategies, and results of recent operations. If management determines that the Company would be able to realize its deferred tax assets in the future
in excess of their net recorded amount, management would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The Company records uncertain tax positions on the basis of a <FONT STYLE="white-space:nowrap">two-step</FONT> process whereby (i)&nbsp;management determines whether it is more likely than not that the tax
positions will be sustained on </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-13 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
the basis of the technical merits of the position and (ii)&nbsp;for those tax positions that meet the <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> recognition threshold,
management recognizes the largest amount of tax benefit that is more than 50&nbsp;percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax
benefits within income tax expense. Any accrued interest and penalties are included within the related tax liability. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Comprehensive Loss
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances from <FONT
STYLE="white-space:nowrap">non-owner</FONT> sources. The Company&#146;s comprehensive loss was the same as its reported net loss for all periods presented. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Segment Reporting </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Operating segments are identified as components of an enterprise
about which separate discrete financial information is available for evaluation by the chief operating decision maker in making decisions on how to allocate resources and assess performance. The Company views its operations and manages its business
as one operating segment. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Net Loss Per Share </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">For the year ended December&nbsp;31, 2018 and the six months ended June&nbsp;30, 2018 and 2019, the net loss per share was recast to include in the numerator the net losses of both the Company and YamadaCo and
include in the denominator the combined weighted-average outstanding shares of both the Company and YamadaCo. Basic net loss per share is computed by dividing the combined net loss by the weighted-average number of common shares outstanding for the
period, without consideration for potentially dilutive securities. The Company has excluded weighted-average unvested shares of 2,728,593 shares from the weighted-average number of common shares outstanding for the six months ended June&nbsp;30,
2019. No shares of common stock were unvested during the year ended December&nbsp;31, 2018. Diluted net loss per share is computed by dividing the combined net loss by the weighted-average number of common shares and dilutive common stock
equivalents outstanding for the period determined using the treasury-stock and <FONT STYLE="white-space:nowrap">if-converted</FONT> methods. Dilutive common stock equivalents are comprised of unvested common stock, warrants and convertible
promissory notes. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Unaudited Pro Forma Net Loss Per Share </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The unaudited pro forma basic and diluted net loss per share reflects (i)&nbsp;the automatic conversion of all outstanding convertible promissory
notes and related accrued interest into&nbsp;6,107,918&nbsp;shares of common stock (at the IPO price of $19.00 per share and assuming the conversion occurs on&nbsp;October&nbsp;29, 2019, the expected closing date of the Company&#146;s IPO), and
(ii)&nbsp;the reclassification of the Takeda Warrant to stockholders&#146; equity, each as of the beginning of the period presented or the issuance date, if later. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The unaudited pro forma basic and diluted net loss per share amounts do not give effect to the issuance of common stock issued in the IPO nor do they give effect to potential dilutive securities where the impact
would be anti-dilutive. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-14 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The following table summarizes the Company&#146;s unaudited pro forma net loss per share (in
thousands, except share and per share data): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Year&nbsp;Ended<BR>December&nbsp;31,<BR>2018</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Six&nbsp;Months</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Ended</B></FONT><br><FONT
STYLE="font-family:ARIAL" SIZE="1"><B>June&nbsp;30,</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Numerator</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,288</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(89,013</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Interest expense on convertible promissory notes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">13</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">831</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Change in fair value of Takeda Warrant</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,277</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Change in fair value of convertible promissory notes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">50</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2,442</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Pro forma net loss</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,225</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(84,463</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Denominator</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Weighted-average shares of common stock outstanding, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6,051,675</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6,640,394</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Pro forma adjustments to reflect assumed weighted-average effect of conversion of convertible promissory notes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">46,754</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,937,902</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Pro forma weighted-average shares of common stock outstanding, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6,098,429</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">8,578,296</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Pro forma net loss per share, basic and diluted</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(0.20</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(9.85</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Recently Adopted Accounting Pronouncements </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">In June 2018, the Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards Update (&#147;ASU&#148;) <FONT STYLE="white-space:nowrap">No.&nbsp;2018-07,</FONT> <I>Compensation&#151;Stock
Compensation (Topic</I><I></I><I>&nbsp;718): Improvements to Nonemployee Share-Based Payment Accounting</I>. This guidance expands the scope of Topic&nbsp;718, <I>Compensation&#151;Stock Compensation</I>, which currently only includes share-based
payments to employees, to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. This ASU supersedes <FONT
STYLE="white-space:nowrap">Subtopic&nbsp;505-50,</FONT> <I>Equity&#151;Equity-Based Payments to <FONT STYLE="white-space:nowrap">Non-Employees</FONT></I> and is effective for public companies for annual periods beginning after December&nbsp;15,
2018, including interim periods within those fiscal years, with early adoption permitted as long as ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2014-09</FONT> has been adopted by the Company. The Company adopted this guidance effective
January&nbsp;1, 2018, and the adoption did not have a material impact on the Company&#146;s financial statements. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In February 2016, the
FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02,</FONT> <I>Leases (Topic 842)</I>, which requires a lessee to recognize a lease liability and a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset for all leases with lease terms of more than 12 months. Additionally, certain qualitative and quantitative disclosures will be required in the
financial statements. This guidance is effective for annual reporting periods beginning after December&nbsp;15, 2018, including interim periods within those fiscal years, and early adoption is permitted. Companies may adopt this guidance using a
modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. The Company adopted this guidance effective January&nbsp;1, 2018, and the adoption did not
have any impact on the Company&#146;s financial statements as the Company did not have any leases through June&nbsp;30, 2019. As </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-15 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
the Company enters into future, material lease agreements, the adoption of this guidance is expected to result in a significant increase in the total assets and liabilities reported on the
balance sheets. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Recently Issued Accounting Pronouncements </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">In August 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-13,</FONT> <I>Fair Value Measurement (Topic 820): Disclosure Framework&#151;Changes to the Disclosure Requirements for Fair Value
Measurement,</I> which eliminates, modifies and adds disclosure requirements on fair value measurements. The standard is effective for annual periods beginning after December&nbsp;15, 2019, including interim periods within those fiscal years, and
early adoption is permitted. The Company is currently evaluating the impact the adoption of ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-13</FONT> will have on the Company&#146;s financial statements. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>2. Related Party Transactions </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Frazier is a
principal stockholder of the Company and is represented on the Company&#146;s board of directors. For the year ended December&nbsp;31, 2018 and the six months ended June&nbsp;30, 2019, the Company conducted its operations within office space
controlled by Frazier and Frazier allocated a portion of the costs associated with this office to the Company. In addition, Frazier paid for various goods and services, such as employee wages, insurance and expense reimbursements and various
administrative services associated with the operations of the Company and charged the Company for those expenses. As of December&nbsp;31, 2018 and June&nbsp;30, 2019, the Company had outstanding accounts payable balances due to Frazier of $45,000
and $50,000, respectively, related to these shared operating expenses. For the year ended December&nbsp;31, 2018 and the six months ended June&nbsp;30, 2018 and 2019, the Company incurred $0.3&nbsp;million, $0.1&nbsp;million and $0.1&nbsp;million,
respectively, of shared operating expenses. In addition to the shared operating expenses, the Company issued convertible promissory notes to Frazier during 2018 and 2019 (see Note 4). </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Mountain Field LLC (&#147;Mountain Field&#148;) is an entity owned by the chairman of the Company&#146;s board of directors. During the year ended
December&nbsp;31, 2018 and the six months ended June&nbsp;30, 2019, the Company charged Mountain Field for certain rent and payroll related expenses. These shared expenses were allocated based on usage of the related facilities and time incurred by
personnel. As of December&nbsp;31, 2018 and June&nbsp;30, 2019, the Company had an outstanding accounts receivable balance from Mountain Field of $19,000 and $15,000, respectively, related to shared operating expenses. For the year ended
December&nbsp;31, 2018 and the six months ended June&nbsp;30, 2018 and 2019, the Company charged Mountain Field $4,000, $3,000 and $0.1&nbsp;million, respectively, for shared expenses. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Takeda became a common stockholder of the Company as of May&nbsp;7, 2019 in connection with the May 2019 license agreement (see Note 3).
</FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>3. Commitments and Contingencies </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>License
Agreement </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">On May&nbsp;7, 2019, the Company entered into a license agreement with Takeda pursuant to which it was granted an
exclusive license to commercialize vonoprazan fumarate in the United States, Canada and Europe (the &#147;Takeda License&#148;). The Company also has the right to sublicense its rights under the
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-16 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
agreement, subject to certain conditions. The agreement will remain in effect, on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis, until the later of (i)&nbsp;the expiration of the last to expire valid patent claim covering vonoprazan fumarate alone or in combination with at
least one other therapeutically active ingredient, (ii)&nbsp;the expiration of the applicable regulatory exclusivity and (iii) 15 years from the date of first commercial sale, unless earlier terminated. The Company may terminate the Takeda License
upon six months&#146; written notice. The Company and Takeda may terminate the Takeda License in the case of the other party&#146;s insolvency or material uncured breach. Takeda may terminate the Takeda License if the Company challenges, or assists
in challenging, licensed patents. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In consideration of the Takeda License, the Company (i)&nbsp;paid Takeda $25.0&nbsp;million in cash,
(ii)&nbsp;issued Takeda 1,084,000 shares of its common stock at a fair value of $5.9&nbsp;million, (iii)&nbsp;issued the Takeda Warrant to purchase 7,588,000 shares of its common stock at an exercise price of $0.00004613 per share at an initial fair
value of $47.9&nbsp;million, and (iv)&nbsp;issued the Takeda Warrant Right to receive an additional common stock warrant should Takeda&#146;s fully-diluted ownership of the Company represent less than a certain specified percentage of the
fully-diluted capitalization, including shares issuable upon conversion of outstanding convertible promissory notes, calculated immediately before the closing of the Company&#146;s IPO, with a nominal initial fair value due to the low probability of
issuance. In addition, the Company is obligated to pay Takeda up to an aggregate of $250.0&nbsp;million in sales milestones upon the achievement of specified levels of product sales, and a low double-digit royalty rate on aggregate net sales of
licensed products, subject to certain adjustments. The Company incurred $0.1&nbsp;million of transaction costs in connection with the Takeda License. The Takeda Warrant has an exercise price of $0.00004613 per share, expires on May&nbsp;7, 2029 and
becomes exercisable upon (i)&nbsp;certain change of control transactions of the Company or (ii)&nbsp;the consummation of an IPO by the Company. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The transaction has been accounted for as an asset acquisition as substantially all of the fair value is concentrated in a group of similar assets. The $78.9&nbsp;million fair value of the consideration paid for
these research and development assets, which have no alternative future use, was recorded as <FONT STYLE="white-space:nowrap">in-process</FONT> research and development in the Company&#146;s combined statement of operations for the six months ended
June&nbsp;30, 2019. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Contingencies </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">In the event the Company becomes subject to claims or suits arising in the ordinary course of business, the Company would accrue a liability for such matters when it is probable that future expenditures will be
made and such expenditures can be reasonably estimated. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>4. Convertible Promissory Notes </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Frazier Convertible Note Financing </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">From January 2018 to April 2019, the Company issued
the Frazier Notes for an aggregate of $2.4&nbsp;million and bearing interest at per annum rates ranging from 1.68% to 2.55%. Of the Frazier Notes, $1.9&nbsp;million were issued in 2018 and $0.5&nbsp;million were issued in April 2019. Due to certain
embedded features within the Frazier Notes, the Company elected to account for these notes and all their embedded features under the fair value option. The Company recorded changes in the fair value of the Frazier Notes in the combined statements of
operations until May 2019, when the Frazier Notes and related accrued interest were exchanged, at their then fair value of $2.4&nbsp;million, for the May 2019 </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-17 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
Notes. For the year ended December&nbsp;31, 2018 and the six months ended June&nbsp;30, 2018, the Company recognized $50,000 and $4,000, respectively, of change in fair value of convertible
promissory notes in the combined statements of operations related to increases in the fair value of the Frazier Notes. For the six months ended June&nbsp;30, 2019, the Company recognized $50,000 of other income in the combined statements of
operations related to decreases in the fair value of the Frazier Notes. For the year ended December&nbsp;31, 2018 and the six months ended June&nbsp;30, 2018 and 2019, the Company recognized $13,000, $4,000 and $15,000, respectively, of interest
expense in connection with the Frazier Notes. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>May 2019 Convertible Note Financing </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">On May&nbsp;7, 2019, the Company entered into a note purchase agreement under which it issued the unsecured May 2019 Notes for an aggregate of
$90.3&nbsp;million, resulting in gross proceeds to the Company of $87.8&nbsp;million in cash and $2.4&nbsp;million related to the exchange of the Frazier Notes and related accrued interest for the May 2019 Notes. Including the conversion of the
Frazier Notes, Frazier purchased $20.0&nbsp;million of the May 2019 Notes. The May 2019 Notes bear interest at a rate of 6% per annum and are subordinated to borrowings under the Company&#146;s loan and security agreement (see Note 5). The May 2019
Notes become payable upon demand of the holders of at least 60% of the outstanding principal amount of the May 2019 Notes, including Frazier, on May&nbsp;7, 2020 (the &#147;Maturity Date&#148;), and become due and payable on May&nbsp;7, 2022,
subject to earlier conversion or repayment in the event the Company completes certain equity financings or a change of control. The May 2019 Notes can be converted/redeemed as follows (i)&nbsp;automatically converted upon a qualified equity
financing, with a conversion price of the lesser of 80% of the price paid per share in such financing or the conversion cap price per share, (ii)&nbsp;optionally converted upon a <FONT STYLE="white-space:nowrap">non-qualified</FONT> equity financing
with a conversion price of 80% of the price paid per share in such financing, (iii)&nbsp;optionally converted any time after the Maturity Date, with a conversion price per share of the conversion cap price per share, (iv)&nbsp;automatically upon an
IPO with a conversion price per share of the lesser of 80% of the IPO price per share, or the conversion cap price per share, and (v)&nbsp;upon certain corporate transactions, receive cash equal to the greater of (A)&nbsp;two times the then
outstanding principal and accrued interest and (B)&nbsp;an amount equal to the amount that would be received as if the May 2019 Notes were converted with a conversion price of the conversion cap price per share. The conversion cap price per share is
defined as $500.0&nbsp;million less the outstanding principal and accrued interest divided by the total of (1)&nbsp;the total number of common shares outstanding immediately prior to conversion, (2)&nbsp;the number of common shares issuable upon
exercise or conversion of exercisable or convertible securities, and (3)&nbsp;the number of shares of capital stock reserved for issuance under the Company&#146;s equity incentive plan. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The note purchase agreement includes, among others, covenants related to delivery of certain financial reports, certain registration rights, voting
provisions regarding the composition of the Company&#146;s board of directors, and limitations on the Company&#146;s ability to pay dividends, incur additional indebtedness or consummate certain changes of control. The note purchase agreement also
contains customary events of default, including bankruptcy, the failure to make payments when due, and certain material adverse changes. Upon the occurrence of an event of default, subject to any specified cure periods, all amounts owed by the
Company may be declared immediately due and payable. As of June&nbsp;30, 2019, the Company was in compliance with all applicable covenants under the note purchase agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Due to certain embedded features within the May 2019 Notes, the Company elected to account for these notes and all their embedded features under the fair value option. For the six months ended
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-18 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
June&nbsp;30, 2019, the Company recognized $2.5&nbsp;million of other expense in the combined statements of operations related to increases in the fair value of the May 2019 Notes. For the six
months ended June&nbsp;30, 2019, the Company recognized $0.8&nbsp;million of interest expense in connection with the May 2019 Notes. As of June 30, 2019, the outstanding principal and accrued interest on the May 2019 Notes was $90.3 million and $0.8
million, respectively. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>5. Long-Term Debt </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Long-term debt consists of the following (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>June&nbsp;30,</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Long-term debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">25,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Unamortized debt discount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(2,551</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Long-term debt, net of debt discount</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22,449</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">On May&nbsp;14, 2019, the Company entered into a loan and security agreement (the &#147;Loan Agreement&#148;, and
all amounts borrowed thereunder the &#147;Term Loans&#148;) with Silicon Valley Bank (&#147;SVB&#148;), as administrative and collateral agent, and lenders including SVB and WestRiver Innovation Lending Fund VIII, L.P. (&#147;WestRiver&#148;). The
Company borrowed $25.0&nbsp;million (&#147;Term Loan A&#148;) at the inception of the Loan Agreement and has the right to borrow an additional $25.0&nbsp;million (&#147;Term Loan B&#148;). Term Loan B is available through March&nbsp;31, 2020,
provided that (i)&nbsp;the Company has received at least $150.0&nbsp;million of net cash proceeds in connection with the issuance and sale, subsequent to April&nbsp;1 2019, of its equity securities and subordinated debt, (ii)&nbsp;the Company has
initiated Phase 3 clinical trials for vonoprazan, and (iii)&nbsp;no event of default has occurred. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The Term Loans bear interest at a
floating rate of the higher of the Wall Street Journal Prime rate plus 1.75% (7.25% at June&nbsp;30, 2019) or 7.25%. The monthly payments consist of interest-only through June&nbsp;1, 2021 or, in the event of positive data with respect to the
Company&#146;s Phase 3 clinical trial in both indications for Vonoprazan sufficient to file an NDA with the FDA, through June&nbsp;1, 2022. Subsequent to the interest-only period, the Term Loans will be payable in equal monthly installments of
principal, plus accrued and unpaid interest through the maturity date of May&nbsp;1, 2024. In addition, the Company is obligated to pay a final payment fee of 8.25% of the original principal amount of the Term Loans. As of June&nbsp;30, 2019, the
final payment fee of $2.1&nbsp;million has been recorded as an other long-term liability. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The Company may elect to prepay all or a
portion of the Term Loans prior to maturity, subject to a prepayment fee of up to 2.0% of the then outstanding principal balance and payment of a pro rata portion of the final payment fee. After repayment, no Term Loan amounts may be borrowed again.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The borrowings under the Loan Agreement are collateralized by substantially all of the Company&#146;s assets, excluding intellectual
property and certain other assets. The Loan Agreement includes affirmative and negative covenants. The affirmative covenants include, among others, covenants requiring the Company to maintain its legal existence and governmental approvals, deliver
certain financial reports, maintain insurance coverage and satisfy certain requirements regarding its operating accounts. The negative covenants include, among others, limitations on the Company&#146;s
</FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-19 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
ability to incur additional indebtedness and liens, merge with other companies or consummate certain changes of control, acquire other companies, engage in new lines of business, make certain
investments, pay dividends, transfer or dispose of assets, amend certain material agreements or enter into various specified transactions. The Loan Agreement also contains customary events of default, including bankruptcy, the failure to make
payments when due, and a material adverse change. Upon the occurrence of an event of default, subject to any specified cure periods, all amounts owed by the Company would begin to bear interest at a rate that is 4.00% above the rate effective
immediately before the event of default and may be declared immediately due and payable by SVB, as collateral agent. As of June&nbsp;30, 2019, the Company was in compliance with all applicable covenants under the Loan Agreement. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In connection with the Loan Agreement, the Company issued the Lender Warrants to purchase stock of the Company. The Lender Warrants become
exercisable only if the Company borrows Term Loan B, and the number, class and per share price of the shares subject to the warrants is dependent on the terms of certain future equity financing transactions of the Company, including an IPO. The
Lender Warrants expire ten years from the date of issuance, subject to earlier termination on September&nbsp;30, 2020 if the Company does not draw down Term Loan B on or before March&nbsp;31, 2020. The Lender Warrants include a put option pursuant
to which, in the event that the Company does not draw down Term Loan B on or before March&nbsp;31, 2020, the warrant holders may require that the Company repurchase the warrants for a total aggregate repurchase price of $0.5&nbsp;million. The put
right is exercisable through September&nbsp;30, 2020. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The initial $0.4&nbsp;million fair value of the Lender Warrants, the
$2.1&nbsp;million final payment fee and $0.2&nbsp;million of debt issuance costs have been recorded as debt discount and are being amortized to interest expense using the effective interest method over the term of the Term Loans. For the six months
ended June&nbsp;30, 2019, the Company recognized $0.3&nbsp;million of interest expense, including amortization of the debt discount, in connection with the Loan Agreement. As of June&nbsp;30, 2019, the Company had outstanding Term Loans of
$25.0&nbsp;million and accrued interest of $0.2&nbsp;million. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Future minimum principal and interest payments under the Term Loans,
including the final payment fee, as of June&nbsp;30, 2019 are as follows (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Year&nbsp;ending&nbsp;December&nbsp;31:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">921</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">2020</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">1,843</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">2021</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">6,609</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">2022</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">9,533</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">2023</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">8,920</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">2024</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">5,599</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total principal and interest payments</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">33,425</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Less interest and final payment fee</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(8,425</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Long-term debt</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">25,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-20 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>6. Stockholders&#146; Deficit </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B><I>Common Stock </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In March 2019, subsequent to the Merger, the Company sold 1,491,072 shares
of the Company&#146;s common stock to Frazier. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In March 2019, the founders granted the Company a repurchase right for the 3,373,408
shares of common stock originally purchased in 2018. The Company has the right, but not the obligation, to repurchase unvested shares in the event the founder&#146;s relationship with the Company is terminated, subject to certain limitations, at the
original purchase price of the stock. The repurchase right lapses for 843,352 shares in March 2019 and the repurchase right for the remaining 2,530,056 shares lapses in equal monthly amounts over the following
<FONT STYLE="white-space:nowrap">48-month</FONT> period ending in March 2023. The fair value of the founder shares at the date the repurchase right was granted is being recognized as stock-based compensation expense on a straight-line basis over the
vesting period. As of June&nbsp;30, 2019, 2,371,928 shares of common stock were subject to repurchase by the Company and the associated repurchase liability was not significant. The amount of recognized and unrecognized stock-based compensation
related to the founder stock was immaterial for all periods presented. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In May 2019, the Company issued Takeda 1,084,000 shares of
common stock in connection with the Takeda License. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%;padding-bottom:0px; "><FONT STYLE="font-family:ARIAL" SIZE="2">For the period from January&nbsp;1, 2019 to May&nbsp;6, 2019,
the Company issued 2,524,852 shares of common stock to various employees and consultants of the Company for aggregate proceeds of approximately $1,000. Upon issuance, these shares were subject to a repurchase option by the Company at the original
purchase price of the shares. The repurchase rights generally lapse as to 25% of the shares on the first anniversary of the vesting commencement date, and the repurchase right lapses as to 1/48</FONT><FONT STYLE="font-family:ARIAL" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">th</SUP></FONT><FONT STYLE="font-family:ARIAL" SIZE="2"> of the shares each <FONT STYLE="white-space:nowrap">one-month</FONT> period thereafter, subject to the purchaser remaining
continuously an employee, consultant or director of the Company. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Equity Incentive Plan </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">The Company&#146;s 2019 Equity Incentive Plan (the &#147;Existing Incentive Plan&#148;) provides for the grant of incentive stock options,
nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, and other stock awards to eligible recipients, including employees, directors or consultants of the Company. As of June&nbsp;30, 2019, the
Company had 2,231,739 shares of common stock authorized for issuance under the Existing Incentive Plan, of which 2,215,479 shares remained available for grant. In May 2019, the Company issued 16,260 shares of common stock under a restricted stock
award, of which 10,840 were unvested as of June&nbsp;30, 2019. For the six months ended June&nbsp;30, 2019, the Company recognized $29,000 of stock-based compensation expense related to restricted stock awards under the Existing Incentive Plan and
the grant date fair value of the award was $5.43 per share, the grant date fair value of the Company&#146;s common stock. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-21 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">A summary of the Company&#146;s unvested shares is as follows: </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Balance&nbsp;at&nbsp;January&nbsp;1,&nbsp;2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Vesting restrictions placed on previously issued shares</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">3,373,408</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Sale of unvested common stock</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2,524,852</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Issuance of unvested restricted stock awards</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">16,260</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Share vesting</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(1,257,270</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Balance at June&nbsp;30, 2019</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">4,657,250</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">For accounting purposes, unvested shares of common stock are considered issued, but not outstanding until they
vest. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Stock-Based Compensation Expense </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Stock-based compensation expense recognized for all equity awards, including founder stock, has been reported in the combined statements of operations as follows (in thousands): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Six&nbsp;Months&nbsp;Ended</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>June&nbsp;30,</B></FONT><br><FONT
STYLE="font-family:ARIAL" SIZE="1"><B>2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Research and development expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">General and administrative expense</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;29</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As of June&nbsp;30, 2019, the Company had $59,000 of unrecognized stock-based compensation expense, which is
expected to be recognized over a weighted-average period of 0.7 years. For the six months ended June&nbsp;30, 2019, the vested fair value of the restricted stock awards was $29,000. There was no stock-based compensation expense for the year ended
December&nbsp;31, 2018. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Valuation of Common Stock </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Prior to obtaining the Takeda License on May&nbsp;7, 2019, the fair value of the Company&#146;s common stock was nominal since the Company was not sufficiently capitalized and held no assets that could be used to
generate future revenues. Subsequent to obtaining the Takeda License and issuing the May 2019 Notes, the Company estimated the fair value of its common stock using methodologies, approaches and assumptions consistent with the American Institute of
Certified Public Accountants Accounting and Valuation Guide: <I>Valuation of Privately Held Company Equity Securities Issued as Compensation </I>(the &#147;Practice Aid&#148;). The Practice Aid prescribes several valuation approaches for setting the
value of an enterprise, such as the cost, income and market approaches, and various methodologies for allocating the value of an enterprise to its common stock. The Company&#146;s 2019 valuations utilized a scenario-based analysis that estimated the
fair value per share based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to the Company, including various IPO, stay private and dissolution scenarios, and
applying a discount for lack of marketability. The Company considered various stay private scenarios using the income approach and allocated the indicated equity value to each class of equity based on the current-value method. The Company also
considered various IPO scenarios </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-22 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
based on expected equity values in an IPO and allocated the indicated equity value to each class of equity on a fully-diluted basis considering the dilutive impacts of the May 2019 Notes and the
Lender Warrants. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Common Stock Reserved for Future Issuance </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">Common stock reserved for future issuance consists of the following: </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>June&nbsp;30,</B></FONT><br><FONT STYLE="font-family:ARIAL" SIZE="1"><B>2019</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Common stock warrants</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">7,588,000</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Shares available for issuance under the Existing Incentive Plan</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">2,215,479</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">9,803,479</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As of December&nbsp;31, 2018, no shares of common stock were reserved for future issuance. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>7. Income Taxes </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">A reconciliation between
the provision for income taxes and income taxes computed using the U.S. federal statutory corporate tax rate is as follows (in thousands): </FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>Year&nbsp;Ended<BR>December&nbsp;31,<BR>2018</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Tax computed at federal statutory rate</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(271</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Permanent differences</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">14</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Change in valuation allowance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;257</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Provision for income taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Significant components of the Company&#146;s net deferred tax assets are as follows (in thousands): </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1px solid #000000"><FONT STYLE="font-family:ARIAL" SIZE="1"><B>December&nbsp;31,<BR>2018</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Deferred tax assets:</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net operating loss carryforwards</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">5</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Accruals and reserves</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">16</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Intangible assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;236</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Total deferred tax assets</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">257</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Valuation allowance</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">(257</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">)&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em"><FONT STYLE="font-family:ARIAL" SIZE="2">Net deferred taxes</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="2">&#150;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-family:ARIAL" SIZE="2">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Based upon the Company&#146;s history of operating losses, the Company is unable to conclude that it is more likely
than not that the benefit of its deferred tax assets will be realized. Accordingly, the Company has provided a full valuation allowance for its deferred tax assets as of December&nbsp;31, 2018. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-23 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As of December&nbsp;31, 2018, the Company had federal net operating loss carryforwards of
approximately $23,000, which do not expire, and no material federal or California research and development credits. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">Pursuant to
Internal Revenue Code Sections 382 and 383, annual use of the Company&#146;s net operating loss and research and development tax credit carryforwards may be limited in the event a cumulative change in ownership of more than 50% occurs within a
three-year period. The Company has not completed a Section&nbsp;382 study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since the Company&#146;s formation. If eliminated, the related asset
would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. Due to the existence of the valuation allowance, limitations created by future ownership changes, if any, will not impact the
Company&#146;s effective tax rate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">As of December&nbsp;31, 2018, there were no material unrecognized tax benefits recorded in the
combined financial statements and the Company does not anticipate any significant changes in its unrecognized tax benefits over the next 12 months. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">The Company is subject to taxation in the United States federal and state jurisdictions. The Company has not yet filed federal income tax and state income tax returns, but upon filing will be subject to examination
by federal and state tax authorities due to the carryforward of unutilized net operating losses and research and development credits.&nbsp;The Company is not currently under examination by any tax authority. The Company&#146;s policy is to recognize
interest and penalties related to income tax matters as a component of income tax expense. The Company has not recognized interest or penalties in its combined statements of operations since inception. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>8. Subsequent Events </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">For purposes of the
financial statements as of December&nbsp;31, 2018 and for the year then ended, and the interim financial statements as of June&nbsp;30, 2019 and for the six months then ended, the Company has completed an evaluation of all subsequent events through
July&nbsp;26, 2019 to ensure these financial statements include appropriate disclosure of events both recognized in the financial statements and events which occurred but were not recognized in the financial statements. The Company has further
evaluated subsequent events for disclosure purposes through October&nbsp;15, 2019. Except as described below, the Company has concluded that no subsequent event has occurred that requires disclosure. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>2019 Incentive Award Plan </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">In October
2019, the board of directors adopted, and the Company&#146;s stockholders approved the 2019 Equity Incentive Plan (the &#147;2019 Plan&#148;), which will become effective in connection with this offering. Under the 2019 Plan, the Company may grant
stock options, stock appreciation rights, restricted stock, restricted stock units and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company or its subsidiaries. An aggregate of 2,700,000
shares of the Company&#146;s common stock will initially be available for issuance under awards granted pursuant to the 2019 Plan. The number of shares initially available for issuance will be increased by (i) the number of shares subject to stock
options or similar awards granted under the Existing Incentive Plan that expire or otherwise terminate without having been exercised in full after the </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-24 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>PHATHOM PHARMACEUTICALS, INC. </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>NOTES TO COMBINED FINANCIAL STATEMENTS&#151;(Continued) </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:ARIAL" SIZE="2"><B>(Information as of June 30, 2019 and thereafter and for the six months ended June 30, 2018 and 2019 is unaudited) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2">
effective date of the 2019 Plan and unvested shares issued pursuant to awards granted under the Existing Incentive Plan that are forfeited to or repurchased by the Company after the effective
date of the 2019 Plan, with the maximum number of shares to be added to the 2019 Plan pursuant to clause (i) above equal to 1,416,788 shares, and (ii)&nbsp;an annual increase on January 1 of each calendar year beginning in 2020 and ending in 2029,
equal to the lesser of (a) 5% of the shares of common stock outstanding on the final day of the immediately preceding calendar year and (b) such smaller number of shares as determined by the board of directors. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Approval of the Employee Stock Purchase Plan </I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT
STYLE="font-family:ARIAL" SIZE="2">In October 2019, the board of directors adopted, and the Company&#146;s stockholders approved, the Employee Stock Purchase Plan (the &#147;ESPP&#148;), which will become effective in connection with this offering.
The ESPP permits participants to purchase common stock through payroll deductions of up to 20% of their eligible compensation, which includes a participant&#146;s gross base compensation for services to the Company, including overtime payments and
excluding sales commissions, incentive compensation, bonuses, expense reimbursements, fringe benefits and other special payments. A total of 270,000 shares of common stock is initially reserved for issuance under the ESPP. In addition, the number of
shares available for issuance under the ESPP will be annually increased on January 1 of each calendar year beginning in 2020 and ending in 2029, by an amount equal to the lesser of: (i) 1% of the shares outstanding on the final day of the
immediately preceding calendar year and (ii) such smaller number of shares as is determined by the board of directors. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:ARIAL" SIZE="2"><B><I>Forward Stock Split
</I></B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2">On October 11, 2019, the Company effected a 2.168-for-1 forward stock split of its common stock (the &#147;Forward Stock
Split&#148;). The par value of the common stock was not adjusted as a result of the Forward Stock Split and the authorized shares were increased to 50,000,000 shares of common stock in connection with the Forward Stock Split. The accompanying
combined financial statements and notes to the combined financial statements give retroactive effect to the Forward Stock Split for all periods presented, unless otherwise indicated. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="2">F-25 </FONT></P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1px;margin-top:0px;margin-bottom:0px;border-bottom:2pt solid #000000">&nbsp;</P>
<P STYLE="line-height:2px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:36px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="4">9,563,157 Shares </FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="5"><B>Phathom Pharmaceuticals, Inc. </B></FONT></P>
<P STYLE="margin-top:24px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="4">Common Stock </FONT></P> <P STYLE="font-size:36px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:24px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g63338g81j47.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:24px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:36px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>


<TR STYLE="page-break-inside:avoid">
<TD VALIGN="top"><FONT STYLE="font-family:ARIAL" SIZE="4"><B>Goldman&nbsp;Sachs&nbsp;&amp;&nbsp;Co.&nbsp;LLC</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="4"><B>Jefferies</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="font-family:ARIAL" SIZE="4"><B>Evercore&nbsp;ISI</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:ARIAL" SIZE="3"><B>Needham &amp; Company </B></FONT></P>
<P STYLE="font-size:36px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:36px;margin-bottom:0px; text-indent:5%"><FONT STYLE="font-family:ARIAL" SIZE="2"><B>Through and including November 18, 2019 (the 25th day after the date of this prospectus) all dealers that effect transactions in these
securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealers&#146; obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments
or subscriptions. </B></FONT></P> <P STYLE="font-size:10px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:2pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g63338g03h86.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g03h86.jpg
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M+SIPB<(G")PB<(G")PB<(G")PB<(J7]7/37LO>QWIRO6H=I4[5M_Z<MKF=H
M9U]UJ6VC5CCAS6=UUG+$$Z^$V)K(DVE ^ZRY[$N/8T91*BL)6PXWE>,XD;['
M?N6;'!H<""0X;<CL1S!\CY>2YT[6]#9L38U%L-63U:80:VR-ZDBF^#DS75R"
MA+;M3J)L]5L<Z_5RFZYW=18[0BKCJ@)I036VR36SZ.P':9L#PN5:(;,W.)8?
M/??O7T$P!!X2.'AX0#RV:"-CN">>_?\ \%/_ $]=(-KKGI$NH;J#-UX_7=2!
MJZ,1J<6;S6FPECWMM&EZTJ?4-MRDBPM@-EH DE4M&ZO",S;4P&)S35BV!B(+
M]76^0GR![1.W(=WAS\2/UY*'/WC:W?=WCX[-&Y:"?/=Q5UY.@GI'5X&ZI/E2
MVE@3TWV706:3[&4IY]ZP;.J>Q,6G%@]IX0VW$165"<AO8RU/*FXFX)M8CYBO
M9;<]_3;ZKY[^SP_XM_D"/YJR')6*<(G")PB<(G")PB<(G")PB<(G"*9]5?FQ
MG^_A_P#AR.?)_?\ #^97U9W?'^07VVG^CA?[Z[_X&>&=_P /YA']WQ_D5"7/
MJODG")PB<(G")PB<(G")PB<(G")PBY0;^]'KN3<&S^K E5.I2IZWTYUITW56
MO-VU-6DIMLV8Q3-=U0K3BXR@;#D;6#5FNS+H!/GALPD9UM:%"&2#4B%%=E0T
MK>P+22>>P.V_P'W7U;(UH;[)+F;EIXMAN3OS&QWV]_HHX5Z+4F(WA8-R7+9[
M^UM3"'>IQ\3H4=6;?FR&-;[WTY-UJK409ZR;MSJ(+*K8I,4*%-@]<5$E>$_U
MS8UCG$7VR@R.#8[^'/N[^8[E/6>SP[;$\/,[; @[[[@;\_'R\%8WT6W3?L/I
MNZ4JZ*W6HB_O2_E%W7:DHX\'EV!M\<" ZYUT$.3 ) N)>+UC3M#UX!-(&%R8
MU%@@F'(,V2R]Y[N31L.?>?T%C(X.=[/\(Y#R[]SMZ$DE6(Z3]!2.FW3 S7)B
MUM[!N<VU;"V%L78N RP,F_; V;>K!>[/99PYTH;D,/.3#N!L5J07(*C"AHZ$
MT\B+%CL,R!L/7Q6+G<1WVV'( >0 V"LCR5BG")PB<(G")PB<(G")PB<(G")P
MBM-6_P#L^#_[I'_Y5KGP/>?>?S7W'</</R6:Y"E.$3A$X1.$3A$X1.$3A$X1
M.$3A%&H_<.LY]+.;&7<@@>C5FTWNF'[5:)2:F$$6'6NP3^K+C$GS[)@7'C,#
M+U63 )D@ZM(\HN.S+%2IL";"DR"+(/[0UG&)3P\G8E%CEQ555>B8I^W &B0Z
MD(0EQ5QGP7""94.JI;6EQ5AD--B,(4E>9F$YQG)%X*GN+55\LI.H4G851MUC
M$5&IWT@-K9R":RS3;U+L4&HV)$H<](A21AV35#R8;T62]_1PVWWDM1YPYV63
M8_KT6=EWVC#[>+U]/NE3A7TX/=*A:1+L0>-;C ME!!QXD+K;TQ!DA :0)*K<
MF1(3L="!A!2G,8A2<M$7G#; H-OCV?Y*VVJW-%3+3ZS;HU9/!K$L ?@?T9.M
MGV1TR5@4:AY5Y<X.2]7FQ\YRB1'1GW<(L][ !?8HG\.A_!Y.Y\S\RHV'D/D$
M]@ OL43^'0_@\;GS/S*;#R'R">P 7V*)_#H?P>-SYGYE-AY#Y!/8 +[%$_AT
M/X/&Y\S\RFP\A\@GL %]BB?PZ'\'C<^9^938>0^03V "^Q1/X=#^#QN?,_,I
ML/(?()[ !?8HG\.A_!XW/F?F4V'D/D$]@ OL43^'0_@\;GS/S*;#R'R">P 7
MV*)_#H?P>-SYGYE-AY#Y!/8 +[%$_AT/X/&Y\S\RFP\A\@GL %]BB?PZ'\'C
M<^9^938>0^03V "^Q1/X=#^#QN?,_,IL/(?()[ !?8HG\.A_!XW/F?F4V'D/
MD$]@ OL43^'0_@\;GS/S*;#R'R">P 7V*)_#H?P>-SYGYE-AY#Y!/8 +[%$_
MAT/X/&Y\S\RFP\A\@GL %]BB?PZ'\'C<^9^938>0^03V "^Q1/X=#^#QN?,_
M,IL/(?()[ !?8HG\.A_!XW/F?F4V'D/D$]@ OL43^'0_@\;GS/S*;#R'R">P
M 7V*)_#H?P>-SYGYE-AY#Y!/8 +[%$_AT/X/&Y\S\RFP\A\@GL %]BB?PZ'\
M'C<^9^938>0^03V "^Q1/X=#^#QN?,_,IL/(?()[ !?8HG\.A_!XW/F?F4V'
MD/D$]@ OL43^'0_@\;GS/S*;#R'R">P 7V*)_#H?P>-SYGYE-AY#Y!/8 +[%
M$_AT/X/&Y\S\RFP\A\@OLF./$QY3\6%'BMH:6^\F'&98R[AAM:_?AM+:5JPG
MQ81X\]L9SV[XQG/(WW[TY#T"^CT2$1::S+AQI;?;#K:)<=E_",K3CWX2ZE:4
MJ\.>V<I__COG'&^W<IV![QNO+[ !?8HG\.A_!Y.Y\S\RHV'D/D$]@ OL43^'
M0_@\;GS/S*;#R'R">P 7V*)_#H?P>-SYGYE-AY#Y!/8 +[%$_AT/X/&Y\S\R
MFP\A\@GL %]BB?PZ'\'C<^9^938>0^03V "^Q1/X=#^#QN?,_,IL/(?()[ !
M?8HG\.A_!XW/F?F4V'D/D$]@ OL43^'0_@\;GS/S*;#R'R">P 7V*)_#H?P>
M-SYGYE-AY#Y!/8 +[%$_AT/X/&Y\S\RFP\A\@GL %]BB?PZ'\'C<^9^938>0
M^03V "^Q1/X=#^#QN?,_,IL/(?()[ !?8HG\.A_!XW/F?F4V'D/D$]@ OL43
M^'0_@\;GS/S*;#R'R">P 7V*)_#H?P>-SYGYE-AY#Y!/8 +[%$_AT/X/&Y\S
M\RFP\A\@GL %]BB?PZ'\'C<^9^938>0^03V "^Q1/X=#^#QN?,_,IL/(?()[
M !?8HG\.A_!XW/F?F4V'D/D$]@ OL43^'0_@\;GS/S*;#R'R">P 7V*)_#H?
MP>-SYGYE-AY#Y!/8 +[%$_AT/X/&Y\S\RFP\A\@GL %]BB?PZ'\'C<^9^938
M>0^03V "^Q1/X=#^#QN?,_,IL/(?()[ !?8HG\.A_!XW/F?F4V'D/D$]@ OL
M43^'0_@\;GS/S*;#R'R">P 7V*)_#H?P>-SYGYE-AY#Y!/8 +[%$_AT/X/&Y
M\S\RFP\A\@LFVVVRVAIIM#33:4H;;;2E#;:$8PE*$(3C"4I2G&,)2G&,8QC&
M,8QCD*5^^$3A$X1.$3A$X1.$3A$X1.$3A$X1<Z[+T3[&LE:FT5_>53CTD3U!
M[*ZC]=0X&KMEUZTA[ELK;>Q=HS0]ZN5)ZEZB0N-:"_.K:AHABHQ=6&$EA].L
M<DR\V#)@[$_S^O-3N/+RW[O#;TY=WJHD>]&6S'R-:A;X@-4P#48M'#UTK4;Q
M+'Q&X&A:;HG,:0["WV&%Y6P5H8NQ1#\ 2+V\+@NR:1%VHW@13CM3*>+O]?N3
MX@^9'EY@JVO3;TQD=$&S%BF[);V!(LNNZY32;SU9(#I;DNO[AZ@=M1#$<\6N
M]P.DH:V=^RJPKY7%+;<RK54'6>U[!M%D,FY\DH)W_7H!_+^2_=\Z8B5KZE*C
MU'A]A,!"E.K0L0/K)*N'S0UXJ!K.^JT'(2VQVQ*P"FCD,[\/RI4<C5Y]I9S
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M9IEW.,9PVZ+#S)S:\XS[L^!;&%=L^[/;W\T>I\A)B=-ZARL3N"7&8/+9"-Y
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MO8@.,%QY8%X RP[*KX/:M;JQU]1*O$R/M6L!]V;,B#66"+ .9\HTNV ,:>#
M7!A-_P!?+[+[4/1=.TY MTFL2[!/<,APM=A8/SXDQ%7HE1FV8C3->5Q,(<-\
MJIU&9<[6Z$]K9+V'PFY$<G8",:*-9@D4^<(G")PB<(OC(D,Q8[\J0XEF/&9=
MD/NKSV0TRRA3CKB\_J2A"5*5G]6,9Y\Y98X8I)I7MCBBC?+(]QV:R.-I>][C
MX-:T$D^06<<;Y9&11M+Y)'MCC8T;N>]Y#6M \2YQ  \RH$Z6&'D:#UW/D-J;
M?LL$M=G<.8[+6J]V,Q<L.K[^_.74G4N>+/?OA6,]\X[<YET+QO;T8Z5M2L<R
M3,5KVHWAPV<3J;+7]0<9\^,9(/!\00K[TIO8=?:BKQN#F8R>IA&EIW &!QU/
M#<(VY>R:!;L.X@JP/.HKGZ<(O+.A0R<*6.(16)L"?&?AS8<II#\:7$DM*9D1
MI#+F%-O,/LK6VZVM.4+0I258SC.<<^-FO!<KSU+4,=BK9ADKV*\S&R0SP3,,
M<L4L;@6OCD8YS'L<"'-)!&Q7U@GFK30V:\LD%B"1DT$T3W1RQ2Q.#XY(WM(<
MQ['M#FN:06N (.X5<]'E7Z&1(]/-G7/02IJ24W6!.>U(6Q<-1L2(.0RHA1:?
M5I9>C)+0Z>>@^-N8TW!&D_)<C3_/3R?HYO2Z:M6^BO,NLMN:?%N?1MRRR9T6
M?T+')6./=7NN;U,][38O08')UN)MAC*U.YP/BM&1O1M<5(\]7K](>,%<ULR:
MT.J*M=\39,/J^2.?MHFJ-/6PT\Z:<V9H6.%T+WSVJO&V6OP'(=5.?.T=; R/
MI2K80IM+@L8]ZY,RX7>NUUJ.A./>K*DD5J7C&,YPTAQ7;.$YYZNFD]9T<9S'
MMYS9NU@-/5HQ_%-8SVHL5BF1-'CQ"VXNV!VC:]VQV7PZ*O8USB;KN46)KYG-
M3R>$4.'P>1R+Y"?#8U@!_C<T>*L-SJBYVG"+1-C:XJ.U*J0J-S#02XV6V\J*
MN7%9?DAR2HLB+%-B'G$Y<'EQZ9+JX4^*MJ0RI2DI<PAQ:55K5FDL%K7"VL%G
MZ%:]4G:]T#IX62RT+AAEA@R-&1PXZM^J)GNKV87,EC)< _A<X'>Z<U)E]*Y6
MOE\-<GJ687,$K8I7QQ7*PECEEHW&-/#8IV#$P35Y6OC> "6DM:1H/3Y?G;52
MFZM9",=W9^LU?(G9(O+^,DF3(.1+#Q;"_'7G#WLZY11?RB$3L)S%FL2W$QW5
MJC/);K/1;J=^;T\W#9:U$_6.D#^SVKJ9D!MQY#'2ST(<K+$X]9V34$-(Y6A9
MVZFQ%,\1/<Z&0,W_ $A8!N*S;\IC:\C=,:F'XWIJT&;5GTK\<-V3'1R-W9VG
M#26OPZY!OUL,D+3(T"1A=//.EJAIPB<(G")PBK=OGVZ<LVC]=@+C:*,[<+S8
MIQ4[3R#8\P@-4M=VPKF/E4B/-A2H+QUX J3!(0ID&2IMA$AA2?R<EZ3/Q3)9
MCHYTKB\]F=..SNI,K9OY+!6F5;[<=@]*9RYU6\T5BO-7DR<F+,U>U7GKRED;
M98W#9=(T'V"CC-<:BOX?%YQF'P6.@J4<Q6=8I&[E]18FKUG[N2&>&=E%E\13
MUYX9XPZ0QR ]^SZ[U*6J5M/WJW[$-;+M1JO!*M&)F0E< I" Q! N6='C8=9@
M#H?DD21;,J4X^R[+5ZE#:<DO(81X=QI30][!YS)ZDSNJ\CJ_-Y#%8["Q7,AC
ML1C&X[&T;5^\^K4KX>K4K\%NW>,TSY8Y)SV>NQTSVQMVUFHM6U,MB<?@L1IV
MEIG%4LA>RLE6E>R5\WKURO3J-L69\G8LS<=:M4$438WLA'73.;$PO.^@[6J=
M8H-OTYL&N 1825+W]#3;YH^&S%46>VA5+!0)! HXTE.7Y,DR1KG=UW.<*DX\
MY6//=6ZJKZVP>&TQGM ZIQ.-I8V>?I/@&>L5:\<#K\FLL'E-+R6KKV &6:7(
M6L1N]YV,HZP_O'N<[?Z4RV3U!A]9:?R5^W>BAT!,</#8G?**C-+Y;'9^.O5:
M\D,BCI5LCLQFQ$?L#V&M:/II+?A78ELL8&SAX@8><?L-HTL4C^:AJYZX 6.7
M49K[_G.NIP?@SX,8Y*CM*1AT#: LIF-AIE]Y>?1UTG7M5YO+8S,T(,=6R4F5
MS/1]<B+@S4&D\7EY\%8DE#WO RE:S6AR4T3"WCQF9Q\S(0R.21V.MM!5-.XG
M&W\9<FNV*,>.Q>M:LG 7874F0QL67@9'P-:3CYX)Y:,4C@[@R&*NQ/D+WQL%
MI.=G7+4X1.$3A%X"OZ+)?N$S_+N<*#W'W'\EZ8_YNQ_<M?X$\*5]N$3A$X15
MXL'8SU0ZV'Y][=+U!LFU*_7C$VTV2CUD?E7U*S"&GL-J^KSD]L]_=RO*?T_I
MDTC6/]7I[0FKLRX?^\YK+Z;Q%0GR/9Z>3##W[=8/%=#Q_P#0^B_4E@?Q9K6&
MFL4/6#%8W.9.SMY@36:'&#XF,^"L/SJBYXG")PBX0]1?1+1?2(=:O513=A&9
M0*-I&G] $6O'(8_VG,9&)L'4A>-LT=A/M$6N$/V=K^[N4\TZU+6PT@O!*D!9
MQD4T)E=!QF>L::P6(GK1B0WY]1F6-SN%I?U6,KT[!]EX<ZK8@$S 6[^PYC7,
M+^,<\R>!KZFSV8@LR&,8^#38BD:P/<UO6Y2Q=KCVFEK;=:P8)"#ML]KG-D#.
M ]9.H'IJU)U-TX+2-KAC$L76;2)N=8)U.UV>@6RKV(1'FCVB%9N5)*@K/7WI
M@0H7KQ)0@I#7,!&"0]:\-R/$FG8[*7,5/)/4?&'RPO@E9-#%9AEB>6N+98)V
M212!LC&2MXV.X9&,<.85RR6*I9:".O<8\LBF9/$^&:6M-%(P%H=%/7?'-$7,
M<^)_5O:71O>W?8K 7#I"T/;^G01TKIJDNGZ;K4>B-5 -KZP'*6<IDK6EF"7&
ME&:K;@LYBS"+$%LU>&&4V)DFHU.((DRR,V7(G377_K!FLA!DWY?KA/>E-@S2
M68XYV3BU%)!.R6&1IB?&^*5[.K+.!K=FM:T-:!\I\)CI\8S#]28*,0KB!E:2
M2"2 U98YJ\D,S'"5DL<L;']:']8YV[G.<7.)I;T32-7]'.^>HGH&(VJ%4&"F
MRPF\NE2OWVZ/2[1LG76W=?0YEX&U*?;"TRP7TU4=N:[VU/M2D2RIUIDK'-%L
M89GMOJWF=%O-X_&ZB;"Z8LJR8_+R5X V*K:IV7"!\S86-CKLFI6:;8O99'NP
ML9S;LM%@'5,'D<GIM\S80^W'D,/'9G)EM5;M9KK#873/=+9DANUKKICQ/D]L
M2/Y.!75,Y7:_9X6!ME!![".2^W)3 .#(1:%B2TE:&I&(L]B0QA]M+KB6W<-^
M8A+B\)5C"U8SS_(XK%YBN*F7QM#*U1(V85LC3KWJXF8'-9*(;,<L8D8U[VM>
M&\30]P! <=[_ $<CD,9,;.-O7,?8+'1&>C:GJ3&-Q:71F6N^-Y8XM:7,XN$E
MK21N JES=!W5@V-U@/D!9/3-.O.-@D@[DAV.< 1H*Y1]S5;(_#7J9.AF[PL<
M<BX;<9=%BV2M>DLNP5P5.<.L=&.H8\E4T;4EQ\O0_9U'^U-W'OE?%DL;%7=-
MDG:*BJA@@MZ9R.HW5,E"&O8^E2BNXF:.2J^L3UJ'7V%?2LZHL1W8^DR#!G3U
M:XV-DE&_).V+'MU4^P7==6SU+!MLT9BYKVVK4E3(Q/9.V<,YT^BMWC>U[+VP
M[NFVNRA/7((LW7KHIXK+RT$"@F-@6/6>PM9A)A!].,M:[UT'Z?CK,5K/98:Q
M3BRFVVHLUQ/["U=CZPJTQ0A ?@'Q:>R' -Y))#7BMUK<C6C_ -)LR9&,N/\
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M<?<?R7IC_F[']RU_@3PI7VX1.$6'.6 +6H;) \1C"X3Y,0'9DRUY0TLF>*1
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MM0#7FN^JS7P=D_=>B*_$>HB56\35#25WU/!UY=:CO*@A2&(DYMDT>UM92Y0
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M;RA8_'K.5^'Q)8\R<C*5,]\^9ZSZNG/@5Y*G>Z?$1%27D^;V'S%^6VA:,I7
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MVN&Q:YK@0YI'(@@@CD5YP0@/40@^L52IPZ]6JV,@"J]7Z[ !A08T5#8:C0Q
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M'D"?Y*@[WIV^F-L+,L*=:;ER)C!-66/SEQ:-YR0^RJ$;V!(=DL1[G*[2*@.
M$!M@0-<*PX$U#I8Q/"TP58K6$+/@/=R\?/P('EZ\E]2OIH*',L#;%0U'>D5<
M1:++6[01MD0>/-/KK^_.F3333M<$QSF&DN36-[&R4^&?F#"("37A&) ^<@F]
M';>.WO\ IM]U'#W[]_\ DX_R^2E/2GI.=&7/=U'T2!T)L_7=_P!T6&88/+?
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MABW!D=OL0&N<-#J#+C$T7=3%8LY&VRQ#C*=2%UBS/:96EE:6Q,W?U,/ 'SR
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M-*M5P<[.(7C'E5(4;?0YCP*9>::>PM.&\]ZSK/3,FL-):CT_6&^2N8:_/@G
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M?/K%T!EY([:=1-4ZJZT330\J!1K!98YU(X5LG9AFQ.AY+(0VTU-+*&U(.\\
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M-4M+Y^N:AM\ $*0X$02<*3ZUO?7!,6TU$?6XTNVNF6@,*LHFEB;'TW\M_?\
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3(G")PB<(G")PB<(G")PB<(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g63338g06o81.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g06o81.jpg
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ME9976(2WN-+3UM<W020F,I?5&"-TLT)1<__$ !X! 0 " P$! 0$!
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M6]->O=>2+1/&.^EIBIKS<\(A+(O$) C(WI>T'/'-5[%CYR$.W"<E@8 Z\:Y
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MLX\^9. WUZ/'BCR"XO#-ZK[CET3E#K8IN%D()'&DZ,[7-1YM#X9:,KIS'?\
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MXT3^^3<E_GD(_E/#X^JS_6_PP?S:M?T/_P!LWM]6O!I_*IS^K+^7'WR;DO\
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M\7QW_$B/PSP:4M1B7?YE 2__ -<-^(5%SQ4XH(:JA,4BO,W4,$VW"0)H:RY
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M[M@JX03649.KHYJ)7<-<\\D%NQ9YI]D3RZS/+'J7N(/;0"@% * 4 H!0"@%
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M/.Z//OM>TI=UWW-W]QGV4*M6!F* 4 H"D&_D.'TF#]]#Z J] * 4 H!0"@%
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M1=3-RT'X)7D&:)=_(,DGR6-^P=I/9 7,GRH]%))@9.'#I@LV>D395R\ ]@F
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M]]KVE+NN^YN_N,^RA5JP,Q0"@% 4@W\AP^DP?OH?0%7H!0"@% * 4 H"#?I
MRG2,LN3[A;BJ*W&1@3+C-(,(P)A60UO%#>RWFIN95B1!0T>'/]>"90"V)CQ8
M4'B]CM'YPX^P!8:VL/#X[33,C)FS*^[3HFF3GO2]+YY"T=<@.D8#:GB6V24U
MWA+R@%YN:-.-'&0<KC9F::L$[(V(=C\X=2*4.#NQ(>6D\).0B$ 0\M@6P^1
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M<V8!,91$T#<.CKL3%V\A6OE+)"&<["981V10L8@N]D<0B@Q5,UZ9\1(S0@4
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M%9#-9A(46#Q/!7"]\,[MWC9=OG?&]\>R)9VM>]K=6A"XO.GK0N2A(H!0"@%
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MB\F$%Z5R_P!YVKK!N2=YFBN.J?Z<T<[]T?OGQW%-$=&4WOJS!H<4 H!0"@%
M* 4!K[RN\F[=7J]D/U3*M5X<-Z'")R5I3W"FP<%&^34KE#1_OD.7&N+9U'%
M* L3DK^C_P"?'JBU-_BHT/70']G-OV4GR4C>D."EF[KWFW/*.C_8>G)%7<\X
MU"@% =>?W)]XU\X?1[C][RW!6E\,/<J \I27LP)NS WW6L'DZ,]J/.S6M'F]
M!0"@% <YW,/5^RSG)7;!4+KN=&!;PXQ49DA<2/D&#M/$ (3RS;/&@]9NOABI
MAFG?))3+&V>&6%[]=C>UN2V'VIE<:2PP5XCJ.JG66/@HBDH9N'C(*@J4BH5^
MRE%P#"M.8AQ"O'3UE&V6F55AMI$:9:959HJ'1G ]6FK,#@UJG"1M8J"@XIS
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M:4=/%=M-,JK*MNV&I8V46XQM][;V7_2KIG^-2C_:=>0^I1A%_P!S5,]/3O\
M9#TOUIZC^(ZT^@HC^[C[VWLO^E73/\:E'^TZ?4HPB_[FJ9Z>G?[(/K3U'\1U
MI]!1']W,B:CX%3O7^TM=SDKLW4KL9$)I&Y(0:CS$BS?N&88LU?N$6>#F--F^
M3E5)#+!'%9PBE=2^-LU<,>KE;UE0]R/7NJM=:J5EC:P53B(.@:P432T4XA7U
M,K$OG$!&N8EZ[<(^HATZ5\VP[5EVCQZ[85I4M-LI-4\]6[=(5.K!5:L5!PM#
MUC<Q-,4+25&P[V(<T6CAV^C81[#NVWRNZ4>/$=,MO$5M6';;:,HMEAI9(O/K
M(_N9WED8D)XNWY'\2TVY0R4(H)K2;:=EL$7SY=RE@K;#52F%E<<%<<5+8*9X
M6SM>V.>5NI>_8-UA8H-VZ=L+1U+JK#MAA51U!R566419?_,Q7'*]]@DIQX]>
MO$I*AT1X\;;1%>1DT1II6D1?_B9)E&_!B^7']9+B-_,^U?\ B>OI]+5!>+J8
M]%!_G#Y_1#3OC.A_21GY0?@Q?+C^LEQ&_F?:O_$]/I:H+Q=3'HH/\X/HAIWQ
MG0_I(S\H2#=%WT(6^^#G-#6G)+96\N.DHB$*$;!'D0L&/SQU)'2TN@4BBC#-
MDB?@  7DFW?&$'#NZY-#+%JFMDCBLM;!+/S=;,(-%T_0451<+!4DZ?/VX9IE
MY$.X='2(YB'3YJTKN)>-S5EA49DPMZI.27GI:HX/*5J]3L+2L5'4:^<.'<2P
MT[AVXE7JJ^AWCEE64>0[MBYIM%:FVG:SE-;EZM>^B.?KL;[6E_FK4$ES+S*;
MBFF=.=!WT1S]=C?:TO\ -22YEYE$TSISH.^B.?KL;[6E_FI)<R\RB:9TYT'?
M1'/UV-]K2_S4DN9>91-,Z<Z#OHCGZ[&^UI?YJ27,O,HFF=.="/;FAQN-<D9'
M"3,/G>O@K>,A"8QZE)291!9=9Z_2=)*-;"Q!3#)+'##+'.ZN:6=L^IUN.5NK
M>U5MT+@'K/A>I:KD?0-*4'1SJAJ/C82(8I=Y2##QZ\B8ET^8:<I!P$8RK#++
M"HTK;3#5I4DRJ7EA,"^%ZK^#:CJ;@Z8@*6C7E)QL+$N6J-=P3;###APVZ:9>
MK%1L*TC2M-(K-AEM)8U1;C2S[VWLO^E73/\ &I1_M.J\?4HPB_[FJ9Z>G?[(
M;J^M/4?Q'6GT%$?W<?>V]E_TJZ9_C4H_VG3ZE&$7_<U3/3T[_9!]:>H_B.M/
MH*(_NX^]M[+_ *5=,_QJ4?[3I]2C"+_N:IGIZ=_L@^M/4?Q'6GT%$?W<T(Z0
M;H+N0?+?=,2V5 ]Z\;X\' :/U+K%VRET@G[<DJ:@$?R$%7S? -KTPUR%NU[V
M4'J*.DG>:7XW+1OG^175_ I3\+@TP8U1J13#B)CJ2J]0U'T=%15&,NVX)\]A
M(*'AFVX=J*>0K]7;3;EIICLCAVU95)LHLT3FOA@JO&81,(=9:WT3$PD' 4S2
M,5%PT-2+3UF,=NW\4_?L,OV89U$N4;1EZRC2.WSQE&D632I)5T7_  8OEQ_6
M2XC?S/M7_B>MJ?2U07BZF/10?YPUE]$-.^,Z'])&?E!^#%\N/ZR7$;^9]J_\
M3T^EJ@O%U,>B@_S@^B&G?&=#^DC/R@_!B^7']9+B-_,^U?\ B>GTM4%XNICT
M4'^<'T0T[XSH?TD9^4.ZX8?C[(</9J'!>2C1DT;*98.T[X99H()I9987ROCE
M?&^6%[X]=CC?J=3JVM?\55^:FTTTU)>V:5<6=9EA69,LLLS3M643'F21[>^B
M.?KL;[6E_FK&2YEYE,IIG3G0=]$<_78WVM+_ #4DN9>91-,Z<Z#OHCGZ[&^U
MI?YJ27,O,HFF=.=!WT1S]=C?:TO\U)+F7F433.G.A5[V;O$4\K]8N@IV!PEE
M_P"K#/K,TW#=7&]OQ7ZW/!-7"]O^]L;U!)^;M^Q888J/GC9FGGEUF&;E=-#'
M//J7RZW')3+&U\NI:]^I:_5ZEKWI*>(3EC/!WR1_]>"?X@U_U:F2YEYE(FF=
M.=!WR1_]>"?X@U_U:27,O,HFF=.=!WR1_P#7@G^(-?\ 5I)<R\RB:9TYT'?)
M'_UX)_B#7_5I)<R\RB:9TYT'?)'_ ->"?X@U_P!6DES+S*)IG3G0TGYI:,(\
MD@4%%P^;0,*O%BQE^]SDI=T@DND19LVZ.#6XL>4SR4PS;9W4LM@EC;'+'K<L
MK]6UJ[;H; [6#"]1E6H*@:1HFCGE"QT?%1#5+MQK##UB+AW#EAERL'!QC2M,
MM.FE;MLL))4DJK-$W9@6PFT+@VCJ=BJ8@Z2C6*4A(.'<,T:Q"-MNVX9\^>-J
M]2*BX5$9:1XB,V&FUFBS1$DI'W][7V;_ $K:5_F"1_[6JK'U*,(O^YJF>GIW
M^R%@OK3U'\1UI]!1']W'WM?9O]*VE?Y@D?\ M:GU*,(O^YJF>GIW^R#ZT]1_
M$=:?041_=Q][7V;_ $K:5_F"1_[6I]2C"+_N:IGIZ=_L@^M/4?Q'6GT%$?W<
MU6Y_=#!O/EEKSC/$8+NSCQ'R&E5-T9R-Q+)),T&9.VR#$((!^XF0>#EUE;LD
M8P]P)=O(,.L47:V:]M8Y*Y)=&=RO1K[ 3@]?51K,TQ2L>\I.(C68F@K;V$[&
M^?Q#UEE5I!F ?(VB/F45$<JS-%DTJ2G1/=)MLX9ZZ0E9*O+_ )9!P]'L0C3F
MFI.XEIXR[AV%:99@5C75B;IJ4WJ+)4NQHD9/X,/RZ_K)\0OYMVA_Q55FOI:H
M+Q=3'HH/\X5V^B&G?&=#^DC/R@_!A^77]9/B%_-NT/\ BJGTM4%XNICT4'^<
M'T0T[XSH?TD9^4'X,/RZ_K)\0OYMVA_Q53Z6J"\74QZ*#_.#Z(:=\9T/Z2,_
M*'6[T<.AR7#;A7H_C7L&<0*23#6(Z8M#1N&EG;B-/E)%L:83%ID+6-L I3/!
M$?(FC9Q=V+:96>(N,4\5$;)K*::K/2CFFZ=CZ4AG3YTXBVG+3MV_991ZRCJ&
M<N%MH[;>,)-ITJI)M>U5)WS1-T57HI]0= T?142]<O7\(R_9>/'#32NFNRQ3
M]^S85XR[;N9>LHLV$[9%E-)*N[W?)'_UX)_B#7_5K^#)<R\RG]^:9TYT'?)'
M_P!>"?X@U_U:27,O,HFF=.=!WR1_]>"?X@U_U:27,O,HFF=.=!WR1_\ 7@G^
M(-?]6DES+S*)IG3G0QAND8QV5J?8,!#R6-LBDMBY0&P=DR>& ]NY?(7225=Y
MM<73C%#'*_54NBW64M;_ -*>5_Q5XS")5J-KA4>M-5X![#PT;3M#1E&PS^,[
M*S"NGT2[5AAM^KET^>H[97[2NW3QJ6)E3T]2J=A:M5LJ_3\8[?/H6B*4A8Y^
MZAD=M1#QTX;1IIARCUXZ=J\5/LHV\89GC:0AR^]K[-_I6TK_ #!(_P#:U4"^
MI1A%_P!S5,]/3O\ 9"X_UIZC^(ZT^@HC^[C[VOLW^E;2O\P2/_:U/J481?\
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M@F<\1Z: 4 H!0"@% * 4 H"F&OS,6^C'_P!55J4QIPIZR%Q+P+ZC5*ON? 4
MH!0"@% * BEYY)\UH[MO6\PXS8[&E$!3A[R<[$AT0=)=K+%>-Q SLH+KYFU<
MWOCB4Y.Y2=OJ\FDVPZXP*BJ#)=9LJBQ5O@U:FBI/7DU;3ZN["HJ-22^2*O\
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M#&+"#N1;4F?M3RW?+U9S%$8FVG:R_P#&:X\<I*LM"JMRW7)D)8*^A\A0"@%
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g63338g10h25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g10h25.jpg
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M>):7M]8A-U68N-35(C%SMM,D.7)T=G>U(T'7)35187'_Q  = 0$!  $% 0$
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MZ.[(5G:\DL)M+JUL ='!+*R$H I;\,C4RK"*R40XDY^KAC*M3CIR6)G#$:<
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M).^WIZ<SV<W]ARL9@,PP 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P
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M&]?AF ?0@X0UVV9;NPH1T-8K//-HNW+;EKJX5=<H)\ISS$+D7-?@)4P*& #
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M # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P
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M++@96OUY[-N\4BS([;S,SXWX='.1<PY LQ&08 , & # !@ P 8 , & # !@
MP 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , &
M# !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8
M , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !
M@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 ,
M& # !@ P 8 , & # !@ P 8 , & # !@ P 8 =9Z];OND5=UQBQ=O6@-&#;4
ML)@.',)_*V;%@Q9RTNW:,F31N63;M6C5NFF@V;()IHH(IZ))::Z:ZZ\?'C29
MI'TA0=)&D&%"QYC.'#AXWQ7%B1(N**Y'C18T>O3VF(\=AJ<AIAAAI"&F66D)
M;;;2E"$I2DB+Z;X#P/@J7@;!DJ5A#"\F5)PIAV1)DR,/TEY^0^]2(;CS[[SD
M13CKSKBE....*4M:U*4I1J,S$5_']>_SUVW]X\Q_K.=([J&DS]8F.OE=7_M
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M.OE=7_M .Y_@/O)PC\FZ-]2#X_KW^>NV_O'F/]9QW4-)GZQ,=?*ZO_: =S_
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ML6+@7407/B?68>V#VV^E'V+^^VR_S-BQ<"ZB"Y\3ZS'H2YH#7# !@ P 8 ,
M& # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P
M 8 , & # !@ P 8 , .J=V$_7Y>'_=^R_P#.9K/B+I6^-'23^_V,?YBJ(^K^
MCOXO\"_N=AGYD@B(,Z".XA@ P 8 , & # !@ P 8 , & %P>@_O9U-_QS?\
M#B89[Y]S!\>>!O\ NQ'_ "C7QXYI_P#BCQ;T4+^9:,.R?GU\'S2# !@ P 8
M5I[G^Y[VL^K?=_X9R;*6TNDO.(>P^@_,//ES7&@& # !@ P 8 , & # !@ P
M 8 , & 'I89MQN P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 ,
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MD.2FY9+@4UN;C;/B5M]SRYC(35/C<M^WB9^U[C)G74<HK&*^#I381L3A4/!
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M:>R3"%QJAR"^R=H'W-#&+RMYBM%9.2L.L08YF"77D0MO$W$@"FBYX)("8W4
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MC^UMMS^C7^_;;G^_GG HK??_ .M3I3]9B3?PC]I,I;#Z/20A[2Z?08M%D%#
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M9W]B]!$,B*W/[<YF)?R"BKM__K4Z4_68DW\(_:3*6P^CTD(>TNGT&+19!0P
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M-WEX3^3E'^IA\>]X?/+:WWB2_P#K&.Z9I(_6#C?Y5U[Z^':%@;O+PG\G*/\
M4P^/>\/GEM;[Q)?_ %C'=,TD?K!QO\JZ]]?#M"P-WEX3^3E'^IA\>]X?/+:W
MWB2_^L8[IFDC]8.-_E77OKX=H6!N\O"?R<H_U,/CWO#YY;6^\27_ -8QW3-)
M'ZP<;_*NO?7P[0L#=Y>$_DY1_J8L7U)N"VC_ &.J<.=M&Q30A_)-T7PHM-I*
M2'/4>!9#?A)VQ>$UFSE/R]--_(62WU\O77;Q>/7CGCUG05CW'54TMX&@5/&F
M+*C E5=3<F%.Q'6)<20WV%*5J/QI$QQEU&LE*M5Q"DZQ$=KD0\XTNX.PC3]&
MV+9D#"V'(4R/34K8EQ*'3(TEA?9<9.NR^S%0ZVK5,RUD*2=C,KV,QV+\^M ^
M<0H;97:6=1V[2<$C06*MX?!)I7$6FCV3.HDD2,,Y*%"3R?'0ZI&X8A* XV 5
M<:7E#5P)JNRT)*2CDB$<+"?5;Y9ME;(CXWW'T%NX[>D8FHR,]EBMZ^);MF1W
M&#POMW9<@4: I*0J>#'I))8\#3.&12;V"UWPXKZ=V6<V7E$<N<_%K71?@HR%
M;0Y5C+:PD>Z)9_)I="(VS:#P1$9$7'S&>PBL1E?S](FL?$MW1O/CU9[<C(A\
MT3[@6C*%V6_!"G&*X24T7$CL)4!R3F:SSBR"Z)B4S2,-UI^W<02)#:4,!K>$
MZF 4X6'CF$F:'2&S4.L0X&1%QW\+9%LY\\MW1F!*,[GEE;R[]N672-KAW9.X
M8;%X\WE)R('#%HPB*6A"F18"9U/Q4M>T[G<PCL/D):16:#CA] /6\9L)P('.
MB=3 P6E=-HIH?X9+M7S=8NBV1^ BONRSMQ/.]L@N9<./69G;;P(]Y%E8:&O=
M*U"];N#@@I2X&7BH6XEPIM+ I!TSM][+;OM2I*@B<)%1VW'*88F<0K9H^E)(
M=+;(8,BDQ ("$W0_91QM=7IM?JR(\\N?FV!K';*WI/.V1>"^\:3R_+ *R]RX
M1EH89$"K9OH]BO#F:HOR8"X.T9JKHE8PB1M[!0+QQ.,4?2LGGZ ^+H#!8QZ8
M/K<<**'&"H^6+P^HKF6SB?#=N$UCOF>1^#:K;MOLN? LA9OK#>,XN(C/$9BG
M%6GJ ?"RC(7%Q[5RU')2[X2NVGHL] V18L6GPE\)%C78Q^FC )8VTVW?2>O8
MXW/ FF@RM;P^3P%Z>D9$9G?P>6_.?HZ!NU__ *U.E/UF)-_"/VDR%L/H])"G
MM+I]!BT604, .E9VD[(]B ?9OL6$"7W= <,'O:W18D2+M*<#Q@L8/L"0M& X
M<P:'46K%@Q:HI-FC1LDDW;-TDT44]$]-=>/P+C#%>*(^+<4QX^)*^PPQB.ML
ML,,UBHM,LLM5.4AMIIM$A*&VVT)2A"$))*$D24D1$1#]PX4PQAI_"V&GW\/4
M-Y]Z@4=UYYVDP''777*=&6XZZXN.:W''%F:EK49J4HS4HS,S,03[4O9OZ1E[
M_>[8'YASKG;CB[OIQ'X[J?UH<_VIX5[V</\ B:G?5@]J7LW](R]_O=L#\PX[
M<<7=].(_'=3^M!VIX5[V</\ B:G?5@]J7LW](R]_O=L#\PX[<<7=].(_'=3^
MM!VIX5[V</\ B:G?5@]J7LW](R]_O=L#\PX[<<7=].(_'=3^M!VIX5[V</\
MB:G?5@]J7LW](R]_O=L#\PX[<<7=].(_'=3^M!VIX5[V</\ B:G?5@]J7LW]
M(R]_O=L#\PX[<<7=].(_'=3^M!VIX5[V</\ B:G?5@]J7LW](R]_O=L#\PX[
M<<7=].(_'=3^M!VIX5[V</\ B:G?5@]J7LW](R]_O=L#\PX[<<7=].(_'=3^
MM!VIX5[V</\ B:G?5@]J7LW](R]_O=L#\PX[<<7=].(_'=3^M!VIX5[V</\
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MM1%GL\4C<?Y!LR&FSE;?48S&)_[0BR;\Z:RQ>D+F()R@& # !@!Z6&;<;@,
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M;9:UTIPP+%>O;JF+3=3L'U.$2>6Q7M.<1$PL_4"SJ 6&'3,+51#H]+U[#+S
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MSL9,24H)?D&"HRZ?Q=YGOS\@7].XMY6(1)V5XK!W2,.=1I>H QP>6KH<'CL
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M)/;7[*#Y?^VVWF$0>RC$?G7[0_O07?\ G3 EBY^L_6'LHQ'YU^T/[T%W_G3
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M.?\ 5&__ (@GGLGW/GQS:/\ ]M*_@9@\OTT_%;C/]EI_C(H[.F?90?+\, &
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M !/1:A0:J_2E4^ILDQ*2Q34,NFV3B'"U'2<,T'K-IS(CRN6\7'SW\>-!@ P
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M !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8
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MP7K#MUQ9^GZE_P @_4'RM'A*?IIWW]M'7^GCM+PI^@:=_L%ZP[=<6?I^I?\
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M^K!:7HJ#?3AF-27V:#TN=.>&0])H-:^:'L6;9#(08%@ P 8 >EAFW&X# !@
MP 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , &
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MX=.G"VVZSAPX6WW5665WW454WV44VVVVYYY /GP 8 , & # #TL,VXW 8 ,
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M,"T?M"S)K'ZQ;AGY^3:QLBJM'"/$N8GJR:8ZV=<D,SSK<B#3I)-T]^,Y#*+
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M:+TU#YJG#TI,_*P_5X8 5> >^E;/U7NO7XK]G<NXND_,0Q_'_P!/I%H<@R#
M"M/<_P!SWM9]6^[_ ,,Y-E+:727G$/8?0?F'GRYKC0# !@ P 8 , & # !@
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M%# "M/<_W/>UGU;[O_#.392VETEYQ#V'T'YAY\N:XT P 8 , & # !@ P 8
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M-6&_G+J>L96M5LF'0%$O-JZ&09E+0A,L^:Q*5EF+9DCK9=*Q W39E$IZ:8Y
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M&_IX9=>8Y*<"!@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 ,
M& # !@ P 8 , & # !@!Y3'A#/?\[Q_7![,?C1-<_8N&O@YA_P#8E*_@&!^,
M\3_"7$/[<JW\?(%/LYL<&& # !@ P 8 , & # !@ P 8 <PG@#?][3U,_P :
M[OX<+@SI&D?X&5GH@?.D(=YT;?#6B]-0^:IP]*3/RL/U>& # !@ P K3W/\
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M\K#]7A@ P 8 , *T]S_<][6?5ON_\,Y-E+:727G$/8?0?F'GRYKC0# !@ P
38 , & # !@ P 8 , & # #__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g63338g12v65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g12v65.jpg
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M&G$]DCRX!D@!W$]I3LTTMB;W+[4VU4@C*$R6B#=ZF+*3J9GI<64-*0TBEP)
M!S*DJ&*?C6G>5BI('EJBDI9)K"&<\IZ%)*4UF4Q#O!8=QPE4VG%Y06(R"4G]
M:K;RMXR[ P_D'?TEA-L%9N9L\Q"Y+UY- I"^(#%TDWH6\3)M:8C2SZ$'G@X?
M'(Y(=XN18^:>??:'2P337]J4T_>IK!3O;=&"STLV"%.H'8@[X.^B*8)ZUHX[
M T78]/W"SARTADVU535:E+P:V9'ZOD4B)I28HP9GH<,'Q\HZ:,"$7"RO3C2.
MBV<+9#6K.]UW4L)ISEY<"E^'V2*+&[$G#-2FIPRG+9G^)2%J==.Y]\2B'W.\
MJ#K?3<[CTQ[!&P\6"362.Y,JSE'1JV: K4E<UOPUI%RDP.N+2F(E+16 -8\0
MKNL-&J0B1E#[#E=O#43<Y)8/5FUIUXDPQ00IJ<33NXRU1PQ.2>"P3ZWUX8)J
M^"V[D:4_)(8U!B$F3FVX[9$3KO6X(,XBHATIUV1K20+G(2]J3>O3R6\];N3:
MRK)W'[!!\NQT]#67*;$:DB3VMV+\)E_989IZ;LFY/^E.2QGY<-$I2,PZNZ2]
MN(GWFJ?L!(M(*\!C8Y7C"TY$I9AV5"M&P#K&RJN4!:K8E8\&N *B]L=GR5:P
MRP; LRMB[-P\L\MPULQ[LT:V4,5Y/JQ;V8_>BCC@<#A6V4E+^=-3T9:DGH6&
M!^O:SHMW!NGM5)NV<$FE3!B5,2?KFIUEKV1@"9,[)8W4A-Y+Y^FXLEG+1 ZJ
M=;-,6#8T1DC->"V"O(HD*C+=P]C_ /-W:G#$VWJR6'?:(8X(85"TW-17G-RF
MUAAIE):L2J/"<]/NS?9^<UZ5I1A&=1\*KXCM&I,YL%>)R>'6EK8D.DO!!)L7
M#RH*Q8O8M'5& N2002 L?DSRH$(3P'#7SK19'"VYI:-8HXX84YYMXX3PELEI
M;SPV%D[$\&=V9,.[8E=8RP37UIVI,?"5Z%K 1L>6-WCNN>PIDB<ZWQ5]LQU7
M4'B0[Q5-1^R#M/' "!$D?"HOBZB^[J'"\99SB\FC3U_>2J2%2U)4>$OYT,KS
MW9Z3)GJ1T_L:JHKW?:NJB@M$C.PXN)MJOJJ+6@2LT;%/82AVM;D&Q64D HK9
MOP^E#9<KZBS:.&C=N_VY35<*Z*J*V2<HL)36"GL96*)-P8MW<VU)YS\V'B+6
M>#IZ1=FJ%MVKYU;K%..1^L.G#3K81:'NQ<C[$OY/(T#5:$FI*L19Z#1QK1->
M,^(,45?0T%(";(ER]BHY0:KI%61-O$*BG-X)*6:<^"763''"X6EC.*\L+LNO
M%WGMZ]94L1\&U.=7_8JQYE/Y07FJ_9WMAV'ZR5 XGB(J@PLUM2/S&-UC8DLW
MA43 VRQE" Z8DVQCV/L95,!HZW? V:19NV=:+OPISS<E/#8PZ1>\22E=AAB<
MO?23FTIX>1&*U(>#%[&PXG5!R9P&!D1E=]PNN=\,8._L4,]0 QB/T-/*SN1Y
M'^0T-&!FA[>Q'\$GVC)SP7-S-G&F)&2ST],DW+I2%"]6E:5EC/[BSI(<DVIP
M10MR_M)K=.<M<I22/]J/P9?<J*6CU4D\[E>QMM5D:ZW,UI''KG8B752K5/+9
M4;M>/,VYVK)D=EP&TQY5HF1'14Q%&D^2(DHQ/G@H8*"&T2ABFO%IRQ[LETD#
M4<DL7$\4\9RE.3T:-7GC%/!)WFVH1K"-(] S\J+=9:.#64)-V2<>B; [!5/V
MEC=E.BQ @59E$=UE:7:26! )2LRUT'LRC>,:MV8-/7ULN.66,M][K_H]YD>R
MJ>>%Z)Y9)PX?^K/69B=6^G78JI.^%I7D;$1D34<YYN)V]7(V)I-)0NC-I)%#
M5?QR*N $0@)7>/1EF(<LE(K;*<[&UBT:H1ZII&N)>NGJDJ%J*>2QWZ/%]Q6*
M.%P)?SE)926&;S>+PQ4ISQ4\3<VP^_F7RMM_QM,N\GU/S'"9BYP'8+;VE_FT
MG^E&O_!=9>#/Q?>BD>7C^YF.^<IQ&M>PH!VF@7>R6=BJ>I> W! + ZTT_3!/
M617=Q5)J,G(#:-P2\J018;UQ.M3K-<5/Q?#;35<7MRY;N$N5.>/%MK5SO32G
MA+-+3,Y$X7 H6VFHW%\&>#4*UK48%N/!R]MWKJUV>N@4*=/07MO'K NJ/=C)
M<$F7<%2[K"8R2FV<B8.:_E#&K%:CB2#@.BX+BIF+$O$D8E'1[B#F##E&EV+5
MCC-S^%J.3V2%2TR<,E=2NR4G)IXSTZ^O$RWZ]=?.WM*=!;XJ,.RKX+?<C(VS
MY!FS$^D*$1%G.! P5&#,N4CK'6!QT['CRQ^6N -31P%!?6: EN+!,CC\VLM9
M)J%K2_X%(HH8J2%N=U2O>)S<M.R;Q,3X!X+#L;4$=+=>V<RK.Q.O4EM_H9:A
M!Q$A4@HGUFUHD]%Z^[ 1UW#DYS8A$B2L:D:]A!<K)VDR8;3*7ZGM7HP6Z(;O
M5HNO+-33>C+!X=6G87=)#%[[%17:1?TOA3<.,EDWJP66A+"[NGU9NJE8.2K3
M>'E[24,5GW(A75JO8P:["NN:9=V#V?DDSJ0]6AF#UQ*X<7FS^I)'&JW5KH_*
MXH3$!Q23!=\I7KB3/VM6FI)XSRSPQ7BQ_%EH(H7$FO>I.!Q34/OI0XSFYX.;
MG)S,G9]X,'M]+)7W.(*GD2K^ZH-VR"168N[@%,@DV W8.;-Z?JV90[6JG<L6
M&U.CJ/%LU2]A:1J'*11N1A+0@VDQ48V7(N[[]T0J6"<']EPZ'HS:QT_?CD5*
M[\&KVW=VSVHE#V3E'NUI@>SP\%. /8=M7BDTA]Q(,$:NJHJV9T7,ID+XJP8D
MV$!GYL\4B,-=1=F]C((N*E1X.W7(L?//OOP(=) U#AE+"[EK><L7CEC/89'5
M'T4O=_X.3M+U$L<E#J^E-RK6P.K%P"=)KM(Y'I=$X\S!:SIA$&K&"!5WLM8'
M%) $J&-@8=I%R"#QI'M9.1D'#FRA=UIX3_ JXX5201J;NRGY7EXLIMDE.:-[
MB]C D;5L.@>M%(O8+8O2IV*3BTP6G%A'PM&=C8G;-GK>4)O&HV.!58T  ]^:
MRJ_8(0-.9$H2)F"X;URV8;&HG*:2E+5/3/'0MD@HH(6Y11.:CS4DFU)83<WK
M<U@I;3!D%X,[NMS'+U;R$8 %K6Q&:M<22-0J\1V@666- NPANQ9"=X1G583I
M":!3D2*-&3<1V"<V$7G(IL^B,VE\7%*AV8BMV+N\RWLD$UIE.4TW*:PTJ6.K
M+!R>)7(?P>/=ME*NF<K<LJUV/TN+@@4[OY4"SZ P\%&.R,VL=YPRC+N.Z6#&
MYBK54@#!WI6G;4'PJ7G&"=;&X.PJ*- .'2[%AAOVM_?HS(]D@]]FT]F/P4EL
M<WG-36ASQ,_.P5-]EXWVJDO9"@JNJ2]6MI=51O6@W#K7GJ\&9P,O')[,YF%E
M3SQQ23IRZM)'I.G3"PH<,V&2!WS'Q:HY1YPZWU97:<YI3FI8]^^)2%PN&[$V
MI17E)9S26>R6&>>R13/?'J=>5^T)UYJ*"1FJ7^D/5V1L<3'B+BM(B#(MJ>D$
M/C)&M(K(&4\A;6$Q^9$T%6@:816?'H=&DQS^#-_;@(:%VZ)-I)+KD((E#$W-
MXY/-YXS>>*SE*>DQDK_P<?9AA(H!9\G.#T+FBMC]'7J=B>4@^9-!H+5G4.$4
MSV10::K;\,2"LQL4*4(OAZZ7_P#(3! 81/N.%$6J#2+K\:NRQU+'?(O[)#BM
M#4>$M<<U_P"EO3@_*7.\'-T@NWKC<K2>6?7\(B/(_JH&I*;R^/7!([/-7?<@
MJR]I3*+N+M) #%+ -K#;;^RSA%=PZ,:N_P#U$IQHFS8:Z3"FGE+"6>>.9%)'
M#$FDW\.\DTE=4FI8:N^EOX*"Z<=J61SJS7]G0JKH/5O5'M+V3[+HV<"L]Y+)
M[9:EK2/L"_AL($0U"""6L-$ZMKRU6G+DG+ROL@G%VK9DS]5=\>LX4+][-2NX
MYYXS)BCAE&TVW'#!#*4DKJ2;G/'X.I9["[DE\'>^N+MGV?L^WI]/1M%6@:ZI
M2 +5,%E4;'1BTB%"!VY'9*W&3J$OYBBQ!S8,$=AFL5FT;3*-/7>I/UPGMHGI
M-V;;<Y883P?65]DE!"DE-7TVUE>U8RRV&N8SX+7MQ+];]?2Z&5B16L9K%Y"I
M%-K36?1*:V3".Z,.N7DUJY+Q@C,$O;#1Z4SAP:46=*)W*6+@P^BRO,4B/L:Q
MREQXX=7E6W5//SG)[+!*%)O#"<L4KDEIE\+5+65C=?@S.XD_DSXFQ,I.HL3M
MKM?(XI%0-UM(*0J9Y;]TQZ<U=; .2&ZNLE$:9C4,'.0+AS$@2,VAZC)DSBZA
M 6</-=9N1:L)O3EW\N&1$-)"L<W*'.&<Y*334UYY%QK!\%]<LP)6J=XXBS^4
MVG./"&M)%(#LZ.*:'JKOJJ9$,Z\@#0Y)JL/T%1VUUP$R?1U@+T8Q0JB[D0UL
MX(J+<.)NO5_2\V&\A4D,O]7))9-/WV[RK ^^G.A?9Z!=MNN]PLH="8C"(3$:
M> 3)D]M)"5#HK'H50CFMY;&:\9 (5#IM'7Y.6[J$=8AS,)C2TJ4?K6!(0H^8
M<\#FI0Q33EWR[[R''"X8EF\9.6;;3UR6E9364S?=G(<)^NG]'_?_ .7& 6O;
MCK=O:["G)'V<'TW5MARZ)E S26>V2-6"&/R9P+/ACHK9*)0"7CQK&",$C<;D
MC&SW=71ZTI;%1;Y]:&NK6G.N=G+K_@UFO,_QV-<<<<<<<<<<<<<<<<<<<<>+
MCCCCW...../<XXXX_HXP0?[@'\*:^G3WTXY\7.^FVO'//^CTVO/'C_\ O@%B
M/),8^,QOS.O,YRWUMW<3BN/9OX#R3&/C,;\SKS.+ZV[N(N/9OX#R3&/C,;\S
MKS.+ZV[N(N/9OX#R3&/C,;\SKS.+ZV[N(N/9OX#R3&/C,;\SKS.+ZV[N(N/9
MOX#R3&/C,;\SKS.+ZV[N(N/9OX#R3&/C,;\SKS.+ZV[N(N/9OX#R3&/C,;\S
MKS.+ZV[N(N/9OX#R3&/C,;\SKS.+ZV[N(N/9OX#R3&/C,;\SKS.+ZV[N(N/9
MOX#R3&/C,;\SKS.+ZV[N(N/9OX#R3&/C,;\SKS.+ZV[N(N/9OX#R3&/C,;\S
MKS.+ZV[N(N/9OX#R3&/C,;\SKS.+ZV[N(N/9OX#R3&/C,;\SKS.+ZV[N(N/9
MOX#R3&/C,;\SKS.+ZV[N(N/9OX#R3&/C,;\SKS.+ZV[N(N/9OX#R3&/C,;\S
MKS.+ZV[N(N/9OX#R3&/C,;\SKS.+ZV[N(N/9OX#R3&/C,;\SKS.+ZV[N(N/9
MOX#R3&/C,;\SKS.+ZV[N(N/9OX%WHV+5"A& Q=1-55IHKKNHEZ;U/;U1PLMQ
MSKZ?C7;W-5...?'QQ[O'/^CW<XVYMLY$I)(E':.SAHZ;Z\\:[+MUD==MO'Z7
MC95/;3CGGQ>/GQ<<[>/GQ<<\^+^C()>*:UEC?),8^,QOS.O,YRWUMW<3BN/9
MOX#R3&/C,;\SKS.+ZV[N(N/9OX#R3&/C,;\SKS.+ZV[N(N/9OX#R3&/C,;\S
MKS.+ZV[N(N/9OX#R3&/C,;\SKS.+ZV[N(N/9OX#R3&/C,;\SKS.+ZV[N(N/9
MOX#R3&/C,;\SKS.+ZV[N(N/9OX#R3&/C,;\SKS.+ZV[N(N/9OX#R3&/C,;\S
MKS.+ZV[N(N/9OX#R3&/C,;\SKS.+ZV[N(N/9OX#R3&/C,;\SKS.+ZV[N(N/9
MOX#R3&/C,;\SKS.+ZV[N(N/9OX#R3&/C,;\SKS.+ZV[N(N/9OX#R3&/C,;\S
MKS.+ZV[N(N/9OX#R3&/C,;\SKS.+ZV[N(N/9OX#R3&/C,;\SKS.+ZV[N(N/9
MOX#R3&/C,;\SKS.+ZV[N(N/9OX#R3&/C,;\SKS.+ZV[N(N/9OX#R3&/C,;\S
MKS.+ZV[N(N/9OX#R3&/C,;\SKS.+ZV[N(N/9OX#R3&/C,;\SKS.+ZV[N(N/9
MOX#R3&/C,;\SKS.+ZV[N(N/9OX'[-JJ+(.$%MB0[GA%9)7GCCASX^>$]]=^>
M./&CXO'SQQXN/'D.---8Y=](N/6B^F<9RE*S  XD8G0>V7104U>(N>=U_3^D
M]*FFMISK_P!'KMMZ;GE3CGCW/%XN.?=RT+DYE8E-26LM?Y)C'QF-^9UYG+WU
MMW<2EQ[-_ >28Q\9C?F=>9Q?6W=Q%Q[-_ >28Q\9C?F=>9Q?6W=Q%Q[-_ >2
M8Q\9C?F=>9Q?6W=Q%Q[-_ >28Q\9C?F=>9Q?6W=Q%Q[-_ >28Q\9C?F=>9Q?
M6W=Q%Q[-_ >28Q\9C?F=>9Q?6W=Q%Q[-_ >28Q\9C?F=>9Q?6W=Q%Q[-_ >2
M8Q\9C?F=>9Q?6W=Q%Q[-_ >28Q\9C?F=>9Q?6W=Q%Q[-_ >28Q\9C?F=>9Q?
M6W=Q%Q[-_ >28Q\9C?F=>9Q?6W=Q%Q[-_ >28Q\9C?F=>9Q?6W=Q%Q[-_ >2
M8Q\9C?F=>9Q?6W=Q%Q[-_ >28Q\9C?F=>9Q?6W=Q%Q[-_ >28Q\9C?F=>9Q?
M6W=Q%Q[-_ >28Q\9C?F=>9Q?6W=Q%Q[-_ >28Q\9C?F=>9Q?6W=Q%Q[-_ >2
M8Q\9C?F=>9Q?6W=Q%Q[-_ >28Q\9C?F=>9Q?6W=Q%Q[-_ >28Q\9C?F=>9Q?
M6W=Q%Q[-_ >28Q\9C?F=>9Q?6W=Q%Q[-_ >28Q\9C?F=>9Q?6W=Q%Q[-_ _K
M6J#&O'B]DAO/TKS&1[)J7?>3['K??<8F2DW Y5V^95)9G39[K,)9K("0RW@4
MMAV@6?5M#FX!!C)YHSW-P8Y.0(W8RTCY^%/1D_=P<ANT:KB7(*1@"YGC.71G
M_&?=SPTRTF?%A3D%6$$EE@R/5[R A@ B?)(BFG+XBNU&-MU^6@YEKLGPX>NN
M=-6S-+=5!'9=5/A==NCZ=;00:SX3X0>S+#8,R<0K>M9$[9K"HZ7B@2>NWSJ0
MSJ?6_P!EJ@@8F%RY5DS#>P@8S00U_*CY47Z@6!2TV<8)QQ*#[L9$+2[OJ3?G
MP^^9EI1?8YU84B?U[8(EE"[)%M7R6T=01>NDBCH">/C3#] V+<R6#L5EF+,8
MKM!D)V>EP P.G ]WR6#1Q"3$A#4I;3)D(NJX&I*KJ;**<KOM>=]O=YYU3?N4
MD^/_ /*>FNO'_9KQ@@EL 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P")"
M+JN!^JJ^^RBG+LEISOM_3Z1(D[23U]SQ>YHGIIIQ_P!FO& 2V , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , 8 P!@$2:75;LT5$=]D]]BP%#G;7^GE)R='-
ME]/=\?\ -50542V__KOSXO%S[N 2V , 8 P!@# & , 8 P!@# & , 8 P!@&
M+/;+MI"NGL 0LRP8/:<NB22A%:1$JVCH4NVA@(0QY?$I%)R$EDT1$(H_SFXX
M#&!)(O8<[.O&L>KN%RXYON/3$I3<C$J:^&&ZNP)2?>SL8N)-K"S,V%!B>P6N
MQHRRFM7VI)J4M$]#'D@LX*F)$P2SXD6A[E"T?)P>F!UQ'Q58A)T2ED79F!-U
MX;>O2IZMNC+2;(:[L('9\=YED9;E=8^L7-"Q1 JRX'>SJ((DX$.30MJHMN^]
MA'9!F\2%/"#8>J5:M]2S%LL%?"R+X5*ZP!@# & , UO$Z=@]>W1PI!^PD,K2
M;SB_ 4PL&&G=FD;F-MB)7-&=IBHMN[0D 0G.),U? 9[#ZZD6HHLR\D9*3U"5
M&FM8./,1T6FVLIR3\6$M6C#QXSQ-D."I0G%6UCQ) 4QXKF"<2Z+\G>8U*N(A
M'^))'>90Y(O)-R".>Q_LF(YD3PP7=G?8]TW]EW)0BN0]<*OG.RH3)!G X..D
M",L'PR*,)2W!JQEO)6<=$-9 A&UR6YE:/HF4&>A%(&L844*JB='.K!0DIN^W
M;\NMME>0)".^]*/RDE]9O, F\ 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P"$CWO7I\M+?6S[ )O & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M"$D'W@A^FXU]HQ6 3> , 8 P!@# & , 8 P!@# & , 8 P#&[M-VVH3I?6K6
MW>QDT<02 O92+A;8TVC$KEJBDC,L2Q(<P]BX<%/%=-5V8,FKR[W9:LTN6_":
MSC159#13ZED6+:-NUMU*RZ!5BLPT,=.Z-TU#0I45'%!#%%?IZ2C@PBI(%=O7
MG.:32<OE6Q;=FV#5%7K5K#JU6BIH*!4BH::F;I:2&.*&&Y04=)'C#1QN=VZI
M8M34](?;;PJG@<^X<!XK2<=V;P@T0?,9.!EP>M*JM%H,L&(3(+N"D43F8.<4
M%.XZ^;*M-M'0"3#0XJP8*91T-P&8Q<INY=./3^#7EE\U0?:%F_M9YA<YW(M?
M_M8OLZTL-J_^T_#86ZK;OYX#.J+9OF[8=VNLX=9%\1>20U[)FE#S ,;@8*6&
M_;(;XB<CC'6T#*I(:4.MPSX?*KD/6K*0J$8C08,98 1? M9X->67S5!]H6;^
MUCPG<C,/_P M'A_U?:?[)YI%P>NGA/\ P(75V97),JM[,3MOO=) "\,QXE2M
ML>UZ--8T1F100)C286CPAAXS8KSDP.'OIR9FDA#1)A$:\ FQ5=P6&10$\&O+
M+YJ@^T+-_:P^<[D8\[6CP_ZOM/\ 9#=CU0[D]=^[D .6?UKG+B?0J-S!Y S!
M9S%)?$%&LH8!04A=#N!TS! "3C1,3) [GAZW:*L=^76R";G9PW<))>;MFP[3
ML"LT=4M6KJK5BEH(:S! J:@IYT,5)242BO4%)2P*<=%2*ZXE%A.4FF_2V+;M
ME\H*M25RR:PZS5Z*GBJU)&Z&GH+M-#1T=+%!<K%'11N4%+1N\H7#[Z2<TTLH
M,^0?7& , 8!IDG(0?%?"@P1:(1R,.#I,,[5XUC%BL8E[$C9>=KTS8FTRCJ=Q
M18R2EYMNE+;"+"4ZQGT;E8\+6":HEM(#9B8 Q,\.^CQ9):#<W@@8 P"$COO2
MC\I)?6;S )O & , 8 P!@# & , 8 P!@# & , 8 P!@# & , A(][UZ?+2WU
ML^P";P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , A)!]X(?IN-?:,
M5@$W@# & , 8 P!@# & , 8 P!@# & , YV/1.GY.B+_ +3M:?8FU,R=S3=*
M*7LFM^GJ9B[G<Z+4/:]4]7KAY_V;)&M P!@'>3Z%G_$3NW]K66_N=I+-=>=[
MI%4.Q:#UZT#8_F=Z.6AVW3^H6<=+^8I,LC & , TQ;-C$F\(&R;3&M+'Y0;3
MLTW&EK*E<0HML<#1XX%FL<E4$ Q.TY)&^U<:!$X#73D.J-K&N;7B\7BL,'W7
M)I6]!)1Q(6T=6R>?F\>O#'$W.X*C & 0D=]Z4?E)+ZS>8!-X P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@$)'O>O3Y:6^MGV 3> , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@$)(/O!#]-QK[1BL F\ 8 P!@# & , 8 P!@#
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M# & , 8 P!@# & , 8 P!@# & , A(][UZ?+2WUL^P";P!@# & , 8 P!@#
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MP0?K@# (2.^]*/RDE]9O, F\ 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M?NZ[<<;:\_\ OUVXXYXY]SGCCG!!_N , A([[TH_*27UF\P";P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# (2/>]>GRTM];/L F\ 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# (20?>"'Z;C7VC%8!-X P!@# & , 8 P!@#
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M+1\5$2\Q.":Z/@XP)T:_NTY^7#K<C9/@@8 P"$COO2C\I)?6;S )O & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , A(][UZ?+2WUL^P";P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , A)!]X(?IN-?:,5@$W@# & , 8 P!@#
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MIT([]_O\N)E_'?>E'Y22^LWF"";P!@# & , 8 P!@# & , 8 P!@# & , 8
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M$W@# & , 8 P!@# & , 8 P!@# & :9[Y2[0#2?A&N&LQ[.S%J$9=;CW5,5
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M 8 P!@# & , 8 P"$D'W@A^FXU]HQ6 3> , 8 P!@# & , 8 P!@# & , 8
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M3MPJDI(8&TG!*:3FCM!S!1GH8 P"$CWO7I\M+?6S[ )O & , 8 P!@# & ,
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MM8E^ZV"9M?S?]#[$_04_KE9-2><'IC;GTBA]3JYJJSV)XT8!="D/PTU#^M"
M?:L3G3M'XOKWT.L^AC.Y9WQA4?IE6]- >NQFE9NX, 8!"1[WKT^6EOK9]@$W
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!"2#[P0_3<:^T8K )O
M& , 8 P!@# & , 8 Y_HY\7'CY_T<?T>/_LP#378WA+KM@O7BU;YWZVQ%%:C
M[MO& V9""-J&R),;#:5( 6"Q0<_A5<RM#=\:Y-\.Y%,S;<%453"&;H_8$U9
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M  R;N5RX3C+9IU</ORV&X+! P!@$)'?>E'Y22^LWF 3> , 8 P!@# & , 8
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MIG HIW7$J..*[>DY3E.3EDRX>=8[0P!@$)(/O!#]-QK[1BL F\ 8 P!@# &
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ME6]- >NQFE9NX, 8!"1[WKT^6EOK9]@$W@# & , 8 P!@# & , 8 P!@# &
M:RO#*_DP>Y/ZJN/M1'<]7R'Z6V%]-7HZ0\ER[Z(6]]"?I:(\PS-M3408 P#K
M?]"B?A%[H_V*I;Z]L7,+<\G\FL']/:'HZJ9LYF/Y5;_T>H>DK1VDY@@SX, 8
M!"2#[P0_3<:^T8K )O & , 8 P!@# & , 8!R2^&@_'-W_53!?\ $2#-*.?K
MIX^QK._6K)N#S(]"?[WK_P"K5C4SF%C+XP"XU/?A;JW]8T(^TPS/J6'\=6/V
MI9_K="?,MKXFM;LRO^JTIW]9^EA^>0P#G8]$Z?DZ(O\ M.UI]B;4S)W--THI
M>R:WZ>IF+N=SHM0]KU3U>N'G_9LD:T# & =Y/H6?\1.[?VM9;^YVDLUUYWND
M50[%H/7K0-C^9WHY:';=/ZA9QTOYBDRR, 8 P#3K[2I)6??=3C0PG$F=O6,S
MF2#$,H3BHB0L=-B;AR"Y=#;.ZS0&TCI%DT+2F1#BE==I[(BCR3F/5QST6Q9S
M0F+3PZNZ>6&4I3Q\IN*P5& , A([[TH_*27UF\P";P!@# & , 8 P!@&-7<B
M-S*9=5[]B-?K3AO+Y/6$I !G%9M&#ZPF^Y<>HP>.(8S(SJLFSJ2(#UW:HE#6
M?Q-XH[T2U'&&Y'EKZ82L&GM6?=^9FGF-=9>W;"I(=;05&\D+"BH*_8.&H#6;
M2J'"Y]38*4WL7AT@G"4LLVQB,!LGL'$YM%09N-Z2\K)XS,&U5SN.O(4C3I*#
M*"S:;T:,93_HS62RDY8:UC.9M<ZW0.:FRZW9ZTN+,@5GVM6\5A\JH8I.G9>J
M8*A"#!WD(?B,*43]+%I!+6#[@\9:/7;PD%U+\@7>J!A"0.RPJW@EJV:^\C+_
M  0, 8!YEGAN_P J?W _MK$OW6P3-K^;_H?8GZ"G]<K)J3S@],;<^D4/J=7-
M56>Q/&C +H4A^&FH?UH0#[5B<Z=H_%]>^AUGT,9W+.^,*C],JWIH#UV,TK-W
M!@# (2/>]>GRTM];/L F\ 8 P!@# & , 8 P!@# & , 8 P#65X97\F#W)_5
M5Q]J([GJ^0_2VPOIJ]'2'DN7?1"WOH3]+1'F&9MJ:B# & =;_H43\(O='^Q5
M+?7MBYA;GD_DU@_I[0]'53-G,Q_*K?\ H]0])6CM)S!!GP8 P"$D'W@A^FXU
M]HQ6 3> , 8 P#'3M['9C+^K/86(U\M-6TSE=/6!&8\ZK=N.=V$S?GXT0$\/
M8.V*S:MF*TL9I/%74?T5GT04Y*I-?6I\:Z]0<:"5@T]J[Z?,:;8OUA[<M:DB
MUL@=+W96%#6O82$Q*A]9M*X*RLBHARM[$(E)9ZG,+0LA]6=C7J F0.+.!JLJ
M,F(Y/AE#V4-;PQA4TBACH3--XO.4W++*>6J6K6MIM6ZUP.;R SKV@M%*RZXL
MNQJU%U[):"?3EX3J2+#H-+Y)M%)I&X*XTWYB4IF(%RW/$ASQZY(QUH>WC1%/
M0\UD+\J(>I9)M^67 S'P0, 8!R2^&@_'-W_53!?\1(,THY^NGC[&L[]:LFX/
M,CT)_O>O_JU8U,YA8R^, N-3WX6ZM_6-"/M,,SZEA_'5C]J6?ZW0GS+:^)K6
M[,K_ *K2G?UGZ6'YY# .=CT3I^3HB_[3M:?8FU,R=S3=**7LFM^GJ9B[G<Z+
M4/:]4]7KAY_V;)&M P!@'>3Z%G_$3NW]K66_N=I+-=>=[I%4.Q:#UZT#8_F=
MZ.6AVW3^H6<=+^8I,LC & , UO3Z+=7''>2'S\[8TVC=]B?86+-0(2N(NC#9
M!ZR8 -6 B<V$C29$\0:-5+:@[$4I*K6;# ,JLJ)QN&.!,GF"0@B+8RR4M>G/
MKP\F*6PV0X*C & 0D=]Z4?E)+ZS>8!-X P"PED]H^O5/3V(UC:%MPV#3F<H-
MG4;!2$CRQW<M7Y-0()=$'^R7(L V/G4%P,;7D#X6E)3S=P$ [D2J"S303)YR
M/RAW:GKQ/HB]GD4MF*$H>*C4FF!N0+.'(H?'(Q#W+=M(#,HW,-6&\89M>7*3
MIKL?T&[EAG"Q</H_%MW#Q(079A4UB=CQ&-SV!R$5+(9+PS"0QB2@W:3X2;"E
M&^CI@08.D>>=%4'""FNW']&^FWIDU=-%=-]-0*GP!@%N;AF)"NZCM.P!+9F\
M*P6N9O,1C,CJON/=$(Q&29MDV?:-EVSG9FNY8II.M6[ENOLAMOPDNDISJIK\
MJW:]2V78EL6G004=)36=95H5ZA@I5$Z*.EJE4IJQ1P4B@B@C='%'1I1J&.&)
MPMW8H7)KZ5C5*CM*V+*LZFBC@H:_:51J5+'1.%4D%'6JU14$<5&XH8X5'##2
M-P.*&*&\E.%K YL_NYO97_571O\ ]-GW_/F:I>Z(Y6?,_)W_ %-I?O(V<\ O
M)CYVM[_6V?\ N\?=S>RO^JNC?_IL^_Y\Q[HCE9\S\G?]3:7[R'@%Y,?.UO?Z
MVS_W>/NYO97_ %5T;_\ 39]_SYCW1'*SYGY._P"IM+]Y#P"\F/G:WO\ 6V?^
M[S:5X-7O-97='BZ.;#BL&C/DVYKK@/[2VQ]OZ]]N'$Z]D/9+V</&_3^MO:NR
M]9^M?6OI?5W7JWJWIDO4LP\T_.):W+W\_P#YTJ=G53\T_FOV#VA!68/9/;WY
MQ]E]E]L5FL3N>TZ.Y<N?"CO7O>RQ/SG\@K,Y$.Q%9M;K]:_.:M+V;V]%5XKG
MM/VA['[%[!5Z"5[VU'?OWO@P7;N,]I&9A,4C /,L\-W^5/[@?VUB7[K8)FU_
M-_T/L3]!3^N5DU)YP>F-N?2*'U.KFJK/8GC1@%T*0_#34/ZT(!]JQ.=.T?B^
MO?0ZSZ&,[EG?&%1^F5;TT!Z[&:5F[@P!@$)'O>O3Y:6^MGV 3> , 8 P!@#
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M $*)^$7NC_8JEOKVQ<PMSR?R:P?T]H>CJIFSF8_E5O\ T>H>DK1VDY@@SX,
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M(P;C6&BR^^WIUU=&K9+51;?^<IOQSOM[NW.99J=2HZC5*K4JO#$J"IU:@JM
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M@2@.3SJRP(NC5!,A8F;4J< I,K2.5,7,.GB,C9L V\1< ;\>H"M=V5?D]6T
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MK#'Q%OYZ$\*S#XA*)87E<U?GT(3%$"V\',UF9"%794=005D#K&$#H>3/ +)
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MKO+8)T>&66IM8-=6+QU]>K^8C$/"<V-(IVGS8ED0\$G;IJ$RF2.B]<@QKV,
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M_P :YSAC^$_%YD<T'P5X_.RH2?O:0^0N_P##J94EY/J?F,/<[!P# & :[_"
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M6UK6'&(400KAP@0ZWWF^[*%K9D>T8]C(]<8R]V--LVL?*R$)+-5E1C>.1]P
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MBP36>%EFJ2CXH];C1K/11=SIIN[(D7;5@Q;Z\\K.WKENU;Z*+K)I[+\6O<N
MN0ZM[+2'=^IIYT$"2684^9>JS14#'!!V<10BZ4L0"X'M5@P1@0*K*[S0,[.B
MFRHY@ER<'.# ]'=%%0@VU67F\_,N!-Q:GOR?$O-Y.(E\ 6^G///8OQ:]RX$7
M(=6]\1Y.(E\ 6^G///8OQ:]RX"Y#JWOB/)Q$O@"WTYYY[%^+7N7 7(=6]\1Y
M.(E\ 6^G///8OQ:]RX"Y#JWOB/)Q$O@"WTYYY[%^+7N7 7(=6]\2DW#.F6Q
M.&=R.,MRLD=R ='Q3B7LTB!]]%-W"4J8AV*A+5R4=QM1H[3D#5DDNL'W;.-"
M.C;E%7C5>BU[EP%Q:M[\1^$ KVCW479/JL:Q)Q"WR[]P.>0 B/6B[QSJ^<-B
MBS)Q'5]A+A?4DW=(/U$-]U.'R+A)QMZX34UU7FLO,N!+A6E.>UOB5GY.(E\
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MNY+%F;L+[/BY%PC%I,/ ##0SDJ)3?!Q,R)QF9OQ;E9=E($HI[6GZ&C(RX>-
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M,\\?)U=1&LNR'=$Y,)##XG7,//[@/63!(T1I&TX<Q=K2D3:&P"1R)$W:ZFD
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M-UA,8W--Q$E+/'9I\OCT:/+L9P0, 8 P!@# & , 8 P!@# & , 8 P!@# &
2, 8 P!@# & , 8 P!@# /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g63338g14x63.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g14x63.jpg
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M-#4Y4U9R<W1VDIBRLR,E456TT6$F)S9#4F*1TO_$ !T! 0 " 04!
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M?'S,DSC\DI>NX["*M<"6XYN8J(:.ALF@+1$6&&3%_IDH9%C(RJUTW;S+A[=
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M #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@
MX . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X .
M#@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X
M . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #
M@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X
M. #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@
M X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X .
M #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@
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MB("/CS+NO%&DL<1YNC&Q?J;YW)V;_)T+@F[V&/LX3V8,$MFNN2K6*W.KOT[
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MP < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P <
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MY<QXH^JP#_M&//QBH_H3S@_OXH?]6TG]*VOW>'+?>ER/GVS^CB_VX'U6 ?\
M:,>?C%1_0GCW\4/^K:3^E;7[O![TN1\^V?T<7^W ^JP#_M&//QBH_H3Q[^*'
M_5M)_2MK]W@]Z7(^?;/Z.+_;@?58!_VC'GXQ4?T)X]_%#_JVD_I6U^[P>]+D
M?/MG]'%_MP/JL _[1CS\8J/Z$\>_BA_U;2?TK:_=X/>ER/GVS^CB_P!N!]5@
M'_:,>?C%1_0GCW\4/^K:3^E;7[O![TN1\^V?T<7^W ^JP#_M&//QBH_H3Q[^
M*'_5M)_2MK]W@]Z7(^?;/Z.+_;@?58!_VC'GXQ4?T)X]_%#_ *MI/Z5M?N\'
MO2Y'S[9_1Q?[<#ZK /\ M&//QBH_H3Q[^*'_ %;2?TK:_=X/>ER/GVS^CB_V
MX'U6 ?\ :,>?C%1_0G@OLX89Z?<VD_I6U^[P>]+D?/MG]'%_MP;>M-O/TTW\
M/#S]==O#]WP\[&,^'C_^/'GO%)YDI5LS)([<URN/'QE8S+F,R]!CRY80' !P
M QG=-CZ4[3UJ6TH(VD"=8UU-+ 4!:/L#-S6D/CI&0;"M"6S1_JPV(8'Y:ZO,
ML7F&V5<+9:KXT]%L+7009V*XT#?MAH-]R>3_ !TM?U6\OD/AV^ IRG#M_@'[
M8:#?<GD_QTM?U6\9#X=O@'*<.W^ ?MAH-]R>3_'2U_5;QD/AV^ <IP[?X!^V
M&@WW)Y/\=+7]5O&0^';X!RG#M_@'[8:#?<GD_P =+7]5O&0^';X!RG#M_@'[
M8:#?<GD_QTM?U6\9#X=O@'*<.W^ ?MAH-]R>3_'2U_5;QD/AV^ <IP[?X!^V
M&@WW)Y/\=+7]5O&0^';X!RG#M_@'[8:#?<GD_P =+7]5O&0^';X!RG#M_@'[
M8:#?<GD_QTM?U6\9#X=O@'*<.W^ ?MAH-]R>3_'2U_5;QD/AV^ <IP[?X#DB
M\H,@< ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P
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M\4^KO(=?;S.,(< ' !P < ' !P < ' !P < .RPYIQJ X . #@ X . #@ X
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M#]F7U@^W)%O^$K_1O'O@?(U_6!0_3,^JA]QCRH_,RJ^F)]9#]F7U@^W)%O\
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MC<Y8..!P < (D]]O@5=J/O$V3^3!#DEM+I+O%5_%/J[R' %YG&$. #@ X .
M#@ X . #@ X ;TO("?"OM;Y/)[\Y-8\HO9U^HQ=&WJ]9#EO<Q#*' !P < '
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MQ;V)MS+?H72:QY%XQO3L)#X-7$W</G39P[/43UMDLM,0"3J:IKK$4LS5Q+(
M/4>EMM-B^U5K;MT=]$%%N21?"/F+7?M/V/T@9Z<="/H*_P##T#4-RPJ' !P
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M)8F26&3<9@--O2W"4@B9:==0PVLR4HE*S.N(19!*,C.YD22,RQUS5#2AP <
M' !P < +NK^!RVTIW#*S@(9613FPI5'X3#0"#ADT7-RF4E6@0 )1=DG+,>V4
M(E'S5IHX?.VK-'97"CEPBCKNIK@DR6(<=^7)<)J/&9<??=,E*)MEI!N.+,D$
MI1DE"349)2:CMH1F,\6,_,DQXD9LW9$IYN.PT1I2;CSRR;;02EFE)&I:B21J
M422OJ9%J*0?!%HL>-QD\SV''(Z7) C0_=1%;=B6$/%AY%GNLV56;J[-GC=9'
M91NLJCOG3.R2JFF==LY&G$/-MO-*S-NH0XVHB,LR%I)2%6,B,KI,CL9$?.1&
M*.M+9=<9=3D<:<6TX@S(S2MM1I6DS(S(\JB,KD9EIH8I'+C&.V>Z@?!+ZN_)
MUI/\VD9YXSKG\M5C\Z5#_P MX>U*'_(M'_-=/_\ $9&?B/\ @]]_L;G_ +._
M-K&Z".72SX'75'Y-U'_FTC/)/:?2?>(+8707<),\@2(D]]O@5=J/O$V3^3!#
MDEM+I+O%5_%/J[R' %YG&$3OZ/=F89U[=6^UL)L8=@Y-%8Q,(2F&9I/5VM[4
MU,AD[IT@[T7523;B]229L63>XPHHV:%E-M$]M<[^%5%>WMH>T21V]73NZO;:
M1"45C]]ZDD9N>;Q/67 0LDZB73&V>-16K9[CL_V$M@+;5B%M-FCW3U&/IDF#
M02-,I9].FVCX_?"/ANEE,16]/816(#._MO/4Q7+,\H5"7)RV916]G6XQ*VE9
MG3V8I;Z-"T=)1^)U!&I *LF$N"#61.LN6JAA5@;;MV2N@LZX+/L*(XW1<+NQ
M)M:^MK]I^ DSV[=3(_1?NW= C)"NT<#AO=KL?V'$/I*%C-@:]K75<$A [+20
MC2MKAYNA7CW=JW=I;AW#4F<$KO%T'.Z@K?11=/*NR&/.FVA%T=EA%]3/GOVW
M$MZV\H;4B(04+F,EF#*<ONM_76"GK<-A;#D9)*;TW9EL2B1!R3FOK9J^PS+"
M0!)I%EAQ=*9:CW16,-&,D%O!R*"C>N7T7O;T<#YMEMA]0DE=Q%?T\UCV'Z2Z
M#%1C?E ^O&(]8[HD6F(LU9!3MRI(XXE#Y>VC[]Y=,??BX0=#1@/;[BNXP+?X
MRS>SM$_';-F"$CWR@#-) ]/:*3+LV6TYMVV^ESX;"YPOMVZWN6X[^W'=U5&!
M^47H8,N31;E9%"B#;]BI(V<T5A<Z-[GU:2I0; )+"'@BN[DJ,DYPUDS5<K%4
M96:D%>FD7I/62QU+=1BY1&F_;VG?F,,WJW<Q6YRZA:$1[\4QF(@GCV?6?6_L
M>K.U%=&.OL+A/F59,)%=!2QI!%)VX5;37V<,0:J2X0R?LG8PX8$D@(]%@\<!
M]'!)1E/@>I'<]NEN'#G"Y<=AE;=K?CZMPTA\N*C>EY 3X5]K?)Y/?G)K'E%[
M.OU&+HV]7K(<M[F(90X . #@ X . $6>NOV1.YWRI&?\U_K1R3V%T>LQ!;3Z
M?40E-R!(X7/E0_AW]@/X6AGYM(7SP1Y7OQC8F_OX/ZJ@#V[Y*?Q?X=_NI_ZU
MG" O.MAV&,O4+-PM;W! YQ(L/,A(X8R^(X'H:.7N4,LG;?\ L=#=5#17?TBV
MG];LLGCS?'/C];PSO>&ZA'I5<IM0E<IYO%?Y1WDDDMS+R:T_!2:DD9W46F8A
MLV(8#]3HM0@1LG+RF2;;Y11H1FY1"OA*(E&162>PCZ!G2KKFK:/Q>J#<C)'F
M4TH9C;#(#%6(#1^-GN9ND4)Q-7<][3;)@M1LG.D4)?J_8N,[QIFPW"^TR"Z[
M!KR*CUVE18=&D2G9+=0PXW6FXT-N-RK52.H)==A*.3RR"C<C+DNE.);:C.(V
MV<<WG5FTWL-5HE3D2ZNQ&;CK@X@<HZY$MR1R;M/\P4TU,(F.26<CE8D=I4+(
MM-I2W"?Y-M*7%4+KS?8VHA($<Y*R<9A+LQ0UI2#2/Y43T(P>M])GF0,5]D7K
M39ZZV7.CEF(E?^PWBB6RJRJ2C5'/-/A?$C5$:C-K>EM$G%F&ZQ**-<B=IU*\
M_.4VK*XCE%FJ0TIMA7WMPRNI230D9\28>=K+LAQ#45TU87Q!28QR;&;4^IG"
M\W<3F;7R:23'<2MY/PT$=B2HE&,XUG:+FX8B<K1H9GJL^)02S&SR:L==3<K&
M,#%W5K8;%F*'*R-A*Y:/+HB2[.1!(C[0.#4R3J0[B'\>&R59+D-(K"JY!D4E
M#]1.IO4ZK(<J#9%(F,M/XAI-4;0RT<IJ9-:?)A]$J/!Y20T3RI1L.1699EL-
M5I2:+,8JBV*>5.:GTI2(+GWB&ZXQ0JI37%O.)C.1(;C)O,+C/S.3CN&TB,3K
M<EV*1V99EK1V#=T#<S?D2\]C3:)BZUF19JY&[2@FQ.]>Q]-V&1;N$R101F8C
M<DY Y3TP9>#LR1CA#8NJUSE]G05:M1:=CU^>XX_4HB(3-)GO(6UYXZW(PPU0
M:HXE1.O,>?L\M*41<NXUYVV23>4B[@UM*I$F?@AB$VVS3Y2I;M4A,K0Z41IR
M/B-RMTUM23::>\R=Y*,DSY!#A17,Q,$O[V+DJ.R^M- ,H^^BE@3:<2-W=5$R
MF<[DX2K'QFE:UK9FD[>>Y4;AT04]W7GC0:3\>5,>Q4FC<C['D9)4MEB.U5$J
MV$\--Q7(=2J%1E+K^')E0-VGG%9*E4FK%47/,VN4=/W1NU'2XT\_YN2$NFQ+
M=4]R;.FK-+Q1B)<EN73H$",BAU^) )J<4ATZI5*6=/1YV[D;+S"SKYMNM,<N
M:U-\M%;2SRCN")',:KA]96-!Z[DTIGANV)+$GYPL;AK:&!8U&X>],F46 ]#W
M42,@:/&31%ALL\41%,@XP4L@CDHL;5]E<=ESZ-!I-5I]+ES*C(K4N$Y(>D04
M0(\2)!<?D);;3YY*=D27Y#K>99I8;8:9,DF\J0?(\@BPJO-JE,GU*+$I[%(B
MS&V&6)JYS\J5-0PPIQQ7FD9MB.PPTYE01O./.NI4KDDL%RT7^<0'*AY:?V^O
M^EK_ "XX =APW_O=#_4I?]&O/I\CXB?R4]Q#YPK^.K\I7>8]W+"HBUTZ^PT6
M^4#VZ_G8W7R3V]1=Q""V=9]YB4O($B,/=GX&_:[Y.-U_FXD?)+:727>*K^*?
M5WD. O!9@7KV;PZ?1]7T!Z$2F/R\(MX[:X2+1LLT,CE,YU_KL8T>,D=LYQ]?
MPQGPYG&$;C;^\H#U\E-;W;#JF"RX8^=L)/$Z.7)A6C)(1#>Q<RA5E=E&9;9N
M[WW;;ZGHT4CT<3QE?UH8>>.-LZZK+:;T))W*]N.IGJ5[;>GP%C,M=O#AJ1G[
M<W953GE+*O*V]/)M*%K"LJ&)=SZ7N^LXG(6N72("N85#YI'9#L 'F"BHN.2!
MB[-!"8D.WRU9E'PY+=X^;>;NXQ.73=\4R/I.P9M3_*(_1?\ @(8=N+\@EB5A
M4E7QVT;)[ R"#S.U)J6N6U #B/'4A=A*1OV77PEN2DLI+KCQ2H)X:++.7S<;
MJ8*;:!6^S;TN^)(MNA%P+A?7K$&>Z]]I^GV]/I.6Y/RDH!,C/](]8UO# ;^6
M]"GT''LW!ABU"QRD(B@,OA@R9-S6J =&1F&Z2NS!IKHA,-$]526,8QYG(-/1
M_.])GIZ!.;I_F]A:^D7 ,[V]91T/N48Q.S]HI9;_ +R(;1M_'Y@\%9]_LG+'
M%7/A0X;8XRNP$=3#/P24O]K5]+ILC(6^R0Q\S I)K(18].&7FW;=U^VW:%]O
M'-VWM[6OQW"QI!Y02!L5S+RNI99$7>F[=Z/R,@[#-WH%R0@E$4LTA-G"GJ[
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MNW@HRSW'8ZCV]<F9"ZB8J<N+1A:,4?R=@S6)$ #8ZJ9T'*%APINX+D6.''K
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ME-R!(X7/E0_AW]@/X6AGYM(7SP1Y7OQC8F_OX/ZJ@#V[Y*?Q?X=_NI_ZUG"
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M,1TY(@?OCGPQKXY\W&<YQCQSX8SGP\<XQ^YC.?#'CG]_PQX_N8X ?G #>EY
M3X5]K?)Y/?G)K'E%[.OU&+HV]7K(<M[F(90X . #@ X . $6>NOV1.YWRI&?
M\U_K1R3V%T>LQ!;3Z?40E-R!(ZT#RZ7^-:[=?[PUM^9.M.>K/)Y^!M%_NY?Z
MPECR;Y1OPSK?]Y#_ %=#&I;G-!PD. #@ X . #@ X . #@!Y:?V^O^EK_+CD
M'L/H/N =PZS_ +S:?[,A_P!K7GB$]I])]X]S(^(G\E/<0^GD"PBUTZ^PT6^4
M#VZ_G8W7R3V]1=Q""V=9]YB4O($B,/=GX&_:[Y.-U_FXD?)+:727>*K^*?5W
MD.OMYG&$. #@!^XSG'[F<X\<9Q];/A];./#./K?O9QG.,X_?QGPSP >.?#&/
M'/AC.<XQX_6QG/AC.<8_<\<XQCQS^_X8_P#3' #\X 9%K"TI34<B<22*)1EV
MY?!B$=*BYC#8K/(V8!E?0Y?C2<<F(@T&=(K[-FZFJV6>KMNHCHHU<([^.<MH
M!:EK3FYY@YG-@E6Q0ZL.#!6^H\.'CH80!C@QL%C\? 1V/,!8($#"B6;5@.&"
MA[5LBBEY^=-UU%EE&P-HQUP < ' #LL.:<:@. #@ X . #@ X . #@ X . #
M@ X . '7L_U2FDIOY2Q_G5/?;'O%53CQUTVSC^VDO[^,9QSTMY*U)+"J;F1?
M^HS-ID6YD>9/*P1GBP[$?\FP^]X: O0+_P"15_B]_P#ZYV1G1_23_P!Q>(ZS
ML?,?H,/0+_Y%7^+W_P#KC.C^DG_N+Q"Q\Q^@Q5DRQ](&[C*;TCK'WQ8>==A\
M;K>SUS(IF3'CR>[;^Y^N-&1DFU27QC&_H'BR>V=M?-QK0TLFXEX^3Y5*%-I<
MN68FUJ0I2+_T34V@S+G21BY+=)I3)*7R2G$NJ;UR&XA*T)7;9F)+BTD>VRC(
M4GT"_P#D5?XO?_ZY?.C^DG_N+Q%+'S'Z##T"_P#D5?XO?_ZXSH_I)_[B\0L?
M,?H,/0+_ .15_B]__KC.C^DG_N+Q"Q\Q^@Q5@9>01DJS.QYZ2#&AVZBH\J.W
M6:OV"RB*B&7+)TEYJS1TFFKOE!TWW3<-E?-7;JI+IIJ:T<2R\A3;O)N-KT4A
M1D:5%<CLHCT-)VU([D9:&1D9D+M+=96EQI2VW$WRK3<E),R,KI/:E5C.RBL9
M'J1D9$8I/H%_\BK_ !>__P!<OG1_23_W%XBECYC]!AZ!?_(J_P 7O_\ 7&='
M])/_ '%XA8^8_08>@7_R*O\ %[__ %QG1_23_P!Q>(6/F/T&.V9Z@8SCJ7U=
MQG'AG'76D\9QGZV<9Q6L9\<9QSQK7/Y:J_YTJ'_ENCVG0_Y%I'YKI_\ XC0D
M5S:QN@< ' ")/?;X%7:C[Q-D_DP0Y);2Z2[Q5?Q3ZN\AP!>9QA#@ X . #@
MX . #@ X . &]+R GPK[6^3R>_.36/*+V=?J,71MZO60Y;W,0RAP < ' !P
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M*5[AP[IWZJVMOL/8TD"AM[%M4?*;B-#8Y.(-[B!A\6S""65ISRQ2,#A&(V&
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M #@ X =EAS3C4!P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P <
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M !P < ' !P < ' #LL.:<:@. #@ X . #@ X . #@ X . #@ X . #@ X .
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M2\]G^MBQ:NB.%!XYU[)%>LLFFR+9?V8/]*EMZDV]& 57@ X . #@ X . #@
MX . #@ X . #@ X . #@ X . #@!$GOM\"KM1]XFR?R8(<DMI=)=XJOXI]7>
M0X O,XPAP < ' !P < ' !P < ' #>EY 3X5]K?)Y/?G)K'E%[.OU&+HV]7K
M(<M[F(90X . #@ X . #@ X =:!Y=+_&M=NO]X:V_,G6G/5GD\_ VB_W<O\
M6$L>3?*-^&=;_O(?ZNAC4MSF@X2' !P < ' !P < ' !P \M/[?7_2U_EQR#
MV'T'W .X=9_WFT_V9#_M:\\0GM/I/O'N9'Q$_DI[B'T\@6#@ X 1A[L_ W[7
L?)QNO\W$CY);2Z2[Q5?Q3ZN\AU]O,XPAP < ' !P < ' !P < ' !P __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g63338g17p85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g17p85.jpg
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M/Z<C(Q'7GW\_IR '7GW\_IR '7GW\_IR '7GW\_IR '7GW\_IR '7GW\_IR
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MS=G@N#F[,K1OCL3&R4O8=9,%R8^378NU_83:^Q?:980H
M                                        &)*Z7S.JLNS_ ,V+$H.L
M)]B7W%SO'"1C]GU=G[J:92]CV78XZNO&.O.<YNRO6_LYDVOL7VF6$*
M                                                      5)Y+\C
MK+Q[=QLFG18BU4O&K=\["F'1+._86Q25TUK>3V$SK$1 EK3N+,SL;6,7:K6)
MU8>Z(USVALE67Z;D[YH"(!9<TMILMIVO5D_4]</'NF]F\?\ 7VT+!!/;&WBK
MRGR:N^J:=2I+5"+U5TK'>+TNTT'^PB3Z\]A\\A&\/&XB,69&2A!E3C5KY*Z^
M[C7J.BS7REF?B>O?M=B%V+M?@C#:^Q>+,\(4
M                                # E\IUOB%M^\'8NQ=K\$3:^Q>+,\
M(4
M  QCZ%AI1=HZDHF,D7,>5Z1@Y?,&KM=D22:F92)&BSA)11L5^R.=H]*B8F'3
M4QFZ^%$C9)D"/8C1.D(#%,Q Z;U5"8URZEWVO<1&O*C&XH;VPJE7GW=,[CB$
M?!=U.+D(M+N(3N%625*51Z=8Y<9P%3=VOE+,_$]>_:[$+L7:_!$VOL7BS/"%
M                                                         P)?
M*=;XA;?O!V+L7:_!$VOL7BS/"%
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M7BS/"%
M   P)?*=;XA;?O!V+L7:_!$VOL7BS/"%
M                              #F]+/-J;]W0M47L;/QNE-8;%EXNULK
M+KMA,0U\9REL.SA3*+&RS8OS5IYKVP$K=EJ!GLO1(+9]!N5O02LT'(2C(75\
MOX_E^$SH':*ZQMM7L53DCK$C;- R]=?J(D9K.",9F/<1KHZ2<FTD&"RQ4'*A
MDR2#%\S4/C!7;1RCE1$XA2>D='AIK7TDTE*Q8[Q%*/KC1[SL1C$LM75V&VQ/
M:MO%=V%JL]MA:QK2%CH)MKVR5>)4B$M9MZ">:99D&UV6M2LH^<K"UZE_RJ?B
MI=AKY2S/Q/7OVNQ"[%VOP1CM?8O%F>$*
M                            !@2^4ZWQ"V_>#L78NU^")M?8O%F>$*
M                                                        '-$U
MBU19.3]EU)=]9;*U7LU[9WKJ.>:=Y8'JU?V575DS/('9UOU3J#>M V'F2F(E
M%-&?F[GI>12BG#!:%5NTW#,&4BX&6FFQKLK3JJUUG2W&.K&,8_%C'5CKSG/X
MO_CGW<__ 'S[H&)BV\]!NRQQVDS%.B3!W*<2=O(LURRAV953O"1QDUC8>G:$
M07.Y*VRKE J*IE<%PF?. /,U\I9GXGKW[78A=B[7X(FU]B\69X0H
M                                                &!+Y3K?$+;]X
M.Q=B[7X(FU]B\69X0H
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M:Z75O3I.O37REF?B>O?M=B%V+M?@C#:^Q>+,\(4
M                                   # E\IUOB%M^\'8NQ=K\$3:^Q>
M+,\(4
M   *!7#0<;9>8\9L=Q/T"U*M&%1EE]=J;.N^N[E5&D,^@Y-*T2%&J;J9J&X&
M;BTZ]HU@A5;O5:Q-,I.H,(]QL"8K=?K=<@A=GX_"UM]W:7] @ &!:^4LS\3U
M[]KL0NQ=K\$3:^Q>+,\(4
M                 # E\IUOB%M^\'8NQ=K\$3:^Q>+,\(4
M                           TEULO7+%DWDGM_I+..=]X<M'[JU03=DZ\
M*3.25CN=TL_(@MX1G9/"P/:U#=]S-')8_NC*"N" ?I;9.NFY[&FO?J6@I3VA
MY"W)K6F#3/5F"3IVQ5>V,IWQ30C1-ZP?,SN9/#5$CID[;F/A5LL0@'YSLK7.
M'+9GF_TG#Q["KV1FUS:H+#EW76T>E+N9]LAW?VU>%;Q2Z$FO*I%.Q2CUDGJB
MY6RA%,A3D>/.V]4E,](;9NO<'C8HD[(ES<ZY@S"#4DL0Z<R]+F2ZVL4I+F+%
M$D5\)LS26<,2K9<YPD H]Q]4-J:P=*Y0;;'H3A<L(A9C(H7"O+*EKCIZ2.:V
M#*:<B8^(1S(*)L$)7..X%GJA&J:YES%)D#1]H\F=$::U_";2V#LF$C:#9I,L
M/6;%#(RET0LDAB%GK,X1K[2DL+%)3:<?6*K:+1,.HMFZ:0M8K5AL<LNRA823
M?-0HSX:YY1Z VY=;7KS6VT*_;[72XW$Q.-(HLEF--$E5:-GLE V-PQ0K5N8P
MCV0CXRS.:G+S:-6EW[*(L9XN3=MVB@K36M&]L-M:KE>[N]>S-?27>N-E)F3[
M@N=<>=[H>$[F[]2K[N>24[DC8CNQIWT?..UM6'=3;NM5+MZ79"4_';J-K@Y^
M"LT:A,UN:B;##NLJ8;2L'(LY:-<Y14,BKA!\P6<-5LI*D.DIA-4W8*$,0W48
MN<8 RP  #E-;&>&7/]>6=(.9*H.[5JIN_FTH"OKUNG[+4H[6/@Z]/2EJXNVI
ME$6:=B%J\XBK%6>1=#M4KF>J=)ZGCW-/KSD9;./XT]6YTILK4ZDRK1Q(1<DP
M:2K^"=/8]XT;3D4G&*RD,X<MU$496-2FXV8AE7\<H<KMFG+Q$K&'<(IE?QKY
MIE5JJ,3DS6;_ ,MHB6TXZG]B[LG$-FS.GKS2JO9=0ZY(\DJ5LC?<# ;+UWMY
MU2]*5E*FS^EN,F8[8[U+#JDS"&P++L19Q*6JM4B+@(,9:-.A;=K^2FG?V^)U
M8:^4LS\3U[]KL0NQ=K\$8;7V+Q9GA"@
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M4\J   &!+Y3K?$+;]X.Q=B[7X(FU]B\69X0H
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MMT=7V'05KY2S/Q/7OVNQ"[%VOP1AM?8O%F>$*
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MC\8OADJ?]J2^P#H>[]T.?&!<?SK7]U.Y[C72A\#+W^;9_P!^/PQ^,7PR5/\
MM27V /=^Z'/C N/YUK^ZCW&NE#X&7O\ -L_[\?AC\8OADJ?]J2^P![OW0Y\8
M%Q_.M?W4>XUTH? R]_FV?]^/PQ^,7PR5/^U)?8 ]W[H<^,"X_G6O[J/<:Z4/
M@9>_S;/^_'X8_&+X9*G_ &I+[ 'N_=#GQ@7'\ZU_=1[C72A\#+W^;9_WX_#'
MXQ?#)4_[4E]@#W?NASXP+C^=:_NH]QKI0^!E[_-L_P"_'X8_&+X9*G_:DOL
M>[]T.?&!<?SK7]U'N-=*'P,O?YMG_?C\,?C%\,E3_M27V /=^Z'/C N/YUK^
MZCW&NE#X&7O\VS_OS#\1)>-L54VU8X5VG(0EAY%;DFH621P?#>2BI&PIN6+Y
MME0A#&0<HG*=,V2ES^,IL8,4Q<='H*M]CO:Y,<7M=T^&U7=>G2MC^\+OM<M1
M>2M=BM=ZPS;/:9+CAAB<N;+B44+:3V-)II=WI?L=INZ]L(W;;945GMUW='&#
M+#;K-&X7,LUKLUW12Y]GFJ%Q*&9+C342J]C54TW; ;N-2@
M  <SM_<:=G;0Y)P5JDJ+4;WJDSVM(M91[8'R5GUP;N:'@W-NI1'UFAU=<7FH
M1SW:%J8['UZWE;8ZLB^G(.%AXEHGLJUIBI]_V=>_9HU'2)_%QTM%O8289-9B
M)DV#F+E(Z5;(/V,I'/6YVCUE(M'*:C9ZU>ME%4'C9=(Z#A%51)5,R9S%R(0M
M$<8./T$[J\A%ZFI[>1ITJM.0$B>/,ZD6\NJYB7B<B]?O%5W<TZCWE?KKR&5F
MUI',$[K=<=0O<"\!#J,@)::^4LS\3U[]KL0NQ=K\$3:^Q>+,\(4
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M3:,J.Z=4          P)?*=;XA;?O!V+L7:_!$VOL7BS/"%
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MJ]/^O>$?V98O^L&&C9]@_P"C^)/U]PS_ -EO\LX-RFL
M  P)?*=;XA;?O!V+L7:_!$VOL7BS/"%                       "L/&/_
M $>0/^T]MO\ XL(-.=#O]'I1_;'CG_Y+O-H]*&OH\_9=A'PMY9X;C-7
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M3DXREX<6OA3A3_CN+X-?*69^)Z]^UV(78NU^",=K[%XLSPA0
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MZ5,M=GE3Y$F;-CNZQ6:9,\G+M,Z%0Q1.'WU6G14G ;(/#
M   !@2^4ZWQ"V_>#L78NU^")M?8O%F>$*                       %8>,
M?^CR!_VGMM_\6$&G.AW^CTH_MCQS_P#)=YM'I0U]'G[+L(^%O+/#<9JX
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M*:IT4B&T38HX9<4U02U'%"FE%$H(4W6BH2(/5GG0
M    # E\IUOB%M^\'8NQ=K\$3:^Q>+,\(4                       *P\
M8_\ 1Y _[3VV_P#BP@TYT._T>E']L>.?_DN\VCTH:^CS]EV$?"WEGAN,U<
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MRA_*<J_ZO\/_ !\'M1Z9?CBN;_2ZP?Q0/;+T6_%A>G^H-L]0#Q;<H?RG*O\
MJ_P_\?![4>F7XXKF_P!+K!_% ]LO1;\6%Z?Z@VSU ;SI/5LMJJ!M#&?MZ5WG
M;A?;'L"9G$*\G5VYY*R%8=U(-XA*5F$T$DU&65"Y*\['/;LE*DF4F.OTG1W@
MRW8*NR^;->=^P8BO*_L37MBB\+REW5!<TJ*V7NK-Y>5*L$%MM\,J7#%9\R:M
M%'Y1PJ"!0JOPL;XJLF*[?=4^P7/%<=@N:X+MP]8K#'>,5Z3(;+=KM#E3)ELC
MLMCBF1Q0S\K3DU]XFXXG$Z3*/?GC
M.4->W)M.6YI76"=.MAR]1C-H15,BE*;C;JE(85=JW-$.6K^ KNGMS:2?1C6P
M8>MKE<[3M;2U[C;9%V^-748QD+#UR(&6S9WJNWL?R:='6=7@,0 ,"U\I9GXG
MKW[78A=B[7X(FU]B\69X0H             5BXK^2^T_]HG>?]^Y$::Z$_ZE
MQI^U?I)^LUK-H=*O]:84_9S@3_L-F+.C<IJ\                    J6WX
M'\-VKP\@VXWZH0=*0S>OG42J[-,F8=K68>F)LNT%ZD,$/4J[6ZVY4*EA=["U
MFLQSQ5=K785-B+5[WWFP.^'7%B0N"%^?Z#U>^MZ,I8YHTT\JL<Z7>RULL%OM
M<](2R"Z2C.:=.K-L&]SZ"LNW>FC)BY6B0B^XG4[)J.0J][_"IX:.PB%WT9W"
M=U9M;SQ-$TMG$ZP8['0A*"UA(CP"EI39CW2KB5LMJAG$>X>3\["1V@Z!5ZN9
MU*%BHRFH/:HXBGT(6)9Q(9GOZ_'FR5;%PNXI6Q6O+V+0>MI5:J/Y25KJCFOM
M\'BI.9V.IM^0?MLI93SW8KM!P[O:3A3MBK.ROY*39&;KR3\S@*O?^*->#:,%
M"\".&5>CJ/$0_&S4[.+UK,YGJ''^##5=I5I#)ZFO@L2@YRLFWC".Z'2)%.#R
M4T(E*U"M2R<>62A(YTW"KTZ7IUZ=?:;U3N*G'#7MUB=BT?2VO:K=X*$/7HBR
M0E>9L9%A%G2>-3$0.B4J97F&$B_B2RN4S2J<(\<PA'I8A91D8*NE*Z#297@;
MPVG&UQ:2W&[5#]O?[*G;[<1>KM,YF)Y-2Z*F<F4+V*C-JY/LK9/=\3'':0\B
M38^P4W[!RG=[025#,UJ;T?CEW+<B8I_1VG[39(BWV'7%1E[/ H4YK"S;R&:J
M/XIMKVSGN=';L%<$QW,C5;6HI/P:26"D821LN$,%,!"K]5Z./CA1^2=$Y,U"
M+D:S8-7U.-I^O*#7X?6T'K^J1\/JU72\8LS7B-?,=ER'<&MEU:TRAY[8\M56
MC8K)5M7DG$/!JQ@M72G/?7?3@7T @   8$OE.M\0MOW@[%V+M?@B;7V+Q9GA
M"@       !H4MM75\#(.8B=V10H669'*F\C):X5Z.D&ASID5(1RR>2*+E YD
ME"*%*JD3)DSD/C&2FQG/F;;C3!UVVJ=8;QQ9AF[[;9XE#:+';;^NNRVJ1%%#
M#'##.L\^U2YLJ)P10QI1P0MPQ0Q+0TS[]DPGBF\+/*ME@PU?]MLD].*3:K)<
MUXVFSSH88G XI4^39HY4Q*.&*%N")I10N%Z4T8[QV:9^%S6/^_M5]K#J^Z'@
M#X<8/^DUR_?3L^TC&GP0Q1Z O;[H/'9IGX7-8_[^U7VL'NAX ^'&#_I-<OWT
M>TC&GP0Q1Z O;[H/'9IGX7-8_P"_M5]K![H> /AQ@_Z37+]]'M(QI\$,4>@+
MV^Z%>>2^S=;6:B5F(K>P:/8)9?;^FU$8R$MD#*R"R:&QZ\JN=)DP?N'*A$4B
MF45,1+)4TRF.?."XSD:IZ8<882O?#5RV&Z<48=O2VS,?='T4NQW=?=V6VU1P
MR\6W5',B@L]FM,V;%#+@3CC<,#4,*<45$FS8?1IA?$MV7[>=LO+#M^W?9)>#
ML:0QVJW73;[)9X(IF&KR@@ACGVBSRY4+CC:A@3B3BB:A56TBZ@_0QI0
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MFPTY-GK>Y+3XM/DT5X?:_LI2IU^:^4LS\3U[]KL0NQ=K\$8[7V+Q9GA"@
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M^2I%ED6>S0110RI<J7"H88(7EA5(8%#!##"I$'K#S@
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MQ)PQ0M)IIIZ2?Q\T^D          8$OE.M\0MOW@[%V+M?@B;7V+Q9GA"@
M     !6'CWY:<H?S^/?[@44:;Z*_SAZ9_P!J%H^JN&#9_2%_4O1=^H$GZQ7^
M6>&Y#6                                               ')2T[.G
MH_I$(VL4*6>R$'<"UY2WU?73F0M["Q.JE)U^C25@V2X>.;O0]6RM41\.22:*
MU,U;;9R%TS%0L7M2T6">AJ?6AEL_&BM::-&O7H;[-_5*QRZE?KT[/)0\Q858
M2&E)=* KS=!W/SBD:R7>$AX-HZ=,6KF8DS(X91C=R]9H+/5T$UG3=,QE2#$H
M[6N>M>L-@Q7<:SLF3P5ZH=$V%/PMFIUDJ%:>[7V;":<UO)UFQQTH5KL:+E=C
MS#ZKV9>N)ES296D["C)DIIBMMXR7%ISIW\N1=UKY2S/Q/7OVNQ"[%VOP1CM?
M8O%F>$*     5CWY_K XM_GN6_Y<W@:<Z3_SHZ%_VCQ_5'$IL[ /YO\ 2G^H
M\'UEN$LX-QFL0                          .8D7_ .^;O'_ZQM6?_P!4
M[@'JXOS'D?K7:_\ M%C/(P?GY:/U1L?_ 'FW'3L>4/7
M !@2^4ZWQ"V_>#L78NU^")M?8O%F>$*        %8>/?EIRA_/X]_N!11IOH
MK_.'IG_:A:/JKA@V?TA?U+T7?J!)^L5_EGAN0U@
M                         !QEMB2LYSJ1?Z\PMLZI0VZJ:E?#U;86S=R'
MUQ=VJ='C':,[#QMMOM)T2='M5U5F:O*U'2S2*A]<NW;J\V]U?8;61QEII\CT
MZ%HI2FK3WOOTKKU;:M"7BJV:E65LX>5RX5^9JU@9M)*4AG3J$L$:YB95LVF(
M1Y'342X78.UTD9*(D&$HQ4,5TP>-7:22Y!B05&<1=#Q+BE.4*];GA]?+PBU9
M).[>W%9FZ:56G(BT4Z,FFECOLJVM<#1;/!1EEH%=M2,U!4.PHKS50CH62?R#
MET+5D[M?*69^)Z]^UV(78NU^",=K[%XLSPA0    "L>_/]8'%O\ /<M_RYO
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M_;%9)"K0DA*L6<O95H9@>5ET8"-<+IO)A6*BTE)*13CD7!V+!,[QSA)N0RF
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M1Q*;.P#^;_2G^H\'UEN$LX-QFL0
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M5#%#E4#456TIW'SSZ(      &!:^4LS\3U[]KL0NQ=K\$3:^Q>+,\(4
MK'OS_6!Q;_/<M_RYO TYTG_G1T+_ +1X_JCB4V=@'\W^E/\ 4>#ZRW"6<&XS
M6(                                                8$OE.M\0MO
MW@[%V+M?@B;7V+Q9GA"@       !6'CWY:<H?S^/?[@44:;Z*_SAZ9_VH6CZ
MJX8-G](7]2]%WZ@2?K%?Y9X;D-8
M                 %%>052WC,[WUK+4AML1U66KS2&8&1J%W/6Z94%87?L3
M.\C5MIUTML@VUL:WC0*7@Y2BR5<N:3)]'V..BDZ[,V%H[DA5^.YTXES&OE+,
M_$]>_:[$+L7:_!&.U]B\69X0H    !6/?G^L#BW^>Y;_ )<W@:<Z3_SHZ%_V
MCQ_5'$IL[ /YO]*?ZCP?66X2S@W&:Q
M                  # E\IUOB%M^\'8NQ=K\$3:^Q>+,\(4        *P\>
M_+3E#^?Q[_<"BC3?17^</3/^U"T?57#!L_I"_J7HN_4"3]8K_+/#<AK
M                                               #XE;HE75<E3+A
M=9-%%57'7V1TFYECHDS[O5V*9G"^2]6/QJ&Z^O\ H ^P      K'OS_6!Q;_
M #W+?\N;P-.=)_YT="_[1X_JCB4V=@'\W^E/]1X/K+<)9P;C-8@
M                                      !\>YT<.,NNUE[H,B5OE7W>
MRRB4YE"I_CZNQP<YC8]SKZ\Y]T ?8         %8>/?EIRA_/X]_N!11IOHK
M_.'IG_:A:/JKA@V?TA?U+T7?J!)^L5_EGAN0U@
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MR_RS3[0&>'?P?(9(MW%<QX"VST,O\LT^T!GAW\'R&2+=Q7,> ML]#+_+-/M
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M-9:UKM6U-:5MI6J6])["ZW@+;/0R_P LT^T#+/#OX/D89(MW%<QX"VST,O\
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M:,^Z91:M<KDY+QXC37X[5]A=4"
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M>YP:*XC5/QU5_'66+ @
M               &)GX&$M4%-5BS1$=/URQQ,C V""F&;>1B)N$F&:T?*Q$I
M'NTU6KZ.DF#A=F^9N4E&[ILLJ@LF=,YBY A-OQ-XOLX!*JL^/6F&E;2L3:VX
MA&NMZDWC5;,S@Y6KMIURU1BB).Y-.K3LW5^ZG15E#UJ8E*^?)H>0=LE@KQU]
M>WQ()X/UZO-9OE5-,*] Q4E <A)G0D*O"PL9"DB].:'KL##:@UXR:Q+5FT0K
ME!CK%/(034B&#IFF)%PX5<.G:RQQ7R?RM)OO+\ 0
M                                    #3[[KVB;3J[ZD;*I];OM.DW4
M.]D:O;H9A/P+UY7IJ/L<"[=14F@Y9K.86P1,7.12ZB)E6$M',9!J9)TU05(!
M%K[BAQB?15?AG7'W3:D/4D)E&LQ.-<U1.-@R6"6CK#-YC6"461JV5E;##Q5A
M?+$2PLXGXYE-J*9E&R3HH$1]'5E.5XE:UV$\;,LW+<2MFVYLV=:L&4>XN&Q[
MM9)-[9;5)HQZ#5GAZ_.BV;)(-&S9A&1;&-AHIHQB(U@R;"O6^UEW@(
E                                             !__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g63338g19t07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g19t07.jpg
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M  (1 0,1 ?_$ !X  0 " @,! 0$            &" 4' P0)"@(!_\0 /Q
M 00" @ #!0@"  4# @< !0,$!@<""  !"1B6%%97U-81$A,5&568V!87"B$B
M(S$F-CAXMR5!87:4L;7_Q  7 0$! 0$                  0(#_\0 ,Q$
M @$"!0,#! $$ @(#      $1 B$2,5&AT4%AD5)QDH&QP? B S+A\1-B0H(C
M<J+_V@ , P$  A$#$0 _ /OXX X X X X X X X X X X X X X X X X X
MX X X X X X!&YG*&,(A\KFA1-PL,B$;.R@BBTPZ4=*L0 MT5=IMD^^\>E'&
M;=HIBCAWECUDIWCCWWUUW]O /E&;;I;I.]3::\22T_%$IO5H[LC,C<CHO4>S
MZ8#/M55JVC\R<L'%7S*QXA7DUO561.H>RS/O9Z.6Q+M"3QN":MFB72A)@O\
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M/_U_Y=\D^_AO["'V\KD]%.4@X X X X X X X X X X X X X X X X X X
MX X X X X X X X X X X!6"Z=V-/M;Y4P@VP&S]#4K,R@!K*AL5M"U(9!Y
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MQK5BS*Y@J_6B?3INT8$):Y4+"JE?P_BL+I_D\H_NO.2Z9YFZMPO$@L:H*O\
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M(C>C,4EX9['Y$*[(AW8\LPZ(B"#QGV]%OV1%K^-^.R=MG*:2V *UUFBKM2Z
MZW4A+(K,Z[POYF5A2:B$<&R?<?<2Q88S;*"'0+%FYKJQKXEE?EV348[52'LC
M,8(-!BZ;1^.1:OV#%TW&G4W;^/TII6Z29@HYX;.HL4G8:;AH/,TV47L)6VX?
M5#RZKI)Z\PJTEBSL_P#[ AVNA&?NJ3C4E:GWSL^)<B8*V; #[A0Z :##'?3[
MH3$XBVF2GS$[DD4T'UD6M%6UU8G+E"*]I)7FM \[;MGND%;O0>)$TK?4H;_-
M?]/J6%@901DG4ASAF2_^8))S;[G^8X='N@EY?A3YSW+D\$' ' ' ' ' ' '
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M<-<1QE7.0:#8L.HF:/0<3))[ YFRE\+GA%V:;20&]%%5Q_08FXF\='^[F[:
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M)6J\H>:_6CX[5;ZR"_-<8*_35\7P)6J\H_6.UFM677VXWI5W?7_C[>IB%_\
2/_\ *XP5^FKXO@F*G7\_8__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g63338g25i85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g25i85.jpg
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M 0$! ?_  !$( ,P!T ,!$0 "$0$#$0'_Q  ?  $  00# 0$!
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MLGLR8[%K(F!IE\IWHUX0'O3CH<19O"+QD^=M73EPHN@X534UWY%*[U+R, 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# ,>/BS_ %:W=3[@YM_":9LN
MAWK3@7O&#YC6=,_57'O=MCY3RY<ZS.11@# & , K:M(*3M"QZ_K0*X:M#%B3
M:*042Z>\[:LVQ.6G6 !@X=[:^[MJU1=$$E%^=>.=N$M=^>/UYCVK#*E6S:D1
MSF5J\UA[6_W*R&-TCD;_ .2HU43K,BI7=;M5JC%1K[5B&NQSO[6NGD;&U79;
M<D5R*N7(9SK%Z.]3W[ON;0])]9.X$LD'3$-+8^9[>QV<1J7B35SP-@1<%Q]C
MT>Z QL7#:H-OX_*D&9V,3 S)P@<.T,+-3:CA=GQH%;'\9:W \0O8K@L4>.20
MRLP66O+"^.C8<Q&.JWVR2OGN1MDA5T<T$<4DCW1HL>JCCT*UH_@SG8[AN'X3
MC<TF!1S128W'8BG9)?KM<KVVL/6.)D%.1T<R))%.^6..-'JDBJK2JK(\/OK7
M6752G+58];Y19!:<=&Z[[&2^Q7_?ZC*?6!324UL]D\A2!]?YC&'5B2X6%=LM
M2@L?'E7*LI^$[1<'NJ5:J\[6:NDF*6L7O4W8I%597Q^SAD%5NCE^ZDD$5IL4
M7"8E!,VM ]Z.U'NE1$ARX:3ZCD+MK1K"JF#T+C<+EM/L:/U<4GLNTDPZBL=B
M:JZ65(\-GA6U.QBMUV-B5>&SX&-==JDWU7X276J;Q#JPB;Z]=@$H3='2^ =@
M;:[BQ_L; VD9I^5R"KC$QD>VM#FH _D4G#B"0H>IRU&'=UG+.1),V22CD<HH
MI@6],L4KS8NK,3PU9Z..V<-IX))AEA9KL,5MD,2?U".PV.)[V/<FLZ/)%BUG
M+D[)/H4]"\)G@PCA,,Q)*]_ :V)7,<CQ2LD-&>6F^>3_ ..?6=-+&Q[&KDV1
M<TEU6HJMVVN07J/X?>CCPY:0LFNK_?6/WUJ^&EMKR@UR QHR 32PK*E%8QA=
M&I#E9&$#01(T'%/B_"\S'JMQ;YYY)!5PSTV7^M8QG216Z3WZMG#6U='K<[/Z
M?8I2/?8@K58;<J+=CMQJR16/>UF4#D5[6YJB.V?)KX)HTCM%\/M5L2=:TCIP
M/_J%>]&QE:Q9M2U(E2E)4>CXT>QCGYV&JC7.1$S;FN$:VJ_>U-:EF562?-RA
M&L[!F=?OR;/39-H1>PR1DHXZ?-4]MU-M&[M<:HX0TV4WVU24UUYWVYX]]SOM
M.RERG4MM:K&VJT%EK%VJU)XFRHU5Y5:CLEZT//[M9U*Y;IO<CW5+,]9SF[G.
M@E?$KDZE5JJG4I'V9)C# & , 8!ZC_A/?5L]*OW?H'_+>,Y,TQ]:<=]XS_,=
M=Z'>JV ^[*OR(49VP[NS^A;@+0)@G1T"CX.N8A-(J:[''997<:[$2^2F9D.?
MU%7-RJHCZBK23@DXR":*$)P7DI!T9GH#5S"Q(!- ^7UHV9$SV[5Y-G)U_'F]
MI(2??F.,7-[HR2F+B9)TG>)JG.%0 -E(4I*RCM61"TC4^7*N7H&+Q,&S'2GA
MJ@S-239R;UVCOR;6-&I,C'1X9;MJ;L]OMR.I2\1^I]IA, W,/GCZ*M(GULD=
M2RX$)4(N+U?=FHY*Y;#X["XX^2#N!;YE'(J^-/WDD(#AK$2,EA61N(R,B;QX
MZ$ZJ_'[LM^968?O_ $1)3%>1Z*LK+E)Z>,WS]\#C\"(D#U=M!%HFZ4D"L] :
M+:G$>(M:<8E,2E>L3'2W:,\QHS)#>K&&MDY&L(U>79X[,_ASY%:7#V5J#JOQ
M&X[)8K+0T138BEGAN&P;76O*[!%Y&VBHEP8?Z*BF''#@R[VUUC4,;265-1[=
MV<=QQL%3X(;B-Y')SQ%NN\8*RMI)4;/! XI(;AA/RW?5K(=XA)[%HMZ49SZN
M(2[9)NRLKF">HA\O'6@H.J-EBK=R%CQ0A)F!($R$Y+\.\D3KEV3=7[,.P<><
M5_**[UI2>0V%:AIR(7!S+=>253"K&=;G1OPA^*XY24ENJ0UY'RQ<0_%\-'";
M_9SLZ10!4RR]GZJ?5V4[+!*/H@Q<,6VBT^=_*6#PN)B^)(]U"GI/.+'C5<(-
MU"4. 3D^LV OI"H5/(1F*2<ZW'!R7P4*Z<H\HX&6W+=_ZS+7V?>BUI<#@P>J
M*YI*R;9-0/L):<P!L+<L>/PJ)QKKS)8'$3$%=$I;1 &QA5P2:2V. "IQ68U?
M%V\2X820H=<N-&(<?(1.2;<UYN3G^_Q**@'BELIJ9[<K^;K1"'U%3]6VWUR5
MT)*Z2B^?EQUUH:YCL*<C%=-F8>4!I/V:HJ"CTF+IVB0=V0&XWY263WV7!6[O
MO1>K)5V^S9W*7.5EVI+RWJ#UK['3 3&HG(;N==9AAL$SW/FXZ(.WS9$"KU<0
M$=(-DRSCC0A,?@@$D2;H-$76S)\>X;C4WO.@C+:J<V?=F511?<NINP<E'QF%
MB['$JR.#GK'@I6;P4G% UB0V(2@/"9J:ASI]OLX=MXA*Y''1!74HT$J/-#X8
MS'M3D=(-S&PC^?B6NT1WGG-SW/*(&I,NKH!O'NPG9>G]:NY>V.YO!V#Z_6_:
M5:H%O_DB6AB3!*YTF_*'&O+)F-*<M^.=U4/?;"I43+\.5.7;NWG!/?$9D<#Z
M@]-NSJU: BI/LU2)"U#,,3.E630.:;])+,[3#8L"+)"RKS=$M+8.+@>I)V)?
M+M11A<MP/=O&R;14,MJIU_JB?KU%WO52]RU^PB3'I'K6K"2Q>;/8B:CE=2&R
M3"L:40!1XVT8345;E2TI/8C*G;0XD72 EX.B@YBQ"-20:4(,3R7D!"IE_/!5
M(_#>(5UF/&A,:'R.1[2,S%*NEC(&K$BZ)#E*VKR:]<P !779+R"4L"VN0% Y
MO']E_AD.9&!)LWPV$$&SO<,ERS]O<F?PW%L[/Q1E'B<,T&TQ*)0U-C^E!;:5
M146;>CIRS[>1^6%VR%=Q=TU;'V[X,YCC=F+UD[I%LKRY,*R9>-LHV[(.A.KE
MGMW:W=EU]?7U9KL,E%/6S%KN@(^PX>B;9BW9J:19^*DHI4)(H]+JXFTBK>?1
M4\,4W6U;&(G.HG(XV2^"N7HY9X*6<"R! <JU>KBG<2=@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , QX^+/]6MW4^X.;?PFF;+H=ZTX%[Q@^8UG3/U5
MQ[W;8^4\N7.LSD48 P!@# /O%%20(H--AGSH87#OV94429+;MWH\D/<)NV+Y
MHX3YU40=-'2*3ANLGMQNDJGIOKSQMKQSE+V-D8Z-[4>Q[7,>QR9M<UR*US7(
MNQ4<BJBHN]%*F/?&]DD;G,?&YKV/:JHYKVJCFN:J;4<U4145-J*F9EF(>+Y8
M;P],[+;]7NJ(WL!:]=S"LKFOMC#)PA,[( S2$OX2;)J!4;!3A40E91-VVD!Z
M1PV.!7AXX,;(O=>(Z\, ">G,T+K-C@JKBV,/PZG:AMT<.=/76"K)!8;8C9PB
MUEL3PL5JQ1Q3RR-CC>JM_P!5K)6;H[3:RZ2>VF$8,S$KM6>I?Q%L%A)[4<]=
MT$C^#2RE>"9^;9998(F.ED8B._TG21OH*0^)5I.Z]JZ#VATLZ?6@7J&BH/U\
MA]DS %=6T\0@]> 50<97<N EV!H\H9:<N'9;9=*/HLMRCI;?AAJT\FTTR(]%
MEKV;=BICN-5&7<0L8E/5@DH^CK8LR))*B))1?(C%R:S+A%=JHGUM;-QBRZ5)
M8K4Z]S <$N/HX=7PR"U/'?\ 2$KU8UCB55COQQ*],W/S2)&Z[E^KJY(4O$?$
MINJ&]A.JO8\9$*R6F'4CKY%>ML#"O!LKVB\E@T4@LTKYL0FS9"7-RKR0D DY
M+*D7 ,N!&;OD&*K84V136;N+LVBU&?#<7PM\UI(,9Q*;%+$C70I+%8FL065;
M JPJQ(VR5V(U)&2.U5<BO5514M0:5WX,3P?%&05%GP7#(<*KQN;-P,M>"O/6
M:ZPB3(]TCF6'JY8WQLUD:J,1$5%DN"^+/9%?12B!X?K9U4*V5UFKSS;T?>LM
MAMAR:RX"*3?G2C N,:OK/XKUS(PY*1$R0@@3@SYNS([(N^6*NR.NN8MC0ZK9
MFQ!S\5Q=E7%;/I5_#X9ZT56P]6QL<QZMJ>DI$]D3&/:VPU7-S363,RZ^F=JM
M#AS685@[[6$U?1</Q":"U+:K,1TCVR,:ZWZ,Z6-TCGQN?7<C7Y.U5RR,6A<L
M3/E29TT_=%#)H@]+%B;Y;=P](DR+E5X_?O'"G/*B[IVZ65<.%M^>=U55-]]N
M>=MN><VYC&1L9'&UK&1M:QC&HB-:QJ(UK6HFQ&M1$1$38B)D:>][Y7ODD<Y\
MDCG/>]RYN>]ZJYSG*NU7.<JJJKO53K\J*1@# & , ]1_PGOJV>E7[OT#_EO&
M<F:8^M..^\9_F.N]#O5; ?=E7Y$)%O'J%K=)2Q-T;^NZM8C<T%0KFXJYARM8
M&XA-XVD-, G"S!*SJTL K #Q:-G'L;-EZ_*1SXS&)L'BC722C!T@:ZT;,BY<
MB<_+XD3S?PT:>E\I>2/2PK+ MGDY)3<;$_B^F9A%(Z1.5!7%,G4XR-LZHYPX
M:$W<3J>+.Q<N>O"<YB9+>3:Q&2 P<I/AGP9KEEX\^:<O)F=:0\+NF2<8BL;>
M6':!'B#P7KK#XL\/C*4E3=B5ZR YW$(!.7T=DU/EHL<D)6"V1+(/,!A@*\AA
M,(0X(B8N!ES9I)VXG67O5>7ERZ\^3G.PD'AG5') -714C8=DJ1FM'#(C\3;
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M_A-,V70[UIP+WC!\QK.F?JKCWNVQ\IY<N=9G(HP!@# & , 8 P!@# & , 8
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M)R(B9'VY25# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P"/K:_P *K,^[Z9_Z<)9*;T]J
M?$A=R^Q?@?NJ?\+JV_\ T&'?Z='87>OM7XA-R>Q/@5]D$C & , 8 P!@# &
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MX,\P\D@'D?'#%J]7)#_BXBY1;\_&C-C\+]_Y5C\)0UW5U9[TYMX*,P!@# &
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MVW^*Y \4;KM%TE4G&B6_&WN<<\<RF2\B;EY^1%ZQ]9/^K/:G(G*N1=SE)4,
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M:KU]1M)<<^[QQS_]?U_KXYXY_P#[QS[G/'_ASQ[O'_QP4C & , 8 P!@# &
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M*OWKWAJYI[,D[MI<'E)4, 8 P!@# & , 8 P!@# & , 8 P!@# & 68=NK8
MPL()BTR14C0@O-J(/@9P3<-DHL2>QR_($5ED;<O-M]?B@T#C0_B5))D/)HF
M*1QX.44^31C5"IJ9Y^Q=G+N4I<N62+U;?8J9ES->3%2?Q5C+OD\8C3 RJ\<
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M# & , 8 P!@# & , 8 P!@# & >H_P"$]]6STJ_=^@?\MXSDS3'UIQWWC/\
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M-1JN7?M=EFNU=JGDLSTEFEE1J,221[T8FYB/<KD:G4U%R3V'0Y<+8P!@# &
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MJ_\ T_8&>D_17ZT.]V6_S*QYG]*_JLSWI4_*LGGVYT><UC & , 8 P!@# &
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M5?\ Z?L#/2?HK]:'>[+?YE8\S^E?U69[TJ?E63S[<Z/.:Q@# & , 8 P!@#
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M[LM_F5CS/Z5_59GO2I^59//MSH\YK& , 8 P!@# & , 8 P!@# & , Y4/\
5?H_\5/\ Y^,A=R^Q?@2F]/:GQ/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g63338g25v11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g25v11.jpg
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M(\]L:JSG%G0U(H;3&<.F8P.D^Y:D$U>1$TGB6B::TF*T_:/X)D,>$W5QL39
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MR, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MPYRX>NIE)([.HU;0B> EY0J0=\'60F3,Q9)!35JZ8J-44$4PS?.B6JT40O\
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M%?=-YW5<ZM^RZ_NR,1F<WW( DJMZ0LZ.&+NIO((V'_0 A,BB^GCIDU6'A_\
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M)(FP:EY?,#NZ#1!V34&" @)@T&#Q00''002/@A(P.*9,D0;GZHK+4G#!!@#
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M,Q:$N).9=RV9G['GTUG,@<RF=6'84HX9IG)E,#SG1#1X5=,A@D0T:CV0P($
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$/9__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g63338g27k60.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g27k60.jpg
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M 0$! 0$! 0$! 0'_P  1" #> ET# 1$  A$! Q$!_\0 '@ !  $% 0$! 0
M          8%!P@)"@0# @'_Q !9$  " @(" 0 %!0@,"P<"! <$!0,& @<
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M #@ X . #@ X . &)MI_?(]_^K'_ /W,G-RU%U%\!@>L^L_B*#R1 < ' !P
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MAH'P\?0/HF=?6*O\I?V;C3+CX>H:!\/'T#Z)G7UBK_*7]FXTRX^'J&@?#Q]
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M+\G['RT4HE6MLN+I2:;WVV%P^5%@X . #@ X . #@ X . #@ X . #@ X .
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MTAIFHH<Y,"]D)A?L "!X"BAOD'C[B)ESZF[Z&5O?$R\@([WRMJ^%Q?/D"P<
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M]0FAG+#UMLTX$1,OG.)$4@9P!V=CK-;MB.ISLLSXZ["1A5VH0G;6=["ODL1
MZN/O(8B)EDT=ERO_ !M\;]A"-/ALWE[MQ\![I_**VD/V"9-J0B;M,)+ YC/M
M22 D"P+KO?J:T!CDBFE%.7Y=TN%FM/ASPDF%9XX%C!E0RC1Q;>9%W[B/81[Q
M-SOD5^VVTR\AF9R!8. #@ X . #@ X . #@ X . #@ X . '@8JE;B* =LM
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M +0 C'IT3-V4((.,2X8P+5Z:%@TGACPE/-A3J5:J(HO*6>-:M !PSZ&#'BC
M+=B:-TJO%<@KM1ZS7"6'H/I\.OHU9!C<_#VD;M?VSZ%60^^Y .HHG .1'M,@
MVL4;$;N(S#&;J;GO/O$6+58LQ]*[I^AU.U"6NN(UZ2955FM/KR5.J1ID%:46
M.R1VZV])0E"H&>.:VV$14T>^^&&CYEJ!"%XZ^<AK(R7"Q>0F1-7K1LY91E>1
MEE,"T!YY)*H"><TZJ'Q-:L87-+!E(056VD$#)"1-EG*G/AB,7YCD1XR=0)$0
M+TMI\Z=L4;JW7Q9+UI@[=$$4]!-,U;X2L9^F3"60#+,LS*9PYEEGFRSDFD<M
M\YLL\FA_9$W/>?>(L6XLQZE^I-5J<9,%>MJ&NPF51HIL0JB@&ZE21!5U=$GD
MZB P]=7@OJ-4!Q R^47H2LU\;J+V*9=@-%SWA8MQ;A^RM4:O.9CNC-<T8IN)
MVWR&9$51',;#E8#W+5YG@3F#E+UFW9V.Q,6.?K>L8>_>%S]YD-V$A$W/>86+
M<7<*N-1Z6$U%>!U&LB.@O;>YMQ42P=F+[RH4H"/=SHA<"H?;HD*---U'+CU(
MJ3*5^?RBK@XH8$C]%TNGGU\VJ&U6NE5=B268?79TRZ1(88>VE?G&$*\A^PI3
M"WTTSL@K.'N>5Q+FSSD[-R[G[7"PIH^LM<"!P+QJ!2X !1A@QPHJNDP%A$"
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M ' !P < ' !P [%O04?@2LOY;KY_05*YDO7V>9C5&KM\B&YKE!<. #@ X .
M#@ X . #@ X . #@ X . #@ X . #@ X . #@ X <V/W0[^XO$C^-;T_FM0\
MT;V]GF,W-G;Y#F=YH,PX . #@ X . #@ X . #@!T6>@'_RL?]A/_.3F;FSM
M\AHWM[/,=0G,QH' !P < ' !P < ' !P < ' !P < ' #3QZ6+]K0W^G9O\
M[:_YZ"?=R:N3'KQE\,+#W(^Y*_W^_P"E_P#R$:=N>@0]R X . #@ X . #@
MX . #@!N,]$[_BM]?^9K#_AV#SZ ?<.?ZKE-_P")@[_MQ0/37[K7Z> ?S<4?
M'#PW"<]^!Z<AP < ' #CT]/!^&I7OY!J-_6O87-4:NWR(9+U]GF8TM<N*!P
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M ' #HL] /_E8_P"PG_G)S-S9V^0T;V]GF.H3F8T#@ X . #@ X . #@ X .
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MAW]Q>)'\:WI_-:AYHWM[/,9N;.WR',[S09AP < ' !P < ' !P < ' #HL]
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M2-1D1$:CTE&1$1J5HDFZC+6>BE*;GGHI(M1$-Q7HG?\ %;Z_\S6'_#L'GO\
M?<.?ZKE-_P")@[_MQ0/3;[K7Z> ?S<4?'#PW"<]^!Z<C%J;\-A?_ .EIS_\
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MPMW7/(01ZBWW([<;]]BS&N_S$O=?O._K?%2I8)==Z\'0Z>UMF+A%@*11=3)
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M#C X . #@!S8_=#O[B\2/XUO3^:U#S1O;V>8S<V=OD.9WF@S#@ X . #@ X
M. #@ X . '19Z ?_ "L?]A/_ #DYFYL[?(:-[>SS&X.E^E&\'K_N,?0U=V^X
MZV*?M*X:151V#3N\*?27FW:&:X76C72#:MMUNDU8]M@)J!P,*H4W(PEQ*%G@
MEP8920=2Y^]0UL?@1[-1VL=M>TN\9;[/W#K'3%&?[*VA=$E-HM5,3+[%96<^
M>8"<ZPO%5:2B&]!Q%$1$,'KQ2M@B]CWE[<^#N3K"+O*3$!$9G8M8]%4VC3KD
MPV"M3DN()]8W'JB6R:P5:SU-?C8>T:&PXXH&MG4*%MP3R+K(JQCLM2*=5V1E
MD8FP:9-EC((0($\D('ARCQFGABREDPABQDEPPRDFDZR[CBCZRRZ[SDSZPS[P
MPQ^7++K#+O'KOK'OY "WE)W#K'8TNQ8:3=$M@SU)L!GJO9/NL\D6-/V$F4('
MS.JMY"XAXXV(:BTUXZ3V.<PW<34;K"?.3VF& -0N/WECU\G?>6/767?76/??
M?77R]Y?M==?+^WWW_P!W77[/?_=P @FS-E574="M&R;E([^:]/5S.'7S7JMH
MO=@["'DCBE^$U"D*+!;+ 7CG+A__ $]"E8GY8^MEB-WCAGWB 6@<^9/C2A?B
M59CM15\X#/(5!XI_# 5-E:SA;_M%%(V6CUTWR6)3(4AQE'&DL&3=O(%6Q!LH
M(#'(YI(XTH38]VR_9JOWC)B*6*>*.>"2.:&;#&6*:+/&2*6//'K+"2.3#OO#
M/#/'OK+'/'OO'+'OKOKOOKO@0/IP < ' #%GPI_!@U5_$;'_ %SL?++^D?9\
M"%4?1+M^)C*;E18:>/2Q?M:&_P!.S?\ VU_ST$^[DU<F/7C+X86'N1]R5_O]
M_P!+_P#D(T[<] A[D!P < ' !P < ' !P < ' #<9Z)W_%;Z_P#,UA_P[!Y]
M /N'/]5RF_\ $P=_VXH'IK]UK]/ /YN*/CAX;A.>_ ].1BU-^&PO_P#2TY_^
M647)V'UE\#%?[?\ R^8REY L' #CT]/!^&I7OY!J-_6O87-4:NWR(9+U]GF8
MTM<N*#)7P^TM7O(CR2U9IFUL7:FOWILU 9,*Y*O@=CQ+ZTZ=Q_#YFP9ZZ.:4
MA9##EF6)-%U%))W\F.7JYXP>1&? "&3.R/!D(VX)Z9JE5:M:F!:ZV5M2Z-?(
M7;>F['7XJ9K_  03',5;720SS!1FL'/8DLX+%'AD;#B+DL[Z['*QFB]M? BR
M,COVB;>NN^KJ$.!]'KLR&PM<+/L33"#7R@73[0;:)MX/!I=["W>',VUZOU\>
M75OB9KNPJ 6A44=A1(%ZC "4NPFK%^4!,\Z77MRW6UW]]06\CZ[ZK"=W'T:5
MWEV9<ZOKC8.M84GTT[CTWJ-)LFYR)MB;(L&I2 LB4:X("K?!)WK4%F%V$3*4
MH1YG9=!FF*23E([""5\",[%JOZ>]MIT<^^U]MLO=^\6+-\(MMK]:S;!)=ZZ^
M,AZM7[P9:@PLY?TO+-.-#!!1-B&U[-+BCC39P'@M90([-+914Y@[$I%#!GWW
MU-ROX7V7W"+>O'N\>K,7^=>C:V5+L^Y5[7-XU_4%X.Z;3H2BK-C;&*BNMLOB
M.D5FX3U=<=7:("L9$.DMKA@"9R@U]+E/&0O;RJ^YU^;.-(LM>HCU;-X6/Q,L
MS+66SWD+([(\1!*92M#69=N'7$[/;FC[=N!TFL[SNHXUZ:HM7X9-66GN@ P7
M;EA\&D0)U@Y63-O=0'*=>-,NC4MFLWUY:C]/?LPMJSUE?X^GH,*^2(#@!V+>
M@H_ E9?RW7S^@J5S)>OL\S&J-7;Y$,MC?$^A7$V13'N&SM.T*IF <F$:5P\M
M898J=L2@/&Q T8LN"DYD_M5JN>$V  I.-^$.DG*- !&3*JW/7;J[+>A>S#1+
M?LS+CGGG?CVB<X^)=,Q,LQ^-EM$9=B1[%3Q2Q?!X?@4^Q#;TPG;I<<%G70I]
M>)V?L3YO]9>T''@M1HQ$1$44'6*^KA;PL7D0G1XGM\?YGWCRZ1T[9*M?+'9V
MKNLYUE%+M9!KVN5IM#8?@/>T-G];!O.;<_YGU6<(O$]-6%X5>GF?? @P<E7;
M.?(3-BVDSRXY7OP++WM BSX9VMQ//WL%%9>.FIM?(LHG^R<:^*TI)&JP3[U/
M1Y5Q@+*E:FIY:\@*T+?A3N5JGU!E*P6R1=Y%X7>_]P^[_$AI5RYF>J^W*^\]
MW7\ T2+;;*W@1>7NPD^OM1:IJ[\U=-L7.]OE$='2$I;!; F#=!8$%FVIL*MX
M91P&]/!LLL=AV 5!7'$YL(U4KJH,; L=3(1R+GU:[9;\CX""26HSOV[<]W68
MRHY N.12Y_OPMG^LKW^E"N?"#$?^T-=_3-4_?GQ]?:+^)J3^C('[JT(USAAR
M8< ' !P < ' !P < ' !P ZZJ5^\VI?ZLH?Z*%Y]X,/?B"A_H>F?N3 ^05:_
M'-6_2<_]Z=$FYS XP. #@ X <V/W0[^XO$C^-;T_FM0\T;V]GF,W-G;Y#F=Y
MH,QDYXXZEI>T,+Y+8HVUGL%;!K\E3U76ME4+4]HO6;9B2,X.3VK82*TK#/FJ
M*,-*15D]:;V5WFX%F C'!6-28X/=XZ_?>'O7;WW"?S^%EVLMTM"FC0MJJI'N
MJ[7U-1;G46"MWY[L%C645E(UO*$BK#5:&[1=6-0L(M]F[I5#:]-$#B%LM&L
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M(SM?.Q7/ROQR&X[KY?DZ^7OY>_D_9[ZZ^3Y>_P#O[^3Y>_D_T?+W_IX%1_>
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M=W/_ $KX_J^\)_X?CW]M4?\ ]4']-VK_ .)X,_956^WA],_H,?X;<GYW<_\
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MB]GJ<F)V'I+N]46]C<Y&W>:DUY2ZD2+838"HXB4OQ1$,;C#7E577A+Z]N?\
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MVIPT&U+HM=K]'K,R\B-;12ZNLKNY=C5ZJ4O%R(FJ[1'1EE*05I99+:#,T()
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MR F]OT)MFAL!DMGJSA=;#FE7! J&"]L79&!%NK0]KK\X H8$XQF92XR(?L2
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M3]U7]SHIIR@P'<:06:S4:IA"G56GN0(MH:,7(84U(HZD5U4RMG252HR*DT_
MHQ6=YZ,\\RDW!*.6Y+K=8F-85F.4N%3\33J?-1+D7E*PTIXELU,E4A,6DE4D
M1WU07&9U5.[?-/MM.J) I%/\34-ZPLF5;VJ49&M9OT5?8SZ[-5(GSBK5""RO
M(Y6CJR+<X1>CO>TP$2 .U/LH((7CE"C +AP[_#0>0NEXE15U4C&[\A,.94Z9
M2Y;F$Y$*FU.?1:$W5ZDE<RHU>&I#)2>D4^*FE,5NI&VRW49]-IT9]M(_76>5
MN?054U-3PHRPJ3%I\^H1D8C8ESX$.JUA=,@J1%@TR42W>8YF9(74'J3 );BX
M,*?.D,K,4KOQBKG5>B.[VQWU8Q]24;=[ROY44O$-50;3*@C<2PON[%[-B\KF
M#Z,F-7B +"Y'BCZC8 DS3#!_A/D8I!4I$D\=6J[6!<-\H]2I9X:?*/!PO6UT
MQ$]Q%3^5M"74:2522\F$49EN>RA.A*C.N.-,?K+E1J1U%;'WI?\ \:YB^NX&
M@5$J\R;TO$%*34%0TKI_R;I1H-2. IM4HY#JX3BEZ<=]IM#C]9ZT+4]+7!3+
MN"QUH](9?K?6AUCI99(!'E&J<]<[FO*\ZLG&E!EV -P3$@6E"$A]]BG91-<F
M48'>'(IY,*%R=5^"YCZKT>73I&)Z]2&850AU9IBI8;HCM)YS$L6329,AUA^I
MQZ@ZFF0WV'HYFQ)-N<J8B*I/XCQ]5\;4:8C!U-J<><QA^CU)R5"E4Q;T&NU=
MNI$W0I#%389:>:I[T-I=0E-/-O$3K!+B%&5((\,">H>B2.AL_:#]3R]#Y]X9
M1]YP]29=19]X9Y9YX>MAZO?J99YY8_+\F667?7???KN^31/O$PK29)UPF5&E
M2-)HEGS:M%2E*3=%CT5*4HM1J,RN.ZFC6;39NEHNFV@W$D9*T5Z):9:1$1*L
MJY7(B(]9$19#K8K  +2A5I>R"$8@%59#$2$</"6(1'\,$R]G.,1A)#-A\O77
M?J2898_+UUW\GR]=<^[>'OQ!0_T/3/W)@?(:M_CFK?I.?^].CX?1CK;\7M'_
M -TT/V#G,#B[%N+N(/HQUM^+VC_[IH?L' 6+<7<0?1CK;\7M'_W30_8. L6X
MNXA:O67C11=?7^T[:-B#M&SK'*P7@665 G2"4BD2&S3*Z'1$2F' &O*!A<H.
MGS./(BPW)I'(SL30J+!:N5S<[6V>^\"219^^P:/?NAW]Q>)'\:WI_-:AY=O;
MV>8HYL[?(<SO-!F/[UWWCWUECWWCECWUWCEUWWUWUWUW\O7?7?7[/7?7?[/7
M?7[/7? #ZSDD$RRSDSS$33Y^TGFGESEEFD__ -Y9),LLY,_V>_\ "S[[[_9_
M;X 5U,MMMK9PKJ\!8[*YDS$S'!3"LW+/.2&2  #*$8&,DK+.*4@8(3+##OO"
M2> >'OK*6/#( G-<TKN>XNJ(M5:_NTQFT+2#5Z.S8I&RU19K(>;D-&.!868X
MRF;. C(B=@7V=[);!"::=,...3-A%RSSU:PL9]HH9='V@*!97QU5O Z=.^SK
M-PL!:=Y"F5V. V.&1)97<X^"X%M"P]ECF"U*B)C)]GWE'C)ZO?)RU>]P"H[9
MU9>].64:H[ P7P.SJ^BM>,"RR*++!B!:0(&HWO):4\\: _KUO9FC328R92P8
MECY%K2%[ MK 6TE)((RZSG(FFRQBC@QREEDDRZ@AQQPBAZ[SR[[ZBBPQQQCC
MZ[]3#'''''KKKKKK@!\N^^^_V>^^^^_DZZ^7OOY?V,>NL<>OV?\ NZZZZZZZ
M_P"[KKKKK]CK@!_. '19Z ?_ "L?]A/_ #DYFYL[?(:-[>SS'4)S,:#EPH%E
M\F _-';^B],[<NN@*]Y,>E\\ND.R+[6-=Z_N+O"G4GT>FK=AUXM#GM*E7*OJ
M)<[7580E[F-?F-V=+E$3 TPAR72AJ>CHD>1F2$VSVZ9D>HRV##R;<OFW=F.L
M?/#%[;MC>4NJ?0^;HV!3%A.H=>FUM/L*'RBPT!<;HIIXVM26BVQ3:WF8;>>
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MRW7S^@J5S)>OL\S&J-7;Y$-S7*"X< ' !P < ' !P < ' !P < ' !P < '
M!P < ' !P < ' !P YL?NAW]Q>)'\:WI_-:AYHWM[/,9N;.WR',[S09AP <
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M8),UJ-@Z6XV!18KV8;$N&966E@58[&SHJ-VE3O-G R^/'JU?RZ\R+9UP(#@
MX . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X .
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MG/G#C2L7,=OPSP^9>5A(APCO>004(,NOP]?B,<$BCTC(=T(KW<SA51VFPKK
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M !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P < ' !P
M< ' !P < ' !P < ' "/VP0]A5;, J&P,:&U]R(M$E?-*K&4>2N)A#&DM".
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.. #@ X . #@ X . '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g63338g28q09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g28q09.jpg
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MR7JBU2L5TKK(>#Z'U&I=<YP"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M/-3P".XK-G+[+%[9FY061QLIDTY0O&4IZ7H.&C:]W"Y+/A:3>">*UW/ U/Y
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M4FV+Y[FE)@Y5LT3-135SP74OI"B@S7-PR;I,&IWSE.%KW6"EFX=)4)9Q?V-
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M"</][\:]2[#^V"V!*!$Y*[60R9L%V6M\]:1P7J6"NDL$CTI&E2FPR:,N32>
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MCI+(TWTJ?%&;:3T%MC<&T-8<>3O(<,0D4-US,=H1PR6:A$)B6B ]^7+CTF;
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M4;69KTRN32VS0]D@3FL[W4<$;GA#FN;2UO;=QD&X_P##78&H^4^N]TD'VO\
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M]+ZR%@NA=17:@D4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H"@.O*<+Z$D?KL9J=#Z5U,C2NA]:*_4$B@% * 4 H!0"@% *
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M-19HJJBFX23<IX97S045;JI+IX*XX99HJ)JXVOAGCE<#V* 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0$/;H2%G_2/)3(.V?0-&"3%6,&G\K1F$+);.
ME+;7\3;O'^NR4HXS7%GFJ#&,BXB_C<<Y$8-"T.9GY$'CHX;LHD2FXG1O6GUW
MW>HF$H0* _.?WF7]G+]UZ HD7\F8[Z"$?-[>I>+Z7UD+!="ZBNU!(H!0"@%
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MI=)%/'^EGGC;[M""R\]S:?3^_P!K:UP_]EH;'_ISJ+X__KQTHFBVGOW2EO\
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MJ5FA5YA=LHCEGG@KEFDGYU;%ET]BVG6[+K-)14M/4XX8*2DH'&Z*)Q4<%*G
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M0C?!8</_ )$RSZ4)U53\OO"^V_**'LE7+;\G_@=87DU+VJL$JE=/.XB@% *
M4 H!0%ONO*@)Z%D?KD:H1I70^M%P4)% * 4 H!0"@*))?)R0>A"OJ"]?G6Q[
MTVIYNKO9J4^ZS/?*S_+JIVBC.0JM#!N"% * 4 H!0&Y' 'WV6K?S<X^CR5U8
M/FM>/+(W]%E+\U;:/&.<'XI,J?S["^<5DG216W4UK"@% * 4 H!0"@% * 4
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M+/I0G55/R^\+[;\HH>R5<MOR?^!UA>34O:JP2J5T\[B* 4 H!0"@% 6^Z\J
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M,1,M*R)F[>QA# +'[#'5W[]]ILI%_)F.^@A'S>WJ7B^E]9"P70NHKM02* 4
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MX074_P"J!KWZ8]^58WDB\&JYY[K/8;.*V\L'A-4O,=5[=:1S;5ZF>4B@% *
M4 H#Z:G0C?!8</\ Y$RSZ4)U53\OO"^V_**'LE7+;\G_ ('6%Y-2]JK!*I73
MSN(H!0"@% * 4!;[KRH">A9'ZY&J$:5T/K1<%"10"@% * 4 H"B27R<D'H0K
MZ@O7YUL>]-J>;J[V:E/NLSWRL_RZJ=HHSD*K0P;@A0"@% * 4!N1P!]]EJW\
MW./H\E=6#YK7CRR-_192_-6VCQCG!^*3*G\^POG%9)TD5MU-:PH!0"@(I.G"
M^"LY??)"%?2SK^NX\G_AA8GZ>G['63IO*#X'6YY/0]LJY\S*K7E210"@% *
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M%'TJ_D-J7Y62#YG:U2#GN>#.0WGVT_Y?1%L>:A[_ &5WFBH=LI"$NM<Q=\4
MH!0"@% =!'1G>]O6_2)*/40-;4>9[XH?VIMOY*SS7KSF_&5#^KME?+5XD(JT
MY7D4 H!0'!!]E'_""ZG_ %0->_3'ORK&\D7@U7//=9[#9Q6WE@\)JEYCJO;K
M2.;:O4SRD4 H!0"@% ?34Z$;X+#A_P#(F6?2A.JJ?E]X7VWY10]DJY;?D_\
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M?!6<OODA"OI9U_7<>3_PPL3]/3]CK)TWE!\#K<\GH>V5<^9E5KRI(H!0"@%
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M!<!69^#WDP0U+XLD7&X+,U)6,#KKV#)DB+4ZE''-EG8^3 AK62BGRC0G9LS
MRI%_)F.^@A'S>WJ7B^E]9"P70NHKM02* 4 H!0"@(H^E7\AM2_*R0?,[6J0<
M]SP9R&\^VG_+Z(MCS4/?[*[S14.V4A"76N8N^* 4 H!0"@.@CHSO>WK?I$E'
MJ(&MJ/,]\4/[4VW\E9YKUYS?C*A_5VROEJ\2$5:<KR* 4 H#@@^RC_A!=3_J
M@:]^F/?E6-Y(O!JN>>ZSV&SBMO+!X35+S'5>W6D<VU>IGE(H!0"@% * ^FIT
M(WP6'#_Y$RSZ4)U53\OO"^V_**'LE7+;\G_@=87DU+VJL$JE=/.XB@% * 4
MH!0%ONO*@)Z%D?KD:H1I70^M%P4)% * 4 H!0"@*))?)R0>A"OJ"]?G6Q[TV
MIYNKO9J4^ZS/?*S_ "ZJ=HHSD*K0P;@A0"@% * 4!N1P!]]EJW\W./H\E=6#
MYK7CRR-_192_-6VCQCG!^*3*G\^POG%9)TD5MU-:PH!0"@(I.G"^"LY??)"%
M?2SK^NX\G_AA8GZ>G['63IO*#X'6YY/0]LJY\S*K7E210"@% * 4!TH?8MOO
M_MO_ *H,\^F70M>5<KW@Y4?/=7[!:)ZOR/>$M>\R5GMUG'>Q5="R(H!0"@%
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M7K,M"IT45CT]'#2UJIUFKT<5(ZY4(E1J.FHX(7&X8(XE"GG.&&)I2A<NVZO
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M_1(@\-SL")N]&OT>GUWWWX21)CK%.9(ZVUZCL5TJ]V"E!XFG.GBZ 9JL[F6
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MWNL&,53A\_*;!'81C2LP6;LV0>4MW0\\TC&[P4F*MG3:T<# X_+;/97X:!N
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'"@% * __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g63338g29j70.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g29j70.jpg
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M #\ W^      !3BGNN9?)R3^DXB)Q+G3D4C&F9>5"HQ!(
M
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M2B/6Q[Q"63XPXN]RWI24D#4]US+Y.2?TG$1.)<Z<BG#&F9>5"HQ!(
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M2:!R)(V:,,LK_>"SUO<3D4^;$J8<526^F7%\2TS,R (
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M$I8'MSQ.HCAY!45,/Q\24R4 @
M                     "G%/=<R^3DG])Q$3B7.G(I&-,R\J%1B"0
M   "$CI5N[VI_)!\],E#7+;N;9ZC<0TET@[+P6J&P%;>.('T)LBF%(2V
M3/\ 11?[!NOZW@_X.3C8=:0;#V0N,JO^BTH4KMLMD*D]QTYSU&$N(O45#
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M51A[;9E4B%?7#7*Z]8>/D(265$45(->%S-\?&0B:8TG\+DE\3O7R:L#B
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MW?-ZR.K#T]I=(V]T9R(7-W%&@'R/4I3EY0J?0"_BW(ZRUMC-R./6+9RMG67
M[2PNOHQ-4T6=HHD'9*2I>3 F&YFE];ZHJ*DI7YI@1$G*<R3>Q6Z_N.DA>N0[
MK.[>EL/LZO*EL:T.-B^66HD7TC )//*7966&VA8\BGEA1F,M<(EZ=UACK-X3
M3D->3.-:/E?,I]O.K C3"ZFCC>7Z*)EOK)56\N"2)X%5;\I8YSJ<?K9S>U)U
MA<>T0?X#M9$-9I9F'R;3.KPQ9=4VIV4AQF2$FRQ+MU??#4Y;(T.SJU'(G+*%
M#E5E(2."WEREX
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MYJ/?4;3^ 3BD;[MKWA&_.4O(Y[4ZX-CS4/<'6=@
M                  !$E9L9MCD=:LYA1<?L%A@54SUPE<=D3*YK)"H^%"BW
MR!.#[64PG4,9J\06$VZNCC*(G&8I8$U6UA)FC3+B]U0]QASJZV!R22=^]R=_
M/WT3*DGLXK^%65%7*$3R,-$IBCN<B5+F1V2:'HS%S6[)']I<R>IUAJ-W9W]
M@?V9X1F)W-H?4"%Y;5:5R2)U18XELF_BSQU:7*"O#=3D$2.E;9VWAJXIE)PH
M:U&9 Z2_1>H,SG.7IT3S)]?9JC=G[X3<D,T?7N7HU1$D>')S4B9KE4JYXI6I
MI"]1^1OU>11ZD$6DBV81]Z=&A*O<VN2N#@RNREW3K5.AJC*GX5C,5<T^#3#"
M43C$HBM1E)U,4CQK:(G\?&=2K%/=<R^3DG])Q$3B7.G(I&-,R\J%1B"0
M     "$CI5N[VI_)!\],E#7+;N;9ZC<0TET@[+P6J&P%;>.('T)LBF%(2V
M  67Y_=ZYN_[RG'/T-:HVK]C+V3L@9Z+]&CS6_V0K8.I7#4ASL$:IXW FJ<
M  )V_<XW?0*^^RZX/5(T8[LH[4HGNR!YXR-8KVWPW<<=S"G1-%8RT0
M&&_/[YIEI^,@OYC1(8 MHMPRNV>K?K901F:U]W6ZJ_EI[U;I<UMQJ&-E0
M9"<5OEXA'B9=ZCR49QM;-W&QWQO$]$TB8DL[[DE=^+''2,$:,8],YYX@
M#L&1CN:CWU&T_@$XI&^[:]X1OSE+R.>U.N#8\U#W!UG8
M                        1K<B9#Q9A]X&-,N67Y5DU=6%BE<_LBCY;:,
M@V43PV6$H8UULIJ^DK>S25TS$J7L-R4S5VA<C7P.$016J?9=$&/#7[\$WY2Q
M8M&#&2'1N/H8JQ-D=;%#VK0-"75(E4R22R*8/IQ6F=ML&.DGEKH]R1Z59SMG
MKUKPZKEF^.MUV/SKKIKJ(/;   4XI[KF7R<D_I.(B<2YTY%(QIF7E0J,02
M        0D=*MW>U/Y(/GIDH:Y;=S;/4;B&DND'9>"U0V K;QQ ^A-D4PI"6
MP   "R_/[O7-W_>4XY^AK5&U?L9>R=D#/1?HT>:W^R%;!U*X:D.=@C5/&X$U
M3@  !.W[G&[Z!7WV77!ZI&C'=E':E$]V0//&1K%>V^&[CCN84Z)HK&6B
M   PWY_?-,M/QD%_,:)# %M%N&5VSU;];*",S6ONZW57\M/>K=+FMN-0QLJ
M  #(3BM\O$(\3+O4>2C.-K9NXV.^-XGHFD3$EG?<DKOQ8XZ1@C1C'IG//$
M   =@R,=S4>^HVG\ G%(WW;7O"-^<I>1SVIUP;'FH>X.L[
M                          " 7I"FU/IR;<3I>Z2";M"2M8:Z-:9=Q[(E
MD?K9$[MG(@]SCB^7U1RNXR6+-8C*H;#;+=)'$[8A-MU"TQ9FEY<F="&F2RA&
MD'-,&=<LIX,J*G@DO@)^@.    4XI[KF7R<D_I.(B<2YTY%(QIF7E0J,02
M        0D=*MW>U/Y(/GIDH:Y;=S;/4;B&DND'9>"U0V K;QQ ^A-D4PI"6
MP   "R_/[O7-W_>4XY^AK5&U?L9>R=D#/1?HT>:W^R%;!U*X:D.=@C5/&X$U
M3@  !.W[G&[Z!7WV77!ZI&C'=E':E$]V0//&1K%>V^&[CCN84Z)HK&6B
M   PWY_?-,M/QD%_,:)# %M%N&5VSU;];*",S6ONZW57\M/>K=+FMN-0QLJ
M  #(3BM\O$(\3+O4>2C.-K9NXV.^-XGHFD3$EG?<DKOQ8XZ1@C1C'IG//$
M   =@R,=S4>^HVG\ G%(WW;7O"-^<I>1SVIUP;'FH>X.L[
M                          ".3D_3$0LZ\6I"]6SQH4N,H@<-;OT>+\BA
MTHD3T@BLFL')LLK-R8[EKZ6P[$L03=YA$QW3Q.;1N5-#9HPO;4N1G.:(T2F#
M!W^N\O>)&P(   "G%/=<R^3DG])Q$3B7.G(I&-,R\J%1B"0         "$CI
M5N[VI_)!\],E#7+;N;9ZC<0TET@[+P6J&P%;>.('T)LBF%(2V    67Y_=ZY
MN_[RG'/T-:HVK]C+V3L@9Z+]&CS6_P!D*V#J5PU(<[!&J>-P)JG   "=OW.-
MWT"OOLNN#U2-&.[*.U*)[L@>>,C6*]M\-W''<PIT316,M$      !AOS^^:9
M:?C(+^8T2& +:+<,KMGJWZV4$9FM?=UNJOY:>]6Z7-;<:AC94   &0G%;Y>(
M1XF7>H\E&<;6S=QL=\;Q/1-(F)+.^Y)7?BQQTC!&C&/3.>>(     [!D8[FH
M]]1M/X!.*1ONVO>$;\Y2\CGM3K@V/-0]P=9V
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M&C'=E':E$]V0//&1K%>V^&[CCN84Z)HK&6B       PWY_?-,M/QD%_,:)#
M%M%N&5VSU;];*",S6ONZW57\M/>K=+FMN-0QLJ   #(3BM\O$(\3+O4>2C.-
MK9NXV.^-XGHFD3$EG?<DKOQ8XZ1@C1C'IG//$     =@R,=S4>^HVG\ G%(W
MW;7O"-^<I>1SVIUP;'FH>X.L[
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M@35.   $[?N<;OH%??9=<'JD:,=V4=J43W9 \\9&L5[;X;N..YA3HFBL9:(
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MDX1_ Q\(WJ<3"1+MIT_</+EENX>NVD1IEJY:9:DJ8%1<9[(_0/X@
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M&"-&,>F<\\0    !V#(QW-1[ZC:?P"<4C?=M>\(WYREY'/:G7!L>:A[@ZSL
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M">*]A8IC5'+Q6&W:M,72LS5AXRRVS?95)-,HI=8?QG]@
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MIG//$     =@R,=S4>^HVG\ G%(WW;7O"-^<I>1SVIUP;'FH>X.L[
M-1SW5[\G_"ORQN[T)6HS38;_ .YI[@*/YR*,)V9_^UH#NB/YN%-+H9W,!@
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MB[$@UVT0LL=CK:F:&1I1Z;[;[ZI6YM1ID:?7???;4DG3&VVV<9SD05"
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MU'OJ-I_ )Q2-]VU[PC?G*7D<]J=<&QYJ'N#K.P
M                  P8O&IN(W(\RS7212B2R641R&K*JM%+QZN>V$TXQ%F)
MU?%*RO)O7%#R[WY-RVYUD,C*40.80R4]GW>'=J4L*HE<J1&B454]Z(O*F;E,
MQ8DPJ8O'&B/K)-(IBH:DN$N\FEIK2?(W;&IF^Q9[N>QM#"V'JM"]M$^3T[4D
MV.+)T-4]G5;'J3A!40  "G%/=<R^3DG])Q$3B7.G(I&-,R\J%1B"0
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M1CN:CWU&T_@$XI&^[:]X1OSE+R.>U.N#8\U#W!UG8
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M:CWU&T_@$XI&^[:]X1OSE+R.>U.N#8\U#W!UG8
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M&XAI+I!V7@M4-@*V\<0/H39%,*0EL    LOS^[US=_WE..?H:U1M7[&7LG9
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MSVIUP;'FH>X.L[
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M]X1OSE+R.>U.N#8\U#W!UG8
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M"<4C?=M>\(WYREY'/:G7!L>:A[@ZSL
M             #%VT^64 J2PRJ_?XS8#L6A(J<^<36,M#$XQ&L];WL!YJRG"
MY:6IDK?,'%1/9ZPN3 D30"(S<^.ZZ)GJ;:1>.N"!W4B9?&:^O@/]<?N6=;<D
MDR=17S;)]-MDR]:Y%.&T/<T["C(;XFZM*EU>X3,)?&=L2E#,$>6$AJ>W-7\(
MLDUCSRG9Y+!I:SLXA4D7]4]US+Y.2?TG$1.)<Z<BD8TS+RH5&()
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M.YJ/?4;3^ 3BD;[MKWA&_.4O(Y[4ZX-CS4/<'6=@
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M4;3^ 3BD;[MKWA&_.4O(Y[4ZX-CS4/<'6=@
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M.IU-NK_?U<#BTERLL)R96ZORD5:.)R
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M\ZFJHVYQ%)EY33= <2[FF&7Z8_A=Z1"ZG<M7F9W[R89R24L-Z>%,9/X.TZ0
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MK32).O:"Y7\2MS7T]^2*LO#CRIOK>":G)9W,U1%7#]F^B89+/DR*IL)#M.@
M          "^=2?_  7C_P"VF_\ QW'4WA[WZJ=K&#O_ *(7=' Y@
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M?VB%55PDHB)@/?$$@
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M+YFJ_P#;EGQA<<TX9L-BYCCJ27LRSOX[^]X/B;Z5_%?3$F"]D7P_IBSV'$Y
M
M
7                           !_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g63338g30a16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g30a16.jpg
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M 0$! 0$! 0$!_\  $0@ [@'* P$1  (1 0,1 ?_$ !\  0 " P # 0$!
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M     1Z/>]N_:%X^\@B/WS[92$$@
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M(<YIW2/(;\K5T?EDA;F&-&,JZ1OT=D$@8X'.G&.D:,^WJS^$[.1O^"
M  &F?(3G52O&JQ8U6U@(9^O<G:/,4TE;]$XL6\Q6IX#*+&9JFCL[LQT/=&Y0
MVQMWL![3L).8Z@D[NET2NCPY-*)A;%;H43$9QG^=F?[F);#Z53BY7,AY&QE?
MK83VNXQR"IXI-UK&P,14>D$CMH^TD2%JA$HDDJCL==-X:Z4O93!/5KRYQ]K9
MI9&%T+;ESS+]/$6"=&=7/GU1$\7CC+E;JU+;\.NR.*YA =W1=$RW3Q4V2!<V
MFMJ&0FDM34O<E#(6JVU7&$,3HXK(<^Z."-O6M<TC4H8%*34]G,,,/+*(
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M,RMU2*8JI5QEP,:6=P9S9S8QSLMDZ^6&.",B9S_//,_O;U @
M                               !'H[[V\=H7C[R"(V>F?;*0@D
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MS:*W$$5\W=8+)8IKXJJ%S=SBNFS555W2*ONE/0T]+0TZ>CEI3G;<+U*B@
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MB:,Q4TYB8F*C.)B=<3&N)?=>-%E!0
M           1Z.^]O':%X^\@B-GIGVRD()          !6'TIWQ.5]\YA/X6
MD8IIOU_J_P *^>-7[DO=:'>J_3/$/FQ3]ZW:HK&:2]X   "WSHG_ (0O/Y'7
M7VTV%]=X[WSNE^0PEVF)%/=]IWO@3RV(_N7&N4&@:F(   #GVV!Y^3;M=)/7
M*T9F7EPC;^FVKMZQHI=W!]AZ'9NQH(B.)V   EL!\^X5VMCGKA&.V[>$;!TV
MR]O5N.\>#[=T.T]C3=!,:9LZP
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M'3;+V]6X[QX/MW0[3V--T$QIFSK
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M(CB=@  ); ?/N%=K8YZX1CMNWA&P=-LO;U;CO'@^W=#M/8TW03&F;.L
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M1CMNWA&P=-LO;U;CO'@^W=#M/8TW03&F;.L
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M?_ _1OU<-RW_  R\_MFV_P 9^L9Y0_\ 4<9_D]F]D'ZVN[/_ (M<WV!=_P#
M?JX;EO\ AEY_;-M_C/UC/*'_ *CC/\GLWL@_6UW9_P#%KF^P+O\ X#]7#<M_
MPR\_MFV_QI3!ND$Y*/LVAS&XR&.&-[S*8\U+M"XDT%&;HW%V2)%.FANA6-B]
M]B#M\:F:_O:;9QMC]N,#^WAK?3[K]YXCN"[;7>ET4K+>%]W58;31H7%8:%*E
M9[7;JBHKJ-&G1H:5"E-764HBE&NC.4QKA_*OW>][F=@N.^;=9KNO*C:+%=5X
MVNHI4KWME.C1KK/9*ZNJII49IY4HBG0HS-&=4QJG5*_-:M2MR-6X+CRTR) E
M/6K%)N>X4G2I2MSU!YF<8SG!916FYF^>YGN:ZYSW!J,S[8YAEV5%8JR.-\#L
MB&S!;+JT8;EC":./[>[&OM42A3X'&[#;-49QOA41?E6-T[2]E]U$O.*.+3&F
M;$'8T#*       UW2<M^,"ZY57'=+?M3&7JC<E#*?4NTX82IYXZ2L1$H4LI,
M<.6EN*IX3QI05(#FI*2<O+9-MG39/A"68?H3E.6>4Y<N6KDV^/4V(!#!4RY/
M<>:\A4KL><W-7<5@4%F:^NIE+WN3-J%@C$Z:CL)G.)O;D:=A.W/J _."EC>I
MW+/3[Y[ANNH&4[,M?(_=.\F./O(3PWR'W%7UJ>+6-FDR_$(DK<_[)(](GB4Q
M]A>S]4)QFQ;8\/<(E[6W+-L=X5K8V\$$[[[H3\:$Y3&V)AG($    *(>1BO=
M!SMAS?/7F%J<-L\IK$&:%<[)-WD#&_W*D>TC=8J>0\9-O&SA#Y3,VY56]=H>
M2#CK$UJN$.L<KY(OD:1[4GKB]?5'%E/KU:]><ZLXN!MRG&6W4T0W5R*60J2U
M]*#YA!IQ!E3(EE$7>U\2E$"=S4.)*PRB/*T[Q#)I)V!:E>(^YDE%.FKHW:H)
M ULSNW'EBRI>&E/TC(61WKHR7-#%#X^YL5=U\I?$[G!ZY.?V*(1R32&*(E[8
M>][R"1MD'8]7!5(WZ0(DJDZ2+61O:54SF!KZ3GMY]LI+7/%RJZMLQWMB*)G@
MN5O<5+BJXQ<N3*R3R3&VOVIX>%2G* MZ<WN1):M@QKL>\N[DB+=&IS?&=O:7
MN8SAPDI&<LU1WWMX[0O'WD$1L],^V4A!(          *P^E.^)ROOG,)_"TC
M%--^O]7^%?/&K]R7NM#O5?IGB'S8I^];M45C-)>\   !;YT3_P (7G\CKK[:
M;"^N\=[YW2_(82[3$BGN^T[WP)Y;$?W+C7*#0-3$   !S[; \_)MVNDGKE:,
MS+RX1M_3;5V]8T4N[@^P]#LW8T$1'$[   2V ^?<*[6QSUPC';=O"-@Z;9>W
MJW'>/!]NZ':>QIN@F-,V=8          /FSY]?\ -G:W_P!'_P#',1&0V^B^
MO/&WBPW_ .)W$TLWO_U283_XY_Y)?#3L?@#]D  !.ZM^,VNNW<1_$#>/LV"O
MIEA+SFN'WK97\'%7T8Q'_N&^/=]H?6J-TF1JA5NZ).RXG!K)9&V:5C8A>W(F
M N%957.%<RC5923A!43_ &M+*MXEVN]L+&_NR1OC,KO*:/\ LK9XG*8XX*8C
M7R9UC[FGT<L$GK2CGV>/*EJ_K1XXB,^/;K1^.=$'?K8CC;NKY&M:6V(R31[1
M%;?:7FQ3Y76D7B=979"++CD%W=#C5)C<:;8\);HP6YNA1\KCU;,1TU5HG% W
M$IR=*-41&K7GJC7L^'HSU,#R?HK^5+,95,+2PVBI9&91(9 @D=5MMB727QSB
M2V/<1YE6FU[3F1*(V7,]+"MBS%S%/'-H;80\)BII%HEX5*G*2*%UD(B=*.?U
M1GMUT?%'/.ODXF59[T.-^/=%R.OTEQ06=6A-;70OTVM6P7Z7ZO<C@T:XKXIJ
M"JC/=#"+:CZ&11JWU\DN%7'TT,R<M5ORMQBEGU]8&J":MAYTHSB<MF<Y1LSF
M=G+EEJ> Y]$YRND3_;DBDBKC"M>K(\C4<4/K7/+"2;/E:UF]Q1\E#)+(C*Z#
MGD%D%AVO*&I=84^LZQF&W$[HO:8O!&V"L+(5M(VXG2V;>/BX^++7U1,,S\8N
MBQNVFIQQZL^=VS$I=8]/3:@,OLR2R*PUSP]5/6O!^3<;;$@J$]X;B,;IY]:2
MJ(V(I;5VA:!T01EN5OBO=\9&=/H1,Q.>7'GR?[6?LU>OBE+IYT=G(2QK3MMI
M<9O3D;H*Q.<37S>1RAJ.FSM>#=(8S0$!J6/0),PG,3)#V1 =(X&E>GZ4IIBZ
MKED67ND:3LY)KENO3")RCGRF.;7GKZ^3G:EV!T2?.BSJBW@,FMJ@TSB;!:<@
M&NC=,;$=$2!52W%^:4)&[/2NDRIN4)?=,HECXVV:K:$<*:9,WJ-S$L,N&&2F
M/H)R\DQ2HQ.>6>>>>?/,3EJF.*,O2L^JSAS9,.XG\N**DLRB[Q-^1KWR,>VN
M2D*7U6TMZFZX9K'VXV1*US60[*%*%SR:L>5"9$JW.)VR:G\(/VV+P><]<3R9
M=40UNG71<SZ6695]JML]AD?G%5U)T:U9Q.:-ZJ4II+%_T3+ML^:<A%+!LG;=
M$NZ2UZRL#$)CA"[K8<>L\M,G):&1>>:K)BE$1EM_O=<1$>J8B6"^-G0Z7?62
MFKC+4N&.39) )R7-'MI-FLO=H[-)G%:%FT!B-OK6*-5Y3INLTDEKOD0LF>,\
MG>IN_*]X0S+WNX; E:0IYV)FEMRB-?-LYHSSU<499>)K1^J.YE1+6"UJX)J>
MM9DGA]HKGY"XV!/&ZG*XE2WB_&*M+L!_60FHJ^7F2!PLAD*M"'][K]ZD;E*$
M2$F9SU?.4N]QJ"=*.>-<:^/CY=FW+;U:EF/";B1<-4<OKODU@R>=2JHJQB3
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M/!SUQ<^OQS&7/Q1EJF/$O0!Y  !'H[[V\=H7C[R"(V>F?;*0@D
M%8?2G?$Y7WSF$_A:1BFF_7^K_"OGC5^Y+W6AWJOTSQ#YL4_>MVJ*QFDO>
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MY,R25G;&,;9+*R:;DO3.>KIDPS.N,9WV[H>BCOO;QVA>/O((C9Z9]LI""0
M        5A]*=\3E??.83^%I&*:;]?ZO\*^>-7[DO=:'>J_3/$/FQ3]ZW:HK
M&:2]X   "WSHG_A"\_D==?;387UWCO?.Z7Y#"7:8D4]WVG>^!/+8C^Y<:Y0:
M!J8@   .?;8'GY-NUTD]<K1F9>7"-OZ;:NWK&BEW<'V'H=F[&@B(XG8  "6P
M'S[A7:V.>N$8[;MX1L'3;+V]6X[QX/MW0[3V--T$QIFSK
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M<H- U,0   '/ML#S\FW:Z2>N5HS,O+A&W]-M7;UC12[N#[#T.S=C01$<3L
M!+8#Y]PKM;'/7",=MV\(V#IME[>K<=X\'V[H=I[&FZ"8TS9U@
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MVR]O5N.\>#[=T.T]C3=!,:9LZP
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M  !+8#Y]PKM;'/7",=MV\(V#IME[>K<=X\'V[H=I[&FZ"8TS9U@
M                             TPYMU]+;)@<&8(C339<"@J?'*G3+FEK
M^0;5^RKH!.8RY31A@5JSF!5S.99LDD)L5CZ*:.3K'XR?)CITKC$K-BZ>,/!,
M3EQY--J^X%NY\L01:55P_P =B# 5-W9QN=SDU:2FRK'C+@GI)RI*JY+NJ5RP
MR6/=3N58L#=+R+$9'6K'3R51@EM,FT?F3RC:"<]7IV:\HR\?+^<MC;3BS7-Z
M5#)%U?2&-11!2R&$L!C \D*_&DK+>6F(5=&(I$5#Y[K51[YK"65GF$&=5JB
MQ5 M8H=64J;W>02:8V"F9"-6K;Z_8W#COO;QVA>/O(/,;/3/ME(02
M   "L/I3OB<K[YS"?PM(Q33?K_5_A7SQJ_<E[K0[U7Z9XA\V*?O6[5%8S27O
M    6^=$_P#"%Y_(ZZ^VFPOKO'>^=TOR&$NTQ(I[OM.]\">6Q']RXUR@T#4Q
M    <^VP//R;=KI)ZY6C,R\N$;?TVU=O6-%+NX/L/0[-V-!$1Q.P  $M@/GW
M"NUL<]<(QVW;PC8.FV7MZMQWCP?;NAVGL:;H)C3-G6
M                        "/1WWMX[0O'WD$1L],^V4A!(          *P
M^E.^)ROOG,)_"TC%--^O]7^%?/&K]R7NM#O5?IGB'S8I^];M45C-)>\   !;
MYT3_ ,(7G\CKK[:;"^N\=[YW2_(82[3$BGN^T[WP)Y;$?W+C7*#0-3$   !S
M[; \_)MVNDGKE:,S+RX1M_3;5V]8T4N[@^P]#LW8T$1'$[   2V ^?<*[6QS
MUPC';=O"-@Z;9>WJW'>/!]NZ':>QIN@F-,V=8
M                   (]'?>WCM"\?>01&STS[92$$@          K#Z4[XG
M*^^<PG\+2,4TWZ_U?X5\\:OW)>ZT.]5^F>(?-BG[UNU16,TE[P   %OG1/\
MPA>?R.NOMIL+Z[QWOG=+\AA+M,2*>[[3O? GEL1_<N-<H- U,0   '/ML#S\
MFW:Z2>N5HS,O+A&W]-M7;UC12[N#[#T.S=C01$<3L  !+8#Y]PKM;'/7",=M
MV\(V#IME[>K<=X\'V[H=I[&FZ"8TS9U@
M              CT=][>.T+Q]Y!$;/3/ME(02          "L/I3OB<K[YS"
M?PM(Q33?K_5_A7SQJ_<E[K0[U7Z9XA\V*?O6[5%8S27O    6^=$_P#"%Y_(
MZZ^VFPOKO'>^=TOR&$NTQ(I[OM.]\">6Q']RXUR@T#4Q    <^VP//R;=KI)
MZY6C,R\N$;?TVU=O6-%+NX/L/0[-V-!$1Q.P  $M@/GW"NUL<]<(QVW;PC8.
MFV7MZMQWCP?;NAVGL:;H)C3-G6
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M^?0V-0H2T.JK4O???PI:J7;]?J_NF*C.^;Z:]7&/W-<_LU[O=V[G]^<@C_\
M>O6\T           %8?2G?$Y7WSF$_A:1BFF_7^K_"OGC5^Y+W6AWJOTSQ#Y
ML4_>MVJ*QFDO>    M\Z)_X0O/Y'77VTV%]=X[WSNE^0PEVF)%/=]IWO@3RV
M(_N7&N4&@:F(   #GVV!Y^3;M=)/7*T9F7EPC;^FVKMZQHI=W!]AZ'9NQH(B
M.)V   EL!\^X5VMCGKA&.V[>$;!TVR]O5N.\>#[=T.T]C3=!,:9LZP
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MF9-W"TZ5,2:>=OG]FA>FVV?[A] _5PW$_ *[OVV^/YB^Y?/INK^&%L_8[J_
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M          &:ZB][?_\ O;/_ ,KQ\5/;Z/WR^2KX_1^]F4>'R
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M\\&(*(Z_4ZW5Z_>M->MU>MMU>MW>YUMNYW.[D$Y9;'D@
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M*IC<1(;V%K):"BB3W!'LUHV&)G/XSMV1Z_&1&7'Z.+;MYO%&IGX0]
:                                _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g63338g34u44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g34u44.jpg
M_]C_X  02D9)1@ ! 0(!>@%Z  #_X5_]:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/CQX.GAM<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z
M;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T
M-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @(" @(" @(CX*(" @/')D9CI2
M1$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D
M9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O
M=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D
M8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @/&1C.F9O<FUA=#YA<'!L:6-A
M=&EO;B]P;W-T<V-R:7!T/"]D8SIF;W)M870^"B @(" @(" @(#QD8SIT:71L
M93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@>&UL.FQA;F<](G@M9&5F875L="(^9S,T=30T/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @
M(" @/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @
M(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A:7(B/D9I;&4@
M3F%M93H@(" @(" @(" @(" @("!G,S1U-#0N86DF(WA!.U5S97)N86UE.B @
M(" @(" @(" @(" @<G(U,#4P-S$F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @
M(" @(#(S+4IU;"TR,#$Y(#$T.C,P.C,P)B-X03M%4U0@5&EM93H@(" @(" @
M(" @(" @(#(S+4IU;"TR,#$Y(# U.C P.C,P)B-X03M38W)I<'0@5F5R<VEO
M;CH@(" @(" @(" R+C4F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V
M+C N,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K)B-X03LF
M(WA!.^* HB Q,S$@0TU92R!B;&%C:R!C:&%R86-T97)S(&-H86YG960@=&\@
M9W)A>7-C86QE+B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P
M<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R8C>$$[2&5L=F5T:6-A)B-X
M03M(96QV971I8V$M0F]L9"8C>$$[2&5L=F5T:6-A+4)O;&1/8FQI<75E)B-X
M03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @(" @(" @(&<S-'4T
M-"YA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R<C(S,#<R."8C>$$[
M3&]C86P@5&EM93H@(" @(" @(" @(" @,C0M2G5L+3(P,3D@,3,Z,30Z-#DF
M(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,C0M2G5L+3(P,3D@,#,Z-#0Z
M-#DF(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-28C>$$[26QL=7-T
M<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @
M(" @(" @($%R='=O<FLF(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C
M:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R
M92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL
M;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[
M)B-X03M(96QV971I8V$F(WA!.TAE;'9E=&EC82U";VQD)B-X03M(96QV971I
M8V$M0F]L9$]B;&EQ=64F(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03M&:6QE($YA;64Z(" @
M(" @(" @(" @(" @9S,T=30T+F%I)B-X03M5<V5R;F%M93H@(" @(" @(" @
M(" @(')R,S(S.38P)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @(" R-2U*
M=6PM,C Q.2 P-#HS.#HR.28C>$$[15-4(%1I;64Z(" @(" @(" @(" @(" R
M-"U*=6PM,C Q.2 Q.3HP.#HR.28C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @
M(" @,BXU)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP+C F(WA!
M.T=R87!H:6,@='EP93H@(" @(" @(" @1FQO=R!#:&%R="8C>$$[)B-X03LJ
M*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS
M=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ
M*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I
M;B!T:&4@9&]C=6UE;G0Z)B-X03LF(WA!.TAE;'9E=&EC828C>$$[2&5L=F5T
M:6-A+4)O;&0F(WA!.TAE;'9E=&EC82U";VQD3V)L:7%U928C>$$[)B-X03LM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TF(WA!.T9I;&4@3F%M93H@(" @(" @(" @(" @("!G,S1U-#0N86DF(WA!
M.U5S97)N86UE.B @(" @(" @(" @(" @<G(R-C8Y,3@F(WA!.TQO8V%L(%1I
M;64Z(" @(" @(" @(" @(#(W+4%U9RTR,#$Y(#$R.C$P.C W)B-X03M%4U0@
M5&EM93H@(" @(" @(" @(" @(#(W+4%U9RTR,#$Y(# R.C0P.C W)B-X03M3
M8W)I<'0@5F5R<VEO;CH@(" @(" @(" R+C4F(WA!.TEL;'5S=')A=&]R(%9E
M<G-I;VXZ(" @(#$V+C N,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!&
M;&]W($-H87)T)B-X03LF(WA!.RHJ*E1H92!P<F5F;&EG:'0@8VAE8VL@:7,@
M8V]M<&QE=&4N(%!L96%S92!E;G-U<F4@;6%N=6%L(&-H96-K<R!A<F4@8V]M
M<&QE=&5D('!E<B!P<F]C97-S+BHJ*B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG
M(&9O;G1S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R8C>$$[
M2&5L=F5T:6-A)B-X03M(96QV971I8V$M0F]L9"8C>$$[2&5L=F5T:6-A+4)O
M;&1/8FQI<75E)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SID97-C<FEP=&EO;CX*(" @
M(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@
M<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM
M9STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @
M(" @(#QX;7 Z365T861A=&%$871E/C(P,3DM,#@M,C=4,3(Z,3 Z,3,K,#4Z
M,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(" @(#QX;7 Z36]D:69Y1&%T
M93XR,#$Y+3 X+3(W5#$R.C$P.C$S*S U.C,P/"]X;7 Z36]D:69Y1&%T93X*
M(" @(" @(" @/'AM<#I#<F5A=&5$871E/C(P,3DM,#@M,C=4,3(Z,3 Z,3(K
M,#4Z,S \+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.D-R96%T;W)4
M;V]L/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+WAM<#I#<F5A
M=&]R5&]O;#X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @
M(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I
M9'1H/C(U-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM
M<$=);6<Z:&5I9VAT/C$P,#PO>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @
M(" @(" @(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*
M(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*
M4F=!0D%G14%304))04%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!
M*S!!04%!04%"04%304%!04%%028C>$$[05%"24%!04%!44%"+RLT041K1FMB
M,DIL04=404%!04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G
M9TQ$06]+0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X
M=V)'>'-C2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X
M9B8C>$$[2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X
M9DAX.&9(>#AF2'@X9DAX.&9(>#AF+SA!04519T%:045!07=%4B8C>$$[04%)
M4D%135)!9B]%06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(
M0T%K2T-W14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-)
M0U%O3$5!04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=%
M,D5I8UE%54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K
M<4MY63-00TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T
M3E9+0G)Y-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V
M63-2,61N9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM
M6B8C>$$[<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%5
M14)1645#04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(
M=T9-2%(T4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15
M:W=G2D-H9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515
M-5!2;&195U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q
M*V8S3T5H66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/
M:W!A86YQ2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$Y531Q-T9867$W
M1EA9<3=&6%EQ-R8C>$$[1EA9<3=&6%EQ-T9867%H3E,Q5WDP,DM+5S=:,5-A
M5DE%6DEP2F9J:TY&1&5M<CA15'15-UEQ>$17+WI!.&HV:G!I96YR1'=I3S5I
M;28C>$$[.5-/1S0U1#9R4$4X:7-N1D-24F=$6'-A,$Y-2W-8=6PX;WDR3FQ"
M8F5:-5AN,#ER=3AI;6QS<'!,;%)C6%-4:'<S-VXP-4$X2$%U,R8C>$$[,G5:
M-F-L>%%M=FQF5V1-.',V<&4R=75E834Y56M6:F%W0UE88C!L:2M/-'%R3$EO
M241)<3!D=6A0-U)'2W,T,"]W03!A1'%.,G1N6B8C>$$[,U%L=5=2-4)%16-(
M9VA#;&IY555"-4%R6#=1,U=O=TI46$9867$W1EA9<3=&6%EQ-T9867$W1E5R
M,79Z4&]7:'1A<G%T,$Q9,VIM3R8C>$$[,G%R<T=957)5;W)"9G1$9'%9<3@U
M.'=X95-T8FTQ9#,X=S-)3C=*0DY)<E<X<G1!,6MJ2DQ$2$=Q>'5A=S-.1U5,
M5E%'3%9O,4-H2R8C>$$[>F%A5&%73C%P9CA!:GDY34YS.7A"8U=0,5,T1E1.
M031-6$)M05 R2%EF<S$V54IR:7)*9DIV;69Y,W!B>FTT.#%4-G-L-G-+5VM-
M."8C>$$[1C)$1TQA3VMJ<4I$2V8S;DU/-U5!,DHV1%I3.4(P-B]T.5%S64PR
M,S5E:&-+2&HU<55A:#A18T-O:D9867$W1EA9<3=&6%EQ-T98628C>$$[<6AD
M5C%+1%1B0V$K;E9M:6A!3'%G0EDQ25AA<%5D+TA+3E1N:FAX;6-U46)C1T4U
M6FE!-6QJ4"]!0W1$45 X06QN=2\K06HO04]Q;28C>$$[868X03!264\V9GE(
M+T9/>B]K5$XS>"LS.51V*U9O84(O=T%S.3,O=T5F.$$Q57@O,%)93S9F>4@O
M1DPO04-*;3<T+V(K<#,O04-T1"8C>$$[45 X06QN=2\K06HO04]Q;5 K:4Q"
M,U0K42\T<&8U17ID.&9T+U4W+T%*5VAO2"],4&0O.$)(+S%5>"\P4EE/-F9Y
M2"]!0E,O>4IM-R8C>$$[-"]B*W!:3"M:6&QQ6E%K,7!C>4M#1T-V2$5W-4MA
M<6%'5'%#2VI$+T%+27-(9% U1"]I;"]K5$XS>"LS.5-7=#5J+TQ6<6-V3#!B
M528C>$$[67-+,F1Q84TQ3U(K,3%.0EA(+U)&9S=P+TEF.%5V.$%);6)V:CEV
M-FQ5*V)F>2]+=7 P36-:1CE/46968F%J241Y-&XT='AY,W!J+R8C>$$[04M)
M<TAD4#5$+VEL+VM43C-X*S,Y4W!C*V1V23DP54YZ<$14;4YN94UY5SEU+T9P
M5%=2;#5/849Z.7)X>"\P4EE/-F9Y2"]&3"]);28C>$$[8G9J.78V;E<S;F)Y
M4&$S2#%I,3!L;TQJ:7EE=$9B,C90>&1U8DQY5G=A334U165/*U X06]I=V0P
M+VM0*TM8*U)-,V9(-V8Q27HO;"8C>$$[84=G9CAS.3,O=T%"2"\Q57=F-DES
M2&10-40O:6PO:U1.,W@K,SE4=BM6;V%"+WEZ,V8X07=%9B]!1E5X+W="15=$
M=6XX:"]X4R]Y2B8C>$$[;3<T+V(K<#,O2S!.02\U6C=V.$$T0U O04MQ62]W
M0VE,0C-4*U$O-'!F-45Z9#AF="]5-R]L84=G9CA!3%!D+SA"2"]!3E9-9CE%
M5R8C>$$[1'5N.&@O>%,O=T%I6G4K4#(O<51J>3DU;S O6&9R2#%33U=0-G1W
M-2MQ1D9E9DML3TQ.+TQM=S!084]053-W06IH<FXU+T4Y>F@V=B8C>$$[47IW
M5GA%8CEY8UIN=4<W1EA9<6MV;3-Z6G S;&93>'%7;U)Z4W=.2W-)5T)66BM4
M06M':G-G<#A0:FER0W!0>C,X:E--2&LP-BMD=R8C>$$[<DE'84<S2D-V5&MT
M5$XP86=R:%9",C,U=2]L9&%Q>3(R9U112S9T1S1J=$Q207E05&MP-'EI;U!"
M86HR1TMR2B]W03%V>6]N9#-N."8C>$$[=5-3=DMW:VM:-TMZ67,T<E)M2FLS
M3S4S>%9C;C5U9FQB2%1H-69M5&E'5F5.;F%#:75+34)36&]W,D]+;S)$.#DO
M23%V17-.=G Q.28C>$$[1$-N,EDT-&)D5D946%E#86Y81EAP*T)867$W1EA9
M<3=&6%EQ<'E83G1%,T=35D5A;&5,34%A9E1I<7HV.5IF.'1%6"]!06$O,7A6
M228C>$$[=D]';U=-+VPS5DQE1V1*2F]K:F%33E15:%=D84XW:C-'83-T9B]&
M<"]J<4A/-TTO>&E0-#902DTT0C=.5W,W3S5V8FQ,83)4,4HS<B8C>$$[=U%%
M06YI0WAP56IS37-X67!:2F--4EI,1$IK:D-01DQ92FEN;$AZ0DE11711>&)J
M>'!,16%L:'E!2'@Y95!X53A.*VU:63=->FYL2"8C>$$[-U(K=G4S.3(W:DA8
M-%)Z4#)(.5AW.2MZ82M54$U,;&5&<4<U0455;&E/>DYX53=0,%DO6E!C8FIB
M161L-F<X;R]A4#$Y96YF>E4Y;R8C>$$[65(O1CEH+U5Q2'E6-6Q#3S5T5C12
M,3E2=EAG;W1+9SAV:C)P43%Y6#AK86EI94AL+U-J*W1J+TM71&QX8R]+6#9L
M3T1Y;')C>G%I4B8C>$$[2GIB;4]":U%.>FI-:6Q/3F$Q2F=C1'0W-4=(6FUA
M4F]!6'8Q2%1I,B]W0FE7571F:4<Y+UHS,2]X45A3950Y96I3,VME04-/-619
M;"8C>$$[8T]P0W4X:&I535%E-49A:6]O4FAL,EAN06E33G!'=695;6M$=$1%
M4U%$>48O25<P+VQ(6%%O9$E5;&A)5FI-:W-:46-O+U8K26QH>"8C>$$[;VTU
M<BMO:7%E>3@O34%%9#1)-W(K-SAC;$AA1TQK5%(Y>#<V*SEU6'E:-6MH-65P
M84)E2VPR0FQH<GA&2W14;CEK8VA5.7--=7ED4B8C>$$[2&Y(-UDO<E=084]!
M.'!F668Q24Y.1#%6-V%+-&IT;6MJ;6)H145O>G,S171T1W!,+UI&96U9=S!E
M57A%:$=W95AF.$%,;3-(531X228C>$$[9VUQ+TA0:W5T9$$Q839J:FMG:$1,
M2WA22W9'<$Q+-F]24FU"0C533#$X9D1*63E&;&U!66IN-6IV02]3150Q5T]*
M24HU95(X>BMH428C>$$[=CE.=F)#5#!R=5 P,W%25&MR8F=!+W-K*TEY=DYP
M-31J56A26C1S,&-G=4I1,E5T<E!0>79N:&=I,6%795)9;VPK<CAP2$E64E5Y
M028C>$$[5DHR-C4Q2',Q+VQ0.#,O9E!09'9F=V8U,S9'8F9P=E)F*W)H8F8X
M04DV4"MU9%,X*W(R,3=:6%A,-G1C4GHX2V,O5&18<%AP6&E4:28C>$$[<71I
M<GIR.#DO=T1L0UDO*UDR3"]!26A*:$-V;G9&1'-69&ER<U9D:7(W2G=*9&ER
M<U9D:7)S5F1I<5A#,V=L,7$V37-A>457,794:R8C>$$[;TY0,VLO:FEQ2RMO
M,E@O3%!&+W=#+S!X5DEV3T=N,E5(;#-5-31916IM;%--4U-+04-65C%O=&9$
M,BMN3F(R=B]I,"]X,41N9&UF-"8C>$$[>$@X9$AK;6-!.6UU:6QL:&M75THR
M:FQ1,5(P2E9G4C-"1S1W>&M9;7=A2TI20D9(8TEH9%8Q4E%G5SAN55)!3$5"
M230T9T%G0F0Y<28C>$$[0FE0<'DP86Y+2W%5='9-=%IW67IF<$<O:W%.<C)T
M='=R9C-!.4U%2U))=U!X3GI*2D(S2F)E<'E:,759,38U8F5:.3=%85A&+TYJ
M."8C>$$[=F<V5%AD8VM2;S5.4G584G=66D=M:TE)4%5%131Y,759:6I/5F8Q
M:6\P=4E'>$=0>4,R3%=D5VAK4U-/.&U$>'8V<6YM>$A-:VMT428C>$$[;6A*
M-4=V:E4K3U)J<7-S4T-*4S).."MV-$I43%0T>4M-4C-C;7!.6#%A4E%S;#=/
M-F@O54-T2S5!8TAL>6]4,7)V6$=7<7EN;DM89B8C>$$[>E!.4G X63522'EA
M3W$V;U9:5&54;%@S9%1).4-E4$1C5B]K*T@U8EE0>D]7<31P9DTK-S=T:RM"
M:B]M:C5F2#<Q9'9-5W5003!%;"8C>$$[.4Y,17=D5U=2:2LP9S1T=3%4,#(K
M:RM*>7<V-TU2=VU:23,U-S@O>#DO95=S851%1%EI068Q2T,V<'%+96PV9'I*
M2#9)<$5567%2428C>$$[158K16IE:'!8=WES86Y)2W%21DYH=U%.,D%B86HQ
M5%4T:T5C9#--:4MA:$9K8T%%='ER44@K658K94UD5&M!;U-K0C=Z-S%/0T).
M;28C>$$[22M3;F,S53DQ35IP,TUK<$-H;E!5.%9#:79I841)6DUK<&TU1WEZ
M:$%21D1K<%I":WHO.'%0.$%P868X.% X06U:;E5E>E@K52]Z9B8C>$$[.3@X
M+S(W+T(O;F9O96=:,4QZ>4-I+S0W5C$O>D17+R]!0V-N>%9'-'$X-B]09CA!
M-5%M4"]M3FDO=T-)4UE1<C4W>%$W1EA9<3=&6"8C>$$[67$K;V9Z0CAS-B\U
M:3 R>7-D2#%E5%)74S<Y5SEU-%I*-#5$8B]6-6\K2V96-4E76FA,2D<T1$]&
M<7171$%C4T5V3S4O3'8O041K3B8C>$$[6C8Y0G%D.34P,&5#>4Q'2#!:5UI)
M,FA753-$9U)',E-*<$)"1S-X8DU&0C-'-UEQ;75I-D8K9'-U<%='<"\T=G-.
M43!E95A46G)G>"8C>$$[*VMY4U=A25AV;S1"2%IH1#9S:B]!3'!W=V)G0GEA
M=4MV5CA69&ER<U9155@O2&%U=BM983,O-4]4-'%J8U939GIH9#9F8657-S(T
M,28C>$$[0THU-T].5CEA2TTX6%E&,4%O86IU8WAD84E(1DE41GAC;E-'6&E$
M:$Y3959F-'8O04,U+S9S.3<O=T%J4B]Z6&Y/941O+S5K=FTW,R8C>$$[:C%8
M.#90>60O:2\X=68X07%Z,W8O23!F.#$T*T1O+S5K=FUV2'%V-3!F:S<O1B\U
M8R\X059N=F8K4F\O-7)X.$A2+WI*9DYE4%9F>B8C>$$[;R]*,RM,+WDU+S9S
M.3<O>4Y(+TYE4&<V4"M:3#5R>#9R*V1(-4\O>&8K6% O5FYV9BM2;R]W0V$X
M9D(P9CAY6'I8:C%8.#90>60O:28C>$$[+W=$3&XO<7HS=CA!>4Y(+T%$6&HT
M3VHO04IK=FUV2'%V-3!F:S<O1B]W0UA0+U9N=F8X06MA4"MA.&9",&8X04UL
M.#$T.58O3VHX;B8C>$$[9C1V+T%#-2\V<SDW+W=!:E(O>EAJ-$]J+VU3*V$X
M97$O;E(K5'8X048O-6,O=T16;G9F*U)O+S5R>#A(4B]Z2F9.95!69GIO+THS
M*R8C>$$[3"]Y-2]W0W)092\X:E(O>EAJ-$]J+VU3*V$X97$O;E(K5'8X6"]L
M>B]W0E=E.2\U1VHO;79(=V1(+TUL.#$T.58O3VHX;F8T=B],;B8C>$$[+W%Z
M,W8O23!F.#$T*T1O+S5K=FUV2'%V-3!F:S<O1B\U8R\Y5V4Y+S5':B]!2G)X
M.$A2+WI*9DYE4%9F>F\O2FTS-6%A>#5C,4@Y228C>$$[+V]7>FYT4%,Y2#$O
M6&9N>35E<'@T-W0P;V,R,UI534UE3'=W4GEU>C<S5V1O;DME2'A#1'IR-T=B
M-70S5TE+3"]J=%A8+TU.8B\X028C>$$[2GEF1E5B:7)Z<C@Y+W=$;$-9+RM9
M,DPO04EH2FA#=FYV1D1.3D0O3&U05CE+,"LX5%8T8F4T=E-R4&%Y<4MR0S$P
M,7!Y5&<W4TTS<28C>$$[0E!T27$O1CEV631Q:F]0>5,X>C-"+V-8,FYY3%=9
M1FA*34M.0DHV5'%A=VIF;E5E1S-81E=*-B\U8VXP53)N<3-6=F1,97AE=D$Y
M<R8C>$$[>G-$2%AI1U!.27E+<T=(5'-C5E-N1E@Q3#5Z."]A1C51:G,S,553
M36(U<&MT;S1V5#5-.$U44SA"-FIX9W1)44DP039S=S9#<$%3."8C>$$[>#@S
M951V>5 P+WI.<E,V,W%T+V)A<G%2;74W<4)9-4I9,$XS2$I$2C9"5S)L5&UX
M=C%92E9M-2MM865+<6%E479/=C56*U4Y0G4Y3"8C>$$[,$]E+V-W>4=1-F1.
M8G0V-W1&2#E61'A-<V-6=59U1%I&*V9/:&MB8W%Z8V-6979%9T%K;6=(531Q
M9W8P,V]V+T%&8TQB+VMD2"]81B8C>$$[6&9P=E)F.$%Q-%<S+TDV4"MU2V]/
M3%=T2"]41C S,38S-&TS='=$-G%5<4AM<C,Y.%92;C9B,%@O<317,R])-E K
M=4MS63@O-G9P,28C>$$[+W=#4V1D:G1*,6QE,D53>D)31%1L2VA5,49147<X
M4#$U:#EO9C--=G@Q8W)1+S-S9G@P94):>3<P:7)A,C Q,6-X5S!!1%14=7-C
M4R8C>$$[:VA15V,X5DA*:4%.>C%*=WAI4V%#2D5!5U4W6'E&-7-:4U)9:F(W
M44TP04E*:SE)2U%8<4=A4W%+=E5S0T)U1&U13DAL-W9T2'5A4"8C>$$[>E=0
M=BLY,'9K4'I8149-;&I14$DX2T53=VUS:V%.239I:B]S<6I6.7AX*S%T:61(
M:TA4-VQ'<7AN<CDV="]Y<F)Z<5,V:E1U5'AN:28C>$$[.&%Z449W86IQ9VLU
M9G1!.4]M+U1*9FMC,V0Y;UDO;F-89CA!655.1#5+.'=3<&9-2558-FA'6G!1
M6EEZ>E5+:V@Y3&EX16Q)-49E<28C>$$[-U4W,4E"9TY,33-T>2]'>DTV;4%R
M>E)6>BM82&UU,&I%;#=B2F%H:5%G:VQJ*TQJ1$Q/>#5+5U5C56=A=%-/,E1L
M;V-S95ER*W=N.28C>$$[1$-/<WAN:V(O=$$O4W S9C5F96%R6C5!8E9:26MA
M4D)C4GI21TYJ131J86I&:'9Z64M&3D=R=%-O27=3,&519%!T5$A6-'HQ53<O
M>28C>$$[2C5Q,"LS;G5,=7E%559S3U4U.6%":6EM;T):5F-S07A5:%149G1G
M;G!-:U%34GDX=VU'<7AY3D$X+V5H2G9,3W5X45<X-7,S:VIU628C>$$[5&-2
M1T5R369354MZ3S9X;#)104]+.&=-<D]#64%.8SDR67IW2DEV:W$R9FLO=T%W
M,V=G3G1A<DE,;$)*0E-7149K65-'=$,T+W="."8C>$$[4%=V4VQ01$I2,# U
M5E$U*S=Z+U554S%%23-:-64O.$%(5D$V:G!7;V%B26MD-T8V3'E+5U%65G%Q
M<G1'5#A*4#=A34UR;FIL2&TR428C>$$[>4-82D-:0FLY5R])>6%'1U!8<%IN
M5T].9G%N2C-)5E(O9D1C;DXQ,E O1CA0,'5O-U8O:"M0-DAP,S9B,%@O<317
M,R]!0T]J+W)M-B8C>$$[9%%G-'1A,&8Y35A49EAR9FEB93-!4'%P4V]E879F
M,WA61V9P=E)F*W)H8F8X:F\O-C1Q."LO3V)58E!59GDY9W4W4U%3479F4G%'
M2"8C>$$[6FM%:7-P.7=W27=Q.$=4:GI8;CEM;S5F3'9I:#9"9#)(-5%Z-FQ*
M-F5O4U)7-4UR5S1T;'5O-"M+:%!2:FM%.%8S3'IC=2]+4E13:28C>$$[+UE(
M3$969E8Y02]+:7HQ<U)26#$R=SEA,F0W0FQL24-3>7$P:U%P0TI0:&=9-T8K
M86M!9D5394MQ4BMB279*-'1O;#!U*W5R;3=G.28C>$$[945X,W)3.#0T-'!O
M-#=:0E="1F\P6'%0=RM(:E=H3E)2;%=*67$K:2]W07@W4'HQ4'$K:WDK6$Y(
M,#=6<D]',W9496I566]:3T5O128C>$$[8S%S<U)E4T8P85=32&AY0DMR54UY
M;FE-0UAN3VYE579Z8U-Z5U-4>59O.7)R561,:&12:3E$;DIC,D9N0VQJ>E-+
M-V=H4F95:5!&0B8C>$$[1S!3=49B,#$O=DU65%114$PS-7%X:3-T-79*9FPW
M5&HV5G(Y8C%&3%-Z85EY;6%"6C)4,')H535O:2MU1TU82&Y(=T-T4EA:5C=4
M<"8C>$$[.$8Q8C)&=$)D,TIV3'%+2D5U3'AK5TUZ4TMO1'E&16]Q.#(K3&EU
M=WA66'A6,DMO2TPO:G186"]!1$17+W=$>6-N>%9'-'%X6#AY;R8C>$$[;V\O
M275R*VUI<'I#3R]%0599>7!5;6Y5-6@Y;V8S379X,6-V42\S<V9X,&901V-U
M.4<R<D931U4P66)G:G%$:7%.+U0R=55!+U-.>B8C>$$[44]:05!7:RLR>FE6
M;38O84UI:&EF2&9R;&YJ5#=Z.#)(:%$W9W%V-6PX=WE):5!Q5GEW4C)L56U6
M*UA.:T524$MV22]!3U!8669--"8C>$$[5&YM9C1I9UE99'=89C1S.#!K54]S
M,S%+,7 Y6FUP5W1F-7-0-6I*+T]L.'EJ.'9J+VUJ-4)1=#ED,7DR-696.5)U
M665F1&XV8S!I,28C>$$[.4E"638P27)W04%8=WE-8S!X>4HK8DDT;TAM079M
M.'@K65IG9VTQ4S=K15HU4F@U-4<T;FE5<717,E!&:5!L:6,X>GIK9FUG65E$
M:R8C>$$[0CAL:F$W<F))16)53&QK1$9W<&UK235--&M:<58V;'='4'9V:C1S
M*S@O3E!H4C=G<C-F;6YZ1F4R:E=L-7%%,7IB<V]2;&UB;5-O9B8C>$$[,4MC
M;7$S,G%%-S<P2#AO<$M7;WE31D5K:&I(0D-*<T-L038U<D<S1SAM:D-X0S-#
M>'5Y1#!U25%P4E-"4F=O-6509DEE3$QV4&-Y."8C>$$[2U!C,TAR,G522D=K
M96\S4TI%07-3<DY)06]51E%&06)A9UEJ-E1H1V%9-FXU<6-51#!#1G5B:5<U
M=4IB:5DX<%IN85-2<4%66FI5-R8C>$$[1&)R:TI%:S)7449#9W!917979GE(
M+S98;B]2<B]W07IS,UA9+W=$1CA0,'5O-U8O:"M0-DAR1V)P,4-#:2\T-U8Q
M+WI$5R\O04-C;B8C>$$[>%9'-'$X,R]!1'II:FDX:7=X4DES8V%8:TMO:6="
M5D%344%!1&]-258T3G Y-TQ96#ET9E)+<E,R<W%4>'))3U-&;S)$04U.<6EO
M,R8C>$$[>%%Z97@O37IZ9G%&.4UL<EHR:C-%+T]9<79Q=VQ6:D4P:CA(5V%-
M<G1.2C!B:V4R-3-66D=.9"].2%1R4V57-W-R0WES,%!'.'5:<"8C>$$[2D]%
M5$LW<7%S<V,W,#E2=FAQ:3<Q1E1I<D)D6"]-4%<Y57-B;7EN:6=31S=33DHK
M06Q*26A02F%C-4AP,"MY4&@X04-4:7)&.%9F5R8C>$$[6&UX9DU,-DA-;FPV
M4EED5V530EE*6$-S<4LP>4-2;41H:%%2.&ED:6%D3C9917!#=&@K8EDP<E=B
M239L<&AU9G$O1'DO<6Y&>&-E=B8C>$$[5G8S;#1V<&96+W,X9C=U2VQE,DMO
M9E1.2R].;7DQ9E-P3"]7;V13,#!W2DAQ8T%J:%$O5U=N:V534499250V4S(U
M5D5O45,T1E9O5"8C>$$[:7)08U9D:7)S5E%56"](875V.$%M1W0O*U1K*TMO
M,T973F9M4'%M;#96-4LQ5%5.57,R=C=#0DEZ4&%)-6E:=UI554%/2T5566<T
M:B8C>$$[04UV;U!)<C1X>&5S9$AG4"]+,G9Y;B\V:W4U+S94<&8K87-N+V]E
M>&0S,R]!2S)V*U@U.34K460O=T%R82]+9B]Q4S=N+W!/;"\U<28C>$$[>"\P
M4%EU-S<O=T)A+W=!=GHW>CAG-R]L8E@U5"]W1%5L,U O045N4R]W1$Y74#A!
M;V5X9#,S+W)8*U@U.34K460O>71R.' O*W!,=28C>$$[9BMK-E@O;7)(+U$Y
M:3=V=B]7=CAV>C=Z.&<W+T%*5S$K52\O049*9'HO,&Y3+SA!3E=0*V@W1C-F
M9CA!<E@K6#4Y-2M19"]Y='(X<"8C>$$[+W=$<5,W;B]!2U1P9BMA<V8Y1#),
M=2LO.6$O>2]0=E!Y1'8K5G1F;% O,4ID>B\P;E,O.#%9+S9(<UAD.2\V,2]L
M*V9E9FM(9CAR828C>$$[+TMF+T%+:W4U+S94<&8X06UR2"]!15!9=3<W+T%.
M82]Y+U!V4'E$=BM6=&9L4#A!.5-88R]W1%-D3"]Z5FHO;V5X9#,S+W)8*U@U
M.28C>$$[-2M19"]W07)A+TMF+W%3-VXO<$]L+S5Q>"\P4%EU-S<O=T)A+W=!
M=GHW>CAG-R]L8E@U5"]W1%5L,U O045N4R]W1$Y74#A!;V5X9"8C>$$[,S,O
M<E@K6#4Y-2M19"]Y='(X<"\K<$QU9BMK-E@O;7)(+U$Y:3=V=B]7=CAV>C=Z
M.&<W+T%*5S$K52\O049*9'HO,&Y3+SA!3E=0*R8C>$$[:#=&,V9F.$%R6"M8
M-3DU*U%E<&9K:#5T.' K668P,2]H+U):3DDK<2]6=G)0<7IT4#9N<65T=W!Y
M2C0X941F9FM4,F9(5&94+T8W*R8C>$$[;CER2U!A1712>B]H.3-6-FIG6DE+
M3"]J=%A8+T%$1%<O=T1Y8VYX5D<T<3@V+U!F+VQ#62]W1&U.:2\T:$IH0W9N
M=D9#<$)C6$9V2B8C>$$[-FM%<GA3045",%EQ,4-+159(:4U64F0Q<BMU,V--
M:T8Q<4XQ8U%Z34AL:6QM:V1866)H;59M24HR-S1Q9TU69&ER-TIW2F1I<G-6
M9"8C>$$[:7)S5F1I<59V9E=6<G)6>#E:=4DT3V1T8CA05615<E-3871/4DAJ
M:7%V.$%P=E)F*W)H8F8X:F\O=T-U2W-%+T]N5W1,=E!Y>CAY,B8C>$$[;'1C
M>'EZ=W=W3WE)=TY53GA&.%-K8D56,DY/;5I';"]V03!A;BLW4'5F2#)B>#!$
M<U9B4E,W<6\V<U%".4]+9U=8<$8O=T1K3C5T<R8C>$$[<EA53&U7.7-#=6UP
M8U!-;TXP0S,Q4TU3>4MP83-647A2<6](2SAX.%,Q6#1S>%)Q-&UT:G8K3SEZ
M1&]::G%0>#A%<E@X;F908G!A="8C>$$[1F%W4U!F0T(W2TIB;41L2VQX8GDS
M2W5+=4964DAB=E5U4E5I:3AQ1VLO>DU'2#5427-T4'EM.#,S3W5A4&\V>'=*
M3')T;VPY<#%W."8C>$$[;T5,=TY%2E=.848K4T$P6F5.9D-O;V-4<5EG13EY
M:E-Z-&=/.6-F>6(O365S2$A34DEL,$$Q<DY(8S)R>'EQ>&I65U-26E-R2S-R
M<"8C>$$[43$V5E!25V\O;6-F978U5$HS9F-O870K5DAN,U-,4S9U.5$P,5E9
M3$MV,71H8S)S:E(P54XX87!+>D1:;'!T=GE7;C)L<5DV:4).028C>$$[<UIA
M6$E"6D@S2F1F*U(O3F1J34E:=$]K:VPY3U-::W1I;'E5:FAP-FI396=:3T%5
M37!02VUX0C9%6DE:66YQ>&QG;4]94FQR*U=F;B8C>$$[4S98;D1:4FU-2W)T
M23$Q84EQ<3A0<G%Z33AQ:%9-93E4=#(V:6U23V5!-B]E>D=L>60S,TI&<6UM
M>6%D8VDR;&QI;&LY3T]2+U)F;28C>$$[14UI:&I'*W=P26QE3'(R3S)74FQB
M5$](0V%1;5-9=7A6.4)F.#1O5%%W>"MB2EIN5T].9C!F>61Y1E5F-S!J8VY.
M8C)H+T0X9C!/>B8C>$$[-T\O:2M(-EAV6#9B,%@O<317,R]!0T]J+W)M=&1M
M<%=.,V$S3W(S8C(P,&,V3&(R-$Q2<TA!4$]F87%K-'%M5TMV3W9Z,R\U46U0
M+R8C>$$[04IJ678K25-947(U-WA1-T9867$W1EA9<2MY8T-867$W1EA9<3=&
M6%EQ-T9867%W1#@X8F5"4'EU.'E42D=Q>7EX465R24%/5&-B:28C>$$[34Q5
M.39D<WE.3"]E0F\Q4#DR9F,K3F,S:F](67$T16=G9S!)-DA&55DR<S9W>G,W
M6#%W6&0U<%A9>795>5A3.$QH>6$W=$MN=W5F,B8C>$$[:'-C:G=J=5IC8W4Y
M1U=V;DQZ6F%Y>%-W87AE3$IB>$,S=#)-.&IE;D5S8VM+3$AY2C1C234U1E1J
M.6YK94Y-0GA24%%-:&UM3W!5528C>$$[.'IE6D5U8E,V5%9R>&)M=VHY1WAN
M5S1L16M%4D)8,#1M1%9294I);W4R2'<T.7=2-&MU.'$P6&Y,>F9%:T-2835Q
M16%7>6E/,E9B<28C>$$[8T-.0GA)5D%(*T5F=3$R2&=01$(T564T2CAA9F5F
M;7)A;#4Y.#5A<&%Z5VUP87AC,VQV3VM556E4=5I+<$-66E%#,5-T5VI6;7 Y
M<"8C>$$[9T,Q4TU%8TU!8D%43%!-:6E53$PU;SAX>5AL>&0O<$LU:FYU:$MS
M-U)3=D='4V5G:U-I141G=U)15C9504AB0TUC87%K2$Y);3=+="8C>$$[1C4P
M.#-X<C99,7$K84AK1V%"-VE6-&UO9VIO.&)-5EEE;4]"0D@R9'5M031O.7=3
M33AX,4M55%-Y>E-V3DMX95=2:3AJ;F-L;4Y35"8C>$$[.'IL9T175%IT6FEH
M,DMV;U@O;D5V+W!Q=BMJ1"]S6GI7.6]F=R](.41S*WIV-'9H*VPY0UIR6%IU
M>%8R2W9/=GHS+S51;5 O04IJ628C>$$[=BM)4UE1<C4W>%$W1EA9<3=&6%EQ
M*VQ*+W=!=TYD='14=3E.;#AO-FI.3D%9+U)U<E97;'1(1#$U17IU:U@R44LO
M07(Y4BLQ54%*5R8C>$$[>2]M5F9"2594>61R=W5P:5%%:W1616%584Y36DI9
M;FU#:CDT4TM!,31N1E8U+TU,535T26@Q5W<X<V%H3&%.-G$S46Y5>'I1>7=Y
M3"8C>$$[1UDO<3!3,T9W.5-8;U5J3S8W,$)R:7%V4"M95$IC43(X6&QR6$I*
M6GI/<5-'>5I956%!2"LY:W$S0EI'1D592V$Y4G1I<454.'IR<28C>$$[4T]Z
M85!Y9C5G1#-,>')/<VQN=T5#4#982C-033$T:6)O=2]W=%=N131Q;3)J*V-*
M.5,Q;513,C!(5DQ(,$9";'9R<4%2,G!::S5H628C>$$[-4]2.51W2D%O1'1I
M<DES5F1I<4,Q<E)D3#%V4S4Y3#%305A.:&-G0V5!;&Q$0E=$1&13<F9A560X
M;$=2:6)#2E)"1D9I4#A!>6]V."8C>$$[<5 X07%8-"\K4C%X+W="5DUU+TY:
M3SEP+TQ9*S1/+S556"M62"]5=G@O.$%)-C0O-G%9+VUS;F5V-6)(,T(S+T%#
M;W8X<5 K<&9J+R8C>$$[04]2,7@O,55X+TY:3SEF>3)0=41V*U9&+VQ2+S%,
M.&8O238T+W=#<6U0-7)*,W(K5W@Y=V0O>6]V.'%0*W!F:B]W0U(Q>"\Q57@O
M3B8C>$$[6D\Y9GDR4'5$=CA!;%)F-55F.$%5=G@O.&IR:B]Q<&HK87ED-B]L
M<V9C2&8X<4PO04-O+S9L*U O:V1C9CE6369Z5U1V6#AT:C=G-R8C>$$[+VQ2
M9C559CE3+T@O04UJ<FHO<7!J*V%Y9#8O;'-F8TAF.'%,+TMJ+T%+;"M0+VMD
M8V8X05942#@Q:S<Q+TQ9*S1/+S556"M62"]5=B8C>$$[>"\X04DV-"\V<5DO
M;7-N978U8D@S0C,O04-O=CAQ4"MP9FHO04]2,7@O,55X+TY:3SEF>3)0=41V
M*U9&+VQ2+S%,.&8O238T+W=#<28C>$$[;5 U<DHS<BM7>#EW9"]Y;W8X<5 K
M<&9J+W=#4C%X+S%5>"].6D\Y9GDR4'5#92M6=DEV;%1Y<CEA+U%';G)9+UA/
M2#%N:3AJ."]3-28C>$$[8U W>&YP5&TS5$LU-5I4*V\R,E%X>&IY1DHY;&).
M,DMU>%9!83%O3VLV,UII>C%7,T8Q8D)X24DR3$M/4V=G1W%L5#-/2W!&+W=!
M<28C>$$[<"],-R]Q>G@O=T1)>6(O;79',60O=T%Q<"],-R]Q>G@O=T1)>6(O
M;79',60O=T%Q<"],-R]Q>G@O=T1)>6(O;79',60O=T%Q<"],-R8C>$$[+W%Z
M>"]W1$EY8B]M=D<Q9"]W07%P+TPW+W%Z>"]W1$EY8B]M=D<Q4T<O,5=9+VPQ
M;VPR<EA6<S$R,%-2*VIQ,75J0G!B9'=I1R]#="8C>$$[1DM$2E)A;CEU;FAH
M5F='<6%N<D-*93 Q2%565U=A4C1/4&Y'>&HU2DDQ<DQ'56M:3TU3=$5K<G%N
M54M(<'-W>%9&3G)7;W19=7$V:"8C>$$[<6IZ96YB,U%:9DY.:'HY1E5T-4I(
M.5-/37=G8TE:5UEF=&A82R]#,GEQ13@W6%=T,TM35T9V9EA*5%5):D596F1E
M9W5O<$%.4&MT<28C>$$[4$=V<'AX3#EC<$=X8S!K;#953D)I<5EE561A5S@P
M>E4T.4QL=E,Y,FQZ3$$Q<F-*<&]A;'-B6D(V,7=H5&XV+W=X=#EP5#A60VEQ
M4R8C>$$[;U,V8E=B;30Q1%=H1'%T,TY(2F)T.5924$XR;C-A=$MJ9VA98E5Q
M1$9.5VY%-W%'<'-E;4M746573'HV=F,S2$LU84]"9E%N5U)B*R8C>$$[3T\S
M65%S.&MJ2D11*V]Y>')Y2E9V:5@O0492:%%X3S%7-5A89DPK<#9R9E-81BMQ
M5T9X<455<6DT=6]F<6%S2G988VPU16MP8TLS=R8C>$$[3#9O0D9!=T]"6'%M
M<&%,-5).,5HS;#DU>'9L37%R87A),3E%<5-Q5EI3<VEI4&-0.5E4;4<K2&M)
M*SE+<55K+U(O-60V;F%#,3!N."8C>$$[>611<WI$1F1.8BMJ<D%J52MQ>#54
M:T5O,'EX4TLQ0T<T:F9F1E5Y=DY,.&HS5FID;W9N>2]J:FU%:VQX9E<R<5)C
M;#E,:&1(.39&6B8C>$$[43!C87%11'5)+SA!2G)I<G11,%AY-5!A5V$R,S5I
M,W1T3&$S855N9E958C%(37AK83-L5EAI-6QL4C!65#!!-D=M2W1E4W)0.'-T
M228C>$$[.'EY5&%,<DTQ-V9Z,7,V14Q*0U=U1RMU0VLX54-C;%!R1&I747!U
M2V9&:7(P,T%R<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69"8C>$$[:7)S
M5F1I<G-69&ER<U9D:7%1>F8T1"]19'8V,S9,+U%8<7<O5D]F,68V<#8Q4C9(
M<#$O9#@O<SA+8CE+67%L3C,O>7!V;3,Q=B]$.28C>$$[84XV;G%F52M0.7<Q
M961F:"]U3U@R=C)/6&%U2W%S6"]!0W%(,&\O4B]W05 K;#92.4AH.5,T*VPY
M6&5V1VTS1#9T-FY48C K6#=.8R8C>$$[5E=A>B]W07%O.4,S*W8X039-.5 V
M,48V4&\X2RMV.$%7=F@U96@X6$@V,3EV;#A02W9,=FEQ<G!V+TMP=E1F.4=F
M;T@P+U0O04AN,28C>$$[8C9N>#E,,2LO1#EN-G@Y2% O2WA60C)F+TMJ<7<O
M52\X358U3CE8.4@Y2#$U.&LU8T]09FYW<E1V5#)X5DY,3"]L5S-O46959C!.
M.28C>$$[6#E0+T%%8C!0<79$,'944#)/3S-(,#8Y3G50=&EQ06<O=T-65&98
M.58U9F]V-C4V,&XV4RMT*VYY-2ML1C9L4')(*S8O5#E+=D0T4"8C>$$[<'A6
M2%@S+TMT3UDK=B]O8FXV,C-R+U9A*W9Z:2]N+V(U*VPW,30K,DMU:R\U5FXV
M;C=Z.4,K<%%F82MQ.'%586Y8,C5F:FEQ0S W+R8C>$$[04I5+SE4=5!Q6#9$
M*W$K=F-F5W8Y-750<F,R.69N>CDV*S-(<#A.3596-68K5E=E;$Y8.415.5DK
M<C9F,6)N.5EP2E@W2'AE<B]E528C>$$[<#A8,G9F1E9V;&8O04I69#E8,"\O
M1"\V3')33#9J=SE,-GI8-G505')Z+V8K<#E8<#ER-"M06$976%EQ-T9867$W
M1EA9<3=&6%EQ-R8C>$$[1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$O
M+UH\+WAM<$=);6<Z:6UA9V4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO>&UP.E1H=6UB;F%I
M;',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R
M:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @
M>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP
M92]297-O=7)C95)E9B,B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B
M/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C,Y,3A%-3@U
M.35#.$4Y,3$Y.44Y.30S1$(Q,#4W-# V/"]X;7!-33I);G-T86YC94E$/@H@
M(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.C,Y,3A%-3@U.35#
M.$4Y,3$Y.44Y.30S1$(Q,#4W-# V/"]X;7!-33I$;V-U;65N=$E$/@H@(" @
M(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z-40R,#@Y,C0Y
M,T)&1$(Q,3DQ-$$X-3DP1#,Q-3 X0S@\+WAM<$U-.D]R:6=I;F%L1&]C=6UE
M;G1)1#X*(" @(" @(" @/'AM<$U-.E)E;F1I=&EO;D-L87-S/F1E9F%U;'0\
M+WAM<$U-.E)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \>&UP34TZ1&5R:79E
M9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \
M<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.D,S.3@U030Y.#9#.$4Y,3$Y.44Y
M.30S1$(Q,#4W-# V/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @(" @(" \
M<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.D,S.3@U030Y.#9#.$4Y,3$Y.44Y
M.30S1$(Q,#4W-# V/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @(" @(" \
M<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/G5U:60Z-40R,#@Y,C0Y,T)&1$(Q
M,3DQ-$$X-3DP1#,Q-3 X0S@\+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*
M(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S/F1E9F%U;'0\+W-T
M4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \+WAM<$U-.D1E<FEV961&
M<F]M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @(" @(" @/')D
M9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A
M=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II
M;G-T86YC94E$/GAM<"YI:60Z-$0P-#8V144R,T%$13DQ,4$Y0C4X0S-&-T0Q
M,$1!,C$\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IW:&5N/C(P,3DM,#<M,C-4,30Z,S Z,#4K,#4Z,S \+W-T179T.G=H
M96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D
M;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E
M06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T
M179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T
M:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N
M:6ED.C,Y,3A%-3@U.35#.$4Y,3$Y.44Y.30S1$(Q,#4W-# V/"]S=$5V=#II
M;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#$Y
M+3 X+3(W5#$R.C$P.C$S*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O
M<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q
M/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(#PO<F1F.D1E<V-R
M:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@
M(" @(" @(" @("!X;6QN<SII;&QU<W1R871O<CTB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]I;&QU<W1R871O<B\Q+C O(CX*(" @(" @(" @/&EL;'5S=')A=&]R
M.E-T87)T=7!0<F]F:6QE/E!R:6YT/"]I;&QU<W1R871O<CI3=&%R='5P4')O
M9FEL93X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR9&8Z1&5S
M8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<%10
M9STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W0O<&<O(@H@(" @(" @
M(" @("!X;6QN<SIS=$1I;3TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+W-4>7!E+T1I;65N<VEO;G,C(@H@(" @(" @(" @("!X;6QN<SIS=$9N=#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T9O;G0C(@H@(" @
M(" @(" @("!X;6QN<SIX;7!'/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O9R\B/@H@(" @(" @(" \>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^
M5')U93PO>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^"B @(" @(" @(#QX
M;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3Y&86QS93PO>&UP5%!G.DAA
M<U9I<VEB;&54<F%N<W!A<F5N8WD^"B @(" @(" @(#QX;7!44&<Z3E!A9V5S
M/C$\+WAM<%109SI.4&%G97,^"B @(" @(" @(#QX;7!44&<Z36%X4&%G95-I
M>F4@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W1$
M:6TZ=SXX-#$N.#@Y-C0X/"]S=$1I;3IW/@H@(" @(" @(" @(" \<W1$:6TZ
M:#XU.34N,C@P,C<S/"]S=$1I;3IH/@H@(" @(" @(" @(" \<W1$:6TZ=6YI
M=#Y0;VEN=',\+W-T1&EM.G5N:70^"B @(" @(" @(#PO>&UP5%!G.DUA>%!A
M9V53:7IE/@H@(" @(" @(" \>&UP5%!G.D9O;G1S/@H@(" @(" @(" @(" \
M<F1F.D)A9SX*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT3F%M
M93Y(96QV971I8V$\+W-T1FYT.F9O;G1.86UE/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z9F]N=$9A;6EL>3Y(96QV971I8V$\+W-T1FYT.F9O;G1&86UI
M;'D^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y-961I=6T\
M+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N
M=%1Y<&4^5'EP92 Q/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @(" @
M(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^,# Q+C P,#PO<W1&;G0Z=F5R<VEO
M;E-T<FEN9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O;7!O<VET93Y&
M86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @(" @(" \<W1&
M;G0Z9F]N=$9I;&5.86UE/DA67U]?7U]?+E!&0CL@2%9?7U]?7RY01DT\+W-T
M1FYT.F9O;G1&:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^2&5L=F5T:6-A
M+4)O;&0\+W-T1FYT.F9O;G1.86UE/@H@(" @(" @(" @(" @(" @(" \<W1&
M;G0Z9F]N=$9A;6EL>3Y(96QV971I8V$\+W-T1FYT.F9O;G1&86UI;'D^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y";VQD/"]S=$9N=#IF
M;VYT1F%C93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/E1Y
M<&4@,3PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N
M=#IV97)S:6]N4W1R:6YG/C P,2XP,# \+W-T1FYT.G9E<G-I;VY3=')I;F<^
M"B @(" @(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T
M1FYT.F-O;7!O<VET93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&
M:6QE3F%M93Y(5D)?7U]?7RY01D([($A60E]?7U\N4$9-/"]S=$9N=#IF;VYT
M1FEL94YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F9O;G1.86UE/DAE;'9E=&EC82U";VQD3V)L
M:7%U93PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @(" @(#QS=$9N
M=#IF;VYT1F%M:6QY/DAE;'9E=&EC83PO<W1&;G0Z9F]N=$9A;6EL>3X*(" @
M(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86-E/D)O;&0@3V)L:7%U93PO
M<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT
M5'EP93Y4>7!E(#$\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SXP,#$N,# P/"]S=$9N=#IV97)S:6]N
M4W1R:6YG/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A
M;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @(" @(" @(" @(" @(#QS=$9N
M=#IF;VYT1FEL94YA;64^2%9"3U]?7U\N4$9".R!(=F)O7S,N<&9M/"]S=$9N
M=#IF;VYT1FEL94YA;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @
M(" @(" @(" \+W)D9CI"86<^"B @(" @(" @(#PO>&UP5%!G.D9O;G1S/@H@
M(" @(" @(" \>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(" @(#QR9&8Z
M4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI/D-Y86X\+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:3Y-86=E;G1A/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(#QR9&8Z;&D^665L;&]W/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D^0FQA8VL\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q
M/@H@(" @(" @(" \+WAM<%109SI0;&%T94YA;65S/@H@(" @(" @(" \>&UP
M5%!G.E-W871C:$=R;W5P<SX*(" @(" @(" @(" @/')D9CI397$^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<$YA;64^1&5F875L="!3=V%T
M8V@@1W)O=7 \+WAM<$<Z9W)O=7!.86UE/@H@(" @(" @(" @(" @(" @(" \
M>&UP1SIG<F]U<%1Y<&4^,#PO>&UP1SIG<F]U<%1Y<&4^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @
M(#PO>&UP5%!G.E-W871C:$=R;W5P<SX*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @
M(" @(" @('AM;&YS.G!D9CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]P9&8O,2XS
M+R(^"B @(" @(" @(#QP9&8Z4')O9'5C97(^061O8F4@4$1&(&QI8G)A<GD@
M,3 N,#$\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^
M"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,  0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( .("40,!$0 "$0$#
M$0'_Q  ?  $  00# 0$!            " 4&!PH$"0L# @'_Q !+$  ! P0!
M  (,# 0$!0,%   % P0&  $"!P@)$Q$2%!48&1I76)67UA87.%9WEIBUT]35
MUR$W>+8C,;>X"B(R.78D0=@E4F&AL?_$ !T! 0 !! ,!               !
M @,$!08'" G_Q !5$0  !0$"!@T&"P8$! <!     0(#! 4&$0<2$Q<A,11!
M455688&4E:&QT=14<9'2U? 5&"(R-E=UL[3!TP@C-5+A\18W='8D,T*U)31B
M@I*RPH3_V@ , P$  A$#$0 _ -_B@!0 H 4 * % "@!0 H 4 * % "@!0 H
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M=WF&?J@2% "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 *
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MG+-^008)=4FI;!51F,?+VS6NFC;%OG:ZEL[X8Y %;H 4 * % "@!0 H 4 *
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MJ0C,XB47E0<=ACL"".!XQJ.)+]?Y=5^G=TZCV[@N/DZKK]6K<T;6KS#.>O\
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M&1ZC&;:@2% "@!0!!/I-?D&<F?H_M]_A:J1\XN7L,4K^:?)VD-#NKPLA0 H
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M!G)GZ/[??X6JD?.+E[#%*_FGR=I#0[J\+(4 * % "@!0 H 4 * % "@!0 H
M]+"L<9 4 * % "@!0 H 4 * % "@!0 H 4 1;YE?R'??2EQU_P!Q>JJ"#U<I
M=I"4E!(4 * % "@#7ZZ3/Y1[7Z.(Q]Y2*OEI^V-_FW'_ -H4;\;5Q]"/V8_\
MMG?]R53\-3AUZ5Y2'H@* % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 *
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M!SX66!FQ@XN,?M%VKYD@LGEA8(,C+0>@6\4Y0Z-%2<Y"[S50M*XOMG7.D)8
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MP\$[DGYE9_ZC7IF-PO\ U=VHZ-<[PSMX-.&UG^?-AX)W)/S*S_U&O3,;A?\
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MG@J/$HO<A-Q'>J[0HU'>1D1)TG<6G1>>X>T97"1LAY"\H>3\3UT5F&R83)]
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M:KY8S#Z'(3]\R^O%6'WZ=-_85/\ OYP]@X#OH6Y]M3ON88ZC*Z2'<04 * %
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M6\Q'6MUY2G<=+RU.+5(7=BFM,-N% "@!0 H W_=1?RGUA]'D*_ML;7TLH?\
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MRULD@A2KS5I.[&,RXB.^_P!.C0.\>/1X!$@(2*Q4((C,8C0D<!CL<CXUF'!
M08AHBP%!@PD<BW8"Q0QBW09#Q[)N@T9M$4F[=%-)/#"P4"L4 * % "@!0 H
MBWS*_D.^^E+CK_N+U500>KE+M(2DH)"@!0 H 4 :F735?+&8?0Y"?OF7UXLP
M^_3IO["I_P!_.'K[ =]"W/MJ=]S#'49720[B"@!0 H 4 * % "@!0 H 4 *
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M$&K"Q9S >0;+8)+MEG((X$.L;J)XID 9D288YN!I)DZ7 +EH 4 * % "@!0
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M-?D&<F?H_M]_A:J1\XN7L,4K^:?)VD-#NKPLA0 H 4 * % "@!0 H 4 * %
M"@#TL*QQD!0 H 4 * % "@!0 H 4 * % "@!0!%OF5_(=]]*7'7_ '%ZJH(/
M5REVD)24$A0 H 4 * //Q_XFK_N/"?Z;]8?W+L6O2>"?Z+N?:LO[F*/,V%OZ
M5(^RH?WLH:\M=FCK * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * %
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M&V7F/M(2FJ!(4 * % $$^DU^09R9^C^WW^%JI'SBY>PQ2OYI\G:0T.ZO"R%
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M2.HV#:;5J<.\KDCM&%4:1.M)2J:;C-3FL5>M/+F'1(E.:B044F<A-.-IHO\
MC<G(0E\G7$:#;*X[U# <=WAQNY&!=M1B.DP'(/;FI^C+Z2"0[$Y%.N,&N^-Z
M$FN5C$0?ZH #X!$\%$'1?5R8Z0+LYD\9L2+56173%+J74>YX;)VGU6EN0G74
M.TR%,M999J+2RJ\FJ&UBO/IF.JDO:21+QFTJ8)2DF37RR^:-8U4:35&YK+2V
MZI.A62M6[*JIT>+22=QV&50FDQF"N4N)BNFE]24K2;GR#.]5T2>!FBM);SX3
MO(_,M'92F5'^DPX7:FDFW0CBS>80C5NV79< <LD8;QQ^_ 1EQAB\CSAHJ7:
MR\KED4+.[9%HT&9D-U:.HSZ?:!+C%0R++=E*[-:A.%>Q(EPTH<;O0;J4NND>
M*X1XBG$,LO(3\AU:DZ:S5-IU2L^IJ13LL\Y:R@0G9K9W/L1)JUM.&2R:4IIH
MR,VC2:R;6\ZRL_EMH)4KM1\0>*V\%&&B(O#]FQ#3+?I6[\<#($C.HS))A*,8
M/QEW:^(3K"9V@0(S'R4E-19@Y;Q%J2<10*T4S:K8%W^.!W#3S:U6*>2JD\]$
M>J!V.^$VW$QWFF&=D5:GI1&-C9#C;B6D/*(WS03SAD1D:$_NQNH5#HU0)-.9
M8EL0$VU^"G&ER6G7WMCTBH*7)V049MQI3KC*32PE:F6TF9&3BOW@^4)X=:1@
MVL)GL)KIB>\:I+N/HZN<S67:8Y"%KSF2ZX=Z@V_H:(Q3=S5P?AD)/A\9@/DQ
MU6ZF<?#MD7L9,913.PI?/.Z17:A(EL1E3X]5:@VGL\IF?3&]CLRDS851?>@&
M3<A]MS(J:;*[*K4:74$\6.0ICT&GQXC\E-/DTAV?9>T2'X%3<V2[$5!GTQAF
MH$;K$=Q&60\X=^30DE-+R)XAF8CETI/ 3B_Q1U2Y*:C9[,"S*%;Z%:A:F)&T
MW.7BNX88^U^6D;J:.I5.-$:SUFTFR!02P),A>G)M/H41B<CNX;$%LQJ3UUM+
M(6DJ]9FDB:J*Y'D4U<TT-*@(>A/IDH:)@F8]0ERU,&A:D*7.8C/I>:N-!8QI
M+56QLU1Z+"-<),MN1'J2()+=3/6S.85&6ZI]3TBGQ(B9!*0E:4P7Y$=3+NA1
MFDE'+,%!.-$=T-%I\0XI-DX>3Z#DUL.9/@!-E'<]J3X7S UO'WF&$UO WB3#
M887&V"LMG#5$Q-L89L$#&U+C6@F/OG^D<D59VI/1DUE671A 1%8)Q!N[#C+H
MLIQ)['V0DU1G-3,<S1'R\9QTL=2W4IWC<:D-4QF4JC))A>#UR4^;2TM',D(K
M45M1%(V,K%DHUO2")R03$EML\4D-J5S85T4G",G)I[(G8#;LCB1_87%:. ]8
MQT[MZ8S;3$%Y!\:HENTY*FJVD^/NW34T.LY#)"L<UVXV8$@&N'2$4?L99++E
MG3=;(_;*T"6HS27(33S4:KO.2W&X+#$^13:J] ;9450J4)MALVFD.RBB.292
M3>2IEG$([I8L99Y3LEU34YUAV51V6XC3LY^1 CU.E,5!QXCI]-FN/N)<=6U&
M5+1'BF3*DOO8ZB,XV1G@-Q((2GAGJ8% ]D;+EFX]<;NWUL/8[K;!2 QHEK31
M<CY'QY$6)@8C4\_GC!U,[02('Y%A'0\HFC,6!5C<-B"I^2/BPK;/VCK:&J[,
M7)BQ68,JGTV+%3";DNHEU%JENFM<AR9%C*2QLA]MK*N,L*6Z3LA_)-);7JF;
M,T13U!A-Q94MZ?%J-1DRSFN1FE1::[4VB0B,B'(D).1L=AUW)MNOI0V;4=C*
M.J6WF2<=&3QE@M]VSR+\9^0N_E(CI+@AMV*<>=?3:?@#N!'D;)-T139(SKS^
MI+;=SBPK& "#PQK(H"*G =;NAI(,!#3(A8=@1[6U:1L".[5:;3<M4+10GJG)
MCQG6S32VH#\5=S4S8>57LEQI1M2'&%E<ILUJQ35G2+(TB/\ "$EFDU.IY&GV
M;G,TN+(E-N8]5?J#$M%[D+9N2049MU*7HS;Z#QDNY,L;%LZ8=&=PQC!OD\?'
M')D:UYP(V]O(;R.'*SD?>12" F]%JSGC&#:/6#/!H'E&&\AIO04I?#T>I+%!
M_=F20]TK?!"\Q:RO/-TEM3;")5HX-/72E%'5DFI**@4>JN*2HS-;1T]3=292
MI7[M"KOEITG8?LE9]ERKNI<D.1;-SJBFJIV0G*.Q7*<<FDMI4DKD/%4$KIKR
MDE\M:,8R29_)ZI>).AH=N4*W'2595J[V/RXX=\6\#C5J@0(0B+;W,[.,RZ8@
MV;G-%M:5HX:L#B@2CI3)HN)?RY@X3Q[J371YE6JB_!<-31$:8M%KE8-LU&E,
MAZG(B-L,.&F]61/9BUN$6DEI947S3(^%T2FQY[1)>.Y4NN4*C$XDB4N,S47)
M;C\AM)F2<M=#0VWC:#0I])W7WBQ-AZ8U[WYXU.-:$Y@'BO(6'=^[-YZY GSL
M4(L=U;*TZ_SS(!&,3%E&#^VOT)6U:Y,QJHKOTM'%R1:PG"1E,B-4)1-U8I:&
M''J6_D[XQ.--O)5 B3DD27%/K0I.R394>,LEY,G"0C'R:<>53HN/2%1%OH9J
MK!N723;<<86BH2X*KU-I90M*MC$\DKD&C*&T:UXF57]YKQSMK79VH(DW=9;>
MSGTI%#L8J/7&PAT=S4D 8;A&&\@[]R1J%<2.Y'O<@<=X)H"%%L7JB#A-'.V,
M1JKLR).?-.P=C,K5EE$N03?[IQ>6-K)M*<)K$QC;3>:R+%(R,R$R*3L27 9)
M6SCE/(1D4FB.;G[UM!,D[E74MF[CXA.*N)N_&,C(A/\ ;Z A\E":ZV?%N,NM
M1SDQKR>8[,QF8O?\;UOI0U#-L1 836,:C0-2C:NTC;&/R=EJZ,%H27=IS8N[
MD1>T-3EFMI5)6O&3J;[3DJ(]5I:THDQSB;'<IKLN>V_"?4C)S3;9APVU.LJE
MO(D(3L=!-HRQLRF6CY.5,8=;BS&:/#0I<63LO9#=2:B4]<>:PA9N0"6],F.)
M:>*&RN.L]D.&ZYL<GHKSI6+/]9:%5U-L0]I?3)>%/HDQV3O00]WOJ"=K=TZP
MCO+H[ (C%6FT'&ZE(MW]9Q%.'P8S$SNG3[(M)&DXC+G8EY>Y'-DLJ-+J13(K
M4^<A]+ZXE.6FG3HY8LMRBMR7WE1"@9?)J>RTA#S<YLT-+CNE&R!*,\:5#INP
MI3L"GK8-A,NI(74H,DR5$:KCD9AA,PYY-94F,A'<8<@NI6XF0RJ3EC211OY4
MA]+:QOL[2\.&VM*(_N](G&\U8P+2*Q.!YM)\]>PXW.\EG,AECILWD^O!*F;U
M=HW3*PXRE\&@RS/O[,MI1G*A+V)/?5^Y<IYMN_OEFAZ02HR4OMQO^6R2E-2E
M_)(S-#R#RKA*R;&IK3=.A[+I\=/[]JH$MJ]E!+8C&F2I3#DF\W'S(GHJ+U&1
M8["RR39IRDB"]<C'&PH 4 * % "@!0!ZT.IS9>.<6]/F@,..S\LQTSJO-G$(
MR]BXXX:S5BD=;J),'LTD,4C"&;9%51\KD5D Y/)NU63046=YMVRWBRI?Q&?_
M *V5]^X/;5,_AE/_ -#$^X;%!^/G<WH3<@?KYQ+_ /DE6'<6Z77W#-O/</J[
MP^/G<WH3<@?KYQ+_ /DE2XMTNON"\]P^KO#X^=S>A-R!^OG$O_Y)4N+=+K[@
MO/</J[Q:T76VQL7D[KW8LDT#L#44/@ND-W0YX6G4JTN8N4D6PIQH P"8"V&L
MMI3\EV,!VN9&X>NR#-@R0[1HEBX46<X)V:+M=^DMWCW2+=#3?JNT'N<6X9[@
MF=4"0H 4 * ()])K\@SDS]']OO\ "U4CYQ<O88I7\T^3M(:'=7A9"@!0 H 4
M * % "@!0 H 4 * % 'I85CC("@!0 H 4 * % "@!0 H 4 * % "@!0 H 4
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MJ+26T8A"UHQL1:D8Z5(7B*-.,A7SD*N,L9*O^I)WD>V0J :62F.(/&L>DL@
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M69;'0Z67)!()1NF:E+,KDEBZ-S^5Q(-)@($JLQ&RN\=7)I8?]:!2)FT#T;D
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MR_N8H\S86_I4C[*A_>RAKRUV:.L H 4 * % "@!0 H 4 * % "@!0 H 4 *
M% "@!0 H 4 * % "@!0 H 4 * % "@!0!ZXW'?Y/^C/H=UE_902O%E2_B,__
M %LK[]P>VJ9_#:?_ *&)^';&8JPAG!0 H 4 * % "@!0!!/I-?D&<F?H_M]_
MA:J1\XN7L,4K^:?)VD-#NKPLA0 H 4 * % "@!0 H 4 * % "@#TL*QQD!0
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MRS.=,_IAF9J._<+FS_KAY*=OCTLM1_429?GJ9XJ?O+,YTS^F&9FH[]PN;/\
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M "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H
M4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H B4/B6J>1DSG4Q6$;+C9J!
MRQAI:>C5CQ6(#MBL=9/&^QHJ/D@0*963D$*8%-@D2@=-[88X-#Y!( I]F_BA
MU^'?A.HMH[]/FOT?E[F+ E&@N(>D!3'"<YR$<W.IBAP=^=D6P)*0(H:JOKF;
M12&BGC;(F[>/0 [1D*^"\50NM(Y4VC!BS9I)39:5NB0-)]9]YC"S%YT;Z& 4
M,@6DC9";BVPH5F] ;V9LG,8-C)3K43)G99]&D6(6"R!MS?)AX[L<N['PP^[G
MP]<+(GJ\4R5" ,CUG[Z^XQ0)(TZ,J12XYLF0*2MG(^]>&,J.NX-OL"M'<9.@
M7(Q$O(B3J%,WL (/+[H=/M;N7KV.VD!6919V$1.F!T&5$@O/5^6Y=W%[F+O/
M2C@;:+OXE(IEMSN35\8V5/)N->1CD6E*C4'Y$2<5/=KJS,2E"4STJC$[/RH5
M\(@[,:JW 9FFD=:-(_EBU'MPG3Z;BU%=HT%<8O73F_.)''H+/]>-MC%',E$;
M*V',-IV;ZEW$W<!3LD+SJ2OUG(3*,'GD;UO XM!RL3C)-R1=1**Z[UR''W/V
M'CV:RP#(]>U=HTEJ+W].T.!O"1Z"A&\"HB;:MV_*B&PRT6</X:--QAYJ?;<\
MDHN!:%C1&0ZS.;!&Y%!ZXN90S6KJ8S",L-+=^AHP8;++SF, ,VH1I,O-YM6D
M_P"N[N:+Q:!,#P+'B]>3.:Q_8PUIN(9L.\/UAC']M3)C&T)P8+Z@VE",8CJ,
M?,(_%N[Y_P IBT-=-6[]0>_F$_8L846?C!,;P$@T^CNO["O_ +BFZ^C'  4<
M";AU9>9R*4Z=UI+-[Q$@S#;!#"CL?B46<N9(2CA20QJ.Z_)FF<:WVC$Y5&PI
M)HJV7E <?. R<DA@MU%PG3JW;M>OBX_?CTX=8SSA]-L):.STEM:;R'8AB501
M[%GVS@9H6LUVO+=718N"CYY'8%QHJ,DS'21&"R2EU6CT$\PFHYCF@VAL 96
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MKJ1IS!U%4<RXL _2=#K/ ##L@Z13BX)A$@G8B52B8C(N$*R VQC>M=BW+,6
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M0%X,A"\P%Q>/3<@M+-;3&'MEX\=>!<9$)[D?%F*#IJZ6";CU;8Q1ETA.K>H
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M7KQN_?26;\6(*"L@>:RY88FW<E.6D'NZ<.\FW<-XO.&ZB:BPX58R"[WY#/\
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MRSI\8-GI >)DCA\Z9?OS!LR0?%"CUV_=N'"@0+JH 4 * % "@!0 H 4 * %
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M0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 * % "@!0 H 4 *
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M_=%2[/KGXUPIW*5*/GI(DW[;JGS]XZ>.L%7#A93,%Y[H_0?5&K8ZLR<Q_6L
M!.!HYN''+AX='1BS 0U/6E346R59#D,VHYM)\<9&W8H9)MD3V-C":6)"UG%
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:@!0 H 4 * % "@!0 H 4 * % "@!0 H _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g63338g35m07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g35m07.jpg
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MC*G O*A6J$B@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M92F"#7XN"!D'_*)^R*$&P_7KE94VVU\87=@=-CF8Y+@]*;^XJIN<IO9H<MR
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M4?H!'ZTOFW969YPC><O#=>3]B97FZ"YLZ,ZUUYV(H!0"@% * 4 H!0"@% *
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M;LXWSPRQ[/9QO:P%-Q]L2OS*A]N<4(RIP+RH5JA(H!0"@% * 4 H!0"@% *
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M621=ER=D>RX^3V"M#A;\&(SUN*U80=:?=R2.HQ>0%,CQQP;@:PC)P>W%^?\
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MV*J=+&10"@(YNM)[BO 3Y.4_I;JVKUNIR[2,5WP1W.XTIMT^^VS 9E<<V@"
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M9CP<5'.(ZV?!F40>8DGQ5=)=P+8 6CVV0T8081YNQ;%6X8@,B<'=R$6;D4.
M'60CITY?"9EQ]L2OS*A]N<4(RIP+RH5JA(H!0"@% * 4 H!0"@% * 4 H"R-
MF>YOL'R(E?F%_7G+8[$;4][D[]611WEF-DMGL^2GG\.<DU45%N@H!0&(^:/O
M:O+_ ,K.,?\ 4PC5E_4T-L&W&:)1Z,^*_NJ"; +*9UC_ $Y.<H=74E1 H!0'
MH?\ J;OWL:(_2_MSSVTK6312V6O_ +%!?AJ;0Z%6Q"'^VQWXJ$]-8Z,CB@%
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M?-NRLSSA&\Y>&Z\G[$RO-T%S9T9UKKSL10"@% * 4 H!0"@% * 4 H!0"@%
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M@;QAV>"X!]AQ[M'";;P85D?-EI55:I_;>7?.#3*(B*BUR<-R7IO7KC-WZY'
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MMH<B-6+:HRT8RS+I[;*2'05\$HGA)\8)M;9=@.6H=S';X(9J-8+KJX&;8S%
MAGX ?8G@WA*V&39"^?%I52E,MWAR'-A&5KA9*-8\B8T\-V_N&MR_4)Y#OI!(
MXE%.-0QZ783HQ$VK@X7V(T;0],*UY&K>#-HYM]9I(-)H8&Z.C4L$L8BH8!.@
MVT@;>Y1LTO'9#+N.&NYYEW\>*^[E.>ILY6KJ5NI6JX.*_%^U3'6J%H%>J9M=
M@LGF]X]!8<P*O(0.[M.#^Q6&6KLI?L71D#$&]M.&VK^\$P4Y'[?/3?7=HJY(
MD2,>UA(K%&[3/,LO%F&NXB<=W#N^ (Z3_P JTW*7_O8KZW4I>F7&EU?@D_5
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M9P5HF5$6_?3$;/5R.)N2U_RS?_H)?]O&OSGZ#]Z 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H#&D__P B<^9!GG].N3'[R>'D4X-8EWD3SK?R(:]5]CY"
M@% * 4 H!0"@% * 4 H!0"@% * ^5\Q9$V3L:2:-2 X@U<,7[!\W2=LGK)VE
MF@Z:.VJ^"B#EJY0441<-UD\TEDL\TU,,L,KVN!^8L6,!C!P4*.8B PABT%B1
M(MHW'C!8P>W3:,!PY@T31:LF+)JBDV:-&R23=LW23113P3PQQL!]U * 4 H"
MP(3JC5NM'4E?:YUM H ]F9.YJ8/(5#X]%G4J,76>.;E9&N#'L539&[DB1<=^
MDLW+GN[]ZMW3NCMQDHHB8DH2JJN-56F*JUH7_0@4 H!0"@% 4<U'H_)$&361
M PY]L-,!I"/;&AC(J@PD$=(MS$?.,D7R"Z;4P"+LVA4,30QP>C"+5N^9+H.4
M$E<0K3%P%8H!0"@% 4>0QV/RX$7B\K!!Y/&9".=AS\=D(QD:!'!!!#-L_%EQ
M!)!R/)#GK911N[8O6ZS9RAGFDLEFGEEC<#X8="H;KN.#X? (G&H/$A/?=Q48
MB (9&X\-N_>N"3Z[ ,&:LQS3)Z1>.R#S)!LGDZ?.G+M>ZCA=53,B(F(E55;U
M557?O+FH0;DM?\LW_P"@E_V\:_.?H/WH!0"@% * 4 H!0"@% * 4 H!0"@%
$* __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g63338g35q69.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g35q69.jpg
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M_\0 'P !  (#  ,! 0$           8'! 4( @,) 0H+_\0 51   @(" @$
M!0<(!P8#! 8+! 4#!@('  $($1(3%!4)%AA8E]76%QDA5UF5F-<B-E9VE):U
M&B,D5=38,3)!"B8G824S-5%UM#0X4F5Q<G1XD;&W_\0 '0$! 0$  @,! 0
M          $"! <#!08)"/_$ %X1   # P<%"PD' @0"!P0+   !$0(%(0,$
M!C%!46$'$G&!\!875I&5EJ&QP='4%5155Y.4T]7A$Q084Y+6\2(R"$)BER,S
M)#0U4G)TLW6"LK0E-T-&8V1S@Z*DTO_:  P# 0 "$0,1 #\ _OXX . #@ X
M. #@ X . #@!\H_E<OE%+7\FSHS7.VZCK6O;/.N^V!-<DI[&\9(1 !":?:[-
MVS@)6"%S3$8S5V(7J"2/&+N(F23O/UL,>N_KZ&49D:4/"<S*6G4I-&9"9M3H
MFY*39E#:,I>1DLPR;:9(B25,U55(BM'QE-J4RU%'?-9[(S23GC4XGI34Y.5E
M6I(F2.0EI7/(V&6C,UDB91$0S-1_/I_M6>[/JBZL^T:V_<G.R-Z"8^FIW[K(
M_$'6>_-/O0<T]\EO@A_M6>[/JBZL^T:V_<G&]!,?34[]UD?B!OS3[T'-/?);
MX(?[5GNSZHNK/M&MOW)QO03'TU._=9'X@;\T^]!S3WR6^"'^U9[L^J+JS[1K
M;]R<;T$Q]-3OW61^(&_-/O0<T]\EO@A_M6>[/JBZL^T:V_<G&]!,?34[]UD?
MB!OS3[T'-/?);X(?[5GNSZHNK/M&MOW)QO03'TU._=9'X@;\T^]!S3WR6^"'
M^U9[L^J+JS[1K;]R<;T$Q]-3OW61^(&_-/O0<T]\EO@A_M6>[/JBZL^T:V_<
MG&]!,?34[]UD?B!OS3[T'-/?);X(?[5GNSZHNK/M&MOW)QO03'TU._=9'X@;
M\T^]!S3WR6^"'^U9[L^J+JS[1K;]R<;T$Q]-3OW61^(&_-/O0<T]\EO@A_M6
M>[/JBZL^T:V_<G&]!,?34[]UD?B!OS3[T'-/?);X(?[5GNSZHNK/M&MOW)QO
M03'TU._=9'X@;\T^]!S3WR6^"'^U9[L^J+JS[1K;]R<;T$Q]-3OW61^(&_-/
MO0<T]\EO@A_M6>[/JBZL^T:V_<G&]!,?34[]UD?B!OS3[T'-/?);X(?[5GNS
MZHNK/M&MOW)QO03'TU._=9'X@;\T^]!S3WR6^"'^U9[L^J+JS[1K;]R<;T$Q
M]-3OW61^(&_-/O0<T]\EO@A_M6>[/JBZL^T:V_<G&]!,?34[]UD?B!OS3[T'
M-/?);X(?[5GNSZHNK/M&MOW)QO03'TU._=9'X@;\T^]!S3WR6^",Y9_[51NL
M]DO!R\2-6QXFG""928[%MG>6&))$</>>/7:3T=]X]9^MUUW^COOKT=\RUDAF
M+++37EF=GFLF?_59&PE_,&F,LD^:;99\AS0LYIEE?O<M!3(E_P"4/[.(OZUG
M_P!WE/\ J3KG10[]'QX,^51N@IA0V.I*OGT.3/!UEW8FW7>74,N4?67?70/H
MZ[[ZQ]/?77_AZ>?GA.?\;%(9"<SB0*@KF:*1EY62)HWM/B-HI.4:8(S+[M S
M14']J2/^%=R2LC)2ITM>A'*2<FV9$[IHA&VR31D7_&L48WYUB[?JBJW^8VW_
M $//!^-VD7 -R\KS[PP\OX4W)PN>O)TT^,'YUB[?JBJW^8VW_0\?C=I%P#<O
M*\^\,'X4W)PN>O)TT^,'YUB[?JBJW^8VW_0\?C=I%P#<O*\^\,'X4W)PN>O)
MTT^,'YUB[?JBJW^8VW_0\?C=I%P#<O*\^\,'X4W)PN>O)TT^,'YUB[?JBJW^
M8VW_ $/'XW:1< W+RO/O#!^%-R<+GKR=-/C!^=8NWZHJM_F-M_T/'XW:1< W
M+RO/O#!^%-R<+GKR=-/C!^=8NWZHJM_F-M_T/'XW:1< W+RO/O#!^%-R<+GK
MR=-/C!^=8NWZHJM_F-M_T/'XW:1< W+RO/O#!^%-R<+GKR=-/C!^=8NWZHJM
M_F-M_P!#Q^-VD7 -R\KS[PP?A3<G"YZ\G33XP?G6+M^J*K?YC;?]#Q^-VD7
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MHQ*$VR\)I(R\R(B(FV6Y=EMAIEIDC'1SKQP05\1#KRV225JX4NB[*W3N5^K
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M>G*$T7_W6?5__D@WR,GO#FB/.)T^+']4O/VQ'Y5AP < ' !P < ' !P < '
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M>S8NN_(_+-BW0O-ES#N]D;<G;*E%I:M#PT,!9L>DLZNH#W1J,)#7X@RFLC6
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M95"1A$R_MX[5U7X+8/HYI7=F][AY/V70%C98D*]'';(M6P[9\VE(H]_H-_\
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M"@R"96\6S/$U47S3QKA,V,)X"YK+A6WWPHA[75[?4E:M$-6V&L8_7DSJ6!A
M+VGM@[$,K'JR8_,DO&6@E-KJ103)+?/'CW@MSSM8^(Q4P,K'XBN(@LP.;&L]
M3N8&:?=C!8:ME!2VQ-.OO%5@[KUNNM+I"AI#Q_7-KG87=I9KH*Y/'V(8WMM=
MUNLCJ<+89@*R0=K@PEM6%(D3JPURM,3F(,G= O&%0ZUJ2JR!GT)QXJ,K%$K6
MLJ^\D@59U+C*:!Y1T:PI*]8<J*Y"LCNE59PMIE5KQ%CN"NIF4"K[!;]%9"
M#25VLCVQ5C#DO(SQ/D:I P%GSB;CH^1-CA:FK6-+#4J%'^1LAO)3QX0PLFBU
M>0NK"81XUANBNB2C51@6CHDNS6(J1F*)'(8RRH3T^R0D1C1@D"%N1NF/Q'%F
M%@0_I;6G7 %*VRW478?6+SUK8*I<*]W<*FBD1BV$\TDWWA.(J,9'CD2"3LIR
M5^1"]]$5W%[0-^M8MEK,7*.8)D3%WZ>H=UP$9'$A*@J\@6Y]RKD:<"3LF0WN
M0)8$+GV9+[][4OO.""/+WF3XFR]I/Z?:Y_$#O6S[][(]H%'CC6Z[@1T9@@2X
M%]*^D?16*H'$CI+CUZ,4_4_4'4O2OKK]'2_UO=.NOT=0\ /3#4JJ/)+*/6:_
M!+/&-#/)"F6Q230AAY+@XI<\!L<I(Q5^>8(V&??>, >>0T76,.7>'8![HJY7
MH ,5<*%+"LP#,78+HE8,8&*]A)C*>#B)A!T/B&=+AA*8-U'U"3)ACG-AGECU
MWT 942A5"$*MA6+XEP.,6 0$00T80>$.'<<. HN,?4 ^,4??>$6,,>'4>'?>
M./76/??7 #(A$$&R[R'%''RRA@'[RAACBR['%ZSQ%@[[PQQ[[A&QDDZ@B[_H
M0]29]1XX]99>D R. #@ X 1Z+^M9_P#=Y3_J3K@!(> &JE1))V6+F=,JF;XP
MPC8M95XDC+$<<CHL<?$[.'LKJ& OKHJ&+J7V<1'74V&.,G767 (/6/7*\)#,
M.(A3"P$YL)"(!U8,,,\C;U?BDDT<<&.$N;+U,/B&6>.61GJ8^\=R>KUZ #UX
M5>LQ@9JXZZBC62!R+I%V"A?B!FOEZCQE!S$Q'Z'R#DQAAZD&RC[ASZBCZRP[
MZPQ] !D%(DARV),:F5&*(,1<8512\0A;#B%WAD%C$#-#F+'B)E%'V+UA%UT/
MW'AW%ZG>&/H+;:"%<&2%'F88QS3*LV#$6()@=DN#R,/"@[], AA7</<Y0L/?
MZ8AY\\XH^_TX8==\ / ZO(&?773)&G8=8E9'=='+ B^NCLQ?<<S.O>()/05D
M%_P>1'7^^R%_X?O/N'^AP ]F2-+D1"7DG5Y%#9$9CDY+Q.R(,RSXFA6<,W</
MM(LB6<,+$C+#+'N8^&(R3O(B/"3H _ T2-?WGD F5 Y2,2&^?8:X0;O-L7#(
M.4TS[AAP[R8DCS30$&]^DF:&62*27+#/+'L"#\@0(A3HF@J52,RA P50L8%H
M<)T2N/+K.-;$7'#B1&!AGUUG@'C)T/CEUUEC'UWUUWP VW !P < ' !P < '
M !P < ' !P < ' !P < ' !P < *VHFHM?:U<7JPT]',"_V6^PLEX=L7MAL;
M=\S@CE@!PF965LX,$4*!YIA4-=73!U] )+(*E5@#YY1]@%D\ ' "-W*II;Y4
M;11['#,37KC7G-7>CC%3@D3IWZXA6RA@,%SC)%EE#*FPC(@DPEBRRZSPRZRQ
MZ[X 46#XJ:Z69'&+75]5OVA+*1I9T]EP2.RP'E;JM3?HX/@RY>J2)7*2C5".
M82MJTV:YC7ESU#.H>QYLI*I[:S[>]1$_G3HAL5PS_HPZTC8PG@36U5AE;%MS
M<+EUF+A769VBV^]WG7L[!#)A-,4.BV'9GC 2$4@+LQ<;BF=2-5H2^ 0O<O1U
M E43A8M\8WC;T[Q\HM!8)"ZJ;;E("6!'Z]='LQN%>>-*W4H:*D?V$''K&9JU
M"J8H"C+"0K!2;BJ2G,59;1(H."*9[:^O:L$[+;ACM_'2B.2W4\[&Z"A-7LEO
M#1+K6> BKEYFLJ6YRW= O@ZQZBL.5MKZVQX?$I&B@=IDTF%4P1OW\3,NV"(G
M%KXB!-M(!>..MQ!7\,N#]B9;!1(;0X8NYR&S\H6YG7WXF>1A'%#@=-86$^7>
M(0X@ BR,-*M!!4@AB01=MM (E]G1_/<,-;XR:V6-U37">V%1UV5?\U$IUC((
M15-<JM0US 1H5_LL.H% ST6+.*(J4PK%;@,DQ+Z3+5( %4^^%=G4>QB9I*MR
M)JVM4:M3XHZVKZY8'7VM]1GIU(]< LBRUS#V2*JP55%2LZOVQ[$SPS4DUNKU
MH.;/(;MI&8@4O V0K\*%IB4].DL5[3%0H80U7"21^.6L14XB)0&\KRY8X9O$
M^-=L39*4D.9ZYSU7WVH8 D1'@Q@U#/$5=C$3ZPQ<41?><F?66.13VTKU@A?Q
M"Q.H336NLJSJI"8AK&)64+1ZTLS<PWL/$EF^<YQ9,&,HRL)6G"RGZ@@Q[&4*
MEH/IB[G]U[*G)GG&:]0HL+D . #@ X . #@ X . #@!'HOZUG_W>4_ZDZX 2
M'@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X
M . #@ X . %*;RB\BY:XJQ\:S=* V[IWAV\DWDKO36N9USW WJ3!5!0G"9G&
M[^)]KLL)3")0.@,3<,H>R,X,\.>[S=A2K?E5F?M2/V?_  R=[<W8E?M<YE#;
M.<R<HP<GF9T&2)K.S8HI'P'@3T.28\E-3!F7^T+[0W@Q.&Y+[+-:7,*;-R;9
M2F?F(;1FSFYT%0<O^Y_*N_VB^3T_R9Y(?CSGMLZA_P"527WAU^%'J,VF7YM&
M?8/7Q >Y_*N_VB^3T_R9Y(?CSC.H?^527WAU^%#-IE^;1GV#U\0'N?RKO]HO
MD]/\F>2'X\XSJ'_E4E]X=?A0S:9?FT9]@]?$![G\J[_:+Y/3_)GDA^/.,ZA_
MY5)?>'7X4,VF7YM&?8/7Q >Y_*N_VB^3T_R9Y(?CSC.H?^527WAU^%#-IE^;
M1GV#U\0'N?RKO]HOD]/\F>2'X\XSJ'_E4E]X=?A0S:9?FT9]@]?$![G\J[_:
M+Y/3_)GDA^/.,ZA_Y5)?>'7X4,VF7YM&?8/7Q >Y_*N_VB^3T_R9Y(?CSC.H
M?^527WAU^%#-IE^;1GV#U\0'N?RKO]HOD]/\F>2'X\XSJ'_E4E]X=?A0S:9?
MFT9]@]?$![G\J[_:+Y/3_)GDA^/.,ZA_Y5)?>'7X4,VF7YM&?8/7Q >Y_*N_
MVB^3T_R9Y(?CSC.H?^527WAU^%#-IE^;1GV#U\0'N?RKO]HOD]/\F>2'X\XS
MJ'_E4E]X=?A0S:9?FT9]@]?$![G\J[_:+Y/3_)GDA^/.,ZA_Y5)?>'7X4,VF
M7YM&?8/7Q >Y_*N_VB^3T_R9Y(?CSC.H?^527WAU^%#-IE^;1GV#U\0'N?RK
MO]HOD]/\F>2'X\XSJ'_E4E]X=?A0S:9?FT9]@]?$![G\J[_:+Y/3_)GDA^/.
M,ZA_Y5)?>'7X4,VF7YM&?8/7Q >Y_*N_VB^3T_R9Y(?CSC.H?^527WAU^%#-
MIE^;1GV#U\0'N?RKO]HOD]/\F>2'X\XSJ'_E4E]X=?A0S:9?FT9]@]?$#V0A
M_*K^VB]XL/R?'<'M,/;]0TWR.ZF[A];KVG47>=ZRPZD[P];U.\\>\>LO1WEU
MWUZ>N0VJ((:25)%0T6<.M%L5)LJ+6*3-,5)96C2*2I(/14M19PBI4.YHOZUG
M_P!WE/\ J3KGS8^E%.R0^5?M)/9,?'SJ+U\O9=2)MC]R>S];OU/:=XONL>\_
M5]'K=X]=8^MZ?1UUUSJUN3RUYS69.\EN9G'F9[OI8;6:IYN<9/,B-I$5"(E5
M"0=A,MY*<UG/F^4+/S2SLV>T<S<Y/ZLU9@N:JHL4K'A['RO_ .8^//[EV3]_
M\S]GEN\[R5\GTM^9BY^2?S;*'[[1OP >Q\K_ /F/CS^Y=D_?_'V>6[SO)7R?
M2WYF&?DG\VRA^^T;\ 'L?*__ )CX\_N79/W_ ,?9Y;O.\E?)]+?F89^2?S;*
M'[[1OP >Q\K_ /F/CS^Y=D_?_'V>6[SO)7R?2WYF&?DG\VRA^^T;\ 'L?*__
M )CX\_N79/W_ ,?9Y;O.\E?)]+?F89^2?S;*'[[1OP >Q\K_ /F/CS^Y=D_?
M_'V>6[SO)7R?2WYF&?DG\VRA^^T;\ 'L?*__ )CX\_N79/W_ ,?9Y;O.\E?)
M]+?F89^2?S;*'[[1OP >Q\K_ /F/CS^Y=D_?_'V>6[SO)7R?2WYF&?DG\VRA
M^^T;\ 'L?*__ )CX\_N79/W_ ,?9Y;O.\E?)]+?F89^2?S;*'[[1OP >Q\K_
M /F/CS^Y=D_?_'V>6[SO)7R?2WYF&?DG\VRA^^T;\ 'L?*__ )CX\_N79/W_
M ,?9Y;O.\E?)]+?F89^2?S;*'[[1OP >Q\K_ /F/CS^Y=D_?_'V>6[SO)7R?
M2WYF&?DG\VRA^^T;\ 'L?*__ )CX\_N79/W_ ,?9Y;O.\E?)]+?F89^2?S;*
M'[[1OP >Q\K_ /F/CS^Y=D_?_'V>6[SO)7R?2WYF&?DG\VRA^^T;\ 'L?*__
M )CX\_N79/W_ ,?9Y;O.\E?)]+?F89^2?S;*'[[1OP >Q\K_ /F/CS^Y=D_?
M_'V>6[SO)7R?2WYF&?DG\VRA^^T;\ 'L?*__ )CX\_N79/W_ ,?9Y;O.\E?)
M]+?F89^2?S;*'[[1OP >Q\K_ /F/CS^Y=D_?_'V>6[SO)7R?2WYF&?DG\VRA
M^^T;\ 'L?*__ )CX\_N79/W_ ,?9Y;O.\E?)]+?F89^2?S;*'[[1OP =0^5W
MIZ]+'QY]'_KZ$NR/3Z/_ %]'_P!/\%)Y;;9WDK2U'?2WYF&?DH\VRA^^T;\
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M4B1<=L"755K'7W,BAP < /G9!\H"+%)(>[TO:$]08G>25>I]J^=5:/CLUO\
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M/+!>641,8N@%!('%AA]W4!5='%#;8A:O(*' !P < ' !P < ' !P < ' !P
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MR0%7%<[";H83++#&7D-HST$J%IVK!.,Z]0Z*Y!0X . #@ X . #@ X . #@
MX . #@ X . #@ X . #@ X . #@ X . #@!'HOZUG_W>4_ZDZX 2'@ X . #
M@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X . #@ X
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M";6XN<ITTW?].=7V\>L)>E&?_#8CYQC=?[N+'ESCZ"9U% 0B(JA48/R>WCL
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MUEZG>?767J^MUZ> 'OX . #@ X . #@ X . #@ X . #@ X . #@ X . #@
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MFYOMWV_^,^-YZBWI;*#_ +F4]_<(;Y3_ /1M#.8=#_DH?1HH/]I-S?;OM_\
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M%57[FR.GI]FU&2\5[ 'U6T]I2K1!LGX[8M<772JD%6_46(RIB"UY#;J55+6
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MM  9-+8UIX17V6(+9NS. 5M ;G'LI6)8>%H)MIQZ/K$>$7AEJ_"PU^RS,W[
M^OY*8(\FZ;6;B4I-7;Y8=@UI#BS9:\*>(PDK2T.%G1]4:5^P.4<T MC<N3 0
M& T4XXW;)&T"(BVZ!Y;'HNJ6%NLV_P!E8\S6^FQV2UJG-@1BHQVPE,(]:KM[
M('KNQ;0AKSM9<%A3FJUMHV0M3IEIN-0<M.S5[1%$OTW_ $N4(1/NALHP=;^*
M=0!U+3ZRY;V:1AWJZRU!V<,1..05ALA]5[I8"9/G6AZL79ZH^M*DJ*2P""G
MH!>@&Z?$R.+ &FT:KCU5;$(1$FH^FNPNH1#9FJ-<H-I-B+?M=]5:EMVOO!K;
M40_AY>5GB<VM#'8![(5E1G'S3UMG&4HKA%E[=UHL0NR2K<K-"0S!SB$9F1$1
M5;<=9I;= $BJU]FU=9'4<1/\O&O7G3]_7HMD7B">Y0LG-QI<3"D]X6>D$[3M
MNQX*ZQPSIDCP*J*[EL2[+P6"ADJL1:FS,5#2Q-,PE9"HIPA557628Z,,!4Q/
M;;O&;9],:BU_4\VUGLMJ65Y4%KZNYFYS"G$9Y)-R07ZIBPB+:V48<T=7MP&@
M]U!"FF8!%#+@1H66?1^44SZ>DDZ"+O"K;6?'_"#I! ]6V9."]3YE2K6,64PF
M9JUDH*RCPEDAR[F6N! &0F7M(\^NL"Q(),L>L9,<>X\\,LH*-QP < (]%_6L
M_P#N\I_U)UP D/ #EW;/C7K6^6)]LB\-;1C#U3K0F;!* JYU/C76]#L%-?!"
M/ *<7LS-60D=FLNZ<OM$M<,LPH#K&N$-.I_?:1H2;5KH[1$BNU2:>(Q'#?%=
MM)<!+*#NC8_4[G&ZS7VTD]Z\CM[:2QTO7-$6K5(0NL(Z@O40HZ$-*9E$B$;0
MM\1V8ITDLI6'*L*BLOQQ6T$B1K?T]W80T"[Q=I,S&Q:TM5[L&2DPNY7#7FMD
MA2B-93ZTVJ@.JN[&&8;4,WDKY>A:MD74#2P.D4/SC-,C5SF20DA%M32=\5VM
M@"6+JPJUZX"Q6_B;K5K?[3L7$ILK=6V5X>=\-4:^Z(#>V"BR:].=KK,?1S[O
M%EBDDS*@0DVDNH_&<\V!%>(ZSS@[9QHG?>M^Q A1QKJ[OH(%6?$C3=CK-//K
MEOL9]; LIMV2S+$VL5:_%B0?7\I9:F$!K1=!K'K"2J1"YE:H&H3,WXE8#F1Q
MSAKFUC*9+?4?5?'6N$ 0CZ]&B[H/6)@/XBT,59\W!K;L&*GE$UAL]J/1U5R5
M62S4M>"NJ]I:F9U')] U5Q)*O-[JF<*D1I520R')R,.FT3:+@5M]M95XGCB"
M51,DVV_@6"MU+04N;RJ32.6L5]U:DH#18TQQ) ,INO5I=9[]<H-4,*,Q.$O/
M<3&,HO')EZ_ME*^& !CZA3KQ76?\ A1QKZA7]0\/M7TPJ(\!M>&#+VNKSS63
MITL.,:OM9&P,,K.PSP1#QY6'89@":?91PL8N#^1 ER7P),@NN\RGMKZE@"%V
M]7<N(S$'BA0T-.#I75EO30 &:C20GL3:SBT]CKNF1T&LB9YK:JN R@@KD T!
M>?N'19A(^!<A/4N<_MKG&JU6=*V@9$<#JVA >ZD:OU16[(GKE?L=E8/M=7V:
MU9 DYPDXBV*;2*K7WP]T4-71@\!)* _5.QA\"1"9VY>)$1<HL1"F**?&7:O6
M"%#"KB$@K.J JIN&U7J/9>QG#R^1SMF=8>+J ;7(4BW&%8J0++ -K02X*J[6
M9SO>T58CON,.3(YL[*#9F,WQI98(A=/>@:ST0[E&EM?CGKHQ1V4V?6Q7!776
MRK\(X$/48DHGUWV,HW&8_'ZFKY8\DM0N-;5,ZN.6&:'@,%T&_#L<<LW4A>SH
M).H$[>DUZQ Y_'36=G('(QW!L"1[MQ&W?V%@,?01V^VJ]V93&?1QH,] R'7+
M:T.-45 F=.6UCV"<T4%UDP+.P*[N<=U71A?&U:PS2CC6>T!)7'C+K>ZC5U+F
M^MV VL[78F$./8%4D,P>6>SA[)-G6/7U',;(#!YV6  5GUPRKCB-.:6I(>DL
MA,2%\7LZ"2_KZC!$(BL+1MQ#;V'7FO-B/Y+Y!=;9$G;VNK56UURO1KI:U;K5
MI/9#C!,$^][JC.R+<J_>%[!2Z)0/*\N;"*X@G,YBN/K*4J038RTW"[<0VK[Q
MVI[[6%'U1*XL4%<H1JHU9)+#4GF;;X2N:+( [4EM%5>TZR+\HFTQGN3.L2CC
M.0U#L# 1HH *A+$SOT_R"58"Q-9:^2ZIH58UW72&):.I+<52R=MD!FPS$PFE
MECZ)R5KU2_UH_:]Q8="KQ8L8L,,>H_3UWED,U-0J$ZY #@ X ?/\?4/@=9=L
M7=J!=*>SM-)M1FWMEZN7;V9R4"NWI";'*TV;=],BW3YDK7BAG'%.Z=.:W",*
MXQZ,;88MLLI\M*TA7' C2NQ"-%U*(A<4:^DR&G86'P!%9:AS$O-*LO6V/(#<
M++7[.L;1Q=)S-O[0J5B"VD06T7VOH4:%@LN62&-9U/G$L?7.I )%PK-NER[J
M-Q@<&252_P JD967QT$=@AFS",%.J\UK.RO8A'*O0/!3.@U:P6NUQT9MNEI4
M6E*<[)\F/?=I_%M2LW*:A84#8H6T[#-A+4B&;,5?W2[4=AGT^G5O)C"39P>/
MZK%,BN*!+>26XD"%#%#)46S8Q>*"M>(]6V]JU(EVBA&W7K!5<]<U>L3[X8,K
MXX#LT8-KME8NM>8W QW>BI)YUER[ M8C0H WI6^$B@]S72CQ6DJ@<:KH0--4
M!4)<2QZ_J)\^\4M)639W>V6U<;RV6>Q5FY-5D%QMX=&L-UI0L 5.N=DUZ([A
MICVTU@442)0Y9)""H,@@)I,I2  I1V<:(L(E94=9+7$$+91:>N]<5'55:[J5
M(72JT7;ZUV7L28XYCG\8NMG;7"QD^\L2"2?5-?O&1F _M?=Q,)\11(X1888<
M(9F9J=?<2 1(2$)SR"AP < ' "N-QU-Q?=1;4HU>*%!?W/7%XJ:,TT@D,(-Q
M8JRT3K"BRPX"C!11S3()2"!1B"8(L,Y8()I<<8\J4#(\0'%MP\.K3/?;6=1Y
MJ\BJ#(0F&G1!,D%?QI::?4!-&-H42P?4;FTD5M]=)V-P;BK-FI:\:1;GSHVL
MS619'/9-$U?KQBJUUZCJK092*Z^S:.I8C4//$#;3)X.=E9U) 7O!N*J,.QKE
MQ-#/(;5\W&Z5TNQZAOA\#Z4);E!E)4SJ*[%F1)!(;'*&V-)0PFB*R[7!$K+&
M^NH#(SN3&^,:CZR%^KO']LBU7%0ZW#4J^;](I_MDCX+D8F62UIEY .MD B]R
MJ%H1GQJ"BDJ$>4,<<,(Y8$:L5KTN$%/X6*X)T)UBF4$T=!B#ZW\=-DU+0>]=
M4RRU%.??J4\K])Z 9C$]@O6NO"*K*TLEBK.N==C&#Y-.@.Q6WS*+N<RT+MG:
M7EB>%>S#&9*1QA7QV$I]?$(1(I66%WP*L:RS>*CP9]99*M3M6V+7C$VTSH=4
MV%NTK=54/K/K?4]9$V/'"NJ%A$$ME=L-&MN>&8*[IC.#?W5F$>#V7N8(\35Y
MG9&VV'3] ,CP1*JK[M4.I!+JWH&_5+4^^:,!E1VEJV,PB9 6P^<T3N[%'T.G
MU^S,;W$(CSF7MFC=18B/;927 ,K-M&>U&.AG8IYBD9D=W>9PT:M0L8U:4KTE
M?T5:!5E0\5-F5PN61M7]6W%-\<MI5/K+^QRK5NK);%WK8X&Z5T6A:KI"."S!
ML*Y9I3!::CHI8Y$X>::T136.R-8BECCC7>9GTGH$(CN+9,"*PK"1*QN%OB)<
M*^+5(ZDPJ%/8]"H);TZ0SL(#G5B2[2DN UBE]1-!V_8JD!K(-3.WE@ECEFQ3
MX9C*O5EB9T(Q,EXD1!4CA=BJJ(_3O$K<]1IK'*NVM)5]E X40:M,^K"O8UR1
MD)7;O1MC75@'5-1:XSF=/*Y?IW0DS\:UV2RV6DT>:W6C'I4*0"-HM-]]AE%3
MM*Q$BA"(=Z14K;(W+KC:H\"/#/80+RXX5RP+ATQ UJ#KIY-F!"E?4P]>J7UC
M4-NC6:F^?7S06J0,*J227M&TKU2U4K>HZO(P-G4*+G;8WE%%6-16DHJ'>F@B
M[M5?<+9%\<&9VE-WZW,IFL:Q'LV_96RNTE25,ZI%?7X*Z **,1G/4E$4!>+"
MJ&L^QEM?S7KR2!XU\N<46,D<SHD<30M=N.(SF_TF4"4UT5" ,_$JZMV$P4J[
M78"B6VL3;;8!73C)WN&HM?(C7VS5Z*ZJHZJ+ +'3-<UEU4$89#FP"ARDBU^N
MR5ZI'LHXRECW0,H1M.(J5%872>A+*^(7SOK5MTN]-$USKQ13%E9S21KEYDUB
ML5.FH;Q*2MRI[.&OUU2R0; I*6&&8EAJ^PP@5UX2J3*671*@XJ9/".T_YUV:
M2B*903#Z5"-[UT+8]@W^"Y5U-16/4E'K-8<8V0XI4<Z6U;;]6V&PH9Y859>3
M2TZ_U\&PUEWU)-*(-[[U$QKUA4LF(G5(R1#6M8:.PTZ0VVPU#*'TE8H]*$45
MA5Z2UDSV?\_%VM8KC;T-,K=?@V+#<4U0KUMKRU4U$RKD0PS-2/W6\:M@[BZK
M_P 'BK&,!,$6-9W+;4FT02%15P+6OUZ!<NFZI9:3KQ/7+:RZ9.1&%H,ZZQ=-
MK)$E3N;8\=UNHC6-[",ZL E(K;%33@WC084YL,CB8$"BR$=CQ#-37;$"JV^@
MM#D%#@!'HOZUG_W>4_ZDZX 2'@!P3O+QLV9?]BWJTTR:H+X[=KRX5'%Q8&^,
MI@^+S3UMHR\,&*#7I-OKV45J<*6)&"G8\M%F5?$W9&NR+Q# T8:(R(N+K([^
MQ<4@,I%4(U_BX^P1W8/C594JFP71:&C(=E/MPN;OBE&LK1UL.EVW<53OE;UZ
M\AKU;9V1S73:HC856S+5ZQX2B!=.)*NALI!,P;!G=B+8A(??U@AVXU'&LC+M
M+0*\0>-NRM@U]X^2(4>KT3.V6&9?KGOMFD"956'9U(?=5Z-5?M4D1K*NX755
MF0(!9]8XJRY^EP$E3QJS/HR&F9+Q1Q0[CQ*T9)DXG8<"*I(W&79&N!CI;'0]
MN'TOJVBF!5NZR4G8#:W677UPL$1%-MU::3[ S5T0QLLUXK4=J*//;JXZK"V'
M6B^MP%Z_0) TZA;$(:#%B9])5E5CVVC:0+IT(>'0A%H%/T_Q+V;7U]<5DAZY
MC:KRJ"8!L)?;K9\YM:UVK+(0[+J>DY]50)L74;C+ RB*:X6"M$3CWZU,&"C-
MFC2XMAG77;"PU6)XDMQU%$"*'%T)W?01/'PUW#\TUM>RGI72%6RM$XU%'=TT
M> @]_2Z=7U]O;OL_'$NHF.:VQKC8-0Q7ZD47?!%8B;$5=R[5B6 PN<2K;?&\
M[%XXI@(A\4"J(TA5!%A"J!V#IK;6A+=L#O584;E<U55.G!U:YY61HR[-L_76
MY/&>[M)R.Q5DL3+)K5-1W@(R4KW/(AFZ7"918!,F)2Z$:+C=H,NT5*K<>+^1
MX-]%VP31EDU55PZ7U ;M9Q8E%>FDQ&K0.N&6VY+M'6EHIU8>U\$P*NRY"KT+
M:H6*D1G88*#U1R+//+HL5P[$O[1$-#*%9IHNV(QJDFA+\M\=JOJ]OA4;&VKN
MSG%N9U UOEA1[51I]NV:YJ->GL%]$2@0+5M3;)08%@6NUM3^(5\1!#7U]5SZ
MQ&+%8]M27]NL6RKCTU]M0K(SQ+V0RQ?1X8:]K*M\0;EC54%DMLZ=,J,JNGT
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MG[>]6?X<+\X,5.2'IM[/_C.D^1F+#)=U+Z?_ -%[-PQ)[C]'_P!;CUEZ?T<
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M,*YT3TFPP"Z*=Y[1ZQ1)&FM=?N^V/;FFUQMTX;&/&T;)4(="S;,*-WK,\X^
MF.2$N8W7W>5.*[GCDQGKV62R7'(;+O#N+MT]8"LS_%[2C%S7F1-*4R 5];>
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MO-K]ISLO^%_Q4_EWQY6</!.:<K/CQ0>27]PLG?)+G\*'T7O-K]ISLO\ A?\
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MN43UPO?F;0KY4&ZBA'JQ=G.BE?S$.M7[L^LY9^__ )=ZPU3^G_Y?HKG7?_\
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MT]K+15$)/-V!D;#)-2]!IMI&EVZ1ZK/Y9:QJ%W?4%X-8(':4-G,-A!E5"R+
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M ' !P < (]%_6L_^[RG_ %)UP D/ !P < ' !P < ' !P < ' !P < ' !P
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M_7L;5/HZ_P#GW_\ %3C?'?GJARG>SH-^]PW#NKUDT!]K2O\ :@Z$YVH.O0X
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MI/M;@Y8H+&K-1%8&"C2VVS2**YUW/')TT[B[]IPAQA58<#XC$4A=7(*' !P
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M8=98]YY?^7'K+'T]]>GK@!Y^GK_[^O\ P[[_ /'_ -.O1Z>__P"'7IZ]/?\
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MAIH&%AH%EO&B/RE$'R$&;<67VS$UFSFJPIY8=4HZ 8NGQKT=SRM&?M>,TD7
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MAF'EQHSYJ25TVPZ!PMOS==V%<;2:[$U$FI=::B R72B;%4>L=]\R*' !P <
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M !P < (]%_6L_P#N\I_U)UP D/ !P < ' !P < ' !P < ' !P < ' !P <
-' !P < ' !P < /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g63338g38z28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g38z28.jpg
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MMM08&24V-T-$5F1R<W9WA9:T)C,X14928F-EAI&RQ(.$P^&AQ=+_Q  = 0$
M @(# 0$              P0! @8'" 4)_\0 8Q$  0," @8%! @.#@@% P4
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MCQD!.M^^I0LDI3$QJ@N(](MM%U<861JS(M>-('>32;5LW*H24B57V<CL]?\
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M0R,6QA;!+%3)8UU&T(H\D(F*>Q<<G(J(JBBH_>MB B0SE4R;;]=QD2,^ 3,
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M ,&4O])T'Z=2EVTMG\!\-FE?F_K8GOYEDC?9#]%@ !O5;_0MUZ_Y*G[#&/\
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MH\76F:S7:.U5]-<A1BAJ:*J,U+4Q5%MK*<9/T=5/"9)G,<Y[H7TW(\38*O\
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M+J0L[(%F#)]'1LW&P=JFX*#ML5'R3EZ^80]TA(V/MT0S=/Y!5K&S;5 9!^!
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M_J_Y5:+Q_"#P)?+\I_F_Q<ERI>+JCXD?YY5?Z9X"#XTGYH4WZ_\ *"7[X_\
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MVM_Q7?(F8ZQ\(6SNQJ0X;2.G B0P!_PO\(E$ _K#M'RB&=R>Q^8\=+N$26.
MSONTM('^C5YXD+K+IB(_8XQ'M&ZT\?\ ^\MB]WT^8OI[<_31F_EXA>%#N/8>
MY6R>,'3U#DJ@4V2LW<_ *)^_EXE6TN;H+U9/'QY>*T4P<X>D.O)1O':.]8.X
M]A[E/DZ@5Q/Y>CMRPJZMAS!Z ZLDCX\O%0'>>T]ZD)S]':&6F>B.?>5&_=S\
M"L@CXG2.;*)72?B_F]F21\>7BHY.'/P5LG/T=H9:9Z(Y]Y4#]W/P*M$YNGL#
M+2K2<.?@K)/%#IZQR<;AV#N4:NDY^CM#-V>D.?<576@FU1!UNNZB52YU^GO%
MM1)2G7>0D;#%ZX7K0XZ]>@9O2>%?HB^I,9-&LDXD67@WJ+"8CE88E;KTPO*(
M/U6,.1K8;NRX9C(99[3GW_/+:M';-O'+>#EQ'S^86PVSBH[-IVX0E6UH93[&
MYW6/L;*XW-"^S[6;9V%XB[(XL+..B62S-4A474.BSCVR)8=PP6,4ZZZRA\'?
MLRY;!N66[OAWG/BN^LPMDPB81,(F$6.9??,Q^44OT3%X19'")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(O('NL'WEH5^ZM2/XJC9X*]G%]3=&GW_%O]GAM>P/8G_NN._O>&OZU^6IFP
M9_95M/\ H^?_ ,HZSG2/L7?]-[W_ #6J?[UM*[9Z>?\ 12U_SAI_[MNB]:R>
M,'3U#GNGWH_![PO)C_1/+O"LDY^CM#-E"K!.?H[0R9GHCGWE%.3Q@Z>H<M*)
M^_EXE6">,'3U#FS/2'/N*B?Z)Y=X5T.8/0'5F[M[>WQ">\_!\%83YB^GMR9F
M_EXA0'<>P]RMD\8.GJ')5 ILE9NY^ 43]_+Q*MI<W07JR>/CR\5HI@YP](=>
M2C>.T=ZP=Q[#W+'3]BK]4B'M@M,[#UJ!C4A7D9N?DV4-$,$ YUGLE(KMF;5(
M/E4763('RCEVGIJBKF93TE/-55$IT8X*>*2::1W4R*-KGO/J:TE4YIH:>-TU
M1+%!$P9OEFD9%&P=;GO+6M'K)"\P];N[3;!>BW+F,?J3(:S6)IPR=Y-&X8]F
M9G5+O*F);E(N(2B.&YU W'5C;+(JII@94&RF](BO;%CZ&,>7G0?);8[-3OR.
MOO,PIG@;R#11MGKVN W"6EB:3LTQDXMZ^NG27A2V:3&5K[E,W/W.VQZ]N?#Z
M9>Z*D+2>+)WD#;HG9GPG8:[JCJEMO:ZEJ-9V0K54]!RQ<ZI(ZSNK*\EV5=D8
MI@Y=QB4TZ^"D36U'4^]10A4*Y%2[^8:.'??+CGD:QD#M_IXTZ+;9@FQFKJ<6
MTM7?3)3B.SMIF0OJ(Y)&LE,+?*IJD,@8YTSJF6*.%[6:O)DKXP[Y^&<=5V)K
MIJ(,/5%/:]&8ON3IG2,A>QKG1B5WD\<.E*X",0QR/D:YVGFYC'EOM*3GZ.T,
MZD9Z(Y]Y78;]W/P*R"/B=(YLHE=)^+^;V9)'QY>*CDX<_!6R<_1VAEIGHCGW
ME0/W<_ JT3FZ>P,M*M)PY^"LD\4.GK')QN'8.Y1JZ3GZ.T,W9Z0Y]Q5=:TZX
MRD<A9J O<(YQ-Z,M6>I$;J&6(H"6I(I628@(NO5R&LS1A 6>R5RJR-;L-Z&9
MEX%E'*"^3@8J>F6E=EW\=,SCCEOV9;<OGMR6KN&>[;GLS'JS69V8FR;'26.8
MM81M$QK*?MC>'?-JO-4OX6Q);%(&8W5S6;&=6>C7UF2.#]^I)*J#*.S+3+ 2
M1,C'I)Y=OWY[L_DV;"C=V[+:>?KV[?A6P6:K9<:L-SI]1/%IVNV5JL*3CP(Z
M%)89V+A3R\@/  &,662=-C2#P143 &S0%EAXPGW'W1=[),P-YR565U"H,%.,
MJQ-WBH0]EDC,RQU>E;+"Q\X_-(N!:1Y642[>HOW1GSHIFS,$&Z@N7!111X:@
M"7&1ZDS'6O[2OE&<!:#(7.IK%I''!=#)6*'4"H"W(Y4<!:!(\$(#B$V;Q1;O
MMR3BB-')S\$J"HE9'JW[O6F8Z]V_U+EF$6.9??,Q^44OT3%X19'")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(O('NL'WEH5^ZM2/XJC9X*]G%]3=&GW_%O]GAM>P/8G_NN._O>&OZU^
M6IFP9_95M/\ H^?_ ,HZSG2/L7?]-[W_ #6J?[UM*[9Z>?\ 12U_SAI_[MNB
M]:R>,'3U#GNGWH_![PO)C_1/+O"LDY^CM#-E"K!.?H[0R9GHCGWE%.3Q@Z>H
M<M*)^_EXE6">,'3U#FS/2'/N*B?Z)Y=X5T.8/0'5F[M[>WQ">\_!\%83YB^G
MMR9F_EXA0'<>P]RZFJVT/H1=-0K!I34]8=.+%J75'+IG8:)$V^$>6J,=,>$6
M105A47AGRJL6H4R$L5NBL,4Z*9K(\F<E,D'(:O#.(J&VTUYK+)=*:U5C6/IK
MA-15$=)*V3;$X3N8(P)F^="7%NN9Y\6FPYKXE/>[/55L]MIKG0SU],YS9Z.*
MJA?4QN9Z;3$'Z9,9\V4 '5N\V31=L7<3QXTCVCI^_=-V+%BW7>/7KQ=)LT9M
M&R1EG+ITY6,1%NW;HD.JNNJ<B221#**&*4HB'RH6/D<V.-CI))'AC&,:7/>]
MQ#6L8UH+G.<X@-: 220 ,U=F<U@+WN:QC&%SG.(:UK6YESG..0:UH!))(  S
M*T2KO=3NY^V&9E8!GM/Z?LWT1)KQ+AQ/EGZS"N7#4P)JN(NQV&&C*_+QASB)
M6\M&R;J-=E**S5TLW,14_9,O1-TBTL$=1)A6XO9/$R9K:<TU5.UK@2&RTU-/
M+40R@>E#+$R5A.BYH=F!PR'I!P;/+)"R_P!&U\<CHW.F$T$3G-.1='/-%'#+
M&3Z,L<CHW#:UQ:03A-K7NF.SAL_[/UGU3H>K&E6KES<M5(?32HTB^UBX*3]O
M?H*EC5Y)O6YEVX;5B%.'?2ROS';%38-QCFRX2\C&-G%S!_1?B;$.(J6U7"T7
M:S43'B>YUE?;ZJB%/1QN!E;$ZJ@8U]7/^Y4T8#LY':Q[=3%*YL.(\=V.SV:H
MKZ.XV^Y53FF*AIJ2L@J3-4O!##(()7.;3Q'W2=Y+<F-T&G6O8T^+^SMW-':H
M[I-#1FTMMK;0U[@*9=##/T6L*%/,667@GPF.WF(" ?N&M-TPJD@BIQ]:1CH)
M^>48&[X$A&<:\82$CWCB/I-PIT:32X9P3AV@J*VB^EZ^I!$-+#/'L=#45$;7
MUMTJXW#1J3+.S4R#5F=\K)(XNJK-@>_XWCCOF)[S5PTM5[M20'.6>2)^9;+#
M"\MIJ"G>"'0!D3M8PZ8B:QS'O]I]GWN1VPKL_)M74=H^PU/L[44SC;]:3-M0
MI(ZJ?W22Z,&]9-:/&.$5 %5%U$5-@\(?@F%R<R20DZ<O_2WCG$!>V2[OM=*[
M,>1V4.M\8!WM=.Q[ZZ5KAL+)JN1A&?FC2=GV/:>CW"MH#7,MS:Z=N1\HN9;6
M/)&T$1.:VE8X':'1T[' Y'/8,O2Y@Q8QC)K'1K-K'Q[)!-NS8L6Z+1FT;I%
MJ2#9LW(FB@BF4 *FDD0A"%  *4 SKS622ODDE>^21[M)\DCB][W'/-SG.)<Y
MQXDDDKEH:U@#&-:QC?-:UH#6M:-@#6C(  ;  ,@KQ.?H[0R=GHCGWE:OW<_
MK((^)TCFRB5TGXOYO9DD?'EXJ.3AS\%;)S]':&6F>B.?>5 _=S\"K1.;I[ R
MTJTG#GX*R3Q0Z>L<G&X=@[E&KI.?H[0S=GI#GW%5UH!M T:1'5>FL%Y_21E"
MWM>[3\7(:A5F8J#N#L<;'T6.<0%8U/TWNE$L2EPN+!%H];DE3OY%Q 4B0.DJ
M^2K[1JWL#<=Y]0VY\=Q!W+1P[,O7LV[.(^?Y,MAMFJ67E=,2I.U2KO8*V7.L
M/%D=1[5JTR6<UZQOXM1:.OES2)8)F/6Y.55JD_</G$40_>ET[%ZQ=-V^#O\
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M-QM?'.(:UN%:HN<2  !=;2223L  VDG8 NT.G@$X5M0 ))Q%3  #,DFW70
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M6QY+M.6FFBCD>\NF>[-^M/T%72TWJTLD\B!;!/&^1SRZ5K2)F2/<?]=@TW-
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M)JHJIF*HFHF8Q#D,4Q3"40'.J7-+26N!:YI+7-<""T@Y$$':"#L(.T%<\!!
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M;+,GI/$6=5HMJG'U5Q6M!EX=I#J+D)-+1$;)?&PA<5X],L;RA#4I2:(5F:8
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MD0B2**92IIIE*0A0*4 #R,YSGN<YSBYSB7.<XDN<XG,N<3F223F2=I.TKT
M&@-: UK0 UH    R  &P #8 -@"L<I?^;!_AB'U9A93E+_S8/\,0^K"+PY[O
MELUNM;]C(^JL5 "I<=FR?"\HN$5$7#Q33Z>Y+!:AQZ92%X16S9,*_<'ZHF $
MF=.6$ ,)N"/:_0_??:K% M\K]&EOD/DI!.316PZ4U$\];G'74K!Q?5#JS7 ^
MD*U>760UC&YSVN37C(9N--)HQU+1U!HU<[C]C >M<2KW=331/<:F.TVO*)+:
MT156_H=VJZSY!61=;0+)D-:C9QP@<?V0]/7R-M9)!GPB K% Z2)P#"5,+,V
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M:<M,;P&.?+DS2<'F1[<O ;1WZHC<,7FU PTDDIO32=%*69:0N]-]/UFQ(0X
M=BG!:6-Y%GM"][A2, HN6[Q6<E&ZQ'SAX_0!)TG'-9.A@/;8'W".*NASB=<A
M75C7:W<\S7!S'6769["US!#&X%H8QVDT[QW/I(+775M&Z2EDR>*-U+39!GO=
M72!S;EHY;B'%[P0XN>,G#T*V .[01^T[JH39KU_TC4T%V@E"NVL.T5D'S2L6
MR>C$!<R-9")M#1G8Z5:Q;%7<QE=EW$V2329N4$YI.5.PBWW"\9=&,EAM_MY9
M;A[<V<:+I2&L-130O.BRHUD#G055/I9-DFC;$8RYI,1C#Y&<DPYC9EUJ_:RY
M4GM=<=HC!<[53R-&;XM"5K9*>;+,LC>9 \ @2!^BQWN)RE_YL'^&(?5G4ZYZ
MOG(VD_U0!';/^V3<M%6>CL;J#HGIK*A2;I:8.PJM[^M<XX02MSFM X,-7=Q]
M8E!<UX(*039+2TE$/G06>.:N$$TN[K%T/27G#%+='W)]%=JZ/RNFIYH0ZC;2
MO^IFU!:/*&OJ(]&?71EXCCE8WR>1S23UG=.D-ENO<]"VC;4T%*_43S1R$5)G
M;LG,0<=46POSBU;M$O=&YVN:' #?9/NSW<]3:6,]5EM=X-JR>%*G\"%&4ROJ
MFUD13X1XMYIZPC'D^B9)4#-S37)SU510.-0L"S,Z;H_#CT98U\O=;Q997.;M
M\J$L H',S_=&UCY&PG,>=JLQ4 ;#"'^:N1#&V&O)&U9N48:[9J#'*:L.XL=3
M-8Z09'9K,M2=XD+<BM2I7]4@;#[!RJW8Z<;2LX1,PE(]CZ=IVW9K  [@.F$O
MJI&OBE-S@"K!,^X?NBE'P9R./H3Q8]H<^LL,1.]CZNN<]OJ.KMKV? \CUKXS
M^DNP-<0VGND@^R;3TP:>S3K&.^%H61T__5%&Q==[S6:=(477"@L++,,H8UUN
MD10F]6KJD@N1LC)61>&O\S(,(5!50HOY%NP>@P0X3I=$&R:RR6M9T+XII:2>
MICJ;36R01ND%)2S5AJ)PP9ED&NHH6/E('F,<]FF?-!TB =J;I(L4]1% Z&OI
MF2O:SRB>.G$46D<@Z75U,CFQ@^DX-=HC:1H@D>L.TIM4Z5[*&CTYK=K#*H1%
M/BT4R1:+)\Q>S5QFGJ"BT16:=' LEW[G)D$CF:(I*IM&[--U+R;QA"L)"1:]
M=V.P7/$-SBM5MIW25,A)D<\%D5+$P@2SU3\CJHHLP'$@N<\MBC:^5[&.YA=+
MK16BBDKJV4,A8/,#<G/F>X$LBA;F-.1^7F@$  %[W-8USAY;=S3[LXVVX=9;
MYHM?M/:[IC:G))"S:+,XJ==N_A/5XL%%9BLS3J5$B;V\0D<4D]RF(;L&,S$)
M3:R4-%A '4DN?XZZ,GX4ME'=**KGN%.TL@NKI(F,\GGDR$51$UF9;232$PZ,
MCGOBE,(,LFNRCXEA;&S;]6U%#4P14DITI:$,>YVMB9F9(I"[89XVY29L#6O9
MK"&,U>;O<WE+_P V#_#$/JSJ9<^3E+_S8/\ #$/JPB^>C7[NL&E^CFVE7MEP
MU7">B7%HB:QJ=J82R),V&GMDM3U-%FP2BBQ;M*;;UX'L:O;G1I>.&,!R]:)(
MK/X=TV5VLG03=K_@RZXU%S\FE#+A76BTF@DDEN5)1.E,KW2Z]CX'U.JE;0,;
M3RZ_1C>7-BJ&/;:N?2Q;[1B6W88-#KHQY'27&X^6,9'15%4R,1M#-4]LC(=.
M,U;C-&8=)[<C)"]A]8B[MX<^_P! ?-Z<Z-$5-D/IL9>;MU$O6."[4=+/D?I8
MY=>NCZU\P.UVYO'=-^Z,,]D.A6Z2B]$=%!=L[G(1ZIW$,Q>UA0I=3+LM'%4!
MJ_GFLU(-M,ZR9X"K9"21;JI&:LI>555]EX$AM/0YT5R8YN=-#/?\1:J2WZV(
MLGDBK6:5GMS7D&:.E?!$^[U@CT7OB+@X/?3P!OFC%DMPZ2,>LPK0S216BS:;
M:S5R Q,?3.#;E6N;GJY)V2R-MU,7!S6R!I&BR:5Q]]]FG9#T V3:XK7]%* P
MKSE^V;(6&U/5#R]TM)FVXQ%9^RO>&]<)<>*CI**9BR@6+A98T9$L2'%//->+
M<;7_ !Q5-J\0WV2K;&Y[J6BCIWT]OH@_86TM''E&QVB&L=._65,K6MUTTA&:
M[MP[ABTX6@=!9K.V!TC6-J*I\[):RJT-H,]1)F]PTB7")FA QSG:J)@.2V=*
M)MX;B;_VN$'S9QC54_W3E_Y,G@OOODGSVTQ&S[;&58*)N$'W&_\ .#YLW9%3
MZ0^FAQ_>9.HJ)TL^1^ECEUZZ/K5PIC[@_6_D#\8N;.B@S&=2!MV>XR'/:.S)
M9UD^A]3G=]M9NRW\?@4Y#*;B[D]_A_ZY0^7)F1P9[*D;MVJD'%0&2;(^X'<=
MNL9U*T4ZO"#]9'Y?QR?-DNK@XU'_ ,3_ /)0Z<WVC_Y&*8#J?*EN_/*/9DC(
MX<MD^>W[4\>*B>^7/; 1L^V,/BK29U@#P(;_  !_;"=N3,9%MRF!W?O;QEO6
MFG+PA_\ D8/E4H*+;P_8X\X?VU/Z\E:R+,>[]7[V_P"!8+Y<CG#D,OMC5/QB
M_P K<?6D_P#UDVA']M _ =X*+2?PC_\ <W_-6R*N/#^QM_-_;D_V_GW9/HQ_
M;/\ V.4.;OL,_P (>.2L@LYW!^Q/D#^WI^'KR1C8]ONO5[QWK4#B[,^9Q.S2
M'7\"D(JYW_>@B.[FX]+Y_GRPT-R&3\_7HGK43W/R]#(9[](=74KZ*SK@?>8\
MX_V]+)-%GVS_ -CE$7/X1Y_A *V5=Y]SN8B/-N_9*(;\W8UFWW3/=[P^OUJ-
M[G[,V9;_ 'P/4K1'#S?]X#S?(Z1[=V66ANB//Z_>GK4+R<MK>/6/7V*T1P]W
M>"/$?#Y4@'S984#^'/P5@CA]P0_J</\ "T/G')QN'8%&KJ+AZ*A0/'"0HB &
M/RI W *)@ 3<$/";@AO'<'A'=N#-V;QMV[=G([5 <N!SY9+334FYW"ZW<\(\
M)/5716(U.::(S\Q2KU%,+5/6BXQ-6&-?V"LRNF\J(4TDY8&510^#VH,3,<9*
MO)>2BY%B#9&.L#9MXY9CD3Z_5GM"T)VY<,\MAWYCCLW<UW7I5H9%Z+/B1U L
M5B::;#!.&A].YV7E[2R8V,TFW=MK#7)2?E'SNL,Q8FDV,C58A-"NNE7#&09,
MHQRR<]\L$Y[]_6L@9;MW5XKO3,+*J.F#%\+<7K)H\%HN1TU%TV1<"V=)[^+<
MMQ5(?B5R;QX"R?!4+O'@F#?A%^G8LE':#]1FU4?-DU46ST[=(SMNDMNXY)!P
M8@K))J\$.-(F<I5-P<(!W!A%_"T;'. ?%78,EPDVX-)(%FJ"@2#4J:J16SX#
MIF!VW*DLLF"*_&)@FJJ0"\%0P"13-6K5BV;LF39!FS:(IMVK1JBFW;-FZ) 3
M20;H)%(DBBD0I2)I)D*0A  I2@  &$55E]\S'Y12_1,7A%D<(F$3")A$PB81
M,(F$3")A%Q^V5>"O%6LM*M,<A+UFWP$S5[%$N0X3:3@I^.<Q,O'N"AN$47L>
M[<-E0 =XD4-DU/434E1!54[S'/3315$$C?2CFA>V2-X];'M:X>L*.:*.>*6"
M5H?%-&^*5AW/CD:6/:?4YI(/:O\ />KVQGK-,[<R?<Q5[!8@JD5M%2;J3;%,
M)(Y"LLXQ)S(ZP QXL&Q9%]HPQ;3,6=R4A52NF48GQ2CTQ#^R)L3VR+"9QV((
M/*)++&&'>]T[I"V.V:>>EJV71[HI-',C1?(<PS,><X[)7/OPPJ9)-4RY.+P-
MC1$& OK0TC+2=0M$C,]X+6^^7WRV[1'3ZW:%V#9V7A6T?IC.Z7OM(B03%(I4
M(FGN:R>J-&<:0_"!$\1%BB$8H \8V6:MUDSE43*</(=-=:RFNT-Z$KGU\5P9
M<C*\YF2I;4"I<Z3[(229ZP'8X.<"""0O0DU#3S4$EM+ VEDI74>K;N9"8M2&
MMZM!F6B=X(!!S"^++8S[HQJ1W)^+VN-EJ>TY7U"O[+4]5A0(=V[58U&N:EP#
MB2I%TFIXB*@3,I"SC"'J3V*CH,J"\T6'20++QJ,B230]08FP50](<F'+_%6B
MCHW4 ?5R,:'U,]#,V.JI8H<QJHY8GR5#9'RZ0BUI.JD+#&>D+)B2IPBR\VF2
MF-34BJT:=A.C#'51EU//))E[H]DC60N8V, OU8&FP/TQMY2*E^J)9R+6VLZ[
M<[0#RXN%9-+0JUS].8N$JWN(X;K1^AU[:)4NJ1R[<YVK./;K0^HJY&XN%F1G
M;EH^>\;JZGH7BD&'9Z:GT:5HC-VIX:IX,^UI#[M1N-542!V3G/(EH6EVB'!K
M7,9]B"'I(D8;Q%/-I3G3%!-)"TB+>"V@J&B"%I&P-&A4D#,MTB"[J&3JG=%.
MZY[5.A6B^UQI':]'-/M&S/7&I+ICIK=M.:S'P8OR/+19'*EI<R;-U?[I&L8N
MGU4\8Z4C"&%*7B8A")"Q.E/I,J,%]'.'[M=,.7&GN=9<]%M"U]?2UT\DNCHP
M0-\G;&YM'2O?)4U >W6$9QRRNDU#13=%B3&-VH*&\4<U%346D:HMI9Z:)C,]
M*65VM+@:BH:UD,.B2T$A[&!FM*^S"M5N!IU=@:C5HIE!5FKPT97:]"1J)6\?
M#P<*R0CHJ+8H%^Y1:,&+9!JW2#P$12(7Y,\R3SS54\U342.FGJ)9)YY7G2?+
M+*\ODD>>+GO<7./$DKNN**."*.&)C8XHF,CCC:,FLC8T-8QHX!K0 /4%\Y&U
M;^I](G6_:<L&JFD6K\%HII1J.LI/WRFDJC^<DX6TO'0.IX*3&M)*%ASU^QNB
M]]^]\C)L4:[*KNB1S1Y$@PCF'=F'NF.2U6&&WW*VS72XT3=325/E#(634[6Z
M,/E<CF2RB:%IU1>R-YGC:TO<V4OD?UK=^CIE?=9*NCK8Z&CJ3K*B 0ND>R4G
M.34-#V,,<I\_1<]HB>3HM<S1:WFEF_4WFR$_H;6#JFJFM]<OK5(!/?)20JME
MCY%V8FY49*FIUZ";C'E4$3M&D5-1#Q(@$3=2KXP'54JP=-N(V5;I:BW6J>C<
M=E)&RH@>QH.S0JC-,=,C8YTD4C2<RV-FP":7HSL[J<1Q5=='4#_6'NBE:X\=
M* 1QC1SW!DC'#9F]VTGJ/0C]3Q/H;62NS>T_M M];M$M/2$"JT&+96F'D+(B
MW6X]G SA)27D&U-J97'[)DX>KRLFO*DX3).0BRJJ.Q^C=^F9DMLGBL-G=:KK
M6DFHK)'4\K("X9/FB+(V&JJ,O-9+411AAR>6/R#53M_1PZ.MB?=;B*Z@IA[C
M3L$T;I<CF(Y Y[A!#GM>R%[R_P!$.9GI+V.VR>YY;/.V;HS'Z36^L1M->4N*
MY#I#=J?#QT?,:5J-VB35DR@6;=-HS<4\R35HUEJ4H*$/(,6R')1BY5C$R\;U
MIAG&=ZPQ<WW"FG?5,JI-.Y4E3*]\5PS<7.?*XESFU(+G.CJAG*QSCI:R-\D4
MG-;UARVWNA;1S1-A= S1HIX6-:^DR #6Q@  PY-:U\!R8YH&CH/:Q[/F";]S
M2[J3=M0:1W.G4BQW8-D^A7!W>6&IQ4W<KHI%U97@H*3,!-+HMW,E.)M1=)U3
M2.3D$7D#8)F4?$B8:(D)FS&[X=CC -+1U>-:&&D^B&KIFTCZ#-L=UDJ!YPBF
MA!(CB+M$U-RC8630Q1LULLK(H%U4,,8KGJ8,-5,E1[44\QJ&U63GT#(CL,D<
MA +Y ,Q#1N<'1R/>X,C8^25?8'L_:!Z8[,>DE/T5TAKZ5>I--CRM&B0\!62E
MGZH\;*6*??$32-*6&=>F5D):0.F0%G*PD;HMF:39JAYMO%XK[]<:FZ7*8S55
M2_2<=H9&P;(X(6$G5PPLR9&P$Y-&9+G%SCW/;K?2VNCAH:.,1P0-T0-A<]V]
M\LCLAI22.S<]V0S)V -  [FSYBNK4DVPCLB*[03_ &I7.A%*>ZZ22C5TYNL@
ME(R"199FDDBA9&E6>R"].86PI&Z FMK*OM[(=5/E!I07*BRJG(OHMQ&+,S#[
M;M5-M+-)K:5AC8=6\DF!U0U@JGTV;C]+/F, !T=7H@ ?']H+,;BZ[&WP.KW$
M$SN#G#3: !*(G.,#9M@]V;&)<QGIYYE;;9QU?87@AW:KN>\QK54(W;"V>VCZ
M*VE-!&S2<D?@MQK2Q7NE5AP$PV=Q:K'@.U;[ITN@,Y5G+8X23^)2D(-#ES]O
M5VC7M[HNQE':ZE^&KRYDECN[G11^4$.@I*J=NK<V0/S8*.M:=34-<-6R4LF=
MH,-0YW7N.<./KH67JW-<RYV\"1^IS$M1!$=-KF:.TU%,1K(BWSW,THQI.;"T
M<2TV[ME4[/W,_4O7*?EX6.VJ]*ZZQTZDZ686B*ECU2M"*D+0M082''@%=U>8
M5(ZM\\P;IIIQ"E<M4*0"MF\4[D+%=T6U$&.J&U0Q2OP]<)GUK*KSB(*"G(EK
M**67:6U$6;::%Y),@GIY2=)TK614N.(I<+U5?(^-MVI(VTSX-F<E7*-"GJ6,
M]]$_;-(T9!ABF9N#"[CO<+]AFJO=EC4?77:"I$+J%*;6<DY;IQ.H4,TLJ+W2
MRO23PJ3Y^UG$')CNKK<C3%@<.%2&,^81-1FFRXG,DJ$_2QBRH9B"BM-FJY:)
MF'F-<9**5U.67"=C26,="YH#:6EU4+0,M!\M3$X9 A18"L,+K34U]Q@CJ7W=
MQ 94QB4.I(GNR<X2 YF>?3D)R\YK(9 3L*V7C.X&=STCM5W>I*M4U$E8!=UR
MUIHY)7QP?2Z,="8%-S<K6.:7]VQ(J4JB<7*WR0CQX2K9RW<L#ILT?A/Z7L9O
MM[:$5%%',&Z#KFRC'E[V[MND]U&UY&8,D=&Q^YS2UX+S]1G1[AQM6ZJ,52^,
MNTFT3J@^2,/JT6MJ7-!VAKZAS=X<'-V#T!@=AO8NK"*2$%LE;-D<")"D*LEH
MCIN=X<"EX(&7?K5M5\Y4W> 57+A54W.8XB.</FQ9BB<DRXCOC\SGHFZUP8./
MFL$X8T9\&M ]2Y%'8;'$ ([/:VY;,Q04NELZW&(N)]9)/K6M>W+W+O9ZVL-!
MIW3^HZ=Z;Z3:F1)%YW2^^U&F0-7/$6ENW."$78%*[%M',C3[ 4"QL^P4(ZY.
MF=O-,6JDM$1XA]S"F/KSAZ[Q5E36UUQH)<H:^CJ:J6H$E.7#.2$3R.:RIA/G
MPO!;I>="]PCE>OEW["EMN]O?3P4U+1U3,Y*2HA@CAT)0-C)=4P%T$GHR-R=E
MLD:"]C5\_.RKW,/;MVQ]2J1IUMW/-7*1LV[*"*E)B8NZJ+L7,U&L7N\M,TD6
M,D5"<B)-)LV9O-46RDNP9U1A$P\',O2Q\#'QW<6(,>83PS0U5;A)MMJ[WB%P
MJY'T@:]L<CV_55R .E%)&7.<V@>(I'5#Y)98F:R9[^O+3A6_WJJ@IK^:R"V6
M@:AC9\VF1C79ZBC.0$C'@!KJL:;6Q-9&QYT(V-VO[L?L*EV:$-&=O78OK,?I
M=)[/+FF0%TA*-%HL643$UYXV:Z?:@C'MB%(^)'.10IEX.^Y:I/0TE!*2I563
M*<<K\>Z-,6&^FYX1Q/.^O9>6U4U++5R%[I))FN=6T6D=K--N=52!F@(9(YA'
MDYT+1];&E@%K%%B"R1-I'6XP1SL@8&M8V-S135.B/2T3E!4:6D9&.C+_ #6R
M$^[^Q'M84[;2V<:#KM4^3LW<VS[TWFLHK\<K3-0H=)!&U5A?AF%?B6[M1.0A
M7#DJ:TE6Y*%EC))@_*0O4F*L.U.%[W66FHTG-B=K*2<C(55%*2:><9;-(M!9
M*UNQD[)8\SH+G]BO$-\ME/7PY-<]NA41 YF"I8 )8CQR!(=&3D71.8_(:62X
M/W1?;(@]A_9>N^KRRC)S>GR?P/TDK[L2'">U'G&SD(<RS4QBBXB:ZW0>6F?3
MX20+1$,Y9)+$>O695+>"L,RXKOU+;0'MI&?3-RF;G[C11.;K ';=&2=Q93PG
M(Y22M>06,=E!B6]1V*U3UA+34.&IHXSE[I4R Z&8XLB =-)NS9&6@Z3F@_&K
M/; &H<YL"77;LOCZ>D=5K3?(S4SD$@JJL]D-)9Q^_96"X2J9BE6<3=KL=B87
M?EBHG3;U"')))"/?MR"'=,'2O;(^E:@Z-;<RF99J6W5-I?/$&M9'B&GCBFIZ
M"%P.BRGH:2DFMVK:&N?<:@P.'TLS2Z[EZ/JY_1_58VK'3ON516PW!D4A<YS[
M-(Y\4U7*#YSIJJHJ(ZW3<2&T< E'[N_1]M:YW1AK$]RJC]IMW*H.M5XJJAHZ
MD@Z.1=V_UU8HC66#YVBH(IN%'3--#5.19<(O#@3.B%X"FY,/.=7T2OGZ;9<&
ML@<RQSUWT0%S 6QQ89D<*V6.-S1FQK)"ZQPR9;*O5DYCSCW13](;(^BQF)'R
MM==8Z7VH#7$.?)?(_I:-[P=CB]@;=)&;S3EPV%8GN(&S:[T[T&L.T/<6ZZM]
MVAY0TA'O9(3K22.GD&\=I1;A59P)G)5[9/K3-B=K"?@RL8%9>'%0R:9\M>R-
MQ>R[8GI<*4#F-MF%(-5+'"&MA==:F.-T[6M9DS0H:5M/2,9D-1-Y9& ,R%4Z
M&,.NM]CJ+_5M<:[$$NL8^3,R"WP/>(G$N\[2JIW35#G9Y2Q>3/.>0*]P"<_1
MVAGGEGHCGWE=S*<GC!T]0Y:43]_+Q*L$\8.GJ'-F>D.?<5$_T3R[PKH<P>@.
MK-W;V]OB$]Y^#X*PGS%]/;DS-_+Q"@.X]A[E;)XP=/4.2J!39*S=S\ HG[^7
MB5;2YN@O5D\?'EXK13!SAZ0Z\E&\=H[U@[CV'N4^3J!7$_EZ.W+"KJV','H#
MJR2/CR\5 =Y[3WJ0G/T=H9:9Z(Y]Y4;]W/P*R"/B=(YLHE=)^+^;V9)'QY>*
MCDX<_!6R<_1VAEIGHCGWE0/W<_ JT3FZ>P,M*M)PY^"LD\4.GK')QN'8.Y1J
MZ3GZ.T,W9Z0Y]Q5=:Y7C9?I-REY&P,+;JI1)B6M$'=Y ]-OTD,&YM];<1+N$
ML1J1;$[704Y-DY@8=4RJ%62*\&/0!^1T'# \X.7 'M'COXK4MS.>9Z^?6NZJ
M="S]?@6T79;C(7R5;JN1/99:)@861>H*+G.V3>,JS'1,("S9$Q4#+L8QB1QP
M.-,W3.8P9C\BR,^)SY9+E&%E,(F$3")A%CF7WS,?E%+]$Q>$61PB81,(F$3"
M)A$PB81,(F$3"+@J.E^FC;4!YJRWT\HZ&J<A!I5E_J2C5().^O:XB=)1& =V
M\C M@<0R:B"!R1BL@=D4R" @B HI\&X;A7NHFVYU;5FWLE,[*$U$QHV3G,&9
MM,7ZD2G,YR!FEM.W:<ZXI*45+JP4U.*MT8B=5"&,5#HAD1&9M'6&/,#S"[1V
M#9L"YUE-6%JJ.Q!LHGVAGNU8OHE47FOC\K RU]D E)!1%_&,T(]G.L*Z]D5Z
MG&VA%DU;-OA5'P3:QF31*)I,3G5,IR'Z*\0BRMP\+K4-L[-,"D9JV9LD<7NA
M?.Q@J9*<O<YWD[YG09G]SR  ^3[16@W)UW-#"ZX.T<ZAVF[)S&AK9&Q.<86R
MAK0-<V,2[/3WY[59QY?63")A$PB81,(F$3")A$PB81,(F$7RJ[;G<$;9J9M?
M05[V<3UFLZ#:N6=O,ZNQRTFSB7&C[U=]RFY253@U4Q&:AK V,N_K,%$D6[U6
M5VXB7#>'JA&3QGZ"PMTO4U#AN:DO>OGN]MIS';GB-\C;FUK-&ECJ)0?<I87:
M+*B:0C60-$K72U)<Q_4M]Z/IJJ\QU%LU45OK)0^L:7M8:)Q=G.^&,CSV2#-T
M4;,]"5Q81'#HEOU"TRH5S3ZH5:AU"+;PE3I==A:I68=H E;14!7HYM$Q$>@
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MF#Y4OM<V=!%FWZ<I]_V-7ZO^%372:/U)4>C]E2]7\I4Z:A_N?UA7G^='Y_\
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M]O4]P\"I G50'>""?28P]@9M]#,'&JE^(S_-:?1!+]SQ_'=\B_OO^M\K=/\
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&! 0PB__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g63338g45n03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g45n03.jpg
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M]7EZ/,\L74:O'&3V6L/E8)^.>#$L<5D!OH\:O"?/RY ]_&J+](F"*;IO/)(
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MD;C_ -[D5L2N?G)<D^\G7[8ZC]2<H[R'=NYF;S+#'W[=*->?_=8YJ\2#Y@$
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MZDXB</'N[/F5""8\G:DR2>[R:OE1:C(/'L*?/\^G&:"^$&H!K^_"Y):F+O\
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MX_P&.1%OM+C5F&FLEL)K*VX_Y+6@T$Y,KI2(M>9P/96&.5CGRN=+*RGNZ7+
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M(GT;^4W:/X_/]7W-7W^N<>ND>CHT:K5?",/N6XH?T_N'\W:YZ:ST7OXUO/\
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M9!4B=.R&)LJO2-B-TN*SV<P3S283,93$/854L/C+]JBTZ(2R+,:TL9D5"S%
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MF[$@BSF-DDD<GCLC5;),C\^78G<WT>1U)'J+:E6NBY5M'6>"F#UV;[$P7#K
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MG=V(5415!9F9B J@$DD #G7J[I$CR2.L<<:L\DCL$1$0%F=V8A555!9F8@
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M+E!QMVG?NQ76F_M-9]DR>JK<>P_96'Y%=3L@:Y\THM957!1AD$3&N=(0+#-
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MLX,"I."IL ?\EU+H?P,K!A]!&IHD?^[S_P#(R_X'=0-/NU_Y2_K&IZ_W#?\
M);]1TL3P:/P<7'W_ )?;?Z;-C=6UUU^5+<W_ "<)_P#3^*U4?0CY*]L?\K-_
M_4.5TT'JH]6]I7/AA_L_$$_YRSE#_CPWJW>K7LZ:?\U&T/U7]4_TA_\ 29_S
ML;O_ /Q^N-RT)APCQ#?#<V5D2I#AMD5O_43;6=?*'39UGN#A!X8*Z1_:-AF6
M&R24X3$=YY4'(]RI&B.^]EJV0Z9=5,55\[T2;:S9A7[N?'8[(R/??CVF.E&!
M8D/' +)\_E\;V=<?U/Z4Y:UPM"63<N$$SGB.#(Y+'1QT$Y/D)+LC>!&/:W8W
MS#EI_5/ZN/1T:-=0V!G.-ZQP7,=C9@<VMQ7!<9N\MR$]WE51J?'ZXBTL)(V.
M<SU9_9AI&CP-<CR)W1P1]Y)&HN;C<?:RV1HXNC&9;F1MUZ56,?RY[,JPQ@G^
M2O>X[F/DJ\L?('6#D\C5Q&.O96])X5/'5+%VU)Y?!@K1--(0"1W-VH0B\\LQ
M"CS(TA[@MSPT)@&.[9W!NENUH]Z<F-I7FS<WCJ-)[3R0"@Q4:26EU9@U7D57
MBLX%O1XOA\,,]7./-,R)+L@;UY4@1W3%]0^G6Y,E:PV#P/V';;VT\/7Q./,^
M?P]62S<<"?,9"6K-<62"Q<NDK,KJI;U='X'=QI<>G74C;6-JYK.Y_P"S(W%N
MW,6,OD!!@,Q;CK4T+08;'0VH:C1SUZ=$!X&1B%%EDY/;K.Z5Y<:< \3L^RU<
M5F(6K^:.$TE!E\&8Z_S+7P=;R'P <Z/$K$)N64]5 6W+\4ADHWQUK923<GMF
MDGO3O"K\;/;*SLG22.+,)1?+[#R%BS1:CDJ.3DFVQDGC-V*0TIYF3U*XXL R
ME4CIP%(QY$:R=O[WP4?5V67#O>CQ&_<?7K7EO8V]C$BW/C%D%*6,7((5<7::
MFN1%R\ER?OE/W)+\^EPTR>E=>$7\UO*?ZQN_?KP3U;O6KXW4_P UMM_5ZZI_
MHC\3;7YT;D^L'TT7JHM7!J//([BWIGE3B5?B6WL<GL?B"Q^.\/RBDLB\?S3!
M[Y$C1MUB62U[F&UAGF@'?- _VFL.>*&ZQKS/9!O2DVU]WYW9]V6[A+2Q>LQ>
MKWJEB)+-#(5N3S7NU908Y4^$P5AV31AW\*5.]N8QNG9^!WC2BI9RJTOJTOK%
M&Y7E>K?Q]D<<3TK<1$D3^2EE/?#(40RQ/V)PN?;F/\T/#QPP_=>$\B+[E?QX
MP"2O,V%J'?H%>7M2KPI]@+7V%UB>WJR(>RN[:L@*9.^"\%%K0A1YC?BJW<UP
M?5HX6SL/J=>CP%_;%;9NY\D)4QF;VW))'AYKXB>6*"[A)2T5>&5D*AJ[O+([
M"/QH.0^JLS=;?O3"A)N#'[HL[SVQC&B?)X/<D<3YF''F5(I)Z6<B"S6)HE<,
M5L(D2(K2>#.?M>G XOD59E^-8[EM)*^>FRBBJ<BJ)I&>G)-678 ]F!*^/N[R
M/D%)B>YGF7RN56]U[=^J0MU9J-NU2L +/4L359U!Y"S5Y&BD /ER Z, >//5
MY4[4-ZI5NUR6KW*\%J!B."T-B)98B1[B4=21[O9K.]8^LC1T:-+]\+G6E[J#
M@]IO7N2EU)UU1$[(>651SF$U<B6NU,UN1_9ICP*PMZL%L(8YO5"A\L[96L]2
M-K)7V5U=RU?-]0<[DZB31P6%Q01+"QI,/!P^/@;N6.25!R\;%>)&Y4@G@\@5
MGT?Q5C"=/<%C+;PR3UGRO>]=G>$^-F<A.O8TD<3GA)5#<QKPP('(X)8%U6NK
M,TOWQ0]:7NWN%&U< QHNI!N;JTUI**3>3F#5D;:G9^'W!*$3  6937/& F9
MD84J.G=&V18XU=*RRND>6KX3?V&R5M)I(((<LKI76-Y29L1>@7M622)#P\BE
MN9!PH)')X!K/J_B;.<V!F<;4>".>>;$LCV&D2("'+T9F[FCCE<$JA"\1GEB
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M&33D2JZ25[EB>6R=K-93(9>\_B7,E<L7;#>?'BV96E94!^YC0MV1H/)$544
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M$SDSR2I,^&HR);M5:HCC?FQ9=(55G>.,(CJY(D/$]@ 0JL$.LK11P:ZN$'!
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=$8Y(2&"-8HD!/)(5%5?/S\O/66Z\=>^CHT:__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g63338g60n53.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g60n53.jpg
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M 0$! 0$! 0$! ?_  !$( *@"70,!$0 "$0$#$0'_Q  ?  $  04! 0$! 0
M        !P4&" D*! ,! @O_Q !4$  !! ,  0 & @D0!@D#!0 % @,$!@ !
M!P@)$1(3%!46&"$X45>1EI?1U1<Q.5-55EAT=Y*4MK?3U-8*(B,R4G@D-T%Q
M=9.QL[@E)S0S8F9VE?_$ !T! 0 " 04!               ! @,$!08'" G_
MQ !6$0  !0("! <(#0D( 0,%     0(#! 41!B$2,4%1!Q,487&!P147D:&Q
MT=/P""(R4U165Y.5EK72U",V-T)257*4X18D<W5VDK3QMB4F8C-%1H*B_]H
M# ,!  (1 Q$ /P#OXP 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8
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M !@ P 8 , & $4]NZA$XURVW=&EQ/CU (45L=!4IQN/-.FB,,#7XL^2TAU4
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M18, & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & #
M!@ P 8 , & # !@!&%RJ18[?>/V.#J-\NI-@M9(W[Y[;;^HQBAV&NP_A&O85
MJ0Y\Q)QM.HVMOV&/>.^M7L>SN=_.7:1B#UES9^(R[1B!=O%FSDH\:7&!"3#A
M*X^2!JU"(LNFIE&B'2.FR3_)K80)7NG6\=MRD4S<L$B1#@)LM/;L<O=06][L
MA!(V)7/L*VO869:R\QVS%32>PM9G?5M/(\^;H//I'G*^-W42UNDS"0L&43,A
MW"L'[)-)5F3NUU@YQ8G1@+AR7(JGTZ.RF;*D.0M TB;'5&/*B1BE:ILF0A$@
M9%RL5MECMGKOLSL7-MUWYX-)\VWQEELN=CZM5K;+CK/BI%DEJR6MW.Z(IAKI
M=?)G!,MH86:;YF*\4Q_-M4SW6H6X,L*QUX9 /:K*$:"2'8$*S+85/C1]-M++
M6>KQZ5_()).JY;2\2?.+2K/C%U:"9IDZQ2E$S(:N<HC1[7%L%4]NKQ:9RJO5
M*VTW10M1R_094&RVH98B,F&!L8JO6&#<R$@NL:2BNK)SI%8^>^5MYW(]=NO6
M5MI"-$\NK=JM8RW]AW%SA?%J?7)O.9,*FTJ1"K,'QI(GAZ50M*G7SGZ>K#>B
MW+:Y4!;<^R.Q+;4IBK)+7HU8F@:6'YFWQT!.VEKUYZ5NNUO()T=619:-^>U[
M]FL3-:>$IOO5^@6*SE;%$H]KY1S6AN"*U;"E>^D*@5A[#.M(ZQ,B519;@UT7
M=@T:(ZQ/8><1,+LH4S[/MKK>Q<][ZNC4),KGMM;?KUZQCY:_&'HQ,YUN2+VE
M)"S!NUQ*_:6S-0$12 *]\[L-4H="(+AT9SHBQE3FE0;:1,^W(JPG=2$V02I^
M9[ .-:Y6+FMEGLUGKMXKYGTBNB=SZ_ 96(O7(A>Q[QY(#[88FC><4R[\RV=)
M2!7)9Y"$)"K?(\TYU6QEN5'G#I8I!0 ?K5LCN[?:<(ZAW,G9H#THXRB%-B][
M7.VK/H,SZ=I=9%TB32=SR(R_9U<VZW:*+3_'?H0"V\UFV837;K8ZK<J59#W<
M)9OU6<A70/%HU )55,>5!</R$.7)J6=8$O3-5U^++^DK[VK8]+C8,RMMVY;/
M=7OX,@T3\9'?P7+M\1$,^LJ+A@ P 8 , & # !@ P 8 , & # !@ P 8 , &
M # #^=J3K[&U)UO[F]ZU@ ]M'_$G^=K\^ #VT?\ $G^=K\^ #VT?\2?YVOSX
M /;1_P 2?YVOSX /;1_Q)_G:_/@ ]M'_ !)_G:_/@ ]M'_$G^=K\^ #VT?\
M$G^=K\^ #VT?\2?YVOSX /;1_P 2?YVOSX /;1_Q)_G:_/@ ]M'_ !)_G:_/
M@!^ZWK?ZV];_ .[?KP _< & # !@ P _/7K[NOPX /7K[NOPZP >O7W=?AU@
M ]>ONZ_#K !Z]?=U^'6 #UZ^[K\.L 'KU]W7X=8 /7K[NOPZP >O7W=?AU@
M]>ONZ_#K !Z]?=U^'6 #UZ^[K\.L 'KU]W7X=8 ?OK]?ZV # !@ P 8 , &
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MU@7&GDI#(^)(FK3J.R_.>8B-NK2J0\RU[;B0"A<VZ?4>J@%GJI,>5N%,>$V
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M2]?5VF,C>WJ[1N$R@R!@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@
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M=SD996"K-:]B;&")!>R]@3G;FOJOMZ.T3+8P_/",N <MPNESY]?03#C#%CA
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MD.Z>@HD)0M2S)1DE*5&JQ).WR^5%/^D__39__0EOM3/^AR/^B.14*<DMR?\
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M)M@/ZI4'\ '?&X0?CSB_ZR5C\8'U<?'S[QO(OR<U#]$8[TG!7\FV _JE0?P
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M":5A1V-O?!IW,D#(>UR]QMS4,H=C,R&XTJ6R_ GGVBPD>/7(H]>IU5'U:0&
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M_L_.H^\'T^HG[]:E^,8?_&8Y/(]X>^:7]T.41_?V?G4?>#Z?43]^M2_&,/\
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M^1_V \ISU+P>_F?1OX)GVC+'E7A%_/.M?Q0?LR$-1&<S'"0P 8 , & # !@
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M-VK&!X=6>J#K-9Q#1$5A<5ZL1Z'.CQ&JC(AI8;8E+6_"ER8<HF(L6.[(I<B
MY)8CLMR5/)00][O?SLEY$N=3J&7)0K3:+>#+GH%@-$ 9>UF-'9ZV4S[(Z-,-
MLDDMOQTV8:<VXIO6YRIGMN>WJ7.%2IO.)?DX?PQ/EQJW6:_39U4BU2I2Z;/K
M=0[IR5(Y35U1)Z6Y:4.-%5XE1TS07*>/TEDK3HP!!:0IIBLUZ'&?I5+H\Z)
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MD*I_6_B,9#946# #DI]*+]N[U[^)\X_LQIV9D>Y+K\IC"OW1]7D(:_<L*A@
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MGWD>8_B<$_PF.\UP3?)Q@SZO4W\.'?0X1?COB?Z9F^F#ZL'CI]Y'F/XG!/\
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MJ7P_GY2GA)#5.K7-WC!$_P!$M_0R9ABE5$U9Q]889D6>.-CQW[E<3,^2-EV
MC8E.EVQ(B:-3'X!3G9;O'/SY*'W"XYV42$MQ6(R4&^\AI3IF3)K,R880DEDV
MEJR--=:U5&)_(&HC7$QZ?&6PV?$-136IV2])6LF&%NI:(C=)!$;[[BC2IU;M
MUDA%X3O2.>0A6D]6I90=R>6YW6OO@>SW6/S8.#Z)TQU0DF+B62T6^M.!2#EO
MCJ*RB):R#=#B-]FN3&>GN7@2;L8PS@3ABFHD1'T+F)Y X3D%@Y2W(T3VZ%J:
M98=)Q),GH$E#2]-$=-CB%'6VTMO4*Q34UQYD=:(1]T6C;G/E$0W)EF:%()YU
MYHVU<>6D:UNIT525&HI?*$..(79'1?-_MW2A%T&D8W,*Y/Z6%'5OI-PH_)Z'
M4^@7RNC7!#Z %BO8T*FTN!ITD %DG!T H/BV)8R(T=;(Q6DQ\U$:@0(JV%I.
M6ZF(XIV*S(F2'HT9U9+(W&HZE\42TDXLFU*0HV](S;-)G<::5B"H2D2$**(T
MJ6VEJ6]'A1V9,EI)H,FW9"&^.-M2FVS<2E:2=-">,TB*PQ S>AL@8 , .^+_
M $7+]CYZG_S>=#_L@X-GG;A9_.2+_DT;_F5 >CN"/\V9?^=2O^%3QTC9U@.T
M@P 8 , & ')3Z47[=WKW\3YQ_9C3LS(]R77Y3&%?NCZO(0U^Y85# !@ P 8
M, & # !@ P 8 , .E3T+WVN_2_Y:"7]1Z/F)>OJ[3&1O;U=HW"909 P 8 ,
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M & # !@ P 8 , .E3T+WVN_2_P"6@E_4>CYB7KZNTQD;V]7:-PF4&0, & #
M!@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 ,
M & # !@ P 8 , & # !@ P 8 01</%KQDZ%8R5QOWCGPB\6XRJ,LQ:;AR+G]
MFL954*'''0U$CAJO32<Y40?#B0(VY4IW;$.+'BM;0PPTA.XL5>K1FD,1JI48
M[+=]!EB;)::1I*-2M!MMU*$Z2E*4=B*ZC,SS,QM[U)I4EU3\BF4^0\NVF\]"
MC.NKT4DE.DXMM2U62DDE<SLDB(LB(6U]2?PS_@D>,?Y!.5_Y4S+W?KO[ZJWT
MC,],,7<*B?N:E?1\3T(?4G\,_P""1XQ_D$Y7_E3'=^N_OJK?2,STP=PJ)^YJ
M5]'Q/0A]2?PS_@D>,?Y!.5_Y4QW?KO[ZJWTC,],'<*B?N:E?1\3T(?4G\,_X
M)'C'^03E?^5,=WZ[^^JM](S/3!W"HG[FI7T?$]"'U)_#/^"1XQ_D$Y7_ )4Q
MW?KO[ZJWTC,],'<*B?N:E?1\3T(?4G\,_P""1XQ_D$Y7_E3'=^N_OJK?2,ST
MP=PJ)^YJ5]'Q/0A]2?PS_@D>,?Y!.5_Y4QW?KO[ZJWTC,],'<*B?N:E?1\3T
M(?4G\,_X)'C'^03E?^5,=WZ[^^JM](S/3!W"HG[FI7T?$]"'U)_#/^"1XQ_D
M$Y7_ )4QW?KO[ZJWTC,],'<*B?N:E?1\3T(?4G\,_P""1XQ_D$Y7_E3'=^N_
MOJK?2,STP=PJ)^YJ5]'Q/0A]2?PS_@D>,?Y!.5_Y4QW?KO[ZJWTC,],'<*B?
MN:E?1\3T(?4G\,_X)'C'^03E?^5,=WZ[^^JM](S/3!W"HG[FI7T?$]")BY]R
M_FG)@LBM\KYW1>9UV62?-2P'/JD I@648DQH<*26D"ZX/&P7B4B&/@1'Y[C"
MI3L:##8<=4U&90C0R9<J:X3LR3(ENDDD$Y)><?<)!&I1();JE*))*4HR21V(
MU*,BN9C6QHD6&@VHD:/%:4HUFW&9;80:S)*36:&DI2:C2E)&HRN9)25[$0OK
M-.-0& # !@ P C>P<<Y#;"TD]:N5\WLQR;IA,PU8*/6#):7J+':B1M22)$7)
MF/ZCQ6&8S&G7EZ:CLM,M^RVVA.IN>\_"(L6XO *-]7C@'WC>/?DSI?Z$Q<]Y
M^$PL6XO 0?5XX!]XWCWY,Z7^A,7/>?A,+%N+P$'U>. ?>-X]^3.E_H3%SWGX
M3"Q;B\!!]7C@'WC>/?DSI?Z$Q<]Y^$PL6XO 0?5XX!]XWCWY,Z7^A,7/>?A,
M+%N+P$'U>. ?>-X]^3.E_H3%SWGX3"Q;B\!!]7C@'WC>/?DSI?Z$Q<]Y^$PL
M6XO 0?5XX!]XWCWY,Z7^A,7/>?A,+%N+P$'U>. ?>-X]^3.E_H3%SWGX3"Q;
MB\!!]7C@'WC>/?DSI?Z$Q<]Y^$PL6XO 0?5XX!]XWCWY,Z7^A,7/>?A,+%N+
MP$'U>. ?>-X]^3.E_H3%SWGX3"Q;B\!"^ZM2J;1H3XRDU*LT\=*E*G2A]6 B
MJ_"DS5,M1U3'X@F)$8>E*8CL,*D.-J>VRRTWM?L-H2F+WUB;6U"YL & # !@
M P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , &
M # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P
M8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & #
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M$Y>I_P!#\O\ 6K%.S^D&%6Y\#^I1SB?7!F[;&GVB)SWJ#Y$D $='ZC7X_3
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M>,AGK,.'F8CG..@")T4E*M<P87H(@^Y;YU=)B:Y54BK(OOQ9VL<V/1B1-X'
ME62L-<SM0,O7KYC\OBS%O73R9\T:;2+)<$<\$$H==Y%:+PW/,^/72*E$(GP5
M!ZV?L;$\9*[,0(UB'0;96.9 QH0[(A'.RQ+>3^A#\0;'<N80%M6>O=U;?Z';
M:0G/AO;O(&Z=>US2^UFI1 HVF'.C%K1$JMBJ!W5;E=*Z%0.7AC-$.W$R<HUD
MZ'7:R'ZK&59&T.L"466H/5V";&R9@H&7KZ^NVVW.? @, & # !@ P 8 , &
M# !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8
M , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !@ P 8 , & # !
%@ P _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g63338g70f21.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g70f21.jpg
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
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M-:+1] S-W+2'1UU(]!+622IZPCX!8D6?LVBP27-@\^>!*ZYO&I+<(RD16T]
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M?1T.TAK8)I/JK2I$KDF&62:>9F0/4?K)9=)%(WS81&"KBJDZW5?U8K9>%%Y
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M^&F#5KT?K(2+!L, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M.R7]%&_2*._?#3!JUZ/UD)%@V& , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M?F9I27]%&_2*._?#3!YM>C]9"18-A@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8!51]57>;UU4^N:8>A'&2]:AQE%]1<[P0];AQ7!]
M??;NI2%R>B !@# & 3"O/U_@_P!,(S]],L\:1S=_]B]_ T?11.=4;6'/>,G7
MXREI=@8 P!@')I[E^=_VL_B2O/\ N?*,N) \2P?LN'[HY*9QS'48[4B&]OC&
MW.H<L8 P!@%J;U*GYR':3ZD8SZ>-,B*V]BN$:^]W=28+3V-8OV>ZWEDO!9 A
M8 U(>)>[ERTBK&+B:3CEBHSB#S>NH#*B%=6I("D?N"S;"IJ$A='MLU3(HP5H
M>!0J.$C5]3(\[+A7<C;4ZV?126PZ40(>8P;(LL^3 LDDDYY%KS?F>_>'\W@4
MWZ5Q :R9!YE"Y";[ @9$4>R,Q:L3NETXO6U0UA6LSD4X>'R4T@G8*0_"*U02
MAHB=:D(C/1[70@5&<HNG PN'S5H]6 UF=C; 8QFP957E@]2>LZ=?5+8)\PDK
M)Z#EE;E6$"5E]10#K?7O6.[A! 8,.]GKV<2J?V+")'6:R:D))05:K'$;&R5L
MYE[(9]:UHN6>>:K+ E5:+7EK-_4)C"D,BPB+*2:42_4*BLS;'YH10,2ATPX=
M+J#6Q@TDS9+&W I@HV$:&BNCN0%V[%$E)2QR0NB9E^-258 P!@$=DOZ*-^D4
M=^^&F#5KT?K(2+!L, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# *J/JJ[S>NJGUS3#T(XR7K4.,HOJ+G>"'K<.*X/K[[=U*0N3T0 ,
M 8 P"85Y^O\ !_IA&?OIEGC2.;O_ +%[^!H^BB<ZHVL.>\9.OQE+2[ P!@#
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M@$=DOZ*-^D4=^^&F#5KT?K(2+!L, 8 P!@# & , 8 P!@# & , 8 P!@# &
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MO"I+<(RH16T]C\P(PIPW0DC0.YW548IO'YL2P)H\JI):$P!$M&9,)&203L^
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MB-EG))74KFM4K3\D3,N'/A+'&#08 P!@$=DOZ*-^D4=^^&F#5KT?K(2+!L,
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M&W.H<L8 P!@%J;U*GYR':3ZD8SZ>-,B*V]BN$:^]W=28+3V-8OV>ZWEDO!9
MA8 U0=^TWC^YZF:&J:.3VIP]'W3);1L*KR,Z$7Y4PEG/J,2$S.KVT:=JQ^QO
M@/(_>6TRE7'XY(3[IU7XB?5TP,S.!CX5,ALF!>M.K N'_/7G3(KP^2\,.=7
M1> 2@Y.HF\MKM&JPL62RN.S4O9[G3M+<R9JUG,AB$6A,160M XF2L >.BL6$
M1F/CI&TCX%%82+:.EV PTDEKS)M1%EZL!-%.TW7FPP4X;5#,Z^[62*#*,^)+
M4E#V#4%ESU!?@XP%JZ.X^\G8L0,6#.7'O@^XD1</LV18.>&W*Y+1JR<!)>I,
MZSD9'!2>AL.*,:,B8W0J.9D=1QIBL+,,.'C=-QPR*C7''"[ BU]L]H>-%?\
M>W<:*);<\\Z^OR,'T\ 8 P".R7]%&_2*._?#3!JUZ/UD)%@V& , 8 P!@# &
M , 8 P!@# & , 8 P!@# & , Y"MK?M1LGZ?3'TB(Y="B<UHVKN>[9*44SGE
M+UE_WK1 <^@^88 P!@%V_P!2G?L([9_6W O0XAD#VW\80;4Z3WS!/MIW%T9U
MVC=PT6N<A\F,8 P"JCZJN\WKJI]<TP]".,EZU#C*+ZBYW@AZW#BN#Z^^W=2D
M+D]$ # & , F%>?K_!_IA&?OIEGC2.;O_L7OX&CZ*)SJC:PY[QDZ_&4M+L#
M& , Y-/<OSO^UG\25Y_W/E&7$@>)8/V7#]T<E,XYCJ,=J1#>WQC;G4.6, 8
MP"U-ZE3\Y#M)]2,9]/&F1%;>Q7"-?>[NI,%I[&L7[/=;RR7@L@0L :I/$ ;7
MN9M.KQ-,65=T?6"5A+[(?0R@99& <X?"X/<=#K6%(>8;,!Q$1;.[RJ2,SKZ'
M M1DLVC%ES*&.'D->-)1[^ 1LDI+-,WW+^:(2VAJZL&3^&I.*S34ET8L"<0O
MMY'HQ(;BA(BBY8]=3JP[G2@EF3B 0^ 0!I5.\T8&@5B/(XUK\.:B+ [JT+CG
M<@9/W#L)I=3R32I/NT]>7"802N2/3-(4<S@'A]E =HUV[J]QUG["]6Y7UMNF
MN1F\ E\7$2OF*S&M)Z!N%*O2<=9GHQ8(E6I>(D:BY,O'I3JL@NY0T&<JS:PS
MGD5<.=):<Y8-P:&-[OMYUJ'R^>00C<$2'26M ;F13!H0<.F+-D-8'^8H7X&F
M735(-)" &5\MXM(@\:?ER\?D[X;'3#%D:(LV*PS)3];3MAUO?*01%M<D(W7L
MHDZ#0YMN4]I=$##*6)P!R(?-ETDUX\43L!5*O_>Z2)B'F\]52A*:.\H5T%;#
M!,J[NZI+:(RH16M@1J9DH2Z0:R=F"(:.UAGNI\:%LWO/''&O#P._*QN2B1YT
M?RZ"ORL;D(QF_7? BK=H!,9+^BC?I%'?OAI@U:]'ZR$BP;# & , 8 P!@# &
M , 8 P!@# & , 8 P!@# & <A6UOVHV3]/ICZ1$<NA1.:T;5W/=LE**9SREZ
MR_[UH@.?0?,, 8 P"[?ZE._81VS^MN!>AQ#('MOXP@VITGOF"?;3N+HSKM&[
MAHM<Y#Y,8P!@%5'U5=YO753ZYIAZ$<9+UJ'&47U%SO!#UN'%<'U]]NZE(7)Z
M( & , 8!,*\_7^#_ $PC/WTRSQI'-W_V+W\#1]%$YU1M8<]XR=?C*6EV!@#
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M46I454.FWE52V P!@# .0K:W[4;)^GTQ](B.70HG-:-J[GNV2E%,YY2]9?\
M>M$!SZ#YA@# & 7;_4IW[".V?UMP+T.(9 ]M_&$&U.D]\P3[:=Q=&==HW<-%
MKG(?)C& , JH^JKO-ZZJ?7-,/0CC)>M0XRB^HN=X(>MPXK@^OOMW4I"Y/1
MP!@# )A7GZ_P?Z81G[Z99XTCF[_[%[^!H^BB<ZHVL.>\9.OQE+2[ P!@# .3
M3W+\[_M9_$E>?]SY1EQ('B6#]EP_=')3..8ZC':D0WM\8VYU#EC & , M3>I
M4_.0[2?4C&?3QID16WL5PC7WN[J3!:>QK%^SW6\LEX+($+ # & , 8 P!@#
M([)?T4;](H[]\-,&K7H_60D6#88 P#&WMI0AGLK1DOJ6/V?):C,'DVZK*51U
MJ(*M7.S7;?E>-3&.'6!$5*H')FJBX>61YPBBJ]&.=U&+UB1;M':0RBR6>$U\
MPWP@6=>R7K4<AG:BRA87K+I*2D-KLC6-(R6M&LYL2V)E;%ASV)P:0PDA&JUD
M11>:.X+$'\'&"R59UR,&QN%$AO*IAZ5&5:59S1*Y9YU)),O^5K6=1D!U1\-^
ML>J]]6[V($R%"43ZT Y6*HNF554_5? N*G)\0L8U\).:DAD.3L6;&CBP5J7G
MTH;[E7HF)@$>&J)#<\3-@K2JDLW7FDF%5P9#8Q@U& , 8 P"D1ZJO\X'JE]3
MDS]-DLGFU#BZ,:[1^X4@&W%C*#:B_P!X0JG9+Y#HP!@# ,A.I'G6=9/XA*7_
M +CQO.;&<3Q7LVG;J].G!<<PGM.@;TZ.M)E.2YHP!@# .0K:W[4;)^GTQ](B
M.70HG-:-J[GNV2E%,YY2]9?]ZT0'/H/F& , 8!=O]2G?L([9_6W O0XAD#VW
M\80;4Z3WS!/MIW%T9UVC=PT6N<A\F,8 P"JCZJN\WKJI]<TP]".,EZU#C*+Z
MBYW@AZW#BN#Z^^W=2D+D]$ # & , F%>?K_!_IA&?OIEGC2.;O\ [%[^!H^B
MB<ZHVL.>\9.OQE+2[ P!@# .33W+\[_M9_$E>?\ <^49<2!XE@_9</W1R4SC
MF.HQVI$-[?&-N=0Y8P!@# +4WJ5/SD.TGU(QGT\:9$5M[%<(U][NZDP6GL:Q
M?L]UO+)>"R!"P P!@# & , \;GW82E*MF4'KZP;(C,4F5C%!P>'@2KS9-T2(
M&5WS,"DY4324:A4Y$3&O0D:='5QK21R%#:.@UWYO;1AL$O.W[D/KP"YZFM4C
M*Q-;6+$)P3@[Y,=+6,:.,2KD$Y6>EQC?9\DU54VU:.2D>D(IJ0TXW8.BL>D
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MG4BK-99#U[)N\>H+IU,N9W>TCELOZ*]T"/-<2P,/:Q]6S8*.KC?KO+)XS2B
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MJYK6F3.INJ,2:5&69?3G-4FBHC*LRDM4U5:D547!D/W7=)>U$%H2=K&[QO\
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8! )I9L1K\K  TG=$FKVS)>E!8G[B 'C#5Q)%Q)0T@U)O1
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M79/U&16# P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8!B59W3>L[6L*P[$D!>7,GUD45(:-+AP[P0@"8)27_ -H1LL8P?!2"?-G<
M1] ;$D3I/WR';144T NP[L:J];NAF?G\B(?]"4!)\V0_F$UFDKD5O'*HD5A'
M=](X"W)D:DMMK; 5,0Q!!63>.CR*PX1$R2 [GAVJ"%H$N7^\N<D)(\"?W2/
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MQ\<5$/RM;QY@V<'F10V!9</',;*B"[E0CR$\GG+XJ9E8,# & , 8 P!@# &
4, 8 P!@# & , 8 P!@# & , _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g63338g74s47.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g74s47.jpg
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M:I),98K#5:-QB24!5W'VV;\XV6R!M['0]>!J F\Y3K=S#TDG9FD:+#LFE3G
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M?09UV+IW#)S!Y&''8@:-&+8A6FL+7%-RI5X0=MBD!$19EDR;!WX<8WF8B=X
MWV0JBX[!0@VO/1*DZ:[/^E_0&DV)T[?='JQ7^&]2HNH6X(7URIG=E8D]NL\A
M'8AU:<AFJ>GT>'MKE2_7L?+C@RQ<Z^?6CD5K!V<8Y%E>+QMY2/+WW!W;MBXD
MPM.75D*2H"LMJ#N>7)D-D=N2SB.P+Z)0^S6"MDTV*K<KDZ+7^9QZ3[5*O2<L
MZJ66N=UTG98IXT_,"!*$HGBP)+7&[]F^;'>'M7>MB3$T"R#@Y)=US 64(S96
MDO1&SG=RU@B[,K,%.//I@,Y.R):R,I]#O(K&NO>M"=:#N-BBEDM!ZH66?MX8
M5I,4(>*&18"&OR-1"+=BI*RGXL.Q8CMO+W);7M!,[JF(JBZ68/3]/-&QP$]]
M<GK*N<J1CKEA]2M;AD1\:<OKSS2/OPJQ4.(V;$ZVEM_91:3L;,"BU?;CTQ:D
MN:Y]'-L6S:C7YHD2W"]H8>I%:&2[M>OMB76B+FUT&GJ=D3-SWT)GU;C7IS,5
MDA1*XW:=0/6-^*IFZE77=BUC$S4E.5AZ!R!/$N[3FGYJQV23,*=1&PJWN4*@
M9#8KDNC<?-M8)NV6TBJY1T6Q=BI0\L<*#'M7(N34KRX7;MKWCK.J;#+),2W'
MSN_T!:JS]<2:)C*;0+)TLE0: J:QEU%O[9;HWDDVH474M2*Z;>V349NXU.%V
MFNQF@S@9I*U.U/,;I3FPY$#UV;VC<]C>T.%0'^\3)MQ=QU5"0>0,>X+M=5T!
M2D2;(&A9-F(A90LQ9KK'LVG[;]G<[AHGB*XJ>2R-M[S0)J0DJ-EM(R<XA5S!
MYBF)F61S UZ[GJ/SWYUT=&\ ]>^D;.TMD)>\&+7=E,C2Z56ADDCQ<%JHV8.0
M9H.KA*P-,Q$E4W\EM$*ETW7RE$8?((Z1XSQB<ED[_EV6<8-2J^@JS#^^4EWR
M*8)/8-*VC!!(M#N0,BN8@Y[LDM?.7QF+Q\6%U<K-RTC(-K2B*XB/EQ""%W?!
MS%'(,@DL[<E$L&9".UQ8>D/+[77].--.--.-->WX3[+;3976_G-B*[I;T]KW
M?0\:$Z=8]WJB4,Y6?3VQ4Y+:4S6H&L[1[.D:-;@6<F^Y$3*5.L7@2L3@M$J4
M]BI+GT$^K;PV<FL**7)H%G *5^<@T1B:SWJ?:9*/*PFTQ05^(/AHM<$B)1$Q
M'H"^D*)U<6T[[DNOA@3B&>3D'SE[-=#45518BW+:JW'8Y&B4DM)1)C,QJ$#O
MLGC\C7YX4;SR/(WMP^D/2&NF>QK)LUANVJH:5\YJ6M'YC?8[6GW!U']; R4V
M=NM6-:F;XQ@K$ Z[0LCJ>3#4SFD%U@OLY)PUR$:6+Q=E46TVZ$NO9-UJLJO,
M74H+RW>4F(M+$E2)M*"+M%MH#HQLMQB3L"17LKE*K9J.J7Q30QB*MEMF)I/>
M/F>RUTS580,@@4,C'='?/)'V7>O<O17H;0^S-J-H@N@MVJQVD5NG'K-!?]P:
M^W&-+M:^_BJF['-!5C3.N)?2C=*Z0 L/3^Q&F,@(!35\E<G)GKL=6V8QF-R%
M6FDPL)N%?:7F[-:E9HD"65SF@BRX$M?WA"^Q4UE H39R[HZV5ND*LY/)XZW<
M>!UG4QQZHBI6L7JUX#<NR$9!]=+'*1V2/'K9YEAM,%S'9/55[6\(:UU'Y13]
MT'6]LEV0V(K@T2*A9_\ -Z#9!E5K?>QM*QAI],N^S1?HMBZ^]"Z)E;:6@L=(
M;=ND1N5[/-:8.Q\RIU#:N9AU!:$^6382GO!7R=@6 W'5;_<B\BJ6,7_G' !?
M941"(' _&J@H=WIRI2PZ;['/FTZLYTI.QBZTK-61M4.W-*Q;#)L_S;F<HK-$
M9(@Y3*F<=?%7SMJ]T\<[2WV V"V3;7TV43IG=!E JLBY&ONSW_! [.A\O;[V
MP(Z0^.X!,%MC&TX/KV$VPBM:PWI6R^*E)V3LG;1FZF.963%.\#XKV88[N]Q%
M?S!0?)(UN1<6 %5;V696H[4C"1. K$XNI8P=S)*LNFY1)$V*TJ5*H78L^7&1
MXN*S !$K8=IB K0QH5(*7$$EIAR\U0Z<::<::V6\=:,$>E_3>G-$'CU]8#[+
M;,%\@?%X#<[XRO\ +K][*Q5Z,3U16,GWT^H_B$+,%.''/*6>:./#++JJS>0/
M%8J[D%K%QU5=P5ER@3F3$-IX01_Z6^PQ)3MM$;SJVP6.7ELM1QS6$E=MW;)H
M<)((X$6\=R8#_1_TI@8^69B->@&J/LU]4[^]*7/,FNMG-*XUV-3"]J@&*5ET
M=Z,4LJ -WFH[,&GCWDUYVL$#E(-?X6#*,'M%JYHNYT!J@7'CHW]0+2=<N=4W
M,=BQRMFHEB8N'38KM7\8[DRO!5"6O,5Z9F$V9@+!B$@""-X$<UG!'9*?2E/)
M94L35MN4Z:0W5MEN/R:>*[$C;!C,-8N LXK1+*X$<,-X@DQ&+*#GI#_L]_/S
M!Y9+>CZ6W-C)HHHL>GVY!+;!QU")7,O]!K.<#:^06L)<=PK]9?=Q]#1H2A60
M0+=6 M9N"M/!>'U9[/?)=2Y)67'%E2JO,'8E-@*TW3;_ )02MEFPE@USKQ7I
M<C84V33+$A,Q(E.VL1Z9QC<0S*#=M( DY=]8[,4@5_DYK%UJ[EE879FQ>XB
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MC&_T@_[!_>]?O0U5[^_[F4GW]W7>7?W+/7?W==?W]]_<;_EUU_M[[_EQS?\
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M/.WK+:#XK9116(Z\4#!,0@BB,4AA&EE:QR+K1?9H*:T%@H3FRP9A:[=:\ [
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MTUU];XYV/H ^N_LM.QC?Z0?]@_O>GRY3_P 3$OZ:Z^M\<['T ?7?V6G8QO\
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MU];YNYV/H ^N_LM:.QC?Z0?]@_O>GRY3_P 3$OZ:Z^M\<['T ?7?V6G8QO\
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M/85+S)80>Q1"R&=NWW7#W573;=8859**X!$6+=>X7(EH7+&RVI4YV2COM&N
MF<AR&9&)]]^@\VFB==F$:VTIC-2^W1U$?52VT-HNNW&760#<=(-=$2'RGYXQ
MG98 A2F<4,Z)&9=,JIQ/RE6IM+.G,;VB!"S24+(4R5BXU*3E(([D(FR \^VI
M>[ );H((:MRW?&QN7U)D^\++# >/."=$5Z:G."'LL=LGQ5(N'<:R8 A8F1*5
M,2Q&ZI^W[W?MT\R5KB!B%UXG"E6BH TO)/U4?IUJ$"HNJ]Z_>AIZQ5U/(M>[
M611BK(O)*N+72U$>26Q(HK3^93JW3M-2B&S+++V.E[+'>MK*2[K6B(R5ISN
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M*O5S4Q&^T1B.GR^3_KXHO_OKVK#?!Z\'K2N3^C5,GT]?;748_P WZ S QJX
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M/S-Z[T9<PO6/2&8Z? #L53ZO=AV]1>'MY-=(2\+>2RN$N]*L?!0J8S=,6\>
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M3_S_ /X=\^9>K/D/^K_T'7UETK_J?^S_ -FMOU#_ -'C_P"[_P"KKGRMU?\
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M34-&<;14U4B*>7.(JBU.\6%P!^Y,D7N%RC4'+I;BOC:ID\ILP01=)$P](J7
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M:ZDE"I0Z\HTUK$Q!-J ;!B9E;9[;."P(-L.;18+:-&@5_"+R#616MY',JHJ
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M->*PM$ 8G8*_%G='NZ2]*^5 P956WY#UU'_"B+IJO&?+Z,2#>)*R*OL]K?P
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M*(:&\56<Y7<3G@#C!'HJ->W#7@(PW42<9-:M&9JLIXN_V ')& 'EXRH,KFN
MMR#%'3)DB#8A!Q+.XOE,3-C8S73CLG%FR6$MJN9;']\RQJV&O#SB378 Y.F)
MJ:%P0@C7N\/BX6SC!1%):/WO]G6=O*#GL=8\P"=R&_*6D:+) 8U.IHVF!^R
M/HS;V.Z1-]5K>;=TZ^#O9[0\>HL83X/4N9<H"JG*JR[@-A%,2$\Z_C^IEBZO
M6;ECHAE[Q+E=QUB\55N,I>1,73E*%DZR\CYW=3+O &$N6UV50XQ Q^1Z782'
MVDX@+S,/CQ;!TT5Z 6EY.[%\"3&+OU@L,QWD]F!3DS6)PJPNR7*:J[WWX+IZ
MIMI*P@^=Q=,YH7WJ7Z[,:AHNNPP>WL-ZO;/XR 0[::M<47NS,-1LE@2,M]Y
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MA;.1[@1B*V39,I;D9B97$17 ZK+ 7:W].EM!2[Z7)KJTLAY4:4-B [5_R<6
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M)AS C$SL "1E/R"(S,^D:M%4\I^F7O5AO>"7H#<+7IY<P)2F]F+^O&DLE#X
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MJ,[1S.;P71#V]-X+HCHOK&]F<UU5A.G1!G7^-FWTYA.S?$EE<.XMN/NN7:8
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M"5M\G;ZTZD#;Y?DXY*->G8WPD\*F"'/PR\/C_P"OT9TX6_\ 7RQL[_\ ;JY
M_GO0<N'7Q=(:AD^_'KO[\]:IF7?W_P#/D%[YX+U#XZ^-R#+L^,?BHG9FWQ?B
M%U:$;;SZ;#EXUZ'C_!CP>,)D_"?PT.8B/S^A.EB_\V*G6<_LZ^??\B]._P#9
MFE_1.=6_C^\=OUU>+/\ Q%ZO_?&K'^)7P;_5)X8_L#TI^Z=/[.OGW_(O3O\
MV9I?T3C^/[QV_75XL_\ $7J_]\:?Q*^#?ZI/#']@>E/W3I_9U\^_Y%Z=_P"S
M-+^B<?Q_>.WZZO%G_B+U?^^-/XE?!O\ 5)X8_L#TI^Z=/[.OGW_(O3O_ &9I
M?T3C^/[QV_75XL_\1>K_ -\:?Q*^#?ZI/#']@>E/W3I_9U\^_P"1>G?^S-+^
MB<?Q_>.WZZO%G_B+U?\ OC3^)7P;_5)X8_L#TI^Z=/[.OGW_ "+T[_V9I?T3
MC^/[QV_75XL_\1>K_P!\:?Q*^#?ZI/#']@>E/W3I_9U\^_Y%Z=_[,TOZ)Q_'
M]X[?KJ\6?^(O5_[XT_B5\&_U2>&/[ ]*?NG3^SKY]_R+T[_V9I?T3C^/[QV_
M75XL_P#$7J_]\:?Q*^#?ZI/#']@>E/W3I_9U\^_Y%Z=_[,TOZ)Q_']X[?KJ\
M6?\ B+U?^^-/XE?!O]4GAC^P/2G[IT_LZ^??\B]._P#9FE_1./X_O';]=7BS
M_P 1>K_WQI_$KX-_JD\,?V!Z4_=.K=JU:U&M7I4J\%.G3@BJU*E6*.O6JUJ\
M>,4%>O!%CA%#!#%AC'%%'CC'''CCAACUCUUUSRJS9L7+#[EQ[K5NTYMFU:LM
M-]BS8>9-<][FD3'.<PB8UK"(V&1$124S.O1T(150FM62JO6KJ6BO70L$H0A(
M"M*4I6(K4E2Q%:UK$06 B(C Q$:Q+.L ', 65FD33.+YRG+0*BK\74M:W6EZ
M_GCEU_++"3#+K&6">+*.Q6L1Q6*\L4\4<F-ITYU'G.D<YB^I>FLI;PV=PUM=
M[&9.BR56:ME4^A#/J)K,9)3T-$T6$&Q#UL2QBRKL[@L/U-A\C@,_CJN6PV6J
MLIY#'W%PRO9KLCU$H]"$Q*!8ERR!R' MZ&+<L#'^=3UWY&/^=F'LR%QN'-5'
M;F>($[GAW+9"69>\Y,5QBSCQZPCNQX=9?+R'>,<!BM'W)AU%<BMU8/WX^"K\
M*C!^/F!C$9@JF&\3<+4$LWA0*%5\S67 K+J# @921U&'(^?HP1NQ5@X Y94;
M5LN_%'X2?P;LOX*YF<KB1M97P[R]DAQ&6..X_$6&<C'!YH@B(&R P7D;TBM.
M30$D,!:59KJTOY]?:^6].--.--.--.--.--.--.-->T>A?5?FA)\B:B2',JD
MF]J:NUC]H]97U9]U';V2# ;9V]#YRF\^$<1[(CLB&0(E2*(USTKEOJ^'!9"L
MXG#(;2*5H"71<CB,J_-7+" L+J6[73(L=7N158RG3G)QD1Y*>JP(@-A,%$<3
M9SB4\B&9'ON-S.*KX2E7>==ERI3ZHE2;-(K2UW;L8R<:7%M=M<B,J[I$BY N
M0V=Q@X@MK-4^X?#2#OU-VN#-ZQ3RA#T=Y'>&PX$\^W1X\&OY>!GK6GI@R-"5
M-7]4 8:MZ/:8K1P(IBX;)8QGDYIH<M0J0F(ZBY@<_9QSZ;%VW@.,S-=*V9(2
M-C/X15[6+ F%;Y&<XQ.RV..8$([#S BD)N*?4'3U;)HN+940193"V',7C2$5
MKGIRQ4RK 7%3BL(RC8EBT!$F?QZ ,1@]1;1GH7P,N.FLV;8>T-(V#Z'H1"4=
MBRP^;8\M?;-<<?8F]'+;EH; >\C;'NU+!#3A?7UI=$@-=ZWR:E4W30;.R=:8
M*Y %6VY#&]1-3;56J7X59R%AU:)RDQ9J)]B4$4X*5YFJ,P-X;,--EFU"G 5F
M*UKNBR=6/R?3:GU&VK>/EM;&UT6ML5'EK;XSF0?=D.YA;1#)43KRD%5:O>4P
M:TVJD*(!FB_Z_P#").EIA;97?3^:IJ=>]X(>I@E[2=L=5U<Y/>^S;?YXV9?O
M%O+>VQ_:)=T]=R7QTA) V<;67HS3:6?6&!T3>8Z.AN%ZA$KS55[O>N,Z>L7&
M#?@IMIKXY:<E5$1RU(HL#=B&'QL55MKK)*K? Q46]6;Z=,**FV*/9IJZCKTU
ME0(1J6+&28[%VR(\1=&*TT9[0<JUIBK#!:VIW!)HZ5:L]+>5]<_:>[-WN.H*
M2]YTMH/HD"'$K@5XI)+*9<O+SQKZM1$"%=*1F]97]G[)+9]5\!:2A0J--GZS
M@'IXD7CV.O;>*R]GI.KCB)S<F-C&,,VF@GJ!&6KV9(S:^PEK*E4/7F^Q+B5M
M).,_>Z_3RN'K=6V\B()5BRK918+4%@4--^(L5H$ 4A#U+MVC].%>O"8=O (
M/<E2A]IW0NZDWV(E5-3:?LJ_G[16E_+.I,$=DW4IYT%CU:O;?=\C5G=G6WJY
MPW6%$6]CJDM@D8AP[*B*JI]6J>HC/BZG])D-S''#KET79+(7LO<EZJ+H)N';
M21PBAY*5KDQ2J1K!)%R.7R2R/6]'5H%2R(2FG1E.-QU'$4O+MOIXIS*[MCN%
M?B[#&"!N:)62XCQ 4Q#!'?8EIWI]F#$A^W1B@WZEG$;:->U;^ID:SYYMB+P
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M;V?FH^L9]WIQQ7TV0^S5OQ>N.:)0ZAE[KWF3*?J//N#&84,CARF_#W\/&7/
MS)GA'WG^'K//".3+''[^\<,N^NL>^8FQO&XIVWC?8SWV_3MNO;?;Y-8D.,XE
MP=>D^,\(*M7@9+;W8*8M3,#OMO,1,Q'R1,^FHWS=J#IQIIQIJ]-:?^KP_P#2
MS_\ GESS3K/\X_ZQ_P#*.O<O#C_-T_[W_C&MU47_ (G_ )__ ,.^?,O5GR'_
M %?^@Z^LNE?]3_V?^S6WZA_Z/'_W?_5USY6ZO_E&?[VOHSI[^1_[O_;J_0']
M\?\ S_\ WZY\\]0_ZW_Y_/KUK%?FA_\ /TZO('_YG7_0Y\Y]3?GE_P#4_P#6
M=>EXW\R?ZHU(>=/U9Z<::<::<::<::<::<::<::<::<::<::^<LL<,<L\\L<
M<,<>\LLLN^L<<<<>OORRRR[^[KK'KKKOOOOOO[NNOY]\Y$2,A$1DB*8$1&)D
MB*9V@1B-YF9F=HB/69](UQ,P,213$1$3,S,[1$1ZS,S/I$1'K,S\FO$/W![>
MS;\RVG-/%LL%*/*8>YN0^;O')ISQ[RCL@@5F+O[^EO'OK*(@1BR^]@[ZRK5L
MODG4DAG]E/@9_ U#I4,7XM>+&+$^J#%5_I#I&\J"'IH"B&5\WFJ[(F)ZA*)%
MF/H-';!1QLV!]LRM>(_*?X5_PK2ZC+)>&/AGD)'IT2;2ZIZHILVG/D,RNQA\
M.\)WC!Q,$N]>66^9F"KUR]D=QF5\I>?IWK\\-.--.--.--.--.--.--.--?T
M ^4Q_AC6?B#S;M+U8JZ3LA=B[8]8 -B56/4.R'C>.TUI#!:MP6UO3;TC618?
M6K"ND&^7X9QT/!AG4YP?:K]W8A9*''SC,'U!;S^4IX=UZ#K4\.RM*[M:O0IM
ML,M]UMZN^#9:4T4QNM"V'LLHG:3#7I.&'IZI@,7;S"<?*[5W,*M0VC:L9"VJ
MNNIVE4;%>175:LW3LRPP!B6#,<H$HB,[&\,:'VIJ+5Y#5U![5]X _'7@K9!A
M=6!29(G;')^B=U+.B2F$<18L#O3[+O%WH2Q]'BK$!6;V53H%?@&Q_C8X]M;J
M#(T[EH;A5W4&9OJ&J#6F_OUAQE%V0&9X 8Q5$*Y*[8*8T8F6#)3LK6JST]C;
ME*H5,;*<@O!].VC6H*_8M%D\@K''$09K*;9%8!O=-JTE(]LH"/C=6(5^R'\\
M"W]+JWMG;F");+JW<S';'G:$$LPE[U%NY.U',):]O*NK&A%0%TU TVKD; 65
M#*1 YB*R'7V20Q8AK/%&#K3)'6L$-2BQZ;=%4&LIB#KW:#[D&FDZVJQ9:N4Q
M$J!R[$H.;!50E1*F4?1.+"RB"N7EH;4O-D6C&X6*5]%*0?>53;7K*.'3,--+
M*_?"*\6BA@NBL&S[)5(0M([O=7+8NQ0^P4<WZXB5@D"\(91*W2\MV!_Y9=VI
M#K^)XK1L.PJUR/\ .,(AQ%J>NXBJX9*9GA)&Y(,E)ZRL6+]!"*M4ZUA>&EK)
M::C;.6@MVU)LS7GMUIB>*F))UG@P![9B,,AMZ,KU\??L/M6@LUV9N$KA8-!,
M8?ALJ[%:+ PRU!>K0L FM!J8<L BX5CX,TP"VIYU]!!W/S.OL \KJ?T\R:[]
M"F5EPGQ@V;J33HYZ'+%G;8YAQ5=)T=:5:N3K!"54[V&W3+4.06$H.#6:9,1,
MZBO,IY/&FC*L40W,4JSC5M1&]6[=.N31IFONWRM%/8F0<,T@25A0$<$)Q.G*
M"[F+R:WXE31.GEFU<F:7EM;I41L F;H,[6/&I ]^(-)1=-P5VD*R@PJ;R_X[
MTWNC1*D^OC^]JCUM?V8B>.M>1AJJQDAKA1\"+9O#8VP;9C*,K*!7(2)'&^&"
MRUK9+\='.,D+CJVY+,S+9N]1R#J]:M7=7IX.QF[,LEOF&C78U?E:PA[D,;Q'
MBPXD0V+<#Y#$0L1@Z-_')LV;-A-BYG:^#K=L4^74=A:F1:LDR8.5J@S@@7,$
M7NS!# EOO=E]D?YQBVYFLV-K[MH*G\".5^,:P*!8!)"Y)^[@VI,.CFZL-1F=
M:K !GID[5\%@:7H1L#X+M:N,/(^[)28KG7HZSRDTX;%3'D[S"1DEN!GQ#J!W
M/BZ/G0M-8HA@62#).:Y1;77(8)0]C_@5BHN]J;N0%/EWE ,0:YAZ,@NE[]^*
M3*BEM$Y)<&N!BR!4SL"7%LT9A]E-#7CPR*DMHU.P=#[3#_2)-@(6B%-'-^'E
MRP41!!TLN6&59'VGHI^1&,N$+*5J=26\<%<I:PDKVI;&>KYF=@&H7=+I;RL2
M;1)Z\^V L&L&PIIQ7#D:MU++T^. 9B8BOCHT8_/.X/;'JOS,P"3&NSI]<E66
MQBNZD2L%L+=FF.\[)*=XF=L]A^"/)CR(F%TT/9",TE_0GV=6M[CAIU2./51+
M1=L^"4?:#U=RUTM#CQ6Y_%KE9:39PO2!D2N+==5[=:.T,KFPI6EK=19FN<&5
MBK82&.ZFLBBZY=<GV*?45BI7&++26 ]E$)!8$P [(N&9$Y!@7-GIS"V0X#6M
MUW,R72]4GT$,L0BO=Z<KW+)>54##GO/)K&&*S/ODJ8W"#6?F7Z1\D"_-?K70
MNO$I)/[V4MHC]4OR0AW7 0>EW)18W<FJS)@-MU]27#N8AL85DHJT[Q!+UT]5
M))[..:M0SKCBQ+M>+S)Y3#9"R]Z\>ZH5NO8L0@UQ1)2!=#V)LDU?-*V@Z1!]
MJN40/QI;D ]3RN%#%9K&UJZ&9%%L:=FO7EX,\\+;!)E"WUA4R5N8HTP1UZM@
M=Y^)'83/UX(>6]5 =CNU<MXQULP>F]0:&TU$[ZD6M;[%K>?F5XV;[03D%ZO:
MW4K1.&SL.QI/2#F+UVT[)5R%M+L.U@@WTN[=@15/V^ECE[C*J)#.6E8J[D+T
MHNMM59R2:]3!.L5QM.@)BM%_((.RJLX1?"(%);0<K'NQ8BFNU8YX*JW+4<?1
MBQ154M1C76+>>17L353)1-DJ&/>%9UI)2B7R3A@I"&3KMM'S-J[6/GSW@5[\
MJ+]S2"#M[TOJ/S9NH*'V&[[FV'L%/WGW16'B!PI6YU]"T1HG7 2XM.QHWU$M
M/IZQD.K2&FNV2D7K.IE;=O)=/![88-^S3Q5S)T&'7KT:U9U#DU$I*(;9R&0M
M,%J 7NVNL>4P"H&&U=S$TZF,ZB/V.J<?6NY6EB[X!:?>M6DWY%3X<)2NMCL=
M562GFSXJPR>,2;B*5:#>^U71@91\.-6@]6S:I5ME>5+C64$E6'!P;3IL=Z(W
MNE=L[NV1!U^N?:2PE4%YWYZ((,)HQQP!PHNB''4:T?8NG79 W9].1MQ<=5RX
MI P7V4K66,Q[^S73)LE:0-QP,$PS*=S89&13/7.I4XY:.GG8VG---O#DXP-D
M.<Q@Y+(([UAT N&.,$ARD5@ ^@ (@(QKSFYV?75M.--.--.--.--.--.--.-
M-.--.--.--.--.--.--.--.--.--.--;O:G:!>?E79HZ\I:ELGA^ZM#:\",Y
MC6&NBKY23=K+?I&^_P E-G+K]L]+<A(*R;(+/RV9R"EW0'UPEP9#9SBGH+BC
MC+U"%UR%G1R-EB@MV0KD^FS%C6W4#(7 \6N@UQ$"[D4L$YC>.PTG!.&MB2*4
ML"_CJJW'3JG9%%U65*SQ<:Y9)0242#)*33Q&%D$3M.W$?C'0+5"X8H:MO9W#
M:[VHX:_@ JKWJ^9YM"!&UD[6]_8C,U5M-95\UW&G9+N%<7*"DHK(^7&I8:,A
M% VU34WMS(IE/F'8]#+-1%F6NKVXKP;*;[0UDJF[O#-Q!$G#.32CE"NX2TQ=
M>P<:X7>63D+ 5;CZL*38J38( NHJE:<Z*.W:XD;H#M2*A]);VQ8[7"[>+//1
M!(;7((__ )[-+UK6KXWT*:_"OC;"7YC1-@A=EN(ZAK9W#SCM[O1<T#'XM.S-
M.]P$0!V)9O;"99L5FERC.Y(7H0=;C%BU,R-B!EAP_*V:S*J"*T@X+'5P6PNS
M5N[BQ<M&LJ.Z7%C 8LJ[GJL\I14&.5:2A02C$5K06WB-6P$CD+!L6/=M4=B6
MR%%9;,)&O=,ZI\U$_*@EVV#K=O)F"U,Z 8&];V #7[TS3UZ0T<O#(5VVP:^;
MQRL47]<MMRR5'Y4SDYH00SG[B#0$OF-:3>N90<N=>M:2  2V+2VLQHPGV7?8
M<L%=E!.!EE(P!<EPM@[;G(\9BT*>)/#@^U5<3#%BF/5:6HI=[5QZAA1,JO!)
MJJNF6!(MEBSY;+@N43_+P#YW!A@A,]LYS.CX[YWYJTK1B(8&9[(*YM&(GKY?
MD.:AF20+D(II%*Q?M5-K;)+]9UBDE[7 445%E1\7^$F38Q@*J(64PN 2T),U
M0R*DA99V[L/8@YL3 B5.J$[CQM&8&!29Z;QBP F6[#!@F<W).!6Z5E;@ZRY9
M2E"G@-<9*8N6CW$Y*J &!A^)?@+3KIKQ9>JM7;W9!@&RN A(![ %,!QQ72?F
MST/O@,KK9N[YX64N=F"%]7HB$SFDUCVEA0*L14:X)VM'6:BE#N7]1W466URF
MEQ6789897-0(:&4QF/8YJXR37PE@6[%E0/54Y H"2ZTB">:OTW1?559B+W)H
M]]===D&,>H\5E,B"5,+&)KRY;*=>NYB&W($VF#T57R*!HG9WE+3JCK_9^PQC
M0YBIM4BDBHWZZ9SJQ;; &R=U:\U<SZMUO9NU5@+U>.+)\COZILR#^'QEVJ-T
M3;I6Z28T,/8@18U,Q>=8J5C4@_.&^4V4K;"65:-FVJY:@9:?%;5!CIJSW"$C
MR(D)/4OD==;PU!%:W9!SPFFNO#ZKF))Z[=^K3;3JR4)7R8EAY(;<=L"@,<0R
M*&MX!]H'G?3KZJ:B%L#%(E2QZ+S](N;37N@ZL[:E@]\;*3-WAP/S>I-:(.RG
MK1/!W]>KL=OY7*71=A8_*2!-PK=U^+.3NUW734N+$>T(Q:$S#)A#V8^J^@;.
M!1 H=;>P;+=N?"Q6]X11.ZMC*-E-(&-[&V/]JV&P2XER%Y&TC( OF,R5A-5"
MRJJY<).O9]PC?&TUB\@Z &IUIU9+&W*H4"B!7 41Q?$4<,]"]%O-CQN8]+J&
M];UG:P6Q6KWQ7 :P=YI\=G7([KL,A*UDUIIR*]N/.:R1/A"HIRQM@T$/E[!'
MC.&4KT5Q=$;4=T[=9S+=>(\H.R#D">F8:,F,'C105AI786JN#P/S-8 R?/%V
M+S/)$50NT-2PE=1\S%N>3P@X0V.U,JK>$M%$BPJB,.;4L+#/)2+8;2C;$FTG
M:SM&6E,HK>B7:M"AX9,&W&5>9:\X9@HFE*K>LLRV4I:YMBA+)#%JGJ'("!D8
M4Q:KD'DY38%]N%J?+<@B9L3VJ:F*F#62W2,*:LK4&:IUNCIS'$P!%ER4ND3B
MYWZY(JR;JX*QSXBM'=NN6Z)6P6(@I:HXJD LC6/,>*]&!OE-0S1W.GN3=MS4
M^F@6LW/9NN S&KS['V%NM5@V@W%[6JZM.PF% FLPY4$'P% .\.R5HIFX$UHF
MO%+.09[('S("HO0FE<O,MHJV6*;%6M0=-1(#;DH<#+9@QDD?YHCV1:+0' \!
MCPX08WD/?<IT5U'W*JVI*U:OIBX\RI#$US756:U\%3[Y%WS42BG,MW@;6ZN(
M/-E1!]&.B[3T;5=\!B(R6BS:N;5+/.YT5?1S"VQ>5T]SM+]JMK0=L5M8VM$U
M+"AIEB_3SD9CK!KF%MP3U%::2TE9Q:&ED)1SL*@$,J"BC88\&JR[T0T9ME52
MI-BY-A\"7Q*UVI1L?TW52MCXK91ZAQ\6.-=TFY5P[%ZNJN:6X=%B52-4;3FN
MKTHKHDAF6L;5AW5VUXB\^Z31S#XWW=G%\E%?VEF52@>RPHL@V&$7:7D1 !&E
MYK:_.P>E55V>CZ&=S-.XJK>VTLS%K^*VC[8<17S>]5YI9_)7[ 5D14#O,J0#
MV53,4A8J9FRP&)3DC(FJ+&UP(7,IO7-F8L4TGP"<;O3^-H5CLOFX?95<DT+M
MK$G,KW,)56:G.QBQA+1R=@Q)*KJ&16@J]QX0R8U:$ZA\V*OI/T)J?<&T7@,B
M:P(>C%A"9UE/6&J9K+:[7]F5D6Z5LWMDZ_ITB!-A7U2<*)&?-:3H:OQ*T]U7
MH$?GU>W.[E'8O&W*-2NRQ;'%ML*:YJ82%EM2; A U;)$(J8Z&&? JZQET"T@
M[<TX4<4G*Y.E>MV%UZA91-9JD*=+CJJMQ7(R*U6$2-JDRL YC884)DDB7<C3
M6WC5PM6<*,UBQ2QL38T[%NM'3M3U<9,NJ\UFG#;OQ5+$L76&<U:*]<C@DRRB
MPMV,<>IL[R-]HY1$%M'*(F2B)V]8@I@9F(GY)D1F8]=H^35$6V\\9F1WGC)1
M S,;^DR,$4#,Q\L011$^G*?EUU^<ZXTXTTXTTXTUF![ 8%==8C[TM;''^[K#
M&+OKK_\ WCR_]O*^WB\?>WFW6!V_R\I./D_ZI#JXH9_,8P8&A>;6$?D@!5.W
M_P#NLM2VGMK8M#[OR;3=@_#_ '?@AH_R_E]W_P"ZIW_LYU^ST!T?<W\S@ZS=
M_EY-M1_Y;$:[-6\4.O:FWENI+:MODXII3M_5RJSJ3U?1N[*777578!:'KK_D
MUA7?]W_2']\ZW:\$O"R[,E:Z.Q[IGY>5C(QOO_U;HQJ\1X[>+5:.*.M<DN/Y
MHKXV?D_ZU&=9R#UAZ'K?=\#:!J/[O[ONI ^_N_\ B*[Y1O\ @V^"%G?O^'N*
M9O\ +O;R\;_]V1C5HOX1_C:G^3\0,J&WR;5<1/\ XXZ=9:'V=Z>@Z^Z';S!A
MU_=_*D _N_\ >'[Y16/@D?!RMSO8\+,(V9G?UNYV/7_=RT:L%_"D\?51LOQ*
MS Q__9X6?_'%SKG_ +:_J7_.)A_ZBO?1N1?R.O@T?JFP7V[/_O?6S\JGX0/Z
MS,Q]BP?[KT_MK^I?\XF'_J*]]&X_(Z^#1^J;!?;L_P#O?3\JGX0/ZS,Q]BP?
M[KT_MK^I?\XF'_J*]]&X_(Z^#1^J;!?;L_\ O?3\JGX0/ZS,Q]BP?[KT_MK^
MI?\ .)A_ZBO?1N/R.O@T?JFP7V[/_O?3\JGX0/ZS,Q]BP?[KT_MK^I?\XF'_
M *BO?1N/R.O@T?JFP7V[/_O?3\JGX0/ZS,Q]BP?[KT_MK^I?\XF'_J*]]&X_
M(Z^#1^J;!?;L_P#O?3\JGX0/ZS,Q]BP?[KT_MK^I?\XF'_J*]]&X_(Z^#1^J
M;!?;L_\ O?3\JGX0/ZS,Q]BP?[KT_MK^I?\ .)A_ZBO?1N/R.O@T?JFP7V[/
M_O?3\JGX0/ZS,Q]BP?[KT_MK^I?\XF'_ *BO?1N/R.O@T?JFP7V[/_O?3\JG
MX0/ZS,Q]BP?[KUL#Y@]6;/=-RJH#<GH!F!*%N?O\./5%>KTC9C&2+Y8OE2W0
MV+(&-*2Y91V"6'66??X<*.$P_.[B3I>$_"1^##X;](>$?4V=\)/ OIW-=5U4
M^\4WL^^WAL20-G(Y[&8J<BT<UD,:L18C'G,!'(KIIO!4+'6_9O +X0_7W5/B
M?T_AO$[QCSF)Z;LMG@/D\(BKELH)KBAA<CDHH++$T<@<D#KP[E,B%,6TRM1?
MJ^^&66../>>66..&./>6667?76../77W]Y=Y=_RZQZZ_GWWWW]W77\^^?AZ(
MD10(C)$4P(B,3)$4SM Q$>LS,^D1'K,^FOU_F8&)DI@8&)DIF=HB(]9F9GTB
M(CY9GY->)'N#V_DUY%M-Z=+=XJV'<P]U=!\W?7;-EUWW'9  +,7?W]+N/?64
M1,E%E]Y[O\=2KE\DZEE,_LA\#/X&@],#B_%KQ:Q8EU*8IO\ 1_2%]4%'3HE$
M,KYS.5V1,3GBB1;CL<T?\B1QLVA]L2M6)_*OX5WPKIZ@G(^&/ACD9C Q+:75
M75-)LQ.<F)E=C#8:PN=XPL3R7D+ZB_RQ[U:L7LGNLROE!S]/]?G9IQIIQIIQ
MIIQIIQIIQIIQIIQIK*6#ANV)&@+9@I:!!K)&Z'"V"%N82)N&.J?1>V-&R394
MZ-DIT.']$9ZL,4M[JC3ZLYR_EH?P80M8F;( (8<")L@1@S$.7 3.(Y% <BXQ
M,S \BVVWG6<L80 HF'*UR9+7)%( 3./,@"9XC)\1YR,1)<1WWVC68_CUY^!E
M6_C-L_+9!PR]E7_B(Q\#( N$*Y=>!Y1?G/A]AP)6I5)AAO>/Y(60K5[M&&"S
M#')CAY>OOOV$[]PV[]H-^ZT9!C-^/\HP"D3/\XQF1*9B9C6?F;&VW?=MP6O;
MNGMVU%!J7MR_,48B:Q_- H@AB)B)U,<O0&^<F.HX9;MV[DW#\2.%!IRV2Y=L
M=+$Q!1JEL:AOLU\SK8E*PP;7(]0VL.KL ^C%9ZECJ5\8]'LW'0HDQ0I=DN/)
M7E4=HN$D0<E]OA/"3.1WCW9(IC:2G??[3R/=A_M"[WQY0+O-O[H\X$3V9W.<
M<Q (+:?>@1B=X&-HS'LS8\()F5X=@.\2RZDOG#DNQM9[ $VE_C8V/FK,(QO]
M#SQ+\QAA/^>*U[=KXV&,OQ?QX]9=;?*U98ILUJ\M0/!#.RON)#;;@H^/)8[>
MG$)B-O3;;6J+=J%M3%FQ"K!<WJAS.VX]]^;0Y<6%OZ\C@IW]=]=,4]O %=/J
M -R:PRDV=UNVE7%,1<<NLO=++\=/L^$IW(1AGNIGUUG6[(UK/P,O]:+\'?\
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M--%TF*K1P$F"#9M*8AX2R82N(L@;U;R,D,>'P*WLUL0B3OE=9 *ONM\M)E(
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M''S/$AE;V@7O\V\1EA2\4K?S8V53^NM/UHPUH3Y_5)BL5\'8*8&474'8R$'
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-C33C33C33C33C37_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g63338g76g88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g76g88.jpg
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M !<! 0$! 0                 ! @/_Q  R$0 " 0(& @$# P0" @,
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M7F=!#L_3':]$W>A'?]U&O,Z"'9^F.UZ)N]"._P"ZC7F=!#L_3':]$W>A'?\
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M#,E5XEBE8=&Z-I3$2W?Q/D^@CH_%IAL5'^QF^Q:O,L;1NGL(4%D*AY2[N6?
M$:Y1/CXB2)FY".J5.9N''!\N'"<J>[FC F3O-ST@7Y.5GLXER@8QT:PT_2H;
M5]779N")X]@2/(>_\@DF?HKB<>CUFDKI7'!Y(3R("B=B:S.6RK=@86D1*2N#
M>DP)'8W?4J).J<UBW-E=EJ=-CSYN;\>/B[B>5\/[$EO!5S&*E=%!NQ5,B@%
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M%9;;[U1GS9K_ -/:R9+KN>>>1#F* 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * Z-)Y:H 8UD,Z2H\+@J"P8M+4R!1DOPIUR@<8'!XPH\^7'Q=DQ
M85.1';ARY,=O-]EE]UUO'-W''% 9T:D;5;5;"ML#G!(YZ%-X9+@4(2$Z!@-+
M\C/LRLC&5AR<OR,R(<7C6!J4$S"F5<87A,H68T:;]DXY;L_N\'%U#36&J6:G
MP6$!^H'J3(/))E9)24M3.-1N4S+<6GL>2A%X$4P^$9VY.82O&L@R2%B@5*\;
MC65X9KGDVC1^*QQ"F>V)?F<;6]]9U2X2'3>U7-H6CV=3CT/47U 4!<A'[O)S
MR"#D6-801'/:O$LS1"0- A)1)A$0(]3ATGQ\)%[W'141Y[6MKD%A8G,-N48E
M?[A[P6(%UR8,KF/NNSK3?U0M+7!YO'KI#/6=Z0F P#%3>5:[;(AV>-GH[4L:
M./E4P?-<2LUD-C$C*21DPQT:2E>(B!U>MO\ E9[=>&]TY0AE?XU7XO\ 0D]?
MO#K*VS'Q!2L^=>#BTW:HO5.:>-Y1618V2H^H4K@R12\SFC"\\*,LHNZ9<AM;
MH\=9 1F"M:O;FO$S7.CB@1J0AQ/W4_,:QO$'!@/4$U,DZ06.- N2G=R?B<L+
MH^&7E;%<OC\<$<C@=[]:7QHP2Z1@33%;Q)##C&"!4L 6XQ4%O*%H7+D[1F28
M+\W N5JK5GXF'HXU.!:>I1IV2#"<O$)#,3IF<RU,!C%H%!,_'#T>F65D(B-Q
M'(T&1:,'8DDIQ%683(UA_:"M)!@CKX.N3'>8=5X+\' F5^M:JGBOM?)V1]WY
MUA'XM$YJ4$\C/$7F3:;.J M#-=]C9!1L2:-G7.Q'^&0T@'$Y&YQ2YA[VB<V<
M@99.0B+PVN;(0H%*&Q4//>) $/3[KS]:G"O_ %'M/!MH#2%PDU^4L)I%XQ-V
M%Z8X>FTE:PR&S3]U\J2G,*P=CITPP6 OW"%QR-Q1,UP(TYD[6\J^5-J-E=U"
M$,KK31QJE6RN_B>3B^=\8Z$S7:-KE=2F&Q"#YCAN((]<1)H,)(,I>?I>@".)
MG:6<1C\#8B8O,"I3G,W9(T#P*Q/Z]:P,*A]N3VI4KCG3+[=)_<L43O/#+/PY
M-T:3X#XY$BU_5/HWPZO@^X8G,<* \G'248<,S41BI>"FC,/&X:5L3@GR)G49
M*AYG?45_.*_,@MQ*$^3*(TUK^?549GTT]1"4A-[A<EV1US:X0A38\=F(GC15
MED4B=I[ 6N'HD,)V57[ 0L_14&IP92^Q<#/CBX(APU+U,?EV5E!2:W.N=['-
M,+"K#EK72-8HY<ZV5"0->MTI;/Y%A(.G:!!J&VK:N&R:;M=W(:E9;([Q\+$<
M 4\O4<3"SJX["D89)F(,D ?+,&(4>3L34?L#)CQD/[@:1KR(1K6',.+>JU)2
MFGJ :FZ]FS]'DL2:X#Q2(,8J6'2=NC25S!ICH*-5R]L'3V22@+!R$6CN/U+B
MV+$2PZ-'EC%&93BXQO3NW\Y<7M@L+>BY7CQ\[:OP>LT=0K4EX"9./[))>VAB
MB%4")#9$61-,@69672JM^&Q-G%HZ+0!ED"04,M.7'+9%3@ #),BD=SLRMH;G
M>E^'*GL#*[7XU]>24H*VBA39'(;I(F)7MS>8S<F9ED<6*X^D:,#,"?']LY>F
MEC+PR3Q,.*6!Z4M/L.7+6XM.!;A0J$:O/AQIUR+(H!IK\37M4+ T(* 4 H!0
M"@% * _-]WL67W^S=?[%MUWL6<>U?=[/'//LV6_\>U==^GZ6\?KQ^O//'% 4
M<UHW,7;#/>VJ!9!<GQASK&?L(4G$S1"WXI2,L3O#(7+6-PN#FYP7H694\8B[
M$E%&GDA6J75LO:7%RN9EKBH:6\5J(KJIVU:UT\:]$/#74><"36_86?E,&.T>
MJX<VDQ:S-H1,):@ ;D:AQ+XH!6^09G)V]M,FZ*0MG<9.X*3UQ2)#.X2!618Z
M>X<W&V]ML%>&&E,RIE?LKOQXEDQ:Y[A*]A<4?M[.&C7! X/<Q89+7AQY>?1F
MQ",2%Y)&:4YCV0,0R/7'C%)\AM:)%'.1Q'1&YX8VF3UWZ<KXV<&UQ$:CS;YK
M>W^B\E""@% * 4 H!0"@,RR;=^< PY&'TMUH:Q?6HQVW:=.QPH(Y((V/8)X*
M2&2L\/CDO-T(ND4I1]9$!!(":_.RYT\I9"1SBK(GF%&WYF'-PTVC4*]8G;28
MF=8\1K34[ZLWF:E&Z[;J6)@+L5L:.*IG+S26&U9;D;$$E1#S#R]RA@59\:?)
ME*2QM&9A&7HP4V+4;>/JW\;',&5R?[R9"-"12=]/OQ^Y#< ]2I?.;$^8T,<Q
MQF.W@;@=^B4?C.;NUEH<7;8C*?\  ]&TLO*:/1)1&LK16S1R1GLYAS6VFMHA
M'+<XDS.[$'*#,BH5X8OYU4:1NZ5UH:MT,B@% * 4 H!0"@,S=KM_G.$)C50?
M&P_ CT7BL:C4GFBO8;91HUO8'/(>O)HRQA#T6N3@%FWSE,<B9(X.%R5N<,0^
M."[4UM*Y\>+^"1#BPBI36?2GY;V4DA2QND\QE+FF\3J=?91PY-JCAC$7<V?;
M&%"!Q8N=HHE*2\H>Z/[4\//+]*"*Z-5*#*-,Z/,/?#;G)ZY+N/VK:A=P2E-R
MJ<U2^Y'BCJ-,K)LH5PZ7# &/@8F6R>%/+[;+-[E-XKV2PLHF\AE60(!P >/*
M*P*\L2/(/BDA83]Y7NI"^QUCY&<>*1&_AK%RTG9/9RX2F==7&SLR_P#'3X4$
MX.,$AF+<@Y*_M*=Y<@W*MM<5HM\2]I8C'W=9CQ8D^9_:4&9*B(?V7O6[&^87
M#$VJEB"Q,KSC)W2@% * CZ6A5Q.HKDP(9\J/ [&,?&8JUYW#)FPM^%Q(1QR:
M$65=F3X%2C$CQJ5F*]3DP)5.:S#Q?=BP9K^+<=P&4>F>IVP>O;=K\*/FAW38
M$7.+0$3CPAV2C67"%VF/)D90/$$O\@-0\IT< U3J^E=EJU2],:V76;EP3/+F
MWKBI1;FS9U(WB:<_JQ.?#5-;YG^Q!H]TQMH'\!/H75.,?:V1>_:YGT9O 9'>
MP4WSY!!Q,+BYA+M')U&^ODO##:EU<BYA<19V6$D:QX>+L#DRDW(%8G7(V?$7
M+0S+Y<S5)/><2KB^7KK'@FR:]-=M-M7<ODB7&& XE,4L6Q!#(2#!TH&DF#9
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M@%,3A& O8[L+)P%X%V8A=5KASPE%;3TW\)?2FL7-%*$% * 4 H!0"@% * 4
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)QT,^*_"Z/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g63338g79w07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g79w07.jpg
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M9',72]T ?M>K-1KE?_$MBW$W\ 1G.W/MF^S#7\?&=8ZJ$L"4'-B3O"\<E#%
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MK\8Q[+H*?V"UC&FSVNTVTI"EWVE+:UJQ?CYN(=?71$C[O*I-8D[!\KO)QR>
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ML>+92K"WR<IM3?A;"8K$Q<EOFGFH=1R,QAW=9$9E!$FM",BDGDAHYPSN!QP
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M&.,8XQGI=8:>3E+B$J\__=CSCSX\?G'\9_'],_C^/],<I*@\'SR/(X)'!_\
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M\^7V/^U;L;5#31:/IBI+U+=W$^JM:>W+.X/J>BFOEJRPO%R9K'Q$)23]IHP
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MI,9R,Q*3\D"4C+;C\1UE;S#3F5MIUEFNU:5HV//'E6'LRGV/N>.1P>#GSO\
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M<M#@X2^D9F2\4^&/M2^U*UUI=;7ZJ2:ITU6L.?2"&.;;R)S&LULD\K6!Y>&
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M_P!?.?;X\^,>/.?YQX\8_.,^<><<I+HIX+ $>"I/##_RGS_+*^1X\^_)Y^G
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MX^GD^/R//(_=C@^_[OS  /GQY\$'R?KGIL_J(ZGJE9L-VD:YW')IH2_;&UU
MM\J'K"GU.VEM16B]5+9)&LV?9.U*2 6#KI.A25#IALB#DWUHX'9UG"NA*/9Q
M]<G@#^OZ_C[Y''Y>?Y?</ \?D/W^<VO^_+0%;$K5$CZSW21&VW3$_L$&V"&K
ME0.UG.I!]-AVY5L*5<+?"&Y #1"7.9HU?'GM6#2EIOS<P!681=L?/GQIQQX]
MQ_7\OYYJ54]1S3MV1 &U>B[5L%]+;49T^)UE6T:IMUGG6R9IZT;P'O.6"G[7
ML&K0X9^E5(DDG/L.Q [E.-R!8R_1:I]P9?XQQ_7D?4#Q]3QSY_?DFZ-[1C-[
M7Z#"K U;&O;GU<T3V1UZ0)0W8-I<A[5LFTQ1<99HJ"$X9'3 '5>F2 RACDAB
M7)(6-;9(E CCI*F"./XD?PRVW&1CC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQC
MC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,
M8XQCC&.,8XQCC&.,9T![7O&E]N=S=D&=ZG'8VJ->B3%7%CX+I;$^P3*FVH5'
M%"'0J%2?EG6648-LN9?BQG&T-M2)"8[B^?G7U?ONA^LOMPZGO=?WVCZ0Z;IW
M=34K0/<%C93:=6J14Z3T1ZH>?:2W;Z.9(H6552201N<]IUM/;:SI2A%IX0VR
MO2Q6)'<1]D*6&]0R2B4]O"0+%$1PS>6*J2!FM]=]Q6KJD()WB'3I9(/NT[@1
MKJI6(\^"C.B*_(>5(MTEU4*2E]EAXR(!0R&&XT<BK[TYB8E [&%:O[-.MMM]
MD-*UOH=++:I==[ 4NFM1L]A)KHGI:Z1S)N9':"821QR7J>OAL=L4=@_',)^V
MMP;^\U=;J25*;6ECEU$/JWK,$*S,)9U';64!U()$4LSQ\LR?JAVDR<CL(-]X
MK.$K5UV9(U))CZI # D.DV0S*)@W]KVTR5:'MIJN)0UUJ/6VXD2P&<3%M$)2
MQ<" \ZB,Z32PS](7_M[VM'5;WJJ3HZ6/I#75*$.BVEV6U0?K#<7K:5@-09:S
MI'JTBAV-T3E+,K5*]:1UA>T(TXF+I"O+8J:]=FK;*>25K<$2QRC6UHHRY^)[
M9 38+-!%V<QKZCNH+"/EJY=I]C6'L<]U/U#.$,5,ELC[?LZV!F2+DM@"%.2)
MD$ ])G28T%67!M29L!HCE^*PEG+J?:C#;>%J\R^UOJ?9?::_V0=&6*<>GM=4
M?#=5;BBEIIH]?1OR3U]<\T[Q5V[ZVG38WK/J11B/O'  7NS>].48-$.I-HDK
M68Z'?KZTK1]IFEA57F"HK,>)+)@AC 8\\'D\G@3K<>\A@/7[0=T3IAR[Z?U.
M^.KI_8I0VT K^5M/0A4:#68"&'99&.UB3 PF4QEUQB-)C2I QB(\PZ[Z!N_M
M\N4M;MMA]G_0[;[HKH]ZVMV/4MJ^FNUO<DD%.*OJ:ZQO-:B42U^V9.XQQ212
M254BDB=]-5Z0BEGK0[C:BGM-D'GAHQPF>?@AY&>P_<%C8]KGM/ 9E95D+*0,
MT6[^1B0K3 [6>MI-JV1N4:HC JAFQ0JX,"?$:,5M;$@_+CYCSWI1L 59&H2B
M%B3$CM2'51I$J-"=SKG_ &B8K-3H>MTOTO+MNI^N*OQ-;47=G!K*M#B]<UAC
MEV,L1CL/+>U]M*H"0"6&)9&,4DL4#6H^BVCDVS["^M:AJI DEF*!IY)N8HI^
M5@5NY L,T9D)+]K,0.Y59AM=H[@V:F"*Y6#.GY$[L&?B'"TK4(.VC9T6L5X*
M[-<^_P!HMR8ZX(R'-$P73$5I,>1GZ3]S[\=KV/N;C;?;3M='3UNIO=%O/]H^
MPAV%N3HS7[FK8AU6MHO.PV6VW(B^'J06*D#78D$4A]#YI'C0J[8U?I>"W+8L
M1;14TD#0Q+M)JTB-8GF"#T:U7N[Y'21Q$W++\W@*3R!@@'?ZL3=+U[9!BA'&
M+G<+64IE-UH$F)+D;66&JA(S,$SUPX;F0V'R,.!)EJ&K?9*K4/C19SN$Y5K]
M=_VBM5/T/K.I[O3U^/>;K<6]'I.EJ$PNVMQ<K&!3-2L-# QI"2S!6FF-9I$M
MN:\45A^.;T_1=A-M/0BNPM4JUH[=O82IZ25HI Y"2H'<>J1&SJ@?AHQZC%!E
MF=+7W;%ZC6)S:>GUZCDBYD%@1$<M,6SK-L2HRY,B2AV# BQ6&X?EAA?MD2%K
MD+>:6W'5'S\GJ?0W4/6&_BV;=6]%GHV6I/7CI0MMX=L;\<T1EDE#P5H8HU@Y
MCC;B20F1G1EC,9[N?VM/6TV@&NVGZ3617,K"LU?T2K=JJ0[LS%_F8>%': >3
MW>*O4#T]J;0N^6U^^,2]6<A<=L5%NG$Z/*A"45@5":@4X>B7 EM,X*KE9;I<
M%S/SO9;2N7)QA/LPWCGL%OJ:S;Z6H=+/7A6K0N/<2R 3/*[M*P23D\=B&4D
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M ?;)LT%=*EIQ#&Q:]G=4VP#B%ELUHD]D;=N7:UDE@K*)B["S<FX>S%7 =*G
M&&.?;_I_+]W''W?3-AVAT5Z[&Z)0ZA8KS>: "HNG-DZ(2:&W:M!#EDUSMK].
MR-A135DL->)3!5AL1>KB3TVZ45ZFV[[BF8Q@U@.0FBG[\%6S:;LK5Y[#_P#!
M!%),W_RQJQ_EEB>W6JKWVK%>LGOW3RQPIX_YI&4<>>/?ZY"=AT[T;#/;^C6/
MMF7F@^Q A8/8U+_M.U>;'QQL$)$KM1%@\AJ1*N T'KL1!;B4BF33I&F#D2B_
MW"LE?U"?^Z=!6Z*ZNM\>ATWN2#[-)K[%=#^(DL)$A'X]W'XYSUGKCI"F3Z_4
MNE#)^TD>PKV'!^H9('E<$_4$<_NSAT1SHY3+2:N];VMNG9=^/%+X=GV6%5K<
M<G*LVPM7ZET^5/AV*AJP%4 4L32=. (%1&UT>+KE76;MV! 2/",LPX.S_P#9
MOU<@!LT*M%?^*]M]/5(_\227A*/WIFL/VE](/XK;"S>;Z+0T^XM=W!]@\=$Q
M-Y/_ !^>,V7K[:Z1I@K:35?TQV2LB9%0U;I378ZKZ0N+HFD=?-!"#(;4E+22
M/L5_[@7=FVB[7BRDW(L/""UTS5V'"8FHB3)!_8.VGBSU%T94/_#8ZEI=_P"/
MRP>LQX^O .1_;ZH__=NG.M+@^CP=,W0AYX\]\YA4?O(\#VY/FT&.T-ADX_ZM
MZJ]H'O/\9(TRHADY_P!/_C;W\B<9_'^=M.<?U3YQXX/1=1/]MUOT6O\ \'87
M['_Y/6<']Q./[;6W_P!CT/UJW_Q==0K@_P#]39\C\B ?O&?O]XK:+GYC=1]W
M+Q_3ZHAKF%G_ +TN6]><<C^R>E7]OKOIP'_DBV\@_B* YQ_:[=M^QT%U*?\
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M)PLHXV_*ELL-(5NMMK^E-=_9*^O3LLD?44:>M&;LO97#"+AH@J^6!G!/<0"
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MPF77/;A;[OQ1FGGV]KI]+LM]<6CJZS6)B"\C<A(:\*\=]BU.W$=>",'EY)&
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MH/"*H\9W.MU>NT]2.CJZ=>C4B_9AKQB->3QR[D?-)(W'+RR,\CGR[,?.;;S
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MIJ^H0GZE==FC5S&$XBR\O1O+68/56^)!^.*@%B42"ND;]XX;U8UB"2^/8.&
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M$Z79MGPM<U"?6=:Z_P!)V^YDT6AZI6>./,)L.]*Y0:\((QF0\\Y7;O-L=JJ
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M3;JFIKBV\HYU&CZ0W.]BDN0QPT=3!_WK=[29:.JK@'@]UJ4?KG!\&&LLTH)
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MW7W<-,8?86K"DJSA-J.%GDBCX8M,W8H'OR2 #]?O/[QQEYI H=S^PBEB2>/
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MM+7*/.<#Z\ZVEGJTF)-C-!'K??C7N76[''S&=D/*)4O7Y&5$:A2QDZ-$AO\
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M(TEM1]\IAA_CZTL?'[\US]==)1GM.]IL?NB]:?\ AZ,4G/[LPF/6A]/&5_\
M(]L;$M*L_P"3%7ZQ]H3"',^/QAJ3'TYB(YY\?C*)&<9_G&?'YY<_L-U*O^TI
MU8?_ (VUU*$#[R#>Y'\.?PRW_;SI@_[.[:F\<CT=1N) ?R*T>WS^?'XY^_\
M3!]27O\ Y96^UAG'C.4J%]/.QSN%XQ_5/SZ[C9\?]N,?\_'']BMR/VY=/'_X
M]WK!_A9./[<:4_L0[I__  :+;'W_ #JC/S_I>NM/G/G5O<_"<8SGY,]--_\
ML\8QY\__ (,]WC_G[?\ M_'YX_L7M>/^^:+\OTYKO_SW'\\?VWU/_P!SWWY_
MH'9__P#/S_+/<SZNO6&:\T-&T3MG,L4]Q,,'77>H^^QDXZ9DY^$8%ARRE(B"
M(TPI-4S!BO$R,& V^^VJ7+CLX6ZBY#T/M998T>YHH(W=1)9EWFN$%>,D=\TQ
M6=G$<:\NY1&;M!X4G@8'6VI;Y4J[MI6^6.+]![)&DD/[$:L]=8U9VX52[JO)
M\L!YS>M?]=[_ -A;2%WOW/@Q?:+EI,ZAZLLRDD]>ZH;SC.8!_82/&(6Q-JYC
M+Q]1*GLN :VZ[)9%PLNK9;$[/8=1Z_IVK/H>BG;]:AAW'53*8MCMCX]2OKO/
M?K=2&'R+&PL60%:63CN,MVIJK>UFCV?4*K\C"2AI0W?5H^_;+:\!;=WM/EG'
MIP\LJ+R0$["\+;PKXL*1A2<8\-XRG"L8QC\?LQGSC'CQX_'CQSSKS[_SSJN1
M[>/RQAQM6582M"LI\^[&%)SE/C^?=C&?QX_KY_CCC)YSRQG"L8RG.,XSCSC.
M,^<9QG^,XSC\9QQC/WC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&
M.,9"T?7]H_M+=M\ O%I%<3->=* *_-)&%[%RN'\*)]E@%T,56JR$R/8X^]7
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MUS0-K6S6MT=?"1:O6M0SF;&TP5./6.[;F+;<AUC65;JU>#E3QFW?:]1$3>(
MYF7-G,G@4.# >E2V\.;6'46;%.&U !(9I;JF(E(Q%!12DTMJ661TC2'ONK'W
M,0%,<A9@%S4S[BK6N35)R8Q##282@/(99[SW5AJ10Q(\LD_92>3L4%F$D852
M6'.G?W\>O/ZCD#%GK%'K,'6]$V.1V#.HE[@5*"WM+:;VFM=U%^1*K3<MF\V>
M_CSM?9J<N+%.Q2@ V-='YG ;*P"O_P!GMEZ0?TXS*UJQ56LMBNTS&I4%ZS,
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M=H:WE*1\7M@\< #[S_/C_P!/S!R1S[G[A^[WYX_EF@$S7;@'5Q\Z,3OQZ59
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M/UT1J+79$ZC67:LEO6J%03$6J:=:O@K:$\&_%>R\J2$^,H9L41O,938Y<+&
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M1#BH7.SC,U:8[*52\I3E&,RE81C,C.$YRG&7<K\)SG&/Q^.5&64A 9)"(_\
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M;0H4<>C+D6:W8),!S+G-H-?%6 ?9SF$D!EJ0]LEMP?([@3Z< (^LA)^A4',
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M#+"U9+!$EU@P]UJH?U*?=ZG_ -LP\<\_)SR "ISLW%BA@,; #!1T .'%Q(\
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M;4Z#'F. 2$LB3DNSP#Q^/'\R?P_#VR.>#Q^'[_?@>Y^_ZYC;KVWV[2"\NK2
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M,.E"5B/%2[TA3'MS,E*7\?C]O,>Q:EM3FQ-VER(E[0O"!((TABC"\^$6*-$
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M@:8U;"64V8EOL@B<-<V1@]4:_,_4(1Q[<^Y/^0/W>_G_ -<<_P!>_/Y?O/\
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AC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g63338g81j47.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63338g81j47.jpg
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M 0$! 0$! 0$!_\  $0@ 3 $2 P$1  (1 0,1 ?_$ !X   (" P$! 0$
M      D*  @%!@<$ 0,+_\0 3!   00" 0($ @0'"P@+    ! $" P4&!P@
M$0D2$R$4%0HB,4$6%S@Y=K6W(R0U46%U=WB1M+89,S8W0G&7UQ@G,D-25EAR
MEKC6_\0 '0$  @(# 0$!            !P@ !@0%"0," ?_$ %<1  (" 0,#
M 0,&" D&"0P#  $" P0%  81!Q(3(0@4,14B-T%1818C,G1U@;.U%S0V0E)Q
M=I&5)#,U<[*T&"9#8F.AMM35)2=%4U155G)W@H7299+!_]H # ,!  (1 Q$
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MBK<*NXQFN7MZYH0V8#&,A8GO)\"RQG1/\V/*OMU;[7LT;QBA+U<SMZU*J\^
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M[=#&R5I1SR49$J1/&I^!->2%P/R771SM]#NF-JL:XVVM0]O:EBID,G'9B/'
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M&HQC&(C6L:U$1K6M1$1K6HB(B(B(B(B(G;I-2222222>23ZDD_$D_63IT
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M8TNG)8FJOVJC7%RJB?<KW?Q]-O[+KDIO=.?17VXX'V%QG03^L1C^X:43VIE
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MX7(^H2/4G53]9C;[-&G\,ZH*I.!7%L(R%T$LVK*NW8Q[5:KA<@,/O@9D1?\
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MQ\Y'8N9=U(67X5@^*9-I//:.KLSX 2[C"KW+MD9KB.0PX_&2ZU.JLG7'R;$
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MDV.JPP\1?DAH$MJ'"D,_#'0!Z:X#>%[8&VFJ;[?%XZQC?Q52KMS&R7*L#3S
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M@.Y)U6N:]>>=)"LBR2>8L&/E[.WA 3M7B4;6K*77F!: E=ELDG)',1L7SEN
MXKE6;9=5:#QTFOM-U6];CN%5=UD!+K2C(KM?LD@K98H9,X^+EDAB#EECPNE6
M&EL9/);E I!=JT7MX\Y*Y3H4IMR6DEAP$$MJ_-7K)X;"RY,AI0S#'=BJQD"G
M.ZKYF*#&8W;)-[NW5?2ID/DRG<R%Z';55XIL_/%5H0V++^:NT6,Y6)@IR'>2
MHC8BN/(/EGIW&ME<9>0.NL4W7C::9R676VR4R#CANW7N)IQNV4,%1Y4EG?Y)
M@5)0""Z\OJS#\UH0C[$49DE0<,(OK&)#/:ML[+SEO%;MVUD[F MG/5!E<5[K
MNC 9.[^%6*>2S3\-:KD;%EWR=:6]C[,D43OVSQLX[4[EJVY]Z8.IE=I;FQ=/
M/U?D&X<5EA:VKN'%TOP4RR1UKOFLV\97K(N+LPT<A6CDEC0-!(B>LG:Q-N4[
MV2\6^1TL3VR1R:!V^^.1CD>Q['Z[R%S'L>U5:YKFJCFN:JHY%14547H2[/!&
M[]K@@@C<F$!!'!!&3K @@^H(/Q&BUO$@[/W2000=M9P@@\@@XNT001Z$$? Z
M$U+5\H<*T/P\"S[EE<4W%G=&#ZTUAL/(->ZEP'$,VU")G> T06MZ^3-;/\*G
M08W?V!#<"N=AJ'4V>.6A]%:M[+8RN#,ZS;1O[CWS)C=F03[PP.0RV7QE;)YK
M)7L?FWQV2LR9644(O<PUJM$ORE!B^^>*W%'8A_Y("0*F'>%#;>Q8\EO6>#9V
M?QV)P^4M8S"XVCD,&F2QM:/%1'(2^^%:MF1ODV?*]D$M2:2O/_RI,9H,2P#%
M=5:MH]:X/6MI\/P3"Q<5QNM264APE/25" !1S$SN?.62L,+7E&$/D)+)?*21
M))-*][@1=R5S,9BQE<A+Y[V1OO<M2\!0\]B?R2%47A40,Q"1J B(%10%4#1[
MI8VGAL/7Q./B\%''8]*52+DL4@KP>*,,[$L[]J@O(Q+R.6=B68G0:>-K?Q(Z
M$\.'EF+^]L9GUIC7&G?\Z?5'9KC9V1.76F8V<K_W$<77FWI:L><UZ>H/29Y?
M?79#ZBM.FZO^,&X^J6S'^?;7+6MU[:7XL<IB:H&6HQ ?.=\GA!,RQCT:QCJW
MH6X! ^U/^+VV^E>]4/94;$UMI;E;X(,5E[9.)O3$_,1<7G#"K2$=RU\E9'(7
MG6^\BE_'EAWB-[_G7XK"=+<<=W<7-+J[ZXI-U78F;><A<U":_P \:R'YD+CV
MM1K$1S4>/KFVB1RL,F:NMVO_ ,7[W2W;:_,OY[=. W?GN/1U@EN1UMLT)".#
MQ'0>UE7B<>C96$_&-3K9;H_XQ4>J>Y7^?C]O[6W!L_ 'XHT\5*2QN?(1@\CN
MEO)5Q22H>"F+F4>DC\E,UO9U]+I? KBV,'KJJIU?BUG9V!DK8! :\#% 2C3"
MIGJC(1Q1HI)YY7JC8XF.>Y41%Z$&5BDGSV2@A1I9ILO<BBB0%GDDDN2)&B*/
M5F=B%4#U)( T8L3+%!@,9/-(L4,.'I2RRNP5(XHZ4;R2.Q]%5$!9F/H "3H2
M?'SD]I3,*;D3L_<N![]N++EID-O!/55_&7?F44T'':KIB\'U'B0M[CVO;&BL
M@;3"";'-#BJ8X@,BVSZT?ZKID>J&G<NTL_1GVOB<%DMMP1;+JP,DTN[-N5)V
MW/-.F1S=UZ]G)16(I(<BL="-)XU=8,;"..WC05VQNW 7Z^Z<OGL;N2>7>MJ=
M6@CVEN6Y NUH:[X["4DL5<9-6ECFQ[2WY'KR-&\V2F//=SJU/AG[<?G&A3-5
M7)>0D9AQJR@[39LF8X[>8?EEU@=7&P[3F96^*Y/7U614RY/K4FB16W  Y9-E
M56LZL5KFN6G=5\*,?N-,Q72JM'==./.QBC:KWJ5?(S$QYVC#<J2S59_=,LED
M_B)&C2*:% ?35QZ39LY';<F&L/::]M.Y+@9#>JV*-VQC80),%?GIVXH;4'OF
M):L/Q\:R/+#,Y'KK+<9Y1ZOE_P"()C]XK8\WML[TGFX#R.T9%OJTS3..X]B9
M-<C^SRJNDR*BS&F*? CH K928Y59,6U9O'=@:;9'32S7Y./AQV?Q\@7U6#,1
MYZU:NI+QZ)-8K6:,Z!N&DA[2O(C/;[;2*P[XZFUK' R$V1V_D(RWH\^'DP-6
MK2>+GAGAKV:UZ!RO*Q3=RG@N"U_>AMHEZH+XH#)Y>#&\(QIT%)D_%HP<E8FS
MH/._<&OVQ3K ]S&S)#(K9%B<YK9/+Y%<B*JH2.D95>H>WBZ]Z#Y6+)W%>]1A
M,D67N')7N'([@.1SR-#7J^&;IUN$(W8Y^20K]H;L8YS&!6[3P&[3P>TG@\<'
M6Q#:3YI1$CR$\XZ4H:.>)Y R<5L$@4B!DC72P).S.'.A6:-'1I*UKG1^;SHU
M51$ZQ7S^PRK!>GUA&*D*_P"&.0;M8@@-VG'<-VGUX/H>.-92;?W\'4OU#KNH
M92R?@;CE[U!!*]PR/*]PY'(]1SR-9?Q!!IRN#W*Z(>-\LC=#[((5C$5SDA$Q
MHXLF3LG=?+"/#+*]?L:QCG+[(O7ATU94Z@;-+$*/PCQ2\GX=SVXT0?ULS!1]
MY&LCJ8K/T]WF%4L?P;RS< <GM2I*['^I54L?L )U8G6)@MCK77M@#/&2$?@^
M)F!DPN1\1 I5!7SCSQ/3NCHY8GLD8Y%5'-<BI[+U6,NCQ9;)QR*4DCR%U'1A
MPRNEF564CZBK @C[1JSXB1)<3BY8V#QR8ZE(CJ>0R/6B96!^L,I!!^PZI[P&
M>T@7F(;"Y)1#>>W)-X9#%\T),8A^-59$D$B=VR1Q6%>8*Y[%5OJCR-15\J]7
MGJ0"K[&C8</'TXVH'4^C(7BM3*&'Q!,<J/P?7AAJB]-2&3?4BGF.7J3NQHV'
MP<)+4A8J?K EBD3D>G*G@Z]'B(?ZF=:_UKN)W[>,)Z^.F'^G<K_8W>7_ &=O
MZ].J'^@<3_;/9?\ VCQ^KY=#G1'U0?1GY?G/C] ^&O\ AC<71'W#]&_3G]([
MY_WO":&VW?I*ZD_H[8O^YYO7XZ]E'I_$CY)5^3*QM[FW&WC[>:MD([>>?!L0
MR7:%/L(*LD=]K0\RNZ VT$A<KV+85Y4\;&30R2?63#3]+-JR5 ?=J&ZMS5\P
M%^ R-VIB)\9),!\.^A!9CA=N ?%*BDE6 _,8RP=5=UQ6S_E.0VIMFSAR_P 6
MQU&WEX,G'"Q].$OV*\DR \\RQ.5 (9K_ '0VT2M:#M39&,Z>UMG>U,R*^#Q?
M7V*W>6W<K59ZSP:0"<Z041CW-28\YT+0JX9J^H6<0.-$CI96-798?%6\YE<=
MAZ*=]S)W*]*NOKVB2Q*L8=R >V./N,DK_!(U9VX"DZUN9RM3!XK(YF^_CIXR
MG8NV&''<8Z\;2%$!X[I).T1Q(/5Y&5!R6&@N:[V=IW+^(FU-:;PQ+D8/M;E#
M-G>Q]PV5=Q4Y&6L..;(SR5AF,Q4E@)K64<J'4(-9A-'C<X9,X"OPP4P&5X\S
M%<>,GB<Y2WKA\KM^[M=L-M%<=B\'#-O':\+6L5C@8[9L1OE0R-FY)LA8M*ZK
M(!?>.0!E( $Q>6P=[9&9Q.X:>Z5S.\&R.5SDL.S-U3"IE<D1)46O*F(9'7!Q
MPX^O49':+F@CQDHPT27@MO>PY#<:, S/)F%"['H82]=;;J[$(RLMJO9^!RI0
MY2VUJ;$8.PJ"[B2 ;*(ZL\4<T(&^#A*ABG;)&T5]0]NQ;8W9DJ%0H^*LLF4P
MLT3I+!-B,DOO-,PS1,\4Z0!GIF:-VCDDK2,C%2"2KTZW)+NC:6,OVPZ96LKX
MO-PRQO%-#E\:WNUP30RJDL#SE4N"&15DCCLHKJK @:+Q;_*H\1?^FC3/_P!<
M-;];#=_\C^E_Z!SO_:G*ZU^S_P"675+]/8'_ +*XK5]NASHD:'8-QEY&\<H+
MAG#G;>(GZV6UN\CJ.,^^<:*L\1H2KVQ*N[BEUQM/%3JS+\+IRK HJ2GI+VLS
M"EJS"WRJL<#R4E*#[MVONEH#OG"W8\KX8*L^[-N6TAO64KQ)7@GRF'N1S4;\
MZ1H@GL5Y:-B9$"^K!.T7)M'=.U5G&Q<W2DQ1GGM0;3W)4>:C6>Q*]B>OBLQ2
MDAO4('D=C!7LQ7J\+N6]%+]UGN-&\ ^1ND<'W")CQN)39/#=A76*V!4)Y6-9
M3B627&&9=1.L!XX8;&&KR?'[8,.R9 ,EB'$.;\*,LZP1U'=FWWVMN#(8-[,=
MU:C5Y*]R)&C2W3NU8+]*QXF+-$TU2S"\D19C%(6C[F[>XV_:>X4W3M_'9Q*L
ME%KBV([%*5UE>I<I6IZ%ZL95"K*L-RM/&DH5/*BK)V)W=H[KU7=6+4ZFIJI/
M!#%J_"N(6AL5JIC"*^EPF,06:PD@E,DC^:64OF(D&'$@>_S2.3O&/$WRHGU>
M_=5NG46Y+?WMN.Y,L:RV+Y=UB#",'PQ#YH9G8#@?6S'[]4GIQ4CH;'VW3A9V
MBKT/&C2%3(0)YCRQ544GU^I5'W:MMU2]7;51^"^*U^%<8\(QRJF,(!"R;<)$
M4MA)!*6Y]MNK8=P0DCQAQ85:PD^9D*-@8K8&Q-D=)(CI7W7J'<EO[LOVIEC6
M22G@E98@P0"' 8N!> S.W)2-2W+'EB2.!P!2.G5.*AM''U86D:..YG65I2I<
MF;<&4G;DJJ+P'D8+PHX4 'D\D_(L5KTYY'9OZQOS9_$:IQ51_4@^7_+X]R7-
MNV9(OA_B?C5)E<Q9/BU@]!&M0=)$658UV7^#F/']L?A&]9KH;AO+Y6P5> KW
M=W9X^Q00.SN[N3W<>FHM*+^$B3(=TGF.R(:17E?%XESUB<-V]O?Y.]B">_M[
M>!V\^NOPP+%J^[YG[_V-;3FGY!A.L]2:KP^.>2#Y;CF)9(RXS[)XJT:,9DK3
M\DR..MGN#B")Y"!J.E#C;#"$C9/K(W):^Q-MXN%8XZU_+9K,7BH;RVKM4U\=
M4:5RQ!CJU3*L$:JJJ]B>0]S2<C\QU**??FY,K,TDEFAB,+AJ09E\-6E:\^2M
MB) H(DM6A$T\C,Q9*\"#M6/@V/V'A..[)P+-->Y<"VRQ;.,6OL4R$!RM:I5/
M?UA-981,>YK_ $IE&)D6"=&J^"9&3,^NQJ]5;&7[6*R-#)TI/%<Q]RM=JR?'
MLGK3)-$Q'(Y7O0=R\\,O*GT.K3E,?5RN-R&,NQ^6GD*=FE:C_IP687AE )!X
M;L<]K<<JW##U U3C609.2>'"W'[^XMK?U.->=X21=&S#/O#*NHQ7),1#+++:
M(P8BV^4@#*0:\-4*,:\J>%[Y)$=><NZ5>J1LUH(8.-UX^^L$:L*Z337*MUT1
M.\LL/FD;MC#_ #$(16  XHN&1[?2M:UF>:?NVID<>UB1D-AX8*=JC&[OV!6F
M\$:=TA3Y[@NRDD\]BP_4F$[#XBX-I7,JYU[@F1Z#PK![<(QT2ED5#L&J*Z,E
MA+(6,&MA?2A/!L1H(I ;0<<X1L,T$7DT=[-9#&;UR.?HRBOD:NY+^0A= >Q9
MQD9Y2A0L2\#\M')$[$20LT;EE9N=[2PF/R>R,?@+\1LXZSMJACYHY".]H/DZ
M")7#A0$G3M66.5%4QS*LL?:RKQY.)]O>9%Q9UF3DUY9Y);PXC98^7D%Q)!-=
M7$.,V=OC 5C<$P#C0F7!5?5"RV9R#1*<>Z<R2-))GIU][S@KU=X99*E>*K ;
MT5E*T 9:\!MQ06Y(H$9F9($EF=88^X^.,*@/"C7QLR>Q:V=B6MV)K<ZT9:SV
M9RK6)UJ2SU(Y9W545YWBA1II.P>20LY'+'7*-#Z:PK)/#LPW1]_ 9;81<Z'/
MQ YI<PZVCZ\NOL8FF1%Q"1006P4KV'5QT(;%#/&&+BC22%O6YW'G;]7J=>W!
M6:.'(0;BBO1]BMX1*DL1["C.6:&0 QRQLY\D;.C'ACK2[;P./M=+J&WK*R38
M^QMR2E)WLGF,4D4H[U<(%6:-B)(I%C'CD1' Y4:_&UT_B.)^&KD>H:3YF/C,
MO%C)Z\LR0J&>^/+RK!;&UR;(#CY17#D7][=W%I>61KPO1GM#R)_A6QO2%/J'
M-W;G5:MF['B>VN\*LB($9:\:4LA'#4K1QAPRUJ]>"&O%&).Y88U7OY'=K\FP
M=&ETHM8.OY4J'9UR-W[U:Q))<QTL]NS)(4*M9LV)YK$TAC[6FD=NP ]NLYR5
MQ]EMPS$UTVUN*FGS>DU!K"]/IRH!+N3$,LN\2QG)@!C9!2(!Y+K'BSZ<R= W
M*@=@7\.V"=89H<;:EDP[Z?*&&":?'V,WEZ\<Z,]<7J=>[;J2M&'5F%>TD<\:
M]X_&1)W]R]RM[[LJB?828KS3PU\A7P>(LR0.J6#1NV*52W$KLCJIL57D@D;Q
MG\7*_:%8JRW3JJJNHJNMI*<(>MJ*< .JJZX.-L(@%=7CQB A"PL1&Q#BC0Q0
M01M1&QQ1M:B=D3JAS32V)I;$\C2S3R/--*Y+/)+*Q>21V/J6=V+,3ZDDG5_A
MABKPQ5X(UB@@CCAAB0!4BBB4)'&BCT5410J@>@  U4%V)5V+<\X<RHYS@#-L
M<=2:K/:N*0=*6_*UMF(K\-R,H9!D*=D=/7Y+<4,1RFK ZD):&X-9(89V7?WV
M6YTY-&PL<B8;="S8Z9@WO%9,K1?WZJC]_8*L\M6"R8_'W"PI<2<,RFC&E%3Z
MD+?KM)&^:VL\.2A4K[O9?%7D-&TZ=G?[U!%:GK+)Y.TUW"&/E58>#F5J*F+Q
MDOD?B^0Y9K7>6EL2N9,1V/@1U4%;'X]+*PX[ \QK;ZFR'&\SP4\]L=C)C^0T
MAS K&-3Z<BL+G*FG]-BYN=+:;6MU:65V]G[U<7L7D8YGACL@&./(T9JT]6W0
MR,<1,0LU;$9DB(CG65%15\]^82!Z<FZJ=J[B=Q8"C8-'*XV2&.>2J6$DF-O1
M68+52_CI)0)36M5Y!'*/) T3L[,&/AORFW_XD.W#]!<@]F755JRG0VQOJ#4H
MM/K@W8,&/R_%Q4N99+6UI63MHK)PZ0W-=B5QBC; :22!\C&JSR'??6S]M=+,
M-'N/;.)KS9B8K%6LYIY\I'C6L#L,]&I+,E0V(@W=!+=@N&)P& )YY NQ-X[F
MZJYM]M;GR]B'#PAI;-;")!BI,FM<F007K<,+W!7E*=L\5&>D)$)!(^;P:SG_
M (R'DO#S<./$$G BRUV'R,*KY!_CAY*G/\2L@WQ/L!; =[FD P))\2,0DD?G
M:Y/,[SH ^FUN2IOC!VD2.1UENJ4E#>-A-C;L+AA$\3#YDC<=CKP>"/0<:/\
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M617BOY):E_.TX;;]SI7R<]4M(8O(P@ENQ6YHE"@2'L7ACK2VI,.T1JW#-2X
M.;!BF%U2@5[[0QUC;'D%%DVEO=7-@YD7QUU?71]A=W!;88(R+,\J6(<>)[(8
MU:SV:O;BS%_-9)HVN7YO)*(4$4,:HB0P001@GQUZU>**O A9BL42*S,06+3X
M#"4-N8>AA,8DBTJ$/CB,S^6:1G=YI[$\G"^2Q9L2RV)W"J'FE=E500HZAUJ-
';C4ZFIK_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
